JP2012528179A - Bicyclic pyrimidine PI3K inhibitor compounds selective for p110δ and methods of use - Google Patents

Abstract

(I) X ¹ is N, X ² is S, (ii) X ¹ is CR ⁷ , X ² is S, (iii) X ¹ is N, X ² is NR ² Or (iv) compounds of formula I (Ia and Ib), wherein X ¹ is CR ⁷ and X ² is O, the stereoisomers, tautomers, metabolites, and pharmaceuticals thereof Those containing an acceptable salt are useful for inhibiting the delta isoform of PI3K and for treating diseases mediated by lipid kinases such as inflammation, immunity, and cancer. Disclosed are methods of using compounds of formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases or related pathological conditions in mammalian cells.

Description

(Cross-reference with related applications)
This non-provisional application filed under section 1.53 (b) of the United States Patent Enforcement Regulations is a US provisional application 61/181252 filed May 27, 2009, which is incorporated by reference in its entirety. And US Patent No. 119, paragraph (e) of 61/287607 filed December 17, 2009.

(Field of Invention)
The present invention relates generally to compounds for treating diseases mediated by lipid kinases such as inflammation, immune disorders, and cancer, and more particularly to compounds that inhibit PI3 kinase activity. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells or related pathological conditions.

  Phosphatidylinositol (PI) is a phospholipid found in cell membranes and plays an important role in intracellular signal transduction. Cell signaling through 3'-phosphorylated phosphoinositides has been linked to various intracellular processes such as malignant transformation, growth factor signaling, inflammation, and immunity (Rameh et al. (1999) J. Biol Chem). , 274: 8347-8350). The causative enzyme that produces these phosphorylated signaling products, phosphatidylinositol 3-kinase (also referred to as PI3-kinase or PI3K), has been identified as a viral oncoprotein-related activator, phosphatidylinositol (PI) and inositol ring Was originally identified as a growth factor receptor tyrosine kinase that phosphorylates its phosphorylated derivative at the 3'-hydroxyl (Panayotou et al. (1992) Trends Cell Biol 2: 358-60).

  Phosphoinositide 3-kinase (PI3K) is a lipid kinase that phosphorylates lipids at the 3-hydroxyl residue of the inositol ring of phosphoinositols (Whitman et al. (1988) Nature, 332: 664). 3′-phosphorylated phospholipids (PIP3) produced by PI3-kinase are kinases with lipid binding domains (including the pleckstrin homology (PH) region), such as Akt and phosphoinositide-dependent kinase-1 (PDK1). Acts as a second messenger to replenish. The binding of Akt to membrane PIP3 translocates Akt to the plasma membrane, thereby bringing Akt into contact with PDK1, which is responsible for the activation of Akt. The tumor suppressor phosphatase PTEN dephosphorylates PIP3 and thus acts as a negative regulator of Akt activation. PI3-kinases Akt and PDK1 are important in the regulation of many intracellular processes including cell cycle regulation, proliferation, survival, apoptosis and motility, and are important in the molecular mechanisms of diseases such as cancer, diabetes and immune inflammation Elements (Vivanco et al. (2002) Nature Rev. Cancer 2: 489; Phillips et al. (1998) Cancer 83:41).

  PI3 kinase is a heterodimer composed of p85 and p110 subunits (Otsu et al., Cell, 65: 91-104 (1991); Hiles et al., Cell, 70: 419-29 (1992)). Four distinct class I PI3Ks have been identified and named 110 kDa catalytic and regulatory subunits, designated PI3Kα (alpha), β (beta), δ (delta) and γ (gamma), each distinct Consists of units. More specifically, three of the catalytic subunits, p110α, p110β, and p110δ each interact with the same regulatory subunit p85, while p110γ interacts with a distinct regulatory subunit p101. The expression pattern of each of these PI3Ks in human cells and tissues is also distinct.

  p110δ isoforms are biological functions involved in immune inflammatory diseases including B cell receptor, T cell receptor signaling, mast cell and monocyte / macrophage FcR signaling, and osteoclast function / RANKL signaling (Deane J and Fruman DA (2004) Annu. Rev. Immunol. 2004. 22: 563-98; Janas et al., The Journal of Immunology, 2008, 180: 739-746; Marone R et al., Biochim Biophy. Acta 2007, 1784: 159-185). Selective introduction of mutants that are deficient in the PI3Kδ gene or inactive as a catalyst for PI3Kδ causes almost complete loss of B cell proliferation and signal transduction and also dysfunction of signal transduction through T cells.

  The present invention relates generally to compounds of formula I having PI3 kinase inhibitory activity and selective binding to the p110δ isoform relative to binding to the p110α isoform. The compounds of formula I exhibit at least a 10-fold selectivity in binding to p110δ relative to the binding of p110α to the isoform.

を有し、その立体異性体、互変異性体、又は薬学的に許容可能な塩を含む。Ｘ^１、Ｘ^２、ｍｏｒ、Ｒ^１、Ｒ^２、Ｒ^２’、及びＲ^３を含む様々な置換基はここに定義する通りである。 The compound of formula I has the structure:

And the stereoisomers, tautomers, or pharmaceutically acceptable salts thereof. The various substituents including X ¹ , X ² , mor, R ¹ , R ² , R ² ′, and R ³ are as defined herein.

  Another aspect of the present invention provides a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier, glidant, diluent or excipient.

  Other aspects of the invention treat a disease or disorder mediated by the p110δ isoform of PI3 kinase, selected from cancer, immune disease, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction and neuropathy There is provided the use of a compound of formula I in the manufacture of a medicament.

  The invention also includes mammalian cells, organisms, or related pathological conditions such as cancer, systemic and local inflammation, immuno-inflammatory diseases such as rheumatoid arthritis, immunosuppression, organ transplant rejection, allergy, ulcerative Colitis, Crohn's disease, dermatitis, asthma, systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma / systemic sclerosis, idiopathic thrombocytopenic purpura (ITP), anti-neutrophil cytoplasmic antibody ( ANCA) for methods of using compounds of formula I for in vitro, in situ, and in vivo diagnosis or treatment of vasculitis, chronic obstructive pulmonary disease (COPD), psoriasis, and for general joint protective effects Also related.

  Other aspects of the invention are selected from cancer, immune disease, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction and neuropathy and have a disease or disorder mediated by the p110δ isoform of PI3 kinase Provided is a method of treating a disease or disorder comprising administering a compound of formula I to a patient. The method includes chemotherapeutic agents, anti-inflammatory agents, immunomodulators, neurotrophic factors, therapeutic agents for cardiovascular diseases, therapeutic agents for liver diseases, antiviral agents, therapeutic agents for blood diseases, therapeutic agents for diabetes, immunity It may further comprise administering a further therapeutic agent selected from therapeutic agents for deficiency diseases.

  Another aspect of the present invention is a kit for treating a condition mediated by the p110δ isoform of PI3 kinase, comprising a pharmaceutical composition comprising a compound of formula I; and instructions for use Provide kit.

  Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims. Those skilled in the art will recognize many methods and materials that can be used to practice the present invention and that are similar or equivalent to those described herein. The present invention is in no way limited to the methods and materials described. If one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, etc. The present application takes precedence.

Definitions As used herein, the term “alkyl” refers to a saturated linear or branched monovalent hydrocarbon group of 1 to 12 carbon atoms (C ₁ -C ₁₂ ), wherein the alkyl group May optionally be independently substituted with one or more substituents described below. In other embodiments, the alkyl group is 1 to 8 carbon atoms (C ₁ -C ₈ ), or 1 to 6 carbon atoms (C ₁ -C ₆ ). Examples of alkyl groups, but are not limited to, methyl (Me, -CH _3), ethyl _{(Et, -CH 2 CH 3)} , 1- propyl (n-Pr, n-propyl, -CH ₂ CH ₂ CH ₃ ), 2-propyl (i-Pr, i-propyl, —CH (CH ₃ ) ₂ ), 1-butyl (n-Bu, n-butyl, —CH ₂ CH ₂ CH ₂ CH ₃ ), 2-methyl- 1-propyl (i-Bu, i-butyl, —CH ₂ CH (CH ₃ ) ₂ ), 2-butyl (s-Bu, s-butyl, —CH (CH ₃ ) CH ₂ CH ₃ ), 2-methyl 2-propyl (t-Bu, t- _{butyl, -C (CH 3) 3)} , 1- pentyl (n- _{pentyl, -CH 2 CH 2 CH 2 CH} 2 CH 3), 2- pentyl (-CH ( _{CH 3) CH 2 CH 2 CH} 3), 3- pentyl _{(-CH (CH 2 CH 3)} 2), 2- methyl-2-butyl _{(-C (CH 3) 2 CH} 2 CH 3), 3- methyl -2-Butyl (- _{H (CH 3) CH (CH} 3) 2), 3- methyl-1-butyl _{(-CH 2 CH 2 CH (CH} 3) 2), 2- methyl-1-butyl _(-CH 2 CH (CH ₃₎ CH ₂ CH ₃ ), 1-hexyl (—CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₃ ), 2-hexyl (—CH (CH ₃ ) CH ₂ CH ₂ CH ₂ CH ₃ ), 3-hexyl (— _{CH (CH 2 CH 3) (} CH 2 CH 2 CH 3)), 2- methyl-2-pentyl _{(-C (CH 3) 2 CH} 2 CH 2 CH 3), 3- methyl-2-pentyl (-CH (CH ₃ ) CH (CH ₃ ) CH ₂ CH ₃ ), 4-methyl-2-pentyl (—CH (CH ₃ ) CH ₂ CH (CH ₃ ) ₂ ), 3-methyl-3-pentyl (—C ( _{CH 3) (CH 2 CH 3} ) 2), 2- methyl-3-pentyl _{(-CH (CH 2 CH 3)} CH (CH 3) 2), 2,3- dimethyl-2-butyl (-C (CH _{3) 2 CH (CH 3)} 2) 3,3-dimethyl-2-butyl _{(-CH (CH 3) C (} CH 3) 3, 1- heptyl, 1-octyl.

The term “alkylene” as used herein refers to a saturated linear or branched divalent hydrocarbon group of 1 to 12 carbon atoms (C ₁ -C ₁₂ ), wherein the alkylene group is In some cases, it may be independently substituted with one or more substituents described below. In other embodiments, the alkylene group is from 1 to 8 carbon atoms (C ₁ -C ₈ ), or from 1 to 6 carbon atoms (C ₁ -C ₆ ). Examples of alkylene groups include, but are not limited to, methylene (—CH ₂ —), ethylene (—CH ₂ —), propylene (—CH ₂ CH ₂ CH ₂ —), and the like.

The term “alkenyl” is a monovalent or branched monovalent of 2 to 8 carbon atoms (C ₂ -C ₈ ) having at least one site of unsaturation, ie a carbon-carbon sp ² double bond. Means a hydrocarbon group, wherein the alkenyl group may optionally be independently substituted with one or more substituents described herein and may have a “cis” and “trans” orientation, or alternatively “E” ”And“ Z ”orientations. Examples include, but are not limited to, ethylenyl or vinyl (—CH═CH ₂ ), allyl (—CH ₂ CH═CH ₂ ), and the like.

The term “alkenylene” is a linear or branched divalent of 2 to 8 carbon atoms (C ₂ -C ₈ ) having at least one site of unsaturation, ie, a carbon-carbon sp ² double bond. Means a hydrocarbon group, wherein an alkenyl group is optionally substituted and includes groups having "cis" and "trans" orientations, or alternatively "E" and "Z" orientations. Examples include, but are not limited to, ethylenylene or vinylene (—CH═CH—), allyl (—CH ₂ CH═CH—), and the like.

The term “alkynyl” refers to a linear or branched monovalent hydrocarbon group of 2 to 8 carbon atoms (C ₂ -C ₈ ) having at least one site of unsaturation, ie, a carbon-carbon sp triple bond. As used herein, an alkynyl group may optionally be independently substituted with one or more substituents described herein. Examples include, but are not limited to, ethynyl (—C≡CH), propynyl (propargyl, —CH ₂ C≡CH), and the like.

The term “alkynylene” refers to a linear or branched divalent hydrocarbon group of 2 to 8 carbon atoms (C ₂ -C ₈ ) having at least one site of unsaturation, ie, a carbon-carbon sp triple bond. Meaning, where the alkynyl group is optionally substituted. Examples include, but are not limited to, ethynylene (—C≡C—), propynylene (propargylene, —CH ₂ C≡C—), and the like.

The terms “carbocycle”, “carbocyclyl”, “carbocyclic ring” and “cycloalkyl” refer to 3 to 12 carbon atoms (C ₃ -C ₁₂ ) as a monocyclic ring as a monocyclic ring, or bicyclic By monocyclic non-aromatic saturated or partially unsaturated ring having 7 to 12 carbon atoms as a formula ring is meant. Bicyclic carbocycles having 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, with 9 or 10 rings Bicyclic carbocycles with atoms can be used as bicyclo [5,6] or [6,6] systems, or bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane and bicyclo [3. 2.2] Can be arranged as a crosslinking system such as nonane. Examples of monocyclic carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohexa- 1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, adamantanyl and the like.

“Aryl” means a monovalent aromatic hydrocarbon group of 6-20 carbon atoms (C ₆ -C ₂₀ ) derived by removing one hydrogen atom from a single carbon atom of a parent aromatic ring system To do. Some aryl groups are represented in the exemplary structures as “Ar”. Aryl includes bicyclic groups containing an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocycle. Typical aryl groups include, but are not limited to, groups derived from benzene (phenyl), substituted benzenes, naphthalene, anthracene, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl and the like including. The aryl group may optionally be independently substituted with one or more substituents described herein.

“Arylene” means a divalent aromatic hydrocarbon group of 6-20 carbon atoms (C ₆ -C ₂₀ ) derived by removing two hydrogen atoms from two carbon atoms of a parent aromatic ring system To do. Some aryl groups are represented in the exemplary structures as “Ar”. Aryl includes bicyclic groups containing an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocycle. Typical arylene groups include, but are not limited to, groups derived from benzene (phenylene), substituted benzene, naphthalene, anthracene, biphenylene, indenylene, indanylene, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydro Including naphthyl and so on. The arylene group may be optionally substituted.

  The terms “heterocycle”, “heterocyclyl” and “heterocyclic ring” are used interchangeably herein, and at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus and sulfur; The remaining ring atoms are C, and one or more ring atoms may optionally be independently substituted with one or more substituents described below, By partially unsaturated (ie having one or more double and / or triple bonds in the ring) is meant a carbocyclic group. Heterocycles are monocyclic with 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P and S), or 7 to 10 ring members ( Bicycles having 4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), for example bicyclo [4,5], [5,5], [5,6 ] Or [6,6] system. Heterocycles are Paquette, Leo A .; "Principles of Modern Heterocyclic Chemistry" (WA Benjamin, New York, 1968), especially chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs "(John Wiley & Sons, New York, 1950 to present), in particular, 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82: 5566. ing. “Heterocyclyl” also includes heterocyclic groups fused to saturated, partially unsaturated rings, or aromatic carbocyclic or heterocyclic rings. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, Azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, Dihydropyranyl, dihydrothienyl, dihydrofuranyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, pyrazolidinyl imidazo Nyl, imidazolidinyl, 2-oxa-5-azabicyclo [2.2.2] octane, 3-oxa-8-azabicyclo [3.2.1] octane, 8-oxa-3-azabicyclo [3.2.1] Octane, 6-oxa-3-azabicyclo [3.1.1] heptane, 2-oxa-5-azabicyclo [2.2.1] heptane, 3-azabicyclo [3.1.0] hexanyl, 3-azabicyclo [ 4.1.0] heptanyl, azabicyclo [2.2.2] hexanyl, 3H-indolylquinodilinyl and N-pyridylurea. Spiro moieties are also included within the scope of this definition. Examples of heterocyclic groups in which two ring atoms are substituted with oxo (═O) moieties are pyrimidinoyl and 1,1-dioxo-thiomorpholinyl. The heterocyclic groups herein may optionally be independently substituted with one or more substituents described herein.

  The term “heteroaryl” refers to a monovalent aromatic group of a 5-membered, 6-membered or 7-membered ring, containing one or more heteroatoms independently selected from nitrogen, oxygen and sulfur. Includes a 20 atom fused ring system (at least one is aromatic). Examples of heteroaryl groups include pyridinyl (eg including 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (eg including 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, Isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinolinyl, indazolinyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, tritinyl , Thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, Zochiazoriru, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Heteroaryl groups may optionally be independently substituted with one or more substituents described herein.

を含む。 Examples of bicyclic heteroaryl groups are

including.

  Heterocyclic or heteroaryl groups may be bonded with carbon (carbon bonds) or with nitrogen (nitrogen bonds) where possible. Examples include, but are not limited to, carbon-bonded heterocycles or heteroaryls are pyridine 2-position, 3-position, 4-position, 5-position, or 6-position, pyridazine 3-position, 4-position, 5-position, or 6-position, pyrimidine 2-position, 4-position, 5-position, or 6-position, pyrazine 2-position, 3-position, 5-position, or 6-position, furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole 2-position, 3 Position, 4 or 5 position, oxazole, imidazole or thiazole position 2, 4 or 5 position, isoxazole, pyrazole or isothiazole position 3, position 4 or position 5, aziridine position 2 or 3 Position, 2nd, 3rd, or 4th position of azetidine, 2nd, 3rd, 4th, 5th, 6th, 7th, or 8th position of quinoline, or 1st, 3rd, 4th position of isoquinoline, 5th, 6th, 7th or 8th To focus. The ring nitrogen atom of the heterocycle or heteroaryl group may be combined with oxygen to form an N-oxide.

  By way of example, but not limitation, nitrogen-attached heterocycles or heteroaryls include aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, Pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 1 of benzimidazole, position 2 of isoindole or isoindoline, position 4 of morpholine, and carbazole, or β- Binds at position 9 of carboline.

  The terms “treat” and “treatment” are curative treatment and prevention whose purpose is to prevent or delay (reduce) unwanted physiological changes or diseases such as the onset or spread of cancer. Means both preventive and preventive measures. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, symptom reduction, disease severity, disease stabilization (ie, no deterioration), whether detectable or undetectable. ) Condition, delayed or slowed disease progression, recovery or alleviation of disease state, and remission (partial or complete). “Treatment” can mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those who already have symptoms or diseases as well as those who are likely to develop symptoms or diseases or those whose symptoms or diseases are to be prevented.

  The phrase “therapeutically effective amount” refers to (i) treating or preventing a particular disease, symptom, or disorder, and (ii) attenuating one or more signs of a particular disease, symptom, or disorder. Means, the amount of a compound of the invention that prevents, delays, or delays the onset of one or more signs of a particular disease, condition, or disease described herein. In the case of cancer, a therapeutically effective amount of the drug reduces the number of cancer cells; reduces tumor size; inhibits cancer cell invasion into surrounding organs (ie slows to some extent, preferably stops) Inhibiting tumor metastasis (ie slowing, preferably stopping to some extent); inhibiting tumor growth to some extent; and / or alleviating one or more of the symptoms associated with cancer to some extent. To the extent that an agent can prevent proliferation and / or kill existing cancer cells, it can be cytostatic and / or cytotoxic. In cancer treatment, efficacy can be measured, for example, by assessing time to progression (TTP) and / or determining response rate (RR).

  As used herein, “inflammatory disease” can mean any disease, disorder, or syndrome in which an excessive or unregulated inflammatory response leads to excessive inflammatory signs, host tissue damage, or loss of tissue function. “Inflammatory disease” also means a condition mediated by leukocyte influx and / or neutrophil chemotaxis.

  “Inflammation” as used herein refers to localization induced by tissue damage or destruction that acts to destroy, dilute, surround and clean (isolate) both the damaging agent and the damaged tissue. Meaning protected reaction. Inflammation is particularly associated with leukocyte influx and / or neutrophil chemotaxis. Inflammation can arise from infection with pathogenic organisms and viruses and from non-infectious means such as reperfusion after trauma or myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune responses. Accordingly, inflammatory diseases that are amenable to treatment with compounds of Formula I include diseases associated with specific defense system responses as well as non-specific defense system responses.

  “Specific defense system” means a component of the immune system that reacts to the presence of specific antigens. Examples of inflammation resulting from specific defense system reactions include classical responses to foreign antigens, autoimmune diseases, and late-type hypersensitivity reactions mediated by T cells. Chronic inflammatory diseases, solid transplant tissues and organs such as rejection of kidney and bone marrow transplants, and graft-versus-host disease (GVHD) are further examples of inflammatory responses of specific defense systems.

  The term “non-specific defense system” as used herein refers to inflammatory diseases mediated by leukocytes (eg, granulocytes and macrophages) that are not capable of immune memory. Examples of inflammation that arises at least in part from non-specific defense system reactions include adult (acute) respiratory distress syndrome (ARDS) or multiple organ injury syndrome; reperfusion injury; acute glomerulonephritis; reactive arthritis; Skin diseases with components; acute purulent meningitis or other central nervous system inflammatory diseases such as stroke; burns; inflammatory bowel disease; granulocyte post-transfusion syndrome; and cytokine-induced toxicity.

  “Autoimmune disease” as used herein refers to any group of diseases in which tissue injury involves a fluid or cell-mediated response to the body's own components.

  As used herein, “allergic disease” means any symptom, tissue damage, or loss of tissue function resulting from allergy. As used herein, “arthritic disease” means any disease characterized by inflammatory lesions of the joint that can result from a variety of etiologies. “Dermatitis” as used herein refers to any of a large family of skin diseases characterized by skin inflammation that can result from a variety of etiologies. As used herein, “graft rejection” refers to organs or cells (eg, bone marrow) characterized by loss of function of the transplanted and surrounding tissues, pain, swelling, leukocytosis, and thrombocytopenia By any immune response that occurs against the transplanted tissue. The therapeutic methods of the present invention include methods for treating diseases associated with inflammatory cell activation.

  “Inflammatory cell activation” is triggered by stimulation of proliferative cell responses (including but not limited to cytokines, antigens or autoantibodies), soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or Production of vasoactive amines, or inflammatory cells (including but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes (ie, eg, neutrophils, basophils, and eosinophils) Cell surface of a new or increased number of mediators (including, but not limited to, major histocompatibility antigens or cell adhesion molecules) in malignant polymorphonuclear leukocytes), mast cells, dendritic cells, Langerhans cells, and endothelial cells) Means expression. Activation of one or a combination of these phenotypes in these cells can contribute to the initiation, perpetuation, or exacerbation of inflammatory diseases.

The term “NSAID” is an acronym for “non-steroidal anti-inflammatory drugs” for analgesia, antipyretic (reducing elevated body temperature and reducing pain without compromising consciousness) At high doses, it is a therapeutic agent with an anti-inflammatory effect (reduction of inflammation). The term “non-steroid” is used to distinguish these drugs from steroids with similar eicosanoid-suppressing anti-inflammatory effects (among a wide range including other effects). As analgesics, NSAIDs are unusual in that they are non-narcotic. NSAIDs include aspirin, ibuprofen, and naproxen. NSAIDs are usually effective for the treatment of acute or chronic conditions where pain and inflammation are present. NSAIDs are generally effective in the symptomatic relief of the following symptoms: rheumatoid arthritis, osteoarthritis, inflammatory arthropathy (eg ankylosing spondylitis, psoriatic arthritis, Reiter syndrome, acute gout, dysmenorrhea, Metastatic bone pain, headache and migraine, postoperative pain, mild to moderate pain due to inflammation and tissue injury, fever, bowel obstruction, and renal colic, most NSAIDs are cyclooxygenase-1 (COX-1) and cyclooxygenase- 2 (COX-2) acts as a non-selective inhibitors of the enzyme cyclooxygenase inhibiting both isozymes. cyclooxygenase (derived from cellular phospholipid bilayer by themselves phospholipase a ₂₎ prostaglandins from arachidonic acid It catalyzes the formation of glandins and thromboxanes, which are (especially) inflammatory processes COX-2 inhibitors include celecoxib, etoroxixib, lumiracoxib, parecoxib, rofecoxib, rofecoxib, and valdecoxib.

  The term “cancer” refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. A “tumor” includes one or more cancer cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid tumors. More specific examples of such cancers are squamous cell carcinoma (eg, epithelial squamous cell carcinoma), lung cancer such as small cell lung cancer, non-small cell lung cancer (“NSCLC”), lung adenocarcinoma, and lung squamous epithelium. Cancer, peritoneal cancer, hepatocellular carcinoma, gastric or stomach cancer, such as gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer, Colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, spawning cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, As well as head and neck cancer.

  A “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer, regardless of mechanism of action. The class of chemotherapeutic agents includes, but is not limited to, alkylating agents, antimetabolites, spindle venom plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, antibodies, tumor affinity photosensitizers, and kinase inhibitors including. Chemotherapeutic agents include compounds used in “targeted therapy” and general chemotherapy. Examples of chemotherapeutic agents include erlotinib (TARCEVAR, Genentech / OSI Pharm.), Docetaxel (TAXOTERR, Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS number 51-21-8), gemcitabine (GEMZAR) (Registered trademark), Lilly), PD-0325901 (CAS number 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum (II), CAS number 15663-27-1), carboplatin (CAS number 41575) 94-4), paclitaxel (TAXOL (registered trademark), Bristol-Myers Squibb Oncology, Princeton, NJ), trastuzumab (Herceptin (registered trader) ), Genentech), temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazaazabicyclo [4.3.0] nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, TEMODAR®, TEMODAL®, Schering Plow), Tamoxifen ((Z) -2- [4- (1,2-diphenylbut-1-enyl) phenoxy] -N , N-dimethyl-ethanamine, NOLVADEX®, ISSUBAL®, VALODEX®, and doxorubicin (ADRIAMYCIN®), Akti-1 / 2, HPPD, and rapamycin.

  Further examples of chemotherapeutic agents include oxaliplatin (ELOXATIN®, Sanofi), bortezomib (VELCADE®, Millennium Pharm.), Sutent (SUNITINIB®, SU11248, Pfizer), letrozole ( FEMARA®, Novartis), Imatinib mesylate (GLEEVEC®, Novartis), XL-518 (Mek inhibitor, Exelixis, International Publication No. 2007/0444515), ARRY-886 (Mek inhibitor, AZD6244, Array) BioPharmaca, Astra Zeneca), SF-1126 (PI3K inhibitor, Semafor Pharmaceuticals), BEZ-235 (PI3K inhibition) Agent, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787 / ZK22284 (Novartis), fulvestrant (FASLODEXR, AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNEy®) Lapatinib (TYKERB (registered trademark), GSK572016, Glaxo Smith Kline), Lonafarnib (SARASAR (registered trademark), SCH66336, Schering Plow), Sorafenib (NEXAVAR (registered trademark), BAY43-9s6, Bayer ES Trademark), AstraZeneca), Irinotecan (CAMPTOSAR®) ), CPT-11, Pfizer), Tipifanib (ZARNESTRA (TM), Johnson & Johnson), ABRAXANE (TM) (Cremophor Free), Paclitaxel's albumin engineered nanoparticle formulation (American PharmaceuticalPartivar, I (RINN, ZD6474, ZACTIMAR, AstraZeneca), chlorambucil, AG1478, AG1571 (SU5271; Sugen), temsirolimus (TORISEL (registered trademark), Wyeth), pazopanib (GlaxoSmithKline), trademark of Kanfosamide (TE) TE Thiotepa and cyclophosphamide (CYTOX AN <(R)>, NEOSA <(R)>); alkyl sulfonates such as busulfan, improsulfan and pipersulfan; aziridines such as benzodepa, carbocon, meteredopa, and uredepa; Ethyleneimine and methylmelamine, such as altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenin (especially bullatacin and bralatacinone) Camptothecin (eg, synthetic analog topotecan); bryostatin Callystatin; CC-1065 (including its adzelesin, carzelesin and bizelesin synthetic analogs); cryptophysin (especially cryptophysin 1 and cryptophysin 8); duostatin; including the synthetic analogs KW-2189 and CB1-TM1; eleutherbin; pancratistatin; sarcodyctyin; spongestatin; Gen mustard, for example, chlorambushi , Chlornafazine, chlorophosphamide, estramustine, ifosfamide, mechloretamine, mechlorethamine oxide hydrochloride, melphalan, novembichine, phenesterine, prednisotin, trophosphamide, uracil mustard; nitrosourea Eg, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as enediyne antibiotics (eg calicheamicin, in particular calicheamicin γ1I and calicheamicin ωI1 (Angew Chem. Intl. Ed. Engl. (1994) 33: 183-186)); dynemycin, such as dynemycin A; bisphosphonates, such as clodronate; esperamicin; and the neocalcinostatin chromophore and related chromoprotein enediyne antibiotics Substance chromophore), aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carcinophilin, chromomycin, dactino Mycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® ( Xorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxyxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin such as mitomycin C, mycophenolic acid, nogamycin Pepromycin, porphyromycin, puromycin, keramycin, rhorubicin, streptonigrin, streptozocin, tubercidine, ubenimex, dinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU) A folic acid analog, eg, denopterin (denopter n), methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiaminpurine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxyfluridine, enocitabine Androgen, eg, carosterone, drostanolone propionate, epithiostanol, mepithiostan, test lactone; anti-adrenal, eg, aminoglutethimide, mitoten, trilostane; folic acid supplement, eg, folic acid; acegraton; aldo Phosphamide glycoside; aminolevulinic acid; eniluracil; am Sacrine; vestlabucil; bisantrene; edatraxate; defofamine; demecoltin; diaziquine; elfornithine; Lonidamine; maytansinoids (eg, maytansine and ansamitocin); mitoguazone; mitozantron; mopidanmol; nitraerine; oxantrone; podophyllinic acid; 2-ethylhydrazine; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxan; rhizoxinine; Triazicon; 2,2 ′, 2 ″ -trichlorotriethylamine; trichothecene (particularly T-2 toxin, verraculin A, roridin A and anguidine); urethane; vindesine; Dacarbazine; Mannomustine; Mitobronitol; Mitractol; Pipobrommann; Gacitosin ne); arabinoside ("Ara-C"); cyclophosphamide; thiotepa; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin); vinblastine; etoposide (VP-16); ifosfamide; Vincristine; NAVELBINE® (vinorelbine); Novantrone; Teniposide; Edatrexate; Daunomycin; Aminopterin; Capecitabine (Xeroda®®, Roche); Ibandronate; CPT-11; Topoisomerase inhibitor RFS; Difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and Derivatives, and the like.

  Also included within the definition of “chemotherapeutic agent” are (i) anti-hormonal agents that act to modulate or inhibit hormonal effects on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), such as tamoxifen (Including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxy tamoxifen, trioxyphene, keoxifen, LY117081, onapristone ST, onapristone (Registered trademark) (tremifine citrate); (ii) an enzyme that regulates estrogen production in the adrenal gland Aromatase inhibitors, eg 4 (5) -imidazole, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestany (Formestanie), Fadrozole, RIVISOR® (borozole), FEMARA® (Letrozole; Novartis), and ARIMIDEX® (Anastrozole; AstraZeneca); (iii) anti-androgen For example, flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and troxacitabine (1,3-dioxola) (Iv) protein kinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, in particular abnormal cell proliferation. Those that inhibit the expression of genes in signal transduction pathways involved in PKC, such as PKC-α, Raf and H-Ras, such as Obrimersen (GENAENSE®, Genta); (vii) ribozymes, such as VEGF inhibitors (Eg, ANGIOZYME®) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines such as ALLOVECTIN®, LEUVECTIN®, and VAXID®; PROLEUKIN (R) rIL-2; topoisomerase 1 inhibitors, such as LURTOTECAN (R); ABARELIX (R) rmRH; (ix) anti-angiogenic agents, such as bevacizumab (AVASTIN (R), Genentech); and Pharmaceutically acceptable salts, acids and derivatives of any of the above.

  Also included in the definition of “chemotherapeutic agent” are therapeutic antibodies such as alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX ( (Registered trademark), Amgen), rituximab (RITUXAN (registered trademark), Genentech / Biogen), pertuzumab (OMNITARG (trademark), 2C4, Genentech), trastuzumab (Herceptin, Genentech), tositumomab (Bexxar, Corixia), and antibody The drug conjugate, gemtuzumab ozogamicin (MYLOTARGR, Wyeth).

  Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents used in combination with the PI3K inhibitors of the present invention are alemtuzumab, apolizumab, acelizumab, atolizumab, bapineuzumab, bevacizumab, bibatuzumab mertansine, cantuzumab mel Tanshin, Cedelizumab, Sertolizumab Pegor, Sidfucizumab, Cidotuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Ellizumab, Felbizumab, Fontlizumab, Gemtuzumab Ozogamib, Inotuzumab Pizumab Lintuzumab, matuzumab, mepolizumab, motavizumab, motobizumab, natalizumab, nimotuzumab, norobizumab, nubabizumab, ocrelizumab, omalizumab, palivizumab, Sukorizumabu, Pekufushitsuzumabu, Pekutsuzumabu, pertuzumab, pexelizumab, Raribizumabu, ranibizumab, Resuribizumabu, Resurizumabu, Reshibizumabu, Roberizumabu, Rupurizumabu, sibrotuzumab, siplizumab, Sontsuzumabu, Takatsu's Mabu tetra Kise Tan, Tadoshizumabu, Tarizumabu, Tefibazumabu, tocilizumab, Torarizumabu, trastuzumab, Tsukotsu Including zumab cell molloykin, toxizuzumab, umabizuzumab, urtoxazumab, and bicilizumab.

  A “metabolite” is a product produced by metabolism in the body of a specific compound or salt thereof. A metabolite of a compound can be identified using routine techniques known in the art, and its activity is determined using tests such as those described herein. Such products may result from, for example, oxidation, hydroxylation, reduction, hydrolysis, amidation, deamidation, esterification, esterification, enzymatic cleavage, etc. of the administered compound. Accordingly, the present invention includes metabolites of a compound of the present invention, including compounds produced by a method comprising contacting the compound of the present invention with a mammal for a time sufficient to produce its metabolite. .

  The term “package insert” means an instruction usually included in a commercial package of therapeutic products, including information on efficacy, usage, dosage, method of administration, contraindications and / or warnings regarding the use of such therapeutic products Used for.

  The term “chiral” refers to a molecule that has the property of not being superimposable on its mirror image pair, while the term “achiral” refers to a molecule that is superimposable on its mirror image pair.

  The term “stereoisomer” refers to compounds that have the same chemical structure but differ with respect to the arrangement of atoms or groups in space. Stereoisomers include enantiomers and diastereomers.

  “Diastereomer” means a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Mixtures of diastereomers can be separated under high resolution analytical procedures such as electrophoresis and chromatography. Diastereomers include geometric isomers, cis / trans and E / A isomers, and atropisomers.

  “Enantiomer” means two stereoisomers of a compound that are non-superimposable mirror images of each other.

  The definition and conventions of stereochemistry used here are generally described in SP Parker, McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic. Follow Compounds (1994), John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of linearly polarized light. When describing optically active compounds, the prefixes D and L, or R and S are used to indicate the absolute configuration of the molecule around its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of rotation of linearly polarized light by the compound, (-) or l means that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. Certain stereoisomers are sometimes referred to as enantiomers, and mixtures of such isomers are often referred to as enantiomeric mixtures. A 50:50 mixture of enantiomers is referred to as a racemic mixture or racemate and can occur when a chemical reaction or process has no stereoselection or stereospecificity. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species lacking optical activity.

  The terms “tautomer” or “tautomeric form” refer to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototrophic tautomers) include interconversions through proton transfer such as keto-enol and imine-enamine isomerization. Valence tautomers include interconversions by some reconstruction of the bonding electrons.

  As used herein, the phrase “pharmaceutically acceptable salt” refers to a pharmaceutically acceptable organic or inorganic salt of an ADC. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, Isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, hydrogen tartrate, ascorbate, succinate, maleate, gentisate, fumarate Acid salt, gluconate, glucuronic acid salt, sugar salt, formate salt, benzoate salt, glutamate salt, “mesyl acid” methanesulfonate salt, ethanesulfonate salt, benzenesulfonate salt, p-toluenesulfonate salt And pamoate (ie, 1,1′-methylene-bis- (2-hydroxy-3-naphthoate)) salts. Pharmaceutically acceptable salts can include other molecules such as acetate ions, succinate ions, or other counter ions. The counter ion can be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt can have more than one charged atom in its structure. When multiple charged atoms are part of the pharmaceutically acceptable salt, they can have multiple counter ions. Thus, a pharmaceutically acceptable salt can have one or more charged atoms and / or one or more counter ions.

  When the compound of the present invention is a base, the desired pharmaceutically acceptable salt can be obtained by any suitable method available in the art, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid. Or with an inorganic acid such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidic acid such as glucuronic acid or galacturon Organic acids such as acids, alpha-hydroxy acids such as citric acid or tartaric acid, amino acids such as aspartic acid or glutamic acid, aromatic acids such as benzoic acid or cinnamic acid, sulfonic acids such as p-toluenesulfonic acid or ethanesulfonic acid It can be prepared by treatment of the free base with acid.

  When the compound of the present invention is an acid, the desired pharmaceutically acceptable salt can be obtained by any suitable method such as an inorganic or organic base such as an amine (primary, secondary or tertiary), alkaline It can be prepared by treatment of the free acid with a metal hydroxide or an alkaline earth metal hydroxide. Examples illustrating suitable salts include, but are not limited to, derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines such as piperidine, morpholine, and piperazine. Organic bases and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

  The phrase “pharmaceutically acceptable” means that the substance or composition is chemically and / or toxicologically compatible with the other ingredients that make up the formulation and / or the mammal being treated therewith. Indicates that there must be.

  “Solvate” means a conjugate or complex of one or more solvent molecules and a compound of the invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

  Unless otherwise indicated, the terms “compounds of the invention” and “compounds of the invention” and “compounds of formula I” include compounds of formula I and stereoisomers, tautomers, solvates, metabolites thereof. Pharmaceutically acceptable salts and prodrugs.

  Any formula or structure given herein, including compounds of Formula I, is also intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.

  Any formula or structure given herein, including a compound of Formula I, is also intended to represent an isotopically labeled form as well as an unlabeled form of the compound. Isotopically labeled compounds have the structure shown by the formula given herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. . Examples of isotopes that can be introduced into the compounds of the present invention are hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine isotopes, such as, but not limited to, 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. Various isotope-labeled compounds of the present invention, for example, those incorporating radioactive isotopes such as 3H, 13C, and 14C. Such isotope-labeled compounds are useful in metabolic experiments, kinetic experiments, detection or imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), such as drug or substrate tissue distribution assays. Or in patient radiotherapy. The therapeutic compounds of the present invention labeled or substituted with deuterium may have improved DMPK (drug metabolism and pharmacokinetics) with respect to distribution, metabolism, and excretion (ADME). Substitution with heavy isotopes such as deuterium may result in certain therapeutic efficacy resulting from greater metabolic stability such as, for example, increased in vivo half-life or reduced dosage requirements. Compounds labeled with 18F may be useful for PET or SPECT studies. The isotopically labeled compounds of the present invention and their prodrugs are generally disclosed in the following schemes or examples, substituting readily available isotope labeled reagents for unisotopically labeled reagents. Prepared by performing the procedure. Furthermore, substitution with heavier isotopes, particularly deuterium (ie, 2H or D), may provide certain therapeutic benefits that result from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Or it may result in an improvement of the treatment index. It is understood that deuterium in this context is considered a substitute for the compound of formula (I). The concentration of such heavy isotopes, particularly deuterium, can be defined by the isotope enrichment factor. In the compounds of the present invention, any atom not specifically designated as a particular isotope is meant to represent a stable isotope of that atom. Unless otherwise defined, when a position is designated as “H” or “hydrogen”, it is understood that the position has hydrogen in its naturally abundant isotopic composition. Accordingly, in the compounds of the present invention, the atom specifically indicated as deuterium (D) is meant to represent deuterium.

から選択される化合物及びその立体異性体、互変異性体、又は薬学的に許容可能な塩を含み、
ここで、（ｉ）Ｘ^１はＮであり、Ｘ^２はＳであり、（ｉｉ）Ｘ^１はＣＲ^７であり、Ｘ^２はＳであり、（ｉｉｉ）Ｘ^１はＮであり、Ｘ^２はＮＲ^２であるか、又は（ｉｖ）Ｘ^１はＣＲ^７であり、Ｘ^２はＯであり；
Ｒ^１は、
Ｃ_１-Ｃ_１２アルキル、
Ｃ_２-Ｃ_８アルケニル、
Ｃ_２-Ｃ_８アルキニル、
Ｃ_６-Ｃ_２０アリール、
Ｃ_２-Ｃ_２０ヘテロシクリル、
Ｃ_３-Ｃ_１２カルボシクリル、
Ｃ_１-Ｃ_２０ヘテロアリール、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＨＲ^２’、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_６-Ｃ_２０アリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキレン)-ＮＨＣ(＝Ｏ)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-Ｎ(Ｃ_１-Ｃ_１２アルキル)Ｒ^２’、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_１-Ｃ_１２アルキル)-Ｎ(Ｃ_１-Ｃ_１２アルキル)Ｒ^２’、
-(Ｃ_２-Ｃ_１２アルケニレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_２０ヘテロアリール)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_２０ヘテロアリール)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-Ｃ(＝Ｏ)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ ヘテロシクリル)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-Ｃ(＝Ｏ)-(Ｃ_１-Ｃ_１２アルキル)、
-Ｃ(＝Ｏ)-ＮＲ^２’-(Ｃ_１-Ｃ_１２アルキル)、及び
-ＣＲ^４＝ＣＲ^５Ｒ^６から選択され、ここで、Ｒ^４はＨ、Ｆ、Ｃｌ、Ｂｒ、Ｉ、及びＣ_１-Ｃ_１２アルキルから選択され、Ｒ^５及びＲ^６はＣ_２-Ｃ_２０ヘテロシクリル、Ｃ_１-Ｃ_２０ヘテロアリール、又はＣ_３-Ｃ_１２カルボシクリルを形成し、
ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール、及びヘテロアリールは、Ｆ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＣＨ_３、-ＣＨ_２ＣＨ(ＣＨ_３)_２、-ＣＨ_２ＮＨ_２、-ＣＨ_２Ｎ(ＣＨ_３)_２、-ＣＨ_２ＣＨ_２ＮＨ_２、-ＣＨ_２ＣＨ_２Ｎ(ＣＨ_３)_２、-ＣＨ_２ＯＨ、-ＣＨ_２ＯＣＨ_３、-ＣＨ_２ＣＨ_２ＯＨ、-Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ_２Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ(ＯＨ)ＣＨ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_２ＣＨ_２ＯＨ、-ＣＨ_２ＣＨ_２ＳＯ_２ＣＨ_３、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＨＯ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯ_２Ｃ(ＣＨ_３)_３、-ＣＯＣＨ_２ＯＨ、-ＣＯＣ(ＯＨ)(ＣＨ_３)_２、-ＣＯＣＨ(ＯＨ)ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＣＨ_２ＣＯＮＨ_２、-ＣＨ_２ＣＯＮ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_２ＣＯＮＨ_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-Ｎ(ＣＨ_３)_２、-ＮＨＣＯＣＨ_３、-Ｎ(ＣＨ_３)ＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、-Ｎ(ＣＨ_３)Ｃ(ＣＨ_３)_２ＣＯＮＨ_２、-Ｎ(ＣＨ_３)ＣＨ_２ＣＨ_２Ｓ(Ｏ)_２ＣＨ_３、＝Ｏ、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、-Ｓ(Ｏ)_２ＣＨ_３、-Ｃ(Ｏ)-シクロプロピル、シクロプロピル、シクロブチル、オキセタニル、及びモルホリノから独立して選択される一又は複数の基で置換されていてもよく；
Ｒ^２及びＲ^２’は、Ｈ、Ｃ_１-Ｃ_１２アルキル、Ｃ_２-Ｃ_８アルケニル、Ｃ_２-Ｃ_８アルキニル、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)、及び-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)から独立して選択され、ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール、及びヘテロアリールは、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＯＨ、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、及び-Ｓ(Ｏ)_２ＣＨ_３から独立して選択される一又は複数の基で置換されていてもよく； Compounds of Formula I of the Invention Compounds of formula I are represented by formulas Ia and Ib:

And a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof selected from
Where (i) X ¹ is N, X ² is S, (ii) X ¹ is CR ⁷ , X ² is S, (iii) X ¹ is N, X ² Is NR ² or (iv) X ¹ is CR ⁷ and X ² is O;
R ¹ is
C ₁ -C ₁₂ alkyl,
C ₂ -C ₈ alkenyl,
C ₂ -C ₈ alkynyl,
C ₆ -C ₂₀ aryl,
C ₂ -C ₂₀ heterocyclyl,
C ₃ -C ₁₂ carbocyclyl,
C ₁ -C ₂₀ heteroaryl,
-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 6} -C ₂₀ aryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) -NHR ² ',
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 3}} -C 12 carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 2}} -C 20 heterocyclyl),
-(C ₁ -C ₁₂ alkylene) -NR ² '-(C ₁ -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 6}} -C 20 aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heterocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 6} -C ₂₀ aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) -NHC (= O) - ( C 1 -C 20 heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 2} -C ₁₂ alkenylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 3} -C ₁₂ carbocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl),
_{-C (= O) - (C} 1 -C 20 heteroaryl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 1} -C ₂₀ heteroaryl),
_{-C (= O) - (C} 1 -C 12 alkyl),
^{-C (= O) -NR 2 '} - (C 1 -C 12 alkyl), and
-CR ⁴ = CR ⁵ selected from R ⁶ , wherein R ⁴ is selected from H, F, Cl, Br, I, and C ₁ -C ₁₂ alkyl, and R ⁵ and R ⁶ are C ₂ -C ₂₀ Forming a heterocyclyl, C ₁ -C ₂₀ heteroaryl, or C ₃ -C ₁₂ carbocyclyl;
Here, alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH (CH ₃ ) ₂ , _{-CH 2 NH 2, -CH 2 N} (CH 3) 2, -CH 2 CH 2 NH 2, -CH 2 CH 2 N (CH 3) 2, -CH 2 OH, -CH 2 OCH 3, -CH 2 _{CH 2 OH, -C (CH 3} ) 2 OH, -CH 2 C (CH 3) 2 OH, -CH (OH) CH (CH 3) 2, -C (CH 3) 2 CH 2 OH, -CH 2 CH ₂ SO ₂ CH ₃ , —CN, —CF ₃ , —CO ₂ H, —CHO, —COCH ₃ , —CO ₂ CH ₃ , —CO ₂ C (CH ₃ ) ₃ , —COCH ₂ OH, —COC ( OH) (CH ₃ ) ₂ , —COCH (OH) CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —CH ₂ CONH ₂ , —CH ₂ CON (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CONH ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , —NHCOCH ₃ , —N (CH ₃ ) COCH ₃ , —NHS (O) ₂ CH ₃ , —N (CH ₃ ) C (CH ₃ ) ₂ CONH ₂ , —N (CH ₃ ) CH ₂ CH ₂ S (O) ₂ CH ₃ , ═O, —OH, —OCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , —S (O) ₂ Optionally substituted with one or more groups independently selected from CH ₃ , —C (O) -cyclopropyl, cyclopropyl, cyclobutyl, oxetanyl, and morpholino;
R ² and R ² ′ are H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl), -(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene) -C (═O)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene)-(C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene , Carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO _{2 CH 3, -CONH 2, -CONHCH} 3, -CO _{(CH 3) 2, -NO 2} , -NH 2, -NHCH 3, -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2 Optionally substituted with one or more groups independently selected from -SCH ₃ , -CH ₂ OCH ₃ , and -S (O) ₂ CH ₃ ;

から選択される二環式ヘテロアリール基であり、
ここで波線は結合部分を示し；
Ｃ_１-Ｃ_１２アルキル、Ｃ_２-Ｃ_８アルケニル、Ｃ_２-Ｃ_８アルキニル、Ｃ_３-Ｃ_１２カルボシクリル、Ｃ_２-Ｃ_２０ヘテロシクリル、Ｃ_６-Ｃ_２０アリール、Ｃ_１-Ｃ_２０ヘテロアリール、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-ＮＨ-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-Ｎ(Ｃ_１-Ｃ_１２アルキル)-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-ＮＨ-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-Ｏ-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-ＮＨ-(Ｃ_３-Ｃ_１２カルボシクリル)、-Ｏ-(Ｃ_３-Ｃ_１２カルボシクリル)、Ｆ、Ｃｌ、Ｂｒ、Ｉ、-ＣＮ、-ＣＯ_２Ｈ、-ＣＯＮＨ_２、-ＣＯＮＨ(Ｃ_１-Ｃ_１２アルキル)、-ＣＯＮ(Ｃ_１-Ｃ_１２アルキル)_２、-ＣＯ(Ｃ_１-Ｃ_１２アルキル)、-ＮＯ_２、-ＮＨ_２、-ＮＨ(Ｃ_１-Ｃ_１２アルキル)、-Ｎ(Ｃ_１-Ｃ_１２アルキル)_２、-ＮＨＣＯ(Ｃ_１-Ｃ_１２アルキル)、-ＮＨＳ(Ｏ)_２(Ｃ_１-Ｃ_１２アルキル)、-Ｎ(Ｃ_１-Ｃ_１２アルキル)Ｓ(Ｏ)_２(Ｃ_１-Ｃ_１２アルキル)、-ＯＨ、-Ｏ(Ｃ_１-Ｃ_１２アルキル)、-ＮＨＣ(＝Ｏ)ＮＨ(Ｃ_１-Ｃ_１２アルキル)、-ＳＨ、-Ｓ(Ｃ_１-Ｃ_１２アルキル)、-Ｓ(Ｏ)(Ｃ_１-Ｃ_１２アルキル)、-Ｓ(Ｏ)_２(Ｃ_１-Ｃ_１２アルキル)、-Ｓ(Ｏ)_２ＮＨ_２、-Ｓ(Ｏ)_２ＮＨ(Ｃ_１-Ｃ_１２アルキル)、及び-Ｓ(Ｏ)_２Ｎ(Ｃ_１-Ｃ_１２アルキル)_２から独立して選択される一又は複数の基で置換されていてもよく、ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール、及びヘテロアリールは、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、＝Ｏ、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＨ、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、及び-Ｓ(Ｏ)_２ＣＨ_３から独立して選択される一又は複数の基で置換されていてもよく； R ³ is

A bicyclic heteroaryl group selected from
Where the wavy line indicates the coupling part;
C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl, C ₃ -C ₁₂ carbocyclyl, C ₂ -C ₂₀ heterocyclyl, C ₆ -C ₂₀ aryl, C ₁ -C ₂₀ heteroaryl, -(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), -NH- (C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), -N (C ₁ -C ₁₂ alkyl) -(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), -NH- (C ₂ -C ₂₀ heterocyclyl), -O- (C ₂ -C ₂₀ heterocyclyl), -NH- (C _3- C ₁₂ carbocyclyl), —O— (C ₃ -C ₁₂ carbocyclyl), F, Cl, Br, I, —CN, —CO ₂ H, —CONH ₂ , —CONH (C ₁ -C ₁₂ alkyl), —CON _{(C 1} -C _{12 alkyl) 2, -CO (C 1 -C} 12 alkyl), - NO _{2 -NH 2, -NH (C 1 -C} 12 _{alkyl), - N (C 1 -C} 12 _{alkyl) 2, -NHCO (C 1 -C} 12 _{alkyl), - NHS (O) 2} (C 1 -C 12 Alkyl), —N (C ₁ -C ₁₂ alkyl) S (O) ₂ (C ₁ -C ₁₂ alkyl), —OH, —O (C ₁ -C ₁₂ alkyl), —NHC (═O) NH (C ₁ -C _{12 alkyl), - SH, -S (C} 1 -C 12 alkyl), - S (O) ( C 1 -C 12 _{alkyl), - S (O) 2} (C 1 -C 12 alkyl), One independently selected from -S (O) ₂ NH ₂ , -S (O) ₂ NH (C ₁ -C ₁₂ alkyl), and -S (O) ₂ N (C ₁ -C ₁₂ alkyl) ₂ Or may be substituted with multiple groups, where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl may optionally be F, Cl, B _{r, I, -CN, -CF 3} , -CO 2 H, -COCH 3, -CO 2 CH 3, -CONH 2, -CONHCH 3, -CON (CH 3) 2, -NO 2, -NH 2, _{-NHCH 3, -NHCOCH 3, -NHS (} O) 2 CH 3, = O, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SH, -SCH 3, -CH 2 Optionally substituted with one or more groups independently selected from OCH ₃ and —S (O) ₂ CH ₃ ;

R ⁷ is H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),-(C ₁ -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl), - _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl), - _{(C 1} -C ₁₂ alkylene) - Selected from (C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, And heteroaryl may optionally be F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO ₂ CH ₃ , —CONH _2. , -CONHCH ₃ , -CON (CH ₃ ) ₂ , -N _{O 2, -NH 2, -NHCH 3} , -NHCOCH 3, -NHS (O) 2 CH 3, = O, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3 It may be substituted with one or more groups independently selected from -CH ₂ OCH _3, and -S (O) ₂ CH _3;

から選択される二環式構造であり、
場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＣＨ_３、-ＣＨ_２ＣＨ_２ＣＨ_３、-ＣＨ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_３、-ＣＨ_２ＯＣＨ_３、-ＣＨＦ_２、-ＣＮ、-ＣＦ_３、-ＣＨ_２ＯＨ、-ＣＨ_２ＯＣＨ_３、-ＣＨ_２ＣＨ_２ＯＨ、-ＣＨ_２Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ(ＣＨ_３)ＯＨ、-ＣＨ(ＣＨ_２ＣＨ_３)ＯＨ、-ＣＨ_２ＣＨ(ＯＨ)ＣＨ_３、-Ｃ(ＣＨ_３)_２ＯＨ、-Ｃ(ＣＨ_３)_２ＯＣＨ_３、-ＣＨ(ＣＨ_３)Ｆ、-Ｃ(ＣＨ_３)Ｆ_２、-ＣＨ(ＣＨ_２ＣＨ_３)Ｆ、-Ｃ(ＣＨ_２ＣＨ_３)_２Ｆ、-ＣＯ_２Ｈ、-ＣＯＮＨ_２、-ＣＯＮ(ＣＨ_２ＣＨ_３)２、-ＣＯＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-Ｎ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_３、-ＮＨＣＨ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_２ＯＨ、-ＮＨＣＨ_２ＣＨ_２ＯＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＣＯＣＨ_２ＣＨ_３、-ＮＨＣＯＣＨ_２ＯＨ、-ＮＨＳ(Ｏ)_２ＣＨ_３、-Ｎ(ＣＨ_３)Ｓ(Ｏ)_２ＣＨ_３、＝Ｏ、-ＯＨ、-ＯＣＨ_３、-ＯＣＨ_２ＣＨ_３、-ＯＣＨ(ＣＨ_３)_２、-ＳＨ、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_３、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_２ＣＨ_３、-Ｓ(Ｏ)ＣＨ_３、-Ｓ(Ｏ)ＣＨ_２ＣＨ_３、-Ｓ(Ｏ)_２ＣＨ_３、-Ｓ(Ｏ)_２ＮＨ_２、-Ｓ(Ｏ)_２ＮＨＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＣＨ_２Ｓ(Ｏ)_２ＣＨ_３から選択される一又は複数の基で置換されていてもよく；
ここでｐ１１０δに対するＩＣ５０結合活性は、ｐ１１０αに対する結合活性より１０倍又はそれ以上低く；
但し、（ｉｉ）Ｘ^１がＣＲ^７であり、Ｘ^２がＳであり、Ｒ^１が-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)であり、Ｒ^３が置換されていてもよいベンゾ[ｄ]イミダゾール-１-イルであり、Ｒ^７がＨである式Ｉｂの化合物は、-Ｓ(Ｏ)_２ＣＨ_３で置換されたＲ^１のＣ_２-Ｃ_２０ヘテロシクリルを除く。 mor is a morpholine group or

A bicyclic structure selected from
In some cases, F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) ₃ , —CH ₂ OCH _{3 , -CHF 2, -CN, -CF 3} , -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -CH 2 C (CH 3) 2 OH, -CH (CH 3) OH, - CH (CH ₂ CH ₃ ) OH, —CH ₂ CH (OH) CH ₃ , —C (CH ₃ ) ₂ OH, —C (CH ₃ ) ₂ OCH ₃ , —CH (CH ₃ ) F, —C (CH _{3) F 2, -CH (CH} 2 CH 3) F, -C (CH 2 CH 3) 2 F, -CO 2 H, -CONH 2, -CON (CH 2 CH 3) 2, -COCH 3, - _{CON (CH 3) 2, -NO} 2, -NH 2, -NHCH 3, -N (CH 3) 2, -NHCH 2 CH 3, -NHCH (CH 3) 2, -NHCH 2 CH 2 OH, - _{HCH 2 CH 2 OCH 3, -NHCOCH} 3, -NHCOCH 2 CH 3, -NHCOCH 2 OH, -NHS (O) 2 CH 3, -N (CH 3) S (O) 2 CH 3, = O, -OH , —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O) NHCH ₂ CH ₃ , —S (O) CH ₃ , _{-S (O) CH 2 CH 3} , -S (O) 2 CH 3, -S (O) 2 NH 2, -S (O) 2 NHCH 3, -S (O) 2 N (CH 3) 2, Optionally substituted with one or more groups selected from —CH ₂ S (O) ₂ CH ₃ ;
Where the IC50 binding activity for p110δ is 10 times or more lower than the binding activity for p110α;
However, (ii) ^{X 1} is CR ^7, an ^{X 2} is S, ^{R 1} is - _{(C 1} -C ₁₂ alkylene) - a _{(C 2} -C ₂₀ heterocyclyl), ^{R 3} is optionally substituted and is also good benzo [d] imidazol-1-yl, the compounds of formula Ib ^{R 7} is H, except for _{C 2} -C ₂₀ heterocyclyl of ^{R 1} substituted with -S (O) ₂ CH ₃ .

を有する、ｍｏｒが未置換モルホリンであるものを含む。 Exemplary Formula I compounds have the structures Ic and Id:

In which mor is unsubstituted morpholine.

を含む。 Exemplary compounds of formula I are (i) thiazolopyrimidines wherein X ¹ is N and X ² is S:

including.

を含む。 Exemplary compounds of formula I are (ii) thienopyrimidines wherein X ¹ is CR ⁷ and X ² is S:

including.

を含む。 Exemplary compounds of formula I include (iii) purines where X ¹ is N and X ² is NR ² :

including.

を含む。 Exemplary Formula I compounds are: (iv) Furanopyrimidines where X ¹ is CR ⁷ and X ² is O:

including.

から選択され、ここで、式中の波線はピリミジン環の４位への結合点を示す。 In a further exemplary embodiment, mor has the structure:

Where the wavy line in the formula indicates the point of attachment to the 4-position of the pyrimidine ring.

を含み、ここで、波線は式Ｉの構造への結合部位を示す。 Exemplary embodiments of R ¹ include groups

Where the wavy line indicates the binding site to the structure of Formula I.

を含む。 Exemplary embodiments of R ¹ are also groups:

including.

から選択される基から独立して選択される一又は複数の基で置換されたＲ^３二環式ヘテロアリールを含む。 Exemplary embodiments include F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) ₃ , — _{CH 2 OCH 3, -CHF 2,} -CH 2 CN, -CN, -CF 3, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, -CH ₂ C (CH ₃ ) ₂ OH, —CH (CH ₃ ) OH, —CH (CH ₂ CH ₃ ) OH, —CH ₂ CH (OH) CH ₃ , —CH ₂ CH (OCH ₃ ) CH ₃ , —C (CH ₃ ) ₂ OH, —CH (CH ₃ ) OCH ₃ , —C (CH ₃ ) ₂ OCH ₃ , —CH (CH ₃ ) F, —C (CH ₃ ) F ₂ , —CH (CH ₂ CH _{3 ) F, -C (CH 2 CH} 3) 2 F, -C (CH 2 CH 3) F 2, -CO 2 H, -CONH 2, -CON (CH 2 CH 3) 2, -COCH 3, -CON (C H ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , —NHCH ₂ CH ₃ , —NHCH (CH ₃ ) ₂ , —NHCH ₂ CH ₂ OH, —NHCH ₂ CH ₂ OCH ₃ , —NHCOCH ₃ , —NHCOCH ₂ CH ₃ , —NHCOCH ₂ OH, —NHS (O) ₂ CH ₃ , —N (CH ₃ ) S (O) ₂ CH ₃ , —OH, —OCH ₃ , — OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O) NHCH ₂ CH ₃ , —S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —CH ₂ S (O ) ₂ CH ₃ , and

R ³ bicyclic heteroaryl substituted with one or more groups independently selected from groups selected from:

を有するプリンであるものを含み、
ここで、Ｒ^８は、Ｈ、Ｆ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＣＨ_３、-ＣＨ_２ＣＨ_２ＣＨ_３、-ＣＨ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_３、-ＣＨ_２ＯＣＨ_３、-ＣＨＦ_２、-ＣＨ_２ＣＮ、-ＣＮ、-ＣＦ_３、-ＣＨ_２ＯＨ、-ＣＨ_２ＯＣＨ_３、-ＣＨ_２ＣＨ_２ＯＨ、-ＣＨ_２Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ(ＣＨ_３)ＯＨ、-ＣＨ(ＣＨ_２ＣＨ_３)ＯＨ、-ＣＨ_２ＣＨ(ＯＨ)ＣＨ_３、-ＣＨ_２ＣＨ(ＯＣＨ_３)ＣＨ_３、-Ｃ(ＣＨ_３)_２ＯＨ、-Ｃ(ＣＨ_３)_２ＯＣＨ_３、-ＣＨ(ＣＨ_３)Ｆ、-Ｃ(ＣＨ_３)Ｆ_２、-ＣＨ(ＣＨ_２ＣＨ_３)Ｆ、-Ｃ(ＣＨ_２ＣＨ_３)_２Ｆ、-ＣＯ_２Ｈ、-ＣＯＮＨ_２、-ＣＯＮ(ＣＨ_２ＣＨ_３)２、-ＣＯＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-Ｎ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_３、-ＮＨＣＨ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_２ＯＨ、-ＮＨＣＨ_２ＣＨ_２ＯＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＣＯＣＨ_２ＣＨ_３、-ＮＨＣＯＣＨ_２ＯＨ、-ＮＨＳ(Ｏ)_２ＣＨ_３、-Ｎ(ＣＨ_３)Ｓ(Ｏ)_２ＣＨ_３、-ＯＨ、-ＯＣＨ_３、-ＯＣＨ_２ＣＨ_３、-ＯＣＨ(ＣＨ_３)_２、-ＳＨ、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_３、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_２ＣＨ_３、-Ｓ(Ｏ)ＣＨ_３、-Ｓ(Ｏ)ＣＨ_２ＣＨ_３、-Ｓ(Ｏ)_２ＣＨ_３、-Ｓ(Ｏ)_２ＮＨ_２、-Ｓ(Ｏ)_２ＮＨＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＣＨ_２Ｓ(Ｏ)_２ＣＨ_３、及び

から選択される基から選択される。 Exemplary embodiments include R ³ bicyclic heteroaryl having the structure:

Including pudding having
Here, R ⁸ is H, F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) _3. , —CH ₂ OCH ₃ , —CHF ₂ , —CH ₂ CN, —CN, —CF ₃ , —CH ₂ OH, —CH ₂ OCH ₃ , —CH ₂ CH ₂ OH, —CH ₂ C (CH ₃ ) _{2 OH, -CH (CH 3) OH} , -CH (CH 2 CH 3) OH, -CH 2 CH (OH) CH 3, -CH 2 CH (OCH 3) CH 3, -C (CH 3) 2 OH, _{-C (CH 3) 2 OCH 3} , -CH (CH 3) F, -C (CH 3) F 2, -CH (CH 2 CH 3) F, -C (CH 2 CH 3) 2 F, -CO _{2 H, -CONH 2, -CON (} CH 2 CH 3) 2, -COCH 3, -CON (CH 3) 2, -NO 2, -NH 2, -NHCH 3, -N (CH 3) 2, - NHCH ₂ CH _{, -NHCH (CH 3) 2,} -NHCH 2 CH 2 OH, -NHCH 2 CH 2 OCH 3, -NHCOCH 3, -NHCOCH 2 CH 3, -NHCOCH 2 OH, -NHS (O) 2 CH 3, -N (CH ₃ ) S (O) ₂ CH ₃ , —OH, —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O ) NHCH ₂ CH ₃ , —S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH _{3 , -S (O) 2 N (} CH 3) 2, -CH 2 S (O) 2 CH 3 and,

Selected from the group selected from

R ⁹ is F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , —CH _{2 OH, -CH 2 CH 2 OH} , -CN, -CF 3, -CO 2 H, -COCH 3, -CO 2 CH 3, -CONH 2, -CONHCH 3, -CON (CH 3) 2, -NO _{2, -NH 2, -NHCH 3,} -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, -CH 2 Independently selected from OCH ₃ and —S (O) ₂ CH ₃ ;
n is 0, 1, 2, 3, or 4.

を含む。 Exemplary Formula I compounds have the structure:

including.

及びその立体異性体、幾何異性体、互変異性体、又は薬学的に許容可能な塩から選択される化合物を含み、
ここで、（ｉ）Ｘ^１はＮであり、Ｘ^２はＳであり、（ｉｉ）Ｘ^１はＣＲ^７であり、Ｘ^２はＳであり、（ｉｉｉ）Ｘ^１はＮであり、Ｘ^２はＮＲ^２であり、又は（ｉｖ）Ｘ^１はＣＲ^７であり、Ｘ^２はＯであり；
Ｒ^１は、
Ｃ_１-Ｃ_１２アルキル、
Ｃ_２-Ｃ_８アルケニル、
Ｃ_２-Ｃ_８アルキニル、
Ｃ_６-Ｃ_２０アリール、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_３-Ｃ_１２カルボシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＨＲ^２、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２-(Ｃ_１-Ｃ_１２アルキル)、
-(Ｃ_１-Ｃ_１２アルキレン)-Ｎ(Ｃ_１-Ｃ_１２アルキル)(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロシクリル)、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２-(Ｃ_１-Ｃ_１２アルキレン)-ＮＨＣ(＝Ｏ)-(Ｃ_１-Ｃ_２０ヘテロアリール)、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-Ｎ(Ｃ_１-Ｃ_１２アルキル)Ｒ^２、
-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)-(Ｃ_１-Ｃ_１２アルキル)-Ｎ(Ｃ_１-Ｃ_１２アルキル)Ｒ^２、
-(Ｃ_１-Ｃ_１２アルキレン)-ＮＲ^２-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-(Ｃ_２-Ｃ_１２アルケニレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-ＮＲ^２-(Ｃ_２-Ｃ_２０ヘテロシクリル)、
-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、及び
-Ｃ(＝Ｏ)-(Ｃ_１-Ｃ_１２アルキル)
から選択され、
ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール、及びヘテロアリールは、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＣＨ_３、-ＣＨ_２ＣＨ(ＣＨ_３)_２、-ＣＨ_２ＯＨ、-ＣＨ_２ＣＨ_２ＯＨ、-Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ(ＯＨ)ＣＨ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_２ＣＨ_２ＯＨ、-ＣＨ_２ＣＨ_２ＳＯ_２ＣＨ_３、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯ_２Ｃ(ＣＨ_３)_３、-ＣＯＣＨ(ＯＨ)ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_２ＣＯＮＨ_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-Ｎ(ＣＨ_３)_２、-ＮＨＣＯＣＨ_３、-Ｎ(ＣＨ_３)ＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、-Ｎ(ＣＨ_３)Ｃ(ＣＨ_３)_２ＣＯＮＨ_２、-Ｎ(ＣＨ_３)ＣＨ_２ＣＨ_２Ｓ(Ｏ)_２ＣＨ_３、＝Ｏ、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、-Ｓ(Ｏ)_２ＣＨ_３、シクロプロピル、オキセタニル、及びモルホリノから独立して選択される一又は複数の基で置換されていてもよく；
Ｒ^２は、Ｈ、Ｃ_１-Ｃ_１２アルキル、Ｃ_２-Ｃ_８アルケニル、Ｃ_２-Ｃ_８アルキニル、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)、及び-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)から選択され、ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール、及びヘテロアリールは、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＯＨ、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、及び-Ｓ(Ｏ)_２ＣＨ_３から独立して選択される一又は複数の基で置換されていてもよく；
Ｒ^３は、

から選択され、ここで、波線は結合部位を示し；
その各々が、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＣＨ_３、-ＣＨ_２ＣＨ_２ＣＨ_３、-ＣＨ(ＣＨ_３)_２、-Ｃ(ＣＨ_３)_３、-ＣＨ_２ＯＣＨ_３、-ＣＨＦ_２、-ＣＮ、-ＣＦ_３、-ＣＨ_２ＯＨ、-ＣＨ_２ＯＣＨ_３、-ＣＨ_２ＣＨ_２ＯＨ、-ＣＨ_２Ｃ(ＣＨ_３)_２ＯＨ、-ＣＨ(ＣＨ_３)ＯＨ、-ＣＨ(ＣＨ_２ＣＨ_３)ＯＨ、-ＣＨ_２ＣＨ(ＯＨ)ＣＨ_３、-ＣＨ_２ＣＨ(ＯＣＨ_３)ＣＨ_３、-Ｃ(ＣＨ_３)_２ＯＨ、-Ｃ(ＣＨ_３)_２ＯＣＨ_３、-ＣＨ(ＣＨ_３)Ｆ、-Ｃ(ＣＨ_３)Ｆ_２、-ＣＨ(ＣＨ_２ＣＨ_３)Ｆ、-Ｃ(ＣＨ_２ＣＨ_３)_２Ｆ、-ＣＯ_２Ｈ、-ＣＯＮＨ_２、-ＣＯＮ(ＣＨ_２ＣＨ_３)２、-ＣＯＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-Ｎ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_３、-ＮＨＣＨ(ＣＨ_３)_２、-ＮＨＣＨ_２ＣＨ_２ＯＨ、-ＮＨＣＨ_２ＣＨ_２ＯＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＣＯＣＨ_２ＣＨ_３、-ＮＨＣＯＣＨ_２ＯＨ、-ＮＨＳ(Ｏ)_２ＣＨ_３、-Ｎ(ＣＨ_３)Ｓ(Ｏ)_２ＣＨ_３、＝Ｏ、-ＯＨ、-ＯＣＨ_３、-ＯＣＨ_２ＣＨ_３、-ＯＣＨ(ＣＨ_３)_２、-ＳＨ、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_３、-ＮＨＣ(＝Ｏ)ＮＨＣＨ_２ＣＨ_３、-Ｓ(Ｏ)ＣＨ_３、-Ｓ(Ｏ)ＣＨ_２ＣＨ_３、-Ｓ(Ｏ)_２ＣＨ_３、-Ｓ(Ｏ)_２ＮＨ_２、-Ｓ(Ｏ)_２ＮＨＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＣＨ_２Ｓ(Ｏ)_２ＣＨ_３、及び

から選択される基から独立して選択される一又は複数の基で置換されていてもよく、
Ｒ^７は、Ｈ、Ｃ_１-Ｃ_１２アルキル、Ｃ_２-Ｃ_８アルケニル、Ｃ_２-Ｃ_８アルキニル、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_３-Ｃ_１２カルボシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-Ｃ(＝Ｏ)-(Ｃ_２-Ｃ_２０ヘテロシクリル)、-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_６-Ｃ_２０アリール)、及び-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_１-Ｃ_２０ヘテロアリール)から選択され、ここで、アルキル、アルケニル、アルキニル、アルキレン、カルボシクリル、ヘテロシクリル、アリール及びヘテロアリールは、場合によってはＦ、Ｃｌ、Ｂｒ、Ｉ、-ＣＨ_３、-ＣＨ_２ＯＨ、-ＣＮ、-ＣＦ_３、-ＣＯ_２Ｈ、-ＣＯＣＨ_３、-ＣＯ_２ＣＨ_３、-ＣＯＮＨ_２、-ＣＯＮＨＣＨ_３、-ＣＯＮ(ＣＨ_３)_２、-ＮＯ_２、-ＮＨ_２、-ＮＨＣＨ_３、-ＮＨＣＯＣＨ_３、-ＮＨＳ(Ｏ)_２ＣＨ_３、-ＯＨ、-ＯＣＨ_３、-Ｓ(Ｏ)_２Ｎ(ＣＨ_３)_２、-ＳＣＨ_３、-ＣＨ_２ＯＣＨ_３、及び-Ｓ(Ｏ)_２ＣＨ_３から独立して選択される一又は複数の基で置換されていてもよく；
またここで、ｐ１１０δに対するＩＣ５０結合活性は、ｐ１１０αに対する結合活性より１０倍又はそれ以上低く；
但し、(ｉｉ)Ｘ^１がＣＲ^７であり、Ｘ^２がＳであり、Ｒ^１が-(Ｃ_１-Ｃ_１２アルキレン)-(Ｃ_２-Ｃ_２０ヘテロシクリル)であり、Ｒ^３が置換されていてもよいベンゾ[ｄ]イミダゾール-１-イルであり、Ｒ^７がＨである式Ｉｆの化合物は、-Ｓ(Ｏ)_２ＣＨ_３で置換されたＲ^１のＣ_２-Ｃ_２０ヘテロシクリルを除く。 Exemplary Formula I compounds are Formulas Ie and If:

And a compound selected from stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof,
Where (i) X ¹ is N, X ² is S, (ii) X ¹ is CR ⁷ , X ² is S, (iii) X ¹ is N, X ² Is NR ² or (iv) X ¹ is CR ⁷ and X ² is O;
R ¹ is
C ₁ -C ₁₂ alkyl,
C ₂ -C ₈ alkenyl,
C ₂ -C ₈ alkynyl,
C ₆ -C ₂₀ aryl,
-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 6} -C ₂₀ aryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) -NHR ^2,
- _{(C 1} -C _{12 ^{alkylene) -NR 2 - (C 1 -C}} 12 alkyl),
- _{(C 1} -C ₁₂ alkylene) -N _{(C 1} -C ₁₂ alkyl) _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 - (C 1 -C}} 12 alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 - (C 1 -C}} 12 alkylene) - _{(C 1} -C ₂₀ heterocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 - (C 1 -C}} 12 alkylene) -NHC (= O) - ( C 1 -C 20 heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -N _{(C 1} -C ₁₂ ^{alkyl) R} 2,
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl) -N _{(C 1} -C ₁₂ ^{alkyl) R} 2,
- _{(C 1} -C _{12 ^{alkylene) -NR 2 - (C 2 -C}} 20 heterocyclyl),
- _{(C 2} -C ₁₂ alkenylene) - _{(C 2} -C ₂₀ heterocyclyl),
-NR _² - _(C ² -C ₂₀ heterocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl), and
_{-C (= O) - (C} 1 -C 12 alkyl)
Selected from
Here, alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH (CH ₃ ) ₂ , —CH ₂ OH, —CH ₂ CH ₂ OH, —C (CH ₃ ) ₂ OH, —CH (OH) CH (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CH ₂ OH, —CH ₂ CH ₂ SO ₂ CH ₃ , —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO ₂ CH ₃ , —CO ₂ C (CH ₃ ) ₃ , —COCH (OH) CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CONH ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , —NHCOCH ₃ , —N ( CH ₃ ) COCH ₃ , —NHS (O) ₂ CH ₃ , —N (CH ₃ ) C _{(CH 3) 2 CONH 2,} -N (CH 3) CH 2 CH 2 S (O) 2 CH 3, = O, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, - May be substituted with one or more groups independently selected from SCH ₃ , —CH ₂ OCH ₃ , —S (O) ₂ CH ₃ , cyclopropyl, oxetanyl, and morpholino;
R ² is H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),-(C ₁ -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl), - _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl), - _{(C 1} -C ₁₂ alkylene) - Selected from (C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, And heteroaryl may optionally be F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO ₂ CH ₃ , —CONH _2. , -CONHCH ₃ , -CON (CH ₃ ) ₂ , -N _{O 2, -NH 2, -NHCH 3} , -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, -CH Optionally substituted with one or more groups independently selected from ₂ OCH ₃ and —S (O) ₂ CH ₃ ;
R ³ is

Where the wavy line indicates the binding site;
Each may optionally be F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) ₃ , — _{CH 2 OCH 3, -CHF 2,} -CN, -CF 3, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -CH 2 C (CH 3) 2 OH, -CH (CH 3 ) OH, —CH (CH ₂ CH ₃ ) OH, —CH ₂ CH (OH) CH ₃ , —CH ₂ CH (OCH ₃ ) CH ₃ , —C (CH ₃ ) ₂ OH, —C (CH ₃ ) ₂ OCH ₃ , —CH (CH ₃ ) F, —C (CH ₃ ) F ₂ , —CH (CH ₂ CH ₃ ) F, —C (CH ₂ CH ₃ ) ₂ F, —CO ₂ H, —CONH ₂ , _{-CON (CH 2 CH 3) 2} , -COCH 3, -CON (CH 3) 2, -NO 2, -NH 2, -NHCH 3, -N (CH 3) 2, -NHCH 2 CH 3, -NH _{H (CH 3) 2, -NHCH} 2 CH 2 OH, -NHCH 2 CH 2 OCH 3, -NHCOCH 3, -NHCOCH 2 CH 3, -NHCOCH 2 OH, -NHS (O) 2 CH 3, -N (CH _{3) S (O) 2 CH} 3, = O, -OH, -OCH 3, -OCH 2 CH 3, -OCH (CH 3) 2, -SH, -NHC (= O) NHCH 3, -NHC (= O) NHCH ₂ CH ₃ , —S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —CH ₂ S (O) ₂ CH ₃ , and

May be substituted with one or more groups independently selected from the group selected from
R ⁷ is H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),-(C ₁ -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl), - _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl), - _{(C 1} -C ₁₂ alkylene) - Selected from (C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl and Heteroaryl is optionally F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO ₂ CH ₃ , —CONH ₂ , -CONHCH ₃ , -CON (CH ₃ ) ₂ , -NO _{2, -NH 2, -NHCH 3,} -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, -CH 2 Optionally substituted with one or more groups independently selected from OCH ₃ and —S (O) ₂ CH ₃ ;
Also here, the IC50 binding activity for p110δ is 10 times or more lower than the binding activity for p110α;
Provided that (ii) X ¹ is CR ⁷ , X ² is S, R ¹ is — (C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), and R ³ is substituted and is also good benzo [d] imidazol-1-yl, the compounds of formula the If ^{R 7} is H, except for _{C 2} -C ₂₀ heterocyclyl of ^{R 1} substituted with -S (O) ₂ CH ₃ .

  The compounds of formula I of the present invention contain asymmetric or chiral centers and may therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to diastereomers, enantiomers and atropisomers, and mixtures thereof, eg racemic mixtures, form part of the invention.

  The invention also includes all geometric and positional isomers. For example, where a compound of Formula I contains a double bond or fused ring, cis and trans forms, and mixtures thereof are included within the scope of the invention. Both single regioisomers or mixtures of regioisomers are also within the scope of the invention.

  In the structure shown here, if the stereochemistry of any particular chiral atom is not specified, all stereoisomers are considered and included as compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular structure, that stereoisomer is so identified and defined.

  The compounds of the present invention may exist in unsolvated forms as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the invention encompasses both solvated and unsolvated forms. Is intended to be.

  The compounds of the invention may also exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The terms “tautomer” or “tautomeric form” refer to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as proton transfer tautomers) include interconversions through proton transfer, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

The present invention is the same as that described herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Also included are isotopically labeled compounds. All isotopes of any particular atom or element identified are considered within the scope of the compounds of the invention and their uses. Exemplary isotopes that can be introduced into the compounds of the present invention are hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine isotopes, such as ² H, ³ H, ¹¹ C, ¹³ C, ¹⁴ C, ¹³ N, ¹⁵ N, ¹⁵ O, ¹⁷ O, ¹⁸ O, ³² P, ³³ P, ³⁵ S, ¹⁸ F, ³⁶ Cl, ¹²³ I and ¹²⁵ I. Certain isotopically-labeled compounds of the present invention (eg, those labeled with ³ H and ¹⁴ C) are useful in compound and / or substrate tissue distribution assays. Tritium ( ³ H) and carbon-14 ( ¹⁴ C) isotopes are useful for their preparation and ease of detection. Furthermore, substitution with heavier isotopes such as deuterium (ie ² H) may result in certain therapeutic benefits arising from greater metabolic stability (eg, increased in vivo half-life or reduced required dosage) ) And thus may be preferred under certain circumstances. Positron emitting isotopes, such as ¹⁵ O, ¹³ N, ¹¹ C and ¹⁸ F, are useful in positron emission tomography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds of the invention are generally prepared according to procedures similar to those disclosed in the schemes and / or examples described below, by substituting nonisotopically labeled reagents with isotope labeled reagents. can do.

Biological Evaluation The relative ability of a compound of formula I as an inhibitor of enzyme activity (or other biological activity) is determined by measuring the concentration at which each compound inhibits activity to a predetermined degree, and then It can be defined by comparing the results. Typically, a preferred measurement is a concentration that inhibits 50% of activity in a biological assay, ie, a 50% inhibitory concentration or “IC ₅₀ ”. The determination of IC ₅₀ values can be accomplished using common techniques known in the art. In general, IC ₅₀ can be determined by measuring the activity of a given enzyme in the presence of a range of concentrations of inhibitor under experiment. Experimentally obtained enzyme activity values are then plotted against the inhibitor concentration used. The concentration of inhibitor exhibiting 50% enzyme activity (as compared to the activity in the absence of any inhibitor) is taken as the IC ₅₀ value. Similarly, other inhibitor concentrations can be defined by appropriate measurements of activity. For example, in some settings it may be desirable to define a 90% inhibitory concentration, ie IC _90, etc.

Thus, a “selective PI3Kδ inhibitor” is a compound that exhibits a 50% inhibitory concentration (IC ₅₀ ) with a PI3Kδ that exhibits an IC ₅₀ value that is at least 10-fold lower for any or all of at least other class IPI3K family members. means.

Measurement of PI3 kinase activity of Formula I compounds is possible by a number of direct and indirect detection methods. Certain exemplary compounds described herein were analyzed for their ability to inhibit the PI3Kα, β, γ, and δ isoforms (Example 901). The range of IC50 values for PI3Kδ inhibition ranged from less than 1 nM (nanomol) to about 10 μM (micromolar). Certain exemplary compounds of the invention had a PI3Kδ inhibition IC ₅₀ value of less than 10 nM. The compound is selective for the p110d (δ) isoform, which is a class IaPI3 kinase, over other class IaPI3 kinases, and thus is a p110δ isoform over the p110α (alpha) and p110β (beta) isoforms. Selective. In particular, they are also selective for p110δ (delta) over p110α (alpha). The compounds are also selective for the pi lOδ isoform over the pi lOγ (gamma), which is a class Ib kinase. The selectivity exhibited by the Formula I compounds of the invention over p110δ (delta) over the PI3 kinase isoform p110α (alpha) as demonstrated by the ratio of biological IC ₅₀ values (Examples). 901), at least 10 times.

  Certain compounds of formula I may have anti-proliferative activity to treat hyperproliferative diseases such as cancer. The compounds of formula I can inhibit the growth of tumors in mammals and may be useful for the treatment of human cancer patients. Compounds of formula I are described in WO 2006/046031; US Patent Application Publication No. 2008/0039459; US Patent Application Publication No. 2008/0076768; US Patent Application Publication No. 2008/0076758, which are hereby incorporated by reference. In vitro cell growth activity and in vivo tumor growth inhibition can be tested according to the methods in WO 2008/0707740; WO 2008/073785.

  Evaluation of drug-induced immunosuppression with the compounds of the present invention includes, for example, a rodent model of induced arthritis and disease scores, T cell-dependent antibody response (TDAR), and healing to assess late-onset hypersensitivity (DTH) Can be performed using in vivo functional tests such as clinical or prophylactic treatment. Other in vivo systems (Burleson GR, Dean JH, and Munson AE. Methods in Immunotoxicology, Vol. 1. Wiley-Liss, New York, 1995) including mouse models of biodefense or tumor resistance to infection were observed It can be considered to elucidate the nature or mechanism of inhibition. In vivo test systems can be complemented by well-established in vitro or ex vivo functional assays for assessment of immune capacity. These assays include B or T cell proliferation in response to mitogens or specific antigens, measurement of signaling through the PI3K pathway in B or T cells or immortalized B or T cell lines, B or T cell signaling It may include measurement of responsive cell surface markers, natural killer (NK) cell activity, mast cell activity, mast cell degranulation, macrophage phagocytosis or killing activity, and neutrophil oxidative burst and / or chemotaxis. In each of these tests, quantification of cytokine production by specific effector cells (eg, lymphocytes, NK, monocytes / macrophages, neutrophils) can be included. In vitro and ex vivo assays can be applied in both preclinical and clinical trials using lymphoid tissues and / or peripheral blood (House RV. “Theory and practice of cytokine assessment in immunotoxicology” (1999) Methods 19:17 -27; Hubbard AK. "Effects of xenobiotics on macrophage function: evaluation in vitro" (1999) Methods; 19: 8-16; Lebrec H et al. (2001) Toxicology 158: 25-29).

  A 6-week detailed study of collagen-induced arthritis (CIA) using an autoimmune mechanism that mimics human arthritis; a rat and mouse model (Example 902). Collagen-induced arthritis (CIA) is one of the most commonly used animal models of human rheumatoid arthritis (RA). The joint inflammation that develops in CIA animals is very similar to that observed in RA patients. Tumor necrosis factor (TNF) block is an effective treatment for CIA, as it is a very effective treatment in the treatment of RA patients. CIA is mediated by both T cells and antibodies (B cells). Macrophages appear to play an important role in mediating tissue damage during disease onset. CIA is induced by immunizing animals with collagen emulsified in Freund's complete adjuvant (CFA). It is most commonly induced in DBA / 1 mouse strains, but the disease can also be induced in Lewis rats.

  There is good evidence that B cells play an important role in the pathogenesis of autoimmunity and / or inflammatory diseases. Protein-based therapeutics that deplete B cells such as Rituxan are effective against autoantibody-driven inflammatory diseases such as rheumatoid arthritis (Rastetter et al. (2004) Annu Rev Med 55: 477). CD69 is an early activation marker in leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. The CD69 human whole blood assay (Example 903) is capable of inhibiting CD69 production by B lymphocytes in human whole blood activated by cross-linking surface IgM with goat F (ab ′) 2 anti-human IgM. Quantify.

  T cell-dependent antibody response (TDAR) is a predictive assay for testing immune function in cases where it is necessary to study the potential immunotoxic effects of a compound. The IgM plaque forming cell (PFC) assay, which uses sheep red blood cells (SRBC) as an antigen, is currently a widely accepted and validated standard test. TDAR has proven to be a highly predictive assay for detection of adult exposure immunotoxicity in mice based on the US National Toxicity Program (NTP) database (MI Luster et al. (1992) Fundam. Appl. Toxicol. 18: 200-210). The usefulness of this assay arises from the fact that it is a holistic measurement that includes several important components of the immune response. TDAR is dependent on the function of the following cell compartments: (1) antigen presenting cells, such as macrophages or dendritic cells; (2) the origin of the response, and helper T cells that are important players in isotype switching; and ( 3) B cells that are the ultimate effector cells and cause antibody production. Chemically induced changes in any one compartment can cause significant changes throughout the TDAR (MP Holsapple In: edited by GR Burleson, JH Dean and AE Munson, Modern Methods in Immunotoxicology, Volume 1, Wiley-Liss Publishers, New York, NY (1995), pp. 71-108). Typically, this assay is performed as an ELISA for measurement of soluble antibodies (RJ Smialowizc et al. (2001) Toxicol. Sci. 61: 164-175) or as a plaque (or antibody) forming cell assay (L. Guo et al. (2002) Toxicol Appl. Pharmacol. 181: 219-227) is performed to detect plasma cells secreting antigen-specific antibodies. The antigens selected are either whole cells (eg sheep erythrocytes) or soluble protein antigens (T. Miller et al. (1998) Toxicol. Sci. 42: 129-135).

Exemplary compounds of formula I in Table 1-3 were made, characterized, and tested for inhibition and selectivity of PI3Kδ by the methods of this invention, which have the following structure and corresponding names ( ChemDraw Ultra, Version 9.0.1, CambridgeSoft Corp., Cambridge MA).

Administration of Formula I Compounds The Formula I compounds of the present invention may be administered by a route appropriate to the condition being treated. Suitable routes are oral, parenteral (including subcutaneous, intramuscular, intravenous, intraarterial, intradermal, intrathecal and epidural), transdermal, rectal, nasal, topical (buccal and lingual) Including vaginal, intraperitoneal, intrapulmonary and intranasal. For local immunosuppressive treatment, the compound can be administered by intralesional administration, including perfusing or contacting the graft and inhibitor prior to transplantation. It will be appreciated that the preferred route may vary with for example the condition of the recipient. When the compound is administered orally, the compound can be formulated as a pill, capsule, tablet, etc. with a pharmaceutically acceptable carrier or excipient. Where the compound is administered parenterally, it can be formulated in a unit dosage injectable form with a pharmaceutically acceptable parenteral vehicle, as described in detail below.

  The dose for treating a human patient can range from about 10 mg to about 1000 mg of the compound of formula I. A typical dose can be about 100 mg to about 300 mg of the compound. Doses are once a day (QID), twice a day (BID), or more frequently, depending on pharmacokinetic and pharmacodynamic properties, including absorption, distribution, metabolism, and excretion of specific compounds Can be administered. In addition, toxic factors may affect the dosage and dosing regimen. When administered orally, pills, capsules or tablets can be taken daily or less frequently for a specific period of time. The regimen can be repeated for many treatment cycles.

Methods of treatment with compounds of formula I The compounds of formula I of the present invention may be used to treat diseases or disorders resulting from abnormal cell proliferation, function or behavior associated with PI3 kinase, particularly the p110δ (delta) isoform of PI3 kinase, eg, immune disorders By methods that are useful for treating human or animal patients suffering from cardiovascular disease, viral infections, inflammation, metabolic / endocrine diseases or neurological disorders, and thus comprising administering to a patient a compound of the invention as described above Can be treated. Human or animal patients suffering from cancer can also be treated by methods comprising administration to a patient of the administration of a compound of the present invention described above. The patient's condition can thereby be improved or ameliorated.

  The compounds of formula I can be used in mammalian cells, organisms or related pathological conditions such as systemic and local inflammation, immune inflammatory diseases such as rheumatoid arthritis, immunosuppression, organ transplant rejection, allergies, ulcerative colitis, clones Disease, dermatitis, asthma, systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, scleroderma / systemic sclerosis, idiopathic thrombocytopenic purpura (ITP), antineutrophil cytoplasmic antibody (ANCA) vasculitis May be useful for in vitro, in situ, and in vivo diagnosis or treatment of chronic obstructive pulmonary disease (COPD), psoriasis, and for general joint protective effects.

  The methods of the present invention also include, for example, arthritic diseases such as rheumatoid arthritis, monoarthritis, osteoarthritis, gout arthritis, spondylitis; Behcet's disease; sepsis, septic shock, endotoxin shock, gram-negative bacterial sepsis, gram Positive bacterial sepsis and toxic shock syndrome; multi-organ injury syndrome secondary to sepsis, trauma, or hemorrhage; eye disorders such as allergic conjunctivitis, spring catarrh, uveitis, and thyroid ophthalmopathy; eosinophilic Granulomas; pulmonary or respiratory diseases such as asthma, chronic bronchitis, allergic rhinitis, ARDS, chronic pulmonary inflammatory diseases (eg chronic obstructive pulmonary disease), silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, blood vessels Inflammation, emphysema, pneumonia, bronchiectasis, and pulmonary oxygen toxicity; myocardial, brain, or limb reperfusion injury; fibrosis, eg, cystic fibrosis; keloid form Or scar tissue formation; atherosclerosis; autoimmune diseases such as systemic lupus erythematosus (SLE), autoimmune thyroiditis, multiple sclerosis, several types of diabetes, and Raynaud's syndrome; and transplant rejection disorders such as GVHD and allograft rejection; chronic glomerulonephritis; inflammatory bowel disease such as chronic inflammatory bowel disease (CIBD), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis; inflammatory skin disease such as contact dermatitis , Atopic dermatitis, psoriasis, or urticaria; fever and myalgia resulting from infection; inflammatory disorders of the central or peripheral nervous system, such as meningitis, encephalitis, and brain or spinal cord injury due to minor trauma; Sjogren's syndrome; diseases related to extravasation of leukocytes; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex-mediated disease; hypotensive shock; type I diabetes; Comprising treating and diseases such as cytokines induced toxicity; sex and delayed hypersensitivity; disease state caused by cachexia and metastasis of leukocytes; burns; granulocyte transfusion associated syndrome.

  The methods of the invention may have utility in the treatment of patients who are or will be exposed to reperfusion injury, i.e. injury resulting from the situation where a tissue or organ undergoes a period of reperfusion following ischemia. The term “ischemia” refers to local tissue anemia due to obstruction of the inflow of arterial blood. Transient ischemia followed by reperfusion characteristically results in neutrophil activation in the affected area and transmigration through the vascular endothelium. The accumulation of activated neutrophils then results in the production of reactive oxygen metabolites, which damage the associated tissue or organ components. This “reperfusion injury” phenomenon is generally associated with symptoms such as vascular stroke (including global and local ischemia), hemorrhagic shock, myocardial ischemia or infarction, organ transplantation, and cerebral vasospasm To do. To illustrate, reperfusion injury occurs at the end of cardiac bypass surgery or during cardiac arrest when the heart stops accepting blood once and begins to perfuse again. It is expected that inhibition of PI3Kδ activity may reduce the amount of reperfusion injury under such circumstances.

Pharmaceutical formulations In order to use a compound of formula I for therapeutic treatment (including prophylactic treatment) of mammals including humans, it is usually formulated as a pharmaceutical composition in accordance with standard medical practice. . According to this aspect of the invention there is provided a pharmaceutical composition comprising a compound of this invention in association with a pharmaceutically acceptable diluent or carrier.

  A typical formulation is prepared by mixing a compound of the present invention and a carrier, diluent or excipient. Suitable carriers, diluents and excipients are well known to those skilled in the art and include carbohydrates, waxes, water soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water Etc. The particular carrier, diluent or excipient used will depend upon the means and purpose for which the compound of the present invention is being applied. Solvents are generally selected based on solvents recognized by those skilled in the art as safely administered to mammals (GRAS). In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (eg, PEG400, PEG300) and the like and mixtures thereof. In addition, the formulation is composed of one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, Other known sweeteners, flavors, flavors and drugs (ie, compounds of the present invention or pharmaceutical compositions thereof) to provide a pleasing appearance or to assist in the manufacture of pharmaceutical products (ie, pharmaceuticals) Additives can be included.

  The formulation can be prepared using routine dissolution and mixing procedures. For example, a bulk drug substance (ie, a compound of the present invention or a stabilized form of the compound (eg, a complex with a cyclodextrin derivative or other known complexing agent) may be added to one or more of the excipients described above. The compounds of the present invention are typically formulated into pharmaceutical dosage forms to facilitate drug dosage control and allow patients to adhere to the prescribed regimen To.

  The applied pharmaceutical composition (or formulation) can be packaged in a variety of forms depending on the method used to administer the drug. Generally, an article for distribution includes a container containing a suitable form of a pharmaceutical formulation therein. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets (sachets), ampoules, plastic bags, metal cylinders and the like. The container may also include an assembly that is tamper proof to prevent inconspicuous access to the contents of the package. Also, a label that describes the contents of the container is attached to the container. The label can also include an appropriate warning.

  Pharmaceutical formulations of the compounds of the invention can be prepared for various routes and types of administration. For example, a compound of formula I having the desired degree of purity, in the form of a lyophilized formulation, a pulverized powder, or an aqueous solution, optionally with a pharmaceutically acceptable diluent, carrier, excipient or stabilizer. (Remington's Pharmaceutical Sciences (1980) 16th edition, edited by Osol, A.). Formulation can be accomplished by mixing with a physiologically acceptable carrier, that is, a carrier that is non-toxic to recipients at the dosage and concentration used, at an appropriate pH, desired degree of purity, at room temperature. The pH of the formulation depends primarily on the particular application and the concentration of the compound, but can range from about 3 to about 8. Formulation of acetate buffer at pH 5 is a suitable embodiment.

  The compound can usually be stored as a solid composition, a lyophilized formulation or an aqueous solution.

  The pharmaceutical compositions of the invention will be formulated, dosed, and administered in a manner consistent with good medical practice, that is, in amount, concentration, schedule, course, vehicle and route of administration. Factors considered in this context include the particular disease being treated, the particular mammal being treated, the clinical symptoms of the individual patient, the cause of the disease, the site of drug delivery, the method of administration, the administration schedule, and the physician Other known factors are included. The “therapeutically effective amount” of the compound to be administered is governed by such considerations and is the minimum amount necessary to prevent, reduce or treat the hyperproliferative disease.

  As a general proposition, the initial pharmaceutically effective amount of inhibitor administered parenterally per dose is in the range of about 0.01-1000 mg / kg, ie about 0.1 to 20 mg / day / day. kg patient weight and the initial range of typical compounds used is 0.3 to 15 mg / kg / day.

  Acceptable diluents, carriers, excipients and stabilizers are non-toxic to recipients at the dosages and concentrations used, and buffers such as phosphate, citrate, and other organic acids; ascorbic acid and methionine Antioxidants including: preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol, etc.); low molecular weight (less than about 10 residues) polypeptide; protein such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymer such as polyvinylpyrrolidone; glycine, glutamine, Amino acids such as sparagin, histidine, arginine, or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; And / or nonionic surfactants such as TWEEN ™, PLURONICS ™ or polyethylene glycol (PEG). The active pharmaceutical ingredients were prepared in colloidal drug delivery systems (eg liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or microemulsions, respectively, eg by coacervation techniques or interfacial polymerization It can be encapsulated in microcapsules such as hydroxymethylcellulose or gelatin-microcapsules and poly- (methyl methacrylate) microcapsules. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

  Sustained release preparations of the compounds of formula I can be prepared. Suitable examples of sustained release formulations include a semipermeable matrix of a solid hydrophobic polymer comprising a compound of formula I, which matrix is in the form of a molded article, for example a film or microcapsule. Examples of sustained release matrices include polyesters, hydrogels (eg, poly (2-hydroxyethyl-methacrylate) or poly (vinyl alcohol)), polylactic acid (US Pat. No. 3,773,919), L-glutamic acid and γ- Copolymers of ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT ™ (injectable microspheres comprising lactic acid-glycolic acid copolymer and leuprolide acetate) and poly- D (−) 3-hydroxybutyric acid is included.

  Formulations include those suitable for the route of administration described in detail herein. The formulations can conveniently be provided in unit dosage form and can be prepared by any of the methods well known in the pharmaceutical arts. Techniques and formulation are generally found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

  Formulations of compounds of formula I suitable for oral administration are prepared as separate units, eg, pills, capsules, cachets or tablets, each containing a predetermined amount of a compound of formula I. sell. Compressed tablets are optionally mixed with binders, lubricants, inert diluents, preservatives, surface active or dispersing agents, and the active ingredient is compressed with a suitable machine in a free flowing form such as powders or granules. Can be prepared. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. Tablets are optionally coated or scored and optionally formulated to provide delayed or controlled release of the active ingredient. Tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, such as gelatin capsules, syrups or elixirs, can be prepared for oral use. Formulations of compounds of formula I intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions are suitable for oral preparations. To provide one or more agents including sweeteners, flavorings, colorants and preservatives. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets are acceptable. These excipients include, for example, inert diluents such as calcium carbonate or sodium, lactose, calcium phosphate or sodium; granulating and disintegrating agents such as corn starch, or alginic acid; binders such as starch, gelatin or acacia; and It can be a lubricant such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or coated by known methods, including microencapsulation that delays disintegration and adsorption in the gastrointestinal tract, thereby providing a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

  For the treatment of the eye or other external tissue, for example mouth and skin, the formulations can be applied as topical ointment or cream containing the active ingredient, for example in an amount of 0.075 to 20% w / w. When formulated in an ointment, the active ingredient can be used with a paraffinic or water-miscible ointment base. Alternatively, the active ingredient can be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base can be a polyhydric alcohol, i.e., two or Alcohols having more hydroxyl groups can be included. Topical formulations may desirably contain compounds that enhance the absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs. The oily phase of the emulsions of this invention can be constructed in a known manner from known ingredients, including a mixture of at least one emulsifier with fat or oil, or with both fat and oil. A hydrophilic emulsifier incorporated together with a lipophilic emulsifier acts as a stabilizer. In addition, the emulsifier together with or without a stabilizer constitutes a so-called emulsified wax, and with the oil and fat, the wax constitutes a so-called emulsified ointment base that forms the oily dispersed phase of the cream formulation. Suitable emulsifiers and emulsion stabilizers for use in the formulations of the present invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, Includes glyceryl mono-stearate and sodium lauryl sulfate.

  Aqueous suspensions of the compounds of formula I contain the active substance in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum and acacia gum, and dispersing or wetting agents such as naturally occurring From the resulting phosphatides (eg lecithin), condensation products of alkylene oxides with fatty acids (eg polyoxyethylene stearate), condensation products of ethylene oxide with long-chain aliphatic alcohols (eg heptadecaethyleneoxycetanol), fatty acids and hexitol anhydrides Condensation products of ethylene oxide with derived partial esters (eg, polyoxyethylene sorbitan monooleate) are included. Aqueous suspensions may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more colorants, one or more flavoring agents and one or more sweeteners such as sucrose or saccharin. Can be included.

  The pharmaceutical composition of the compound of formula I may be in the form of a sterile injectable preparation, for example a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. Sterile injectable formulations are also solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as those prepared from 1,3-butane-diol solutions or lyophilized powders. sell. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils can conventionally be used as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used for the preparation of injections as well.

  The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans is approximately 1 to 1000 mg formulated with a suitable and convenient amount of carrier material that can vary from about 5 to about 95% (weight: weight) of the total composition. It may contain an active substance. The pharmacological composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution for intravenous infusion may contain about 3 to 500 μg of active ingredient per milliliter of solution to allow an appropriate volume of infusion to occur at a rate of about 30 mL / hour.

  Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions that may contain antioxidants, buffers, bacteriostats and solutes that make the intended recipient's blood and formulation isotonic; and suspensions And aqueous and non-aqueous sterile suspensions which may contain thickeners.

  Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations at a concentration of about 0.5 to 20% w / w, for example about 0.5 to 10%, for example about 1.5% w / w.

  Formulations suitable for topical administration in the mouth include lozenges containing active ingredients in flavor bases, usually sucrose and acacia or tragacanth; active ingredients in inert bases such as gelatin and glycerin, or sucrose and acacia Including pastilles; and gargles containing the active ingredients in a suitable liquid carrier.

  Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or salicylate.

  Formulations suitable for intrapulmonary or nasal administration are for example particle sizes in the range of 0.1 to 500 microns in increments of microns such as 0.1 to 500 microns (eg 0.5, 1, 30 microns, 35 microns, etc.). And are administered by rapid inhalation through the nasal route or by inhalation through the mouth to reach the alveolar sac. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration can be prepared by routine methods and can be delivered with other therapeutic agents such as compounds previously used in the treatment or prevention of diseases as described below.

  Formulations suitable for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing, in addition to the active ingredient, a carrier as known to be suitable in the art. it can.

  The formulation can be packaged in unit-dose or multi-dose containers, such as sealed ampoules and vials, and freeze-dried conditions that require only the addition of a sterile liquid carrier for injection, such as water, just prior to use. Can be saved. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Suitable unit dosage formulations are those containing a daily dosage or daily sub-dosage unit as described above, or an appropriate fraction thereof, of the active ingredient.

  The present invention further provides veterinary compositions containing at least one active ingredient as described above together with a veterinary carrier. A veterinary carrier is a substance useful for the purpose of administering the composition and may be a solid, liquid or gaseous substance which is inert or acceptable in the veterinary field and compatible with the active ingredient. These veterinary compositions can be administered parenterally, orally or by any other desired route.

Combination Therapy The compounds of Formula I may be used alone or in combination with other therapeutic agents for the treatment of the diseases or disorders described herein, such as inflammation or hyperproliferative diseases (eg cancer). it can. In certain embodiments, the compound of Formula I has a second therapeutic compound that has anti-inflammatory or anti-hyperproliferative properties or that is useful for the treatment of inflammation, immune response disease, or hyperproliferative disease (eg, cancer); Used in combination regimens as a pharmaceutical combination formulation or combination therapy. The second therapeutic agent can be an NSAID anti-inflammatory agent. The second therapeutic agent can be a chemotherapeutic agent. The second compound of the pharmaceutical combination formulation or dosing regimen preferably has complementary activity to the compound of formula I so as not to adversely affect each other. Such compounds are preferably present in combination in amounts that are effective for the purpose intended. In one embodiment, the composition of the invention combines a compound of Formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt or prodrug thereof, in combination with a therapeutic agent such as NSAID. contains.

  Combination therapy can be administered as a simultaneous or sequential regimen. When administered sequentially, the concomitant drug can be administered in two or more doses. Co-administration includes co-administration using separate formulations or a single pharmaceutical formulation and preferably in any order where both (or all) active agents have time to act on their biological activity simultaneously. Sequential administration.

  Suitable dosages for any of the above co-administered drugs are those currently in use and are reduced due to the combined action (synergism) of the newly identified drug and other chemotherapeutic agents or treatments be able to.

  Combination therapy results in a “synergistic effect” when the active ingredients used together are greater than the sum of the effects obtained using the compounds separately, and “synergistic”, that is, the effect is achieved. I understand. The synergistic effect is when the active ingredients are (1) co-formulated and administered or delivered simultaneously as a combined unit dosage formulation; (2) delivered alternately or concurrently as separate formulations; or (3) It can be achieved by certain other regimens. When delivered in alternation therapy, a synergistic effect can be achieved when the compounds are administered or delivered sequentially by different injections, for example in separate syringes. In general, during alternation therapy, an effective dose of each active ingredient is administered sequentially, ie, serially, whereas in combination therapy, effective doses of two or more active ingredients are administered together.

  In certain embodiments of the treatment, the compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt or prodrug thereof is another chemotherapeutic such as those described herein. It may be combined with agents, hormonal agents or antibody agents, and may be combined with surgical therapy and radiation therapy. Thus, the combination therapy according to the invention comprises the administration of at least one compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt or prodrug thereof, and at least one other cancer treatment. Including the use of law. The amount of compound of formula I and other pharmaceutically active chemotherapeutic agents and the relative timing of administration are selected to achieve the desired combined therapeutic effect.

Metabolites of compounds of formula I Also within the scope of the invention are in vivo metabolites of the compounds of formula I described herein. Such products can result from, for example, oxidation, reduction, hydrolysis, amidation, deamidation, esterification, esterolysis, enzymatic degradation, etc. of the administered compound. Accordingly, the present invention includes a metabolite of a compound of formula I, including a compound produced by a method comprising contacting the mammal with a compound of the present invention for a period sufficient to produce the metabolite.

Metabolites typically prepare radiolabeled (eg, ¹⁴ C or ³ H) isotopes of compounds of the invention and transfer them to, for example, animals such as rats, mice, guinea pigs, monkeys, or humans ( Administer parenterally at a detectable dose (eg, greater than about 0.5 mg / kg) and allow sufficient time for metabolism to occur (typically about 30 seconds to 30 hours), urine, blood or other Identified by isolating the conversion product from a biological sample. These products are easily isolated because they are labeled (others are isolated by the use of antibodies capable of binding epitopes that survive in the metabolite). The structure of the metabolite is determined by routine methods such as MS, LC / MS or NMR analysis. In general, analysis of metabolites is done in the same way as general drug metabolism studies well known to those skilled in the art. Metabolites are useful in diagnostic assays for therapeutic dosing of the compounds of the invention, unless they are otherwise found in vivo.

Articles of Manufacture In another embodiment of the invention, an article of manufacture or “kit” comprising a compound of formula I useful for the treatment of the diseases and disorders described above is provided. In one embodiment, the kit includes a container containing a compound of formula I. The kit may further comprise a label or package insert on or associated with the container. The term “package insert” is routinely included in a commercial package of therapeutic products, including information about indications, usage, dosage, administration, contraindications and / or warnings regarding the use of such therapeutic products. Used to refer to instructions. Suitable containers include, for example, bottles, vials, syringes, blister packs, and the like. The container can be formed from a variety of materials such as glass or plastic. The container may contain a compound of formula I or a formulation thereof effective to treat the condition and may have a sterile access port (eg, an intravenous solution having a stopper pierceable with a hypodermic needle. Can be a bag or a vial). At least one active agent in the composition is a compound of formula I. The label or package insert indicates that the composition is used for the treatment of selected conditions such as cancer. The label or package insert may also indicate that the patient being treated has a disease such as a hyperproliferative disease, neurodegeneration, cardiac hypertrophy, pain, migraine or neurotraumatic disease or event. In one embodiment, the label or package insert indicates that the composition containing a compound of formula I can be used to treat a disease resulting from abnormal cell proliferation. The label or package insert may also indicate that the composition can be used to treat other diseases. Alternatively or additionally, the article of manufacture further comprises a second container comprising a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution and dextrose solution. sell. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

  The kit may further comprise instructions for administration of the compound of Formula I and, if present, the second pharmaceutical formulation. For example, if the kit comprises a first composition comprising a compound of formula I and a second pharmaceutical formulation, the kit may be used to simultaneously administer the first and second pharmaceutical compositions to a patient in need thereof. It may further comprise instructions for sequential or separate administration.

  In other embodiments, the kit is suitable for delivery of a solid oral form of a compound of formula I, such as a tablet or capsule. Such a kit preferably includes a number of unit dosages. Such kits can include cards having dosages arranged in order of their intended use. An example of such a kit is a “blister pack”. Blister packs are well known in the packaging industry and are widely used for packaging pharmaceutical unit dosage forms. If desired, memory aids can be provided, for example, in the form of numbers, letters, or other marks, or with a calendar insert that specifies the days in the treatment schedule to which the dose can be administered.

  According to one embodiment, the kit comprises (a) a first container containing a compound of formula I therein; optionally (b) a second container containing a second pharmaceutical formulation therein. Wherein the second pharmaceutical formulation comprises a second compound having anti-hyperproliferative activity. Alternatively or additionally, the kit may further comprise a third container comprising a pharmaceutically acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution and dextrose solution. . It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

  In certain other embodiments, where the kit comprises a composition of Formula I and a second therapeutic agent, the kit comprises a container for containing separate compositions, such as a divided bottle or a divided foil packet, etc. Although included, separate compositions may also be contained in a single undivided container. Typically, the kit includes instructions for administration of the separate components. Kit forms when the separate components are preferably administered in different dosage forms (eg, oral and parenteral), administered at different dosing intervals, or where the individual components of the combination are desired by the prescribing physician Is particularly advantageous.

Preparation of Formula I Compounds The compounds of formula I are particularly well known in the chemical arts, especially in light of the description contained herein, and each of which is specifically incorporated herein by reference. , Katritzky and Rees, Elsevier, 1997, eg 3 volumes; Liebigs Annalen der Chemie, (9): 1910-16, (1985); Helvetica Chimica Acta, 41: 1052-60, (1958); Arzneimittel-Forschung, 40 (12): 1328-31, (1990) can be synthesized by synthetic routes including methods similar to those of other heterocycles. Starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) Or are readily prepared using methods well known to those skilled in the art (eg, Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-23, Wiley, NY (1967-2006 edition) or Beilsteins Handbuch der organischen Chemie, 4, Aufl. Ed. Springer-Verlag, Berlin, including supplements (also Beilstein online database) Prepared by the method described in).

In certain embodiments, thiazolopyrimidine compounds of formula I (X ¹ is N and X ² is S) are well known for preparing thiazoles, pyrimidines, thiazolopyrimidines. (US Pat. No. 6,608,053; US Pat. No. 6,492,383; US Pat. No. 6,232,320; US Pat. No. 6,187,777; US Pat. No. 3,663,156; US Pat. No. 3,661,908; US Pat. No. 3,475,429) U.S. Patent No. 5,075,305; U.S. Patent Application Publication No. 2003/220365; British Patent Application Publication No. 1,390,658; British Patent Application Publication No. 1,393,161;

In certain embodiments, purine compounds of formula I (X ¹ is N and X ² is NR ² ) can be prepared using well-known procedures for preparing purines (Hammarstrom (2007) tetrahedron Lett. 48 (16): 2823-2827; Cerna et al. (2006) Organic Letters 8 (23): 5389-5392; Chang et al. (2006) J. Med. Chem. 49 (10): 2861- 2867; Yang et al. (2005) J. Comb. Chem. 7: 474-482; Liu et al. (2005) J. Comb. Chem. 7: 627-636; Hocek et al. (2004) Synthesis 17: 2869-2876; Hammarstrom et al. (2003) tetorahedron Lett. 44: 8361-8363; Hammarstrom et al. (2002) tetorahedron Lett. 43: 8071-8073; Booth et al. (1987) J. Chem. Soc, Perkin Trans. 1: Organic and Bio-Organic Chem. 7 : 1521-1526; Booth et al. (1981) J. Chem. Soc., Chemical Communications 15: 788-789; Yoneda et al. (1976) J. Chem. Soc., Perkin Trans. 1: Organic and Bio-Organic Chem. 14 : 1547-1550; Taylor et al. (1971) J. Org. Chem. 36 (21): 3211-3217; Lister, JH; Fenn, MD The purins, Supplementary 1, John Wiley & Sons, 1996, Volume 54; The Chem istry of cyclic compounds, Editors Weissberger, A .; Taylor EC, Wiley Interscience, 1971, 24th edition; Legraverend, M .; Grierson, DS (2006) Bioorg. Med. Chem. 14: 3987-4006; Hocek, M. (2003) Eur. J. Org. Chem. 245-254; US Pat. No. 7,122,665; US Pat. No. 6,743,919; US Pat. No. 5,332,744; US Pat. No. 4,728,644; 2008/0058297; US Patent Application Publication No. 2003/0139427; International Publication No. 2008/043031).

  Synthetic chemical transformations and protecting group methodologies (protection and deprotection) useful for the synthesis of compounds of formula I and the necessary reagents and intermediates are known in the art, eg R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); TW Greene and P. G.M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley and Sons (1999); and L. Paquette, Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons. (1995) and its successors are included.

  Compounds of formula I can be prepared alone or as a compound library comprising at least two, for example 5 to 1000 compounds, or 10 to 100 compounds. A library of compounds of formula I may be prepared by a “split and mix” approach, or by multiple parallel synthesis methods using either solution phase or solid phase chemistry, or by procedures known to those skilled in the art. Can do. Thus, according to a further aspect of the invention there is provided a compound library comprising at least two compounds, or pharmaceutically acceptable salts thereof.

  Purine compounds can be prepared using 2,4,8-trichloropurine as a starting material. The three chloro groups can be substituted with various substituents. More specifically, the most reactive chloro group (ie, 4-position chloro) is replaced with a morpholino group to form morpholinopurine.

  For illustrative purposes, Scheme 1 shows a general method for preparing the purine compounds of formula I as well as key intermediates. See the General Procedures and Examples section for a more detailed description of the individual reaction steps. One skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds of the present invention. Certain starting materials and reagents are shown and discussed in the general procedure, examples, scheme 1, but are readily substituted with other starting materials and reagents to provide various derivatives and / or reaction conditions be able to. Also, many of the exemplary compounds prepared by the described methods can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.

式Ｉの化合物の調製では、中間体の離れた官能基の保護（例えば、第一級又は第二級アミン）が必要となりうる。そのような保護の必要性は、離れている官能基の性質や調製方法の条件に依存して変わるであろう。適当なアミノ保護基は、アセチル、トリフルオロアセチル、ｔ-ブトキシカルボニル（ＢＯＣ）、ベンジルオキシカルボニル（ＣＢｚ）及び９-フルオレニルメチルオキシカルボニル（Ｆｍｏｃ）を含む。そのような保護の必要性は、当業者によって容易に決定される。保護基とその使用の一般的な記載は、T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991を参照のこと。 Scheme 1

Preparation of compounds of formula I may require protection of intermediate functional groups (eg, primary or secondary amines). The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyloxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see TW Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

Separation process In the process for the preparation of the compounds of formula I, it may be advantageous to separate reaction products from one another and / or from starting materials. The desired product of each step or series of steps is separated and / or purified to a desired degree of homogeneity by techniques common in the art. Typically such separations include multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography includes, for example, reverse phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and equipment; small scale analysis; simulated moving bed (SMB) and preparative thin or thick layer chromatography And numerous methods including small thin layer and flash chromatography techniques.

  Another class of separation methods involves the treatment of the mixture with reagents selected to bind to or separate the desired products, unreacted starting materials, reaction byproducts, and the like. Such reagents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media and the like. Alternatively, the reagent may be an acid for basic materials, a base for acidic materials, a binding reagent such as an antibody, a binding protein, a selective chelating agent such as a crown ether, a liquid / liquid ion extraction reagent (LIX). Or the like. The selection of an appropriate separation method depends on the nature of the relevant material, e.g. boiling point and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, material in acidic and basic media in multiphase extraction. Depends on stability etc.

  Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and / or fractional crystallization. Enantiomers are converted to diastereomeric mixtures by reacting with appropriate optically active compounds (eg chiral auxiliary groups such as chiral alcohols or Mosher acid chlorides) to separate the diastereomers The diastereomers can be separated by converting (eg, hydrolyzing) the corresponding pure enantiomer. Also, some of the compounds of this invention may be atropisomers (eg, substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated using chiral HPLC columns.

  Single stereoisomers, for example enantiomers substantially free of the stereoisomers, can be obtained by resolution of racemic mixtures using methods such as the formation of diastereomers using optically active resolving agents. (Eliel, E. and Wilen, S. “Stereochemistry of Organic Compounds,” John Wiley & Sons, Inc., New York, 1994; Lochmuller, CH, (1975) J. Chromatogr., 113 (3): 283-302. ). The racemic mixture of chiral compounds of the present invention comprises (1) formation of ionic diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, Separation and isolation by any suitable method including separation of diastereomers and conversion to pure stereoisomers, and (3) separation of substantially pure or enriched stereoisomers under direct chiral conditions be able to. See Drug Stereochemistry, Analytical Methods and Pharmacology, ”Irving W. Wainer, Marcel Dekker, Inc., New York (1993).

  In method (1), diastereomeric salts may be enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, α-methyl-β-phenylethylamine (amphetamine), carboxylic acids and sulfonic acids, etc. It can be formed by reaction with an asymmetric compound carrying an acidic functional group. Diastereomeric salts can be induced to separate by fractional crystallization or ionic chromatography. For the separation of optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids such as camphorsulfonic acid, tartaric acid, mandelic acid or lactic acid can result in the formation of diastereomeric salts.

Alternatively, in method (2), the substrate to be resolved reacts with one enantiomer of the chiral compound to form a diastereomeric pair (E. and Wilen, S. “Stereochemistry of Organic Compounds”, John Wiley & Sons , Inc., 1994, p. 322). Diastereomeric compounds are obtained by reacting an asymmetric compound with an enantiomerically pure chiral derivatizing reagent, such as a menthyl derivative, followed by separation and hydrolysis of the diastereomers to obtain pure or enriched enantiomers. Can be formed. The method for measuring optical purity is in the presence of a base or Mosher ester, a racemic mixture of α-methoxy-β- (trifluoromethyl) acetic acid phenyl (Jacob III. J. Org. Chem. (1982) 47: 4165), This involves making a chiral ester such as a menthyl ester, for example (-) menthyl chloroformate, and analyzing the ¹ H NMR spectrum for the presence of two atropisomeric enantiomers or diastereomers. Stable diastereomers of atropisomeric compounds can be separated and isolated by normal phase and reverse phase chromatography according to the atropisomeric naphthyl-isoquinoline separation method (WO 96/15111). In method (3), a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography ”(1989) WJ Lough, Chapman and Hall, New York; Okamoto, J. Chromatogr., (1990) 513: 375-378) Enriched or purified enantiomers are used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism. Can be identified by the method.

鈴木タイプのカップリング反応は、２-クロロ-プリン２１のピリミジン環の２位に、縮合二環式複素環又は縮合二環式ヘテロアリールを結合させるのに有用である。鈴木タイプのカップリング反応は、チアゾロピリミジン類（ｉ）、チエノピリミジン類（ｉｉ）、フラノピリミジン類（ｉｖ）及びピロロピリミジン類（ｖ）のピリミジン環の２位において縮合二環式複素環又は縮合二環式ヘテロアリールを結合させるのに有用である。例えば、２１は、約１．５当量の４-(４,４,５,５-テトラメチル-１,３,２-ジオキサボロラン-２-イル)１Ｈ-ピロロ[２,３-ｃ]ピリジン２４と組み合わされ、１モル濃度の水溶液としての３当量の炭酸ナトリウムと等体積のアセトニトリルに溶解することができる。触媒量、又はそれ以上の、低原子価のパラジウム試薬、例えばビス(トリフェニルホスフィン)パラジウム(ＩＩ)ジクロライドを加える。様々なボロン酸又はボロン酸エステル類を、示されたインダゾールボロン酸エステルの代わりに使用することができる。また別法では、縮合二環式複素環又は縮合二環式ヘテロアリールの窒素を、例えばＮ-ＴＨＰのように、保護することができる。ある場合には、水性層のｐＨを調節するために炭酸ナトリウムの代わりに酢酸カリウムを使用した。ついで、反応は、Ｂｉｏｔａｇｅ Ｏｐｔｉｍｉｚｅｒ（Ｂｉｏｔａｇｅ社）のようなマイクロ波反応器中で加圧下で、１０分から３０分間、約１４０−１５０℃に加熱される。内容物を酢酸エチル又は他の有機溶媒で抽出する。有機層の蒸発後、鈴木カップリング産物２２を、シリカ又は逆相ＨＰＬＣによって精製することができる。置換基Ｒ^１’、Ｒ^２’、Ｒ^４’は、定義されたようなＲ^１、Ｒ^２、Ｒ^４であるか、又はその保護された形態又は前駆体でありうる。 General preparation procedure
General procedure A C-2 Suzuki coupling

The Suzuki type coupling reaction is useful for attaching a fused bicyclic heterocycle or fused bicyclic heteroaryl to the 2-position of the pyrimidine ring of 2-chloro-purine 21. Suzuki-type coupling reactions include thiazolopyrimidines (i), thienopyrimidines (ii), furanopyrimidines (iv) and pyrrolopyrimidines (v) at the 2-position of the pyrimidine ring, Useful for attaching fused bicyclic heteroaryls. For example, 21 is about 1.5 equivalents of 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 1H-pyrrolo [2,3-c] pyridine 24 and Can be combined and dissolved in 3 equivalents of sodium carbonate as a 1 molar aqueous solution and an equal volume of acetonitrile. A catalytic amount or more of a low valent palladium reagent, such as bis (triphenylphosphine) palladium (II) dichloride, is added. Various boronic acids or boronic esters can be used in place of the indicated indazole boronic esters. Alternatively, the nitrogen of the fused bicyclic heterocycle or fused bicyclic heteroaryl can be protected, such as N-THP. In some cases, potassium acetate was used instead of sodium carbonate to adjust the pH of the aqueous layer. The reaction is then heated to about 140-150 ° C. under pressure in a microwave reactor such as Biotage Optimizer (Biotage) for 10-30 minutes. The contents are extracted with ethyl acetate or other organic solvent. After evaporation of the organic layer, the Suzuki coupling product 22 can be purified by silica or reverse phase HPLC. The substituents R ¹ ′, R ² ′, R ⁴ ′ can be R ¹ , R ² , R ⁴ as defined, or can be protected forms or precursors thereof.

A variety of palladium catalysts can be used in the Suzuki coupling process to form compounds comprising exemplary embodiment 22. Suzuki coupling is a palladium-mediated cross-coupling reaction of a heteroaryl halide such as 21 with a boronic acid such as 24. PdCl2 (PPh ₃ ) ₂ , Pd (t-Bu) ₃ , PdCl ₂ dppfCH ₂ Cl ₂ , Pd (PPh ₃ ) ₄ , Pd (Oac) / PPh ₃ , Cl ₂ Pd [(Pet ₃ )] ₂ , Pd ( _{DIPHOS) 2, Cl 2 Pd (} Bipy), [PdCl (Ph 2 PCH 2 PPh 2)] 2, Cl 2 Pd [P (o-tol) 3] 2, Pd 2 (dba) 3 / P (o-tol ) ₃ , Pd ₂ (dba) / P (furyl) ₃ , Cl ₂ Pd [P (furyl) ₃ ] ₂ , Cl ₂ Pd (PmePh ₂ ) ₂ , Cl ₂ Pd [P (4-F-Ph) ₃ ] ₂ , Cl ₂ Pd [P (C ₆ F ₆ ) ₃ ] ₂ , Cl ₂ Pd [P (2-COOH-Ph) (Ph) ₂ ] ₂ , Cl ₂ Pd [P (4-COOH-Ph) (Ph ) _{2] 2,} and encapsulated catalysts Pd EnCat (TM) 30, Pd EnCat (TM) TPP30, and Pd (II) En Containing at (TM) BINAP30 (U.S. Patent Application Publication No. 2004/0254066), the lower valence Pd (II) and Pd (0) catalyst may be used in the Suzuki coupling reaction.

エタノールのような溶媒中の２,６-ジクロロプリン中間体２７にモルホリン又はモルホリンアナログ、及びトリエチルアミン（Ｎｅｔ_３、１．５当量、６３μｌ）のような非求核性塩基を加える。あるいは、アセトニトリルを溶媒として用いることができ、炭酸カリウムを塩基として用いることができる。反応混合物を室温で約１時間又は一晩攪拌し、真空下で揮発性物質を取り除き、残留物をＤＣＭとブラインの間で分配する。混合物が不溶性の場合、超音波処理し、固形生成物を濾過により回収した。硫酸マグネシウムで乾燥させ、溶媒を蒸発させて、しばしば結晶固形物として、又は倍散によりＮ’-(２-クロロプリン-６-イル)-アミン置換中間体２８を得る。置換基Ｒ^１’及びＲ^２は定義されたＲ^１及びＲ^２であるか、又はその保護された形態又は前駆体でありうる。 General Procedure B C-6 Nitrogen Replacement

To the 2,6-dichloropurine intermediate 27 in a solvent such as ethanol is added a morpholine or morpholine analog and a non-nucleophilic base such as triethylamine (Net ₃ , 1.5 eq, 63 μl). Alternatively, acetonitrile can be used as a solvent and potassium carbonate can be used as a base. The reaction mixture is stirred at room temperature for about 1 hour or overnight, volatiles are removed under vacuum, and the residue is partitioned between DCM and brine. If the mixture was insoluble, it was sonicated and the solid product was collected by filtration. Dry with magnesium sulfate and evaporate the solvent to obtain the N ′-(2-chloropurin-6-yl) -amine substituted intermediate 28, often as a crystalline solid or by trituration. The substituents R ¹ ′ and R ² can be defined R ¹ and R ² or can be protected forms or precursors thereof.

９-Ｈプリン中間体２９をＤＭＦ中に取り上げ、２当量の炭酸セシウムを反応混合物に加える。反応を５０℃まで加熱したところで、１から３当量のハロゲン化アルキルＲ^２’-Ｘを反応混合物に加える。反応をＴＬＣ又はＬＣ／ＭＳでモニタリングし、反応が完了するまで、典型的には数時間、撹拌する。反応混合物をＥｔＯＡｃ及び水で抽出し、有機層を乾燥させ、濾過し、濃縮して粗９-アルキル化プリン３０を得、これを直接次の反応に使用するか又は逆相ＨＰＬＣで精製する。置換基Ｒ^１’、Ｒ^３’及びＲ^４’は定義されたＲ^１、Ｒ^３及びＲ^４であるか又はその保護された形態又は前駆体でありうる。

ピペリジン基のＮ-アルキル化の実施態様では、アセトニトリル（２．０ｍＬ）中の４-((９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジニウム塩化物又は４-((２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジニウム塩化物（０．４ｍｍｏｌ）、炭酸カリウム（０．２５ｇ、１．８ｍｍｏｌ）の懸濁液に求電子試薬（１．４ｍｍｏｌ）を加える。生じた混合物を圧力チューブ内で約９５℃で５−１８時間攪拌する。反応混合物を濾過し、濃縮し、ＲＰ-ＨＰＬＣで精製することができる。 General Procedure C N-9 Nitrogen Alkylation

The 9-H purine intermediate 29 is taken up in DMF and 2 equivalents of cesium carbonate are added to the reaction mixture. Reaction was heated to 50 ° C. is added an alkyl halide R ^{2 '-X} from 1 3 equivalents to the reaction mixture. The reaction is monitored by TLC or LC / MS and stirred typically for several hours until the reaction is complete. The reaction mixture is extracted with EtOAc and water, the organic layer is dried, filtered and concentrated to give the crude 9-alkylated purine 30, which is used directly in the next reaction or purified by reverse phase HPLC. The substituents R ¹ ′, R ³ ′ and R ⁴ ′ can be defined R ¹ , R ³ and R ⁴ or can be protected forms or precursors thereof.

In an embodiment of N-alkylation of the piperidine group, 4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6- in acetonitrile (2.0 mL) Morpholino-9H-purin-8-yl) methyl) piperidinium chloride or 4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H- Electrophilic reagent (1.4 mmol) is added to a suspension of purin-8-yl) methyl) piperidinium chloride (0.4 mmol), potassium carbonate (0.25 g, 1.8 mmol). The resulting mixture is stirred in a pressure tube at about 95 ° C. for 5-18 hours. The reaction mixture can be filtered, concentrated and purified by RP-HPLC.

一般に、Ｎ-９-テトラヒドロピラニル置換３１をメタノール溶液中で触媒量のパラ-トルエンスルホン酸（ＰＴＳＡ）で処理し、約５０℃に、テトラヒドロピラン（ＴＨＰ）基が取り除かれて化合物３２が得られるまで加熱することができる。反応はＬＣ-ＭＳ又はＴＬＣでモニターすることができる。置換基Ｒ^１’及びＲ^３’は定義されたＲ^１及びＲ^３であるか又はその保護された形態又はその前駆体でありうる。 General Procedure D THP Deprotection

In general, N-9-tetrahydropyranyl substituted 31 is treated with a catalytic amount of para-toluenesulfonic acid (PTSA) in methanol solution to remove the tetrahydropyran (THP) group at about 50 ° C. to give compound 32. Can be heated until The reaction can be monitored by LC-MS or TLC. The substituents R ¹ ′ and R ³ ′ can be R ¹ and R ³ as defined, or protected forms thereof or precursors thereof.

一般に、置換３３をジクロロメタン中に懸濁させたところで、３当量のヒューニッヒ塩基（ＤＩＰＥＡ）及び１．５当量のアミン（ＮＨＲ_２）を反応混合物に加える。他の溶媒、例えばテトラヒドロフラン及びメタノール、又は溶媒混合物を用いることができる。反応はＴＬＣ又はＬＣ-ＭＳによって、通常は３０分以内である完了するまで、モニターする。反応混合物を水で抽出し、有機層を乾燥させ、濾過し、濃縮乾固する。中間体３４を粗物質のまま次の反応に取り上げることができ又は場合によってはカラムクロマトグラフィーで精製する。 General Procedure E Substitution of alkyl bromides with amines:

In general, once substitution 33 is suspended in dichloromethane, 3 equivalents of Hunig base (DIPEA) and 1.5 equivalents of amine (NHR ₂ ) are added to the reaction mixture. Other solvents such as tetrahydrofuran and methanol, or solvent mixtures can be used. The reaction is monitored by TLC or LC-MS until complete, usually within 30 minutes. The reaction mixture is extracted with water and the organic layer is dried, filtered and concentrated to dryness. Intermediate 34 can be taken up in the next reaction as crude material or optionally purified by column chromatography.

ｎが１から１２である２,６,８置換９-アルキルカルボキシルプリン３５をジメチルホルムアミド（ＤＭＦ）中の１．５当量のＨＡＴＵ（２-(７-アザ-１Ｈ-ベンゾトリアゾール-１-イル)-１,１,３,３-テトラメチルウロニウムヘキサフルオロホスフェート）、過剰（例えば３当量）のアルキルアミン（ＨＮＲ^１０Ｒ^１１）及び過剰（例えば３当量）の炭酸セシウムで処理する。あるいは、他のカップリング試薬を用いることができる。反応を完了するまで攪拌し、飽和重炭酸塩溶液と共に酢酸エチル中で抽出する。有機層を乾燥させ、濾過し、濃縮して、アシル化された粗中間体を得、これを逆相ＨＰＬＣで精製して生成物３６を得る。置換基Ｒ^１’及びＲ^３’は定義されたＲ^１及びＲ^３であるか又はその保護された形態又はその前駆体でありうる。 General procedure F- amide coupling

2,6,8-substituted 9-alkylcarboxypurine 35 wherein n is 1 to 12 is 1.5 equivalents of HATU (2- (7-aza-1H-benzotriazol-1-yl) in dimethylformamide (DMF) -1,1,3,3-tetramethyluronium hexafluorophosphate), excess (eg 3 equivalents) of alkylamine (HNR ¹⁰ R ¹¹ ) and excess (eg 3 equivalents) of cesium carbonate. Alternatively, other coupling reagents can be used. Stir until the reaction is complete and extract in ethyl acetate with saturated bicarbonate solution. The organic layer is dried, filtered and concentrated to give the acylated crude intermediate, which is purified by reverse phase HPLC to give product 36. The substituents R ¹ ′ and R ³ ′ can be R ¹ and R ³ as defined, or protected forms thereof or precursors thereof.

マイクロ波バイアル中の中間体３７に、１．２当量の臭化アリール、１当量のヨウ化銅（Ｉ）又は銅チオフェン-カルボキシレート、及び１,４-ジオキサンを溶媒として加える。反応混合物を窒素下で５分間脱気した後、０．１２当量のテトラキス(トリフェニルホスフィン)パラジウム（０）を加える。反応をＣＥＭ又はＢｉｏｔａｇｅマイクロ波で１４０℃で２０−３０分間加熱する。粗反応混合物を濾過し、Ｂｉｏｔａｇｅ Ｉｓｏｌｕｔｅ ｓｃｘ−２ベーシックｓｐｅカートリッジに定期的に通過させた後、順相又は逆相クロマトグラフィーで精製して純粋な生成物３８を得る。置換基Ｒ^２及びＲ^３’は定義されたＲ^２及びＲ^３であるか又はその保護された形態又は前駆体でありうる。 General Procedure G Still Coupling

To intermediate 37 in the microwave vial is added 1.2 equivalents of aryl bromide, 1 equivalent of copper (I) iodide or copper thiophene-carboxylate, and 1,4-dioxane as solvent. The reaction mixture is degassed under nitrogen for 5 minutes before adding 0.12 equivalents of tetrakis (triphenylphosphine) palladium (0). The reaction is heated with CEM or Biotage microwave at 140 ° C. for 20-30 minutes. The crude reaction mixture is filtered, periodically passed through a Biotage Isolute scx-2 basic sp cartridge, and then purified by normal phase or reverse phase chromatography to give the pure product 38. The substituents R ² and R ³ ′ can be defined R ² and R ³ or can be protected forms or precursors thereof.

General Procedure N-9 Alkylation of H Purines Scheme 1 illustrates the synthesis of polyfunctionalized purines starting with protection of 2,6-dichloro-9H-purine as the tetrahydropyranyl group (THP) of the N-9 nitrogen. A general preparation method is shown. Replacing the more reactive chloro group with morpholine yields 4- (2-chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) morpholine. The C-8 proton is removed with a strong base and reacted with various electrophiles (R ¹ ). After deprotection with a weak acid, N-9 is N-9 alkylated with various electrophiles (R ² ). Suzuki coupling of C-2 chloro by General Procedure A using various boronate reagents and palladium catalysts produces carbon bond _C 2 _{-C 20} heterocyclyl and carbon bond _C 1 _{-C 20} heteroaryl as ^{R 3.}

マイクロ波チューブにＸｐｈｏｓ（２-ジシクロヘキシルホスフィノ-２’,４’,６’-トリイソプロピルビフェニル、ＣＡＳ登録番号５６４４８３-１８-７、０．１当量）、トリス（ジベンジリデンアセトン）ジパラジウム（０）（０．０５当量）、炭酸セシウム（２当量）、対応する２-クロロプリン３９（１当量）及びベンゾイミダゾールのようなアミン（１．２当量）を充填する。容器を排気し、窒素を再充填した後、ＤＭＦ又は１,４-ジオキサンを加える。混合物をマイクロ波機器、例えばＢｉｏｔａｇｅで約１４０℃で約２５−３５分間加熱する。反応混合物を室温まで冷却し、濾過し、濃縮する。典型的には、粗生成物４０はフラッシュクロマトグラフィー又はＲＰ-ＨＰＬＣによって精製する。
あるいは、反応を修正した手順によって実施することができる：マイクロ波チューブに酢酸パラジウム（０．１０当量）、ビス(トリ-ｔ-ブチルホスフィン)パラジウム（０．１０当量）、ナトリウムｔ−ブトキシド（２当量）、対応する２-クロロプリン３９（１当量）及びアミン（２当量）を充填する。容器を排気し、窒素を再充填した後、トルエンを加える。混合物をＢｉｏｔａｇｅマイクロ波で約１４０℃で２５−３５分間加熱する。反応混合物を室温まで冷却し、濾過し、濃縮する。典型的には、粗生成物４０をフラッシュクロマトグラフィー又はＲＰ-ＨＰＬＣで精製する。 General Procedure I C-2 halobuchwald coupling of amine-heteroaryls

A microwave tube was charged with Xphos (2-dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, CAS Registry Number 564483-18-7, 0.1 equivalent), tris (dibenzylideneacetone) dipalladium (0 ) (0.05 eq), cesium carbonate (2 eq), the corresponding 2-chloropurine 39 (1 eq) and an amine such as benzimidazole (1.2 eq). The vessel is evacuated and refilled with nitrogen before adding DMF or 1,4-dioxane. The mixture is heated in a microwave instrument such as Biotage at about 140 ° C. for about 25-35 minutes. The reaction mixture is cooled to room temperature, filtered and concentrated. Typically, the crude product 40 is purified by flash chromatography or RP-HPLC.
Alternatively, the reaction can be performed by a modified procedure: palladium acetate (0.10 equiv), bis (tri-t-butylphosphine) palladium (0.10 equiv), sodium t-butoxide (2 Eq), the corresponding 2-chloropurine 39 (1 eq) and amine (2 eq). The vessel is evacuated and refilled with nitrogen before adding toluene. The mixture is heated in a Biotage microwave at about 140 ° C. for 25-35 minutes. The reaction mixture is cooled to room temperature, filtered and concentrated. Typically, the crude product 40 is purified by flash chromatography or RP-HPLC.

  The Buchwald (and Suzuki) coupling is carried out with a chloro {[t-butyl XPhos] [2- (2-aminoethylphenyl) palladium (II)) / [t-butyl XPhos] mixture (molar concentration PdP / P = 1: 1). ), Chloro (2-di-t-butylphosphino-2 ′, 4 ′, 6′-tri-i-propyl-1,1′-biphenyl) [2- (2-aminoethyl) phenyl] palladium (II) ), Chloro (2-dicyclohexylphosphino-2 ′, 6′-dimethoxy-1,1′-biphenyl) [2- (2-aminoethylphenyl)] palladium (II) methyl-t-butyl ether adduct, chloro [ 2- (Dicyclohexylphosphino) -3,6-dimethoxy-2′-4′-6′-tri-i-propyl-1,1′-biphenyl] [2- (2-aminoethyl) phenyl] palladium (II ), Chloro (2-dicyclohexylphosphino-2 ′, 6′-di-i-propoxy-1,1′-biphe L) [2- (2-aminoethylphenyl)] palladium (II), methyl-t-butyl ether adduct, chloro (2-dicyclohexylphosphino-2 ′, 4 ′, 6′-tri-i-propyl-1) , 1′-biphenyl) [2- (2-aminoethyl) phenyl] palladium (II) methyl-t-butyl ether adduct can be used with various ligands and palladium catalysts.

  2-dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, Xphos (CAS registry number 564483-18-7), racemic-2-di-t-butylphosphino-1,1′-binaphthyl ( CAS registration number 255836-67-0), 2- (di-t-butylphosphino) biphenyl, John Phos (CAS registration number 224311-51-7), 2-di-t-butylphosphino-2 '-(N , N-dimethylamino) biphenyl (CAS registry number 224311-49-3), 2-di-t-butylphosphino-2'-methylbiphenyl (CAS registry number 255837-19-5), 2-di-t- Butylphosphino-3,4,5,6-tetramethyl-2 ′, 4 ′, 6′-tri-i-propylbiphenyl (CAS registry number 857356-94-6), 2-di-t-butylphosphino -2 ', 4', 6'-tri-i-propyl- 1,1′-biphenyl, t-butyl XPhos (CAS registry number 564483-19-8), 2- (dicyclohexylphosphino) biphenyl (CAS registry number 247940-06-3), 2-dicyclohexylphosphino-2 ′, 6'-dimethoxy-1,1'-biphenyl, S-Phos (CAS registration number 657408-07-6), 2'-dicyclohexylphosphino-2,6-dimethoxy-3-sulfonato-1,1'-biphenyl water Japanese sodium salt, 2- (dicyclohexylphosphino) -3,6-dimethoxy-2′-4′-6′-tri-i-propyl-1,1′-biphenyl (BrettPhos), 2- (dicyclohexylphosphino ) -2 ′-(N, N-dimethylamino) biphenyl, DavePhos (CAS registry number 213697-53-1), 2-dicyclohexylphosphino-2 ′, 6′-di-i-propoxy- 1,1′-biphenyl, RuPhos (CAS registration number 787618-22-8), 2′-dicyclohexylphosphino-2,6-di-i-propyl-4-sulfonato-1,1′-biphenyl hydrate sodium Salt (CAS registry number 870245-84-4), 2-dicyclohexylphosphino-2'-methylbiphenyl, MePhos (CAS registry number 251320-86-2), 2- (dicyclohexylphosphino) -2 ', 4', 6′-tri-i-propyl-1,1′-biphenyl, X-Phos (CAS registration number 564483-18-7) 2-diphenylphosphino-2 ′-(N, N-dimethylamino) biphenyl (CAS registration) Various phosphorus ligands including the number 240417-00-9) can also be used for Buchwald (and Suzuki) couplings. See Mauger, C. C. and Mignani, G. A. Aldrichimica Acta (2006) 39:17; Schlummer, B. and Scholz, U. Adv. Synth. Catal. (2004) 346: 1599. Buchwald and Suzuki coupling reagents are available from commercial sources including Strem Chemicals, Inc., 7 Mulliken Way, Newburyport, MA 01950-4098 USA.

ブッフバルトカップリングに対する一般的手順Ｉを介して２-クロロプリン３９を１,２-ジアミノベンゼンと反応させて２-アミノヘテロアリール中間体４１を得、これを２つの可能な経路の一つを経て４２に転換する。上段の経路では；中間体４１及びＲ^８官能基を持つ酸（１．５当量）及びＨＡＴＵ（１．５当量）をＤＭＦ（１００当量）に溶解させたところで、Ｎ,Ｎ-ジイソプロピルエチルアミン（３−５当量）を加える。反応を一晩室温で攪拌し、濃縮乾固させる。粗物質を酢酸（１００当量）に溶解し、９０℃で１８時間加熱して生成物４２まで環化させる。中央の経路では、４１を直接Ｒ^８官能基を持つ酸（又はエステル）に溶解させ、一晩還流して生成物４２に環化させる。下方の経路では、４１を例えばｉＰｒ_２Ｎｅｔのような第三級アミン塩基の存在下で無水物（１から１．５当量）でアシル化する。最終生成物を逆相ＨＰＬＣで精製し、エナンチオマーが存在し分離が必要となる場合はつづいてキラルＳＦＣ（超臨界流体クロマトグラフィー）によって精製することができる（Liu等(2003) Chromatographia 58(11/12):775-779）。 General Procedure J. Formation of multi-step benzimidazoles by Buchwald coupling of amino-heteroaryls

2-Chloropurine 39 is reacted with 1,2-diaminobenzene via the general procedure I for Buchwald coupling to give the 2-aminoheteroaryl intermediate 41, which passes through one of two possible routes. Convert to 42. In the upper route; intermediate 41 and an acid having an R ⁸ functional group (1.5 eq) and HATU (1.5 eq) were dissolved in DMF (100 eq) to give N, N-diisopropylethylamine (3 -5 equivalents). The reaction is stirred overnight at room temperature and concentrated to dryness. The crude material is dissolved in acetic acid (100 equivalents) and heated to 90 ° C. for 18 hours to cyclize to product 42. In the central route, 41 is dissolved directly in an acid (or ester) with R ⁸ functionality and refluxed overnight to cyclize to product 42. In the lower route, 41 is acylated with an anhydride (1 to 1.5 equivalents) in the presence of a tertiary amine base such as iPr ₂ Net. The final product is purified by reverse phase HPLC and can be purified by chiral SFC (supercritical fluid chromatography) if enantiomers are present and separation is required (Liu et al. (2003) Chromatographia 58 (11 / 12): 775-779).

Ｎ,Ｎ-ジメチルホルムアミド中の２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルフォリノ-９Ｈ-プリン-８-カルボン酸４２（１当量）、ＨＢＴＵ（１．５当量）の混合液にトリエチルアミン（ＴＥＡ）を加える。生じた混合物を約５分間室温で攪拌し、アミン（Ｒ_２ＮＨ、１当量）を加える。反応混合物をついで室温で２−１８時間攪拌する。反応混合物を濃縮し、ＲＰ-ＨＰＬＣで精製して、アミド生成物４３を得る。他のカップリング剤、例えばＨＡＴＵ、ＨＣＴＵ、ＴＢＴＵ、及びＰｙＢＯＰを使用することができる。 General Procedure K C2-Carboxylamide Formation

2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carboxylic acid 42 (1 equivalent) in N, N-dimethylformamide; Triethylamine (TEA) is added to a mixture of HBTU (1.5 eq). The resulting mixture is stirred for about 5 minutes at room temperature and an amine (R ₂ NH, 1 eq) is added. The reaction mixture is then stirred at room temperature for 2-18 hours. The reaction mixture is concentrated and purified by RP-HPLC to give the amide product 43. Other coupling agents such as HATU, HCTU, TBTU, and PyBOP can be used.

アミン基の還元的アミノ化のための一般的手順の例示的な実施態様では、１,２-ジクロロエタン中の４-(８-(アゼチジン-３-イルメチル)-２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-９Ｈ-プリン-６-イル)モルホリン又は４-(８-(アゼチジン-３-イルメチル)-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-９Ｈ-プリン-６-イル)モルホリン（１当量）の懸濁液にケトン（約１．５−２．０当量）を加える。生じた混合物を室温で１５分間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（約１．５−２．０当量）を加える。ついで反応を室温で約１８時間攪拌する。反応をついでメタノールを加えてクエンチした。混合物はＲＰ-ＨＰＬＣを含むクロマトグラフィーによって精製することができる。また、混合物はＩｓｏｌｕｔｅ ＳＣＸ-２カラムに充填し、ＭｅＯＨで洗浄し、ＭｅＯＨ中の２ＭのＮＨ_３で溶出して、所望の生成物を得る。

General Procedure L Reductive Amination

In an exemplary embodiment of the general procedure for the reductive amination of amine groups, 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H--) in 1,2-dichloroethane. Benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine or 4- (8- (azetidin-3-ylmethyl) -2- (2-methyl-1H-benzo [d ] To a suspension of imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine (1 eq) is added ketone (about 1.5-2.0 eq). The resulting mixture is stirred at room temperature for 15 minutes before sodium triacetoxyborohydride (about 1.5-2.0 equivalents) is added. The reaction is then stirred at room temperature for about 18 hours. The reaction was then quenched by adding methanol. The mixture can be purified by chromatography including RP-HPLC. The mixture is also loaded onto an Isolute SCX-2 column, washed with MeOH and eluted with 2M NH ₃ in MeOH to give the desired product.

In an exemplary embodiment of the reductive amination of the 2-carboxaldehyde purine intermediate, 9-methyl-2- (2-methyl-benzimidazol-1-yl) -6-morpholine-4 in CH 2 Cl 2 (4 mL). -Yl-9H-purine-8-carbaldehyde (where R ² is methyl and R ³ is 2-methyl-benzimidazol-1-yl) (0.1 g, 0.264 mmol), AcOH ( 0.03 mL, 0.53 mmol) and the amine mixture were stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (78 mg, 0.37 mmol) was added and stirring continued for 18 hours. A saturated solution of potassium carbonate (K2CO3) was added and the product was extracted with CH2Cl2 (4x). The combined organics were dried (MgSO4) and concentrated. Purification by flash chromatography using CH2Cl2: methanol: ammonium hydroxide (100: 5: 0.5) gave the 2-aminomethyl product.

Alternatively, acetic acid (2 mmol) and trimethoxymethane (10 mmol) in a mixture of aldehyde (1 mmol) and amine (1-1.2 mmol) in 1,2-dichloroethane (8-20 mL), or micronized 4Å (angstrom) Molecular sieve was added. The mixture was stirred at room temperature for 0.5-4 hours. Sodium triacetoxyborohydride (1.1-1.5 mmol) was added. The resulting mixture was stirred at room temperature for 4-20 hours. The contents were partitioned between DCM and dilute NaOH. The organic layer was separated. The aqueous layer was extracted with DCM. The combined organic solution was dried (Na ₂ SO ₄ ). The crude material was purified by chromatography or reverse phase HPLC or used directly if sufficiently pure for subsequent conversion.

  The chemical reactions described in the examples can be readily adapted to prepare many other PI3K inhibitors of the present invention, and alternative methods for preparing the compounds of this invention are It is considered to be in range. For example, the synthesis of non-exemplary compounds according to the present invention can be performed by other modifications known in the art other than those described, by modifications obvious to those skilled in the art, for example, by appropriately protecting reactive functional groups. It can be carried out successfully by utilizing appropriate reagents and / or by routinely changing the reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having utility for preparing other compounds of the invention.

  Chiral SFC (supercritical fluid chromatography) can be used to separate enantiomers (Liu et al. (2003) Chromatographia 58 (11/12): 775-779).

¹ H NMR spectra were recorded at room temperature using a Varian Unity Inova (400 MHz) equipped with a triple resonance 5 mm probe. Chemical shifts are expressed in ppm compared to tetramethylsilane. The following abbreviations were used: br = broad signal, s = single line, d = double line, dd = double double line, t = triple line, q = quadruple line, m = multiple line.

High pressure liquid chromatography—A mass spectrometry (LCMS) experiment to measure retention time (R _T ) and associated mass ions can be performed, for example, by one of the following methods. The spectrometer has an electrospray source that operates in positive and negative ion modes. Further detection was achieved using a Sedex 85 evaporative light scattering detector.

Method A: Phenomenex Luna 3 μm C ₁₈ (2) Waters Platform LC 4 connected to a Hewlett Packard HP1100LC system with a diode array detector and a 100 position autosampler using a flow rate of 30 × 4.6 mm and 2 mL / min. Experiments were performed on a pole mass spectrometer. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in methanol (solvent B). The initial solvent system is 95% solvent A and 5% solvent B for the first 0.5 minutes, followed by a gradient to 5% solvent A and 95% solvent B over the next 4 minutes. It was. The final solvent system was kept constant for an additional minute.

Method B: Phenomenex Luna 3 μm C ₁₈ (2) Waters Platform LC 4 connected to a Hewlett Packard HP1100LC system with a diode array detector and 100 position autosampler using a flow rate of 30 × 4.6 mm and 2 mL / min. Experiments were performed on a pole mass spectrometer. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The initial solvent system is 95% solvent A and 5% solvent B for the first 0.50 minutes, followed by a gradient to 5% solvent A and 95% solvent B over the next 4 minutes. It was. The final solvent system was kept constant for an additional minute.

Method C: Phenomenex Luna 3 μm C ₁₈ (2) Waters ZMD quadrupole mass spectrometry connected to a Waters 1525 LC system equipped with a Waters 996 diode array detector and a Waters 2700 autosampler using a flow rate of 30 × 4.6 mm and 2 mL / min. Experiments were conducted in total. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in methanol (solvent B). The initial solvent system is 95% solvent A and 5% solvent B for the first 0.5 minutes, followed by a gradient to 5% solvent A and 95% solvent B over the next 4 minutes. It was. The final solvent system was kept constant for an additional minute.

Method D: Phenomenex Luna 3 μm C ₁₈ (2) Waters ZMD quadrupole mass spectrometry connected to a Waters 1525 LC system equipped with a Waters 996 diode array detector and a Waters 2700 autosampler using a flow rate of 30 × 4.6 mm and 2 mL / min. Experiments were conducted in total. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The initial solvent system is 95% solvent A and 5% solvent B for the first 0.5 minutes, followed by a gradient to 5% solvent A and 95% solvent B over the next 4 minutes. It was. The final solvent system was kept constant for an additional minute.

Method E: Waters connected to a Hewlett Packard HP1100LC system with a DAD UV detector and CTC HTS PAL autosampler using a Higgins Clipeus 5 μm C18 100 × 3.0 mm column (at 40 ° C.) and a flow rate of 1 mL / min. Experiments were performed on a Micromass ZQ2000 quadrupole mass spectrometer. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in methanol (solvent B). The initial solvent system was 85% solvent A and 15% solvent B for the first minute, followed by a gradient to 5% solvent A and 95% solvent B over the next 12 minutes. The final solvent system was kept constant for an additional 7 minutes.

Method F: Waters Micromass ZQ2000 four using a Higgins Clipeus 5 micron C ₁₈ 100 × 3.0 mm column and 1 mL / min flow rate and connected to a Hewlett Packard HP1100LC system equipped with a DAD UV detector and a CTC HTS PAL autosampler. Experiments were performed on a pole mass spectrometer. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The initial solvent system was 85% solvent A and 15% solvent B for the first minute, followed by a gradient to 5% solvent A and 95% solvent B over the next 14 minutes. The final solvent system was kept constant for an additional 5 minutes.

  Microwave experiments were performed using a CEM Explorer, Smith Synthesizer or Biotage Initiator® using a single mode resonator and dynamic field tuning, both of which provide reproducibility and control. Temperatures of 40-250 ° C. can be achieved and pressures up to 20 Bar can be reached.

  Unless otherwise stated, all reactions were carried out inert, ie under an argon or nitrogen atmosphere.

R ¹ Reagents:

Example 1 3- (Tetrahydropyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester

−２０℃の無水ＴＨＦ（２００ｍＬ）中のジイソプロピルアミン（３５．２ｍＬ、０．２５ｍｏｌ）の溶液にヘキサン（１００ｍＬ、０．２５ｍｏｌ）中の２．５Ｍのｎ-ブチルリチウム溶液を１０分かけてアルゴン雰囲気下で加えた。反応混合物を−２０℃で１５分間攪拌した。無水ＴＨＦ（１６０ｍＬ）中のテトラヒドロピラン-４-オン（２１．０ｍＬ、０．２３ｍｏｌ）の溶液を２０分かけて滴下して加えた（内部温度＜−６５℃）。反応混合物を３時間−７８℃で攪拌し、ついで無水ＴＨＦ（２４０ｍＬ）中のＮ,Ｎ-ビス(トリフルオロメタンスルホニル)アニリン（８６．４ｇ、０．２４ｍｍｏｌ）の溶液を４５分かけて滴下して加えた。生じた混合物を−７８℃で１．５時間攪拌し、ついで室温に達しさせ、１８時間攪拌した。溶媒を真空下で除去して残留物を得、これをＥｔＯＡｃ（５００ｍＬ）と水（２５０ｍＬ）の間で分配した。有機層を分離し、水（２５０ｍＬ）、水中の２ＭのＮａＯＨ（３×３００ｍＬ）及びブライン（２×２００ｍＬ）で洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮して、トリフルオロメタンスルホン酸３,６-ジヒドロ-２Ｈ-ピラン-４-イルエステルを褐色油（４３．７ｇ、８３％）として得た。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ５．８３−５．８０（ｍ，１Ｈ）；４．２６（ｄｄ，Ｊ＝２．９，０．４Ｈｚ，２Ｈ）；３．８９（ｔ，Ｊ＝５．５Ｈｚ，２Ｈ）；２．４６（ｔｔｄ，Ｊ＝５．５，２．９，１．４Ｈｚ，２Ｈ）。 Step 1: Trifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester

To a solution of diisopropylamine (35.2 mL, 0.25 mol) in anhydrous THF (200 mL) at −20 ° C. was added 2.5 M n-butyllithium solution in hexane (100 mL, 0.25 mol) over 10 minutes with argon. Added under atmosphere. The reaction mixture was stirred at −20 ° C. for 15 minutes. A solution of tetrahydropyran-4-one (21.0 mL, 0.23 mol) in anhydrous THF (160 mL) was added dropwise over 20 minutes (internal temperature <−65 ° C.). The reaction mixture was stirred for 3 hours at −78 ° C., then a solution of N, N-bis (trifluoromethanesulfonyl) aniline (86.4 g, 0.24 mmol) in anhydrous THF (240 mL) was added dropwise over 45 minutes. added. The resulting mixture was stirred at −78 ° C. for 1.5 hours, then allowed to reach room temperature and stirred for 18 hours. The solvent was removed under vacuum to give a residue that was partitioned between EtOAc (500 mL) and water (250 mL). The organic layer was separated and washed with water (250 mL), 2M NaOH in water (3 × 300 mL) and brine (2 × 200 mL), dried over Na ₂ SO ₄ , filtered and concentrated to trifluoromethanesulfone. The acid 3,6-dihydro-2H-pyran-4-yl ester was obtained as a brown oil (43.7 g, 83%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 5.83-5.80 (m, 1H); 4.26 (dd, J = 2.9, 0.4 Hz, 2H); 3.89 (t, J = 5.5 Hz, 2H); 2.46 (ttd, J = 5.5, 2.9, 1.4 Hz, 2H).

Step 2: 3- (3,6-Dihydro-2H-pyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester

  Zinc activation: TMS-Cl: 1,2-dibromoethane (6.2 mL) in a suspension of zinc powder (20.3 g, 0.31 mol) and Celpure® P65 in anhydrous DMA (48 mL). The 7: 5 (v: v) mixture was added dropwise. The reaction mixture was stirred for 45 minutes at room temperature.

  Zinc insertion: A solution of 3-iodoazetidine-1-carboxylic acid tert-butyl ester (72.9 g, 0.26 mol) in anhydrous DMA (120 mL) was added dropwise to the above mixture over 30 min. The reaction mixture was stirred for 1 hour at room temperature.

Coupling reaction: trifluoromethanesulfonic acid 3,6-dihydro-2H-pyran-4-yl ester (42.7 g, 0.18 mol), Pd (dppf) Cl ₂ .DCM (4.5 g, 5.5 mmol) and A mixture of CuI (2.1 g, 11.0 mmol) was sonicated for 5 minutes. The vessel was then evacuated and refilled with argon. The zincate mixture was quickly filtered through a grade 3 sinter funnel and added to the palladium-containing mixture. The resulting reaction mixture was stirred at 85 ° C. for 18 hours and then cooled to room temperature. EtOAc (1 L) and 1 M aqueous solution of ammonium chloride (0.5 L) were added and the mixture was stirred for 30 minutes. Water (0.5 L) was added to the reaction mixture and the organic layer was separated, washed with water and brine, washed with Na ₂ SO ₄ , filtered and concentrated.

Purification: The residue was taken up in cyclohexane (ca. 200 mL) and loaded onto a column of 600 g silica gel 60 pretreated with cyclohexane. The product was eluted with a gradient of EtOAc in cyclohexane (0% -50%). Appropriate fractions were combined and concentrated to give the title compound as a dark oil (22.85 g, 52%). The combined fractions were combined and concentrated to give a residue that was subjected to automated flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 5:95 to 50:50). Appropriate fractions were combined to give 3- (3,6-dihydro-2H-pyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester as a dark oil (7.8 g, 18%). . ¹ H NMR (400 MHz, CHCl ₃ -d): δ 5.56-5.53 (m, 1H); 4.17-4.13 (m, 2H); 4.02 (t, J = 8.6 Hz, 2H); 3.85-3.78 (m, 4H); 3.20-3.09 (m, 1H); 2.11-2.06 (m, 2H); 1.44 (s, 9H) .

Step 3: 3- (3,6-Dihydro-2H-pyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester (28.6 g, 0.12 mol) and 10% palladium on charcoal in IMS (500 mL) (5.0 g) of the mixture was stirred under hydrogen (4 bar) at room temperature for 36 hours. The reaction mixture was filtered through a Celite® bed washed with IMS. The filtrates were combined and concentrated to give a residue which was reacted as described above for 18 hours. The reaction mixture is treated as described above to give a residue which is dried under reduced pressure to give 3- (tetrahydropyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester as a beige solid. Obtained as a product (26.7 g, 92%). ¹ H NMR (300 MHz, CHCl ₃ -d): δ 4.03-3.90 (m, 4H); 3.63 (dd, J = 8.6, 5.7 Hz, 2H); 3.37 (td, J = 11.8, 2.0 Hz, 2H); 2.32-2.19 (m, 1H); 1.63-1.48 (m, 3H); 1.44 (s, 9H); 29-1.12 (m, 2H).

Example 2 (4-Methylpiperidin-4-yl) pyrrolidin-1-ylmethanone

ＤＭＦ（１０ｍＬ）中の４-メチルピペリジン-１,４-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（２２９ｍｇ、０．９４ｍｍｏｌ）の溶液にＤＩＰＥＡ（０．４９３ｍＬ、２．８３ｍｍｏｌ）、ピロリジン（０．１１８ｍＬ、１．４１ｍｍｏｌ）及びＨＡＴＵ（５３７ｍｇ、１．４１ｍｍｏｌ）を加えた。反応混合物を室温で１８時間攪拌し、ついで水とＥｔＯＡｃの間で分配した。有機層を分離し、０．１ＮのＨＣｌ水溶液及びブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮して４-メチル-４-(ピロリジン-１-カルボニル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを白色固形物（２７９ｍｇ、１００％）として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ４．００分；［Ｍ＋Ｎａ］^＋３１９ Step 1: 4-Methyl-4- (pyrrolidine-1-carbonyl) piperidine-1-carboxylic acid tert-butyl ester

To a solution of 4-methylpiperidine-1,4-dicarboxylic acid mono-tert-butyl ester (229 mg, 0.94 mmol) in DMF (10 mL), DIPEA (0.493 mL, 2.83 mmol), pyrrolidine (0.118 mL, 1.41 mmol) and HATU (537 mg, 1.41 mmol) were added. The reaction mixture was stirred at room temperature for 18 hours and then partitioned between water and EtOAc. The organic layer was separated, washed with 0.1N aqueous HCl and brine, dried over Na ₂ SO ₄ , filtered and concentrated to 4-methyl-4- (pyrrolidine-1-carbonyl) piperidine-1-carboxyl. The acid tert-butyl ester was obtained as a white solid (279 mg, 100%). LCMS (Method H): R _T 4.00 min; [M + Na] ⁺ 319

Step 2: 4-Methyl-4- (pyrrolidine-1-carbonyl) piperidine-1-carboxylic acid tert-butyl ester (296 mg, 1.0 mmol) in TFA (5 mL), DCM (5 mL) and water (0.1 mL) ) Was stirred for 2 hours at room temperature and then concentrated under reduced pressure for 2 hours. The residue was taken up in MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. Solvent was removed to give the desired product as a white solid (196 mg, 66%). LCMS (Method A): R _T 0.31 min; [M + H] ⁺ 197

工程１：３-メチルピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル

ＩＭＳ（５ｍＬ）中の３-メチルピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル３-メチルエステル（３７０ｍｇ、１．５２ｍｍｏｌ）の溶液に１Ｍの水酸化ナトリウム（２．０ｍＬ、２．０ｍｍｏｌ）の水溶液を加えた。反応混合物を室温で２時間攪拌し、ついで減圧下で濃縮した。残留物をＥｔＯＡｃと０．１ＭのＨＣｌの水溶液の間で分配した。有機層を分離し、ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮して、所望の生成物を白色固形物（３４８ｍｇ、１００％）として得た。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ３．８５−３．７５（ｍ，１Ｈ）；３．５２−３．４１（ｍ，２Ｈ）；３．２７−３．１５（ｍ，１Ｈ）；２．３９−２．３０（ｍ，１Ｈ）；１．８３−１．７４（ｍ，１Ｈ）；１．５１−１．４０（ｍ，９Ｈ）；１．３８（ｓ，３Ｈ）。 Example 3 (3-Methylpyrrolidin-3-yl) pyrrolidin-1-ylmethanone

Step 1: 3-Methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester

To a solution of 3-methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (370 mg, 1.52 mmol) in IMS (5 mL) was added 1 M sodium hydroxide (2.0 mL, 2.0 mmol). ) Was added. The reaction mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure. The residue was partitioned between EtOAc and 0.1 M aqueous HCl. The organic layer was separated, washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated to give the desired product as a white solid (348 mg, 100%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 3.85-3.75 (m, 1H); 3.52-3.41 (m, 2H); 3.27-3.15 (m, 1H) 2.39-2.30 (m, 1H); 1.83-1.74 (m, 1H); 1.51-1.40 (m, 9H); 1.38 (s, 3H).

ＤＭＦ（１０ｍＬ）中の３-メチルピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル（３４８ｍｇ、１．５２ｍｍｏｌ）の溶液にＤＩＰＥＡ（０．５３ｍＬ、３．０４ｍｍｏｌ）、ピロリジン（０．２５ｍＬ、３．０４ｍｍｏｌ）及びＨＡＴＵ（６９３ｍｇ、１．８２ｍｍｏｌ）を加えた。反応混合物を室温で１８時間攪拌し、ついで水とＥｔＯＡｃの間で分配した。有機層を分離し、０．１ＮのＨＣｌ水溶液及びブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮して所望の生成物を白色固形物（３３４ｍｇ、７８％）として得た。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ３．６１−３．３８（ｍ，８Ｈ）；２．００−１．７９（ｍ，６Ｈ）；１．４７−１．４４（ｍ，９Ｈ）；１．３３（ｓ，３Ｈ）。 Step 2: 3-Methyl-3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester

To a solution of 3-methylpyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (348 mg, 1.52 mmol) in DMF (10 mL) was added DIPEA (0.53 mL, 3.04 mmol), pyrrolidine (0.25 mL, 3.04 mmol) and HATU (693 mg, 1.82 mmol) were added. The reaction mixture was stirred at room temperature for 18 hours and then partitioned between water and EtOAc. The organic layer was separated, washed with 0.1 N aqueous HCl and brine, dried over Na ₂ SO ₄ , filtered and concentrated to give the desired product as a white solid (334 mg, 78%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 3.61-3.38 (m, 8H); 2.00-1.79 (m, 6H); 1.47-1.44 (m, 9H) 1.33 (s, 3H).

Step 3: 3-Methyl-3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester (330 mg, 1.17 mmol) in TFA (5 mL), DCM (5 mL) and water (0.1 mL). ) Was stirred at room temperature for 2 hours and then concentrated under reduced pressure. The residue was taken up in MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed to give (3-methylpyrrolidin-3-yl) pyrrolidin-1-ylmethanone as a white solid (169 mg, 79%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 3.55-3.40 (m, 5H); 3.06-2.92 (m, 2H); 2.32-2.20 (m, 2H) 2.01-1.82 (m, 5H); 1.71 (m, 1H); 1.33 (s, 3H).

工程１：４-(２-(メタンスルホニル)エチル)-３,３-ジメチルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

工程２：ＭｅＯＨ（１５ｍＬ）中の３,３-ジメチルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５００ｍｇ、２．３３ｍｍｏｌ）及びメチルビニルスルホン（５１０μＬ、６１９ｍｇ、５．８３ｍｍｏｌ）の混合物を６５℃まで５．５時間加熱し、ついで室温で９６時間攪拌した。反応混合物を真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−３％）で精製して、１-(２-(メタンスルホニル)エチル)-２,２-ジメチルピペラジンを白色のロウ状固形物（５５０ｍｇ、７４％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ３．４７−３．４０（ｍ，２Ｈ）；３．１５（ｓ，２Ｈ）；３．０９（ｔ，Ｊ＝６．４Ｈｚ，２Ｈ）；３．０３（ｓ，３Ｈ）；２．８９（ｔ，Ｊ＝６．４Ｈｚ，２Ｈ）；２．５８−２．５０（ｍ，２Ｈ）；１．４５（ｓ，９Ｈ）；１．０４（ｓ，６Ｈ）。 Example 4 1- (2- (Methanesulfonyl) ethyl) -2,2-dimethylpiperazine

Step 1: 4- (2- (Methanesulfonyl) ethyl) -3,3-dimethylpiperazine-1-carboxylic acid tert-butyl ester

Step 2: A mixture of 3,3-dimethylpiperazine-1-carboxylic acid tert-butyl ester (500 mg, 2.33 mmol) and methyl vinyl sulfone (510 μL, 619 mg, 5.83 mmol) in MeOH (15 mL) to 65 ° C. Heated for 5.5 hours, then stirred at room temperature for 96 hours. The reaction mixture was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-3%) to give 1- (2- (methanesulfonyl) ethyl) -2,2-dimethylpiperazine as a white wax. Obtained as a solid (550 mg, 74%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.47-3.40 (m, 2H); 3.15 (s, 2H); 3.09 (t, J = 6.4 Hz, 2H); 3.03 (S, 3H); 2.89 (t, J = 6.4 Hz, 2H); 2.58-2.50 (m, 2H); 1.45 (s, 9H); 1.04 (s, 6H) ).

Step 3: A mixture of 4- (2-methanesulfonylethyl) -3,3-dimethylpiperazine-1-carboxylic acid tert-butyl ester (510 mg, 1.59 mmol) and TFA (5 mL) in DCM (10 mL) at room temperature. For 2 hours. The reaction mixture is loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product is eluted with 2M NH ₃ / MeOH to give 1- (2- (methanesulfonyl) ethyl) -2, 2-Dimethylpiperazine was obtained as a white solid (320 mg, 91%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.49 (s, 1H); 3.12-3.03 (m, 5H); 2.92-2.84 (m, 4H); 2.60 (s , 2H); 2.53-2.47 (m, 2H); 1.06 (s, 6H).

工程１：３-(２,２-ジメチルモルホリン-４-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（１５ｍＬ）中の２,２-ジメチルモルホリン（２６０ｍｇ、２．２６ｍｍｏｌ）及び３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（４６４ｍｇ、２．７１ｍｍｏｌ）の混合物を室温で２時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（９５７ｍｇ、４．５２ｍｍｏｌ）を加えた。生じた混合物を１６時間攪拌し、ついでＤＣＭで希釈し、Ｈ_２Ｏで洗浄した。有機相を乾燥させ(相分離器)、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−４０％）で精製して表題化合物を油（４９２ｍｇ、８１％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ３．９５−３．８５（ｍ，２Ｈ）；３．８０−３．７１（ｍ，４Ｈ）；３．０７−２．８８（ｍ，１Ｈ）；２．３２−２．２２（ｍ，２Ｈ）；２．１４−２．０６（ｍ，２Ｈ）；１．４４（ｓ，９Ｈ）；１．２５（ｓ，６Ｈ）。 Example 5 4-Azetidin-3-yl-2,2-dimethylmorpholine

Step 1: 3- (2,2-Dimethylmorpholin-4-yl) azetidine-1-carboxylic acid tert-butyl ester

After stirring a mixture of 2,2-dimethylmorpholine (260 mg, 2.26 mmol) and 3-oxoazetidine-1-carboxylic acid tert-butyl ester (464 mg, 2.71 mmol) in DCE (15 mL) at room temperature for 2 hours, Sodium triacetoxyborohydride (957 mg, 4.52 mmol) was added. The resulting mixture was stirred for 16 hours, then diluted with DCM and washed with H ₂ O. The organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-40%) to give the title compound as an oil (492 mg, 81%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.95-3.85 (m, 2H); 3.80-3.71 (m, 4H); 3.07-2.88 (m, 1H); 2 .32-2.22 (m, 2H); 2.14-2.06 (m, 2H); 1.44 (s, 9H); 1.25 (s, 6H).

Step 2: A mixture of 3- (2,2-dimethylmorpholin-4-yl) azetidine-1-carboxylic acid tert-butyl ester (492 mg, 1.82 mmol) and TFA (5 mL) in DCM (10 mL) at room temperature. Stir for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH to give 4-azetidin-3-yl-2,2-dimethylmorpholine as white Obtained as a solid (302 mg, 97%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.73 (t, J = 4.8 Hz, 2H); 3.64-3.51 (m, 4H); 3.18-3.11 (m, 1H) 2.23 (t, J = 4.8 Hz, 2H); 2.23-2.07 (m, 1H); 2.06 (s, 2H); 1.25 (s, 6H).

Example 6 4-Azetidin-3-yl-thiomorpholine 1,1-dioxide

ＥｔＯＨ（５０ｍＬ）中の３-アミノアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１０．０ｇ、５８．１ｍｍｏｌ）の還流溶液にＥｔＯＨ（５０ｍＬ）中のジビニルスルホン（５．９ｍＬ、６．８６ｇ、５８．１ｍｍｏｌ）の溶液を滴下して加えた。生じた混合物を１５．５時間還流状態で攪拌させ、室温まで冷却し、真空下で濃縮した。生じたベージュ色の固体をＥｔ_２Ｏで倍散させ、表題化合物を白色固形物（１０．８ｇ、６４％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ３．９７（ｄｄ，Ｊ＝８．８，７．１Ｈｚ，２Ｈ）；３．７６（ｄｄ，Ｊ＝８．８，７．１Ｈｚ，２Ｈ）；３．３６−３．２６（ｍ，１Ｈ）；３．１３−３．０５（ｍ，４Ｈ）；２．９０−２．８３（ｍ，４Ｈ）；１．４４（ｓ，９Ｈ）。 Step 1: 3- (1,1-Dioxo-1-thiomorpholin-4-yl) azetidine-1-carboxylic acid tert-butyl ester

To a refluxing solution of 3-aminoazetidine-1-carboxylic acid tert-butyl ester (10.0 g, 58.1 mmol) in EtOH (50 mL) was added divinyl sulfone (5.9 mL, 6.86 g, EtOH (50 mL), 58.1 mmol) was added dropwise. The resulting mixture was allowed to stir at reflux for 15.5 hours, cooled to room temperature, and concentrated in vacuo. The resulting beige solid was triturated with Et ₂ O to give the title compound as a white solid (10.8 g, 64%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.97 (dd, J = 8.8, 7.1 Hz, 2H); 3.76 (dd, J = 8.8, 7.1 Hz, 2H); 36-3.26 (m, 1H); 3.13-3.05 (m, 4H); 2.90-2.83 (m, 4H); 1.44 (s, 9H).

Step 2: 3- (1,1-Dioxo-1-thiomorpholin-4-yl) -azetidine-1-carboxylic acid tert-butyl ester (3.35 g, 11.5 mmol) and TFA (DCM in 30 mL) 15 mL) was stirred at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 4-azetidin-3-yl-thiomorpholine 1,1- The dioxide was obtained as a white solid (2.0 g, 91%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.64-3.53 (m, 4H); 3.49-3.39 (m, 1H); 3.08 (m, 4H); 2.86-2 79 (m, 4H); 1.83 (s, 1H).

Example 7 Methyl (piperidin-4-yl) (tetrahydro-furan-3-yl) amine

ＤＣＭ（１０ｍＬ）中の４-(メチルアミノ)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）、ジヒドロフラン-３-オン（１４５μＬ、１６１ｍｇ、１．８７ｍｍｏｌ）、４Å粉末化モレキュラーシーブ（５５０ｍｇ）及びＤＩＰＥＡ（３２３μＬ、２４１ｍｇ、１．８７ｍｍｏｌ）の混合物を室温で３０分間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（３９６ｍｇ、１．８７ｍｍｏｌ）を加えた。反応混合物を１６時間室温で攪拌し、ついでＤＣＭで希釈して、Ｈ_２Ｏで洗浄した。有機相を乾燥（Ｎａ_２ＳＯ_４）させ、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して表題化合物を油（１３２ｍｇ、５０％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ４．３３−４．０５（ｍ，２Ｈ）；４．０１−３．９１（ｍ，１Ｈ）；３．９０−３．７３（ｍ，２Ｈ）；３．６８−３．４８（ｍ，１Ｈ）；３．４７−３．２３（ｍ，１Ｈ）；２．７２−２．５６（ｍ，２Ｈ）；２．２１（ｓ，３Ｈ）；２．１１−１．９４（ｍ，１Ｈ）；１．９３−１．７８（ｍ，１Ｈ）；１．７６−１．６３（ｍ，２Ｈ）；１．７６−１．６３（ｍ，１Ｈ）；１．５４−１．４６（ｍ，２Ｈ）；１．４６（ｓ，９Ｈ）。 Step 1: 4- [Methyl (tetrahydrofuran-3-yl) amino] piperidine-1-carboxylic acid tert-butyl ester

4- (Methylamino) piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.93 mmol), dihydrofuran-3-one (145 μL, 161 mg, 1.87 mmol), 4 （powdered molecular in DCM (10 mL) A mixture of sieves (550 mg) and DIPEA (323 μL, 241 mg, 1.87 mmol) was stirred at room temperature for 30 minutes before adding sodium triacetoxyborohydride (396 mg, 1.87 mmol). The reaction mixture was stirred for 16 hours at room temperature, then diluted with DCM and washed with H ₂ O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as an oil (132 mg, 50%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.33-4.05 (m, 2H); 4.01-3.91 (m, 1H); 3.90-3.73 (m, 2H); 3 .68-3.48 (m, 1H); 3.47-3.23 (m, 1H); 2.72-2.56 (m, 2H); 2.21 (s, 3H); 2.11 -1.94 (m, 1H); 1.93-1.78 (m, 1H); 1.76-1.63 (m, 2H); 1.76-1.63 (m, 1H); 1 .54-1.46 (m, 2H); 1.46 (s, 9H).

Step 2: Mix a mixture of 4- [methyl (tetrahydrofuran-3-yl) amino] piperidine-1-carboxylic acid tert-butyl ester (132 mg, 0.46 mmol) and TFA (2 mL) in DCM (5 mL) at room temperature. Stir for hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give methyl (piperidin-4-yl) (tetrahydro-furan-3- Yl) amine was obtained as a white solid (84 mg, quantitative). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.98-3.91 (m, 1H); 3.88-3.83 (m, 1H); 3.80-3.73 (m, 1H); 3 .61-3.53 (m, 1H); 3.42-3.35 (m, 1H); 3.26-3.14 (m, 2H); 2.71-2.53 (m, 2H) 2.57-2.4 (m, 1H); 2.23 (s, 3H); 2.05-1.97 (m, 1H); 1.93-1.7 (m, 1H); 1 .78-1.72 (m, 2H); 1.64-1.49 (m, 2H).

Example 8 Methylpiperidin-4-yl (tetrahydropyran-4-yl) amine

Step 1: 4- [Methyl (tetrahydropyran-4-yl) amino] piperidine-1-carboxylic acid tert-butyl ester

4-Methylaminopiperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.93 mmol), tetrahydropyran-3-one (187 mg, 1.87 mmol), 4Å powdered molecular sieve (550 mg) in DCM (10 mL) And a mixture of DIPEA (323 μL, 241 mg, 1.87 mmol) was stirred at room temperature for 30 minutes, and then sodium triacetoxyborohydride (396 mg, 1.87 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours, then diluted with DCM and washed with H ₂ O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) and 4- [methyl (tetrahydropyran-4-yl) amino] piperidine-1-carboxylic acid tert-butyl ester As an oil (101 mg, 36%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.24-4.07 (m, 2H); 4.06-3.96 (m, 2H); 3.43-3.32 (m, 2H); 2 .78-2.63 (m, 4H); 2.25 (s, 3H); 1.77-1.60 (m, 8H); 1.46 (s, 9H).

Step 2: A mixture of 4- [methyl (tetrahydropyran-4-yl) -amino] -piperidine-1-carboxylic acid tert-butyl ester (101 mg, 0.34 mmol) and TFA (2 mL) in DCM (5 mL). Stir at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give methylpiperidin-4-yl (tetrahydropyran-4-yl). The amine was obtained as a white solid (66 mg, 97%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.05-3.97 (m, 2H); 3.38 (td, J = 10.9, 3.8 Hz, 2H); 3.19 (d, J = 12.1 Hz, 2H); 2.84-2.57 (m, 5H); 2.27 (s, 3H); 1.80-1.49 (m, 8H).

工程１：４-(メチル(オキセタン-３-イル)アミノ)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（６ｍＬ）中の４-(メチルアミノ)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）及びオキセタン-３-オン（５６ｍｇ、０．７８ｍｍｏｌ）の混合物を室温で２時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（２６４ｍｇ、１．２４ｍｍｏｌ）を加えた。生じた混合物を１６時間攪拌し、ついでＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた油をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ／ＤＣＭ、０−２０％）で精製し、４-(メチル(オキセタン-３-イル)アミノ)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを油（４０ｍｇ、１６％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ４．６６（ｔ，Ｊ＝６．６Ｈｚ，２Ｈ）；４．６１（ｔ，Ｊ＝６．６Ｈｚ，２Ｈ）；４．１６（ｓ，２Ｈ）；３．９５（ｐ，Ｊ＝６．６Ｈｚ，１Ｈ）；２．６３（ｔ，Ｊ＝１２．５Ｈｚ，２Ｈ）；２．３９（ｔｔ，Ｊ＝１１．７，３．７Ｈｚ，１Ｈ）；２．２０（ｓ，３Ｈ）；１．６０（ｄ，Ｊ＝１２．５Ｈｚ，２Ｈ）；１．４６（ｓ，９Ｈ）；１．４４−１．２８（ｍ，２Ｈ）。 Example 9 Methyl (oxetane-3-yl) piperidin-4-ylamine

Step 1: 4- (Methyl (oxetane-3-yl) amino) piperidine-1-carboxylic acid tert-butyl ester

A mixture of 4- (methylamino) piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.93 mmol) and oxetan-3-one (56 mg, 0.78 mmol) in DCE (6 mL) was stirred at room temperature for 2 hours. After that, sodium triacetoxyborohydride (264 mg, 1.24 mmol) was added. The resulting mixture was stirred for 16 hours, then loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH. The resulting oil was purified by column chromatography (Si-PCC, MeOH / DCM, 0-20%) and 4- (methyl (oxetane-3-yl) amino) piperidine-1-carboxylic acid tert-butyl ester as an oil. (40 mg, 16%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.66 (t, J = 6.6 Hz, 2H); 4.61 (t, J = 6.6 Hz, 2H); 4.16 (s, 2H); 3 .95 (p, J = 6.6 Hz, 1H); 2.63 (t, J = 12.5 Hz, 2H); 2.39 (tt, J = 11.7, 3.7 Hz, 1H); 20 (s, 3H); 1.60 (d, J = 12.5 Hz, 2H); 1.46 (s, 9H); 1.44 to 1.28 (m, 2H).

Step 2: Mix a mixture of 4- (methyl (oxetane-3-yl) amino) piperidine-1-carboxylic acid tert-butyl ester (150 mg, 0.55 mmol) and TFA (4 mL) in DCM (10 mL) at room temperature. Stir for hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give methyl (oxetane-3-yl) piperidin-4-ylamine as white Obtained as a solid (94 mg, quantitative). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.67 (t, J = 6.7 Hz, 2H); 4.61 (t, J = 6.7 Hz, 2H); 3.97 (p, J = 6. 7.14 (d, J = 12.3 Hz, 2H); 2.56 (td, J = 12.2, 4.0 Hz, 2H); 2.48-2.26 (m, 2H) 2.22 (s, 3H); 1.63 (d, J = 12.3 Hz, 2H); 1.40 (qd, J = 12.2, 4.0 Hz, 2H).

工程１：３-(３-オキソピペラジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＡｃＯＨ（０．７ｍＬ）及びＤＣＥ（５０ｍＬ）中のピペラジン-２-オン(１．５２ｇ、１５．１ｍｍｏｌ)、３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２．０ｇ、１１．６ｍｍｏｌ）及びトリメチルオルトギ酸エステル（１２．８ｍＬ、１２．４ｇ、１１７ｍｍｏｌ）の混合物を５時間攪拌した後、トリアセトキシ水素化ホウ素（４．９ｇ、２３．２ｍｍｏｌ）を加えた。生じた混合物を１６時間攪拌し、ついでＤＣＭ及びＨ_２Ｏの間で分配した。有機層を乾燥（Ｎａ_２ＳＯ_４）させ、真空下で濃縮した。生じた油をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物を泡（８２７ｍｇ、２８％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ６．２４（ｓ，１Ｈ）；３．９７（ｄｄ，Ｊ＝８．９，７．１Ｈｚ，２Ｈ）；３．８２（ｄｄ，Ｊ＝５．２，２．２Ｈｚ，２Ｈ）；３．４０（ｔｄ，Ｊ＝５．２，２．２Ｈｚ，２Ｈ）；３．２４−３．１５（ｍ，１Ｈ）；３．０７（ｓ，２Ｈ）；２．６０（ｔ，Ｊ＝５．４Ｈｚ，２Ｈ）；１．４４（ｓ，９Ｈ）。 Example 10 4-Azetidin-3-ylpiperazin-2-one

Step 1: 3- (3-Oxopiperazin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

Piperazin-2-one (1.52 g, 15.1 mmol), 3-oxoazetidine-1-carboxylic acid tert-butyl ester (2.0 g, 11.6 mmol) in AcOH (0.7 mL) and DCE (50 mL) and After stirring a mixture of trimethylorthoformate ester (12.8 mL, 12.4 g, 117 mmol) for 5 hours, triacetoxyborohydride (4.9 g, 23.2 mmol) was added. The resulting mixture was stirred for 16 hours and then partitioned between DCM and H ₂ O. The organic layer was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting oil was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as a foam (827 mg, 28%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 6.24 (s, 1H); 3.97 (dd, J = 8.9, 7.1 Hz, 2H); 3.82 (dd, J = 5.2) 2.40 (td, J = 5.2, 2.2 Hz, 2H); 3.24-3.15 (m, 1H); 3.07 (s, 2H); 60 (t, J = 5.4 Hz, 2H); 1.44 (s, 9H).

Step 2: 3- (3-Oxopiperazin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (400 mg, 1.57 mmol) and TFA (3 mL) in DCM (6 mL) were stirred at room temperature for 2 hours. . The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 4-azetidin-3-ylpiperazin-2-one as white Obtained as a solid (227 mg, 93%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 6.08 (s, 1H); 3.63-3.56 (m, 3H); 3.42-3.35 (m, 3H); 3.31 (t , J = 6.74 Hz, 1H); 3.03 (s, 2H); 2.59-2.51 (m, 2H).

工程１：３-((Ｓ)-３-ヒドロキシピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（１０ｍＬ）中の(Ｓ)-ピロリジン-３-オール（２６１ｍｇ、３．０ｍｍｏｌ）、３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５１３ｍｇ、３．０ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（１．０ｇ）の混合物を室温で６時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（１．２７ｇ、６．０ｍｍｏｌ）を加えた。反応混合物をセライトで濾過し、ＤＣＭで洗浄した。濾液を真空下で濃縮し、生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、アセトン：ＤＣＭ、０−４０％）で精製して、３-((Ｓ)-３-ヒドロキシピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを褐色油（３９０ｍｇ、５４％）として得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ０．２８ｍｉｎ［Ｍ＋Ｈ］^＋２４３．０ Example 11 (S) -1-azetidin-3-ylpyrrolidin-3-ol

Step 1: 3-((S) -3-hydroxypyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

(S) -Pyrrolidin-3-ol (261 mg, 3.0 mmol), 3-oxoazetidine-1-carboxylic acid tert-butyl ester (513 mg, 3.0 mmol) and 4Å powdered molecular sieve (1) in DCE (10 mL) 0.0 g) was stirred at room temperature for 6 hours, after which sodium triacetoxyborohydride (1.27 g, 6.0 mmol) was added. The reaction mixture was filtered through celite and washed with DCM. The filtrate was concentrated under vacuum and the resulting residue was purified by column chromatography (Si-PCC, acetone: DCM, 0-40%) to give 3-((S) -3-hydroxypyrrolidin-1-yl. ) Azetidine-1-carboxylic acid tert-butyl ester was obtained as a brown oil (390 mg, 54%). LCMS (Method A): R _T 0.28 min [M + H] ⁺ 243.0

Step 2: A mixture of 3-((S) -3-hydroxypyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (390 mg, 1.61 mmol) and TFA (2 mL) in DCM (4 mL). Stir at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give the title compound as a white solid (244 mg, quantitative) . ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.40-4.33 (m, 1H); 3.70-3.60 (m, 4H); 3.44-3.34 (m, 1H); 2 88-2.77 (m, 1H); 2.73-2.52 (m, 3H); 2.47 (dd, J = 10.1, 5.2 Hz, 1H); 2.30-2. 12 (m, 2H); 1.84-1.69 (m, 1H).

工程１：３-((Ｒ)-３-ヒドロキシピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（１０ｍＬ）中のＩ-ピロリジン-３-オール（２６１ｍｇ、３．０ｍｍｏｌ）、３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５１３ｍｇ、３．０ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（１．０ｇ）の混合物を室温で６時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（１．２７ｇ、６．０ｍｍｏｌ）を加えた。反応混合物をセライトで濾過し、ＤＣＭで洗浄した。濾液を真空下で濃縮し、生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、アセトン：ＤＣＭ、０−４０％）で精製し、３-((Ｒ)-３-ヒドロキシピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを褐色油として得た（４７９ｍｇ、６６％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ０．２８分［Ｍ＋Ｈ］^＋２４３．０ Example 12 (R) -1-azetidin-3-ylpyrrolidin-3-ol

Step 1: 3-((R) -3-hydroxypyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

I-pyrrolidin-3-ol (261 mg, 3.0 mmol), 3-oxoazetidine-1-carboxylic acid tert-butyl ester (513 mg, 3.0 mmol) and 4Å powdered molecular sieve (1.0 g) in DCE (10 mL). ) Was stirred at room temperature for 6 hours, and then sodium triacetoxyborohydride (1.27 g, 6.0 mmol) was added. The reaction mixture was filtered through celite and washed with DCM. The filtrate was concentrated under vacuum and the resulting residue was purified by column chromatography (Si-PCC, acetone: DCM, 0-40%) and 3-((R) -3-hydroxypyrrolidin-1-yl) Azetidine-1-carboxylic acid tert-butyl ester was obtained as a brown oil (479 mg, 66%). LCMS (Method A): R _T 0.28 min [M + H] ⁺ 243.0

Step 2: A mixture of 3- (I-3-hydroxypyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (479 mg, 1.98 mmol) and TFA (3 mL) in DCM (6 mL) at room temperature. Stir for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH to give the title compound as a white solid (260 mg, 92%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.41-4.33 (m, 1H); 3.69-3.58 (m, 4H); 3.45-3.32 (m, 1H); 2 .88-2.79 (m, 1H); 2.65 (d, J = 10.1 Hz, 1H); 2.55-2.41 (m, 3H); 2.30-2.12 (m, 2H); 1.83-1.70 (m, 1H).

工程１：４-メチル-３-オキソピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＭＦ（２０ｍＬ）中の３-オキソピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５００ｍｇ、２．５０ｍｍｏｌ）の溶液を氷浴上で冷やし、水素化ナトリウム（１２０ｍｇ、３．００ｍｍｏｌ、鉱油中６０％の分散液）を加え、生じた混合物を１０分間攪拌した。ヨウ化メチル（２３３μＬ、５３２ｍｇ、３．７５ｍｍｏｌ）を加え、生じた混合物を室温で１８時間攪拌した。反応混合物をＨ_２Ｏでクエンチし、ＥｔＯＡｃで抽出した。組み合わせた有機物を乾燥（Ｎａ_２ＳＯ_４）し、真空下で濃縮し、４-メチル-３-オキソピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを黄色油として得た（３００ｍｇ、５６％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ４．０８（ｓ，２Ｈ）；３．６５（ｔ，Ｊ＝５．４Ｈｚ，２Ｈ）；３．３５（ｔ，Ｊ＝５．４Ｈｚ，２Ｈ）；３．００（ｓ，３Ｈ）；１．４７（ｓ，９Ｈ）。 Example 13 1-Methylpiperazin-2-one

Step 1: 4-Methyl-3-oxopiperazine-1-carboxylic acid tert-butyl ester

A solution of 3-oxopiperazine-1-carboxylic acid tert-butyl ester (500 mg, 2.50 mmol) in DMF (20 mL) was cooled on an ice bath and sodium hydride (120 mg, 3.00 mmol, 60% in mineral oil). Dispersion) was added and the resulting mixture was stirred for 10 minutes. Methyl iodide (233 μL, 532 mg, 3.75 mmol) was added and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with H ₂ O and extracted with EtOAc. The combined organics were dried (Na ₂ SO ₄ ) and concentrated in vacuo to give 4-methyl-3-oxopiperazine-1-carboxylic acid tert-butyl ester as a yellow oil (300 mg, 56%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.08 (s, 2H); 3.65 (t, J = 5.4 Hz, 2H); 3.35 (t, J = 5.4 Hz, 2H); 3 0.00 (s, 3H); 1.47 (s, 9H).

Step 2: A mixture of 4-methyl-3-oxopiperazine-1-carboxylic acid tert-butyl ester (300 mg, 1.40 mmol) and TFA (1 mL) in DCM (2 mL) was stirred at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH to give 1-methylpiperazin-2-one as a white solid (128 mg 80%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.52 (s, 2H); 3.32 (t, J = 5.5 Hz, 2H); 3.09 (t, J = 5.5 Hz, 2H); 2 97 (s, 3H); 1.83 (s, 1H).

工程１：３-(４-メチル-３-オキソピペラジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（４ｍＬ）中の１-メチルピペラジン-２-オン（１２８ｍｇ、１．１２ｍｍｏｌ）、３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２３１ｍｇ、１．３５ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（１５０ｍｇ）の混合物を１．５時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（４７５ｍｇ、２．２４ｍｍｏｌ）を加えた。反応混合物をセライトで濾過し、ＤＣＭで洗浄した。濾液を真空下で濃縮し、生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、３-(４-メチル-３-オキソピペラジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを油として得た（２１１ｍｇ、７０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ３．９９−３．９２（ｍ，２Ｈ）；３．８１（ｄｄ，Ｊ＝８．８，５．１Ｈｚ，２Ｈ）；３．３６（ｔ，Ｊ＝５．５Ｈｚ，２Ｈ）；３．２０−３．１４（ｍ，１Ｈ）；３．０８（ｔ，Ｊ＝５．５Ｈｚ，２Ｈ）；２．９７（ｓ，３Ｈ）；２．７０−２．５６（ｍ，２Ｈ）；１．４４（ｓ，９Ｈ）。 Example 14 4-Azetidin-3-yl-1-methylpiperazin-2-one

Step 1: 3- (4-Methyl-3-oxopiperazin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

1-methylpiperazin-2-one (128 mg, 1.12 mmol), 3-oxoazetidine-1-carboxylic acid tert-butyl ester (231 mg, 1.35 mmol) and 4Å powdered molecular sieve (150 mg) in DCE (4 mL) Was stirred for 1.5 hours at room temperature and then sodium triacetoxyborohydride (475 mg, 2.24 mmol) was added. The reaction mixture was filtered through celite and washed with DCM. The filtrate was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give 3- (4-methyl-3-oxopiperazin-1-yl). Azetidine-1-carboxylic acid tert-butyl ester was obtained as an oil (211 mg, 70%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.99-3.92 (m, 2H); 3.81 (dd, J = 8.8, 5.1 Hz, 2H); 3.36 (t, J = 5.5 Hz, 2H); 3.20-3.14 (m, 1H); 3.08 (t, J = 5.5 Hz, 2H); 2.97 (s, 3H); 2.70-2. 56 (m, 2H); 1.44 (s, 9H).

Step 2: A mixture of 3- (4-methyl-3-oxopiperazin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (211 mg, 0.78 mmol) and TFA (2 mL) in DCM (4 mL). Stir at room temperature for 2 hours. The reaction mixture was washed with MeOH / DCM. Loaded on an Isolute® SCX-2 cartridge and eluted the product with 2M NH ₃ / MeOH to give 4-azetidin-3-yl-1-methylpiperazin-2-one as a white solid ( 125 mg, 95%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.63 (m, 4H); 3.37-3.27 (m, 3H); 3.03 (s, 2H); 2.96 (s, 3H); 2.58 (t, J = 5.6 Hz, 2H); 2.13-1.97 (m, 1H).

Example 15 2-Azetidin-3-ylpropan-2-ol

５０ｍＬの丸底フラスコに無水ＴＨＦ（１０ｍＬ）中のアゼチジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル３-メチルエステル（１ｇ、４．６５ｍｍｏｌ）の溶液を４℃、窒素下で充填した。Ｅｔ_２Ｏ（３．７２ｍＬ、１１．１５ｍｍｏｌ）中の３．０Ｍの臭化メチルマグネシウムの溶液を５分かけて滴下して加え、反応混合物を５時間室温で攪拌した。反応物をＮＨ_４Ｃｌ（５ｍＬ）及び水（１０ｍＬ）の飽和水溶液でクエンチした。水性相をＥｔＯＡｃ（２０ｍＬ）で抽出した。有機層を硫酸ナトリウムで乾燥させ、真空下で濃縮して、３-(１-ヒドロキシ-１-メチルエチル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た（０．８ｇ、８０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．９５−３．７５（ｍ，４Ｈ）；２．６０−２．５０（ｍ，１Ｈ）；１．４３（ｓ，９Ｈ）；１．１７（ｓ，６Ｈ）。 Step 1: 3- (1-Hydroxy-1-methylethyl) azetidine-1-carboxylic acid tert-butyl ester

A 50 mL round bottom flask was charged with a solution of azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (1 g, 4.65 mmol) in anhydrous THF (10 mL) at 4 ° C. under nitrogen. A solution of 3.0 M methylmagnesium bromide in Et ₂ O (3.72 mL, 11.15 mmol) was added dropwise over 5 minutes and the reaction mixture was stirred for 5 hours at room temperature. The reaction was quenched with a saturated aqueous solution of NH ₄ Cl (5 mL) and water (10 mL). The aqueous phase was extracted with EtOAc (20 mL). The organic layer was dried over sodium sulfate and concentrated under vacuum to give 3- (1-hydroxy-1-methylethyl) azetidine-1-carboxylic acid tert-butyl ester as a colorless oil (0.8 g, 80 %). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.95-3.75 (m, 4H); 2.60-2.50 (m, 1H); 1.43 (s, 9H); 1.17 (s, 6H).

Step 2: 3- (1-hydroxy-1-methylethyl) azetidine-1-carboxylic acid tert-butyl ester (0.8 g, 3.72 mmol) in DCM / TFA (3 mL / 3 mL) in a 25 mL round bottom flask The solution was filled. The reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 2-azetidin-3-ylpropan-2-ol as a white solid (0.36 g, 84% ). _{^{1 H NMR (CDCl 3, 400MHz}} ) δ3.55-3.62 (m, 4H); 2.75-2.65 (m, 1H); 1.15 (s, 6H).

工程１：３-フルオロ-[１,３’]ビアゼチジニル-１’-カルボン酸ｔｅｒｔ-ブチルエステル

１０ｍＬの丸底フラスコにＤＣＥ（３ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．１４ｇ、０．８２ｍｍｏｌ）、３-フルオロアゼチジン塩酸塩（０．１ｇ、０．９ｍｍｏｌ）、トリメトキシメタン（０．８８ｍＬ、８．５ｍｍｏｌ）及び酢酸（０．０４６ｍＬ、０．８１ｍｍｏｌ）の溶液を充填した。反応混合物を室温で３時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．２６ｇ、１．２２ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。反応混合物をＤＣＭと水の間で分配させ；有機相をブラインで洗浄し、硫酸ナトリウムで乾燥させ、濃縮した。残留物をフラッシュクロマトグラフィーで精製（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、勾配４０：６０から１００：０）し、３-フルオロ-[１,３’]ビアゼチジニル-１’-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た（０．１０９ｇ、５９％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ５．１５（ｄｔ，Ｊ＝５７．１，５．３Ｈｚ，１Ｈ）；３．９３（ｄｄ，Ｊ＝９．１，７．０Ｈｚ，２Ｈ）；３．７４−３．５９（ｍ，４Ｈ）；３．４５−３．３８（ｍ，１Ｈ）；３．３１−３．２５（ｍ，１Ｈ）；３．２３−３．１７（ｍ，１Ｈ）；１．４３（ｓ，９Ｈ）。 Example 16 3-Fluoro- [1,3 ′] biazetidinyl

Step 1: 3-Fluoro- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester

A 10 mL round bottom flask was charged with 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.14 g, 0.82 mmol), 3-fluoroazetidine hydrochloride (0.1 g, 0.9 mmol) in DCE (3 mL). , A solution of trimethoxymethane (0.88 mL, 8.5 mmol) and acetic acid (0.046 mL, 0.81 mmol). The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.26 g, 1.22 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was partitioned between DCM and water; the organic phase was washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 40:60 to 100: 0) and 3-fluoro- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester Obtained as a colorless oil (0.109 g, 59%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 5.15 (dt, J = 57.1, 5.3 Hz, 1H); 3.93 (dd, J = 9.1, 7.0 Hz, 2H); 3.74 -3.59 (m, 4H); 3.45-3.38 (m, 1H); 3.31-3.25 (m, 1H); 3.23-3.17 (m, 1H); 1 .43 (s, 9H).

Step 2: In a 25 mL round bottom flask of 3-fluoro- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester (0.109 g, 0.47 mmol) in DCM / TFA (2 mL / 2 mL). The solution was filled. The reaction mixture was stirred for 90 minutes at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 3-fluoro- [1,3 ′] biazetidinyl as a colorless oil (0.058 g, 94% ). ¹ H NMR (CDCl ₃ , 400 MHz) δ 5.14 (dp, J = 57.2, 5.3 Hz, 1H); 3.75-3.46 (m, 8H); 3.34-3.24 (m , 1H); 3.27-3.10 (m, 1H).

Example 17 1-Azetidin-3-ylpiperidin-4-ol

１０ｍＬの丸底フラスコにＤＣＥ（５０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１ｇ、５．８４ｍｍｏｌ）、４−ヒドロキシピペリジン（０．６５ｇ、６．４２ｍｍｏｌ）及び４Åモレキュラーシーブ（１０ｇ）の溶液を充填した。反応混合物を４時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２．４８ｇ、１１．６８ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製し（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、勾配０：１００から１００：０）、３-(４-ヒドロキシピペリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た（０．３４ｇ、２３％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．９２（ｔ，Ｊ＝７．８Ｈｚ，２Ｈ）；３．８７−３．７２（ｍ，３Ｈ）；３．０７（ｍ，１Ｈ）；２．６８−２．６３（ｍ，２Ｈ）；２．０９−２．０３（ｍ，２Ｈ）；１．９６−１．９１（ｍ，２Ｈ）；１．６９−１．５５（ｍ，２Ｈ）；１．４３（ｓ，９Ｈ）。 Step 1: 3- (4-Hydroxypiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

A 10 mL round bottom flask was charged with 3-oxoazetidine-1-carboxylic acid tert-butyl ester (1 g, 5.84 mmol), 4-hydroxypiperidine (0.65 g, 6.42 mmol) and 4Å molecular sieves (DC mL (50 mL)). 10 g) of solution was charged. The reaction mixture was stirred for 4 hours at room temperature. Sodium triacetoxyborohydride (2.48 g, 11.68 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 100: 0), 3- (4-hydroxypiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester As a colorless oil (0.34 g, 23%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.92 (t, J = 7.8 Hz, 2H); 3.87-3.72 (m, 3H); 3.07 (m, 1H); 2.68- 2.63 (m, 2H); 2.09-2.03 (m, 2H); 1.96-1.91 (m, 2H); 1.69-1.55 (m, 2H); 43 (s, 9H).

Step 2: 3- (4-Hydroxypiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (0.34 g, 1.33 mmol) in DCM / TFA (4 mL / 4 mL) in a 25 mL round bottom flask Of solution. The reaction mixture was stirred for 7 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 1-azetidin-3-ylpiperidin-4-ol as a colorless oil (0.194 g, 94% ). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.75-3.68 (m, 1H); 3.67-3.51 (m, 4H); 3.25-3.17 (m, 1H); 66-2.56 (m, 3H); 2.03-1.84 (m, 5H); 1.65-1.53 (m, 2H).

Example 18 1-Azetidin-3-yl-4-fluoropiperidine

１０ｍＬの丸底フラスコに、ＤＣＥ（５０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１ｇ、５．８４ｍｍｏｌ）、４−フルオロピペリジン塩酸塩（０．９７ｇ、６．４２ｍｍｏｌ）及び４Åモレキュラーシーブ（１０ｇ）の溶液を充填した。反応混合物を４時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２．４８ｇ、１１．６８ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、勾配０：１００から１００：０）、ついで（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から５：９５）で精製して、３-(４-フルオロピペリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た（０．５９ｇ、３９％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．８０−４．５８（ｍ，１Ｈ）；３．９７−３．８９（ｍ，２Ｈ）；３．８５−３．７６（ｍ，２Ｈ）；３．０８（ｔ，Ｊ＝６．４Ｈｚ，１Ｈ）；２．５０−２．２８（ｍ，４Ｈ）；１．９９−１．８２（ｍ，４Ｈ）；１．４８−１．３８（ｍ，９Ｈ）。 Step 1: 3- (4-Fluoropiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

To a 10 mL round bottom flask was added 3-oxoazetidine-1-carboxylic acid tert-butyl ester (1 g, 5.84 mmol), 4-fluoropiperidine hydrochloride (0.97 g, 6.42 mmol) and 4Å in DCE (50 mL). A solution of molecular sieve (10 g) was charged. The reaction mixture was stirred for 4 hours at room temperature. Sodium triacetoxyborohydride (2.48 g, 11.68 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 100: 0) followed by (Si-PPC, MeOH: DCM, 0: 100 to 5:95) to give 3- (4-Fluoropiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester was obtained as a colorless oil (0.59 g, 39%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.80-4.58 (m, 1H); 3.97-3.89 (m, 2H); 3.85-3.76 (m, 2H); 08 (t, J = 6.4 Hz, 1H); 2.50-2.28 (m, 4H); 1.99-1.82 (m, 4H); 1.48-1.38 (m, 9H) ).

Step 2: A 25 mL round bottom flask was charged with 3- (4-fluoro-piperidin-1-yl) -azetidine-1-carboxylic acid tert-butyl ester (0.59 g, 2 in DCM / TFA (4 mL / 4 mL)). .26 mmol) solution. The reaction mixture was stirred at room temperature for 6 hours. The reaction mixture was loaded onto an Isolute (® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 1-azetidin-3-yl-4- Fluoropiperidine was obtained as a pale yellow oil (0.263 g, 74%) ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.60 (m, 1H); 3.64-3.52 (m, 4H); 3.26-3.18 (m, 1H); 2.45-2.38 (m, 2H); 2.28-2.17 (m, 2H); 1.96-1.81 (m, 4H) )

Example 19 1-Azetidin-3-yl-4,4-difluoropiperidine

１０ｍＬの丸底フラスコにＤＣＥ（８ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．５１ｇ、３ｍｍｏｌ）、４,４-ジフルオロピペリジン塩酸塩（０．７１ｇ、４．５ｍｍｏｌ）及び４Åモレキュラーシーブ（０．８ｇ）の溶液を充填した。反応混合物を７時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（１．２７ｇ、６ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、０：１００から７５：２５の勾配）で精製して、３-(４,４-ジフルオロピペリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを黄色油として得た（０．６９ｇ、８３％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．９４（ｄｄ，Ｊ＝８．７，７．１Ｈｚ，２Ｈ）；３．７８（ｄｄ，Ｊ＝８．７，５．３Ｈｚ，２Ｈ）；３．１７−３．１０（ｍ，１Ｈ）；２．４５−２．４１（ｍ，４Ｈ）；２．１０−１．９４（ｍ，４Ｈ）；１．４３（ｓ，９Ｈ）。 Step 1: 3- (4,4-Difluoropiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

In a 10 mL round bottom flask 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.51 g, 3 mmol), 4,4-difluoropiperidine hydrochloride (0.71 g, 4.5 mmol) in DCE (8 mL) and A solution of 4M molecular sieves (0.8 g) was charged. The reaction mixture was stirred for 7 hours at room temperature. Sodium triacetoxyborohydride (1.27 g, 6 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 75:25) to give 3- (4,4-difluoropiperidin-1-yl) azetidine-1-carboxylic acid The tert-butyl ester was obtained as a yellow oil (0.69 g, 83%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.94 (dd, J = 8.7, 7.1 Hz, 2H); 3.78 (dd, J = 8.7, 5.3 Hz, 2H); 3.17 -3.10 (m, 1H); 2.45-2.41 (m, 4H); 2.10-1.94 (m, 4H); 1.43 (s, 9H).

Step 2: A 25 mL round bottom flask was charged with 3- (4,4-difluoropiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (0.684 g, 2 mL) in DCM / TFA (4 mL / 4 mL). .47 mmol) solution. The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 1-azetidin-3-yl-4,4-difluoropiperidine as a pale yellow oil (0.279 g, 64 %). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.64-3.54 (m, 4H); 3.30-3.25 (m, 1H); 2.43-2.37 (m, 4H); 06-1.93 (m, 5H).

Example 20 [1,3 ′] Biazetidinyl-3-ol

１０ｍＬの丸底フラスコに、ＤＣＥ（８ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．５２ｇ、３．１ｍｍｏｌ）、アゼチジン-３-オール塩酸塩（０．５ｇ、４．６ｍｍｏｌ）及び４Åモレキュラーシーブ（０．７ｇ）の溶液を充填した。反応混合物を７時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（１．３ｇ、６．１３ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製し（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、勾配０：１００から４０：６０）、３-ヒドロキシ-[１,３’]ビアゼチジニル-１’-カルボン酸ｔｅｒｔ-ブチルエステルを黄色油として得た（０．６９ｇ、９９％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．４５−４．３５（ｍ，１Ｈ）；３．９６（ｄｄ，Ｊ＝９．３，６．７Ｈｚ，２Ｈ）；３．７４（ｄｄ，Ｊ＝９．３，４．５Ｈｚ，２Ｈ）；３．６６（ｔｄ，Ｊ＝８．８，６．７Ｈｚ，２Ｈ）；３．４０−３．３７（ｍ，１Ｈ）；３．２０（ｔｄ，Ｊ＝８．８，４．５Ｈｚ，２Ｈ）；１．４３（ｓ，９Ｈ）。 Step 1: 3-Hydroxy- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester

To a 10 mL round bottom flask was added 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.52 g, 3.1 mmol), azetidin-3-ol hydrochloride (0.5 g, 4.6 mmol) in DCE (8 mL). ) And 4Å molecular sieves (0.7 g). The reaction mixture was stirred for 7 hours at room temperature. Sodium triacetoxyborohydride (1.3 g, 6.13 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 40:60) and 3-hydroxy- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester was purified. Obtained as a yellow oil (0.69 g, 99%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.45-4.35 (m, 1H); 3.96 (dd, J = 9.3, 6.7 Hz, 2H); 3.74 (dd, J = 9 .3, 4.5 Hz, 2H); 3.66 (td, J = 8.8, 6.7 Hz, 2H); 3.40-3.37 (m, 1H); 3.20 (td, J = 8.8, 4.5 Hz, 2H); 1.43 (s, 9H).

Step 2: To a 25 mL round bottom flask, 3-hydroxy- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester (0.69 g, 3.05 mmol) in DCM / TFA (4 mL / 4 mL). Of solution. The reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give [1,3 ′] biazetidinyl-3-ol as a colorless oil (0.225 g, 58%). LCMS (Method A): R _T = 0.29 min, [M + H] ⁺ 288.9

Example 21 1-Azetidin-3-yl-4-methylpiperidin-4-ol

５０ｍＬの丸底フラスコに、ＤＣＥ（２０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．５７ｇ、３．３３ｍｍｏｌ）、４-メチルピペリジン-４-オール（０．４６ｇ、３．９９ｍｍｏｌ）及び４Åモレキュラーシーブ（３．３４ｇ）の溶液を充填した。反応混合物を室温で６時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（１．４１ｇ、６．６６ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、溶液を真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製し（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、０：１００から１００：０）、３-(４-ヒドロキシ-４-メチルピペリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た（０．４９ｇ、５５％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．９３（ｄｄ，Ｊ＝８．７，７．１７Ｈｚ，２Ｈ）；３．８２（ｄｄ，Ｊ＝８．７，５．５Ｈｚ，２Ｈ）；３．１５−３．０７（ｍ，１Ｈ）；２．５８−２．４４（ｍ，２Ｈ）；２．２７（ｔｄ，Ｊ＝１１．０，３．５Ｈｚ，２Ｈ）；１．７７−１．５４（ｍ，４Ｈ）；１．４２（ｓ，９Ｈ）；１．２６（ｔ，Ｊ＝６．７Ｈｚ，３Ｈ）。 Step 1: 3- (4-Hydroxy-4-methylpiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

To a 50 mL round bottom flask was added 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.57 g, 3.33 mmol), 4-methylpiperidin-4-ol (0.46 g, 3.30 mL) in DCE (20 mL). 99 mmol) and 4M molecular sieves (3.34 g) were charged. The reaction mixture was stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (1.41 g, 6.66 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the solution was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, 0: 100 to 100: 0), 3- (4-hydroxy-4-methylpiperidin-1-yl) azetidine-1-carboxylic acid tert -Butyl ester was obtained as a colorless oil (0.49 g, 55%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.93 (dd, J = 8.7, 7.17 Hz, 2H); 3.82 (dd, J = 8.7, 5.5 Hz, 2H); 3.15 −3.07 (m, 1H); 2.58-2.44 (m, 2H); 2.27 (td, J = 11.0, 3.5 Hz, 2H); 1.77-1.54 ( m, 4H); 1.42 (s, 9H); 1.26 (t, J = 6.7 Hz, 3H).

Step 2: A 25 mL round bottom flask was charged with 3- (4-hydroxy-4-methylpiperidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (0.2 g) in DCM / TFA (3 mL / 3 mL). , 0.74 mmol) solution. The reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 1-azetidin-3-yl-4-methylpiperidin-4-ol as a colorless oil (0.107 g, 85%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.61 (t, J = 7.3 Hz, 2H); 3.54 (t, J = 7.3 Hz, 2H); 3.29-3.15 (m, 1H) 3.04 (s, 2H); 2.40 (d, J = 10.8 Hz, 2H); 2.30-2.18 (m, 2H); 1.67-1.56 (m, 4H) ); 1.23 (s, 3H).

ＤＣＥ（６０ｍＬ）中のピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．５６ｇ、８．３８ｍｍｏｌ）及びオキセタン-３-オン（５００ｍｇ、６．９４ｍｍｏｌ）の溶液を雰囲気温度で９０分間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２．３４ｇ、１１．０４ｍｍｏｌ）を加え、混合物を１７時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。生成物を収集し、減圧下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９９：１から９８：２）で精製し、４-オキセタン-３-イルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを白色固形物として得た（１．０ｇ、５９％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３、４００ＭＨｚ）δ４．６９−４．５８（ｍ、４Ｈ）；３．５１−３．４４（ｍ、５Ｈ）；２．２７（ｍ、４Ｈ）及び１．４６（ｓ、９Ｈ）。 Example 22 4-Oxetane-3-ylpiperazine-1-carboxylic acid tert-butyl ester

A solution of piperazine-1-carboxylic acid tert-butyl ester (1.56 g, 8.38 mmol) and oxetan-3-one (500 mg, 6.94 mmol) in DCE (60 mL) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (2.34 g, 11.04 mmol) was added and the mixture was stirred for 17 hours and then loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 99: 1 to 98: 2) and 4-oxetane-3-ylpiperazine-1-carboxylic acid tert-butyl ester Was obtained as a white solid (1.0 g, 59%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.69-4.58 (m, 4H); 3.51-3.44 (m, 5H); 2.27 (m, 4H) and 1.46 (s, 9H).

無水ＴＨＦ（２ｍＬ）中の２-オキソ-７-アザスピロ[３．５]ノナン-７-カルボン酸ベンジルエステル（１６４ｍｇ、０．６０ｍｍｏｌ）の撹拌溶液に、トルエン／ＴＨＦ（０．５６ｍＬ、０．７８ｍｍｏｌ）中の１．４Ｍの臭化メチルマグネシウム溶液を−７８℃、窒素雰囲気下にて滴下して加えた。１時間後、溶液を飽和ＮＨ_４Ｃｌ_（ａｑ）でクエンチした後、生じた混合物をＥｔＯＡｃと水の間で分配した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、蒸発して残留物を得、これをカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、シクロヘキサン中０−７０％ＥｔＯＡｃ）で精製して、２-ヒドロキシ-２-メチル-７-アザスピロ[３．５]ノナン-７-カルボン酸ベンジルエステル（９６ｍｇ、５５％）を無色油として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ４．１３分，［Ｍ＋Ｈ］^＋２９０．４ Example 23 2-Hydroxy-2-methyl-7-azaspiro [3.5] nonane-7-carboxylic acid benzyl ester

To a stirred solution of 2-oxo-7-azaspiro [3.5] nonane-7-carboxylic acid benzyl ester (164 mg, 0.60 mmol) in anhydrous THF (2 mL) was added toluene / THF (0.56 mL, 0.78 mmol). ) Was added dropwise at −78 ° C. under a nitrogen atmosphere. After 1 hour, the solution was quenched with saturated NH ₄ Cl _(aq) and the resulting mixture was partitioned between EtOAc and water. The organic layer was dried (Na ₂ SO ₄ ) and evaporated to give a residue that was purified by column chromatography (Si-PCC, 0-70% EtOAc in cyclohexane) to give 2-hydroxy-2-methyl. -7-Azaspiro [3.5] nonane-7-carboxylic acid benzyl ester (96 mg, 55%) was obtained as a colorless oil. LCMS (Method H): R _T 4.13 min, [M + H] ⁺ 290.4.

アゼチジン塩酸塩（９６ｍｇ、１．０３ｍｍｏｌ）をＤＭＦ（１７ｍＬ）中のＩ-ピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）、ＨＡＴＵ（３９１ｍｇ、１．０３ｍｍｏｌ）及びＤＩＰＥＡ（４１０μＬ、２．３５ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌した後、真空下で濃縮させた。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥（ＭｇＳＯ_４）させ、減圧下で濃縮し、Ｉ-３-(アゼチジン-１-カルボニル)-ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１０ｍＬ）中のＩ-３-(アゼチジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、反応混合物を雰囲気温度で１時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生成物を収集し、真空下で濃縮して、アゼチジン-１-イル-Ｉ-ピロリジン-３-イルメタノンを褐色油として得た（７７ｍｇ、５４％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．１８（ｔ，Ｊ＝７．７Ｈｚ，２Ｈ）；４．０１（ｔ，Ｊ＝７．７Ｈｚ，２Ｈ）；３．１８−３．０４（ｍ，３Ｈ）；２．９６（ｍ，１Ｈ）；２．８８−２．７１（ｍ，２Ｈ）；２．３５−２．２３（ｍ，２Ｈ）及び２．０４−１．８４（ｍ，２Ｈ）。 Example 24 Azetidin-1-yl-I-pyrrolidin-3-ylmethanone

Azetidine hydrochloride (96 mg, 1.03 mmol) was added I-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93 mmol), HATU (391 mg, 1.03 mmol) in DMF (17 mL) and To a solution of DIPEA (410 μL, 2.35 mmol) was added and the resulting mixture was stirred at ambient temperature for 1 hour and then concentrated in vacuo. The resulting oil was partitioned between EtOAc and water. The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated under reduced pressure to give I-3- (azetidine-1-carbonyl) -pyrrolidine-1-carboxylic acid tert-butyl ester. Obtained as a colorless oil. TFA (3 mL) is added to a solution of I-3- (azetidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester in DCM (10 mL) and the reaction mixture is stirred at ambient temperature for 1 hour, then Isolute. (Registered trademark) SCX-2 cartridge (10 g) was filled. The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give azetidin-1-yl-I-pyrrolidin-3-ylmethanone as a brown oil (77 mg, 54%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.18 (t, J = 7.7 Hz, 2H); 4.01 (t, J = 7.7 Hz, 2H); 3.18-3.04 (m, 3H) 2.96 (m, 1H); 2.88-2.71 (m, 2H); 2.35-2.23 (m, 2H) and 2.04-1.84 (m, 2H).

アゼチジン塩酸塩（９６ｍｇ、１．０３ｍｍｏｌ）をＤＭＦ（１７ｍＬ）中のＩ-ピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）、ＨＡＴＵ（３９１ｍｇ、１．０３ｍｍｏｌ）及びＤＩＰＥＡ（４１０μＬ、２．３５ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌し、ついで真空下で濃縮した。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、減圧下で濃縮して、Ｉ-３-(アゼチジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１０ｍＬ）中のＩ-３-(アゼチジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、反応混合物を雰囲気温度で１時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３に溶出させ、生成物を収集し、真空下で濃縮して、アゼチジン-１-イル-(Ｓ)-ピロリジン-３-イルメタノンを褐色油として得た（１３０ｍｇ、９１％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．２１−４．１１（ｍ，２Ｈ）；４．０２（ｔ，Ｊ＝７．７Ｈｚ，２Ｈ）；３．１８−３．０７（ｍ，２Ｈ）；２．９５（ｄｄ，Ｊ＝１１．５，７．７Ｈｚ，１Ｈ）；２．８８−２．７１（ｍ，１Ｈ）；２．３３−２．２２（ｍ，２Ｈ）；２．１５（ｍ，２Ｈ）及び２．０５−１．８２（ｍ，２Ｈ）。 Example 25 Azetidin-1-yl- (S) -pyrrolidin-3-ylmethanone

Azetidine hydrochloride (96 mg, 1.03 mmol) was added I-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93 mmol), HATU (391 mg, 1.03 mmol) in DMF (17 mL) and To a solution of DIPEA (410 μL, 2.35 mmol) was added and the resulting mixture was stirred at ambient temperature for 1 hour and then concentrated under vacuum. The resulting oil was partitioned between EtOAc and water. The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated under reduced pressure to give I-3- (azetidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester. Obtained as a colorless oil. TFA (3 mL) is added to a solution of I-3- (azetidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester in DCM (10 mL) and the reaction mixture is stirred at ambient temperature for 1 hour, then Isolute. (Registered trademark) SCX-2 cartridge (10 g) was filled. The cartridge is washed with methanol and the desired product is subsequently eluted in 2M NH ₃ in MeOH, the product is collected and concentrated under vacuum to azetidin-1-yl- (S) -pyrrolidine- 3-ylmethanone was obtained as a brown oil (130 mg, 91%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.21-4.11 (m, 2H); 4.02 (t, J = 7.7 Hz, 2H); 3.18-3.07 (m, 2H); 2.95 (dd, J = 11.5, 7.7 Hz, 1H); 2.88-2.71 (m, 1H); 2.33-2.22 (m, 2H); 2.15 (m , 2H) and 2.05-1.82 (m, 2H).

ピロリジン（５１μＬ、１．０３ｍｍｏｌ）をＤＭＦ中のＩ-ピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）、ＨＡＴＵ（３９１ｍｇ、１．０３ｍｍｏｌ）及びＤＩＰＥＡ（４１０μＬ、２．３５ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌し、ついで真空下で濃縮した。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させた（ＭｇＳＯ_４）、減圧下で濃縮してＩ-３-(ピロリジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１０ｍＬ）中のＩ-３-(ピロリジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、反応混合物を雰囲気温度で１時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。ついで、カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出させ、生成物を収集し、減圧下で濃縮してピロリジン-１-イル-(Ｒ)-ピロリジン-３-イルメタノンを黄色油として得た（１２１ｍｇ、７７％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．５０−３．４２（ｍ，３Ｈ）；３．１９（ｓ，１Ｈ）；３．１４（ｓ，１Ｈ）；３．００（ｓ，２Ｈ）；２．９６−２．５９（ｍ，３Ｈ）；２．０４−１．９２（ｍ，３Ｈ）及び１．８９−１．８１（ｍ，２Ｈ）。 Example 26 Pyrrolidin-1-yl- (R) -pyrrolidin-3-ylmethanone

Pyrrolidine (51 μL, 1.03 mmol) was added I-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93 mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL, 2 in DMF). .35 mmol) and the resulting mixture was stirred at ambient temperature for 1 hour and then concentrated under vacuum. The resulting oil was partitioned between EtOAc and water. The organic layer was separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated under reduced pressure to give I-3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester. Obtained as a colorless oil. TFA (3 mL) is added to a solution of I-3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester in DCM (10 mL) and the reaction mixture is stirred at ambient temperature for 1 hour, then Isolute. (Registered trademark) SCX-2 cartridge (10 g) was filled. The cartridge is then washed with methanol and the desired product is subsequently eluted with 2M NH ₃ in MeOH, and the product is collected and concentrated under reduced pressure to pyrrolidin-1-yl- (R) -pyrrolidine. -3-ylmethanone was obtained as a yellow oil (121 mg, 77%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.50-3.42 (m, 3H); 3.19 (s, 1H); 3.14 (s, 1H); 3.00 (s, 2H); 2 96-2.59 (m, 3H); 2.04-1.92 (m, 3H) and 1.89-1.81 (m, 2H).

ピロリジン（５１μＬ、１．０３ｍｍｏｌ）をＤＭＦ中の(Ｓ)-ピロリジン-１,３-ジカルボン酸１-ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．９３ｍｍｏｌ）、ＨＡＴＵ（３９１ｍｇ、１．０３ｍｍｏｌ）及びＤＩＰＥＡ（４１０μＬ、２．３５ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌し、ついで真空下で濃縮した。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して、(Ｓ)-３-(ピロリジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１０ｍＬ）中の(Ｓ)-３-(ピロリジン-１-カルボニル)ピロリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、反応混合物を雰囲気温度で１時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。ついで、カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３に溶出させた。生成物を収集し、真空下で濃縮して表題化合物を淡い褐色油として得た（１１０ｍｇ、７０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．０１（ｍ，３Ｈ）；３．５２−３．４１（ｍ，３Ｈ）；３．２５−３．１１（ｍ，２Ｈ）；３．１０−２．９７（ｍ，２Ｈ）；２．８９（ｄｔ，Ｊ＝１１．４，７．５Ｈｚ，１Ｈ）；２．１１−１．９９（ｍ，１Ｈ）；２．０１−１．９１（ｍ，２Ｈ）及び１．９３−１．８２（ｍ，２Ｈ）。 Example 27 Pyrrolidin-1-yl- (S) -pyrrolidin-3-ylmethanone

Pyrrolidine (51 μL, 1.03 mmol) was added (S) -pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester (200 mg, 0.93 mmol), HATU (391 mg, 1.03 mmol) and DIPEA (410 μL) in DMF. 2.35 mmol) and the resulting mixture was stirred at ambient temperature for 1 hour and then concentrated under vacuum. The resulting oil was partitioned between EtOAc and water. The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ), concentrated in vacuo and tert-butyl (S) -3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylate. The ester was obtained as a colorless oil. TFA (3 mL) was added to a solution of (S) -3- (pyrrolidine-1-carbonyl) pyrrolidine-1-carboxylic acid tert-butyl ester in DCM (10 mL) and the reaction mixture was stirred at ambient temperature for 1 h. It was then loaded into an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted in 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give the title compound as a pale brown oil (110 mg, 70%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.01 (m, 3H); 3.52-3.41 (m, 3H); 3.25-3.11 (m, 2H); 3.10-2. 97 (m, 2H); 2.89 (dt, J = 11.4, 7.5 Hz, 1H); 2.11-1.99 (m, 1H); 2.01-1.91 (m, 2H) ) And 1.93-1.82 (m, 2H).

アゼチジン塩酸塩の塩（５１５ｍｇ、５．５０ｍｍｏｌ）をＤＭＦ（１００ｍＬ）中のアゼチジン-１,３-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（１．０ｇ、４．９７ｍｍｏｌ）、ＨＡＴＵ（２．０９ｇ、５．５０ｍｍｏｌ）及びＤＩＰＥＡ（２．１８ｍＬ、１２．５２ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌し、ついで真空下で濃縮した。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して３-(アゼチジン-１-カルボニル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１５ｍＬ）中の３-(アゼチジン-１-カルボニル)-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、混合物を雰囲気温度で１時間攪拌し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。ついで、カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生成物を収集し、真空下で濃縮して表題化合物を無色油として得た（２６０ｍｇ、３７％）。^１Ｈ ＮＭＲ（ＣＤ_３ＯＤ，４００ＭＨｚ）δ４．１９−４．０８（ｍ，２Ｈ）；４．０７−３．９２（ｍ，２Ｈ）；３．９１−３．７８（ｍ，２Ｈ）；３．７２−３．５２（ｍ，３Ｈ）及び２．３６−２．２１（ｍ，２Ｈ）。 Example 28 Azetidin-3-yl-azetidin-1-ylmethanone

Azetidine hydrochloride salt (515 mg, 5.50 mmol) was added azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (1.0 g, 4.97 mmol), HATU (2.09 g, 5 mL) in DMF (100 mL). .50 mmol) and DIPEA (2.18 mL, 12.52 mmol) were added and the resulting mixture was stirred at ambient temperature for 1 h and then concentrated in vacuo. The resulting oil was partitioned between EtOAc and water. The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated in vacuo to give 3- (azetidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester as a colorless oil. Obtained. TFA (3 mL) is added to a solution of 3- (azetidine-1-carbonyl) -azetidine-1-carboxylic acid tert-butyl ester in DCM (15 mL), and the mixture is stirred at ambient temperature for 1 hour, and Isolute®. ) Filled SCX-2 cartridge (25 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated in vacuo to give the title compound as a colorless oil (260 mg, 37%). ¹ H NMR (CD ₃ OD, 400 MHz) δ 4.19-4.08 (m, 2H); 4.07-3.92 (m, 2H); 3.91-3.78 (m, 2H); 3 .72-3.52 (m, 3H) and 2.36-2.21 (m, 2H).

ピロリジン（２７１μＬ、５．５０ｍｍｏｌ）をＤＭＦ（１００ｍＬ）中のアゼチジン-１,３-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（１．０ｇ、４．９７ｍｍｏｌ）、ＨＡＴＵ（２．０９ｇ、５．５０ｍｍｏｌ）及びＤＩＰＥＡ（２．１８ｍＬ、１２．５２ｍｍｏｌ）の溶液に加え、生じた混合物を雰囲気温度で１時間攪拌し、ついで真空下で濃縮した。生じた油をＥｔＯＡｃと水の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して３-(ピロリジン-１-カルボニル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色油として得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１５ｍＬ）中の３-(ピロリジン-１-カルボニル)-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルの溶液に加え、混合物を雰囲気温度で１時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。ついで、カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を溶出させた。生成物を収集し、真空下で濃縮して表題化合物を無色油として得た（５５０ｍｇ、７２％）。^１Ｈ ＮＭＲ（ＣＤ_３ＯＤ，４００ＭＨｚ）δ３．９３−３．６５（ｍ，５Ｈ）；３．４３−３．２８（ｍ，４Ｈ）及び２．００−１．８１（ｍ，４Ｈ）。 Example 29 Azetidin-3-yl-pyrrolidin-1-ylmethanone

Pyrrolidine (271 μL, 5.50 mmol) was added azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (1.0 g, 4.97 mmol), HATU (2.09 g, 5.50 mmol) in DMF (100 mL) and To a solution of DIPEA (2.18 mL, 12.52 mmol), the resulting mixture was stirred at ambient temperature for 1 hour and then concentrated under vacuum. The resulting oil was partitioned between EtOAc and water. The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated in vacuo to give 3- (pyrrolidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester as a colorless oil. Obtained. TFA (3 mL) is added to a solution of 3- (pyrrolidine-1-carbonyl) -azetidine-1-carboxylic acid tert-butyl ester in DCM (15 mL) and the mixture is stirred at ambient temperature for 1 hour, then Isolute (registered). TMSCX-2 cartridge (25 g) was loaded. The cartridge was then washed with methanol and the desired product continued to elute 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give the title compound as a colorless oil (550 mg, 72%). _{^{1 H NMR (CD 3 OD,}} 400MHz) δ3.93-3.65 (m, 5H); 3.43-3.28 (m, 4H) and 2.00-1.81 (m, 4H).

工程１：２-(１-(ｔｅｒｔ-ブトキシカルボニル)ピペリジン-４-イリデン)マロン酸ジエチルエステル

無水ＴＨＦ（５０ｍＬ）にＣＣｌ_４（１０ｍＬ）中のＴｉＣｌ_４（１３．７５ｍＬ、０．１２６ｍｏｌ）溶液を０℃で滴下して加えた。生じた黄色の懸濁液に無水ＴＨＦ（５０ｍＬ）中の４-オキソピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１０ｇ、０．０５ｍｏｌ）の溶液及びマロン酸ジエチル（６．８５ｍＬ、０．０５ｍｏｌ）の溶液を加え、続いてピリジン（２６ｍＬ）を加えた。暗黄色の懸濁液を雰囲気温度まで暖めて、雰囲気温度で１７時間攪拌し、ついでＥｔＯＡｃ及びクエン酸（１０％、水性）の間で分配した。有機層を分離し、水とブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して、２-(１-(ｔｅｒｔ-ブトキシカルボニル)ピペリジン-４-イリデン)マロン酸ジエチルエステルを褐色油として得た（１７ｇ、１００％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．２７−４．１８（ｍ，４Ｈ）；３．５５−３．４４（ｍ，４Ｈ）；２．６５（ｍ，４Ｈ）；１．４９（ｓ，９Ｈ）及び１．３２−１．２６（ｍ，６Ｈ）。 Example 30 4-Oxetane-3-ylpiperidine

Step 1: 2- (1- (tert-Butoxycarbonyl) piperidine-4-ylidene) malonic acid diethyl ester

A solution of TiCl ₄ (13.75 mL, 0.126 mol) in CCl ₄ (10 mL) was added dropwise at 0 ° C. to anhydrous THF (50 mL). The resulting yellow suspension was added to a solution of 4-oxopiperidine-1-carboxylic acid tert-butyl ester (10 g, 0.05 mol) and diethyl malonate (6.85 mL, 0.05 mol) in anhydrous THF (50 mL). Was added followed by pyridine (26 mL). The dark yellow suspension was warmed to ambient temperature and stirred at ambient temperature for 17 hours, then partitioned between EtOAc and citric acid (10%, aqueous). The organic layer is separated, washed with water and brine, then dried (MgSO ₄ ) and concentrated in vacuo to give 2- (1- (tert-butoxycarbonyl) piperidine-4-ylidene) malonic acid diethyl ester. Obtained as a brown oil (17 g, 100%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.27-4.18 (m, 4H); 3.55-3.44 (m, 4H); 2.65 (m, 4H); 1.49 (s, 9H) and 1.32-1.26 (m, 6H).

０℃でＩＭＳ（２００ｍＬ）に、ＮａＢＨ_４（１．８７ｇ、０．０４７ｍｏｌ）とＩＭＳ（２００ｍＬ）中の２-(１-(ｔｅｒｔ-ブトキシカルボニル)ピペリジン-４-イリデン)マロン酸ジエチルエステル（１７ｇ、０．０５０ｍｏｌ）の溶液を加えた。生じた混合物を雰囲気温度まで温め、１時間攪拌し、ついで水でクエンチし、真空下で濃縮した。生じた油をついでＥｔＯＡｃと水の間で分配した。有機層を分離し、ブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して表題化合物を黄色油として得た（１４．６ｇ、８５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝３．９０分，［Ｍ＋Ｎａ］^＋３６６。 Step 2: 2- (1- (tert-Butoxycarbonyl) piperidin-4-yl) malonic acid diethyl ester

At 0 ° C. to IMS (200 mL) was added 2- (1- (tert-butoxycarbonyl) piperidin-4-ylidene) malonic acid diethyl ester (17 g) in NaBH ₄ (1.87 g, 0.047 mol) and IMS (200 mL). , 0.050 mol) solution was added. The resulting mixture was warmed to ambient temperature and stirred for 1 hour, then quenched with water and concentrated in vacuo. The resulting oil was then partitioned between EtOAc and water. The organic layer was separated, washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo to give the title compound as a yellow oil (14.6 g, 85%). LCMS (Method H): R _T = 3.90 min, [M + Na] ⁺ 366.

無水ＴＨＦ（１００ｍＬ）及び無水トルエン（１００ｍＬ）中の２-(１-(ｔｅｒｔ-ブトキシカルボニル)ピペリジン-４-イル)マロン酸ジエチルエステル（１４．６ｇ、０．０４３ｍｏｌ）の溶液にＬｉＢＨ_４（２．１ｇ、０．９６ｍｏｌ）を少しずつ加えた。生じた混合物を６０℃で１７時間加熱し、ついで２４時間雰囲気温度で攪拌した。反応混合物をＨＣｌ（０．１Ｍ、３５０ｍＬ）水溶液にゆっくりと加え、ついでＥｔＯＡｃで抽出した。有機層を分離し、ブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：ＭｅＯＨ１００：０から９８：２から９５：５から９０：１０から８０：２０）で精製して、表題化合物を無色の油として得た（６．９１ｇ、６３％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．９０−３．７５（ｍ，４Ｈ）；２．７５−２．５８（ｍ，４Ｈ）；１．７７−１．６１（ｍ，４Ｈ）；１．５２（ｍ，１Ｈ）；１．４５（ｓ，９Ｈ）及び１．２６−１．１３（ｍ，１Ｈ）。 Step 3: 4- (2-Hydroxy-1- (hydroxymethyl) ethyl) piperidine-1-carboxylic acid tert-butyl ester

To a solution of 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) malonic acid diethyl ester (14.6 g, 0.043 mol) in anhydrous THF (100 mL) and anhydrous toluene (100 mL) was added LiBH ₄ (2 0.1 g, 0.96 mol) was added in small portions. The resulting mixture was heated at 60 ° C. for 17 hours and then stirred at ambient temperature for 24 hours. The reaction mixture was slowly added to aqueous HCl (0.1 M, 350 mL) and then extracted with EtOAc. The organic layer was separated and washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH 100: 0 to 98: 2 to 95: 5 to 90:10 to 80:20) to give the title compound as a colorless oil ( 6.91 g, 63%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.90-3.75 (m, 4H); 2.75-2.58 (m, 4H); 1.77-1.61 (m, 4H); 52 (m, 1H); 1.45 (s, 9H) and 1.26-1.13 (m, 1H).

Step 4: To a solution of 4- (2-hydroxy-1- (hydroxymethyl) ethyl) piperidine-1-carboxylic acid tert-butyl ester (7.62 g, 0.029 mol) in anhydrous THF (100 mL) at 0 ° C. , N-BuLi (1.6 M in hexane, 18.4 mL, 0.029 mol) was added dropwise. The resulting mixture was stirred at 0 ° C. for 30 minutes. A solution of toluenesulfonyl chloride (5.26 g, 0.028 mol) in anhydrous THF (50 mL) was added via cannula. The thickened reaction mixture was warmed to ambient temperature and stirred for 2 hours. A solution of n-BuLi (1.6 M in hexanes, 18.4 mL, 0.029 mol) was added dropwise and the reaction mixture was heated at 60 ° C. for 2 hours and then concentrated under vacuum. The resulting oil was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, pentane: EtOAc; gradient from 100: 0 to 20:80) to give 4-oxetane-3-ylpiperidine-1-carboxylic acid tert-butyl ester. Obtained as a white solid (5.33 g, 75%). TFA (10 mL) is added to a solution of 4-oxetane-3-yl-piperidine-1-carboxylic acid tert-butyl ester (7.1 g, 0.029 mol) in DCM (100 mL) and the mixture is at ambient temperature for 2 hours. Stir. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (50 g), the cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: 2M NH _{3 in} MeOH 100: 0 to 98: 2 to 95: 5 to 90:10 to 85:15 to 80:20) 4-Oxetane-3-ylpiperidine gave a colorless oil that solidified as it was (2.05 g, 49%). ¹ H NMR (CDCl ₃ , 300 MHz) δ 4.75 (dd, J = 7.9, 6.0 Hz, 2H); 4.52-4.42 (m, 2H); 3.14-3.04 (m , 2H); 2.81-2.67 (m, 1H); 2.61 (td, J = 12.2, 2.6 Hz, 2H); 1.85 to 1.68 (m, 1H); 1 .60 (m, 2H) and 1.02 (qd, J = 12.2, 4.0 Hz, 2H).

ＤＣＭ（１０ｍＬ）中の３-(テトラヒドロピラン-４-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（７３０ｍｇ、３．０ｍｍｏｌ）の溶液に水（０．１５ｍＬ）及びＴＦＡ（１０ｍＬ）を加えた。反応混合物を室温で４時間攪拌し、減圧下で濃縮して残留物を得、これをＭｅＯＨ中に取り上げた。生じた溶液をＭｅＯＨで洗浄したＳＣＸ-２カートリッジ（１０ｇ）に充填した。所望の生成物をＭｅＯＨ中の２Ｍのアンモニア溶液で溶出させた。適当な画分を組み合わせ、濃縮して、３-(テトラヒドロピラン-４-イル)アゼチジンを黄色油として得た（３９３ｍｇ、９２％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ３．９６（ｄｄ，Ｊ＝１１．０，４．０，２Ｈ）；３．６５（ｄｄ，Ｊ＝８．０，８．０Ｈｚ，２Ｈ）；３．４４（ｄｄ，Ｊ＝７．６，７．６Ｈｚ，２Ｈ）；３．３７（ｄｄｄ，Ｊ＝１１．９，１１．９，２．１，２Ｈ）；２．５０（ｍ，１Ｈ）；１．７５（ｍ，１Ｈ）；１．５３（ｍ，２Ｈ）；１．１８（ｄｄｄ，Ｊ＝２５．０，１１．９，４．３，２Ｈ）。 Example 31 3- (Tetrahydropyran-4-yl) azetidine

To a solution of 3- (tetrahydropyran-4-yl) azetidine-1-carboxylic acid tert-butyl ester (730 mg, 3.0 mmol) in DCM (10 mL) was added water (0.15 mL) and TFA (10 mL). . The reaction mixture was stirred at room temperature for 4 hours and concentrated under reduced pressure to give a residue that was taken up in MeOH. The resulting solution was loaded onto an SCX-2 cartridge (10 g) washed with MeOH. The desired product was eluted with 2M ammonia solution in MeOH. Appropriate fractions were combined and concentrated to give 3- (tetrahydropyran-4-yl) azetidine as a yellow oil (393 mg, 92%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.96 (dd, J = 11.0, 4.0, 2H); 3.65 (dd, J = 8.0, 8.0 Hz, 2H); 44 (dd, J = 7.6, 7.6 Hz, 2H); 3.37 (ddd, J = 11.9, 11.9, 2.1, 2H); 2.50 (m, 1H); 1 .75 (m, 1H); 1.53 (m, 2H); 1.18 (ddd, J = 25.0, 11.9, 4.3, 2H).

工程１：３-(４-クロロブチリルアミノ)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＭ（１０ｍＬ）中の３-アミノアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（７３０ｍｇ、４．２４ｍｍｏｌ）及びトリエチルアミン（１．７４ｍＬ、１．２９ｇ、１２．７２ｍｍｏｌ）の混合物を０℃に冷却した後、４-クロロブチリルクロライド（５２３μＬ、６５７ｍｇ、４．６６ｍｍｏｌ）を加えた。生じた混合物を１６時間攪拌した後、Ｈ_２Ｏでクエンチし、ＤＣＭで抽出した。組み合わせた有機抽出物をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、３０−７０％）で精製して、３-(４-クロロブチリルアミノ)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを褐色油として得た（１．０４ｇ、８９％）。 Example 32 1-Azetidin-3-ylpyrrolidin-2-one

Step 1: 3- (4-Chlorobutyrylamino) azetidine-1-carboxylic acid tert-butyl ester

A mixture of 3-aminoazetidine-1-carboxylic acid tert-butyl ester (730 mg, 4.24 mmol) and triethylamine (1.74 mL, 1.29 g, 12.72 mmol) in DCM (10 mL) was cooled to 0 ° C. Later 4-chlorobutyryl chloride (523 μL, 657 mg, 4.66 mmol) was added. The resulting mixture was stirred for 16 hours before being quenched with H ₂ O and extracted with DCM. The combined organic extracts were washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 30-70%) to give 3- (4-chlorobutyrylamino) azetidine-1-carboxylic acid tert-butyl ester as a brown oil (1.04 g, 89%).

Step 2: 3- (2-Oxopyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

A solution of 3- (4-chlorobutyrylamino) azetidine-1-carboxylic acid tert-butyl ester (1.04 g, 3.76 mmol) in DMF (15 mL) was cooled to 0 ° C. before NaH (180 mg, 4 mg .51 mmol) was added. The resulting mixture was stirred for 2 h before being quenched with H ₂ O and extracted with EtOAc. The organic phase was washed with H ₂ O and brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 20-100%) to give 3- (2-oxopyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester. Obtained as a brown oil (320 mg, 35%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 4.99 (m, 1H), 4.15 (m, 2H), 3.97 (m, 2H), 3.57 (t, J = 7.0 Hz, 2H) ), 2.42 (t, J = 8.1 Hz, 2H), 2.15 to 2.02 (m, 2H) and 1.45 (s, 9H)

A mixture of 3- (2-oxopyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (320 mg, 1.33 mmol) and TFA (1.5 mL) in DCM (3 mL) was stirred at room temperature for 4 hours. did. The reaction mixture is loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH to give 1-azetidin-3-ylpyrrolidin-2-one as a white solid (174 mg, 93%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 5.05 (m, 1H), 3.85-3.76 (m, 4H), 3.61 (m, 2H), 2.41 (m, 2H) and 2.07 (m, 2H)

工程１：３-(３,３-ジフルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ＤＣＥ（１０ｍＬ）中の３,３-ジフルオロピロリジン塩酸塩（２００ｍｇ、１．１７ｍｍｏｌ）、３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２８４ｍｇ、１．９９ｍｍｏｌ）及びトリエチルアミン（２９５μＬ、２２１ｍｇ、２．１８ｍｍｏｌ）の混合物を１時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（７４５ｍｇ、３．５２ｍｍｏｌ）を加えた。生じた混合物を７２時間攪拌し、ついでＤＣＭで希釈し、Ｈ_２Ｏで洗浄した。有機相を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−５０％）で精製して、３-(３,３-ジフルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た（１９３ｍｇ、６３％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ３．９５（ｍ，２Ｈ），３．８２（ｄｄ，Ｊ＝８．９，４．９Ｈｚ，２Ｈ），３．３２（ｍ，１Ｈ），２．９１（ｍ，２Ｈ），２．８２−２．６３（ｍ，２Ｈ），２．３３−２．３２（ｍ，２Ｈ）及び１．４３（ｓ，９Ｈ）。 Example 33 1-Azetidin-3-yl-3,3-difluoropyrrolidine

Step 1: 3- (3,3-Difluoropyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

3,3-Difluoropyrrolidine hydrochloride (200 mg, 1.17 mmol), 3-oxoazetidine-1-carboxylic acid tert-butyl ester (284 mg, 1.99 mmol) and triethylamine (295 μL, 221 mg, 2.21) in DCE (10 mL). 18 mmol) was stirred for 1 hour at room temperature, then sodium triacetoxyborohydride (745 mg, 3.52 mmol) was added. The resulting mixture was stirred for 72 hours, then diluted with DCM and washed with H ₂ O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-50%) and tert-butyl 3- (3,3-difluoropyrrolidin-1-yl) azetidine-1-carboxylate. The ester was obtained as a colorless oil (193 mg, 63%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.95 (m, 2H), 3.82 (dd, J = 8.9, 4.9 Hz, 2H), 3.32 (m, 1H), 2.91 (M, 2H), 2.82-2.63 (m, 2H), 2.33-2.32 (m, 2H) and 1.43 (s, 9H).

A mixture of 3- (3,3-difluoropyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester (193 mg, 0.74 mmol) and TFA (1 mL) in DCM (2 mL) was stirred at room temperature for 2 hours. did. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH to give 1-azetidin-3-yl-3,3-difluoropyrrolidine white Obtained as a solid (122 mg, quantitative). ¹ H NMR (CDCl ₃ , 300 MHz): δ 3.63 (m, 4H), 3.48 (m, 1H), 2.87 (t, J = 13.1 Hz, 2H), 2.70 (t, J = 7.0 Hz, 2H) and 2.29 (m, 2H)

工程１：３,３-ジフルオロ-[１,３’]ビアゼチジニル-１’-カルボン酸ｔｅｒｔ-ブチルエステル

２５ｍＬの丸底フラスコにＤＣＥ（１０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．４ｇ、２．３４ｍｍｏｌ）、３,３-ジフルオロアゼチジン塩酸塩（０．３６４ｇ、２．８０ｍｍｏｌ）及び４Åモレキュラーシーブ（２．４３ｇ）の溶液を充填した。反応混合物を室温で３時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．９９ｇ、４．６７ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製し（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から１０：９０の勾配）、表題化合物を無色の油として得た（０．３３ｇ、５７％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ４．０２−３．６９（ｍ，４Ｈ），３．６５（ｔ，Ｊ＝１２．１５Ｈｚ，４Ｈ），３．５５−３．４８（ｍ，１Ｈ），１．４３（ｓ，９Ｈ）。 Example 34 3,3-Difluoro- [1,3 '] biazetidinyl

Step 1: 3,3-Difluoro- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester

To a 25 mL round bottom flask was added 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol), 3,3-difluoroazetidine hydrochloride (0.364 g, 2. 80 mmol) and 4Å molecular sieves (2.43 g) were charged. The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.99 g, 4.67 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give the title compound as a colorless oil (0.33 g, 57%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 4.02-3.69 (m, 4H), 3.65 (t, J = 12.15 Hz, 4H), 3.55 to 3.48 (m, 1H) , 1.43 (s, 9H).

Step 2: 3,3-Difluoro- [1,3 ′] biazetidinyl 3,3-Difluoro- [1,3 ′] biazetidinyl-1′-carvone in DCM / TFA (3 mL / 3 mL) in a 10 mL round bottom flask A solution of acid tert-butyl ester (0.15 g, 0.61 mmol) was charged. The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ to give 3,3-difluoro- [1,3 ′] biazetidinyl as a colorless oil (0.033 g, 37%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.73-3.55 (m, 8H), 3.57-3.43 (m, 1H), 2.77 (s, 1H)

工程１：４-(３,３-ジフルオロアゼチジン-１-イル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

１０ｍＬの丸底フラスコに、ＤＣＥ（１０ｍＬ）中の４-オキソピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．４ｇ、０．２０ｍｍｏｌ）、３,３-ジフルオロアゼチジン塩酸塩（０．３１ｇ、０．２４ｍｍｏｌ）及び４Åモレキュラーシーブ（２．４ｇ）の溶液を充填した。反応混合物を室温で３時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．８５ｇ、４．０１ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮し、４-(３,３-ジフルオロアゼチジン-１-イル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た（０．５３ｇ、９６％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ３．９４−３．９０（ｍ，２Ｈ），３．５７（ｔ，Ｊ＝１１．９Ｈｚ，４Ｈ），２．９６−２．８１（ｍ，２Ｈ），２．３４−２．２３（ｍ，１Ｈ），１．７１−１．５８（ｍ，２Ｈ），１．４５（ｓ，９Ｈ），１．３５−１．２１（ｍ，２Ｈ）。 Example 35 4- (3,3-Difluoroazetidin-1-yl) piperidine

Step 1: 4- (3,3-Difluoroazetidin-1-yl) piperidine-1-carboxylic acid tert-butyl ester

A 10 mL round bottom flask was charged with 4-oxopiperidine-1-carboxylic acid tert-butyl ester (0.4 g, 0.20 mmol), 3,3-difluoroazetidine hydrochloride (0.31 g, in DCE (10 mL)). 0.24 mmol) and 4M molecular sieves (2.4 g) were charged. The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.85 g, 4.01 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo to give 4- (3,3-difluoroazetidin-1-yl) piperidine-1-carboxylic acid tert-butyl ester as a colorless oil ( 0.53 g, 96%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.94-3.90 (m, 2H), 3.57 (t, J = 11.9 Hz, 4H), 2.96-2.81 (m, 2H) , 2.34-2.23 (m, 1H), 1.71-1.58 (m, 2H), 1.45 (s, 9H), 1.35-1.21 (m, 2H).

Step 2: 4- (3,3-Difluoroazetidin-1-yl) piperidine A 25 mL round bottom flask was charged with 4- (3,3-difluoroazetidin-1-yl in DCM / TFA (3 mL / 3 mL). ) A solution of piperidine-1-carboxylic acid tert-butyl ester (0.265 g, 0.96 mmol) was charged. The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product eluted in 2M NH ₃ to give 4- (3,3-difluoroazetidin-1-yl) piperidine as a white solid (0.154 g, 91% ). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.54 (t, J = 11.9 Hz, 4H), 3.10 (dt, J = 12.7, 3.9 Hz, 2H), 2.59 (td, J = 11.9, 2.6 Hz, 2H), 2.24-2.13 (m, 1H), 1.76-1.65 (m, 2H), 1.30-1.15 (m, 2H) ).

工程１：３-ヒドロキシ-３-メチルアゼチジン-１-カルボン酸ベンジルエステル

Ｅｔ_２Ｏ（０．９８ｍＬ、２．９２ｍｍｏｌ）中の３．０Ｍのメチル臭化マグネシウムの溶液に０℃で無水ＴＨＦ（５ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ベンジルエステル（０．５ｇ、２．４４ｍｍｏｌ）の溶液をアルゴン存在下で５分かけて滴下して加えた。反応混合物を１８時間室温で攪拌し、ついでＮＨ_４Ｃｌ（２．５ｍＬ）及び水（５ｍＬ）の飽和水溶液を加えてクエンチした。水性相をＥｔＯＡｃ（１０ｍＬ）で抽出した。有機層を分離し、硫酸ナトリウムで乾燥させ、真空下で濃縮して、３-ヒドロキシ-３-メチルアゼチジン-１-カルボン酸ベンジルエステルを無色の油として得た（０．５４ｇ、９９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝３．６０分，［Ｍ＋Ｈ］^＋２２１．９ Example 36 3-Methyl- [1,3 ′] biazetidinyl-3-ol

Step 1: 3-hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester

A solution of 3.0 M methylmagnesium bromide in Et ₂ O (0.98 mL, 2.92 mmol) at 0 ° C. with 3-oxoazetidine-1-carboxylic acid benzyl ester (0.5 g, in anhydrous THF (5 mL)). 2.44 mmol) was added dropwise over 5 minutes in the presence of argon. The reaction mixture was stirred for 18 hours at room temperature and then quenched by the addition of a saturated aqueous solution of NH ₄ Cl (2.5 mL) and water (5 mL). The aqueous phase was extracted with EtOAc (10 mL). The organic layer was separated, dried over sodium sulfate and concentrated in vacuo to give 3-hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester as a colorless oil (0.54 g, 99%). . LCMS (Method A): R _T = 3.60 min, [M + H] ⁺ 221.9.

２５ｍＬの丸底フラスコに、ＥｔＯＨ（５ｍＬ）中の３-ヒドロキシ-３-メチルアゼチジン-１-カルボン酸ベンジルエステル（０．５７ｇ、２．５８ｍｍｏｌ）及び酢酸（０．２５ｍＬ）を充填した。反応混合物に窒素３２を流し、１０％Ｐｄ／Ｃ（６７ｍｇ、０．２９ｍｍｏｌ）を加えた。反応混合物を室温で水素雰囲気下で３６時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３を溶出せ、３-メチルアゼチジン-３-オールをオレンジ色の油として得た（０．１２５ｇ、５６％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ３．１９−３．０３（ｍ，４Ｈ），１．４５（ｓ，３Ｈ）。 Process 2: 3-methylazetidine-3-ol

A 25 mL round bottom flask was charged with 3-hydroxy-3-methylazetidine-1-carboxylic acid benzyl ester (0.57 g, 2.58 mmol) and acetic acid (0.25 mL) in EtOH (5 mL). The reaction mixture was flushed with nitrogen 32 and 10% Pd / C (67 mg, 0.29 mmol) was added. The reaction mixture was stirred at room temperature under a hydrogen atmosphere for 36 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 3-methylazetidin-3-ol as an orange oil (0.125 g, 56%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.19-3.03 (m, 4H), 1.45 (s, 3H).

１０ｍＬの丸底フラスコに、ＤＣＥ（５ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．２１ｇ、１．２３ｍｍｏｌ）、３-メチルアゼチジン-３-オール（０．１３ｇ、１．４８ｍｍｏｌ）及び４Åモレキュラーシーブ（１．２ｇ）の溶液を充填した。反応混合物を室温で３時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．５２ｇ、２．４７ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、溶液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、０：１００から１００：０）で精製し、３-ヒドロキシ-３-メチル-[１,３’]ビアゼチジニル-１’-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た（０．０９ｇ、３０％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ３．９３（ｄｄ，Ｊ＝９．２，７．２Ｈｚ，２Ｈ），３．８２−３．７０（ｍ，２Ｈ），３．５０−３．４０（ｍ，１Ｈ），３．３２（ｄ，Ｊ＝８．１Ｈｚ，２Ｈ），３．２１（ｄ，Ｊ＝８．１Ｈｚ，２Ｈ），１．５１（ｓ，３Ｈ），１．４３（ｓ，９Ｈ）。 Step 3: 3-hydroxy-3-methyl- [1,3 ′] biazetidinyl-1′-carboxylic acid tert-butyl ester

A 10 mL round bottom flask was charged with 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.21 g, 1.23 mmol), 3-methylazetidin-3-ol (0.13 g, 1 mL) in DCE (5 mL). .48 mmol) and 4M molecular sieves (1.2 g) were charged. The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.52 g, 2.47 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the solution was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, 0: 100 to 100: 0) and tert-3-hydroxy-3-methyl- [1,3 ′] biazetidinyl-1′-carboxylic acid tert- The butyl ester was obtained as a colorless oil (0.09 g, 30%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.93 (dd, J = 9.2, 7.2 Hz, 2H), 3.82-3.70 (m, 2H), 3.50-3.40 ( m, 1H), 3.32 (d, J = 8.1 Hz, 2H), 3.21 (d, J = 8.1 Hz, 2H), 1.51 (s, 3H), 1.43 (s, 9H).

Step 4: 3-Methyl- [1,3 ′] biazetidinyl-3-ol In a 10 mL round bottom flask, 3-hydroxy-3-methyl- [1,3 ′] biazetidinyl in DCM / TFA (2 mL / 2 mL). A solution of -1′-carboxylic acid tert-butyl ester (0.09 g, 0.37 mmol) was charged. The reaction mixture was stirred for 90 minutes at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 3-methyl- [1,3 ′] biazetidinyl-3-ol as a colorless oil (0.04 g 76%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 3.68-3.51 (m, 6H), 3.25 (d, J = 7.6 Hz, 2H), 3.15 (d, J = 7.6 Hz, 2H), 1.49 (s, 3H).

工程１：３-(Ｉ-３-フルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

２５ｍＬの丸底フラスコに、ＤＣＥ（１０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．４ｇ、２．３４ｍｍｏｌ）、Ｉ-３-フルオロピロリジン塩酸塩（０．３５ｇ、２．８ｍｍｏｌ）及び４Åモレキュラーシーブ（２．４３ｇ）の溶液を充填した。反応混合物を２．５時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．９９ｇ、４．６８ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、３０：７０から１００：０の勾配)で精製し、３-(Ｉ-３-フルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た（０．３４８ｇ、６１％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ５．３０−５．２０（ｍ，３Ｈ），４．０１−３．９２（ｍ，２Ｈ），３．９１−３．８２（ｍ，２Ｈ），２．８７−２．７８（ｍ，２Ｈ），２．１７−２．１１（ｍ，３Ｈ），１．４３（ｓ，９Ｈ）。 Example 37 (R) -1-azetidin-3-yl-3-fluoropyrrolidine

Step 1: 3- (I-3-fluoropyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

To a 25 mL round bottom flask was added 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol), I-3-fluoropyrrolidine hydrochloride (0.35 g, 2. 8 mmol) and 4 mol molecular sieves (2.43 g) were charged. The reaction mixture was stirred for 2.5 hours at room temperature. Sodium triacetoxyborohydride (0.99 g, 4.68 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 30:70 to 100: 0) and tert-3- (I-3-fluoropyrrolidin-1-yl) azetidine-1-carboxylic acid tert -The butyl ester was obtained as a colorless oil (0.348 g, 61%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 5.30-5.20 (m, 3H), 4.01-3.92 (m, 2H), 3.91-3.82 (m, 2H), 2 .87-2.78 (m, 2H), 2.17-2.11 (m, 3H), 1.43 (s, 9H).

Step 2: (R) -1-azetidin-3-yl-3-fluoropyrrolidine In a 25 mL round bottom flask was added 3- (I-3-fluoropyrrolidin-1-yl) in DCM / TFA (5 mL / 5 mL). A solution of azetidine-1-carboxylic acid tert-butyl ester (0.175 g, 0.72 mmol) was charged. The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and (R) -1-azetidin-3-yl-3-fluoropyrrolidine was eluted with 2M NH ₃ in MeOH to give the title compound as a colorless oil (0.088 g, 85 %). ¹ H NMR (300 MHz, CDCl ₃ ): δ 5.31-5.07 (m, 1H), 3.73-3.56 (m, 4H), 3.55-3.21 (m, 1H), 2 .95-2.87 (m, 2H), 2.83-2.74 (m, 2H), 2.66 (m, 1H), 2.28-1.95 (m, 2H)

工程１：３-((Ｓ)-３-フルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

２５ｍＬの丸底フラスコに、ＤＣＥ（１０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．４ｇ、２．３４ｍｍｏｌ）、(Ｓ)-３-フルオロピロリジン塩酸塩（０．３５ｇ、２．８ｍｍｏｌ）及び４Åモレキュラーシーブ（２．４３ｇ）の溶液を充填した。反応混合物を２．５時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．９９ｇ、４．６８ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、３０：７０から１００：０の勾配）で精製し、３-((Ｓ)-３-フルオロピロリジン-１-イル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを無色の油として得た（０．３４２ｇ、６０％）。^１Ｈ ＮＭＲ（３００ＭＨｚ，ＣＤＣｌ_３）：δ５．３４−５．１０（ｍ，１Ｈ），４．０１−３．９３（ｍ，２Ｈ），３．９１−３．８１（ｍ，２Ｈ），３．４１−３．３１（ｍ，１Ｈ），２．９４−２．６７（ｍ，３Ｈ），２．５６−２．４６（ｍ，１Ｈ），２．２４−２．０６（ｍ，２Ｈ），１．４３（ｓ，９Ｈ）。 Example 38 (S) -1-azetidin-3-yl-3-fluoropyrrolidine

Step 1: 3-((S) -3-Fluoropyrrolidin-1-yl) azetidine-1-carboxylic acid tert-butyl ester

A 25 mL round bottom flask was charged with 3-oxoazetidine-1-carboxylic acid tert-butyl ester (0.4 g, 2.34 mmol), (S) -3-fluoropyrrolidine hydrochloride (0.35 g, in DCE (10 mL). 2.8 mmol) and 4 mol molecular sieves (2.43 g) were charged. The reaction mixture was stirred for 2.5 hours at room temperature. Sodium triacetoxyborohydride (0.99 g, 4.68 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, 30:70 to 100: 0 gradient) and 3-((S) -3-fluoropyrrolidin-1-yl) azetidine-1-carvone The acid tert-butyl ester was obtained as a colorless oil (0.342 g, 60%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 5.34-5.10 (m, 1H), 4.01-3.93 (m, 2H), 3.91-3.81 (m, 2H), 3 41-3.31 (m, 1H), 2.94-2.67 (m, 3H), 2.56-2.46 (m, 1H), 2.24-2.06 (m, 2H) , 1.43 (s, 9H).

Step 2: (S) -1-azetidin-3-yl-3-fluoropyrrolidine In a 25 mL round bottom flask was added 3- (I-3-fluoropyrrolidin-1-yl) in DCM / TFA (6 mL / 6 mL). A solution of azetidine-1-carboxylic acid tert-butyl ester (0.228 g, 0.93 mmol) was charged. The reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and (S) -1-azetidin-3-yl-3-fluoropyrrolidine was eluted with 2M NH ₃ in MeOH to give the title compound as a colorless oil (0.108 g 75%). ¹ H NMR (300 MHz, CDCl ₃ ): δ 5.46-4.86 (m, 1H), 4.05-3.79 (m, 4H), 3.78-3.20 (m, 1H), 2 .95-2.80 (m, 2H), 2.70-2.62 (m, 2H), 2.46-2.37 (m, 1H), 2.29-1.97 (m, 2H)

工程１：４-ｔｅｒｔ-ブチル-３-オキソピペラジン-１-カルボン酸ベンジルエステル

ＤＣＭ（５０ｍＬ）中の(２-ｔｅｒｔ-ブチルアミノエチル)カルバミン酸ベンジルエステル（１．４４ｇ、５．７５ｍｍｏｌ）及びトリエチルアミン（２．４ｍＬ、１７．２６ｍｍｏｌ）の溶液に、室温でクロロアセチルクロライド（０．５５ｍＬ、６．９ｍｍｏｌ）を滴下して加え、反応混合物を室温で６時間攪拌した。水性相をＥｔＯＡｃで抽出した（１０ｍＬ）。反応混合物をＤＣＭ及び飽和ＮａＨＣＯ_３水溶液の間で分配した。有機層を分離し、硫酸ナトリウムで乾燥させ、真空下で濃縮した。褐色の残留物を無水ＴＨＦ（５０ｍＬ）中に溶解させ、鉱油中の水素化ナトリウム６０％（０．３４５ｇ、８．６３ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。反応混合物を水でクエンチし、ＥｔＯＡｃと水の間で分配した。有機層をブラインで洗浄し、分離し、硫酸ナトリウムで乾燥させ、真空下で濃縮した。残留物をＭｅＯＨに溶解させ、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨを用いて溶出させて、４-ｔｅｒｔ-ブチル-３-オキソピペラジン-１-カルボン酸ベンジルエステルを黄色油として得た（１．５７ｇ、９４％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝３．９６分，［Ｍ＋Ｈ］^＋２９１．２ Example 39 1-tert-Butylpiperazin-2-one

Step 1: 4-tert-Butyl-3-oxopiperazine-1-carboxylic acid benzyl ester

To a solution of (2-tert-butylaminoethyl) carbamic acid benzyl ester (1.44 g, 5.75 mmol) and triethylamine (2.4 mL, 17.26 mmol) in DCM (50 mL) at room temperature was added chloroacetyl chloride (0 .55 mL, 6.9 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 6 hours. The aqueous phase was extracted with EtOAc (10 mL). The reaction mixture was partitioned between DCM and saturated aqueous NaHCO ₃ solution. The organic layer was separated, dried over sodium sulfate and concentrated under vacuum. The brown residue was dissolved in anhydrous THF (50 mL), sodium hydride 60% (0.345 g, 8.63 mmol) in mineral oil was added and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with water and partitioned between EtOAc and water. The organic layer was washed with brine, separated, dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in MeOH, loaded onto an Isolute® SCX-2 cartridge and eluted with MeOH to give 4-tert-butyl-3-oxopiperazine-1-carboxylic acid benzyl ester as a yellow oil. Obtained (1.57 g, 94%). LCMS (Method A): R _T = 3.96 min, [M + H] ⁺ 291.2

Step 2: 1-tert-Butylpiperazin-2-one In a 10 mL round bottom flask was added 4-tert-butyl-3-oxopiperazine-1-carboxylic acid benzyl ester (0.75 g, 2. mL) in EtOH (5 mL). 58 mmol) of solution. The reaction mixture was flushed with nitrogen and 10% Pd / C (67 mg, 0.13 mmol) was added. The reaction mixture was stirred for 18 hours under hydrogen atmosphere. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 1-tert-butylpiperazin-2-one as a gray oil (0.276 g, 69%). ¹ H NMR (300 MHz, CDCl ₃ ): δ3.50 (s, 2H), 3.37 (t, J = 5.5 Hz, 2H), 3.06 (t, J = 5.5 Hz, 2H), 1 .48-1.41 (m, 9H)

２-ブロモ-２-メチルプロピオン酸エチルエステル（１５５μＬ、１．０６ｍｍｏｌ）を無水アセトニトリル（１ｍＬ）中の炭酸カリウム（１４５ｍｇ、１．０５ｍｍｏｌ）及び(１Ｓ,４Ｓ)-２,５-ジアザビシクロ[２.２.１]ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、１．０１ｍｍｏｌ）の溶液に加えた。生じた反応混合物を８０℃で４８時間加熱し、ついで雰囲気温度まで冷却し、ＥｔＯＡｃと水の間で分配した。有機層を分離し、ブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ，ＤＣＭ：ＭｅＯＨ；１００：０から９８：２）で精製して、(１Ｓ,４Ｓ)-５-(１-エトキシカルボニル-１-メチルエチル)-２,５-ジアザビシクロ[２.２.１]ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステルを淡褐色の油として得た。無水ＴＨＦ（５ｍＬ）中の(１Ｓ,４Ｓ)-５-(１-エトキシカルボニル-１-メチルエチル)-２,５-ジアザビシクロ[２.２.１]-ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステル（１ｍｍｏｌ）の溶液に、０℃でＬｉＡｌＨ_４（ＴＨＦ中１Ｍ、３．２ｍＬ、３．２ｍｍｏｌ）の溶液を滴下して加えた。反応混合物を雰囲気温度まで温め、１時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３に溶出させた。生成物を収集し、真空下で濃縮して、表題化合物を褐色油として得た（１６８ｍｇ、９９％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ３．３７（ｂｓ，１Ｈ）；３．３１（ｄ，Ｊ＝１０．２Ｈｚ，１Ｈ）；３．２１（ｄ，Ｊ＝１０．２Ｈｚ，１Ｈ）；３．１５−３．００（ｍ，２Ｈ）；２．８１−２．６１（ｍ，２Ｈ）；２．４５（ｓ，２Ｈ）；１．７６（ｄ，Ｊ＝１０．０Ｈｚ，１Ｈ）；１．５６（ｄ，Ｊ＝１０．０Ｈｚ，１Ｈ）；１．４６（ｔ，Ｊ＝５．０２Ｈｚ，１Ｈ）；１．０３（ｓ，３Ｈ）及び１．００（ｓ，２Ｈ）。 Example 40 (2- (1S, 4S) -2,5-diazabicyclo [2.2.1] hept-2-yl-2-methylpropan-1-ol

2-Bromo-2-methylpropionic acid ethyl ester (155 μL, 1.06 mmol) was added to potassium carbonate (145 mg, 1.05 mmol) and (1S, 4S) -2,5-diazabicyclo [2. 2.1] A solution of heptane-2-carboxylic acid tert-butyl ester (200 mg, 1.01 mmol) was added. The resulting reaction mixture was heated at 80 ° C. for 48 hours, then cooled to ambient temperature and partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 98: 2) to give (1S, 4S) -5- (1-ethoxycarbonyl-1-methylethyl)- 2,5-Diazabicyclo [2.2.1] heptane-2-carboxylic acid tert-butyl ester was obtained as a light brown oil. (1S, 4S) -5- (1-Ethoxycarbonyl-1-methylethyl) -2,5-diazabicyclo [2.2.1] -heptane-2-carboxylic acid tert-butyl ester in anhydrous THF (5 mL) To the solution of (1 mmol), a solution of LiAlH ₄ (1M in THF, 3.2 mL, 3.2 mmol) was added dropwise at 0 ° C. The reaction mixture was warmed to ambient temperature and stirred for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) and washed with MeOH before eluting the desired product into 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give the title compound as a brown oil (168 mg, 99%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 3.37 (bs, 1H); 3.31 (d, J = 10.2 Hz, 1H); 3.21 (d, J = 10.2 Hz, 1H); 15-3.00 (m, 2H); 2.81-2.61 (m, 2H); 2.45 (s, 2H); 1.76 (d, J = 10.0 Hz, 1H); 56 (d, J = 10.0 Hz, 1H); 1.46 (t, J = 0.02 Hz, 1H); 1.03 (s, 3H) and 1.00 (s, 2H).

メタンスルホニル塩化物（１２０μＬ、１．５５ｍｍｏｌ）及びＤＩＰＥＡ（１８７μＬ、１．０７ｍｍｏｌ）を、ＤＣＭ（２０ｍＬ）中の(１Ｓ,４Ｓ)-２,５-ジアザビシクロ[２.２.１]ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、１．０１ｍｍｏｌ）の溶液に加え、反応混合物を１７時間雰囲気温度で攪拌し、ついでＥｔＯＡｃと水の間で分配した。有機層を分離し、ブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して(１Ｓ,４Ｓ)-５-メタンスルホニル-２,５-ジアザビシクロ[２.２.１]-ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステルを得た。ＴＦＡ（３ｍＬ）をＤＣＭ（１０ｍＬ）中の(１Ｓ,４Ｓ)-５-メタンスルホニル-２,５-ジアザビシクロ[２.２.１]ヘプタン-２-カルボン酸ｔｅｒｔ-ブチルエステルに加え、混合物を３０分間雰囲気温度で攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填し；カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生成物を収集し、真空下で濃縮して、表題化合物を白色固形物として得た（１７０ｍｇ、９６％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．３７（ｄ，Ｊ＝２．０Ｈｚ，１Ｈ）；３．８３（ｄ，Ｊ＝２．０Ｈｚ，１Ｈ）；３．４１（ｄｄ，Ｊ＝９．２，２．１９Ｈｚ，１Ｈ）；３．２５（ｄ，Ｊ＝９．２Ｈｚ，１Ｈ）；３．２０（ｄ，Ｊ＝１０．３Ｈｚ，１Ｈ）；３．０１（ｄｄ，Ｊ＝１０．３，２．１４Ｈｚ，１Ｈ）；２．８９（ｓ，３Ｈ）；及び１．７９（ｂｓ，２Ｈ） Example 41 (1S, 4S) -2-Methanesulfonyl-2,5-diazabicyclo [2.2.1] heptane

Methanesulfonyl chloride (120 μL, 1.55 mmol) and DIPEA (187 μL, 1.07 mmol) were added to (1S, 4S) -2,5-diazabicyclo [2.2.1] heptane-2- in DCM (20 mL). To a solution of carboxylic acid tert-butyl ester (200 mg, 1.01 mmol), the reaction mixture was stirred at ambient temperature for 17 hours and then partitioned between EtOAc and water. The organic layer was separated, washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo to (1S, 4S) -5-methanesulfonyl-2,5-diazabicyclo [2.2.1] -heptane. -2-Carboxylic acid tert-butyl ester was obtained. TFA (3 mL) was added to (1S, 4S) -5-methanesulfonyl-2,5-diazabicyclo [2.2.1] heptane-2-carboxylic acid tert-butyl ester in DCM (10 mL) and the mixture was added to 30 mL. Stir for 1 minute at ambient temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g); after washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give the title compound as a white solid (170 mg, 96%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.37 (d, J = 2.0 Hz, 1H); 3.83 (d, J = 2.0 Hz, 1H); 3.41 (dd, J = 9.2) , 2.19 Hz, 1H); 3.25 (d, J = 9.2 Hz, 1H); 3.20 (d, J = 10.3 Hz, 1H); 3.01 (dd, J = 10.3, 2.14 Hz, 1H); 2.89 (s, 3H); and 1.79 (bs, 2H)

ＤＣＭ（１１ｍＬ）中の２,２-ジメチルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．０ｇ４．６０ｍｍｏｌ）及びＮＥｔ_３（１．３ｍＬ、９．３４ｍｍｏｌ）の混合物を０℃に冷却した後、ＤＣＭ（２ｍＬ）中のメタンスルホニル塩化物（５８０ｍｇ、５．００ｍｍｏｌ）の溶液を滴下して加えた。反応混合物を室温まで温め、３０分間攪拌した後、Ｈ_２Ｏを加えた。有機相を乾燥させ（相分離器）、真空下で濃縮した。生じた残留物をＤＣＭ（１０ｍＬ）に溶解させ、ＴＦＡ（２ｍＬ）を加えた。得られた混合物を室温になるまで３０分間攪拌し、ついで真空下で濃縮した。生じた残留物をＤＣＭ及び飽和ＮａＨＣＯ_３水溶液の間で分配し、水性相を、Ｈ_２Ｏ及びＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填した。生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、表題化合物を得た（８００ｍｇ、９０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ０．２９分［Ｍ＋Ｈ］^＋１９３．３ Example 41a 3,3-Dimethyl-1- (methylsulfonyl) piperazine

After cooling a mixture of 2,2-dimethylpiperazine-1-carboxylic acid tert-butyl ester (1.0 g 4.60 mmol) and NEt ₃ (1.3 mL, 9.34 mmol) in DCM (11 mL) to 0 ° C. A solution of methanesulfonyl chloride (580 mg, 5.00 mmol) in DCM (2 mL) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 30 minutes before H ₂ O was added. The organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was dissolved in DCM (10 mL) and TFA (2 mL) was added. The resulting mixture was stirred for 30 minutes until room temperature and then concentrated under vacuum. The resulting residue was partitioned between DCM and saturated aqueous NaHCO ₃ and the aqueous phase was loaded onto an Isolute® SCX-2 cartridge washed with H ₂ O and MeOH. The product was eluted with 2M NH ₃ / MeOH to give the title compound (800 mg, 90%). LCMS (Method A): R _T 0.29 min [M + H] ⁺ 193.3

ＴＨＦ（５ｍＬ）中の４-(１-エトキシカルボニル-１-メチルエチル)ピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５００ｍｇ、１．６７ｍｍｏｌ）の溶液に０℃でＬｉＡｌＨ_４（３ｍＬ、ＴＨＦ中１Ｍ）を滴下して加えた。生じた混合物を２．５時間攪拌し、Ｈ_２Ｏ（０．１ｍＬ）、２０％水性ＮａＯＨ（０．１ｍＬ）及びＨ_２Ｏ（０．３ｍＬ）でクエンチした。混合物をＥｔＯＡｃ及びＨ_２Ｏで希釈し、セライト（登録商標）で濾過し、ついで有機層を分離し、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物を無色の油として得た（２１７ｍｇ、５０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ５．３０（１Ｈ，ｂｒｄ ｓ），３．４２（６Ｈ，ｍ），３．３５（４Ｈ，ｂｒｄ ｓ），２．５１（６Ｈ，ｂｒｄ ｓ），１．０３（９Ｈ，ｓ） Example 41b 4- (2-hydroxy-1,1-dimethylethyl) piperazine-1-carboxylic acid tert-butyl ester

A solution of 4- (1-ethoxycarbonyl-1-methylethyl) piperazine-1-carboxylic acid tert-butyl ester (500 mg, 1.67 mmol) in THF (5 mL) at 0 ° C. with LiAlH ₄ (3 mL, 1M in THF). ) Was added dropwise. The resulting mixture was stirred for 2.5 hours and quenched with H ₂ O (0.1 mL), 20% aqueous NaOH (0.1 mL) and H ₂ O (0.3 mL). The mixture was diluted with EtOAc and H ₂ O and filtered through Celite®, then the organic layer was separated, dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as a colorless oil (217 mg, 50%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 5.30 (1H, brd s), 3.42 (6H, m), 3.35 (4H, brd s), 2.51 (6H, brd s), 1 .03 (9H, s)

ＤＣＭ（３ｍＬ）中の４-(２-ヒドロキシ-１,１-ジメチルエチル)ピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１１０ｍｇ、０．４３ｍｍｏｌ）の溶液にＴＦＡ（１ｍＬ）を加え、生じた混合物を３時間攪拌した。反応混合物をＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨに溶出し、表題化合物をオフホワイトの固形物として得た（６２ｍｇ、９１％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ３．３２（２Ｈ，ｓ），２．９０（５Ｈ，ｔ，Ｊ＝４．７８Ｈｚ），２．３８−２．１３（４Ｈ，ｍ），１．０３（６Ｈ，ｓ） Example 41c 2-Methyl-2-piperazin-1-ylpropan-1-ol

To a solution of 4- (2-hydroxy-1,1-dimethylethyl) piperazine-1-carboxylic acid tert-butyl ester (110 mg, 0.43 mmol) in DCM (3 mL) was added TFA (1 mL) and the resulting mixture Was stirred for 3 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted into 2M NH ₃ / MeOH to give the title compound as an off-white solid (62 mg, 91 %). ¹ H NMR (CDCl ₃ , 400 MHz): δ 3.32 (2H, s), 2.90 (5H, t, J = 4.78 Hz), 2.38-2.13 (4H, m), 1.03 (6H, s)

工程１：７-オキセタン-３-イル-４,７-ジアザスピロ[２.５]オクタン-４-カルボン酸ベンジルエステル

ＤＣＥ（１０ｍＬ）中の４,７-ジアザスピロ[２.５]オクタン-４-カルボン酸ベンジルエステルオキサレート（２００ｍｇ、０．５９ｍｍｏｌ）、オキセタン-３-オン（５０ｍｇ、０．６９ｍｍｏｌ）、ＮＥｔ_３（８２μＬ、０．５９ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（１．０ｇ）の混合物を室温で２時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（１６４ｍｇ、０．７８ｍｍｏｌ）を加えた。得られた混合物を６８時間攪拌した後、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させ、表題化合物を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．０１分，［Ｍ＋Ｈ］^＋３０３．３ Example 41d 7-oxetane-3-yl-4,7-diazaspiro [2.5] octane

Step 1: 7-Oxetane-3-yl-4,7-diazaspiro [2.5] octane-4-carboxylic acid benzyl ester

4,7-diazaspiro [2.5] octane-4-carboxylic acid benzyl ester oxalate (200 mg, 0.59 mmol), oxetane-3-one (50 mg, 0.69 mmol), NEt ₃ (10 mL) in DCE (10 mL). A mixture of 82 μL, 0.59 mmol) and 4Å powdered molecular sieve (1.0 g) was stirred at room temperature for 2 hours, and then sodium triacetoxyborohydride (164 mg, 0.78 mmol) was added. The resulting mixture was stirred for 68 hours before being loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH to give the title compound. LCMS (Method H): R _T 2.01 min, [M + H] ⁺ 303.3.

ＩＭＳ（３ｍＬ）中の７-オキセタン-３-イル-４,７-ジアザスピロ[２.５]オクタン-４-カルボン酸ベンジルエステルの溶液に１０％Ｐｄ／Ｃ（６０ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で室温で２０時間攪拌した。反応混合物をセライト（商標登録）で濾過し、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させ、表題化合物を得た（９０ｍｇ、９０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ４．６３−４．６３（２Ｈ，ｍ），３．５０−３．４２（２Ｈ，ｍ），３．００−２．９８（２Ｈ，ｍ），２．３５−２．２５（２Ｈ，ｍ），２．１５（２Ｈ，ｓ），２．０５−２．０３（２Ｈ，ｍ），０．６８−０．６３（２Ｈ，ｍ），０．５２−０．５１（２Ｈ，ｍ） Process 2: 7-oxetane-3-yl-4,7-diazaspiro [2.5] octane

To a solution of 7-oxetane-3-yl-4,7-diazaspiro [2.5] octane-4-carboxylic acid benzyl ester in IMS (3 mL) was added 10% Pd / C (60 mg) and the resulting mixture was Stir at room temperature for 20 hours under H ₂ atmosphere. The reaction mixture was filtered through Celite® and loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product eluted with 2M NH ₃ / MeOH to give the title compound (90 mg, 90%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 4.63-4.63 (2H, m), 3.50-3.42 (2H, m), 3.00-2.98 (2H, m), 2 .35-2.25 (2H, m), 2.15 (2H, s), 2.05-2.03 (2H, m), 0.68-0.63 (2H, m), 0.52 -0.51 (2H, m)

ｉ）３-(メトキシメチルカルバモイル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

ジクロロメタン（５ｍＬ）中のＮ,Ｏ-ジメチルヒドロキシルアミン塩酸塩（７７３ｍｇ、７．９３ｍｍｏｌ）及びジイソプロピルエチルアミン（１．３８ｍＬ、７．９３ｍｍｏｌ）の混合物をジクロロメタン（１０ｍＬ）中のアゼチジン-１,３-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（１．０ｇ、５．３０ｍｍｏｌ）及びＮ-(３-ジメチルアミノプロピル)-Ｎ’-エチルカルボジイミド塩酸塩（１．２７ｇ、６．６３ｍｍｏｌ）の混合物に加えた。生じた反応混合物を室温、窒素雰囲気下で１６時間攪拌した。有機相を水（１×２５ｍＬ）、１０％クエン酸水溶液（２×２５ｍＬ）、ブライン（１×３０ｍＬ）で洗浄し、硫酸ナトリウムで乾燥させた。溶媒を真空下で減じて表題化合物を淡黄色の油として得た（１．０６ｇ、８２％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．１４（２Ｈ，ｍ），４．０５（２Ｈ，ｔ，Ｊ＝８．７２Ｈｚ），３．６６（４Ｈ，ｓ），３．２０（３Ｈ，ｓ），１．４３（９Ｈ，ｓ）。 Example 41e 1-azetidin-3-yl-2-methylpropan-1-ol

i) 3- (Methoxymethylcarbamoyl) azetidine-1-carboxylic acid tert-butyl ester

A mixture of N, O-dimethylhydroxylamine hydrochloride (773 mg, 7.93 mmol) and diisopropylethylamine (1.38 mL, 7.93 mmol) in dichloromethane (5 mL) was converted to azetidine-1,3-dicarboxylic acid in dichloromethane (10 mL). To a mixture of acid mono-tert-butyl ester (1.0 g, 5.30 mmol) and N- (3-dimethylaminopropyl) -N′-ethylcarbodiimide hydrochloride (1.27 g, 6.63 mmol). The resulting reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The organic phase was washed with water (1 × 25 mL), 10% aqueous citric acid (2 × 25 mL), brine (1 × 30 mL) and dried over sodium sulfate. The solvent was reduced in vacuo to give the title compound as a pale yellow oil (1.06 g, 82%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.14 (2H, m), 4.05 (2H, t, J = 8.72 Hz), 3.66 (4H, s), 3.20 (3H, s ), 1.43 (9H, s).

無水テトラヒドロフラン（１５ｍＬ）中の３-(メトキシメチルカルバモイル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．０６ｇ、４．３４ｍｍｏｌ）の溶液をアルゴンガス下で４℃に冷却した。２Ｍのイソプロピルマグネシウムクロリド（４．３５ｍＬ、８．６８ｍｍｏｌ）の溶液を滴下して加え、生じた混合物を４℃で５分間攪拌した。室温まで温度が上がるまで待ち、１時間攪拌し、ついで４０℃で１時間攪拌した。反応混合物を塩化アンモニウム（５ｍＬ）と水（１０ｍＬ）の飽和溶液でクエンチした。水性相を酢酸エチル（３×２０ｍＬ）で抽出した。有機層を硫酸ナトリウムで乾燥させ、濾過し、溶媒を真空下で減じて、表題化合物を淡黄色の油として得た（９５０ｍｇ、９６％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．０３−４．０１（４Ｈ，ｍ），３．５９−３．５９（１Ｈ，ｍ），２．６１−２．６１（１Ｈ，ｍ），１．４３（９Ｈ，ｓ），１．１１（６Ｈ，ｄ，Ｊ＝６．９４Ｈｚ）。 ii) 3- (Isobutyryl) azetidine-1-carboxylic acid tert-butyl ester

A solution of 3- (methoxymethylcarbamoyl) azetidine-1-carboxylic acid tert-butyl ester (1.06 g, 4.34 mmol) in anhydrous tetrahydrofuran (15 mL) was cooled to 4 ° C. under argon gas. A solution of 2M isopropylmagnesium chloride (4.35 mL, 8.68 mmol) was added dropwise and the resulting mixture was stirred at 4 ° C. for 5 minutes. The mixture was waited for the temperature to rise to room temperature, stirred for 1 hour, and then stirred at 40 ° C. for 1 hour. The reaction mixture was quenched with a saturated solution of ammonium chloride (5 mL) and water (10 mL). The aqueous phase was extracted with ethyl acetate (3 × 20 mL). The organic layer was dried over sodium sulfate, filtered and the solvent reduced in vacuo to give the title compound as a pale yellow oil (950 mg, 96%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.03-4.01 (4H, m), 3.59-3.59 (1H, m), 2.61-2.61 (1H, m), 1 .43 (9H, s), 1.11 (6H, d, J = 6.94 Hz).

水素化ホウ素ナトリウム（２３７ｍｇ、６．２６ｍｍｏｌ）をエタノール（７．５ｍＬ）中の３-(イソブチリル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（０．９５ｇ、４．１８ｍｍｏｌ）の溶液に加えた。生じた反応混合物を２時間室温で攪拌した。飽和炭酸水素塩（２５ｍＬ）を加え、生じた混合物を更に１５分間攪拌した。水性相をジクロロメタンで抽出した（３×２５ｍＬ）。有機層を硫酸ナトリウムで乾燥させ、溶媒を真空下で減じ、粗生成物を黄色油として得た。残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、酢酸エチル：シクロヘキサン：勾配０：１００から４０：６０）で精製した。溶媒を真空下で減じて、表題化合物を無色の油として得た（８４０ｍｇ、８８％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ３．９１−３．９０（３Ｈ，ｍ），３．７１（１Ｈ，ｄｄ，Ｊ＝８．５４，６．０４Ｈｚ），３．５１（１Ｈ，ｄｄ，Ｊ＝７．２１，４．９７Ｈｚ），２．７０−２．６３（１Ｈ，ｍ），１．６５−１．６３（１Ｈ，ｍ），１．４４（９Ｈ，ｓ），０．９０（６Ｈ，ｔ，Ｊ＝６．５９Ｈｚ）。 iii) 3- (1-hydroxy-2-methylpropyl) azetidine-1-carboxylic acid tert-butyl ester

Sodium borohydride (237 mg, 6.26 mmol) was added to a solution of 3- (isobutyryl) azetidine-1-carboxylic acid tert-butyl ester (0.95 g, 4.18 mmol) in ethanol (7.5 mL). The resulting reaction mixture was stirred for 2 hours at room temperature. Saturated bicarbonate (25 mL) was added and the resulting mixture was stirred for an additional 15 minutes. The aqueous phase was extracted with dichloromethane (3 × 25 mL). The organic layer was dried over sodium sulfate and the solvent was reduced in vacuo to give the crude product as a yellow oil. The residue was purified by column chromatography (Si-PCC, ethyl acetate: cyclohexane: gradient 0: 100 to 40:60). The solvent was reduced in vacuo to give the title compound as a colorless oil (840 mg, 88%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 3.91-3.90 (3H, m), 3.71 (1H, dd, J = 8.54, 6.04 Hz), 3.51 (1H, dd, J = 7.21, 4.97 Hz), 2.70-2.63 (1H, m), 1.65-1.63 (1H, m), 1.44 (9H, s), 0.90 ( 6H, t, J = 6.59 Hz).

iv) Add trifluoroacetic acid (3 mL) to a solution of 3- (1-hydroxy-2-methylpropyl) azetidine-1-carboxylic acid tert-butyl ester (0.84 g, 3.66 mmol) in dichloromethane (12 mL). It was. The resulting reaction mixture was stirred for 40 minutes at room temperature. The solvent was reduced under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was subsequently eluted using a mixture of DCM and 2M NH _{3 in} MeOH. The solvent was reduced in vacuo to give 1-azetidin-3-yl-2-methylpropan-1-ol as a white solid (0.42 g, 88%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 3.63-3.62 (3H, m), 3.53-3.51 (2H, m), 2.88-2.87 (1H, m), 1 .62-1.62 (1H, m), 0.89 (6H, dd, J = 6.84, 4.72 Hz)

Example 41f (azetidin-3-ylmethyl) methyl (tetrahydrofuran-3-yl) amine

ＤＣＭ（１０ｍＬ）中の３-エチルアミノメチル-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、１．０ｍｍｏｌ）、ジヒドロフラン-３-オン（０．１５５ｍＬ、２．０ｍｍｏｌ）、ジイソプロピルエチルアミン（０．３４７ｍＬ、２．０ｍｍｏｌ）及び４Åモレキュラーシーブ（６００ｍｇ）の混合物を室温で３０分間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（４２４ｍｇ、２ｍｍｏｌ）を加え、生じた反応混合物を窒素雰囲気下、室温で６０時間攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をカラムクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、勾配０：１００から５：９５）で精製して、表題化合物を無色の油として得た（２５７ｍｇ、９５％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．０４−３．９２（３Ｈ，ｍ），３．８３（１Ｈ，ｄｄ，Ｊ＝８．８９，６．９０Ｈｚ），３．７５（１Ｈ，ｑ，Ｊ＝８．０７Ｈｚ），３．６４（１Ｈ，ｄｄ，Ｊ＝８．８７，６．２１Ｈｚ），３．５６−３．５５（２Ｈ，ｍ），３．１４（１Ｈ，ｍ），２．６７−２．６６（２Ｈ，ｍ），２．５１（１Ｈ，ｄｄ，Ｊ＝１２．３３，７．２０Ｈｚ），２．１７（３Ｈ，ｓ），２．０５（１Ｈ，ｓ），１．８９−１．７９（１Ｈ，ｍ），１．４４（９Ｈ，ｓ）。 i) 3-{[Methyl (tetrahydrofuran-3-yl) -amino] methyl} azetidine-1-carboxylic acid tert-butyl ester

3-Ethylaminomethyl-azetidine-1-carboxylic acid tert-butyl ester (200 mg, 1.0 mmol), dihydrofuran-3-one (0.155 mL, 2.0 mmol), diisopropylethylamine (0 347 mL, 2.0 mmol) and 4 mol molecular sieves (600 mg) were stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (424 mg, 2 mmol) was added and the resulting reaction mixture was stirred at room temperature for 60 hours under a nitrogen atmosphere. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) to give the title compound as a colorless oil (257 mg, 95%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.04-3.92 (3H, m), 3.83 (1H, dd, J = 8.89, 6.90 Hz), 3.75 (1H, q, J = 8.07 Hz), 3.64 (1H, dd, J = 8.87, 6.21 Hz), 3.56-3.55 (2H, m), 3.14 (1H, m), 2. 67-2.66 (2H, m), 2.51 (1H, dd, J = 12.33, 7.20 Hz), 2.17 (3H, s), 2.05 (1H, s), 1. 89-1.79 (1H, m), 1.44 (9H, s).

ii) Trifluoroacetic acid (3 mL) of 3-{[methyl (tetrahydrofuran-3-yl) amino] methyl} azetidine-1-carboxylic acid tert-butyl ester (257 mg, 0.95 mmol) in dichloromethane (12 mL). Added to the solution. The resulting reaction mixture was stirred for 1.5 hours at room temperature. The solvent was reduced under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge is washed with DCM / MeOH and the desired product is subsequently extracted with 2M NH ₃ in DCM and MeOH to give (azetidin-3-ylmethyl) methyl (tetrahydrofuran-3-yl) amine as colorless. As an oil (140 mg, 86%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 3.94 (1H, td, J = 8.62, 4.35 Hz), 3.84 (1H, dd, J = 8.76, 6.50 Hz), 3. 76-3.65 (3H, m), 3.62 (1H, dd, J = 8.76, 6.50 Hz), 3.38 (2H, t, J = 7.31 Hz), 3.09-3 .07 (1H, m), 2.99-2.88 (1 H, m), 2.64 (1 H, dd, J = 12.50, 7.22 Hz), 2.53 (1 H, dd, J = 12.50, 7.22 Hz), 2.15 (3 H, s), 2.01 (1 H, dtd, J = 12.34, 7.72, 3.21 Hz), 1.83 (1 H, dtd, J = 12.35, 8.40, 6.96 Hz)

ｉ）３-[(メチル(オキセタン-３-イル)アミノ)メチル]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

Example 41g (azetidin-3-ylmethyl) methyloxetane-3-ylamine

i) 3-[(Methyl (oxetane-3-yl) amino) methyl] azetidine-1-carboxylic acid tert-butyl ester

A mixture of 3- (methylamino) methylazetidine-1-carboxylic acid tert-butyl ester (450 mg, 2.25 mmol), oxetan-3-one (135 mg, 1.88 mmol) in dichloromethane (10 mL) Stir for hours at room temperature. Sodium triacetoxyborohydride (797 mg, 3.76 mmol) was added and the resulting reaction mixture was stirred at room temperature for 18 hours under a nitrogen atmosphere. The mixture was diluted with water, the phases were separated, and the aqueous phase was extracted with EtOAc (2 × 25 mL). The combined organic layers were dried over sodium sulfate, filtered, the solvent reduced in vacuo and the residue purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) The compound was obtained as a colorless oil (330 mg, 69%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.64 (2H, t, J = 6.58 Hz), 4.57 (2H, t, J = 6.26 Hz), 4.01 (2H, t, J = 8.40 Hz), 3.57-3.55 (3 H, m), 2.71-2.61 (1 H, m), 2.41 (2 H, d, J = 7.57 Hz), 2.08 ( 3H, s), 1.44 (9H, s).

ii) A solution of trifluoroacetic acid (3 mL) in 3-[(methyl (oxetane-3-yl) amino) methyl] azetidine-1-carboxylic acid tert-butyl ester (330 mg, 1.29 mmol) in dichloromethane (12 mL) Added to. The resulting reaction mixture was stirred for 1.5 hours at room temperature. The solvent was reduced under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge is washed with DCM / MeOH and the desired product is subsequently extracted with 2M NH ₃ in DCM and MeOH, and (azetidin-3-ylmethyl) methyl (oxetan-3-yl) amine is purified in colorless. Obtained as an oil (180 mg, 90%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.64 (2H, t, J = 6.59 Hz), 4.57 (2H, t, J = 6.31 Hz), 3.72 (2H, t, J = 7.87 Hz), 3.58-3.49 (1 H, m), 3.37 (2 H, t, J = 7.22 Hz), 2.92-2.82 (1 H, m), 2.44 ( 3H, m), 2.06 (3H, s)

ｉ）３-((Ｓ)-３-ヒドロキシピロリジン-１-カルボニル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

(Ｓ)-ピロリジン-３-オール（０．２７６ｇ、３．１７ｍｍｏｌ）を、ジクロロメタン（７ｍＬ）中のアゼチジン-１,３-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（０．４ｇ、２．１１ｍｍｏｌ）及びＮ-(３-ジメチルアミノプロピル)-Ｎ’-エチルカルボジイミド塩酸塩（０．６１ｇ、３．１７ｍｍｏｌ）の混合物に加えた。生じた反応混合物を窒素雰囲気下、室温で４８時間攪拌した。混合物をＤＣＭ（１０ｍＬ）で希釈し、水（１×１５ｍＬ）、１０％クエン酸水溶液（２×１５ｍＬ）及びブライン（２×１５ｍＬ）で洗浄し、硫酸ナトリウムで乾燥させた。溶媒を真空下で減じて表題化合物を無色の油として得た（０．４６ｇ、８１％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．５５−４．４８（１Ｈ，ｍ），４．１７（２Ｈ，ｓ），４．０５−４．０４（２Ｈ，ｍ），３．５０−３．４７（５Ｈ，ｍ），２．０１−２．００（２Ｈ，ｍ），１．４３（９Ｈ，ｄ，Ｊ＝０．９６Ｈｚ）。 Example 41h Azetidin-3-yl-((S) -3-hydroxypyrrolidin-1-yl) methanone

i) 3-((S) -3-Hydroxypyrrolidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester

(S) -pyrrolidin-3-ol (0.276 g, 3.17 mmol) was added to azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (0.4 g, 2.11 mmol) in dichloromethane (7 mL) and To a mixture of N- (3-dimethylaminopropyl) -N′-ethylcarbodiimide hydrochloride (0.61 g, 3.17 mmol). The resulting reaction mixture was stirred at room temperature for 48 hours under a nitrogen atmosphere. The mixture was diluted with DCM (10 mL), washed with water (1 × 15 mL), 10% aqueous citric acid (2 × 15 mL) and brine (2 × 15 mL) and dried over sodium sulfate. The solvent was reduced in vacuo to give the title compound as a colorless oil (0.46 g, 81%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.55-4.48 (1H, m), 4.17 (2H, s), 4.05-4.04 (2H, m), 3.50-3 .47 (5H, m), 2.01-2.00 (2H, m), 1.43 (9H, d, J = 0.96 Hz).

ii) A solution of trifluoroacetic acid (3 mL) in 3-((S) -3-hydroxypyrrolidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester (460 mg, 1.7 mmol) in dichloromethane (12 mL). Was added. The resulting reaction mixture was stirred for 2 hours at room temperature. The solvent was reduced under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge is washed with DCM / MeOH and the desired product is subsequently extracted with 2M NH ₃ in DCM and MeOH to produce azetidin-3-yl-((S) -3-hydroxypyrrolidin-1-yl. ) Methanone was obtained as a colorless oil (243 mg, 84%). ¹ H NMR (400 MHz, DMSO, d ₆ ): δ 4.28-4.18 (1H, m), 3.72-3.17 (10H, m), 2.11-2.10 (1H, m) , 1.81-1.80 (2H, m)

ｉ）３-((Ｒ)-３-ヒドロキシピロリジン-１-カルボニル)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル

(Ｒ)-ピロリジン-３-オール（０．２７６ｇ、３．１７ｍｍｏｌ）をジクロロメタン（７ｍＬ）中のアゼチジン-１,３-ジカルボン酸モノ-ｔｅｒｔ-ブチルエステル（０．４ｇ、２．１１ｍｍｏｌ）及びＮ-(３-ジメチルアミノプロピル)-Ｎ’-エチルカルボジイミド塩酸塩（０．６１ｇ、３．１７ｍｍｏｌ）の混合物に加えた。生じた反応混合物を窒素雰囲気下、室温で１８時間攪拌した。混合物をＤＣＭ（１０ｍＬ）で希釈し、水（１×１５ｍＬ）、１０％クエン酸水溶液（２×１５ｍＬ）及びブライン（２×１５ｍＬ）で洗浄し、硫酸ナトリウムで乾燥させた。溶媒を真空下で減じて表題化合物を無色の油として得た（０．４２ｇ、７４％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．５４−４．５２（１Ｈ，ｍ），４．１１−４．０９（４Ｈ，ｍ），３．５０−３．４８（５Ｈ，ｍ），２．０１−２．００（２Ｈ，ｍ），１．４３（９Ｈ，ｄ，Ｊ＝０．７８Ｈｚ） Example 41i Azetidin-3-yl-((R) -3-hydroxypyrrolidin-1-yl) methanone

i) 3-((R) -3-hydroxypyrrolidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester

(R) -Pyrrolidin-3-ol (0.276 g, 3.17 mmol) was added to azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (0.4 g, 2.11 mmol) and N in dichloromethane (7 mL). To a mixture of-(3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (0.61 g, 3.17 mmol). The resulting reaction mixture was stirred at room temperature for 18 hours under a nitrogen atmosphere. The mixture was diluted with DCM (10 mL), washed with water (1 × 15 mL), 10% aqueous citric acid (2 × 15 mL) and brine (2 × 15 mL) and dried over sodium sulfate. The solvent was reduced in vacuo to give the title compound as a colorless oil (0.42 g, 74%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.54-4.52 (1H, m), 4.11-4.09 (4H, m), 3.50-3.48 (5H, m), 2 .01-2.00 (2H, m), 1.43 (9H, d, J = 0.78 Hz)

ii) A solution of trifluoroacetic acid (3 mL) in 3-((R) -3-hydroxypyrrolidine-1-carbonyl) azetidine-1-carboxylic acid tert-butyl ester (420 mg, 1.55 mmol) in dichloromethane (12 mL). Added to. The resulting reaction mixture was stirred for 2 hours at room temperature. The solvent was reduced under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge is washed with DCM / MeOH and the desired product is subsequently extracted with 2M NH ₃ in DCM and MeOH to give azetidin-3-yl-((R) -3-hydroxypyrrolidin-1-yl. ) Methanone was obtained as a colorless oil (225 mg, 85%). ¹ H NMR (400 MHz, DMSO, d ₆ ): δ 4.26-4.22 (1H, m), 3.47-3.44 (10H, m), 2.13-2.09 (1H, m) , 1.81 (2H, m)

R ³ Reagents:

４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（２４８ｍｇ、１．２６ｍｍｏｌ）、ジカルボン酸ジ-ｔｅｒｔ-ブチル（３０２ｍｇ、１．３８ｍｍｏｌ）、ＤＭＡＰ（３１ｍｇ、０．２５ｍｍｏｌ）、トリエチルアミン（１４０ｍｇ、１．３８ｍｍｏｌ）及びアセトニトリル（８ｍＬ）の混合物を室温で２．５時間攪拌した。反応混合物を蒸発させ、残留物をカラムクロマトグラフィー（Ｓｉ-ＰＰＣ，シクロヘキサン：ＥｔＯＡｃ、０：１００から５０：５０勾配）で精製して、表題化合物（３１６ｍｇ、８４％）を無色の油として得た。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝４．０７分，［Ｍ＋Ｈ−^ｔＢｕ］^＋２４１（^７９Ｂｒ），２４３（^８１Ｂｒ） Example 42 4-Bromo-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester

4-Bromo-1H-pyrrolo [2,3-c] pyridine (248 mg, 1.26 mmol), di-tert-butyl dicarboxylate (302 mg, 1.38 mmol), DMAP (31 mg, 0.25 mmol), triethylamine (140 mg) , 1.38 mmol) and acetonitrile (8 mL) were stirred at room temperature for 2.5 hours. The reaction mixture was evaporated and the residue was purified by column chromatography (Si-PPC, cyclohexane: EtOAc, 0: 100 to 50:50 gradient) to give the title compound (316 mg, 84%) as a colorless oil. . LCMS (Method C): R _T = 4.07 min, [M + H− ^t Bu] ⁺ 241 ( ⁷⁹ Br), 243 ( ⁸¹ Br)

ＤＣＭ（１０ｍＬ）中の４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（３１６ｍｇ、１．０６ｍｍｏｌ）の溶液にＮａＨＣＯ_３（１０ｍＬ）の飽和水溶液を加え、生じた混合物を０℃に冷却した。３-クロロ過安息香酸（Ｈ_２Ｏ中７０−７５％）（５２４ｍｇ、２．１３ｍｍｏｌ）を室温まで温めた反応混合物に加え、更に２０時間攪拌した。混合物を水及びＤＣＭの間で分配し、水性層をＤＣＭで抽出した（２×１０ｍＬ）。組み合わせた有機抽出物を乾燥させ（相分離器）、蒸発させて、表題化合物をオレンジ色の固形物として得た（３１７ｍｇ、９５％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ３．４８分，［Ｍ＋Ｈ］^＋３１３（^７９Ｂｒ），３１５（^８１Ｂｒ） Example 43 4-Bromo-6-oxypyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester

To a solution of 4-bromo-1H-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester (316 mg, 1.06 mmol) in DCM (10 mL) was added a saturated aqueous solution of NaHCO ₃ (10 mL). The resulting mixture was cooled to 0 ° C. 3-Chloroperbenzoic acid (70-75% in H ₂ O) (524 mg, 2.13 mmol) was added to the reaction mixture warmed to room temperature and stirred for an additional 20 hours. The mixture was partitioned between water and DCM and the aqueous layer was extracted with DCM (2 × 10 mL). The combined organic extracts were dried (phase separator) and evaporated to give the title compound as an orange solid (317 mg, 95%). LCMS (Method _C): R T 3.48 ^{min, [M + H] + 313} (79 Br), 315 (81 Br)

工程１：１-ベンゼンスルホニル-１Ｈ-ピロロ[３,２-ｃ]ピリジン

１００ｍＬの丸底フラスコに、無水ＴＨＦ（５０ｍＬ）中の１Ｈ-ピロロ[３,２-ｃ]ピリジン(1.０ｇ、８．４ｍｍｏｌ）の溶液を充填した。ＮａＨ（鉱油中６０％、０．４１ｇ、１０．２ｍｍｏｌ）を加え、反応混合物を５分間室温で攪拌した。この溶液に０℃でベンゼンスルホニル塩化物（１．３５ｍＬ、１０．２ｍｍｏｌ）を滴下し、生じた混合物を室温で２時間攪拌した。反応混合物を水（３０ｍＬ）でクエンチし、ＥｔＯＡｃ（３×１００ｍＬ）で抽出した。有機層を混合し、乾燥（Ｎａ_２ＳＯ_４）させ、真空下で濃縮して、表題化合物を白色固形物として得た（１．２９ｇ、５５％）。^１Ｈ ＮＭＲ（ＤＭＳＯ，３００ＭＨｚ）：δ８．９５（ｓ，１Ｈ）；８．４９（ｄ，Ｊ＝５．８Ｈｚ，１Ｈ）；８．１３−８．０５（ｍ，２Ｈ）；８．０２−７．９４（ｍ，２Ｈ）；７．７９−７．７１（ｍ，１Ｈ）；７．６９−７．５９（ｍ，２Ｈ）；７．０１（ｄｄ，Ｊ＝３．７，０．９Ｈｚ，１Ｈ）。 Example 44 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [3,2-c] pyridine

Step 1: 1-Benzenesulfonyl-1H-pyrrolo [3,2-c] pyridine

A 100 mL round bottom flask was charged with a solution of 1H-pyrrolo [3,2-c] pyridine (1.0 g, 8.4 mmol) in anhydrous THF (50 mL). NaH (60% in mineral oil, 0.41 g, 10.2 mmol) was added and the reaction mixture was stirred for 5 minutes at room temperature. To this solution was added benzenesulfonyl chloride (1.35 mL, 10.2 mmol) dropwise at 0 ° C., and the resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3 × 100 mL). The organic layers were combined, dried (Na ₂ SO ₄ ) and concentrated in vacuo to give the title compound as a white solid (1.29 g, 55%). ¹ H NMR (DMSO, 300 MHz): δ 8.95 (s, 1H); 8.49 (d, J = 5.8 Hz, 1H); 8.13-8.05 (m, 2H); 8.02- 7.94 (m, 2H); 7.79-7.71 (m, 1H); 7.69-7.59 (m, 2H); 7.01 (dd, J = 3.7, 0.9 Hz) , 1H).

１００ｍＬの丸底フラスコに、ジオキサン（２０ｍＬ）中の１-ベンゼンスルホニル-１Ｈ-ピロロ[３,２-ｃ]ピリジン（０．６ｇ、２．３ｍｍｏｌ）の溶液を充填した。生じた溶液にｍＣＰＢＡ（０．６ｇ、３．４５ｍｍｏｌ）を加え、混合物を室温で３０分間攪拌した。反応混合物を真空下で濃縮させ、ついで残留物をＤＣＭ（５０ｍＬ）中に溶解させ、亜硫酸ナトリウム水溶液、炭酸水素ナトリウム水溶液及びブラインで連続して洗浄した。有機層を分離し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮して、表題化合物を白色固形物として得た（０．６ｇ、９５％）。^１Ｈ ＮＭＲ（ＤＭＳＯ，３００ＭＨｚ）：δ８．６１（ｄｄ，Ｊ＝１．８，０．７Ｈｚ，１Ｈ）；８．１３（ｄｄ，Ｊ＝７．２，１．８Ｈｚ，１Ｈ）；８．０９−８．０４（ｍ，２Ｈ）；８．０１（ｄ，Ｊ＝３．７Ｈｚ，１Ｈ）；７．９２（ｄ，Ｊ＝７．２Ｈｚ，１Ｈ）；７．８０−７．７３（ｍ，１Ｈ）；７．６９−７．６１（ｍ，２Ｈ）；６．８３（ｄｄ，Ｊ＝３．７，０．８Ｈｚ，１Ｈ）。 Step 2: 1-Benzenesulfonyl-1H-pyrrolo [3,2-c] pyridine 5-oxide

A 100 mL round bottom flask was charged with a solution of 1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridine (0.6 g, 2.3 mmol) in dioxane (20 mL). To the resulting solution was added mCPBA (0.6 g, 3.45 mmol) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo, then the residue was dissolved in DCM (50 mL) and washed successively with aqueous sodium sulfite, aqueous sodium bicarbonate and brine. The organic layer was separated then dried (Na ₂ SO ₄ ) and concentrated under vacuum to give the title compound as a white solid (0.6 g, 95%). ¹ H NMR (DMSO, 300 MHz): δ 8.61 (dd, J = 1.8, 0.7 Hz, 1H); 8.13 (dd, J = 7.2, 1.8 Hz, 1H); 8.09 −8.04 (m, 2H); 8.01 (d, J = 3.7 Hz, 1H); 7.92 (d, J = 7.2 Hz, 1H); 7.80-7.73 (m, 1H); 7.69-7.61 (m, 2H); 6.83 (dd, J = 3.7, 0.8 Hz, 1H).

窒素下、温度計プローブ及び凝縮器／不活性ガスバブラー（Ｃｌａｉｓｅｎヘッドを介する）を備えた２５０ｍＬの丸底フラスコに、アセトニトリル（５０ｍＬ）及びジオキサン（５０ｍＬ）中の１-ベンゼンスルホニル-１Ｈ-ピロロ[３,２-ｃ]ピリジン５-オキシド（３．５ｇ、１２．８ｍｍｏｌ）の溶液を充填した。この溶液にオキシ臭化リン（１２ｇ、４０．９ｍｍｏｌ）を滴下して加え、生じた混合物を７０℃で１８時間攪拌した。形成された沈殿物を濾過により取り除き、ジオキサンで数回洗浄した。溶液を真空下で濃縮し、ＤＣＭ、水及びブラインの間で分配した。有機層を分離させ、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、シクロヘキサン中０−２０％のＥｔＯＡｃ）で精製して、所望の生成物を得た（３．１ｇ、７２％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ８．２３（ｄ，Ｊ＝５．７Ｈｚ，１Ｈ）；７．９４−７．８５（ｍ，３Ｈ）；７．６７−７．５９（ｍ，２Ｈ）；７．５５−７．４８（ｍ，２Ｈ）；６．７５（ｄｄ，Ｊ＝３．７，０．８Ｈｚ，１Ｈ）。 Step 3: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine

Under nitrogen, a 250 mL round bottom flask equipped with a thermometer probe and a condenser / inert gas bubbler (via Claisen head) was charged with 1-benzenesulfonyl-1H-pyrrolo [3 in acetonitrile (50 mL) and dioxane (50 mL). , 2-c] pyridine 5-oxide (3.5 g, 12.8 mmol) was charged. To this solution was added phosphorus oxybromide (12 g, 40.9 mmol) dropwise and the resulting mixture was stirred at 70 ° C. for 18 hours. The formed precipitate was removed by filtration and washed several times with dioxane. The solution was concentrated under vacuum and partitioned between DCM, water and brine. The organic layer was separated then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PCC, 0-20% EtOAc in cyclohexane) to give the desired product (3.1 g, 72%). ¹ H NMR (CDCl ₃ , 300 MHz): δ 8.23 (d, J = 5.7 Hz, 1H); 7.94-7.85 (m, 3H); 7.67-7.59 (m, 2H) 7.55-7.48 (m, 2H); 6.75 (dd, J = 3.7, 0.8 Hz, 1H).

窒素下、温度計プローブ及び凝縮器／不活性ガスバブラー（Ｃｌａｉｓｅｎヘッドを介する）を備えた５０ｍＬの丸底フラスコに、無水ＴＨＦ（８ｍＬ）中の１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[３,２-ｃ]ピリジン（０．４３ｇ、１．２７ｍｍｏｌ）の溶液を充填した。生じた溶液に−３５℃でリチウムジイソプロピルアミド（ヘプタン／ＴＨＦ／エチルベンゼン中２．０Ｍ、１．２７ｍＬ、２．５４ｍｍｏｌ）の溶液を滴下して加え、混合物を−３５℃で３０分間攪拌した。ヨウ化メチル（０．４８ｍＬ、７．６３ｍｍｏｌ）を滴下して加え、溶液を室温にし、３時間攪拌した。反応を１ＮのＨＣｌ（３ｍＬ）の添加によりクエンチした。溶液を水（７ｍＬ）で希釈し、ＥｔＯＡｃ（２×５０ｍＬ）で抽出した。有機抽出物をプールし、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ，０−１００％のＥｔＯＡｃ：シクロヘキサン）で精製して、所望の生成物を白色粉末として得た（０．４３ｇ、９６％）。ＬＣＭＳ（方法Ａ）Ｒ_Ｔ＝４．６７分，［Ｍ＋Ｈ］^＋３５１（^７９Ｂｒ），３５３（^８１Ｂｒ） Step 4: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [3,2-c] pyridine

Under nitrogen, a 50 mL round bottom flask equipped with a thermometer probe and condenser / inert gas bubbler (via Claisen head) was charged with 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3 in anhydrous THF (8 mL). , 2-c] pyridine (0.43 g, 1.27 mmol) was charged. To the resulting solution was added dropwise at −35 ° C. a solution of lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 1.27 mL, 2.54 mmol) and the mixture was stirred at −35 ° C. for 30 min. Methyl iodide (0.48 mL, 7.63 mmol) was added dropwise and the solution was allowed to reach room temperature and stirred for 3 hours. The reaction was quenched by the addition of 1N HCl (3 mL). The solution was diluted with water (7 mL) and extracted with EtOAc (2 × 50 mL). The organic extracts were pooled, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, 0-100% EtOAc: cyclohexane) to give the desired product as a white powder (0.43 g, 96%). LCMS (Method A) R _T = 4.67 min, [M + H] ⁺ 351 ( ⁷⁹ Br), 353 ( ⁸¹ Br)

工程１：１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン

５０ｍＬの丸底フラスコに、無水ＤＣＭ（２０ｍＬ）中の４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．７ｇ、３．５５ｍｍｏｌ）の溶液を充填した。ＮａＯＨ（０．４３ｇ、１０．７ｍｍｏｌ）及びベンゼントリエチルアンモニウムクロリド（０．０１６ｇ、０．０７ｍｍｏｌ）を加え、反応混合物を室温で３時間攪拌した。反応混合物をセライト（登録商標）で濾過し、セライト床をＤＣＭで洗浄し、生じた濾液を真空下で濃縮した。生じた固形残留物をジエチルエーテルで倍散し、沈殿物を濾過により集めて、表題化合物をオフホワイトの固形物として得た（０．９６ｇ、８０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝４．２９分，［Ｍ＋Ｈ］^＋３３７（^７９Ｂｒ），３３９（^８１Ｂｒ） Example 45 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [2,3-c] pyridine

Step 1: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine

A 50 mL round bottom flask was charged with a solution of 4-bromo-1H-pyrrolo [2,3-c] pyridine (0.7 g, 3.55 mmol) in anhydrous DCM (20 mL). NaOH (0.43 g, 10.7 mmol) and benzenetriethylammonium chloride (0.016 g, 0.07 mmol) were added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered through Celite®, the Celite bed was washed with DCM and the resulting filtrate was concentrated under vacuum. The resulting solid residue was triturated with diethyl ether and the precipitate was collected by filtration to give the title compound as an off-white solid (0.96 g, 80%). LCMS (Method A): R _T = 4.29 min, [M + H] ⁺ 337 ( ⁷⁹ Br), 339 ( ⁸¹ Br)

窒素下、温度計プローブ及び凝縮器／不活性ガスバブラー（Ｃｌａｉｓｅｎヘッドを介する）を備えた５０ｍＬの丸底フラスコに、無水ＴＨＦ（１０ｍＬ）中の１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．９６ｇ、２．８４ｍｍｏｌ）の溶液を充填した。生じた溶液に−３５℃でリチウムジイソプロピルアミド（ヘプタン／ＴＨＦ／エチルベンゼン中２．０Ｍ、２．８４ｍＬ、５．６８ｍｍｏｌ）の溶液を滴下して加え、混合物をついで−３５℃で４５分間攪拌した。ヨウ化メチル（１．０６ｍＬ、１７．０４ｍｍｏｌ）を反応混合物に滴下して加えた。生じた溶液を室温にし、３時間攪拌した。反応物を１ＮのＨＣｌ（５ｍＬ）の溶液を加えてクエンチし；溶液を水（１５ｍＬ）で希釈し、ＥｔＯＡｃ（２×７５ｍＬ）で抽出した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製した（Ｓｉ-ＰＰＣ、０−１００％ＤＣＭ：シクロヘキサン）。残留物をＥｔＯＡｃ（２ｍＬ）で倍散し、沈殿物を濾過により回収して、表題化合物を白色固形物として得た（０．３９ｇ、３９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝４．４７分，［Ｍ＋Ｈ］^＋３５１（^７９Ｂｒ），３５３（^８１Ｂｒ） Step 2: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [2,3-c] pyridine

Under nitrogen, a 50 mL round bottom flask equipped with a thermometer probe and condenser / inert gas bubbler (via Claisen head) was charged with 1-benzenesulfonyl-4-bromo-1H-pyrrolo [2 in anhydrous THF (10 mL). , 3-c] pyridine (0.96 g, 2.84 mmol) was charged. To the resulting solution was added dropwise at −35 ° C. a solution of lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 2.84 mL, 5.68 mmol) and the mixture was then stirred at −35 ° C. for 45 min. Methyl iodide (1.06 mL, 17.04 mmol) was added dropwise to the reaction mixture. The resulting solution was brought to room temperature and stirred for 3 hours. The reaction was quenched by the addition of a solution of 1N HCl (5 mL); the solution was diluted with water (15 mL) and extracted with EtOAc (2 × 75 mL). The organic layer was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The residue was purified by flash chromatography (Si-PPC, 0-100% DCM: cyclohexane). The residue was triturated with EtOAc (2 mL) and the precipitate was collected by filtration to give the title compound as a white solid (0.39 g, 39%). LCMS (Method A): R _T = 4.47 min, [M + H] ⁺ 351 ( ⁷⁹ Br), 353 ( ⁸¹ Br)

１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．３４ｇ、１．０ｍｍｏｌ）をＴＨＦ（５ｍＬ）及びジエチルエーテル（５ｍＬ）に溶解させ、溶液を−７８℃に冷却した。ｎ−ブチルリチウム（ヘキサン中０．７５６Ｍ、１．２ｍＬ、５．０ｍｍｏｌ）を５分かけて加え、ついで混合物を１５分間攪拌した後、塩化トリブチルすず（０．３９ｇ、１．２ｍｍｏｌ）を１０分かけて加えた。反応混合物を−７８℃で１時間攪拌し、ついで室温に温め、シクロヘキサン（５０ｍＬ）で希釈した。反応混合物を水（３×３０ｍＬ）とついでブラインで洗浄し、有機相を乾燥させ（ＭｇＳＯ_４）、蒸発させた。粗残留物をシクロヘキサン中３０％のＥｔＯＡｃを用いたアルミナ上のクロマトグラフィーで精製した。物質を更にフラッシュクロマトグラフィーで精製し（Ｓｉ-ＰＰＣ）、シクロヘキサン中５−１０％のＥｔＯＡｃで溶出して、表題の生成物を得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ９．２３（ｓ，１Ｈ），８．３６（ｓ，１Ｈ），７．９１−８．００（ｍ，２Ｈ），７．７１，ｄ，Ｊ＝１．１Ｈｚ，１Ｈ），７．５５−７．６３（ｍ，１Ｈ），７．４２−７．５３（ｍ，２Ｈ），６．５９（ｄ，Ｊ＝１．１Ｈｚ，１Ｈ），１．４５−１．６５（ｍ，６Ｈ），１．２１−１．３８（ｍ，６Ｈ），１．０９−１．２０（ｍ，６Ｈ），０．８５（ｔ，Ｊ＝７．５Ｈｚ，９Ｈ）。 Example 46 1-Benzenesulfonyl-4-tributylstannanyl-1H-pyrrolo [2,3-c] pyridine

1-Benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine (0.34 g, 1.0 mmol) is dissolved in THF (5 mL) and diethyl ether (5 mL) and the solution is brought to -78 ° C. Cooled down. n-Butyllithium (0.756M in hexane, 1.2 mL, 5.0 mmol) was added over 5 minutes, then the mixture was stirred for 15 minutes before tributyltin chloride (0.39 g, 1.2 mmol) was added for 10 minutes. Added over. The reaction mixture was stirred at −78 ° C. for 1 hour, then warmed to room temperature and diluted with cyclohexane (50 mL). The reaction mixture was washed with water (3 × 30 mL) followed by brine and the organic phase was dried (MgSO ₄ ) and evaporated. The crude residue was purified by chromatography on alumina using 30% EtOAc in cyclohexane. The material was further purified by flash chromatography (Si-PPC) eluting with 5-10% EtOAc in cyclohexane to give the title product. ¹ H NMR (CDCl ₃ , 300 MHz): δ9.23 (s, 1H), 8.36 (s, 1H), 7.91-8.00 (m, 2H), 7.71, d, J = 1 .1 Hz, 1H), 7.55-7.63 (m, 1H), 7.42-7.53 (m, 2H), 6.59 (d, J = 1.1 Hz, 1H), 1.45 -1.65 (m, 6H), 1.21-1.38 (m, 6H), 1.09-1.20 (m, 6H), 0.85 (t, J = 7.5 Hz, 9H) .

５-ブロモ-２-メチル-３-ニトロピリジン（２１７ｍｇ、１ｍｍｏｌ）をＴＨＦ（１０ｍＬ）に溶解し、溶液を−５０℃にアルゴン下で冷却した。ビニル臭化マグネシウム（３ｍＬ、ＴＨＦ中１Ｍ）を直ちに一回で加えると、明るいオレンジ色の溶液が生じた。オレンジ色の溶液を−４０℃で３０分間攪拌し、反応をＮＨ_４Ｃｌ（１０ｍＬの飽和水溶液）の添加によってクエンチした。混合物を水で希釈し、ＥｔＯＡｃ（２×１０ｍＬ）で抽出した。組み合わせた有機抽出物を乾燥させ（ＭｇＳＯ_４）、濃縮した。粗物質を、シクロヘキサン中ＥｔＯＡｃ（２０−８０％）を溶出液として用いたシリカクロマトグラフィー（Ｓｉ-ＰＰＣ）で精製して、淡黄色の結晶性固形物として生成物を得た（６３ｍｇ、３０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３）８．２３（ｓ，１Ｈ），７．４１−７，４５（ｍ，１Ｈ），６．６２−６．６５（ｍ，１Ｈ），２．７３（ｓ，３Ｈ） Example 47 4-Bromo-7-methyl-1H-pyrrolo [2,3-c] pyridine

5-Bromo-2-methyl-3-nitropyridine (217 mg, 1 mmol) was dissolved in THF (10 mL) and the solution was cooled to −50 ° C. under argon. Vinyl magnesium bromide (3 mL, 1 M in THF) was immediately added in one shot resulting in a bright orange solution. The orange solution was stirred at −40 ° C. for 30 minutes and the reaction was quenched by the addition of NH ₄ Cl (10 mL of saturated aqueous solution). The mixture was diluted with water and extracted with EtOAc (2 × 10 mL). The combined organic extracts were dried (MgSO ₄ ) and concentrated. The crude material was purified by silica chromatography (Si-PPC) using EtOAc in cyclohexane (20-80%) as eluent to give the product as a pale yellow crystalline solid (63 mg, 30% ). ¹ H NMR (CDCl ₃ ) 8.23 (s, 1H), 7.41-7, 45 (m, 1H), 6.62-6.65 (m, 1H), 2.73 (s, 3H)

６-メチル-１Ｈ-ピロロ[３,２-ｃ]ピリジン-４-オール(J.Het.Chem.,1996,303)（１６１ｍｇ、１．０９ｍｍｏｌ）及びオキシ臭化リン（１．８７ｇ、過剰）の混合物を、シールしたチューブ中で１２０℃で５０分間加熱した。反応混合物を水（１０ｍＬ）に注ぎ、水性ＮａＨＣＯ_３で塩基性（ｐＨ８）にし、有機生成物をＤＣＭ中に抽出した。有機層を乾燥させ（相分離器）、蒸発し、残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、シクロヘキサン：酢酸エチル、１００：０から７０：３０の勾配）で精製して、４-ブロモ-６-メチル-１Ｈ-ピロロ[３,２-ｃ]ピリジン（２０ｍｇ、１２％）を白色固形物として得た。ＬＣＭＳＲ_Ｔ＝２．００分，［Ｍ＋Ｈ］^＋２１１ Example 48 4-Bromo-6-methyl-1H-pyrrolo [3,2-c] pyridine

6-Methyl-1H-pyrrolo [3,2-c] pyridin-4-ol (J. Het. Chem., 1996, 303) (161 mg, 1.09 mmol) and phosphorus oxybromide (1.87 g, excess) The mixture was heated at 120 ° C. for 50 minutes in a sealed tube. The reaction mixture was poured into water (10 mL), made basic (pH 8) with aqueous NaHCO ₃ and the organic product was extracted into DCM. The organic layer was dried (phase separator) and evaporated, the residue was purified by column chromatography (Si-PCC, cyclohexane: ethyl acetate, gradient from 100: 0 to 70:30) to give 4-bromo-6 -Methyl-1H-pyrrolo [3,2-c] pyridine (20 mg, 12%) was obtained as a white solid. LCMSR _T = 2.00 min, [M + H] ⁺ 211

ビニル臭化マグネシウム（ＴＨＦ中１Ｍ、３７．５ｍＬ、３７．５０ｍｍｏｌ）の攪拌懸濁液に、ＴＨＦ中の３-ブロモ-２-メチル-５-ニトロピリジン（２．５０ｇ、１１．５２ｍｍｏｌ）の溶液を窒素雰囲気下、０℃で滴下して加えた。生じた溶液を室温まで温め、１日攪拌し、ついで飽和ＮＨ_４Ｃｌ（水性）でクエンチした。生じた混合物をＥｔＯＡｃ及び水の間で分配し、有機層を分離し、乾燥させ（ＭｇＳＯ_４）、蒸発し、赤い粗油を得、これをカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、シクロヘキサン中５０−１００％のＥｔＯＡｃ）と、続く逆相ＨＰＬＣ（Ｐｈｅｎｏｍｅｎｅｘ Ｇｅｍｉｎｉ ５ｕ Ｃ１８，メタノール５−７５％の勾配で水中０．１％のギ酸）によって精製した。関連するＨＰＬＣ画分をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄し、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させ、表題化合物を淡黄色の固形物として得た（２２ｍｇ、１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．２３分，［Ｍ＋Ｈ］^＋２１１．１（^７９Ｂｒ），２１３．１（^８１Ｂｒ） Example 49 4-Bromo-5-methyl-1H-pyrrolo [2,3-c] pyridine

A solution of 3-bromo-2-methyl-5-nitropyridine (2.50 g, 11.52 mmol) in THF in a stirred suspension of vinylmagnesium bromide (1M in THF, 37.5 mL, 37.50 mmol). Was added dropwise at 0 ° C. under a nitrogen atmosphere. The resulting solution was warmed to room temperature, stirred for 1 day, and then quenched with saturated NH ₄ Cl (aq). The resulting mixture was partitioned between EtOAc and water, the organic layer was separated, dried (MgSO ₄ ) and evaporated to give a red crude oil which was column chromatographed (Si-PCC, 50-100 in cyclohexane). % EtOAc) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 0.1% formic acid in water with a gradient of 5-75% methanol). The relevant HPLC fractions are loaded onto an Isolute® SCX-2 cartridge, the cartridge is washed with MeOH and the desired product is eluted with 2M NH ₃ in MeOH to give the title compound as a pale yellow solid (22 mg, 1%). LCMS (Method H): R _T 2.23 min, [M + H] ⁺ 211.1 ( ⁷⁹ Br), 213.1 ( ⁸¹ Br)

工程１：１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン

５０ｍＬの丸底フラスコに、無水ＤＣＭ（２０ｍＬ）中の４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．７ｇ、３．５５ｍｍｏｌ）の溶液を充填した。ＮａＯＨ（０．４３ｇ、１０．７ｍｍｏｌ）及びベンゼントリエチルアンモニウムクロリド（０．０１６ｇ、０．０７ｍｍｏｌ）を加え、反応混合物を室温で３時間攪拌した。反応混合物をセライトで濾過し、セライト床をＤＣＭで洗浄し、生じた濾液を真空下で濃縮した。生じた固形残留物をジエチルエーテルで倍散し、沈殿物を濾過により収集して、表題化合物をオフホワイトの固形物として得た（０．９６ｇ、８０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝４．２９分，［Ｍ＋Ｈ］＋３３７（^７９Ｂｒ），３３９（^８１Ｂｒ） Example 50 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [2,3-c] pyridine

Step 1: 1-Benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine

A 50 mL round bottom flask was charged with a solution of 4-bromo-1H-pyrrolo [2,3-c] pyridine (0.7 g, 3.55 mmol) in anhydrous DCM (20 mL). NaOH (0.43 g, 10.7 mmol) and benzenetriethylammonium chloride (0.016 g, 0.07 mmol) were added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was filtered through celite, the celite bed was washed with DCM, and the resulting filtrate was concentrated in vacuo. The resulting solid residue was triturated with diethyl ether and the precipitate was collected by filtration to give the title compound as an off-white solid (0.96 g, 80%). LCMS (Method A): R _T = 4.29 min, [M + H] +337 ( ⁷⁹ Br), 339 ( ⁸¹ Br)

無水ＴＨＦ（１０ｍＬ）中の１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．９６ｇ、２．８４ｍｍｏｌ）の溶液に、−３５℃でリチウムジイソプロピルアミド（ヘプタン／ＴＨＦ／エチルベンゼン中２．０Ｍ、２．８４ｍＬ、５．６８ｍｍｏｌ）の溶液を滴下して加えた。混合物を−３５℃で４５分間攪拌し、ヨウ化メチル（１．０６ｍＬ、１７．０４ｍｍｏｌ）を滴下して加えた。生じた溶液を室温にまでして、３時間攪拌した。反応混合物を１ＮのＨＣｌ（５ｍＬ）の水溶液を加えてクエンチし；溶液を水（１５ｍＬ）で希釈し、ＥｔＯＡｃ（２×７５ｍＬ）で抽出した。有機抽出物を組み合わせ、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製した（Ｓｉ-ＰＰＣ，ＤＣＭ：シクロヘキサン、勾配０：１００から１００：０）。残留物をＥｔＯＡｃ（２ｍＬ）で倍散し、濾過により収集して、表題化合物を白色固形物として得た（０．３９ｇ、３９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝４．４７分，［Ｍ＋Ｈ］^＋３５１（^７９Ｂｒ），３５３（^８１Ｂｒ） Step 2: 1-Benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [2,3-c] pyridine

To a solution of 1-benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine (0.96 g, 2.84 mmol) in anhydrous THF (10 mL) at −35 ° C. at lithium diisopropylamide (heptane / A solution of 2.0M in THF / ethylbenzene, 2.84 mL, 5.68 mmol) was added dropwise. The mixture was stirred at −35 ° C. for 45 minutes and methyl iodide (1.06 mL, 17.04 mmol) was added dropwise. The resulting solution was allowed to reach room temperature and stirred for 3 hours. The reaction mixture was quenched by addition of an aqueous solution of 1N HCl (5 mL); the solution was diluted with water (15 mL) and extracted with EtOAc (2 × 75 mL). The organic extracts were combined, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The residue was purified by flash chromatography (Si-PPC, DCM: cyclohexane, gradient 0: 100 to 100: 0). The residue was triturated with EtOAc (2 mL) and collected by filtration to give the title compound as a white solid (0.39 g, 39%). LCMS (Method A): R _T = 4.47 min, [M + H] ⁺ 351 ( ⁷⁹ Br), 353 ( ⁸¹ Br)

無水ＴＨＦ（１０ｍＬ）中の１-ベンゼンスルホニル-４-ブロモ-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．６３ｇ、１．８６ｍｍｏｌ）の溶液に、−３５℃でリチウムジイソプロピルアミド（ヘプタン／ＴＨＦ／エチルベンゼン中２Ｍ、１．８６ｍＬ、３．７７ｍｍｏｌ）の溶液を滴下して加えた。反応混合物を−３５℃で３０分間攪拌し、ついでヨウ化エチル（０．９０ｍＬ、１１．１８ｍｍｏｌ）を滴下して加えた。生じた溶液を室温にまでして、４時間攪拌した。反応混合物を１ＮのＨＣｌ（５ｍＬ）の溶液の添加によりクエンチし；溶液を水（１５ｍＬ）で希釈し、ＥｔＯＡｃ（２×７５ｍＬ）で抽出した。有機抽出物を組み合わせ、ブラインで洗浄し、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。残留物をフラッシュクロマトグラフィーで精製した（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン０：１００から７０：３０）。残留物をＥｔＯＡｃ（２ｍＬ）で倍散し、濾過により収集し、表題化合物を白色固形物として得た（０．２７ｇ、４０％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝４．６５分，［Ｍ＋Ｈ］^＋３６７（^７９Ｂｒ），３６９（^８１Ｂｒ） Example 51 1-Benzenesulfonyl-4-bromo-2-ethyl-1H-pyrrolo [2,3-c] pyridine

To a solution of 1-benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine (0.63 g, 1.86 mmol) in anhydrous THF (10 mL) at −35 ° C. at lithium diisopropylamide (heptane / A solution of 2M in THF / ethylbenzene, 1.86 mL, 3.77 mmol) was added dropwise. The reaction mixture was stirred at −35 ° C. for 30 minutes and then ethyl iodide (0.90 mL, 11.18 mmol) was added dropwise. The resulting solution was allowed to reach room temperature and stirred for 4 hours. The reaction mixture was quenched by the addition of a solution of 1N HCl (5 mL); the solution was diluted with water (15 mL) and extracted with EtOAc (2 × 75 mL). The organic extracts were combined, washed with brine, dried (Na ₂ SO ₄ ) and concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane 0: 100 to 70:30). The residue was triturated with EtOAc (2 mL) and collected by filtration to give the title compound as a white solid (0.27 g, 40%). LCMS (Method H): R _T = 4.65 min, [M + H] ⁺ 367 ( ⁷⁹ Br), 369 ( ⁸¹ Br)

工程１：２-ブロモ-５-メチルピリジン１-オキシド

クロロホルム（７ｍＬ）中の２-ブロモ-５-メチルピリジン（２．０ｇ、１１．６ｍｍｏｌ）及び３-クロロ過安息香酸（３．０ｇ、１４．８ｍｍｏｌ）の混合物を５０℃で３時間攪拌し、室温まで冷やし、濾過した。濾液を減圧下で濃縮して残留物を得、これをフラッシュクロマトグラフィーで精製して（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＥｔＯＡｃ、０：１００から１０：９０の勾配）、２-ブロモ-５-メチルピリジン１-オキシドを白色固形物として得た（２．０ｇ、９１％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ８．２４（ｓ，１Ｈ）；７．５２（ｄ，Ｊ＝８．３Ｈｚ，１Ｈ）；６．９３（ｄ，Ｊ＝８．３３Ｈｚ，１Ｈ）；２．２９（ｓ，３Ｈ）。 Example 52 5-Bromo-8-methylimidazo [1,2-a] pyridine

Step 1: 2-Bromo-5-methylpyridine 1-oxide

A mixture of 2-bromo-5-methylpyridine (2.0 g, 11.6 mmol) and 3-chloroperbenzoic acid (3.0 g, 14.8 mmol) in chloroform (7 mL) was stirred at 50 ° C. for 3 hours, Cool to room temperature and filter. The filtrate was concentrated under reduced pressure to give a residue which was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 10:90), 2-bromo-5-methylpyridine. 1-oxide was obtained as a white solid (2.0 g, 91%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.24 (s, 1H); 7.52 (d, J = 8.3 Hz, 1H); 6.93 (d, J = 8.33 Hz, 1H) 2.29 (s, 3H).

ＤＣＭ（４０ｍＬ）及びトリフルオロベンゼン（１７ｍＬ）中の２-ブロモ-５-メチルピリジン１-オキシド（２．０ｇ、１０．６ｍｍｏｌ）の溶液に、０℃でｔｅｒｔ-ブチルアミン（８．０ｍＬ、７６．７ｍｍｏｌ）及びｐ-トルエンスルホン酸無水物（１１．４ｇ、３５．０ｍｍｏｌ）を少しずつ加えた。反応混合物を０℃で１．５時間攪拌し、ついで濾過した。濾液を濃縮して残留物を得、これをフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、Ｅｔ_２Ｏ：ペンタン、勾配０：１００から１００：０）で精製して、(６-ブロモ-３-メチルピリジン-２-イル)-ｔｅｒｔ-ブチルアミンを無色の油として得た（５００ｍｇ、１９％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ６．９８（ｄ，Ｊ＝７．５Ｈｚ，１Ｈ）；６．５９（ｄ，Ｊ＝７．５Ｈｚ，１Ｈ）；４．０５（ｓ，１Ｈ）；１．９６（ｓ，３Ｈ）；１．４７（ｓ，９Ｈ）。 Step 2: (6-Bromo-3-methylpyridin-2-yl) -tert-butylamine

To a solution of 2-bromo-5-methylpyridine 1-oxide (2.0 g, 10.6 mmol) in DCM (40 mL) and trifluorobenzene (17 mL) at 0 ° C., tert-butylamine (8.0 mL, 76. 7 mmol) and p-toluenesulfonic anhydride (11.4 g, 35.0 mmol) were added in portions. The reaction mixture was stirred at 0 ° C. for 1.5 hours and then filtered. The filtrate was concentrated to give a residue that was purified by flash chromatography (Si-PPC, Et ₂ O: pentane, gradient 0: 100 to 100: 0) to give (6-bromo-3-methylpyridine- 2-yl) -tert-butylamine was obtained as a colorless oil (500 mg, 19%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 6.98 (d, J = 7.5 Hz, 1H); 6.59 (d, J = 7.5 Hz, 1H); 4.05 (s, 1H) 1.96 (s, 3H); 1.47 (s, 9H).

ＤＣＥ（２ｍＬ）及びＴＦＡ（２ｍＬ）中の(６-ブロモ-３-メチルピリジン-２-イル)-ｔｅｒｔ-ブチルアミン（５００ｍｇ、２．０６ｍｍｏｌ）の溶液をマイクロ波反応器で１０分間１２０℃で加熱し、ついで減圧下で濃縮した。残留物をＭｅＯＨに取り上げ、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３に溶出させ、６-ブロモ-３-メチルピリジン-２-イルアミンを白色固形物として得た（３５９ｍｇ、９３％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．１１（ｄ，Ｊ＝７．５Ｈｚ，１Ｈ）；６．７７（ｄ，Ｊ＝７．５Ｈｚ，１Ｈ）；４．５０（ｓ，２Ｈ）；２．０７（ｓ，３Ｈ）。 Step 3: 6-Bromo-3-methylpyridin-2-ylamine

A solution of (6-bromo-3-methylpyridin-2-yl) -tert-butylamine (500 mg, 2.06 mmol) in DCE (2 mL) and TFA (2 mL) was heated in a microwave reactor for 10 minutes at 120 ° C. And then concentrated under reduced pressure. The residue was taken up in MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 6-bromo-3-methylpyridin-2-ylamine as a white solid (359 mg, 93%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.11 (d, J = 7.5 Hz, 1H); 6.77 (d, J = 7.5 Hz, 1H); 4.50 (s, 2H) 2.07 (s, 3H).

Step 4: A mixture of 6-bromo-3-methylpyridin-2-ylamine (359 mg, 1.92 mmol) and chloroacetaldehyde (1 mL, 50 wt% in water) in IMS (4 mL) at 100 ° C. for 1.5 h. Stir in the sealed tube, then cool to room temperature and fill an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and then eluted with 2M NH ₃ in MeOH to give 5-bromo-8-methylimidazo [1,2-a] pyridine as a beige solid (387 mg, 95%) . ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.79 (d, J = 1.3 Hz, 1H); 7.69 (d, J = 1.3 Hz, 1H); 6.96 (d, J = 7.3 Hz, 1H); 6.91 (dq, J = 7.3, 1.1 Hz, 1H); 2.61 (d, J = 1.1 Hz, 3H).

工程１：２-ブロモ-３-フルオロピリジン１-オキシド

クロロホルム（３．５ｍＬ）中の２-ブロモ-３-フルオロピリジン（１．０ｇ、５．７ｍｍｏｌ）及び３-クロロ過安息香酸（１．５ｇ、７．４ｍｍｏｌ）の混合物を１８時間５０℃で攪拌し、室温まで冷やし、濾過した。濾液を減圧下で濃縮して残留物を得、これをフラッシュクロマトグラフィーで精製して（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＥｔＯＡｃ、勾配０：１００から５：９５）、２-ブロモ-３-フルオロピリジン１-オキシドを白色固形物として得た（８７８ｍｇ、８０％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ８．２５（ｄｔ，Ｊ＝６．６，１．３Ｈｚ，１Ｈ）；７．２５−７．１７（ｍ，１Ｈ）；７．０６（ｄｄｄ，Ｊ＝８．７，６．６，１．３Ｈｚ，１Ｈ）。 Example 53 5-Bromo-6-fluoroimidazo [1,2-a] pyridine

Step 1: 2-Bromo-3-fluoropyridine 1-oxide

A mixture of 2-bromo-3-fluoropyridine (1.0 g, 5.7 mmol) and 3-chloroperbenzoic acid (1.5 g, 7.4 mmol) in chloroform (3.5 mL) was stirred at 50 ° C. for 18 hours. And cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give a residue that was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 5:95), 2-bromo-3-fluoropyridine 1 The oxide was obtained as a white solid (878 mg, 80%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.25 (dt, J = 6.6, 1.3 Hz, 1H); 7.25-7.17 (m, 1H); 7.06 (ddd, J = 8.7, 6.6, 1.3 Hz, 1H).

ＤＣＭ（１０ｍＬ）及びトリフルオロベンゼン（４ｍＬ）中の２-ブロモ-３-フルオロピリジン１-オキシド（５１１ｍｇ、２．７ｍｍｏｌ）の溶液に、５０℃でｔｅｒｔ-ブチルアミン（２．５ｍＬ、２３．９ｍｍｏｌ）及びｐ-トルエンスルホン酸無水物（３．７ｇ、１１．４ｍｍｏｌ）を少しずつ加えた。反応混合物を５０℃で２時間攪拌し、ついで濾過した。濾液を濃縮して残留物を得、これをフラッシュクロマトグラフィーで精製して（Ｓｉ-ＰＰＣ、Ｅｔ_２Ｏ：ペンタン、勾配０：１００から５：９５）、(６-ブロモ-５-フルオロピリジン-２-イル)-ｔｅｒｔ-ブチルアミンを無色油として得た（３０ｍｇ、５％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．１３（ｄｄ，Ｊ＝８．８，７．３Ｈｚ，１Ｈ）；６．２９（ｄｄ，Ｊ＝８．８，２．５Ｈｚ，１Ｈ）；４．４９（ｓ，１Ｈ）；１．４０（ｓ，９Ｈ）。 Step 2: (6-Bromo-5-fluoropyridin-2-yl) -tert-butylamine

To a solution of 2-bromo-3-fluoropyridine 1-oxide (511 mg, 2.7 mmol) in DCM (10 mL) and trifluorobenzene (4 mL) at 50 ° C., tert-butylamine (2.5 mL, 23.9 mmol). And p-toluenesulfonic anhydride (3.7 g, 11.4 mmol) was added in portions. The reaction mixture was stirred at 50 ° C. for 2 hours and then filtered. The filtrate was concentrated to give a residue, which was purified by flash chromatography (Si-PPC, Et ₂ O: pentane, gradient 0: 100 to 5:95) and (6-bromo-5-fluoropyridine- 2-yl) -tert-butylamine was obtained as a colorless oil (30 mg, 5%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.13 (dd, J = 8.8, 7.3 Hz, 1H); 6.29 (dd, J = 8.8, 2.5 Hz, 1H); 4.49 (s, 1H); 1.40 (s, 9H).

ＤＣＥ（２ｍＬ）及びＴＦＡ（２ｍＬ）中の(６-ブロモ-５-フルオロピリジン-２-イル)-ｔｅｒｔ-ブチルアミン（４６ｍｇ、０．１９ｍｍｏｌ）の溶液を１２０℃で１０分間マイクロ波反応器中で加熱し、ついで減圧下で濃縮した。残留物をＭｅＯＨ中に取り上げ、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（５ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させ、６-ブロモ-５-フルオロピリジン-２-イルアミンをオフホワイトの固形物として得た（２５ｍｇ、７１％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．２１（ｄｄ，Ｊ＝８．７，７．２Ｈｚ，１Ｈ）；６．３９（ｄｄ，Ｊ＝８．７，２．７Ｈｚ，１Ｈ）；４．８９−３．７５（ｓ，２Ｈ）。 Step 3: 6-Bromo-5-fluoropyridin-2-ylamine

A solution of (6-bromo-5-fluoropyridin-2-yl) -tert-butylamine (46 mg, 0.19 mmol) in DCE (2 mL) and TFA (2 mL) was placed in a microwave reactor at 120 ° C. for 10 minutes. Heated and then concentrated under reduced pressure. The residue was taken up in MeOH and loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH to give 6-bromo-5-fluoropyridin-2-ylamine as an off-white solid (25 mg, 71%) . ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.21 (dd, J = 8.7, 7.2 Hz, 1H); 6.39 (dd, J = 8.7, 2.7 Hz, 1H); 4.89-3.75 (s, 2H).

Step 4: Seal a mixture of 6-bromo-5-fluoropyridin-2-ylamine (25 mg, 0.13 mmol) and chloroacetaldehyde (0.1 mL, 50 wt% in water) in IMS (2 mL) at 100 ° C. for 18 hours. The mixture was stirred in the tube, then cooled to room temperature and loaded into an Isolute® SCX-2 cartridge (5 g). The desired product was washed with MeOH and then eluted with 2M NH ₃ in MeOH to give 5-bromo-6-fluoroimidazo [1,2-a] pyridine as a yellow oil (25 mg, 89% ). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.84 (s, 1H); 7.76 (m, 1H); 7.61 (ddd, J = 9.73, 4.67, 0.71 Hz, 1H); 7.21-7.16 (m, 1H).

ＩＭＳ（４ｍＬ）中の６-ブロモ-４-メチル-ピリジン-２-イルアミン（３７４ｍｇ、２．０ｍｍｏｌ）及びクロロアセトアルデヒド（１ｍＬ、水中５０重量％）の混合物を１００℃で１８時間シールしたチューブ内で攪拌した後、室温まで冷却し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、ついで生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。溶媒を除去した後、残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、勾配０：１００から５：９５）で精製して、５-ブロモ-７-メチル-イミダゾ[１,２-ａ]ピリジンをオレンジ色の固形物として得た（３４０ｍｇ、８２％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．７２−７．７０（ｍ，１Ｈ）；７．６３−７．６２（ｍ，１Ｈ）；７．３８−７．３７（ｍ，１Ｈ）；６．９２−６．９０（ｍ，１Ｈ）；２．４０（ｍ，３Ｈ）。 Example 54 5-Bromo-7-methyl-imidazo [1,2-a] pyridine

A mixture of 6-bromo-4-methyl-pyridin-2-ylamine (374 mg, 2.0 mmol) and chloroacetaldehyde (1 mL, 50 wt% in water) in IMS (4 mL) in a sealed tube at 100 ° C. for 18 hours. After stirring, it was cooled to room temperature and filled into an Isolute (R) SCX-2 cartridge (10 g). The cartridge was washed with MeOH and then the product was eluted with 2M NH ₃ in MeOH. After removal of solvent, the residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) to give 5-bromo-7-methyl-imidazo [1,2-a ] Pyridine was obtained as an orange solid (340 mg, 82%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.72-7.70 (m, 1H); 7.63-7.62 (m, 1H); 7.38-7.37 (m, 1H) 6.92-6.90 (m, 1H); 2.40 (m, 3H).

ＩＭＳ（４ｍＬ）中の６-ブロモピリジン-２-イルアミン（１．０ｇ、５．６ｍｍｏｌ）及び１-クロロプロパン-２-オン（０．５ｍＬ、６．３ｍｍｏｌ）の混合物を３６時間還流下で攪拌した後、室温まで冷却し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、ついで所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。溶媒を除去した後、残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：Ｅｔ_２Ｏ、０：１００から１０：１００の勾配）で精製して、５-ブロモ-２-メチルイミダゾ[１,２-ａ]ピリジンを黄色油として得た（５４７ｍｇ、４５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝０．３１分及び２．０４分，［Ｍ＋Ｈ］^＋２１１（^７９Ｂｒ）及び２１３（^８１Ｂｒ） Example 55 5-Bromo-2-methylimidazo [1,2-a] pyridine

A mixture of 6-bromopyridin-2-ylamine (1.0 g, 5.6 mmol) and 1-chloropropan-2-one (0.5 mL, 6.3 mmol) in IMS (4 mL) was stirred at reflux for 36 hours. Thereafter, it was cooled to room temperature and filled into an Isolute® SCX-2 cartridge (20 g). The cartridge was washed with MeOH and then the desired product was eluted with 2M NH ₃ in MeOH. After removal of the solvent, the residue was purified by flash chromatography (Si-PPC, MeOH: Et ₂ O, gradient 0: 100 to 10: 100) to give 5-bromo-2-methylimidazo [1,2 -a] Pyridine was obtained as a yellow oil (547 mg, 45%). LCMS (Method H): R _T = 0.31 min and 2.04 min, [M + H] ⁺ 211 ( ⁷⁹ Br) and 213 ( ⁸¹ Br)

Example 56 5-Bromo- [1,2,4] triazolo [4,3-a] pyridine

ブタノール（１００ｍＬ）中の２,６-ジブロモピリジン（１．４４ｇ、６．１ｍｍｏｌ）及びヒドラジン（１．６５ｍＬ、３２．２ｍｍｏｌ）の混合物を１８時間環流下で攪拌した。反応混合物を室温まで冷却し、減圧下で濃縮した。残留物を飽和炭酸水素ナトリウム水溶液及びＥｔＯＡｃの間で分配した。有機層を分離し、ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮して、(６-ブロモピリジン-２-イル)ヒドラジンを白色固形物として得た(１．０ｇ、９２％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．３６−７．２８（ｍ，１Ｈ）；６．８２（ｄ，Ｊ＝７．７０Ｈｚ，１Ｈ）；６．６７（ｄ，Ｊ＝７．７Ｈｚ，１Ｈ）；５．９７（ｓ，１Ｈ）；３．８０（ｓ，２Ｈ）。 Step 1: (6-Bromopyridin-2-yl) hydrazine

A mixture of 2,6-dibromopyridine (1.44 g, 6.1 mmol) and hydrazine (1.65 mL, 32.2 mmol) in butanol (100 mL) was stirred at reflux for 18 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate and EtOAc. The organic layer was separated, washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated to give (6-bromopyridin-2-yl) hydrazine as a white solid (1.0 g, 92 %). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.36-7.28 (m, 1H); 6.82 (d, J = 7.70 Hz, 1H); 6.67 (d, J = 7. 7 Hz, 1H); 5.97 (s, 1H); 3.80 (s, 2H).

Step 2: A solution of (6-bromopyridin-2-yl) hydrazine (500 mg, 2.66 mmol) in diethoxymethyl acetate (2.5 mL) was stirred at room temperature for 18 hours. The reaction mixture was diluted with pentane and filtered. The precipitate was washed with pentane and dried under vacuum at 50 ° C. for 1 hour to give 5-bromo- [1,2,4] triazolo [4,3-a] pyridine as a beige solid (410 mg 78%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.98 (s, 1H); 7.83 (dt, J = 9.2, 0.9 Hz, 1H); 7.22 (dd, J = 9. 2, 7.0 Hz, 1 H); 7.09 (dd, J = 7.0, 0.9 Hz, 1 H).

Example 57 8-Benzyloxy-5-bromo-imidazo [1,2-a] pyridine

酢酸（２０ｍＬ）中の６-ブロモピリジン-３-オール（２．５ｇ、１４．４ｍｍｏｌ）の溶液に０℃で発煙硝酸（０．９ｍＬ、２２．４ｍｍｏｌ）を加えた。反応混合物を室温で１時間、ついで６０℃で１時間攪拌した。反応混合物を０℃まで冷却し、１０Ｍの水性水酸化物をｐＨ４−５（約２５ｍＬ）まで滴下して加えた。生じた混合物を水で希釈し、減圧下で部分的に濃縮した。残留物をＥｔＯＡｃで二回抽出した。有機画分を組み合わせ、水とブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。残留物をトルエンで共沸させて、６-ブロモ-２-ニトロピリジン-３-オールをオレンジ色の固形物として得た（２．２ｇ、７１％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＤＭＳＯ−ｄ_３）：δ１１．９２（ｓ，１Ｈ）；７．８６−７．８３（ｄ，Ｊ＝８．６Ｈｚ，１Ｈ）；７．６１（ｄ，Ｊ＝８．６Ｈｚ，１Ｈ）。 Step 1: 6-Bromo-2-nitropyridin-3-ol

To a solution of 6-bromopyridin-3-ol (2.5 g, 14.4 mmol) in acetic acid (20 mL) was added fuming nitric acid (0.9 mL, 22.4 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour and then at 60 ° C. for 1 hour. The reaction mixture was cooled to 0 ° C. and 10 M aqueous hydroxide was added dropwise to pH 4-5 (about 25 mL). The resulting mixture was diluted with water and partially concentrated under reduced pressure. The residue was extracted twice with EtOAc. The organic fractions were combined, washed with water and brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was azeotroped with toluene to give 6-bromo-2-nitropyridin-3-ol as an orange solid (2.2 g, 71%). ¹ H NMR (400 MHz, DMSO-d ₃ ): δ 11.92 (s, 1H); 7.86-7.83 (d, J = 8.6 Hz, 1H); 7.61 (d, J = 8. 6Hz, 1H).

無水ＤＭＦ（１５ｍＬ）中の６-ブロモ-２-ニトロピリジン-３-オール（１．０ｇ、４．６ｍｍｏｌ）の溶液に０℃で鉱油（２００ｍｇ、５．０ｍｍｏｌ）中の６０％水素化ナトリウムを加えた。反応混合物を０℃で５分間攪拌し、室温で１５分間攪拌した。臭化ベンジル（０．６ｍＬ、５．０ｍｍｏｌ）を滴下して加え、生じた混合物を６０℃で１時間攪拌し、室温まで冷却し、水で希釈し、ＥｔＯＡｃで抽出した。有機層を分離し、水とブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、Ｅｔ_２Ｏ：ペンタン、勾配０：１００から１００：０）で精製して３-ベンジルオキシ-６-ブロモ-２-ニトロピリジンを黄色固形物として得た（９５６ｍｇ、６７％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．６０（ｄ，Ｊ＝８．６Ｈｚ，１Ｈ）；７．４１−７．３５（ｍ，６Ｈ）；５．２５（ｓ，２Ｈ）。 Step 2: 3-Benzyloxy-6-bromo-2-nitropyridine

A solution of 6-bromo-2-nitropyridin-3-ol (1.0 g, 4.6 mmol) in anhydrous DMF (15 mL) at 60C with 60% sodium hydride in mineral oil (200 mg, 5.0 mmol). added. The reaction mixture was stirred at 0 ° C. for 5 minutes and at room temperature for 15 minutes. Benzyl bromide (0.6 mL, 5.0 mmol) was added dropwise and the resulting mixture was stirred at 60 ° C. for 1 h, cooled to room temperature, diluted with water and extracted with EtOAc. The organic layer was separated, washed with water and brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by flash chromatography (Si-PPC, Et ₂ O: pentane, gradient 0: 100 to 100: 0) to give 3-benzyloxy-6-bromo-2-nitropyridine as a yellow solid. (956 mg, 67%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.60 (d, J = 8.6 Hz, 1H); 7.41-7.35 (m, 6H); 5.25 (s, 2H).

酢酸（２５ｍＬ）及びＩＭＳ（２５ｍＬ）中の３-ベンジルオキシ-６-ブロモ-２-ニトロピリジン（１．６ｇ、５．２ｍｍｏｌ）及び鉄粉（２．９ｇ、５１．８ｍｍｏｌ）の混合物を１時間環流下で攪拌し、ついで室温まで冷却し、セライトパッドで濾過した。濾液を減圧下で濃縮して残留物を得、これを飽和炭酸水素ナトリウム水溶液及びＥｔＯＡｃの間で分配した。有機層を分離し、水とブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、勾配０：１００から４０：６０）で精製して、３-ベンジルオキシ-６-ブロモピリジン-２-イルアミンを淡黄色固形物として得た（１．０ｇ、７１％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＨＣｌ_３−ｄ）：δ７．４１−７．３４（ｍ，５Ｈ）；６．８２（ｄ，Ｊ＝８．１Ｈｚ，１Ｈ）；６．７１（ｄ，Ｊ＝８．１Ｈｚ，１Ｈ）；５．０４（ｓ，２Ｈ）；４．８０（ｓ，２Ｈ）。 Step 3: 3-Benzyloxy-6-bromopyridin-2-ylamine

A mixture of 3-benzyloxy-6-bromo-2-nitropyridine (1.6 g, 5.2 mmol) and iron powder (2.9 g, 51.8 mmol) in acetic acid (25 mL) and IMS (25 mL) for 1 hour. Stir at reflux then cool to room temperature and filter through a celite pad. The filtrate was concentrated under reduced pressure to give a residue that was partitioned between saturated aqueous sodium bicarbonate and EtOAc. The organic layer was separated, washed with water and brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 40:60) to give 3-benzyloxy-6-bromopyridin-2-ylamine as a pale yellow solid. (1.0 g, 71%). ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.41-7.34 (m, 5H); 6.82 (d, J = 8.1 Hz, 1H); 6.71 (d, J = 8. 1 Hz, 1H); 5.04 (s, 2H); 4.80 (s, 2H).

Step 4: A mixture of 3-benzyloxy-6-bromopyridin-2-ylamine (1.0 g 3.6 mmol) and chloroacetaldehyde (1.2 mL, 50 wt% in water) in IMS (12 mL) at reflux for 1 hour. Stir and then concentrate under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate and EtOAc. The organic layer was separated, washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by flash chromatography (Si-PPC, MeOH: Et ₂ O, gradient 0: 100 to 1:99) to give 8-benzyloxy-5-bromo-imidazo [1,2-a] pyridine. Was obtained as a beige solid (960 mg, 88%). LCMS (Method _H) R T 3.08 ^{min; [M + H] + 303} (79 Br) and ³⁰⁵ (81 Br)

工程１：３-フルオロ-２-ニトロ-Ｎ-(トリフェニルホスホラニリデン)ベンゼンアミン

ＴＨＦ（４ｍＬ）及び水（１ｍＬ）中の１-アジド-３-フルオロ-２-ニトロベンゼン（５００ｍｇ、２．７５ｍｍｏｌ）の溶液にトリフェニルホスフィン（７２０ｍｇ、２．７５ｍｍｏｌ）を加えた。反応混合物を４５分間室温で攪拌し、ついで水及びＥｔＯＡｃの間で分配した。有機層を分離し、ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、Ｅｔ_２Ｏ）で精製して、所望の生成物を黄色固形物として得た（８４４ｍｇ、７３％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ４．３６分；［Ｍ＋Ｈ］^＋４１７ Example 58 3-Fluoro-2-nitrophenylamine

Step 1: 3-Fluoro-2-nitro-N- (triphenylphosphoranylidene) benzenamine

To a solution of 1-azido-3-fluoro-2-nitrobenzene (500 mg, 2.75 mmol) in THF (4 mL) and water (1 mL) was added triphenylphosphine (720 mg, 2.75 mmol). The reaction mixture was stirred for 45 minutes at room temperature and then partitioned between water and EtOAc. The organic layer was separated, washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by flash chromatography (Si-PCC, Et ₂ O) to give the desired product as a yellow solid (844 mg, 73%). LCMS (Method A): R _T 4.36 min; [M + H] ⁺ 417.

Step 2: In a 2-5 mL microwave vial equipped with a magnetic follower 3-fluoro-2-nitro-N- (triphenylphosphoranylidene) benzenamine (585 mg, 1.4 mmol), water (3 mL) and TFA ( 0.1 mL). The reaction mixture was irradiated at 160 ° C. for 15 minutes and then partitioned between water and EtOAc. The organic layer was separated and washed with saturated aqueous sodium bicarbonate and brine, dried over Na ₂ SO ₄ , filtered and concentrated. The residue was purified by flash chromatography (Si-PCC, 0-100% Et ₂ O in pentane) to give 3-fluoro-2-nitrophenylamine as an orange solid (218 mg, 100% ). ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.22 (ddd, J = 8.2, 8.2, 5.5 Hz, 1H); 6.57 (ddd, J = 8.5, 1.4, 1 6.4 (ddd, J = 11.3, 8.2, 1.4 Hz, 1H).

ジカルボン酸ジ-ｔｅｒｔ-ブチル（９５１ｍｇ、４．３６ｍｍｏｌ）を水（５ｍＬ）中の(１Ｈ-ベンゾイミダゾール-２-イル)メチルアミン（５８３ｍｇ、３．９６ｍｍｏｌ）の懸濁液に加え、生じた反応混合物を３５℃で２時間攪拌した。混合物を水で希釈し、ＤＣＭ（２×１５ｍＬ）及びＥｔＯＡｃ（２×１５ｍＬ）で抽出した。組み合わせた有機層を硫酸ナトリウムで乾燥させ、溶媒を真空下で減じた。粗残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０：１００から３０：７０の勾配）で精製して、表題化合物を淡褐色固形物として得た（７２０ｍｇ、７４％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ７．５５（１Ｈ，ｄ，Ｊ＝８．０４Ｈｚ），７．３８（１Ｈ，ｄ，Ｊ＝７．８５Ｈｚ），７．１６（２Ｈ，ｔｄ，Ｊ＝７．６５，１．２７Ｈｚ），６．９９（１Ｈ，ｔｄ，Ｊ＝７．７５，１．２０Ｈｚ），３．１４（３Ｈ，ｄ，Ｊ＝４．９９Ｈｚ），１．６７（９Ｈ，ｓ） Example 59 2-Methylaminobenzimidazole-1-carboxylic acid tert-butyl ester

Di-tert-butyl dicarboxylate (951 mg, 4.36 mmol) was added to a suspension of (1H-benzimidazol-2-yl) methylamine (583 mg, 3.96 mmol) in water (5 mL) and the resulting reaction The mixture was stirred at 35 ° C. for 2 hours. The mixture was diluted with water and extracted with DCM (2 × 15 mL) and EtOAc (2 × 15 mL). The combined organic layers were dried over sodium sulfate and the solvent was reduced under vacuum. The crude residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, gradient 0: 100 to 30:70) to give the title compound as a light brown solid (720 mg, 74%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.55 (1H, d, J = 8.04 Hz), 7.38 (1H, d, J = 7.85 Hz), 7.16 (2H, td, J = 7.65, 1.27 Hz), 6.99 (1 H, td, J = 7.75, 1.20 Hz), 3.14 (3 H, d, J = 4.99 Hz), 1.67 (9 H, s) )

Formula I (i) thiazole intermediate wherein (i) X ¹ is N and X ² is S

ＤＣＥ（２００ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（３．０ｇ１０．５４ｍｍｏｌ）及び４-アゼチジン-３-イルモルホリン（１．８ｇ、１２．６６ｍｍｏｌ）の溶液を雰囲気温度で２時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（３．５ｇ、１６．５ｍｍｏｌ）を加え、混合物を１８時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（５０ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出した。溶離液を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ１００：０から９９：１から９８：２から９５：５）で精製して、４-(５-クロロ-２-((３-モルホリノアゼチジン-１-イル)メチル)チアゾロ[５,４-ｄ]ピリミジン-７-イル)モルホリンをクリーム状固形物として得た（２．６６ｇ、６１％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．６８分，［Ｍ＋Ｈ］^＋４１１．３ Example 65a 4- (5-Chloro-2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine

5-chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (3.0 g 10.54 mmol) and 4-azetidin-3-ylmorpholine (1) in DCE (200 mL). .8 g, 12.66 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (3.5 g, 16.5 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (50 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The eluent was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 99: 1 to 98: 2 to 95: 5) to give 4- (5-chloro-2-((3-morpholino Azetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine was obtained as a cream solid (2.66 g, 61%). LCMS (Method C): R _T = 2.68 min, [M + H] ⁺ 411.3.

ジオキサン（１０ｍＬ）中の２-[４-(５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-イルメチル)-ピペラジン-１-イル]-イソブチルアミド（１．０ｇ２．２ｍｍｏｌ）、ヘキサブチル二すず（１．４ｍＬ、２．７ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（１６１ｍｇ、０．２ｍｍｏｌ）の混合物を脱気し、ついで１５０℃で３０分間マイクロ波照射に供した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。ついで、カートリッジをＭｅＯＨで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３に溶出した。適当な画分を混合し、濃縮して残留物を得、これをフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から１０：９０の勾配）で精製した。適当な画分を組み合わせ、濃縮して、２-メチル-２-(４-((７-モルホリノ-５-(トリブチルスタニル)チアゾロ[５,４-ｄ]ピリミジン-２-イル)メチル)ピペラジン-１-イル)プロパンアミドを黄色油として得た（１．１ｇ、６７％）。ＬＣＭＳ（方法Ｃ）Ｒ_Ｔ＝４．８３分；［Ｍ＋Ｈ］^＋６９４．１（^１１６Ｓｎ）６９６．１（^１１８Ｓｎ） Example 65b 2-Methyl-2- (4-((7-morpholino-5- (tributylstannyl) thiazolo [5,4-d] pyrimidin-2-yl) methyl) piperazin-1-yl) propanamide

2- [4- (5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-ylmethyl) -piperazin-1-yl] -isobutyramide (1) in dioxane (10 mL) 0.0g2.2 mmol), hexabutyl distin (1.4 mL, 2.7 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (161 mg, 0.2 mmol) was degassed Then, it was subjected to microwave irradiation at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted into 2M NH ₃ in MeOH. Appropriate fractions were combined and concentrated to give a residue, which was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90). Appropriate fractions were combined and concentrated to give 2-methyl-2- (4-((7-morpholino-5- (tributylstannyl) thiazolo [5,4-d] pyrimidin-2-yl) methyl) piperazine -1-yl) propanamide was obtained as a yellow oil (1.1 g, 67%). LCMS (Method C) R _T = 4.83 min; [M + H] ⁺ 694.1 ( ¹¹⁶ Sn) 696.1 ( ¹¹⁸ Sn)

５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン（５．１ｇ、０．０２ｍｏｌ）をＴＨＦ（２００ｍＬ）に懸濁させ、生じた溶液を−７８℃まで冷却したところ、出発物質が溶液から沈殿した。ＬｉＨＭＤＳ（ＴＨＦ中１Ｍ、２５ｍＬ、１．２５当量）を、攪拌した懸濁液に滴下して加えた。添加が完了した後、混合物を３０分間攪拌し、ついでＤＭＦ（９ｍＬ、６当量）を加え、生じた溶液を−７８℃で１５分間攪拌し、ついで０℃まで温め、１５分間攪拌した。その溶液を再び−７８℃まで冷却し、〜０．５ＭのＨＣｌ（６００ｍＬ）の攪拌溶液中に（広い径口の二重末端針を介して）カニューレ処理した。生成物が溶液から淡黄色の粉末として沈殿した。これを焼結ガラス漏斗を通した濾過により分離し、水で洗浄し、真空下で一晩乾燥させて、５ｇの５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（８７．７％）を得た。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ３．８３−３．８８（ｍ，４Ｈ），４．０６−４．１５（ｍ，２Ｈ），４．７２（ｍ，２Ｈ）及び９．９５（ｓ，１Ｈ）。 Example 65c 5-chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde

5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine (5.1 g, 0.02 mol) was suspended in THF (200 mL) and the resulting solution was cooled to −78 ° C. However, the starting material precipitated from solution. LiHMDS (1M in THF, 25 mL, 1.25 equiv) was added dropwise to the stirred suspension. After the addition was complete, the mixture was stirred for 30 minutes, then DMF (9 mL, 6 eq) was added and the resulting solution was stirred at −78 ° C. for 15 minutes, then warmed to 0 ° C. and stirred for 15 minutes. The solution was again cooled to −78 ° C. and cannulated into a stirred solution of ˜0.5 M HCl (600 mL) (through a wide-bore double-ended needle). The product precipitated from solution as a pale yellow powder. This is isolated by filtration through a sintered glass funnel, washed with water and dried overnight under vacuum to give 5 g of 5-chloro-7-morpholin-4-yl-thiazolo [5,4-d]. Pyrimidine-2-carbaldehyde (87.7%) was obtained. ¹ H NMR (400 MHz, CDCl ₃ ): δ 3.83-3.88 (m, 4H), 4.06-4.15 (m, 2H), 4.72 (m, 2H) and 9.95 (s , 1H).

ＤＣＥ（２０ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（４００ｍｇ、１．４０ｍｍｏｌ）、４-アゼチジン-３-イルチオモルホリン-１,１-ジオキシド（３２１ｍｇ、１．６９ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（６００ｍｇ）の混合物を室温で４時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（５９５ｍｇ、２．８０ｍｍｏｌ）を加えた。反応混合物を６５時間攪拌した後、セライトで濾過し、ＤＣＭで洗浄した。有機相をブラインで洗浄し（×１）、真空下で濃縮して５-クロロ-２-[３-(１,１-ジオキソ-１-チオモルホリン-４-イル)アゼチジン-１-イルメチル]-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジンをオレンジ色の粉末として得た（５７２ｍｇ、８９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．４３分［Ｍ＋Ｈ］^＋４５９．２ Example 65d 5-chloro-2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine

5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (400 mg, 1.40 mmol), 4-azetidin-3-ylthiomorpholine- in DCE (20 mL) A mixture of 1,1-dioxide (321 mg, 1.69 mmol) and 4Å powdered molecular sieve (600 mg) was stirred at room temperature for 4 hours, and then sodium triacetoxyborohydride (595 mg, 2.80 mmol) was added. The reaction mixture was stirred for 65 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated in vacuo to give 5-chloro-2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl]- 7-morpholin-4-ylthiazolo [5,4-d] pyrimidine was obtained as an orange powder (572 mg, 89%). LCMS (Method H): R _T 2.43 min [M + H] ⁺ 459.2.

ＤＣＥ（４０ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（６５０ｍｇ、２．２８ｍｍｏｌ）、３-(テトラヒドロピラン-４-イル)アゼチジン（３１３ｍｇ、２．２２ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（１．２ｇ）の混合物を室温で４時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（９４１ｍｇ、４．４４ｍｍｏｌ）を加えた。反応混合物を２４時間攪拌した後、セライトで濾過し、ＤＣＭで洗浄した。有機相をブラインで洗浄し（×１）、真空下で濃縮した。残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−２０％）で精製して、５-クロロ-７-モルホリン-４-イル-２-[３-(テトラヒドロピラン-４-イル)アゼチジン-１-イルメチル]チアゾロ[５,４-ｄ]ピリミジンをオレンジ色の粉末として得た（６３０ｍｇ、６７％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．５４分［Ｍ＋Ｈ］^＋４１０．２ Example 65e 5-Chloro-7-morpholin-4-yl-2- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] thiazolo [5,4-d] pyrimidine

5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (650 mg, 2.28 mmol), 3- (tetrahydropyran-4-yl) in DCE (40 mL) A mixture of azetidine (313 mg, 2.22 mmol) and 4Å powdered molecular sieve (1.2 g) was stirred at room temperature for 4 hours, and then sodium triacetoxyborohydride (941 mg, 4.44 mmol) was added. The reaction mixture was stirred for 24 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 5-chloro-7-morpholin-4-yl-2- [3- (tetrahydropyran-4-yl) Azetidin-1-ylmethyl] thiazolo [5,4-d] pyrimidine was obtained as an orange powder (630 mg, 67%). LCMS (Method A): R _T 2.54 min [M + H] ⁺ 410.2

ＤＣＥ（８５ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（５．１１ｇ、１７．９ｍｍｏｌ）、２-ピペリジン-４-イルプロパン-２-オール（３．０８ｇ、２１．５ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（９ｇ）の混合物を１．５時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（７．６１ｇ、３５．９ｍｍｏｌ）を加えた。反応混合物を６０時間攪拌した後、セライトで濾過し、セライト床をＤＣＭで洗浄した。有機相をブラインで洗浄し、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：ＤＣＭ、０−１００％）で精製して、２-[１-(５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチル)ピペリジン-４-イル]プロパン-２-オールをオレンジ色の固形物として得た（４．９６ｇ、６７％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．７７分［Ｍ＋Ｈ］^＋４１２．２ Example 65f 2- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propan-2-ol

5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (5.11 g, 17.9 mmol), 2-piperidin-4-ylpropane in DCE (85 mL) A mixture of -2-ol (3.08 g, 21.5 mmol) and 4Å powdered molecular sieve (9 g) was stirred for 1.5 hours at room temperature, then sodium triacetoxyborohydride (7.61 g, 35.9 mmol). Was added. The reaction mixture was stirred for 60 hours, then filtered through celite, and the celite bed was washed with DCM. The organic phase was washed with brine and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: DCM, 0-100%) to give 2- [1- (5-chloro-7-morpholin-4-ylthiazolo [5,4-d ] Pyrimidin-2-ylmethyl) piperidin-4-yl] propan-2-ol was obtained as an orange solid (4.96 g, 67%). LCMS (Method A): R _T 2.77 min [M + H] ⁺ 412.2

無水ＴＨＦ（４０ｍＬ）中の（メトキシメチル）トリフェニルホスホニウムクロライド（３．３７ｇ、９．８３ｍｍｏｌ）の攪拌懸濁液に、ＴＨＦ（９．８ｍＬ、９．８ｍｍｏｌ）中のＬｉＨＭＤＳの１Ｍ溶液を、窒素雰囲気下、０℃で滴下して加えた。１５分後、溶液を−７８℃に冷却し、無水ＴＨＦ（４０ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（２．０ｇ、７．０２ｍｍｏｌ）の懸濁液を加えた。混合物を室温まで温め、５分後、更に１．５時間攪拌し、Ｈ_２Ｏでクエンチした。生じた沈殿物を濾過し、ＥｔＯＡｃで洗浄し、真空下で乾燥させて、５-クロロ-２-((Ｅ)-２-メトキシビニル)-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン（７３０ｍｇ、３３％）を淡黄色固形物として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，３００ＭＨｚ）：δ７．４８（ｄ，Ｊ＝１２．８Ｈｚ，１Ｈ），６．０１（ｄ，Ｊ＝１２．８Ｈｚ，１Ｈ），４．４４−４．２４（ｂｒｓ，４Ｈ），３．８３（ｍ，４Ｈ），３．７９（ｓ，３Ｈ）。 Example 65g 5-chloro-2-((E) -2-methoxyvinyl) -7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine

To a stirred suspension of (methoxymethyl) triphenylphosphonium chloride (3.37 g, 9.83 mmol) in anhydrous THF (40 mL) was added a 1M solution of LiHMDS in THF (9.8 mL, 9.8 mmol) to nitrogen. It was added dropwise at 0 ° C. in an atmosphere. After 15 minutes, the solution was cooled to −78 ° C. and 5-chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (2.0 g) in anhydrous THF (40 mL). 7.02 mmol) was added. The mixture was warmed to room temperature and after 5 minutes, stirred for an additional 1.5 hours and quenched with H ₂ O. The resulting precipitate was filtered, washed with EtOAc, dried under vacuum to give 5-chloro-2-((E) -2-methoxyvinyl) -7-morpholin-4-yl-thiazolo [5.4] -d] pyrimidine (730 mg, 33%) was obtained as a pale yellow solid. ¹ H NMR (CDCl ₃ , 300 MHz): δ 7.48 (d, J = 12.8 Hz, 1H), 6.01 (d, J = 12.8 Hz, 1H), 4.44-4.24 (brs, 4H), 3.83 (m, 4H), 3.79 (s, 3H).

５-クロロ-２-((Ｅ)-２-メトキシビニル)-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン（７３０ｍｇ、２．３３ｍｍｏｌ）を３７重量％ＨＣｌ_（ａｑ）／ＴＨＦ（４：８ｍＬ）中で５０℃で２時間攪拌した。溶液を冷やし、ＥｔＯＡｃ及び飽和ＮａＨＣＯ_{３（ａｑ）}の間で分配し、有機層を分離して、ブラインで洗浄した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮して残留物を得（１．４ｇ）、これをＤＣＥ（３０ｍＬ）に取り上げた。２-ピペリジン-４-イルプロパン-２-オール（３００ｍｇ、２．１０ｍｍｏｌ）及び粉末化４Åモレキュラーシーブをついで加えた。反応混合物を５時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（９００ｍｇ、４．２５ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄し、ついで所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製し、表題化合物をオレンジ色の固形物として得た（２工程にわたって１２０ｍｇ、１２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．５５分，［Ｍ＋Ｈ］^＋４２６．５ Example 65h 2- {1- [2- (5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-yl) ethyl] piperidin-4-yl} propane-2- Oar

5-chloro-2-((E) -2-methoxyvinyl) -7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine (730 mg, 2.33 mmol) was added at 37 wt% HCl _(aq) / The mixture was stirred in THF (4: 8 mL) at 50 ° C. for 2 hours. The solution was cooled and partitioned between EtOAc and saturated NaHCO _{3 (aq)} and the organic layer was separated and washed with brine. The organic layer was dried (Na ₂ SO ₄ ) and concentrated in vacuo to give a residue (1.4 g) that was taken up in DCE (30 mL). 2-Piperidin-4-ylpropan-2-ol (300 mg, 2.10 mmol) and powdered 4Å molecular sieve were then added. The reaction mixture was stirred for 5 hours at room temperature, sodium triacetoxyborohydride (900 mg, 4.25 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH, then the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as an orange solid (120 mg, 12% over 2 steps). LCMS (Method H): R _T = 2.55 min, [M + H] ⁺ 426.5

ＴＨＦ（３０ｍＬ）中の５-クロロ-２-メチル-７-モルホリン-４-イル-チアゾロ[５,４-ｄ]ピリミジン（５００ｍｇ、１．８５ｍｍｏｌ）の撹拌溶液に窒素雰囲気下、−７８℃でＴＨＦ（２．８０ｍＬ、２．８０ｍｍｏｌ）中の１ＭのＬｉＨＭＤＳ溶液を滴下して加えた。２時間後、溶液をＣＯ_２（ｓ）の床上に注ぎ、生じた混合物を室温まで温めた。混合物をＤＣＭ及び０．１ＭのＨＣｌ（水性）の間で分配し、有機層を分離し、乾燥させ(相分離器)、真空下で濃縮した。生じた粗物質をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−５％のＭｅＯＨ）で精製して残留物（２００ｍｇ）を得、その一部（５８ｍｇ）をＤＭＦ（２ｍＬ）に取り上げ、２-ピペリジン-４-イルプロパン-２-オール（３２ｍｇ、０．２２ｍｍｏｌ）、ＨＡＴＵ（８４ｍｇ、０．２２ｍｍｏｌ）及びＤＩＰＥＡ（０．１０ｍＬ、０．５５ｍｍｏｌ）を加えた。反応混合物を室温で１８時間攪拌し、混合物をＥｔＯＡｃ及び水の間で分配し、有機層を乾燥させ（ＭｇＳＯ_４）、蒸発させて、暗オレンジ色の油を得た。カラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製し、表題化合物（４０ｍｇ、４９％）を暗オレンジ色の固形物として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．９６分，［Ｍ＋Ｈ］^＋４４０．４ Example 65i 2- (5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-yl) 1- [4- (1-hydroxy-1-methylethyl) piperidine-1 -Il] Ethanon

A stirred solution of 5-chloro-2-methyl-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine (500 mg, 1.85 mmol) in THF (30 mL) at −78 ° C. under a nitrogen atmosphere. A 1M LiHMDS solution in THF (2.80 mL, 2.80 mmol) was added dropwise. After 2 hours, the solution was poured onto a bed of CO _{2 (s)} and the resulting mixture was allowed to warm to room temperature. The mixture was partitioned between DCM and 0.1 M HCl (aq) and the organic layer was separated, dried (phase separator) and concentrated in vacuo. The resulting crude material was purified by flash chromatography (Si-PCC, 0-5% MeOH in DCM) to give a residue (200 mg), a portion (58 mg) taken up in DMF (2 mL), 2- Piperidin-4-ylpropan-2-ol (32 mg, 0.22 mmol), HATU (84 mg, 0.22 mmol) and DIPEA (0.10 mL, 0.55 mmol) were added. The reaction mixture was stirred at room temperature for 18 hours, the mixture was partitioned between EtOAc and water, the organic layer was dried (MgSO ₄ ) and evaporated to give a dark orange oil. Purification by column chromatography (Si-PCC, 0-10% MeOH in DCM) gave the title compound (40 mg, 49%) as a dark orange solid. LCMS (Method H): R _T 3.96 min, [M + H] ⁺ 440.4.

１,４-ジオキサン（５ｍＬ）中の５-クロロ-７-モルホリン-４-イル-２-(３-モルホリン-４-イルアゼチジン-１-イルメチル)-チアゾロ[５,４-ｄ]ピリミジン（５００ｍｇ、１．２２ｍｍｏｌ）、１,２-ジアミノベンゼン（３００ｍｇ、２．７７ｍｍｏｌ）、酢酸パラジウム（８０ｍｇ、０．３６ｍｍｏｌ）、ＢＩＮＡＰ（１１０ｍｇ、０．１８ｍｍｏｌ）及び炭酸セシウム（６００ｍｇ、１．８４ｍｍｏｌ）の混合物にアルゴンガスをパージした後、１５０℃で３０分間マイクロ波照射に供した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出させた。生成物を収集し、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ中２ＭのＮＨ_３１００：０から９９：１から９８：２から９７：３）で精製し、Ｎ１-(７-モルホリノ-２-((３-モルホリノアゼチジン-１-イル)メチル)チアゾロ[５,４-ｄ]ピリミジン-５-イル)ベンゼン-１,２-ジアミンを白色固形物として得た（２８３ｍｇ、４８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．４０分，［Ｍ＋Ｈ］^＋４８３。 Example 65j N1- (7-morpholino-2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-5-yl) benzene-1,2-diamine

5-Chloro-7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) -thiazolo [5,4-d] pyrimidine (500 mg, in 1,4-dioxane (5 mL) 1.22 mmol) to a mixture of 1,2-diaminobenzene (300 mg, 2.77 mmol), palladium acetate (80 mg, 0.36 mmol), BINAP (110 mg, 0.18 mmol) and cesium carbonate (600 mg, 1.84 mmol). After purging with argon gas, it was subjected to microwave irradiation at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (25 g) and washed with MeOH before eluting the desired product using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, 2M NH ₃ in DCM: MeOH 100: 0 to 99: 1 to 98: 2 to 97: 3) and N1- (7-morpholino-2- ((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-5-yl) benzene-1,2-diamine was obtained as a white solid (283 mg, 48%). LCMS (Method H): R _T = 2.40 min, [M + H] ⁺ 483.

１,４-ジオキサン（５ｍＬ）中の２-[１-(５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチル)ピペリジン-４-イル]プロパン-２-オール（５００ｍｇ、１．２１ｍｍｏｌ）、ヘキサブチル二すず（９１０μＬ、１．８１ｍｍｏｌ）及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（８５ｍｇ、０．１１６ｍｍｏｌ）の混合物にアルゴンガスをパージし、ついで１５０℃で３０分間マイクロ波照射に供した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９８：２から９５：５）で精製して、表題化合物を黄色固形物として得た（６８１ｍｇ、８４％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．３１（ｍ，４Ｈ）；３．８２（ｍ，６Ｈ）；３．０５（ｍ，２Ｈ）；２．１６（ｍ，２Ｈ）；１．７４（ｍ，２Ｈ）；１．６５−１．５４（ｍ，７Ｈ）；１．４３−１．２４（ｍ，９Ｈ）；１．１９（ｓ，６Ｈ）；１．１３（ｍ，６Ｈ）；０．８８（ｔ，Ｊ＝７．３Ｈｚ，９Ｈ） Example 65k 2- [1- (7-morpholin-4-yl-5- (stannanyl) thiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propane-2- Oar

2- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propane-2- in 1,4-dioxane (5 mL) Argon gas was added to a mixture of all (500 mg, 1.21 mmol), hexabutyldistin (910 μL, 1.81 mmol) and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (85 mg, 0.116 mmol). Purge, then subject to microwave irradiation at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 98: 2 to 95: 5) to give the title compound as a yellow solid (681 mg, 84%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.31 (m, 4H); 3.82 (m, 6H); 3.05 (m, 2H); 2.16 (m, 2H); 1.74 (m , 2H); 1.65-1.54 (m, 7H); 1.43-1.24 (m, 9H); 1.19 (s, 6H); 1.13 (m, 6H); 88 (t, J = 7.3 Hz, 9H)

Example 65l 4- (5-chloro-2-((4- (oxetane-3-yl) piperidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde (1.0 g 3.52 mmol), 4-oxetan-3-ylpiperidine (536 mg, 4 mL) in DCE (30 mL) .23 mmol) and molecular sieves (4 kg, powder, 6.56 g) were stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (1.49 g, 7.05 mmol) was added and the mixture was stirred for 6 hours, then filtered through a pad of Celite® and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 97: 3) to give the title compound as a creamy solid (334 mg, 41%). LCMS (Method A): R _T = 2.48 min, M + H ⁺ = 410

ＤＭＦ（３ｍＬ）中の(５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イル)酢酸（８０ｍｇ、０．２５ｍｍｏｌ）、２-メチル-２-ピペラジン-１-イルプロパン-１-オール（４８ｍｇ、０．３１ｍｍｏｌ）、ＨＡＴＵ（１１６ｍｇ、０．３１ｍｍｏｌ）及びＤＩＰＥＡ（１３３μＬ、０．７６ｍｍｏｌ）の混合物を室温で６５時間攪拌し、ついでＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物をオレンジ色の固形物として得た（６５ｍｇ、５６％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．０２分［Ｍ＋Ｈ］^＋４５５．３ Example 65m 2- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl) -1- [4- (2-hydroxy-1,1-dimethylethyl) piperazine- 1-Il] Ethanon

(5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl) acetic acid (80 mg, 0.25 mmol), 2-methyl-2-piperazine-1- in DMF (3 mL) A mixture of ilpropan-1-ol (48 mg, 0.31 mmol), HATU (116 mg, 0.31 mmol) and DIPEA (133 μL, 0.76 mmol) was stirred at room temperature for 65 hours and then washed with MeOH. ) Loaded on SCX-2 cartridge and eluted product with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as an orange solid (65 mg, 56%). LCMS (Method H): R _T 2.02 min [M + H] ⁺ 455.3.

ジオキサン（６０ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン（３．０ｇ１１．７ｍｍｏｌ）、２-エチルベンゾイミダゾール（１．８８ｇ、１２．９ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（５３４ｍｇ、０．６０ｍｍｏｌ）、ＸＰｈｏｓ（１．１１ｇ、２．３４ｍｍｏｌ）及びＣｓ_２ＣＯ_３（７．６２ｇ、２３．４ｍｍｏｌ）の混合物にアルゴンガスをパージした後た後、シールしたチューブ内で１２０℃で１６時間加熱した。反応混合物をセライト（登録商標）で濾過し、濾液をＥｔＯＡｃ及びＨ_２Ｏの間で分配した。有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：ＤＣＭ、０−９０％）で精製し、続いて^ｉＰｒＯＡｃから再結晶化させ、表題化合物を得た（３．１７ｇ、７４％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．７４分［Ｍ＋Ｈ］^＋３６７．１ Example 65n 5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine (3.0 g 11.7 mmol), 2-ethylbenzimidazole (1.88 g, 12.9 mmol), tris ( After purging a mixture of dibenzylideneacetone) dipalladium (534 mg, 0.60 mmol), XPhos (1.11 g, 2.34 mmol) and Cs ₂ CO ₃ (7.62 g, 23.4 mmol) with argon gas, Heated in sealed tube at 120 ° C. for 16 hours. The reaction mixture was filtered through Celite® and the filtrate was partitioned between EtOAc and H ₂ O. The organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: DCM, 0-90%) followed by recrystallization from ⁱ PrOAc to give the title compound (3.17 g, 74%). LCMS (Method A): R _T 2.74 min [M + H] ⁺ 367.1

ＴＨＦ（６０ｍＬ）中の５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン（１．９２ｇ、５．２３ｍｍｏｌ）の溶液を−４０℃に冷却した後、ＬｉＨＭＤＳ（６．３ｍＬ、６．２８ｍｍｏｌ、ＴＨＦ中１Ｍ)を滴下して加えた。生じた混合物を−５℃まで３０以上かけて温め、ついで混合物を−３０℃に冷却し、ＴＨＦ（６ｍＬ）中の１-クロロ-２-ヨードエタン（２．０ｇ、１０．４７ｍｍｏｌ）を加えた。生じた混合物を０℃まで温め、ついでＮＨ_４Ｃｌでクエンチし、ＥｔＯＡｃで抽出した。組み合わせた有機物をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：ＤＣＭ、５０−８０％）と続く^ｉＰｒＯＡｃからの再結晶化によって精製し、表題化合物を黄色固形物として得た（１．５８ｇ、６２％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．５０分［Ｍ＋Ｈ］^＋４９３．０ Example 65o 5- (2- Ethylbenzimidazol -1-yl) -2-iodo-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine

A solution of 5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine (1.92 g, 5.23 mmol) in THF (60 mL) at −40 ° C. After cooling, LiHMDS (6.3 mL, 6.28 mmol, 1 M in THF) was added dropwise. The resulting mixture was warmed to −5 ° C. over 30 and then the mixture was cooled to −30 ° C. and 1-chloro-2-iodoethane (2.0 g, 10.47 mmol) in THF (6 mL) was added. The resulting mixture was warmed to 0 ° C. and then quenched with NH ₄ Cl and extracted with EtOAc. The combined organics were washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: DCM, 50-80%) followed by recrystallization from ⁱ PrOAc to give the title compound as a yellow solid (1.58 g, 62 %). LCMS (Method A): R _T 3.50 min [M + H] ⁺ 493.0

ＤＣＭ（７ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルボン酸（２００ｍｇ、０．６７ｍｍｏｌ）、２-ピペリジン-４-イルプロパン-２-オール（１０５ｍｇ、０．７３ｍｍｏｌ）、ＨＡＴＵ（２７８ｍｇ、０．７３ｍｍｏｌ）及びＤＩＰＥＡ（１３０μＬ、０．７５ｍｍｏｌ）の混合物を室温で１８時間攪拌した。反応混合物を真空下で濃縮し、生じた残留物をカラムクロマトグラフィーで精製して（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−２％）、表題化合物を白色固形物として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ５．１５（１Ｈ，ｄ，Ｊ＝１３．３６Ｈｚ），４．７９（１Ｈ，ｄ，Ｊ＝１３．２５Ｈｚ），４．３５（４Ｈ，ｂｒｄｓ），３．８５（４Ｈ，ｔ，Ｊ＝４．７５Ｈｚ），３．１６−３．１３（１Ｈ，ｍ），１．９２（２Ｈ，ｔ，Ｊ＝１５．３９Ｈｚ），１．７５−１．６０（１Ｈ，ｍ），１．４９−１．３８（４Ｈ，ｍ），１．２２（６Ｈ，ｄ，Ｊ＝６．９７Ｈｚ）。 Example 65p (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-[4- (1-hydroxy-1-methylethyl) piperidin-1-yl] methanone

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carboxylic acid (200 mg, 0.67 mmol), 2-piperidin-4-ylpropan-2-ol in DCM (7 mL) A mixture of (105 mg, 0.73 mmol), HATU (278 mg, 0.73 mmol) and DIPEA (130 μL, 0.75 mmol) was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-2%) to give the title compound as a white solid. ¹ H NMR (CDCl ₃ , 400 MHz): δ 5.15 (1H, d, J = 13.36 Hz), 4.79 (1H, d, J = 13.25 Hz), 4.35 (4H, brds), 3 .85 (4H, t, J = 4.75 Hz), 3.16-3.13 (1H, m), 1.92 (2H, t, J = 15.39 Hz), 1.75-1.60 ( 1H, m), 1.49-1.38 (4H, m), 1.22 (6H, d, J = 6.97 Hz).

ＤＣＭ（３ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルボン酸（１００ｍｇ、０．３３ｍｍｏｌ）、３,３-ジメチル-１-オキセタン-３-イルピペラジン（６２ｍｇ、０．３６ｍｍｏｌ）、ＨＡＴＵ（２７８ｍｇ、０．３７ｍｍｏｌ）及びＤＩＰＥＡ（６５μＬ、０．３７ｍｍｏｌ）の混合物を室温で１８時間攪拌した。反応混合物を真空下で濃縮させ、生じた残留物をカラムクロマトグラフィーで精製して（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−２％）、表題化合物を黄色固形物として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．６７分，［Ｍ＋Ｈ］^＋４５３．３ Example 65q (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-(2,2-dimethyl-4-oxetan-3-ylpiperazin-1-yl) methanone

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carboxylic acid (100 mg, 0.33 mmol), 3,3-dimethyl-1-oxetane-3- in DCM (3 mL) A mixture of irpiperazine (62 mg, 0.36 mmol), HATU (278 mg, 0.37 mmol) and DIPEA (65 μL, 0.37 mmol) was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-2%) to give the title compound as a yellow solid. LCMS (Method H): R _T 2.67 min, [M + H] ⁺ 453.3.

ジオキサン（３０ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（１．０ｇ、３．５１ｍｍｏｌ）、２-エチルベンゾイミダゾール（５１２ｍｇ、３．７１ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（９０ｍｇ、２．５ｍｏｌ％）、ＸＰｈｏｓ（１５８ｍｇ、１０ｍｏｌ％）及びＣｓ_２ＣＯ_３（１．６ｇ、４．９１ｍｍｏｌ）の混合物にアルゴンガスをパージした後、ついで１１５℃で１７時間加熱した。反応混合物をセライト（登録商標）で濾過し、これを熱いジオキサンで洗浄し、濾液を真空下で濃縮した。生じた残留物をＥｔ_２Ｏで倍散し、生じた褐色固形物を濾過により回収して、真空下で乾燥させ、表題化合物を得た（１．２３ｇ、８８％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ１０．０１（１Ｈ，ｓ），８．０９−８．０９（１Ｈ，ｍ），７．７５−７．７４（１Ｈ，ｍ），７．３３−７．２６（２Ｈ，ｍ），５．００−４．００（４Ｈ，ｂｒｄ ｓ），３．９３（４Ｈ，ｔ，Ｊ＝４．７２Ｈｚ），３．３７（２Ｈ，ｑ，Ｊ＝７．４５Ｈｚ）１．４６（３Ｈ，ｔ，Ｊ＝７．４５Ｈｚ）。 Example 65r 5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde (1.0 g, 3.51 mmol) in 2-oxane (30 mL), 2-ethylbenzimidazole (512 mg, 3. 71 mmol), tris (dibenzylideneacetone) dipalladium (90 mg, 2.5 mol%), XPhos (158 mg, 10 mol%) and Cs ₂ CO ₃ (1.6 g, 4.91 mmol) after purging with argon gas Then, it was heated at 115 ° C. for 17 hours. The reaction mixture was filtered through Celite®, which was washed with hot dioxane, and the filtrate was concentrated in vacuo. The resulting residue was triturated with Et ₂ O and the resulting brown solid was collected by filtration and dried under vacuum to give the title compound (1.23 g, 88%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 10.01 (1H, s), 8.09-8.09 (1H, m), 7.75-7.74 (1H, m), 7.33-7 .26 (2H, m), 5.00-4.00 (4H, brds), 3.93 (4H, t, J = 4.72 Hz), 3.37 (2H, q, J = 7.45 Hz) ) 1.46 (3H, t, J = 7.45 Hz).

ＤＣＥ（３０ｍＬ）中の５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（１．２ｇ、３．０４ｍｍｏｌ）の溶液に、ＭｅＯＨ（３ｍＬ）及びＮａＢＨ_４（１１９ｍｇ、３．１５ｍｍｏｌ）を加え、生じた混合物を室温で４時間攪拌した。反応混合物を真空下で濃縮させ、生じた残留物をＨ_２Ｏで倍散した。生じた固形物を濾過により収集し、真空下で乾燥させ、表題化合物を得た（１．１８ｇ、９８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．４２分，［Ｍ＋Ｈ］^＋３９７．４ Example 65s [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl] methanol

Of 5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde (1.2 g, 3.04 mmol) in DCE (30 mL) To the solution was added MeOH (3 mL) and NaBH ₄ (119 mg, 3.15 mmol) and the resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated under vacuum and the resulting residue was triturated with H ₂ O. The resulting solid was collected by filtration and dried under vacuum to give the title compound (1.18 g, 98%). LCMS (Method H): R _T 2.42 min, [M + H] ⁺ 397.4.

ＤＣＭ（６０ｍＬ）中の[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イル]メタノール（１．１８ｇ、２．９７ｍｍｏｌ）の懸濁液にＰＢｒ_３（３．３６ｍＬ、３．３６ｍｍｏｌ、ＤＣＭ中１Ｍの溶液）を加え、生じた混合物を室温で１時間攪拌した。反応混合物をＤＣＭで希釈し、有機相をＨ_２Ｏとブラインで洗浄し、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮し、表題化合物を黄色固形物として得た（６７３ｍｇ、４９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．２４分，［Ｍ＋Ｈ］^＋４５９．１及び４６１．１（１：１） Example 65t 2-Bromomethyl-5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine

[5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl] methanol (1.18 g, 2.97 mmol) in DCM (60 mL). ) Was added PBr ₃ (3.36 mL, 3.36 mmol, 1 M solution in DCM) and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with DCM and the organic phase was washed with H ₂ O and brine, then dried (MgSO ₄ ) and concentrated in vacuo to give the title compound as a yellow solid (673 mg, 49%). LCMS (Method H): R _T 3.24 min, [M + H] ⁺ 459.1 and 461.1 (1: 1).

トリメチル亜リン酸エステル（１０ｍＬ）中の２-ブロモメチル-５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン（６７０ｍｇ、１．４６ｍｍｏｌ）の混合物を１時間還流下で加熱（１２０℃）し、ついで真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−２％）、ついで（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−５％）で精製して、表題化合物を黄色固形物として得た（６２０ｍｇ、８７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．４６分，［Ｍ＋Ｈ］^＋４８９．３ Example 65u [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] phosphonic acid dimethyl ester

2-Bromomethyl-5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine (670 mg, 1.46 mmol) in trimethyl phosphite (10 mL) The mixture was heated at reflux (120 ° C.) for 1 hour and then concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-2%) followed by (Si-PCC, MeOH: EtOAc, 0-5%) to give the title compound as a yellow solid Obtained (620 mg, 87%). LCMS (Method H): R _T 2.46 min, [M + H] ⁺ 489.3.

ＴＨＦ（０．５ｍＬ）中のジイソプロピルアミン（２００μＬ、１．４２ｍｍｏｌ）の溶液に、−７８℃でｎ-ＢｕＬｉ（５５６μＬ、１．４２ｍｍｏｌ、ヘキサン中２．５Ｍ）に加え、生じた混合物を２０分間攪拌した。生じた溶液をＴＨＦ（１１ｍＬ）中の[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチル]ホスホン酸ジメチルエステル（６２０ｍｇ、１．２７ｍｍｏｌ）の懸濁液に−７８℃で加えた。生じた混合物を室温に温めた後、ＴＨＦ（１．５ｍＬ）中の３-オキソ-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２５０ｍｇ、１．４６ｍｍｏｌ）の溶液を加えた。生じた混合物を室温で５時間攪拌し、ついでＨ_２Ｏでクエンチした。混合物を真空下で濃縮し、残留物をＤＣＭ及びブラインの間で分配した。有機相を乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をシリカパッドで濾過して、表題化合物を得た（４９３ｍｇ、７３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．７２分，［Ｍ＋Ｈ］^＋５３４．３ Example 65v 3- [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethylene] azetidine-1-carboxylic acid tert-butyl ester

To a solution of diisopropylamine (200 μL, 1.42 mmol) in THF (0.5 mL) at −78 ° C. is added n-BuLi (556 μL, 1.42 mmol, 2.5 M in hexane) and the resulting mixture is added for 20 minutes. Stir. The resulting solution was diluted with [5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] phosphonic acid dimethyl ester in THF (11 mL) ( 620 mg, 1.27 mmol) suspension at −78 ° C. After the resulting mixture was warmed to room temperature, a solution of 3-oxo-azetidine-1-carboxylic acid tert-butyl ester (250 mg, 1.46 mmol) in THF (1.5 mL) was added. The resulting mixture was stirred at room temperature for 5 hours and then quenched with H ₂ O. The mixture was concentrated under vacuum and the residue was partitioned between DCM and brine. The organic phase was dried (MgSO ₄ ) and concentrated under vacuum. The resulting residue was filtered through a silica pad to give the title compound (493 mg, 73%). LCMS (Method H): R _T 3.72 min, [M + H] ⁺ 534.3.

Example 65w 2-azetidin-3-ylmethyl-5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine

ＡｃＯＨ（２０ｍＬ）中の３-[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチレン]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（４９３ｇ、０．９２ｍｍｏｌ）の溶液に１０％Ｐｄ（ＯＨ）_２／Ｃ（２００ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で２時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄した。濾液をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（ＭｅＯＨで洗浄した）に充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出して、表題化合物を得た。 Step 1: 3- [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] azetidine-1-carboxylic acid tert-butyl ester

3- [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethylene] azetidine-1-carboxylic acid tert in AcOH (20 mL) 10% Pd (OH) ₂ / C (200 mg) was added to a solution of butyl ester (493 g, 0.92 mmol) and the resulting mixture was stirred under H ₂ atmosphere for 2 hours. The reaction mixture was filtered through Celite® and washed with EtOAc. The filtrate was loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product eluted with 2M NH ₃ / MeOH to give the title compound.

Step 2: 3- [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] azetidine-1- in DCM (10 mL) To the carboxylic acid tert-butyl ester solution was added TFA (3 mL) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture is loaded onto an Isolute® SCX-2 cartridge that has been washed with MeOH and the product is eluted with 2M NH ₃ / MeOH to give 2-azetidin-3-ylmethyl-5- (2-ethylbenzoate). Imidazole-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine was obtained as a yellow oil (209 mg, 52% over 2 steps). ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.98 (1H, m), 7.75-7.74 (1H, m), 7.28-7.25 (2H, m), 4 .41 (4H, brd s), 3.89-3.84 (5H, m), 3.59 (2H, t, J = 7.25 Hz), 3.48 (2H, s), 3.36- 3.34 (5H, m), 1.43 (3H, t, J = 7.47 Hz)

ＤＣＥ（１０ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルバルデヒド（２８５ｍｇ、１．００ｍｍｏｌ）、４-アゼチジン-３-イルピペラジン-２-オン(１９０ｍｇ、１.２２ｍｍｏｌ)及び４Å粉末化モレキュラーシーブ（１．０ｇ）の混合物を室温で５時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（４２０ｍｇ、１．９８ｍｍｏｌ）を加えた。得られた混合物を１６時間攪拌した後、セライト（登録商標）で濾過し、これをＤＣＭで洗浄した。濾液を真空下で濃縮し、生じた残留物をカラムクロマトグラフィーで精製して（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、２−１０％）、表題化合物を得た（３２１ｍｇ、７５％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ１．９６及び０．３３分［Ｍ＋Ｈ］^＋４２４．３ Example 65x 4- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) azetidin-3-yl] piperazin-2-one

5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde (285 mg, 1.00 mmol), 4-azetidin-3-ylpiperazin-2-one in DCE (10 mL) A mixture of (190 mg, 1.22 mmol) and 4Å powdered molecular sieve (1.0 g) was stirred at room temperature for 5 hours, and then sodium triacetoxyborohydride (420 mg, 1.98 mmol) was added. The resulting mixture was stirred for 16 hours and then filtered through Celite®, which was washed with DCM. The filtrate was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 2-10%) to give the title compound (321 mg, 75%). LCMS (Method A): R _T 1.96 and 0.33 min [M + H] ⁺ 424.3

ＤＣＭ（６ｍＬ）中の５-クロロ-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-カルボン酸（３０１ｍｇ、１．０ｍｍｏｌ）の懸濁液にオキサリルクロリド（８４７μＬ、１０．００ｍｍｏｌ）を加え、生じた混合物を室温で１時間攪拌し、ついで真空下で濃縮し、トルエンと共沸させた。生じた黄色の固体を、ＤＣＭ（６ｍＬ）及びＮＥｔ_３（４１８μＬ、３．００ｍｍｏｌ）の懸濁液に０℃で懸濁させた後、４-アゼチジン-３-イルモルホリン（１４２ｍｇ、１．００ｍｍｏｌ）を加えた。生じた混合物を室温に温め、１時間後についで更に３０分間攪拌した。反応混合物をＤＣＭ及びＨ_２Ｏの間で分配し、有機相を乾燥し（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をＥｔＯＡｃで倍散し、真空下で乾燥させ、表題化合物をオフホワイトの固形物として得た（２６９ｍｇ、６３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．１９分［Ｍ＋Ｈ］^＋４２５．３ Example 65y (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-(3-morpholin-4-ylazetidin-1-yl) methanone

To a suspension of 5-chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carboxylic acid (301 mg, 1.0 mmol) in DCM (6 mL) was added oxalyl chloride (847 μL, 10.00 mmol). ) And the resulting mixture was stirred at room temperature for 1 hour, then concentrated in vacuo and azeotroped with toluene. The resulting yellow solid was suspended in a suspension of DCM (6 mL) and NEt ₃ (418 μL, 3.00 mmol) at 0 ° C. followed by 4-azetidin-3-ylmorpholine (142 mg, 1.00 mmol). Was added. The resulting mixture was warmed to room temperature and stirred for 1 hour and then for an additional 30 minutes. The reaction mixture was partitioned between DCM and H ₂ O and the organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was triturated with EtOAc and dried under vacuum to give the title compound as an off-white solid (269 mg, 63%). LCMS (Method H): R _T 2.19 min [M + H] ⁺ 425.3.

窒素雰囲気下で−７８℃に冷却した無水テトラヒドロフラン中の５-クロロ-７-モルホリン-４-イル-チアゾロ[４,５-ｄ]ピリミジン（２ｇ、７．７９ｍｍｏｌ）の懸濁液に、リチウムビス（トリメチルシリル）アミド（１１．７ｍＬ、１１．６８ｍｍｏｌ）を−７８℃で滴下して加え、生じた反応混合物を−７８℃で１時間攪拌した。ついで、ＤＭＦをゆっくりと加え、混合物を更に３０分間攪拌した。温度を−５℃に１０分かけて上昇させ、ついで再び−７８℃に冷却した。生じた反応混合物をカニューレを介して１Ｍの氷冷ＨＣｌ（４００ｍＬ）中に移し、激しく攪拌した。水性相を酢酸エチル（２×１５０ｍＬ）で抽出した。有機層を水（１×１２５ｍＬ）、ブライン（２×１２５ｍＬ）で洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過した。溶媒を真空下で減じて、表題化合物をオレンジブラウン色の固形物として得た（１．８２ｇ、８２％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ１０．１９（１Ｈ，ｓ），４．０３（４Ｈ，ｔ，Ｊ＝４．９０Ｈｚ），３．８７（４Ｈ，ｔ，Ｊ＝４．９０Ｈｚ）。 Example 65z 5-chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidine-2-carbaldehyde

To a suspension of 5-chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidine (2 g, 7.79 mmol) in anhydrous tetrahydrofuran cooled to −78 ° C. under a nitrogen atmosphere was added lithium bis. (Trimethylsilyl) amide (11.7 mL, 11.68 mmol) was added dropwise at −78 ° C., and the resulting reaction mixture was stirred at −78 ° C. for 1 hour. DMF was then added slowly and the mixture was stirred for an additional 30 minutes. The temperature was raised to −5 ° C. over 10 minutes and then cooled again to −78 ° C. The resulting reaction mixture was transferred via cannula into 1M ice-cold HCl (400 mL) and stirred vigorously. The aqueous phase was extracted with ethyl acetate (2 × 150 mL). The organic layer was washed with water (1 × 125 mL), brine (2 × 125 mL), dried over Na ₂ SO ₄ and filtered. The solvent was reduced in vacuo to give the title compound as an orange brown solid (1.82 g, 82%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 10.19 (1H, s), 4.03 (4H, t, J = 4.90 Hz), 3.87 (4H, t, J = 4.90 Hz).

１,２-ジクロロエタン（１５ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[４,５-ｄ]ピリミジン-２-カルバルデヒド（２５０ｍｇ、０．８８ｍｍｏｌ）、４-アゼチジン-３-イル-モルホリン（１５０ｍｇ、１．０５ｍｍｏｌ）及び４Åモレキュラーシーブ（１．０ｇ）の混合物を窒素雰囲気下、室温で１．５時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２８０ｍｇ、１．３２ｍｍｏｌ）を加え、生じた反応混合物を室温で１６時間攪拌した。溶媒を真空下で減じ、残留物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＤＣＭ／ＭｅＯＨで洗浄し、所望の生成物を続いてＤＣＭ及びＭｅＯＨ中の２ＭのＮＨ_３の混合物を使用して抽出した。生じた残留物を更にカラムクロマトグラフィーで精製した（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ：０：１００から６：９４（体積)）。溶媒を真空下で減じて表題化合物を黄色固形物として得た（１６５ｍｇ、４６％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．３１分，［Ｍ＋Ｈ］^＋４１１．^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．１１（２Ｈ，ｓ），３．９５（４Ｈ，ｔ，Ｊ＝４．８５Ｈｚ），３．８３（４Ｈ，ｔ，Ｊ＝４．８４Ｈｚ），３．７４−３．６７（６Ｈ，ｍ），３．２２（２Ｈ，ｔ，Ｊ＝６．８４Ｈｚ），３．１２−３．１１（１Ｈ，ｍ），２．３４（４Ｈ，ｓ） Example 66a 5-chloro-7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) -thiazolo [4,5-d] pyrimidine

5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidine-2-carbaldehyde (250 mg, 0.88 mmol), 4-azetidine-3- in 1,2-dichloroethane (15 mL) A mixture of yl-morpholine (150 mg, 1.05 mmol) and 4 mol molecular sieve (1.0 g) was stirred at room temperature for 1.5 hours under nitrogen atmosphere. Sodium triacetoxyborohydride (280 mg, 1.32 mmol) was added and the resulting reaction mixture was stirred at room temperature for 16 hours. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with DCM / MeOH and the desired product was subsequently extracted using a mixture of 2M NH ₃ in DCM and MeOH. The resulting residue was further purified by column chromatography (Si-PCC, MeOH: DCM: 0: 100 to 6:94 (volume)). The solvent was reduced in vacuo to give the title compound as a yellow solid (165 mg, 46%). LCMS (Method A): R _T 2.31 min, [M + H] ⁺ 411. ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.11 (2H, s), 3.95 (4H, t, J = 4.85 Hz), 3.83 (4H, t, J = 4.84 Hz), 3 .74-3.67 (6H, m), 3.22 (2H, t, J = 6.84 Hz), 3.12-3.11 (1H, m), 2.34 (4H, s)

１,２-ジクロロエタン（２０ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[４,５-ｄ]ピリミジン-２-カルバルデヒド（４００ｍｇ、１．４ｍｍｏｌ）、２-ピペリジン-４-イル-プロパン-２-オール（２４２ｍｇ、１．７ｍｍｏｌ）、及び４Åモレキュラーシーブ（１．５ｇ）の混合物を室温で６時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（５９３ｍｇ、２．８ｍｍｏｌ）を加え、生じた反応混合物を窒素雰囲気下、室温で１８時間攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をカラムクロマトグラフィー(Ｓｉ-ＰＰＣ、(ＥｔＯＡｃ中１０％のＭｅＯＨ）：ＥｔＯＡｃ、０：１００から２０：８０の勾配）で精製して、表題化合物をオレンジ色の固形物として得た（３４４ｍｇ、６０％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ３．９８−３．９３（６Ｈ，ｍ），３．８５（５Ｈ，ｍ），３．０８（２Ｈ，ｍ），２．２８（２Ｈ，ｍ），１．７９（２Ｈ，ｍ），１．４８（３Ｈ，ｍ），１．２３−１．２１（６Ｈ，ｍ）。 Example 66b 2- [1- (5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propan-2-ol

5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidine-2-carbaldehyde (400 mg, 1.4 mmol), 2-piperidine-4- in 1,2-dichloroethane (20 mL) A mixture of yl-propan-2-ol (242 mg, 1.7 mmol) and 4 mol molecular sieves (1.5 g) was stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (593 mg, 2.8 mmol) was added and the resulting reaction mixture was stirred at room temperature for 18 hours under a nitrogen atmosphere. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (Si-PPC, (10% MeOH in EtOAc): EtOAc, gradient 0: 100 to 20:80) to give the title compound as an orange solid (344 mg 60%). ¹ H NMR (400 MHz, CDCl ₃ ): δ 3.98-3.93 (6H, m), 3.85 (5H, m), 3.08 (2H, m), 2.28 (2H, m), 1.79 (2H, m), 1.48 (3H, m), 1.23-1.21 (6H, m).

１,２-ジクロロエタン（１５ｍＬ）中の５-クロロ-７-モルホリン-４-イル-チアゾロ[４,５-ｄ]ピリミジン-２-カルバルデヒド（２５０ｍｇ、０．８８ｍｍｏｌ）、２-ピペラジン-１-イル-イソブチルアミド（１７３ｍｇ、１．０１ｍｍｏｌ）及び４Åモレキュラーシーブ（１．０ｇ）の混合物を窒素雰囲気下、室温で４時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２８０ｍｇ、１．３２ｍｍｏｌ）を加え、生じた反応混合物を室温で１６時間攪拌した。溶媒を真空下で減じ、残留物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをＤＣＭ／ＭｅＯＨで洗浄し、所望の生成物を続いてＤＣＭ及びＭｅＯＨ中の２ＭのＮＨ_３の混合物で溶出した。生じた残留物を更にカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ：０：１００から６：９４の勾配）で精製した。溶媒を真空下で減じて表題化合物を黄色固形物として得た（２７５ｍｇ、６０％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．４１分，［Ｍ＋Ｈ］^＋４４０．^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ７．０４（１Ｈ，ｂｒｓ），５．２２（１Ｈ，ｂｒｓ），３．９７−３．９５（６Ｈ，ｍ），３．８５（４Ｈ，ｔ，Ｊ＝４．８０Ｈｚ），２．６７（８Ｈ，ｍ），１．２５（６Ｈ，ｓ） Example 66c 2- [4- (5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidin-2-ylmethyl) piperazin-1-yl] isobutyramide

5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidine-2-carbaldehyde (250 mg, 0.88 mmol), 2-piperazine-1- in 1,2-dichloroethane (15 mL) A mixture of yl-isobutyramide (173 mg, 1.01 mmol) and 4 mol molecular sieves (1.0 g) was stirred at room temperature for 4 hours under a nitrogen atmosphere. Sodium triacetoxyborohydride (280 mg, 1.32 mmol) was added and the resulting reaction mixture was stirred at room temperature for 16 hours. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with DCM / MeOH and the desired product was subsequently eluted with a mixture of 2M NH ₃ in DCM and MeOH. The resulting residue was further purified by column chromatography (Si-PCC, MeOH: DCM: 0: 100 to 6:94 gradient). The solvent was reduced in vacuo to give the title compound as a yellow solid (275 mg, 60%). LCMS (Method H): R _T 2.41 min, [M + H] ⁺ 440. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.04 (1H, brs), 5.22 (1H, brs), 3.97-3.95 (6H, m), 3.85 (4H, t, J = 4.80 Hz), 2.67 (8H, m), 1.25 (6H, s)

１,４-ジオキサン（１．２ｍＬ）中の２-[４-(５-クロロ-７-モルホリン-４-イル-チアゾロ[４,５-ｄ]ピリミジン-２-イルメチル)ピペラジン-１-イル]イソブチルアミド（１２０ｍｇ、０．２７ｍｍｏｌ）、ＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-ＮＭｅ_２)}_２（１９．５ｍｇ、０．０２７ｍｍｏｌ）及びヘキサブチル二すず（０．２０３ｍＬ、０．４０５ｍｍｏｌ）の混合物にアルゴンガスをパージし、１５０℃で３０分間マイクロ波照射を施した。粗残留物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２０ｇ）に充填し、ＤＣＭ／ＭｅＯＨで洗浄して、所望の生成物を続いてＤＣＭ及びＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物を更にカラムクロマトグラフィーで精製した（Ｓｉ-ＰＣＣ、シクロヘキサン：アセトン、１００：０から６０：４０の勾配）。溶媒を真空下で減じて表題化合物を黄色ガムとして得た（２１０ｍｇ、６２％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ４．２６分，［Ｍ＋Ｈ］^＋６９４（^１１６Ｓｎ）６９６（^１１８Ｓｎ）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ７．０６（１Ｈ，ｓ），５．２０（１Ｈ，ｓ），３．９７（２Ｈ，ｓ），３．９２（４Ｈ，ｔ，Ｊ＝４．６０Ｈｚ），３．８４（４Ｈ，ｔ，Ｊ＝４．６０Ｈｚ），２．６５（８Ｈ，ｍ），１．６０−１．５８（６Ｈ，ｍ），１．３５−１．３３（６Ｈ，ｍ），１．２５（６Ｈ，ｓ），１．１６−１．１４（６Ｈ，ｍ），０．８７（９Ｈ，ｔ，Ｊ＝７．３２Ｈｚ） Example 66d 2- [4- (7-morpholin-4-yl-5- (stannanylyl) thiazolo [4,5-d] pyrimidin-2-ylmethyl) piperazin-1-yl] isobutyramide

2- [4- (5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidin-2-ylmethyl) piperazin-1-yl] in 1,4-dioxane (1.2 mL) Of isobutyramide (120 mg, 0.27 mmol), PdCl ₂ {P ^t Bu ₂ (Ph-p-NMe ₂ )} ₂ (19.5 mg, 0.027 mmol) and hexabutyl distin (0.203 mL, 0.405 mmol) The mixture was purged with argon gas and subjected to microwave irradiation at 150 ° C. for 30 minutes. The crude residue was loaded onto an Isolute® SCX-2 cartridge (20 g), washed with DCM / MeOH and the desired product was subsequently eluted with DCM and 2M NH ₃ in MeOH. The resulting residue was further purified by column chromatography (Si-PCC, cyclohexane: acetone, 100: 0 to 60:40 gradient). The solvent was reduced in vacuo to give the title compound as a yellow gum (210 mg, 62%). LCMS (Method A): R _T 4.26 min, [M + H] ⁺ 694 ( ¹¹⁶ Sn) 696 ( ¹¹⁸ Sn). ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.06 (1H, s), 5.20 (1H, s), 3.97 (2H, s), 3.92 (4H, t, J = 4.60 Hz) ), 3.84 (4H, t, J = 4.60 Hz), 2.65 (8H, m), 1.60-1.58 (6H, m), 1.35-1.33 (6H, m) ), 1.25 (6H, s), 1.16-1.14 (6H, m), 0.87 (9H, t, J = 7.32 Hz)

ＴＨＦ（０．５ｍＬ）中のジイソプロピルアミン（１２１μＬ、０．８６ｍｍｏｌ）の溶液に、−７８℃でｎ-ＢｕＬｉ（３３６μＬ、０．８６ｍｍｏｌ、ヘキサン中２．５Ｍ）を加え、生じた混合物を３０分間攪拌した。生じた溶液をＴＨＦ（６ｍＬ）中の[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチル]ホスホン酸ジメチルエステル（３７５ｍｇ、０．７７ｍｍｏｌ）の懸濁液に−７８℃で加えた。生じた混合物を室温まで温めた後、ＴＨＦ（１ｍＬ）中の４-オキソピペリジン-１-カルボン酸ベンジルエステル（２０６ｍｇ、０．８８ｍｍｏｌ）の溶液を加えた。生じた混合物を３時間室温で攪拌し、ついでＨ_２Ｏでクエンチした。混合物を真空下で濃縮し、残留物をＥｔＯＡｃ及びＨ_２Ｏ間で分配した。有機相を乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：ペンタン、５０−７５％）で精製し、４-[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチレン]ピペリジン-１-カルボン酸ベンジルエステル（３００ｍｇ、６６％）を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．９８分，［Ｍ＋Ｈ］^＋５９６．４ Example 66e 4- [5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethylene] piperidine-1-carboxylic acid benzyl ester

To a solution of diisopropylamine (121 μL, 0.86 mmol) in THF (0.5 mL) at −78 ° C. was added n-BuLi (336 μL, 0.86 mmol, 2.5 M in hexane) and the resulting mixture was added for 30 minutes. Stir. The resulting solution was diluted with [5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] phosphonic acid dimethyl ester in THF (6 mL) ( 375 mg, 0.77 mmol) was added at −78 ° C. After the resulting mixture was warmed to room temperature, a solution of 4-oxopiperidine-1-carboxylic acid benzyl ester (206 mg, 0.88 mmol) in THF (1 mL) was added. The resulting mixture was stirred for 3 hours at room temperature and then quenched with H ₂ O. The mixture was concentrated in vacuo and the residue was partitioned between EtOAc and _{H 2} O. The organic phase was dried (MgSO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: pentane, 50-75%) and 4- [5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo. [5,4-d] pyrimidin-2-ylmethylene] piperidine-1-carboxylic acid benzyl ester (300 mg, 66%) was obtained. LCMS (Method H): R _T 3.98 min, [M + H] ⁺ 596.4.

ＡｃＯＨ（２０ｍＬ）中の４-[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチレン]ピペリジン-１-カルボン酸ベンジルエステル（３００ｍｇ、０．５０ｍｍｏｌ）の溶液に１０％Ｐｄ(ＯＨ)_２／Ｃ（２００ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で２時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄した。濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、２ＭのＮＨ_３／ＭｅＯＨ：ＤＣＭ、０−１０％）で精製し、５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イル-２-ピペリジン-４-イルメチルチアゾロ[５,４-ｄ]ピリミジン（９６ｍｇ、４１％）を得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ７．９９−７．９８（１Ｈ，ｍ），７．７４−７．７３（１Ｈ，ｍ），７．３０−７．２６（２Ｈ，ｍ），４．４３（４Ｈ，ｓ），３．８８（４Ｈ，ｔ，Ｊ＝４．７４Ｈｚ），３．３３（２Ｈ，ｑ，Ｊ＝７．４８Ｈｚ），３．１２−３．０８（２Ｈ，ｍ），２．９９（２Ｈ，ｄ，Ｊ＝７．１４Ｈｚ），２．６３（２Ｈ，ｔｄ，Ｊ＝１２．１２，２．５４Ｈｚ），２．０３−１．９１（１Ｈ，ｍ），１．７９（２Ｈ，ｂｒｄｄ，Ｊ＝１３．１８Ｈｚ），１．４２（３Ｈ，ｔ，Ｊ＝７．４８Ｈｚ），１．３０−１．２９（２Ｈ，ｍ） Example 66f 5- (2- Ethylbenzimidazol -1-yl) -7-morpholin-4-yl-2-piperidin-4-ylmethylthiazolo [5,4-d] pyrimidine

Benzyl 4- [5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethylene] piperidine-1-carboxylate in AcOH (20 mL) To a solution of the ester (300 mg, 0.50 mmol) was added 10% Pd (OH) ₂ / C (200 mg) and the resulting mixture was stirred for 2 h under H ₂ atmosphere. The reaction mixture was filtered through Celite® and washed with EtOAc. The filtrate was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH, and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, _NH of 2M 3 / MeOH: DCM, 0-10 %) to give 5- (2-ethyl-l-yl) -7-morpholin -4 There was obtained -yl-2-piperidin-4-ylmethylthiazolo [5,4-d] pyrimidine (96 mg, 41%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.98 (1H, m), 7.74-7.73 (1H, m), 7.30-7.26 (2H, m), 4 .43 (4H, s), 3.88 (4H, t, J = 4.74 Hz), 3.33 (2H, q, J = 7.48 Hz), 3.12-3.08 (2H, m) , 2.99 (2H, d, J = 7.14 Hz), 2.63 (2H, td, J = 12.12, 2.54 Hz), 2.03-1.91 (1H, m), 1. 79 (2H, brdd, J = 13.18 Hz), 1.42 (3H, t, J = 7.48 Hz), 1.30-1.29 (2H, m)

ＤＣＭ（１ｍＬ）中の５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イル-２-ピペリジン-４-イルメチルチアゾロ[５,４-ｄ]ピリミジン（９６ｍｇ、０．２１ｍｍｏｌ）、酢酸１-クロロカルボニル-１-メチルエチルエステル（４０μＬ、０．２８ｍｍｏｌ）及びＮＥｔ_３（４０μＬ、０．３１ｍｍｏｌ）の混合物を３０分間室温で攪拌し、ついで真空下で濃縮した。生じた残留物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、酢酸２-{４-[５-(２-エチルベンゾイミダゾール-１-イル)-７-モルホリン-４-イルチアゾロ[５,４-ｄ]ピリミジン-２-イルメチル]ピペリジン-１-イル}-１,１-ジメチル-２-オキソエチルエステルを得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．１９分［Ｍ＋Ｈ］^＋５９２．２ Example 66g Acetic acid 2- {4- [5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] piperidin-1-yl} -1,1-dimethyl-2-oxoethyl ester

5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-yl-2-piperidin-4-ylmethylthiazolo [5,4-d] pyrimidine (96 mg, 0) in DCM (1 mL) .21 mmol), acetic acid 1-chlorocarbonyl-1-methylethyl ester (40 μL, 0.28 mmol) and NEt ₃ (40 μL, 0.31 mmol) were stirred for 30 minutes at room temperature and then concentrated in vacuo. The resulting residue was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH and the product was eluted with 2M NH ₃ / MeOH to give acetic acid 2- {4- [5- (2-ethylbenzoate). Imidazole-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] piperidin-1-yl} -1,1-dimethyl-2-oxoethyl ester was obtained. LCMS (Method A): R _T 3.19 min [M + H] ⁺ 592.2

Formula I (ii) thiophenyl intermediate (where (ii) X ¹ is CR ⁷ and X ² is S)

ＤＭＦ（４０ｍＬ）中の６-ブロモメチル-２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン（５００ｍｇ、１．４３ｍｍｏｌ）、１-オキサ-４,９-ジアザ-スピロ[５.５]ウンデカン-３-オン（３１５ｍｇ、１．８５ｍｍｏｌ）及び炭酸カリウム（４５０ｍｇ、３．２６ｍｍｏｌ）の溶液を１８時間雰囲気温度で攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。溶離液を収集し、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ１００：０から９８：２から９５：５）で精製して、９-(２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)-１-オキサ-４,９-ジアザスピロ[５.５]ウンデカン-３-オンを白色固形物として得た（５１５ｍｇ、８２％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝２．５１分，［Ｍ＋Ｈ］^＋４３８．１ Example 70a 9- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -1-oxa-4,9-diazaspiro [5.5] undecane-3 -on

6-Bromomethyl-2-chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidine (500 mg, 1.43 mmol), 1-oxa-4,9-diaza-spiro in DMF (40 mL) [5.5] A solution of undecan-3-one (315 mg, 1.85 mmol) and potassium carbonate (450 mg, 3.26 mmol) was stirred at ambient temperature for 18 hours, then an Isolute® SCX-2 cartridge (10 g ). The cartridge was washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The eluent was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 98: 2 to 95: 5) to give 9- (2-chloro-4-morpholin-4-yl-thieno [3 , 2-d] pyrimidin-6-ylmethyl) -1-oxa-4,9-diazaspiro [5.5] undecan-3-one (515 mg, 82%) as a white solid. LCMS (Method A): R _T = 2.51 min, [M + H] ⁺ 438.1

ジオキサン（１０ｍＬ）中の２-[４-(２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)-ピペラジン-１-イル]イソブチルアミド（１．０ｇ２．３ｍｍｏｌ）、ヘキサブチル二すず（１．４ｍＬ、２．７ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（１６１ｍｇ、０．２ｍｍｏｌ）の混合物を脱気し、ついで１５０℃で３０分間マイクロ波照射を施した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。適当な画分を組み合わせ、濃縮して残留物を得、これをフラッシュクロマトグラフィーで精製した（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から１０：９０の勾配）。適当な画分を組み合わせ、濃縮して、２-[４-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)-ピペラジン-１-イル]イソブチルアミドを白色フォームとして得た（０．９ｇ、５６％）。ＬＣＭＳ（方法Ｃ）Ｒ_Ｔ＝３．８８分；［Ｍ＋Ｈ］^＋６９３．１（^１１６Ｓｎ）６９５．１（^１１８Ｓｎ） Example 70b 2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl] isobutyramide

2- [4- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl] isobutyramide (1.D) in dioxane (10 mL). 0 g 2.3 mmol), hexabutyl distin (1.4 mL, 2.7 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (161 mg, 0.2 mmol) were degassed, Next, microwave irradiation was performed at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. Appropriate fractions were combined and concentrated to give a residue that was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient from 0: 100 to 10:90). Appropriate fractions were combined and concentrated to give 2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl)- Piperazin-1-yl] isobutyramide was obtained as a white foam (0.9 g, 56%). LCMS (Method C) R _T = 3.88 min; [M + H] ⁺ 693.1 ( ¹¹⁶ Sn) 695.1 ( ¹¹⁸ Sn)

ＤＣＥ（５０ｍＬ）中の２-クロロ-７-メチル-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（１．００ｇ、３．３６ｍｍｏｌ）の溶液に、２-(ピペラジン-１-イル)イソブチルアミド（６３０ｍｇ、３．６９ｍｍｏｌ）、トリメチルオルトギ酸エステル（３．６７ｍＬ、３３．５８ｍｍｏｌ）及び酢酸（０．１９ｍＬ、３．３６ｍｍｏｌ）を加えた。３時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（１．１０ｇ５．０３ｍｍｏｌ）を加え、生じた混合物を更に１７時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、ＭｅＯＨ／ＤＣＭ中の２ＭのＮＨ_３で溶出した。生じた残留物をＭｅＯＨで倍散して、２-[４-(２-クロロ-７-メチル-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミドを白色固形物として得た（１．１２ｇ、７４％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．８８分，［Ｍ＋Ｈ］^＋４５３ Example 70c 2- [4- (2-Chloro-7-methyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyramide

To a solution of 2-chloro-7-methyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidine-6-carbaldehyde (1.00 g, 3.36 mmol) in DCE (50 mL) was added 2 -(Piperazin-1-yl) isobutyramide (630 mg, 3.69 mmol), trimethylorthoformate (3.67 mL, 33.58 mmol) and acetic acid (0.19 mL, 3.36 mmol) were added. After stirring for 3 hours at room temperature, sodium triacetoxyborohydride (1.10 g 5.03 mmol) was added and the resulting mixture was stirred for an additional 17 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was triturated with MeOH to give 2- [4- (2-chloro-7-methyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine- 1-yl] isobutyramide was obtained as a white solid (1.12 g, 74%). LCMS (Method C): R _T = 2.88 min, [M + H] ⁺ 453

ジオキサン（２ｍＬ）中の２-[４-(２-クロロ-７-メチル-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミド（１９４ｍｇ、０．４３ｍｍｏｌ）、ヘキサブチル二すず（３７３ｍｇ、０．６４ｍｍｏｌ）、ＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（３０ｍｇ、１０ｍｏｌ％）の混合物に窒素ガスをパージし、マイクロ波反応器で１５０℃で２０分間加熱した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄し、ＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から０５：９５の勾配）で精製して、２-[４-(７-メチル-４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミドを無色の油として得た（１９２ｍｇ、６３％）。ＬＣＭＳ（方法Ｄ）：Ｒ_Ｔ２．９２分，［Ｍ＋Ｈ］^＋７０５（^１１６Ｓｎ），７０７（^１１８Ｓｎ） Example 70d 2- [4- (7-Methyl-4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl ] Isobutyramide

2- [4- (2-Chloro-7-methyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyramide in dioxane (2 mL) (194 mg, 0.43 mmol), hexabutyl distin (373 mg, 0.64 mmol), PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (30 mg, 10 mol%) was purged with nitrogen gas And heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 05:95) to give 2- [4- (7-methyl-4-morpholin-4-yl- 2- (Tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyramide was obtained as a colorless oil (192 mg, 63%). LCMS (Method D): R _T 2.92 min, [M + H] ⁺ 705 ( ¹¹⁶ Sn), 707 ( ¹¹⁸ Sn)

ＤＣＥ（４０ｍＬ）中の２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（２．０ｇ、７．１ｍｍｏｌ）及び４-ピペリジン-４-イル-モルホリン（１．４ｇ、８．５ｍｍｏｌ）の混合物を１．５時間室温で攪拌し、ついでトリアセトキシ水素化ホウ素（２．２ｇ、１０．６ｍｍｏｌ）を加えた。反応混合物を室温で１８時間攪拌し、ついでＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（７０ｇ）に充填した。カートリッジをＭｅＯＨ／ＤＣＭ（１／１：ｖ／ｖ）で洗浄して、所望の生成物を（ＭｅＯＨ中２ＭのＮＨ_３）／ＤＣＭ（１／１：ｖ／ｖ）で溶出した。溶媒を除去し、残留物を熱ＩＭＳ中で倍散して、濾過し、６０℃で１時間、真空下で乾燥させ、２-クロロ-４-モルホリン-４-イル-６-(４-モルホリン-４-イル-ピペリジン-１-イルメチル)-チエノ[３,２-ｄ]ピリミジンを白色固形物として得た（２．６ｇ、８４％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ０．３４分及び１．６７分；［Ｍ＋Ｈ］^＋４３８ Example 70e 2-Chloro-4-morpholin-4-yl-6- (4-morpholin-4-yl-piperidin-1-ylmethyl) -thieno [3,2-d] pyrimidine

2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidine-6-carbaldehyde (2.0 g, 7.1 mmol) and 4-piperidin-4-yl- in DCE (40 mL) A mixture of morpholine (1.4 g, 8.5 mmol) was stirred for 1.5 hours at room temperature, then triacetoxyborohydride (2.2 g, 10.6 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours, then diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (70 g). The cartridge was washed with MeOH / DCM (1/1: v / v) and the desired product was eluted with (2M NH _{3 in} MeOH) / DCM (1/1: v / v). The solvent is removed and the residue is triturated in hot IMS, filtered, dried under vacuum at 60 ° C. for 1 hour, and 2-chloro-4-morpholin-4-yl-6- (4-morpholine -4-yl-piperidin-1-ylmethyl) -thieno [3,2-d] pyrimidine was obtained as a white solid (2.6 g, 84%). LCMS (Method C): R _T 0.34 min and 1.67 min; [M + H] ⁺ 438

ジオキサン（１０ｍＬ）中の２-クロロ-４-モルホリン-４-イル-６-(４-モルホリン-４-イル-ピペリジン-１-イルメチル)チエノ[３,２-ｄ]ピリミジン（８７４ｍｇ、２．０ｍｍｏｌ）、ヘキサブチル二すず（１．１ｍＬ、２．２ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（７１ｍｇ、０．１ｍｍｏｌ）の混合物を脱気し、ついで１５０℃で２０分間マイクロ波照射を施した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。適当な画分を組み合わせ、濃縮して残留物を得、これをフラッシュクロマトグラフィーに供した（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＥｔＯＡｃ、勾配０：１００から４０：６０）。適当な画分を組み合わせ、濃縮して、４-モルホリン-４-イル-６-(４-モルホリン-４-イル-ピペリジン-1-イルメチル)-2-(トリブチルスタンナニル(stannanyl))チエノ[3,2-d]ピリミジンを淡黄色油として得た（８２３ｍｇ、５９％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．７２分；［Ｍ＋Ｈ］^＋６９２（^１１６Ｓｎ）６９４（^１１８Ｓｎ） Example 70f 4-morpholin-4-yl-6- (4-morpholin-4-yl-piperidin-1-ylmethyl) -2- (tributylstannanyl) thieno [3,2-d] pyrimidine

2-Chloro-4-morpholin-4-yl-6- (4-morpholin-4-yl-piperidin-1-ylmethyl) thieno [3,2-d] pyrimidine (874 mg, 2.0 mmol) in dioxane (10 mL) ), Hexabutyl distin (1.1 mL, 2.2 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-P-Nme ₂ )} ₂ (71 mg, 0.1 mmol), then degassed For 20 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. Appropriate fractions were combined and concentrated to give a residue that was subjected to flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 40:60). Appropriate fractions were combined and concentrated to give 4-morpholin-4-yl-6- (4-morpholin-4-yl-piperidin-1-ylmethyl) -2- (tributylstannanyl) thieno [3 , 2-d] pyrimidine was obtained as a pale yellow oil (823 mg, 59%). LCMS (Method C): R _T = 2.72 min; [M + H] ⁺ 692 ( ¹¹⁶ Sn) 694 ( ¹¹⁸ Sn)

ＤＣＥ（１００ｍＬ）中の２-クロロ-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（５．０ｇ、１７．７ｍｍｏｌ）及びジメチルピペリジン-４-イルアミン（２．７ｇ、２１．２ｍｍｏｌ）の混合物を室温で４時間攪拌し、ついでトリアセトキシ水素化ホウ素（５．６ｇ、２６．５ｍｍｏｌ）を加えた。反応混合物を室温で１８時間攪拌した後、ＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２×７０ｇ）に充填した。カートリッジをＭｅＯＨ／ＤＣＭ（１／１：ｖ／ｖ）で洗浄して、所望の生成物を（ＭｅＯＨ中２ＭのＮＨ_３）／ＤＣＭ（１／１：ｖ／ｖ）で溶出させた。溶媒を除去し、残留物をＩＭＳから沈殿させ、[１-(２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペリジン-４-イル]ジメチルアミンを白色固形物として得た（４．４５ｇ、６４％）。ＬＣＭＳ（方法Ｂ）：Ｒ_Ｔ０．３７分及び１．８５分；［Ｍ＋Ｈ］^＋３９６ Example 70g [1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] dimethylamine

2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidine-6-carbaldehyde (5.0 g, 17.7 mmol) and dimethylpiperidin-4-ylamine (2.7 g) in DCE (100 mL). 21.2 mmol) was stirred at room temperature for 4 hours, then triacetoxyborohydride (5.6 g, 26.5 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours, then diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (2 × 70 g). The cartridge was washed with MeOH / DCM (1/1: v / v) and the desired product was eluted with (2M NH _{3 in} MeOH) / DCM (1/1: v / v). Solvent was removed and the residue was precipitated from IMS and [1- (2-chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] dimethyl. The amine was obtained as a white solid (4.45 g, 64%). LCMS (Method B): R _T 0.37 min and 1.85 min; [M + H] ⁺ 396

ジオキサン（１０ｍＬ）中の[１-(２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペリジン-４-イル]ジメチルアミン（１．０ｇ、２．５ｍｍｏｌ）、ヘキサブチル二すず（１．５ｍＬ、３．０ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（１２８ｍｇ、０．１８ｍｍｏｌ）の混合物を脱気し、ついで１６０℃で２０分間マイクロ波照射を施した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。ついで、カートリッジをＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。適当な画分を組み合わせ、濃縮して残留物を得、これをフラッシュクロマトグラフィーに供した（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、勾配０：１００から４０：６０）。適当な画分を組み合わせ、濃縮して、ジメチル-[１-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペリジン-４-イル]アミンを淡黄色の油として得た（８７９ｍｇ、５４％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．７６分；［Ｍ＋Ｈ］^＋６５０（^１１６Ｓｎ）６５２（^１１８Ｓｎ） Example 70h Dimethyl- [1- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] amine

[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] dimethylamine (1.0 g, 2 mL in dioxane (10 mL) .5 mmol), hexabutyl distin (1.5 mL, 3.0 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (128 mg, 0.18 mmol), then degassed Microwave irradiation was performed at 160 ° C. for 20 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. Appropriate fractions were combined and concentrated to give a residue that was subjected to flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 40:60). Combining and concentrating appropriate fractions, dimethyl- [1- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperidine -4-yl] amine was obtained as a pale yellow oil (879 mg, 54%). LCMS (Method C): R _T = 2.76 min; [M + H] ⁺ 650 ( ¹¹⁶ Sn) 652 ( ¹¹⁸ Sn)

ＤＣＥ（１５ｍＬ）中の２-クロロ-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（１３６ｍｇ、０．４８ｍｍｏｌ）、１-アゼチジン-３-イルピペリジン-４-オール（９０ｍｇ、０．５８ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（２６０ｍｇ）の混合物を５時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（２０２ｍｇ、０．９６ｍｍｏｌ）を加えた。生じた混合物を１８時間攪拌し、ついでセライト（登録商標）で濾過し、濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物を淡黄色の油として得た（１５３ｍｇ、７５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．８８分［Ｍ＋Ｈ］^＋４２４．３ Example 70i 1- [1- (2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl) azetidin-3-yl] piperidin-4-ol

2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidine-6-carbaldehyde (136 mg, 0.48 mmol), 1-azetidin-3-ylpiperidin-4-ol in DCE (15 mL) A mixture of (90 mg, 0.58 mmol) and 4Å powdered molecular sieve (260 mg) was stirred for 5 hours before sodium triacetoxyborohydride (202 mg, 0.96 mmol) was added. The resulting mixture was stirred for 18 hours, then filtered through Celite®, the filtrate was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH, and the product was loaded with 2M NH ₃ / MeOH / DCM. Eluted with. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as a pale yellow oil (153 mg, 75%). LCMS (Method H): R _T 1.88 min [M + H] ⁺ 424.3

ＤＣＥ（２０ｍＬ）中の２-クロロ-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（４００ｍｇ、１．４２ｍｍｏｌ）、３,３-ジメチル-１-オキセタン-３-イルピペラジン（２９０ｍｇ、１．７１ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（５００ｍｇ）の混合物を３時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（４２０ｍｇ、１．９８ｍｍｏｌ）を加えた。生じた混合物を１８時間攪拌し、セライト（登録商標）で濾過した。濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製し、表題化合物をクリーム状の固形物として得た（３０５ｍｇ、４９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．１２分，［Ｍ＋Ｈ］^＋４３８．３ Example 70j 2-chloro-6- (2,2-dimethyl-4-oxetane-3- ylpiperazin -1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine

2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidine-6-carbaldehyde (400 mg, 1.42 mmol), 3,3-dimethyl-1-oxetane-3- in DCE (20 mL) A mixture of irpiperazine (290 mg, 1.71 mmol) and 4Å powdered molecular sieve (500 mg) was stirred for 3 hours at room temperature, and then sodium triacetoxyborohydride (420 mg, 1.98 mmol) was added. The resulting mixture was stirred for 18 hours and filtered through Celite®. The filtrate was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH, and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a creamy solid (305 mg, 49%). LCMS (Method H): R _T 2.12 min, [M + H] ⁺ 438.3.

ＴＨＦ（１５０ｍＬ）中の(２-クロロ-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-イルメチル)ホスホン酸ジメチルエステル（３．０ｇ７．９４ｍｍｏｌ）の懸濁液に、−７８℃でＬｉＨＭＤＳ（８．８ｍＬ、８．８０ｍｍｏｌ、ＴＨＦ中１Ｍの溶液）を加え、生じた混合物を３０分間攪拌し、ついで室温まで温めた後、ＴＨＦ（２０ｍＬ）中の３-オキソ-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．５１ｇ、８．８２ｍｍｏｌ）の溶液を加えた。反応混合物を１６時間室温で攪拌し、ついでＨ_２Ｏ及びＭｅＯＨでクエンチし、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：ＤＣＭ、５−１００％）で精製し、表題化合物を黄色固形物として得た（２．１４ｇ、６３％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．９７分［Ｍ＋Ｈ］^＋４２３．３ Example 70k 3- (2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester

To a suspension of (2-chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl) phosphonic acid dimethyl ester (3.0 g 7.94 mmol) in THF (150 mL) was added -78. LiHMDS (8.8 mL, 8.80 mmol, 1M solution in THF) was added at 0 ° C. and the resulting mixture was stirred for 30 minutes and then allowed to warm to room temperature before 3-oxo-azetidine-1 in THF (20 mL). -A solution of carboxylic acid tert-butyl ester (1.51 g, 8.82 mmol) was added. The reaction mixture was stirred for 16 hours at room temperature, then quenched with H ₂ O and MeOH and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: DCM, 5-100%) to give the title compound as a yellow solid (2.14 g, 63%). LCMS (Method A): R _T 3.97 min [M + H] ⁺ 423.3.

ジオキサン（２５ｍＬ）中の３-(２-クロロ-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．１ｇ、２．５１ｍｍｏｌ）、２-エチルベンゾイミダゾール（４００ｍｇ、２．７４ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（１１５ｍｇ、０．１３ｍｍｏｌ）、ＸＰｈｏｓ（２４０ｍｇ、０．５０ｍｍｏｌ）及びＣｓ_２ＣＯ_３（１．２５ｇ、３．８４ｍｍｏｌ）の混合物にアルゴンをパージし、ついで１１０℃で１６時間加熱した。反応混合物をセライト（登録商標）で濾過し、ＤＣＭで洗浄し、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製し、表題化合物をオレンジ色の固形物として得た（１．５ｇ、定量的）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．４０分［Ｍ＋Ｈ］^＋５３３．４ Example 70l 3- [2- (2-Ethylbenzimidazol-1-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethylene] azetidine-1-carboxylic acid tert-butyl ester

3- (2-Chloro-4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (1.1 g, 2. mL) in dioxane (25 mL). 51 mmol), 2-ethylbenzimidazole (400 mg, 2.74 mmol), tris (dibenzylideneacetone) dipalladium (115 mg, 0.13 mmol), XPhos (240 mg, 0.50 mmol) and Cs ₂ CO ₃ (1.25 g, 3.84 mmol) of the mixture was purged with argon and then heated at 110 ° C. for 16 hours. The reaction mixture was filtered through Celite®, washed with DCM and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as an orange solid (1.5 g, quantitative). LCMS (Method A): R _T 3.40 min [M + H] ⁺ 533.4.

ＥｔＯＨ（３０ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-イルメチレン]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．５ｇ、２．５１ｍｍｏｌ）の溶液に１０％Ｐｄ／Ｃ（２７５ｍｇ）に加え、生じた混合物をＨ_２雰囲気下で６５時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＨで洗浄し、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物をオレンジ色の油として得た（０．７１ｇ、５３％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．２２分［Ｍ＋Ｈ］^＋５３５．４ Example 70m 3- [2- (2-Ethylbenzimidazol-1-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl] azetidine-1-carboxylic acid tert-butyl ester

3- [2- (2-Ethylbenzimidazol-1-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethylene] azetidine-1-carboxylic acid tert in EtOH (30 mL) -To a solution of butyl ester (1.5 g, 2.51 mmol) was added 10% Pd / C (275 mg) and the resulting mixture was stirred for 65 h under H ₂ atmosphere. The reaction mixture was filtered through Celite®, washed with EtOH and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as an orange oil (0.71 g, 53%). LCMS (Method A): R _T 3.22 min [M + H] ⁺ 535.4.

ＤＣＭ（３ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-イルメチル]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（７００ｍｇ、１．３１ｍｍｏｌ）の溶液にＴＦＡ（０．５ｍＬ）を加え、生じた混合物を１８時間室温で攪拌した。反応混合物を真空下で濃縮させ、生じた残留物を、ＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、表題化合物をオレンジ色のガムとして得た（５２２ｍｇ、９１％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ１．８０分［Ｍ＋Ｈ］^＋４３５．４ Example 70n 6-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidine

3- [2- (2-Ethylbenzimidazol-1-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl] azetidine-1-carboxylic acid tert in DCM (3 mL) To a solution of -butyl ester (700 mg, 1.31 mmol) was added TFA (0.5 mL) and the resulting mixture was stirred for 18 hours at room temperature. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give the title compound Obtained as an orange gum (522 mg, 91%). LCMS (Method A): R _T 1.80 min [M + H] ⁺ 435.4

Formula I (iii) Purine Intermediate (where (iii) X ¹ is N and X ² is NR ² )

５-アミノ-１-メチル-１Ｈ-イミダゾール-４-カルボニトリル１のシアノ基を硫酸で加水分解して５-アミノ-１-メチル-１Ｈ-イミダゾール-４-カルボキサミド２を得た。尿素で環化させ、９-メチル-１Ｈ-プリン-２,６(３Ｈ,９Ｈ)-ジオン３を得た。五塩化リン及びオキシ塩化リンで塩素化して２,６-ジクロロ-９-メチル-９Ｈ-プリン４（ＣＡＳ登録２３８２-１０-７）を得た。 Example 75a 2,6-Dichloro-9-methyl-9H-purine 4

The cyano group of 5-amino-1-methyl-1H-imidazole-4-carbonitrile 1 was hydrolyzed with sulfuric acid to give 5-amino-1-methyl-1H-imidazole-4-carboxamide 2. Cyclization with urea gave 9-methyl-1H-purine-2,6 (3H, 9H) -dione 3. Chlorination with phosphorus pentachloride and phosphorus oxychloride gave 2,6-dichloro-9-methyl-9H-purine 4 (CAS Registry 2382-10-7).

メタノール（５００ｍＬ）中の４-(２-クロロ-９-(テトラヒドロ-２Ｈ-ピラン-２-イル)-９Ｈ-プリン-６-イル)モルホリン（１００ｇ）に５０℃でｐ-トルエンスルホン酸一水和物（６ｇ）を加えた。反応物を３０分間攪拌したところ、白色固形物が溶液から沈殿した。固形物を濾過し、ブフナー漏斗で回収し、メタノールで洗浄し、真空下で乾燥させて、４-(２-クロロ-９Ｈ-プリン-６-イル)モルホリンを得た。炭酸セシウム（２００ｇ）及びヨードメタン（３０ｍＬ）を続いてＤＭＦ中の４-(２-クロロ-９Ｈ-プリン-６-イル)モルホリンの撹拌溶液に５０℃で加えた。反応物をｌｃ−ｍｓによって、完了するまで約３０分間モニタリングしたところで、溶媒を濃縮乾固した。続いて水中に粗反応物を懸濁させて、４-(２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（７２ｇ）を白色固形物として沈殿させ、これを濾過し、真空下で一晩乾燥させた。

Example 75b 2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol

4- (2-Chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) morpholine (100 g) in methanol (500 mL) at 50 ° C. with p-toluenesulfonic acid monohydrate A Japanese product (6 g) was added. The reaction was stirred for 30 minutes when a white solid precipitated out of solution. The solid was filtered and collected on a Buchner funnel, washed with methanol and dried under vacuum to give 4- (2-chloro-9H-purin-6-yl) morpholine. Cesium carbonate (200 g) and iodomethane (30 mL) were then added to a stirred solution of 4- (2-chloro-9H-purin-6-yl) morpholine in DMF at 50 ° C. The reaction was monitored by lc-ms for about 30 minutes to complete when the solvent was concentrated to dryness. The crude reaction is then suspended in water to precipitate 4- (2-chloro-9-methyl-9H-purin-6-yl) morpholine (72 g) as a white solid that is filtered and vacuumed Dried under overnight.

  Stirring of 4- (2-chloro-9-methyl-9H-purin-6-yl) morpholine (10 g) and N, N, N ′, N′-tetramethylethylenediamine (9.0 mL) in tetrahydrofuran (200 mL) To the solution was added 2.5 M n-butyllithium in tetrahydrofuran (35 mL) at −78 ° C. The solution was stirred at −40 ° C. for 30 minutes and re-cooled to −78 ° C. when DMF (8 mL) was added and the reaction was stirred for an additional hour. The reaction was quenched into a 0.25 N cold HCl solution via a 10 mL serum pipette aliquot. Ice was added to keep the quenching solution below 5 ° C. to prevent the formation of by-products during processing. 2-Chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde (11 g) precipitated as a pale yellow solid, which was filtered, washed with water and dried under vacuum.

ジクロロエタン（６００mL）及びＴＨＦ（４００ｍＬ）の混合物中の粗２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メタノール（１６．５ｇ）の溶液に０℃で三臭化リン（１１ｍＬ）を滴下して加えた。反応物を１時間攪拌したところで、沈殿した固形物を濾過し、水で洗浄して、回収し、乾燥させて、４-(８-(ブロモメチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（１５．６ｇ）を白色固形物として得た。
２-(ピペリジン-４-イル)プロパン-２-オール(０．７３ｇ)を４-(８-(ブロモメチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（１．６ｇ）と一般的手順Ｃを介して反応させ、２-(１-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（１．７６ｇ）を白色固形物として得た。 A solution of 2-chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde (17.2 g) in MeOH (800 mL) was treated with sodium borohydride (5 g) in portions at 0 ° C. The reaction was warmed to room temperature and stirred for 15 minutes. The reaction mixture was quenched with a solution of saturated sodium bicarbonate. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to give crude 2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methanol (16.9 g) as a white solid. Obtained.

Phosphorous tribromide at 0 ° C. in a solution of crude 2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methanol (16.5 g) in a mixture of dichloroethane (600 mL) and THF (400 mL) (11 mL) was added dropwise. When the reaction was stirred for 1 hour, the precipitated solid was filtered, washed with water, collected and dried to give 4- (8- (bromomethyl) -2-chloro-9-methyl-9H-purine. -6-yl) morpholine (15.6 g) was obtained as a white solid.
2- (Piperidin-4-yl) propan-2-ol (0.73 g) was converted to 4- (8- (bromomethyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (1.6 g And 2- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -Ole (1.76 g) was obtained as a white solid.

ジオキサン（１５ｍＬ）中のＰｄ_２(ｄｂａ)_３（１６１ｍｇ、０．１８ｍｍｏｌ）、Ｘｐｈｏｓ（ＣＡＳ登録番号５６４４８３-１８-７，３３６ｍｇ、０．７２ｍｍｏｌ）、２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（１．０ｇ、３．５２ｍｍｏｌ）、２-エチル-１Ｈ-ベンゾイミダゾール（５００ｍｇ、３．７３ｍｍｏｌ）、炭酸セシウム（２．３ｇ、７ｍｍｏｌ）の混合物を５分間脱気し、３０分間１４５℃でマイクロ波照射下で加熱した。反応混合物をまだ熱い間にセライトパッドで濾過し、パッドを熱いジオキサンで洗浄した。生成物が淡黄色固形物として直ちに沈殿した。その固形物を濾過し、真空下５０℃で乾燥させ、９-メチル-２-(２-メチルベンゾイミダゾール-１-イル)-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（６５０ｍｇ、５０％）を得た。更なる物質を母液から回収することができたであろう。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．３９分；［Ｍ＋ＭｅＯＨ］^＋４１０ Example 75c 9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde

Pd ₂ (dba) ₃ (161 mg, 0.18 mmol), Xphos (CAS Registry Number 564483-18-7, 336 mg, 0.72 mmol) in dioxane (15 mL), 2-chloro-9-methyl-6-morpholine- A mixture of 4-yl-9H-purine-8-carbaldehyde (1.0 g, 3.52 mmol), 2-ethyl-1H-benzimidazole (500 mg, 3.73 mmol), cesium carbonate (2.3 g, 7 mmol) was added. Degas for 5 minutes and heat at 145 ° C. for 30 minutes under microwave irradiation. The reaction mixture was filtered through a celite pad while still hot and the pad was washed with hot dioxane. The product immediately precipitated as a pale yellow solid. The solid was filtered, dried at 50 ° C. under vacuum, and 9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde ( 650 mg, 50%). Additional material could have been recovered from the mother liquor. LCMS (Method H): R _T 3.39 min; [M + MeOH] ⁺ 410

ジオキサン（８０ｍＬ）中のＰｄ_２(ｄｂａ)_３（４５８ｍｇ、０．５ｍｍｏｌ）、Ｘｐｈｏｓ（９５４ｍｇ、２．０ｍｍｏｌ）、２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（５．６４ｇ、２０．０ｍｍｏｌ）、２-エチル-１Ｈ-ベンゾイミダゾール（３．２１ｇ、２２．０ｍｍｏｌ）、炭酸セシウム（９．７８ｇ、３０．０ｍｍｏｌ）の混合物を５分間脱気し、１８時間還流下で加熱した。反応混合物を熱いままのセライトのパッドで濾過し、パッドを熱いジオキサンで洗浄した。組み合わせた濾液を減圧下で濃縮して残留物を得、これをＥｔ_２Ｏ（約１００ｍＬ）で倍散し、濾過し、真空下で５０℃にて乾燥させ、２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒドを黄色固形物として得た（４．５ｇ）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．６３分；［Ｍ＋ＭｅＯＨ］^＋４２４ Example 75d 2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

Pd ₂ (dba) ₃ (458 mg, 0.5 mmol), Xphos (954 mg, 2.0 mmol), 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8 in dioxane (80 mL) A mixture of 2-carbaldehyde (5.64 g, 20.0 mmol), 2-ethyl-1H-benzimidazole (3.21 g, 22.0 mmol) and cesium carbonate (9.78 g, 30.0 mmol) was degassed for 5 minutes. And heated at reflux for 18 hours. The reaction mixture was filtered through a hot pad of celite and the pad was washed with hot dioxane. The combined filtrate was concentrated under reduced pressure to give a residue which was triturated with Et ₂ O (ca. 100 mL), filtered, dried at 50 ° C. under vacuum and 2- (2-ethylbenzimidazole). -1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde was obtained as a yellow solid (4.5 g). LCMS (Method H): R _T 3.63 min; [M + MeOH] ⁺ 424

ジオキサン（３ｍＬ）及びＤＭＦ（１ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（２１０ｍｇ、０．７９ｍｍｏｌ）、２-シクロプロピルベンゾイミダゾール（１５０ｍｇ、０．９５ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（４４ｍｇ、０．０５ｍｍｏｌ）、Ｘｐｈｏｓ（９０ｍｇ、０．１８ｍｍｏｌ）及びＣｓ_２ＣＯ_３（６１８ｍｇ、１．９０ｍｍｏｌ）の混合物にアルゴンをパージし、ついでマイクロ波反応器で４５分１４５℃で加熱した。反応混合物をセライトのパッドで濾過し、ＥｔＯＡｃで洗浄した。濾液を真空下で濃縮し、カラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−７５％）で精製して、２-(２-シクロプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒドをオレンジ色の固形物として得た（２８２ｍｇ、８９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．７９分，［Ｍ＋Ｈ］^＋４３６．４ Example 75e 2- (2-Cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (210 mg, 0.79 mmol), 2-cyclopropylbenzimidazole (2 mL) in dioxane (3 mL) and DMF (1 mL). A mixture of 150 mg, 0.95 mmol), tris (dibenzylideneacetone) dipalladium (44 mg, 0.05 mmol), Xphos (90 mg, 0.18 mmol) and Cs ₂ CO ₃ (618 mg, 1.90 mmol) was purged with argon. Then it was heated in a microwave reactor at 145 ° C. for 45 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-75%) to give 2- (2-cyclopropylbenzimidazol-1-yl) -9-methyl-6. -Morpholin-4-yl-9H-purine-8-carbaldehyde was obtained as an orange solid (282 mg, 89%). LCMS (Method H): R _T 3.79 min, [M + H] ⁺ 436.4.

１,４-ジオキサン（１０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（５００ｍｇ、１．７８ｍｍｏｌ）、２-(１Ｈ-ベンゾイミダゾール-２-イル)エタノール（３３５ｍｇ、２．０６ｍｍｏｌ）、Ｐｄ_２ｄｂａ_３（４０ｍｇ、０．０４３ｍｍｏｌ）、Ｘｐｈｏｓ（８５ｍｇ、０．１８ｍｍｏｌ）及び炭酸セシウム（８４０ｍｇ、２．５８ｍｍｏｌ）の混合物にアルゴンガスをパージし、ついで１４５℃で３０分間マイクロ波照射を施した。反応混合物をセライト（登録商標）のパッドで濾過し、濾液を真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：ＭｅＯＨ；１００：０から９８：２から９５：５から９０：１０）で精製して、２-[２-(２-ヒドロキシエチル)ベンゾイミダゾール-１-イル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒドを黄色固形物として得た（４８７ｍｇ、６７％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ９．９３（ｓ，１Ｈ）；８．１６−８．１２（ｍ，１Ｈ）；７．７６−７．７２（ｍ，１Ｈ）；７．３５−７．２９（ｍ，２Ｈ）；４．５２（ｍ，４Ｈ）；４．２０（ｔ，Ｊ＝５．３Ｈｚ，２Ｈ）；４．１４（ｓ，３Ｈ）；３．９１（ｍ，５Ｈ）及び３．５７（ｔ，Ｊ＝５．３Ｈｚ，２Ｈ）。 Example 75f 2- [2- (2-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (500 mg, 1.78 mmol), 2- (1H-benzimidazole- in 1,4-dioxane (10 mL) Purge argon gas into a mixture of 2-yl) ethanol (335 mg, 2.06 mmol), Pd ₂ dba ₃ (40 mg, 0.043 mmol), Xphos (85 mg, 0.18 mmol) and cesium carbonate (840 mg, 2.58 mmol) Then, microwave irradiation was performed at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of Celite® and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; 100: 0 to 98: 2 to 95: 5 to 90:10) to give 2- [2- (2-hydroxyethyl) benzo Imidazole-1-yl] -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde was obtained as a yellow solid (487 mg, 67%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.93 (s, 1H); 8.16-8.12 (m, 1H); 7.76-7.72 (m, 1H); 7.35-7. 29 (m, 2H); 4.52 (m, 4H); 4.20 (t, J = 5.3 Hz, 2H); 4.14 (s, 3H); 3.91 (m, 5H) and 3 .57 (t, J = 5.3 Hz, 2H).

ＤＣＭ（６ｍＬ）中の[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]メタノール（２００ｍｇ、０．５１ｍｍｏｌ）の懸濁液及びＤＭＦ（１００μＬ）にオキサリルクロリド（１２９μＬ、１．５２ｍｍｏｌ）を加え、生じた溶液を室温で１９時間攪拌した。反応混合物を真空下で油まで濃縮し、これをカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製し、８-クロロメチル-２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンを不純な混合物として得、これを次の反応に直接使用した。 Example 75g 8-chloromethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine

Of [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] methanol (200 mg, 0.51 mmol) in DCM (6 mL) Oxalyl chloride (129 μL, 1.52 mmol) was added to the suspension and DMF (100 μL) and the resulting solution was stirred at room temperature for 19 hours. The reaction mixture was concentrated under vacuum to an oil which was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) and 8-chloromethyl-2- (2-ethylbenzimidazole-1- Yl) -9-methyl-6-morpholin-4-yl-9H-purine was obtained as an impure mixture and used directly in the next reaction.

ＤＣＥ（２０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（４００ｍｇ、１．４２ｍｍｏｌ）、４-アゼチジン-３-イルチオモルホリン-１,１-ジオキシド（３２４ｍｇ、１．７０ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（９００ｍｇ）の混合物を４時間室温で攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（６０２ｍｇ、２．８４ｍｍｏｌ）を加えた。反応混合物を４０時間攪拌し、ついでセライトで濾過し、ＤＣＭで洗浄した。有機相をブラインで洗浄し（×１）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１５％）で精製して、２-クロロ-８-[３-(１,１-ジオキソ-１-チオモルホリン-４-イル)アゼチジン-１-イルメチル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンをクリーム状固形物として得た（５８７ｍｇ、９１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．２５分［Ｍ＋Ｈ］^＋４５６．３ Example 75h 2-Chloro-8- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -9-methyl-6-morpholin-4-yl-9H-purine

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (400 mg, 1.42 mmol), 4-azetidin-3-ylthiomorpholine-1, in DCE (20 mL), A mixture of 1-dioxide (324 mg, 1.70 mmol) and 4Å powdered molecular sieve (900 mg) was stirred for 4 hours at room temperature, and then sodium triacetoxyborohydride (602 mg, 2.84 mmol) was added. The reaction mixture was stirred for 40 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give 2-chloro-8- [3- (1,1-dioxo-1-thiomorpholine-4- Yl) azetidin-1-ylmethyl] -9-methyl-6-morpholin-4-yl-9H-purine was obtained as a cream solid (587 mg, 91%). LCMS (Method H): R _T 2.25 min [M + H] ⁺ 456.3.

ＤＣＥ（８ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（２３５ｍｇ、０．８２ｍｍｏｌ）、４-アゼチジン-３-イルモルホリン（１２２ｍｇ、０．８６ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（３００ｍｇ）の混合物を室温で３時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（３４６ｍｇ、１．６３ｍｍｏｌ）を加えた。反応混合物を６５時間攪拌した後、セライトで濾過し、ＤＣＭで洗浄した。有機相をブラインで洗浄し、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−２０％）で精製して、２-クロロ-９-メチル-６-モルホリン-４-イル-８-(３-モルホリン-４-イルアゼチジン-１-イルメチル)-９Ｈ-プリンをクリーム状固形物として得た（１６５ｍｇ、４９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．２２分［Ｍ＋Ｈ］^＋４０８．２ Example 75i 2-Chloro-9-methyl-6-morpholin-4-yl-8- (3-morpholin-4-ylazetidin-1-ylmethyl) -9H-purine

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (235 mg, 0.82 mmol), 4-azetidin-3-ylmorpholine (122 mg, 0) in DCE (8 mL) .86 mmol) and 4Å powdered molecular sieves (300 mg) were stirred at room temperature for 3 hours, after which sodium triacetoxyborohydride (346 mg, 1.63 mmol) was added. The reaction mixture was stirred for 65 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 2-chloro-9-methyl-6-morpholin-4-yl-8- (3-morpholine- 4-Ilazetidin-1-ylmethyl) -9H-purine was obtained as a cream solid (165 mg, 49%). LCMS (Method A): R _T 2.22 min [M + H] ⁺ 408.2.

Example 75j 2- (2- Ethylbenzimidazol -1-yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -8- [3- (tetrahydropyran-4-yl) azetidine -1-ylmethyl] -9H-purine

Step 1: 2- (2-Ethylbenzimidazol-1-yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine-8-carbaldehyde

Step 1: 2-Chloro-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine-8-carbaldehyde (0.8 g, 2.27 mmol) in dioxane (10 mL), 2-Ethyl-1H-benzimidazole (0.4 g, 2.72 mmol), Xphos (0.216 g, 0.45 mmol), Pd ₂ (dba) ₃ (0.104 g, 0.11 mmol) and Cs ₂ CO ₃ ( 1.48 g, 4.54 mmol) was subjected to microwave irradiation at 145 ° C. for 45 minutes. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 75:25) and 2- (2-ethylbenzimidazol-1-yl) -6-morpholin-4-yl -9- (Tetrahydropyran-2-yl) -8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine was obtained as a yellow foam (0.444 g, 43%). . LCMS (Method A): R _T = 4.05 min, [M + H] ⁺ 494.4

Step 2: In a 10 mL round bottom flask was added 2- (2-ethylbenzimidazole-1) in DCE (5 mL), trimethoxymethane (0.518 mL, 4.8 mmol) and acetic acid (0.03 mL, 0.48 mmol). -Yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine-8-carbaldehyde (0.22 g, 0.48 mmol), 3- (tetrahydropyran-4-yl) ) A solution of azetidine hydrochloride (0.093 g, 0.53 mmol) was charged. The reaction mixture was stirred for 4 hours at room temperature. Sodium triacetoxyborohydride (0.152 g, 0.72 mmol) was added and the reaction mixture was stirred for an additional 72 hours at room temperature. The suspension is partitioned between DCM and water; the organic layer is separated, washed with brine, dried over sodium sulfate, concentrated and 2- (2-ethylbenzimidazol-1-yl) -6- Morpholin-4-yl-9- (tetrahydropyran-2-yl) -8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine was obtained as an orange oil (0 .356 g, 99%). LCMS (Method A): R _T = 2.97 min, [M + H] ⁺ 587.4.

ＤＭＦ（２ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-８-(４-オキセタン-３-イル-ピペリジン-１-イルメチル)-９Ｈ-プリン（０．２ｇ、０．４９ｍｍｏｌ）、ベンゼン-１,２-ジアミン（０．１０６ｇ、０．９８ｍｍｏｌ）、Ｘｐｈｏｓ（０．０４７ｇ、０．０９８ｍｍｏｌ）、Ｐｄ_２（ｄｂａ）_３（０．０２２ｇ、０．０２５ｍｍｏｌ）及びＣｓ_２ＣＯ_３（０．３２ｇ、０．９８ｍｍｏｌ）の混合物に１５０℃で３０分間マイクロ波照射を施した。懸濁液をセライトで濾過し、溶液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から１０：９０の勾配）で精製し、Ｎ-[９-メチル-６-モルホリン-４-イル-８-(４-オキセタン-３-イル-ピペリジン-１-イルメチル)-９Ｈ-プリン-２-イル]ベンゼン-１,２-ジアミンを黄色の泡として得た（０．１１７ｇ、５０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝２．１４分，［Ｍ＋Ｈ］^＋４７９．２ Example 75k N- [9-Methyl-6-morpholin-4-yl-8- (4-oxetan-3-yl-piperidin-1-ylmethyl) -9H-purin-2-yl] benzene-1,2- Diamine

2-Chloro-9-methyl-6-morpholin-4-yl-8- (4-oxetan-3-yl-piperidin-1-ylmethyl) -9H-purine (0.2 g, 0. 0) in DMF (2 mL). 49 mmol), benzene-1,2-diamine (0.106 g, 0.98 mmol), Xphos (0.047 g, 0.098 mmol), Pd ₂ (dba) ₃ (0.022 g, 0.025 mmol) and Cs ₂ CO ₃ (0.32 g, 0.98 mmol) was subjected to microwave irradiation at 150 ° C. for 30 minutes. The suspension was filtered through celite and the solution was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) and N- [9-methyl-6-morpholin-4-yl-8- (4-oxetane). -3-yl-piperidin-1-ylmethyl) -9H-purin-2-yl] benzene-1,2-diamine was obtained as a yellow foam (0.117 g, 50%). LCMS (Method A): R _T = 2.14 min, [M + H] ⁺ 479.2.

２５ｍＬの丸底フラスコにＤＣＥ（７ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（０．１７３ｇ、０．６５ｍｍｏｌ）、３-(テトラヒドロピラン-４-イル)アゼチジン塩酸塩（０．１３８ｇ、０．７８ｍｍｏｌ）及び４Åモレキュラーシーブ（０．９ｇ）の溶液を充填した。反応混合物を５時間室温で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（０．２７４ｇ、１．２９ｍｍｏｌ）を加え、反応混合物を１８時間室温で攪拌した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＥｔＯＡｃ、０：１００から１０：９０の勾配）で精製し、２-クロロ-９-メチル-６-モルホリン-４-イル-８-[３-(テトラヒドロピラン-４-イル)アゼチジン-１-イルメチル]-９Ｈ-プリンを白色の泡として得た（０．１１７ｇ、４５％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝２．４０分，［Ｍ＋Ｈ］^＋４０７．２ Example 75l 2-Chloro-9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine

A 25 mL round bottom flask was charged with 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.173 g, 0.65 mmol), 3- (tetrahydro) in DCE (7 mL). A solution of pyran-4-yl) azetidine hydrochloride (0.138 g, 0.78 mmol) and 4Å molecular sieves (0.9 g) was charged. The reaction mixture was stirred for 5 hours at room temperature. Sodium triacetoxyborohydride (0.274 g, 1.29 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 10:90) and purified by 2-chloro-9-methyl-6-morpholin-4-yl-8- [3- (Tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine was obtained as a white foam (0.117 g, 45%). LCMS (Method A): R _T = 2.40 min, [M + H] ⁺ 407.2.

ＤＭＦ（２．５ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-８-[３-(テトラヒドロピラン-４-イル)アゼチジン-１-イルメチル]-９Ｈ-プリン（０．２５ｇ、０．６１ｍｍｏｌ）、ベンゼン-１,２-ジアミン（０．１３３ｇ、１．２３ｍｍｏｌ）、Ｘｐｈｏｓ（０．０５９ｇ、０．１２３ｍｍｏｌ）、Ｐｄ_２（ｄｂａ）_３（０．０２８ｇ、０．０３１ｍｍｏｌ）及びＣｓ_２ＣＯ_３（０．１７ｇ、１．２３ｍｍｏｌ）の混合物に１５０℃で３０分間マイクロ波照射を施した。懸濁液をセライトで濾過し、濾液を真空下で濃縮した。残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から１０：９０の勾配）で精製し、表題化合物を褐色の泡として得た（０．２３４ｇ、８０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝２．２０分，［Ｍ＋Ｈ］^＋４７９．４ Example 75m N- {9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purin-2-yl} benzene-1, 2-diamine

2-Chloro-9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine (0. 0) in DMF (2.5 mL). 25 g, 0.61 mmol), benzene-1,2-diamine (0.133 g, 1.23 mmol), Xphos (0.059 g, 0.123 mmol), Pd ₂ (dba) ₃ (0.028 g, 0.031 mmol) And Cs ₂ CO ₃ (0.17 g, 1.23 mmol) were subjected to microwave irradiation at 150 ° C. for 30 minutes. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give the title compound as a brown foam (0.234 g, 80%). LCMS (Method A): R _T = 2.20 min, [M + H] ⁺ 479.4.

ジオキサン（２．５ｍＬ）及びＮＭＰ（０．２５ｍＬ）中の２-[１-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル)-ピペリジン-４-イル]プロパン-２-オール（５００ｍｇ、１．２３ｍｍｏｌ）、ヘキサブチル二すず（０．９２８ｍＬ、１．８４ｍｍｏｌ）、ＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（８８ｍｇ、０．１２２ｍｍｏｌ）の混合物を脱気し、１５０℃で４５分間マイクロ波照射に供した。反応混合物をセライトで濾過し、濾液を真空下で濃縮した。残留物をＤＣＭ（１０ｍＬ）に溶解させ、水（１０ｍＬ）で洗浄した。有機層を分離し、硫酸ナトリウムで乾燥させ、真空下で濃縮した。残留物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出させた。溶液を濃縮し残留物を得、これをフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から７．５：９２．５の勾配）と続いて（Ｓｉ-ＰＰＣ、ＥｔＯＡｃ：シクロヘキサン、勾配０：１００から１００：０）で精製した。適当な画分を組み合わせて、表題化合物を淡黄色の油として得た（２３６ｍｇ、２９％）。ＬＣＭＳ（方法Ａ）Ｒ_Ｔ＝４．５８分；［Ｍ＋Ｈ］^＋６６３．３（^１１６Ｓｎ）６６５．３（^１１８Ｓｎ） Example 75n 2- [1- (9-Methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purin-8-ylmethyl) piperidin-4-yl] propane-2- Oar

2- [1- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -piperidine-4- in dioxane (2.5 mL) and NMP (0.25 mL) Yl] propan-2-ol (500 mg, 1.23 mmol), hexabutyl distin (0.928 mL, 1.84 mmol), PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (88 mg, 0. 1). 122 mmol) was degassed and subjected to microwave irradiation at 150 ° C. for 45 minutes. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was dissolved in DCM (10 mL) and washed with water (10 mL). The organic layer was separated, dried over sodium sulfate and concentrated under vacuum. The residue was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The solution was concentrated to give a residue which was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 7.5: 92.5) followed by (Si-PPC, EtOAc: cyclohexane, gradient 0: 100 to 100: 0). Appropriate fractions were combined to give the title compound as a pale yellow oil (236 mg, 29%). LCMS (Method A) R _T = 4.58 min; [M + H] ⁺ 663.3 ( ¹¹⁶ Sn) 665.3 ( ¹¹⁸ Sn)

無水ＴＨＦ（１０ｍＬ）中の(メトキシメチル)トリフェニルホスホニウムクロライド（１．４９ｇ、４．３５ｍｍｏｌ）の懸濁懸濁液に、窒素雰囲気下、０℃でＴＨＦ（４．３５ｍＬ、４．３５ｍｍｏｌ）中のＬｉＨＭＤＳの１Ｍ溶液を滴下して加えた。１５分後、無水ＴＨＦ（１０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（１．０２ｇ、３．６２ｍｍｏｌ）の懸濁液を加えた。３０分後、混合物を室温まで温め、更に１時間攪拌し、ついでＨ_２Ｏでクエンチした。混合物をＥｔＯＡｃ及び０．５ＭのＨＣｌ（水性）の間で分配し、有機層を分離し、水とついでブラインで洗浄した。有機層を乾燥させ（Ｎａ_２ＳＯ_４）、蒸発させ、残留物を得（２．２ｇ）、これをＭｅＯＨに溶解し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させて、残留物を得（８６０ｍｇ）、これを３７重量％ＨＣｌ（水性）／ＴＨＦ（８：１６ｍＬ）に取り上げた。得られた混合物を５０℃で２時間攪拌し、ついで冷却し、ＥｔＯＡｃ及び飽和ＮａＨＣＯ_３（水性）の間で分配した。有機層を分離し、ブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、シクロヘキサン中０−１００％ＥｔＯＡｃ）で精製して、表題化合物を（２工程にわたって４５１ｍｇ、４２％）オレンジ色の固形物として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．２９分，［Ｍ＋Ｈ］^＋２９６．２ Example 75o (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde

A suspension of (methoxymethyl) triphenylphosphonium chloride (1.49 g, 4.35 mmol) in anhydrous THF (10 mL) was added to THF (4.35 mL, 4.35 mmol) at 0 ° C. under a nitrogen atmosphere. A 1M solution of LiHMDS was added dropwise. After 15 minutes, a suspension of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.02 g, 3.62 mmol) in anhydrous THF (10 mL) was added. It was. After 30 minutes, the mixture was warmed to room temperature, stirred for an additional hour, and then quenched with H ₂ O. The mixture was partitioned between EtOAc and 0.5M HCl (aq) and the organic layer was separated and washed with water followed by brine. The organic layer was dried (Na ₂ SO ₄ ) and evaporated to give a residue (2.2 g) which was dissolved in MeOH, loaded onto an Isolute® SCX-2 cartridge and the cartridge washed with MeOH. The desired product was then eluted with 2M NH ₃ in MeOH to give a residue (860 mg) that was taken up in 37 wt% HCl (aq) / THF (8:16 mL). The resulting mixture was stirred at 50 ° C. for 2 h, then cooled and partitioned between EtOAc and saturated NaHCO ₃ (aq). The organic layer was separated and washed with brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PCC, 0-100% EtOAc in cyclohexane) to give the title compound (451 mg, 42% over 2 steps) as an orange solid. LCMS (Method H): R _T 3.29 min, [M + H] ⁺ 296.2.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１５０ｍｇ、０．５１ｍｍｏｌ）の溶液に２-ピペリジン-４-イルプロパン-２-オール（１１０ｍｇ、０．７７ｍｍｏｌ）、トリメチルオルトギ酸エステル（０．５５ｍＬ、５．０２ｍｍｏｌ）及び酢酸（０．０３ｍＬ、０．５２ｍｍｏｌ）を加えた。反応混合物を５時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１５４ｍｇ、０．７３ｍｍｏｌ）を加え、生じた混合物を更に２時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）によって精製して、表題化合物をオフホワイトの固形物として得た（１０９ｍｇ、５１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．５４分，［Ｍ＋Ｈ］^＋４２３．５ Example 75p 2- {1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] piperidin-4-yl} propan-2-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (150 mg, 0.51 mmol) in DCE (10 mL) was added 2-piperidin-4-ylpropane. -2-ol (110 mg, 0.77 mmol), trimethylorthoformate (0.55 mL, 5.02 mmol) and acetic acid (0.03 mL, 0.52 mmol) were added. The reaction mixture was stirred for 5 hours at room temperature, sodium triacetoxyborohydride (154 mg, 0.73 mmol) was added and the resulting mixture was stirred for an additional 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as an off-white solid (109 mg, 51%). LCMS (Method H): R _T = 2.54 min, [M + H] ⁺ 423.5

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１０ｍｇ、０．３７ｍｍｏｌ）の溶液に２-ピペラジン-１-イルイソブチルアミド（９０ｍｇ、０．５３ｍｍｏｌ）、トリメチルオルトギ酸エステル（０．２０ｍＬ、１．８６ｍｍｏｌ）及び酢酸（０．０２ｍＬ、０．３７ｍｍｏｌ）を加えた。反応混合物を３時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１１８ｍｇ、０．５６ｍｍｏｌ）を加え、生じた混合物を更に２日間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ中０−２０％ＭｅＯＨ）で精製し、表題化合物を淡黄色の固形物として得た（７１ｍｇ、４２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．４０分，［Ｍ＋Ｈ］^＋４５１．５ Example 75q 2- {4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] piperazin-1-yl} isobutyramide

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (110 mg, 0.37 mmol) in DCE (10 mL) 2-piperazin-1-ylisobutyl Amide (90 mg, 0.53 mmol), trimethylorthoformate (0.20 mL, 1.86 mmol) and acetic acid (0.02 mL, 0.37 mmol) were added. The reaction mixture was stirred for 3 hours at room temperature, sodium triacetoxyborohydride (118 mg, 0.56 mmol) was added and the resulting mixture was stirred for another 2 days. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-20% MeOH in EtOAc) to give the title compound as a pale yellow solid (71 mg, 42%). LCMS (Method H): R _T = 2.40 min, [M + H] ⁺ 451.5.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１６ｍｇ、０．３９ｍｍｏｌ）の溶液に２,２-ジメチルモルホリン（６８ｍｇ、０．５９ｍｍｏｌ）、トリメチルオルトギ酸エステル（０．２２ｍＬ、１．９６ｍｍｏｌ）及び酢酸（０．０２ｍＬ、０．３９ｍｍｏｌ）を加えた。反応混合物を３時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１２５ｍｇ、０．５９ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ中０−１０％のＭｅＯＨ）で精製して、表題化合物を淡黄色の固形物として得た（１００ｍｇ、６５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．５１分，［Ｍ＋Ｈ］^＋３９５．４ Example 75r 2-Chloro-8- [2- (2,2-dimethylmorpholin-4-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (116 mg, 0.39 mmol) in DCE (10 mL) was added 2,2-dimethylmorpholine (68 mg). 0.59 mmol), trimethylorthoformate ester (0.22 mL, 1.96 mmol) and acetic acid (0.02 mL, 0.39 mmol) were added. The reaction mixture was stirred for 3 hours at room temperature, sodium triacetoxyborohydride (125 mg, 0.59 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in EtOAc) to give the title compound as a pale yellow solid (100 mg, 65%). LCMS (Method H): R _T = 2.51 min, [M + H] ⁺ 395.4.

ＤＣＥ（２０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（３００ｍｇ、１．０１ｍｍｏｌ）の溶液に２-アゼチジン-３-イルプロパン-２-オール（１１８ｍｇ、１．０２ｍｍｏｌ）、トリメチルオルトギ酸エステル（１．１１ｍＬ、１０．１４ｍｍｏｌ）及び酢酸（０．０６ｍＬ、１．０１ｍｍｏｌ）を加えた。反応混合物を６時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（３２３ｍｇ、１．５２ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製し、表題化合物を淡黄色の油として得た（９０ｍｇ、２３％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝２．３７分，［Ｍ＋Ｈ］^＋３９５．２ Example 75s 2- {1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] azetidin-3-yl} propan-2-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (300 mg, 1.01 mmol) in DCE (20 mL) 2-azetidin-3-ylpropane -2-ol (118 mg, 1.02 mmol), trimethylorthoformate (1.11 mL, 10.14 mmol) and acetic acid (0.06 mL, 1.01 mmol) were added. The reaction mixture was stirred for 6 hours at room temperature, sodium triacetoxyborohydride (323 mg, 1.52 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as a pale yellow oil (90 mg, 23%). LCMS (Method A): R _T = 2.37 min, [M + H] ⁺ 395.2.

ＤＣＥ（１５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（２００ｍｇ、０．６８ｍｍｏｌ）の溶液に４-メチルピペリジン-４-オール（１１７ｍｇ、１．０１ｍｍｏｌ）、トリメチルオルトギ酸エステル（０．７４ｍＬ、６．７６ｍｍｏｌ）及び酢酸（０．０４ｍＬ、０．６８ｍｍｏｌ）を加えた。反応混合物を１．５時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１８７ｍｇ、１．３５ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＮＨ_３／ＭｅＯＨ中の２Ｍので溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−２０％２ＭのＮＨ_３／ＭｅＯＨ）で精製し、表題化合物を無色の油として得た（４５ｍｇ、１７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．２４分，［Ｍ＋Ｈ］^＋３９５．５ Example 75t 1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -4-methylpiperidin-4-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (200 mg, 0.68 mmol) in DCE (15 mL) 4-methylpiperidin-4-ol (117 mg, 1.01 mmol), trimethylorthoformate (0.74 mL, 6.76 mmol) and acetic acid (0.04 mL, 0.68 mmol) were added. The reaction mixture was stirred for 1.5 hours at room temperature, sodium triacetoxyborohydride (187 mg, 1.35 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M in NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-20% 2M NH ₃ / MeOH in DCM) to give the title compound as a colorless oil (45 mg, 17%). LCMS (Method H): R _T = 2.24 min, [M + H] ⁺ 395.5.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１５０ｍｇ、０．５１ｍｍｏｌ）の溶液に３-メチル-アゼチジン-３-オール（６５ｍｇ、０．７５ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を室温で２時間攪拌し、トリアセトキシ水素化ホウ素ナトリウム（２１５ｍｇ、１．０１ｍｍｏｌ）を加え、生じた混合物を更に１７時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を淡黄色の油として得た（８３ｍｇ、４５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．２９分，［Ｍ＋Ｈ］^＋３６７．５ Example 75u 1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -3-methyl-azetidin-3-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (150 mg, 0.51 mmol) in DCE (10 mL) was added 3-methyl-azetidine-3- All (65 mg, 0.75 mmol) and powdered 4M molecular sieves were added. The reaction mixture was stirred at room temperature for 2 hours, sodium triacetoxyborohydride (215 mg, 1.01 mmol) was added and the resulting mixture was stirred for an additional 17 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as a pale yellow oil (83 mg, 45%). LCMS (Method H): R _T = 2.29 min, [M + H] ⁺ 367.5.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１５７ｍｇ、０．５３ｍｍｏｌ）の溶液に７-アザスピロ[３.５]ノナン-２-オール（１０９ｍｇ、０．７７ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を４時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（２２５ｍｇ、１．０６ｍｍｏｌ）を加え、反応混合物を更に１６時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄し、ついで所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３を溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％２ＭのＮＨ_３／ＭｅＯＨ）で精製し、表題化合物を無色の油として得た（１５５ｍｇ、６９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．４１分，［Ｍ＋Ｈ］^＋４２１．５ Example 75v 7- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -7-azaspiro [3.5] nonan-2-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (157 mg, 0.53 mmol) in DCE (10 mL) 7-azaspiro [3.5] Nonan-2-ol (109 mg, 0.77 mmol) and powdered 4Å molecular sieves were added. The reaction mixture was stirred for 4 hours at room temperature, sodium triacetoxyborohydride (225 mg, 1.06 mmol) was added and the reaction mixture was stirred for an additional 16 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH, then the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM) to give the title compound as a colorless oil (155 mg, 69%). LCMS (Method H): R _T = 2.41 min, [M + H] ⁺ 421.5.

ＤＣＥ（５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（６９ｍｇ、０．２３ｍｍｏｌ）の溶液に、３-イソプロピル-アゼチジン-３-オール（２７ｍｇ、０．２３ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を２時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（９９ｍｇ、０．４７ｍｍｏｌ）を加え、生じた混合物を更に２日間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％２ＭのＮＨ_３／ＭｅＯＨ）で精製して、表題化合物を淡黄色の油として得た（３０ｍｇ、３３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．６５分，［Ｍ＋Ｈ］^＋３９５．５ Example 75w 1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -3-isopropyl-azetidin-3-ol

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (69 mg, 0.23 mmol) in DCE (5 mL) was added 3-isopropyl-azetidine-3. -All (27 mg, 0.23 mmol) and powdered 4M molecular sieves were added. The reaction mixture was stirred for 2 hours at room temperature, sodium triacetoxyborohydride (99 mg, 0.47 mmol) was added and the resulting mixture was stirred for an additional 2 days. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM) to give the title compound as a pale yellow oil (30 mg, 33%). LCMS (Method H): R _T = 2.65 min, [M + H] ⁺ 395.5.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１６７ｍｇ、０．５７ｍｍｏｌ）の溶液に１-イソプロピルピペラジン-２-オン（８７ｍｇ、０．６１ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を１時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（２３９ｍｇ、１．１３ｍｍｏｌ）を加え、生じた混合物を更に１６時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％２ＭのＮＨ_３／ＭｅＯＨ）で精製し、表題化合物を淡黄色の油として得た（５１ｍｇ、３３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝３．３１分，［Ｍ＋Ｈ］^＋４２２．５ Example 75x 4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -1-isopropylpiperazin-2-one

1-isopropylpiperazin-2-one in a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (167 mg, 0.57 mmol) in DCE (10 mL) (87 mg, 0.61 mmol) and powdered 4 粉末 molecular sieves were added. The reaction mixture was stirred for 1 hour at room temperature, sodium triacetoxyborohydride (239 mg, 1.13 mmol) was added and the resulting mixture was stirred for an additional 16 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, and then the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM) to give the title compound as a pale yellow oil (51 mg, 33%). LCMS (Method H): R _T = 3.31 min, [M + H] ⁺ 422.5

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１７ｍｇ、０．４０ｍｍｏｌ）の溶液に３-オキサ-８-アザビシクロ[３.２.１]オクタン（５４ｍｇ、０．４８ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を２時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１６８ｍｇ、０．７９ｍｍｏｌ）を加え、生じた混合物を更に１６時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３に溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を淡黄色の油として得た（８０ｍｇ、５１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３４分，［Ｍ＋Ｈ］^＋３９３．５ Example 75xx 2-chloro-9-methyl-6-morpholin-4-yl-8- [2- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) ethyl] -9H- Pudding

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (117 mg, 0.40 mmol) in DCE (10 mL) was added 3-oxa-8-azabicyclo [ 3.2.1] Octane (54 mg, 0.48 mmol) and powdered 4Å molecular sieves were added. The reaction mixture was stirred for 2 hours at room temperature, sodium triacetoxyborohydride (168 mg, 0.79 mmol) was added and the resulting mixture was stirred for an additional 16 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, then the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as a pale yellow oil (80 mg, 51%). LCMS (Method H): R _T = 2.34 min, [M + H] ⁺ 393.5.

ＤＣＥ（１５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１８４ｍｇ、０．６２ｍｍｏｌ）の溶液に６-イソプロピルピペラジン-２-オン（１０６ｍｇ、０．７５ｍｍｏｌ）及び粉末化４Åモレキュラーシーブを加えた。反応混合物を６時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（３６４ｍｇ、１．７２ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製し、表題化合物を淡黄色の油として得た（９３ｍｇ、３５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝３．４４分，［Ｍ＋Ｈ］^＋４２２．４ Example 75y 4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -6-isopropylpiperazin-2-one

6-Isopropylpiperazin-2-one in a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (184 mg, 0.62 mmol) in DCE (15 mL) (106 mg, 0.75 mmol) and powdered 4M molecular sieves were added. The reaction mixture was stirred for 6 hours at room temperature, sodium triacetoxyborohydride (364 mg, 1.72 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then the desired product was eluted with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as a pale yellow oil (93 mg, 35%). LCMS (Method H): R _T = 3.44 min, [M + H] ⁺ 422.4.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１９ｍｇ、０．４０ｍｍｏｌ）の溶液に３,３-ジメチルモルホリン．ＨＣｌ（６１ｍｇ、０．４０ｍｍｏｌ）、トリエチルアミン（０．０６ｍＬ、０．４０ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。室温で４時間攪拌した後にトリアセトキシ水素化ホウ素ナトリウム（１７１ｍｇ、０．８０ｍｍｏｌ）を加え、生じた混合物を更に１６時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−７％ＭｅＯＨ）で精製して、表題化合物を淡黄色の油として得た（４４ｍｇ、２８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．４５分，［Ｍ＋Ｈ］^＋３９５．５ Example 75z 2-chloro-8- [2- (3,3-dimethylmorpholin-4-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (119 mg, 0.40 mmol) in DCE (10 mL) was added 3,3-dimethylmorpholine. HCl (61 mg, 0.40 mmol), triethylamine (0.06 mL, 0.40 mmol) and powdered 4Å molecular sieves were added. After stirring at room temperature for 4 hours, sodium triacetoxyborohydride (171 mg, 0.80 mmol) was added and the resulting mixture was stirred for an additional 16 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. It was. The resulting residue was purified by column chromatography (Si-PCC, 0-7% MeOH in DCM) to give the title compound as a pale yellow oil (44 mg, 28%). LCMS (Method H): R _T = 2.45 min, [M + H] ⁺ 395.5.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１５ｍｇ、０．３９ｍｍｏｌ）の溶液に４-アゼチジン-３-イル-チオモルホリン,１-１-ジオキシド（７４ｍｇ、０．３９ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を４時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１６５ｍｇ、０．７８ｍｍｏｌ）を加え、生じた混合物を更に２日間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％２ＭのＮＨ_３／ＭｅＯＨ）で精製し、表題化合物を淡黄色の油として得た（９３ｍｇ、５１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．２５分，［Ｍ＋Ｈ］^＋４７０．３ Example 75aa 2-Chloro-8- {2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-yl] -ethyl} -9-methyl-6-morpholine-4 -Ile-9H-pudding

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (115 mg, 0.39 mmol) in DCE (10 mL) 4-azetidin-3-yl- Thiomorpholine, 1-1-dioxide (74 mg, 0.39 mmol) and powdered 4Å molecular sieves were added. The reaction mixture was stirred for 4 hours at room temperature, sodium triacetoxyborohydride (165 mg, 0.78 mmol) was added and the resulting mixture was stirred for another 2 days. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then the desired product was eluted with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM) to give the title compound as a pale yellow oil (93 mg, 51%). LCMS (Method H): R _T = 2.25 min, [M + H] ⁺ 470.3.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（６０ｍｇ、０．２０ｍｍｏｌ）の溶液に４,４-ジフルオロピペリジンＨＣｌ（４２ｍｇ、０．２６ｍｍｏｌ）、トリエチルアミン（０．０４ｍＬ、０．２６ｍｍｏｌ）、粉末４Åモレキュラーシーブ及びトリアセトキシ水素化ホウ素ナトリウム（８６ｍｇ、０．４１ｍｍｏｌ）を加えた。反応混合物を５時間室温で攪拌し、反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−５％のＭｅＯＨ）で精製し、表題化合物を淡黄色の油として得た（３０ｍｇ、３７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．６１分，［Ｍ＋Ｈ］^＋４０１．５ Example 75bb 2-Chloro-8- [2- (4,4-difluoropiperidin-1-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (60 mg, 0.20 mmol) in DCE (10 mL) was added 4,4-difluoropiperidine HCl ( 42 mg, 0.26 mmol), triethylamine (0.04 mL, 0.26 mmol), powdered 4Å molecular sieves and sodium triacetoxyborohydride (86 mg, 0.41 mmol) were added. The reaction mixture was stirred for 5 hours at room temperature and the reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-5% MeOH in DCM) to give the title compound as a pale yellow oil (30 mg, 37%). LCMS (Method H): R _T = 2.61 min, [M + H] ⁺ 401.5.

ＤＣＥ（１５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（７２ｍｇ、０．２４ｍｍｏｌ）の溶液に１-(テトラヒドロピラン-４-イル)ピペラジン(６０ｍｇ、０.３５ｍｍｏｌ)、粉末４Åモレキュラーシーブ及びトリアセトキシ水素化ホウ素ナトリウム（１０３ｍｇ、０．４９ｍｍｏｌ）を加えた。反応混合物を１７時間室温で攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を黄色固形物として得た（３７ｍｇ、３４％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．４６分，［Ｍ＋Ｈ］^＋４５０．５ Example 75cc 2-Chloro-9-methyl-6-morpholin-4-yl-8- {2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl} -9H-purine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (72 mg, 0.24 mmol) in DCE (15 mL) was added 1- (tetrahydropyran-4- Yl) piperazine (60 mg, 0.35 mmol), powdered 4Å molecular sieves and sodium triacetoxyborohydride (103 mg, 0.49 mmol) were added. The reaction mixture was stirred for 17 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and the cartridge was washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give the title compound as a yellow solid (37 mg, 34%). LCMS (Method H): R _T = 2.46 min, [M + H] ⁺ 450.5

ＤＣＥ（１０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（２３５ｍｇ、０．８３ｍｍｏｌ）、(２-(１Ｓ,４Ｓ)-２,５-ジアザビシクロ[２.２.１]ヘプタ-２-イル-２-メチルプロパン-１-オール（１６８ｍｇ、０．９９ｍｍｏｌ）及びモレキュラーシーブ（４Å、粉末状、１ｇ）の溶液を雰囲気温度で４時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２６５ｍｇ、１．２５ｍｍｏｌ）を加え、混合物を１８時間攪拌し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；９０：１０）で精製して、表題化合物を黄褐色の固形物として得た（５０ｍｇ、１４％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３９分，Ｍ＋Ｈ^＋＝４３６． Example 75dd 2-[(1S, 4S) -5- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -2,5-diazabicyclo [2.2. 1] Hept-2-yl] -2-methylpropan-1-ol

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (235 mg, 0.83 mmol), (2- (1S, 4S) -2,5 in DCE (10 mL) -A solution of diazabicyclo [2.2.1] hept-2-yl-2-methylpropan-1-ol (168 mg, 0.99 mmol) and molecular sieves (4Å, powder, 1 g) was stirred at ambient temperature for 4 hours Sodium triacetoxyborohydride (265 mg, 1.25 mmol) was added and the mixture was stirred for 18 hours and loaded onto an Isolute® SCX-2 cartridge (25 g) The cartridge was washed with methanol and the desired continue the product was eluted with 2M NH ₃ in MeOH. the product was collected and concentrated in vacuo. the resulting residue was purified by flash chromatography (Si-PP , DCM:. MeOH; 90: 10) to give the title compound as a tan solid (50mg, 14%) LCMS (method _H): R T = 2.39 ^{min, M} + H + = 436 .

ＤＣＥ（１２ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（２２７ｍｇ、０．８１ｍｍｏｌ）、(１Ｓ,４Ｓ)-２-メタンスルホニル-２,５-ジアザビシクロ[２.２.１]ヘプタン（１７０ｍｇ、０．９７ｍｍｏｌ）及びモレキュラーシーブ（４Å、粉末、１ｇ）の溶液を雰囲気温度で３時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（２５５ｍｇ、１．２０ｍｍｏｌ）を加え、混合物を１７時間攪拌し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３で溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；９８：２）て表題化合物を白色固形物として得た（３５０ｍｇ、９８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．５１分，Ｍ＋Ｈ^＋＝４４２。 Example 75ee 2-chloro-8-((1S, 4S) -5-methanesulfonyl-2,5-diazabicyclo [2.2.1] hept-2-ylmethyl) -9-methyl-6-morpholine-4- IL-9H-pudding

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (227 mg, 0.81 mmol), (1S, 4S) -2-methanesulfonyl-2 in DCE (12 mL) , 5-Diazabicyclo [2.2.1] heptane (170 mg, 0.97 mmol) and molecular sieves (4 kg, powder, 1 g) were stirred at ambient temperature for 3 hours. Sodium triacetoxyborohydride (255 mg, 1.20 mmol) was added and the mixture was stirred for 17 hours and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: MeOH; 98: 2) to give the title compound as a white solid (350 mg, 98%). LCMS (Method H): R _T = 2.51 min, M + H ⁺ = 442.

無水ＴＨＦ（２５ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（１．０ｇ、３．５５ｍｍｏｌ）、４-オキセタン-３-イルピペリジン（６００ｍｇ、４．２５ｍｍｏｌ）及びモレキュラーシーブ（４Å、粉末、５ｇ）の溶液を雰囲気温度で５時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（１．５ｇ、７．０８ｍｍｏｌ）を加え、混合物を１８時間攪拌し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３に溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９９：１から９８：２から９５：５から９０：１０）で精製して表題化合物を白色の泡として得た（０．８２ｇ、５７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３８分，Ｍ＋Ｈ^＋＝４０８。 Example 75ff 2-chloro-9-methyl-6-morpholin-4-yl-8- (4-oxetane-3- ylpiperidin -1-ylmethyl) -9H-purine

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.0 g, 3.55 mmol), 4-oxetan-3-ylpiperidine (25 mL) in anhydrous THF (25 mL) A solution of 600 mg, 4.25 mmol) and molecular sieves (4 kg, powder, 5 g) was stirred at ambient temperature for 5 hours. Sodium triacetoxyborohydride (1.5 g, 7.08 mmol) was added and the mixture was stirred for 18 hours and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with methanol and the desired product was subsequently eluted in 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 99: 1 to 98: 2 to 95: 5 to 90:10) to give the title compound as a white foam. (0.82 g, 57%). LCMS (Method H): R _T = 2.38 min, M + H ⁺ = 408.

ＤＣＥ（１０ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１３７ｍｇ、０．４６ｍｍｏｌ）の溶液に２,２-ジメチルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（９９ｍｇ、０．４６ｍｍｏｌ）、粉末状４Åモレキュラーシーブ及びトリアセトキシ水素化ホウ素ナトリウム（１４６ｍｇ、０．６９ｍｍｏｌ）を加えた。室温で２０時間攪拌した後、反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％ＭｅＯＨ）で精製して残留物を得、これをＤＣＭ（３ｍＬ）中に取り上げた。ついで、ＴＦＡ（１ｍＬ）を加え、反応混合物を室温で２時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３に溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−１０％ＭｅＯＨ）で精製して残留物（２８ｍｇ）を得、これをＤＣＭ（４ｍＬ）中に取り上げた。溶液を０℃に冷却し、Ｎｅｔ_３（０．０３ｍＬ、０．２１ｍｍｏｌ）及びメタンスルホニルクロリド（０．０３ｍＬ、０．３９ｍｍｏｌ）を加えた。１０分後、反応混合物を室温まで温め、６０分間攪拌した。反応混合物をＤＣＭ及び飽和ＮａＨＣＯ_３（水性）の間で分配し、有機層を分離して、疎水性フリットを通過させ、真空下で蒸発させた。この残留物をＭｅＯＨ／ＤＣＭに取り上げ、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、ＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出させ、２-クロロ-８-[２-(４-メタンスルホニル-３,３-ジメチルピペラジン-１-イル)-エチル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（３工程にわたって３５ｍｇ、１６％）を黄色油として得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．８２分，［Ｍ＋Ｈ］^＋４７２．４ Example 75 gg 2-chloro-8- [2- (4-methanesulfonyl-3,3-dimethylpiperazin-1-yl) -ethyl] -9-methyl-6-morpholin-4-yl-9H-purine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (137 mg, 0.46 mmol) in DCE (10 mL) 2,2-dimethylpiperazine-1 -Carboxylic acid tert-butyl ester (99 mg, 0.46 mmol), powdered 4Å molecular sieves and sodium triacetoxyborohydride (146 mg, 0.69 mmol) were added. After stirring at room temperature for 20 hours, the reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, and then the desired product was washed with 2M NH in DCM. Elute with ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give a residue that was taken up in DCM (3 mL). TFA (1 mL) was then added and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product into 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give a residue (28 mg) that was taken up in DCM (4 mL). The solution was cooled to 0 ° C. and Net ₃ (0.03 mL, 0.21 mmol) and methanesulfonyl chloride (0.03 mL, 0.39 mmol) were added. After 10 minutes, the reaction mixture was warmed to room temperature and stirred for 60 minutes. The reaction mixture was partitioned between DCM and saturated NaHCO ₃ (aq), the organic layer was separated, passed through a hydrophobic frit and evaporated under vacuum. The residue was taken up in MeOH / DCM, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, then eluted with 2M NH ₃ / MeOH in DCM, 2-chloro-8- [2 -(4-Methanesulfonyl-3,3-dimethylpiperazin-1-yl) -ethyl] -9-methyl-6-morpholin-4-yl-9H-purine (35 mg, 16% over 3 steps) as a yellow oil Obtained. LCMS (Method H): R _T = 2.82 min, [M + H] ⁺ 472.4.

ＤＣＥ（１５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（１１８ｍｇ、０．４０ｍｍｏｌ）の溶液に１,１-ジオキソ-テトラヒドロ-１-チオフェン-３-イルアミン（１０７ｍｇ、０．８０ｍｍｏｌ）及び粉末４Åモレキュラーシーブを加えた。反応混合物を３０分間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１６９ｍｇ、０．８０ｍｍｏｌ）を加え、生じた混合物を更に１８時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨに溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＤＣＭ中０−７％ＭｅＯＨ）で精製して、[２-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-エチル]-(１,１-ジオキソ-テトラヒドロ-１-チオフェン-３-イル)アミンを黄色油として得た（４５ｍｇ、２７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３８分，［Ｍ＋Ｈ］^＋４１５．４ Example 75hh [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -ethyl]-(1,1-dioxo-tetrahydro-1-thiophene-3- Yl) amine

To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (118 mg, 0.40 mmol) in DCE (15 mL) was added 1,1-dioxo-tetrahydro- 1-thiophen-3-ylamine (107 mg, 0.80 mmol) and powdered 4Å molecular sieves were added. The reaction mixture was stirred for 30 minutes at room temperature, sodium triacetoxyborohydride (169 mg, 0.80 mmol) was added and the resulting mixture was stirred for an additional 18 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then the desired product was eluted with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-7% MeOH in DCM) to give [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine- 8-yl) -ethyl]-(1,1-dioxo-tetrahydro-1-thiophen-3-yl) amine was obtained as a yellow oil (45 mg, 27%). LCMS (Method H): R _T = 2.38 min, [M + H] ⁺ 415.4.

Example 75ii 3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -pyrrolidine-1-carboxylic acid tert-butyl ester

Zinc activation: 7: 5 of TMS-Cl: 1,2-dibromoethane (25 μL) in a suspension of zinc powder (128 mg, 0.99 mmol) and Celpure® P65 in anhydrous DMA (4 mL). v: v) The mixture was added. The reaction mixture was stirred for 10 minutes at room temperature.

Zinc insertion: A solution of 3-iodopyrrolidine-1-carboxylic acid tert-butyl ester (470 g 1.58 mmol) in anhydrous DMA (2 mL) was added dropwise. The reaction mixture was stirred at room temperature for 45 minutes.

Coupling reaction: 2-chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine (400 mg, 1.05 mmol), Pd (dppf) Cl ₂ .DCM in DMA (4 mL). A mixture of 42 mg, 5 mol%) and CuI (20 mg, 10 mol%) was evacuated and backfilled with argon. The zincate mixture was quickly filtered (PTFE) and added onto the palladium-containing mixture. The resulting reaction mixture was stirred at 85 ° C. for 18 hours and cooled to room temperature. The mixture was partitioned between EtOAc and 1M aqueous ammonium chloride. The organic layer was separated, washed with water, brine and dried (Na ₂ SO ₄ ). The resulting residue was purified by column chromatography (Si-PCC, 0-100% EtOAc in cyclohexane) to give 3- (2-chloro-9-methyl-6-morpholin-4-yl-9H-purine-8. -Yl) -pyrrolidine-1-carboxylic acid tert-butyl ester was obtained as an orange oil (79 mg, 18%). LCMS (Method H): R _T = 4.48 min, [M + H] ⁺ 423.5.

ＤＣＥ（１８ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（２１２ｍｇ、０．７５ｍｍｏｌ）、３-イソプロピルピペラジン-２-オン（１２８ｍｇ、０．９０ｍｍｏｌ）及び粉末４Åモレキュラーシーブの混合液を室温で攪拌した。４時間後、トリアセトキシ水素化ホウ素ナトリウム（３１８ｍｇ、１．５０ｍｍｏｌ）を加え、生じた混合物を更に１７時間攪拌した。反応混合物をセライト（登録商標）で濾過し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、ＭｅＯＨで洗浄した後、所望の生成物をＤＣＭ中の２ＭのＮＨ_３／ＭｅＯＨで溶出した。ＥｔＯＡｃで生じた残留物を倍散して、４-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル)-３-イソプロピルピペラジン-２-オンを黄色油として得た（１９８ｍｇ、６５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．８２分，［Ｍ＋Ｈ］^＋４０８．４ Example 75jj 4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -3-isopropylpiperazin-2-one

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (212 mg, 0.75 mmol), 3-isopropylpiperazin-2-one (128 mg, 0) in DCE (18 mL) .90 mmol) and powder 4Å molecular sieves were stirred at room temperature. After 4 hours, sodium triacetoxyborohydride (318 mg, 1.50 mmol) was added and the resulting mixture was stirred for an additional 17 hours. The reaction mixture was filtered through Celite®, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, and then the desired product was eluted with 2M NH ₃ / MeOH in DCM. The resulting residue with EtOAc was triturated to give 4- (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -3-isopropylpiperazin-2-one as yellow Obtained as an oil (198 mg, 65%). LCMS (Method H): R _T = 2.82 min, [M + H] ⁺ 408.4.

ＴＨＦ（８０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（２．９５ｇ、１１．７ｍｍｏｌ）及びＴＭＥＤＡ（２．６ｍＬ、２．０３ｇ、１７．５ｍｍｏｌ）の懸濁液を−７８℃に冷却した後、ｎ-ＢｕＬｉ（９．８ｍＬ、２４．５ｍｍｏｌ、ヘキサン中２．５Ｍの溶液）を滴下して加えた。生じた混合物を−４０℃まで温め、４０分間攪拌した。混合物を−７８℃まで再び冷却し、１-クロロ-２-ヨードエタン（３．７ｍＬ、７．８ｇ、４０．８ｍｍｏｌ）を加えた。生じた混合物を２時間以上かけて室温まで温めた後、ＮＨ_４Ｃｌでクエンチして、ＥｔＯＡｃ（×４）で抽出した。組み合わせた有機物を乾燥し（Ｎａ_２ＳＯ_４）、真空下で濃縮し、２-クロロ-８-ヨード-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンを黄色固形物として得た（４．０２ｇ、９１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ４．０９分［Ｍ＋Ｈ］^＋３７９．９ Example 75 kk 2-chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine

Of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.95 g, 11.7 mmol) and TMEDA (2.6 mL, 2.03 g, 17.5 mmol) in THF (80 mL). After the suspension was cooled to −78 ° C., n-BuLi (9.8 mL, 24.5 mmol, 2.5 M solution in hexane) was added dropwise. The resulting mixture was warmed to −40 ° C. and stirred for 40 minutes. The mixture was cooled again to −78 ° C. and 1-chloro-2-iodoethane (3.7 mL, 7.8 g, 40.8 mmol) was added. The resulting mixture was allowed to warm to room temperature over 2 h before being quenched with NH ₄ Cl and extracted with EtOAc (× 4). The combined organics were dried (Na ₂ SO ₄ ) and concentrated in vacuo to give 2-chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine as a yellow solid ( 4.02 g, 91%). LCMS (Method H): R _T 4.09 min [M + H] ⁺ 379.9

ジオキサン（９０ｍＬ）中のクロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（４．０ｇ１５．８ｍｍｏｌ）、２−エチルベンゾイミダゾール（２．８ｇ、１９．０ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（７２４ｍｇ、０．７９ｍｍｏｌ）、Ｘｐｈｏｓ（１．５ｇ、３．１６ｍｍｏｌ）及びＣｓ_２ＣＯ_３（１０．３ｇ、３１．６ｍｍｏｌ）の混合物にアルゴンをパージした後、１２０℃で１６時間シールした反応器で加熱した。反応混合物をセライトのパッドで濾過し、ＥｔＯＡｃで洗浄した。濾液を真空下で濃縮し、カラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンをオレンジ色の固形物として得た（３．４９ｇ、９６％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．４６分，［Ｍ＋Ｈ］^＋３６４．５ Example 75ll 2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine

Chloro-9-methyl-6-morpholin-4-yl-9H-purine (4.0 g 15.8 mmol), 2-ethylbenzimidazole (2.8 g, 19.0 mmol), tris (dibenzylidene) in dioxane (90 mL) A mixture of acetone) dipalladium (724 mg, 0.79 mmol), Xphos (1.5 g, 3.16 mmol) and Cs ₂ CO ₃ (10.3 g, 31.6 mmol) was purged with argon and then at 120 ° C. for 16 hours. Heated in a sealed reactor. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give 2- (2-ethylbenzimidazol-1-yl) -9-methyl-6- Morpholin-4-yl-9H-purine was obtained as an orange solid (3.49 g, 96%). LCMS (Method H): R _T 3.46 min, [M + H] ⁺ 364.5.

ＴＨＦ（２５ｍＬ）中の２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１．６７ｇ、４．５８ｍｍｏｌ）及びＴＭＥＤＡ（１．０ｍＬ、７９９ｍｇ、６．８８ｍｍｏｌ）の懸濁液を−７８℃まで冷却した後、ｎ-ＢｕＬｉ（２．８ｍＬ、６．８８ｍｍｏｌ、ヘキサン中２．５Ｍの溶液）を滴下して加えた。生じた混合物を４０分間攪拌した後、１-クロロ-２-ヨードエタン（６２９μＬ、１．３ｇ、６．８８ｍｍｏｌ）を加えた。生じた混合物を−７８℃で１時間攪拌した後、Ｈ_２Ｏでクエンチし、室温まで温めた。淡黄色の沈殿物を濾過により回収し、更にＨ_２Ｏで洗浄して濾過し、真空下５０℃で乾燥させた。２-(２-エチルベンゾイミダゾール-１-イル)-８-ヨード-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンを淡黄色粉末として得た（２．０ｇ、９０％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．７４分［Ｍ＋Ｈ］^＋４９０．２ Example 75 mm 2- (2-Ethylbenzimidazol-1-yl) -8-iodo-9-methyl-6-morpholin-4-yl-9H-purine

2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (1.67 g, 4.58 mmol) and TMEDA (1.0 mL) in THF (25 mL). , 799 mg, 6.88 mmol) was cooled to −78 ° C. and then n-BuLi (2.8 mL, 6.88 mmol, 2.5 M solution in hexane) was added dropwise. The resulting mixture was stirred for 40 minutes before 1-chloro-2-iodoethane (629 μL, 1.3 g, 6.88 mmol) was added. The resulting mixture was stirred at −78 ° C. for 1 h before being quenched with H ₂ O and warmed to room temperature. A pale yellow precipitate was collected by filtration, further washed with H ₂ O, filtered and dried at 50 ° C. under vacuum. 2- (2-Ethylbenzimidazol-1-yl) -8-iodo-9-methyl-6-morpholin-4-yl-9H-purine was obtained as a pale yellow powder (2.0 g, 90%). LCMS (Method H): R _T 2.74 min [M + H] ⁺ 490.2.

ＤＣＥ（１０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（１６５ｍｇ、０．５９ｍｍｏｌ）、１-(テトラヒドロピラン-４-イル)ピペラジン（１１０ｍｇ、０．６５ｍｍｏｌ）及びモレキュラーシーブ（４Å、粉末、７５０ｍｇ）の混合物を雰囲気温度で４時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（１７０ｍｇ、０．８０ｍｍｏｌ）を加え、混合物を１８時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをついでメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出させた。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ、１００：０から９８：２から９５：５から９０：１０）で精製して、２-クロロ-９-メチル-６-モルホリン-４-イル-８-[４-(テトラヒドロピラン-４-イル)ピペラジン-１-イルメチル]-９Ｈ-プリンを白色固形物として得た（２５０ｍｇ、９８％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．２７（ｍ，４Ｈ），４．０１（ｄｄ，Ｊ＝１１．５，４．２Ｈｚ，２Ｈ），３．８１（ｍ，７Ｈ），３．６９（ｓ，２Ｈ），３．３６（ｄｄ，Ｊ＝１２．５，１０．９Ｈｚ，２Ｈ），２．５５（ｍ，８Ｈ），２．４０（ｍ，１Ｈ），１．７５（ｄ，Ｊ＝１２．５Ｈｚ，２Ｈ）及び１．５６（ｍ，２Ｈ） Example 75nn 2-Chloro-9-methyl-6-morpholin-4-yl-8- [4- (tetrahydropyran-4-yl) piperazin-1-ylmethyl] -9H-purine

2-Chloro-9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (165 mg, 0.59 mmol), 1- (tetrahydropyran-4-yl) piperazine (10 mL) in DCE (10 mL) 110 mg, 0.65 mmol) and molecular sieves (4 kg, powder, 750 mg) were stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (170 mg, 0.80 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 95: 5 to 90:10) to give 2-chloro-9-methyl-6-morpholine- 4-yl-8- [4- (tetrahydropyran-4-yl) piperazin-1-ylmethyl] -9H-purine was obtained as a white solid (250 mg, 98%). ¹ H NMR (CDCl ₃ , 400 MHz) δ 4.27 (m, 4H), 4.01 (dd, J = 11.5, 4.2 Hz, 2H), 3.81 (m, 7H), 3.69 ( s, 2H), 3.36 (dd, J = 12.5, 10.9 Hz, 2H), 2.55 (m, 8H), 2.40 (m, 1H), 1.75 (d, J = 12.5Hz, 2H) and 1.56 (m, 2H)

８-ブロモメチル-２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（３．９２ｇ、１１．３ｍｍｏｌ）及び亜リン酸トリメチル（２０ｍＬ、ｍｍｏｌ）の混合物を２時間還流下で加熱した（１２０℃）。反応混合物を真空下で濃縮させて蛍光緑の固体とし、これをＨ_２Ｏで倍散した。生じた淡緑色の固形物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、表題化合物を緑色固形物を得た（３．３６ｇ、７９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．４５分［Ｍ＋Ｈ］^＋３７６．１ Example 76a (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) phosphonic acid dimethyl ester

A mixture of 8-bromomethyl-2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (3.92 g, 11.3 mmol) and trimethyl phosphite (20 mL, mmol) was refluxed for 2 hours. Heated (120 ° C.). The reaction mixture was concentrated in vacuo to a fluorescent green solid that was triturated with H ₂ O. The resulting pale green solid was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a green solid (3.36 g, 79%). LCMS (Method A): R _T 3.45 min [M + H] ⁺ 376.1.

ＴＨＦ（３ｍＬ）中のジイソプロピルアミン（１．４ｍＬ、９．８ｍｍｏｌ）の溶液に−７８℃でｎ-ＢｕＬｉ（３．９ｍＬ、９．８ｍｍｏｌ、ヘキサン中２．５Ｍ）を加え、生じた混合物を２０分間攪拌した。生じた溶液を−７８℃でＴＨＦ（８０ｍＬ）中の淡い緑色の溶液(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル)ホスホン酸ジメチルエステル（３．３６ｇ、８．９ｍｍｏｌ）に加えた。生じた混合物を室温に温めた後、ＴＨＦ（１０ｍＬ）中の３-オキソ-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．７６ｇ、１０．２ｍｍｏｌ）の溶液を加えた。生じたピンク色の混合物を１６時間攪拌した後、Ｈ_２Ｏでクエンチした。混合物を真空下で濃縮し、残留物をＤＣＭ及びブラインの間で分配した。有機相を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−７０％）で精製し、表題化合物を緑色の粉末として得た（３．４６ｇ、９２％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ６．３３−６．３２（１Ｈ，ｍ），４．９１−４．９０（２Ｈ，ｍ），４．７１−４．７０（２Ｈ，ｍ），４．２８（４Ｈ，ｂｒｄｓ），３．８１（４Ｈ，ｔ，Ｊ＝４．７４Ｈｚ），３．７１（３Ｈ，ｓ），１．４８（９Ｈ，ｓ）。 Example 76b 3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester

To a solution of diisopropylamine (1.4 mL, 9.8 mmol) in THF (3 mL) at −78 ° C. was added n-BuLi (3.9 mL, 9.8 mmol, 2.5 M in hexanes) and the resulting mixture was added to 20 Stir for minutes. The resulting solution was a pale green solution (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) phosphonic acid dimethyl ester in THF (80 mL) at −78 ° C. (3. 36 g, 8.9 mmol). After the resulting mixture was warmed to room temperature, a solution of 3-oxo-azetidine-1-carboxylic acid tert-butyl ester (1.76 g, 10.2 mmol) in THF (10 mL) was added. The resulting pink mixture was stirred for 16 hours and then quenched with H ₂ O. The mixture was concentrated under vacuum and the residue was partitioned between DCM and brine. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-70%) to give the title compound as a green powder (3.46 g, 92%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 6.33-6.32 (1H, m), 4.91-4.90 (2H, m), 4.71-4.70 (2H, m), 4 .28 (4H, brds), 3.81 (4H, t, J = 4.74 Hz), 3.71 (3H, s), 1.48 (9H, s).

ジオキサン（１５ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．４ｇ、３．３３ｍｍｏｌ）、２-エチルベンゾイミダゾール（５８４ｍｇ、３．９９ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（１５２ｍｇ、０．１７ｍｍｏｌ）、ＸＰｈｏｓ（３１７ｍｇ、０．６６ｍｍｏｌ）及びＣｓ_２ＣＯ_３（２．１７ｇ、６．６５ｍｍｏｌ）の混合物にアルゴンをパージし、シールしたチューブ中で１２０℃で１６時間加熱した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄し、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−１００％）で精製して、表題化合物をクリーム状の固形物として得た（１．１ｇ、６２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．２０分［Ｍ＋Ｈ］^＋５３１．４ Example 76c 3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine-1-carboxylic acid tert-butyl ester

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (1.4 g, 3. mL) in dioxane (15 mL). 33 mmol), 2-ethylbenzimidazole (584 mg, 3.99 mmol), tris (dibenzylideneacetone) dipalladium (152 mg, 0.17 mmol), XPhos (317 mg, 0.66 mmol) and Cs ₂ CO ₃ (2.17 g, 6.65 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 16 hours. The reaction mixture was filtered through Celite®, washed with EtOAc, and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-100%) to give the title compound as a creamy solid (1.1 g, 62%). LCMS (Method H): R _T 3.20 min [M + H] ⁺ 531.4

ＥｔＯＨ（４０ｍＬ）及びＡｃＯＨ（１５ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．１ｇ、２．０７ｍｍｏｌ）の溶液に１０％Ｐｄ／Ｃ（２００ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で６５時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄し、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、７０−１００％）で精製して、表題化合物をオレンジ色の油として得た（０．９２ｇ、８３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．０１分［Ｍ＋Ｈ］^＋５３３．４ Example 76d 3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert-butyl ester

3- [2- (2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine- in EtOH (40 mL) and AcOH (15 mL) To a solution of 1-carboxylic acid tert-butyl ester (1.1 g, 2.07 mmol) was added 10% Pd / C (200 mg) and the resulting mixture was stirred for 65 h under H ₂ atmosphere. The reaction mixture was filtered through Celite®, washed with EtOAc, and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 70-100%) to give the title compound as an orange oil (0.92 g, 83%). LCMS (Method H): R _T 3.01 min [M + H] ⁺ 533.4.

ＤＣＭ（６ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（９１７ｍｇ、１．７２ｍｍｏｌ）の溶液にＴＦＡ（３ｍＬ）を加え、生じた混合物を室温で３時間攪拌した。反応混合物をＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、表題化合物を無色の油として得た（６４７ｍｇ、８７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．８３分［Ｍ＋Ｈ］^＋４３３．３ Example 76e 8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert in DCM (6 mL) To a solution of -butyl ester (917 mg, 1.72 mmol) was added TFA (3 mL) and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give the title compound as a colorless oil (647 mg, 87%) . LCMS (Method H): R _T 1.83 min [M + H] ⁺ 433.3.

ＤＭＦ（１．５ｍＬ）中の２-イソプロピル-３-オキソピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５８ｍｇ、０．２４ｍｍｏｌ）の溶液に０℃でＮａＨ（１１ｍｇ、０．２９ｍｍｏｌ、鉱油中６０％の分散液）を加え、生じた混合物を室温で３０分間攪拌した後、ＤＭＦ（１．５ｍＬ）中の８-ブロモメチル-２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１００ｍｇ、０．２２ｍｍｏｌ）を加えた。得られた混合物を１９時間攪拌した後、ＥｔＯＡｃ及びＨ_２Ｏの間で分配した。有機相を乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、表題化合物を黄色油として得た（１０４ｍｇ、７７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．０３分［Ｍ＋Ｈ］^＋６１８．４ Example 76f 4- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -2-isopropyl-3-oxopiperazine- 1-carboxylic acid tert-butyl ester

To a solution of 2-isopropyl-3-oxopiperazine-1-carboxylic acid tert-butyl ester (58 mg, 0.24 mmol) in DMF (1.5 mL) at 0 ° C. NaH (11 mg, 0.29 mmol, 60% in mineral oil) And the resulting mixture was stirred at room temperature for 30 minutes and then 8-bromomethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6 in DMF (1.5 mL). -Morpholin-4-yl-9H-purine (100 mg, 0.22 mmol) was added. The resulting mixture was stirred for 19 hours and then partitioned between EtOAc and H ₂ O. The organic phase was dried (MgSO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a yellow oil (104 mg, 77%). LCMS (Method H): R _T 3.03 min [M + H] ⁺ 618.4

ＤＣＥ（１５ｍＬ）中の(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)アセトアルデヒド（２１０ｍｇ、０．７１ｍｍｏｌ）、メチル-(３-メチル-１,１-ジオキソテトラヒドロチオフェン-３-イル)アミン（１１６ｍｇ、０．７１ｍｍｏｌ）、トリアセトキシ水素化ホウ素ナトリウム（３０１ｍｇ、１．４２ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（２８０ｍｇ）の混合物を２３時間攪拌した。反応混合物をセライト（登録商標）で濾過し、濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、表題化合物を淡黄色の固形物として得た（８７ｍｇ、２８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．０１分［Ｍ＋Ｈ］^＋４４３．２ Example 76g [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] methyl- (3-methyl-1,1-dioxotetrahydrothiophene-3 -Il) amine

(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (210 mg, 0.71 mmol), methyl- (3-methyl-1,1) in DCE (15 mL) A mixture of -dioxotetrahydrothiophen-3-yl) amine (116 mg, 0.71 mmol), sodium triacetoxyborohydride (301 mg, 1.42 mmol) and 4Å powdered molecular sieves (280 mg) was stirred for 23 hours. The reaction mixture was filtered through Celite® and the filtrate was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a pale yellow solid (87 mg, 28%). LCMS (Method H): R _T 2.01 min [M + H] ⁺ 443.2

ＤＭＦ（２０ｍＬ）中の８-ブロモメチル-２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（４００ｍｇ、１．１６ｍｍｏｌ）、３,３-ジメチルピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２５０ｍｇ、１．１７ｍｍｏｌ）及びＫ_２ＣＯ_３（１７６ｍｇ、１．２８ｍｍｏｌ）の混合物を室温で１６時間攪拌した。反応混合物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製し、表題化合物を得た（１５０ｍｇ、２７％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ４．２６（４Ｈ，ｂｒｄｓ），３．８２−３．８０（９Ｈ，ｍ），３．３３（２Ｈ，ｂｒｄｓ），３．２２（２Ｈ，ｂｒｄｓ），２．４２−２．３５（２Ｈ，ｍ），１．４５（９Ｈ，ｓ），１．１５（６Ｈ，ｓ）。 Example 76h 4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester

8-Bromomethyl-2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (400 mg, 1.16 mmol), 3,3-dimethylpiperazine-1-carboxylic acid tert- in DMF (20 mL) A mixture of butyl ester (250 mg, 1.17 mmol) and K ₂ CO ₃ (176 mg, 1.28 mmol) was stirred at room temperature for 16 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that was washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound (150 mg, 27%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 4.26 (4H, brds), 3.82-3.80 (9H, m), 3.33 (2H, brds), 3.22 (2H, brds), 2.42-2.35 (2H, m), 1.45 (9H, s), 1.15 (6H, s).

ＤＣＭ（３０ｍＬ）中の４-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル)-３,３-ジメチル-ピペラジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２８８ｍｇ、０．６０ｍｍｏｌ）の溶液にＴＦＡ（３ｍＬ）を加え、混合物を室温で１時間攪拌した。反応混合物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨに溶出させ、表題化合物を白色固形物（１９９ｍｇ、８７％）として得た。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ４．２６（４Ｈ，ｂｒｄ ｓ），３．８４−３．７７（９Ｈ，ｍ），２．８４（２Ｈ，ｔ，Ｊ＝４．８７Ｈｚ），２．７４（２Ｈ，ｓ），２．４３（２Ｈ，ｔ，Ｊ＝４．８９Ｈｚ），１．２１（６Ｈ，ｓ）。 Example 76i 2-Chloro-8- (2,2-dimethylpiperazin-1-ylmethyl) -9-methyl-6-morpholin-4-yl-9H-purine

4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -3,3-dimethyl-piperazine-1-carboxylic acid tert-butyl ester in DCM (30 mL) To a solution of (288 mg, 0.60 mmol) was added TFA (3 mL) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH to give the title compound as a white solid (199 mg, 87%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 4.26 (4H, brds), 3.84-3.77 (9H, m), 2.84 (2H, t, J = 4.87 Hz), 2. 74 (2H, s), 2.43 (2H, t, J = 4.89 Hz), 1.21 (6H, s).

ＤＣＥ（１０ｍＬ）中の２-クロロ-８-(２,２-ジメチルピペラジン-１-イルメチル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１９８ｍｇ、０．５２ｍｍｏｌ）、オキセタン-３-オン（４２ｍｇ、０．５８ｍｍｏｌ）及び４Å粉末化モレキュラーシーブの混合物を室温で４時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（１４４ｍｇ、０．６８ｍｍｏｌ）を加えた。反応混合物を１６時間攪拌し、ついでＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させ、表題化合物を得た（１９２ｍｇ、８５％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ４．６３（２Ｈ，ｔ，Ｊ＝６．４８Ｈｚ），４．５５（２Ｈ，ｔ，Ｊ＝６．０８Ｈｚ），４．２７（４Ｈ，ｂｒｄ ｓ），３．８４−３．８０（７Ｈ，ｍ），３．４９（２Ｈ，ｓ），３．３８−３．３７（１Ｈ，ｍ），２．５０−２．４０（２Ｈ，ｍ），２．２３−２．０４（４Ｈ，ｍ），１．２０（６Ｈ，ｓ） Example 76j 2-chloro-8- (2,2-dimethyl-4-oxetane-3- ylpiperazin -1-ylmethyl) -9-methyl-6-morpholin-4-yl-9H-purine

2-Chloro-8- (2,2-dimethylpiperazin-1-ylmethyl) -9-methyl-6-morpholin-4-yl-9H-purine (198 mg, 0.52 mmol), oxetane-in DCE (10 mL) A mixture of 3-one (42 mg, 0.58 mmol) and 4Å powdered molecular sieve was stirred at room temperature for 4 hours, after which sodium triacetoxyborohydride (144 mg, 0.68 mmol) was added. The reaction mixture was stirred for 16 hours and then loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product eluted with 2M NH ₃ / MeOH to give the title compound (192 mg, 85%) . ¹ H NMR (CDCl ₃ , 400 MHz): δ 4.63 (2H, t, J = 6.48 Hz), 4.55 (2H, t, J = 6.08 Hz), 4.27 (4H, brds), 3.84-3.80 (7H, m), 3.49 (2H, s), 3.38-3.37 (1H, m), 2.50-2.40 (2H, m), 2. 23-2.04 (4H, m), 1.20 (6H, s)

ＤＣＭ（３ｍＬ）中の８-(２,２-ジメチルピペラジン-１-イルメチル)-２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１４０ｍｇ、０．２９ｍｍｏｌ）、１-アミノシクロプロパンカルボン酸（６４ｍｇ、０．３２ｍｍｏｌ）、ＨＡＴＵ（１２０ｍｇ、０．３２ｍｍｏｌ）及びＤＩＰＥＡ（５６μＬ、０．３２ｍｍｏｌ）の混合物を室温で６０時間攪拌した。反応混合物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−２％）で精製し、表題化合物を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．５６分，［Ｍ＋Ｈ］^＋６７３．７ Example 76k (1- {4- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -3,3-dimethyl Piperazine-1-carbonyl} cyclopropyl) carbamic acid tert-butyl ester

8- (2,2-Dimethylpiperazin-1-ylmethyl) -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (3 mL) (140 mg, 0.29 mmol) A mixture of 1-aminocyclopropanecarboxylic acid (64 mg, 0.32 mmol), HATU (120 mg, 0.32 mmol) and DIPEA (56 μL, 0.32 mmol) was stirred at room temperature for 60 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that was washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-2%) to give the title compound. LCMS (Method H): R _T 2.56 min, [M + H] ⁺ 673.7.

ＥｔＯＨ（１６ｍＬ）中の２-(２-シクロプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルバルデヒド（５００ｍｇ、１．２４ｍｍｏｌ）の懸濁液にＡｇＮＯ_３（２６５ｍｇ、１．５６ｍｍｏｌ）を加え、続いてＨ_２Ｏ（５ｍＬ）中のＮａＯＨ（３０２ｍｇ、７．５ｍｍｏｌ）の溶液を加えた。生じた黒色の懸濁液を３０分間室温で攪拌した後、セライト（登録商標）で濾過し、生じた濾液を真空下で濃縮した。生じた残留物をＨ_２Ｏに溶解し、ＮａＯＨ水溶液の添加により塩基性にした。水性相をＤＣＭで抽出し、ついでＨＣｌでｐＨ２まで酸性化した。水性相を真空下で半分量まで濃縮した後、氷上で冷却した。生じた沈殿物を濾過により回収して、真空下で乾燥させ、表題化合物を得た（２８０ｍｇ、５５％）。^１Ｈ ＮＭＲ（ＤＭＳＯ，４００ＭＨｚ）：δ８．１２−８．１１（１Ｈ，ｍ），７．７２−７．６８（１Ｈ，ｍ），７．４４−７．４３（２Ｈ，ｍ），４．６０（４Ｈ，ｂｒｄ ｓ），４．０４（３Ｈ，ｓ），３．９０−３．７０（４Ｈ，ｍ），３．０６−３．００（１Ｈ，ｍ），１．３３−１．３１（４Ｈ，ｍ） Example 76l 2- (2-cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylic acid

Suspension of 2- (2-cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (500 mg, 1.24 mmol) in EtOH (16 mL) To the suspension was added AgNO ₃ (265 mg, 1.56 mmol) followed by a solution of NaOH (302 mg, 7.5 mmol) in H ₂ O (5 mL). The resulting black suspension was stirred for 30 minutes at room temperature and then filtered through Celite® and the resulting filtrate was concentrated in vacuo. The resulting residue was dissolved in H ₂ O and made basic by addition of aqueous NaOH. The aqueous phase was extracted with DCM and then acidified to pH 2 with HCl. The aqueous phase was concentrated to half volume under vacuum and then cooled on ice. The resulting precipitate was collected by filtration and dried under vacuum to give the title compound (280 mg, 55%). ¹ H NMR (DMSO, 400 MHz): δ 8.12-8.11 (1H, m), 7.72-7.68 (1H, m), 7.44-7.43 (2H, m), 4. 60 (4H, brd s), 4.04 (3H, s), 3.90-3.70 (4H, m), 3.06-3.00 (1H, m), 1.33-1.31 (4H, m)

ＤＣＥ（６０ｍＬ）及びＤＭＦ（２０ｍＬ）中の２-クロロ-６-モルホリン-４-イル-９-(テトラヒドロピラン-２-イル)-９Ｈ-プリン-８-カルバルデヒド（１．０６ｇ、３．０１ｍｍｏｌ）及び４-アゼチジン-３-イルピペラジン-２-オン（５６０ｍｇ、３．６１ｍｍｏｌ）の混合物を室温で１０分間攪拌した後、４Å粉末化モレキュラーシーブ（３．０ｇ）を加え、続いてトリアセトキシ水素化ホウ素ナトリウム（１．２８ｇ、６．０４ｍｍｏｌ）を加えた。生じた混合物を６４時間攪拌した後、セライト（登録商標）で濾過し、ＤＣＭで洗浄した。濾液を真空下で濃縮し、生じた残留物をＥｔＯＡｃに溶解させ、ＮａＨＣＯ_３、Ｈ_２Ｏ及びブラインで洗浄した。有機相を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮し、表題化合物を黄色ガムとして得た（９９７ｍｇ、６７％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．１９及び２．１１分［Ｍ−Ｃ_５Ｈ_９Ｏ＋Ｈ］^＋４０７．３ Example 76m 4- {1- [2-chloro-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purin-8-ylmethyl] azetidin-3-yl} piperazine-2- on

2-Chloro-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine-8-carbaldehyde (1.06 g, 3.01 mmol) in DCE (60 mL) and DMF (20 mL) ) And 4-azetidin-3-ylpiperazin-2-one (560 mg, 3.61 mmol) was stirred at room temperature for 10 minutes, followed by addition of 4Å powdered molecular sieves (3.0 g) followed by triacetoxyhydrogen. Sodium borohydride (1.28 g, 6.04 mmol) was added. The resulting mixture was stirred for 64 hours, then filtered through Celite® and washed with DCM. The filtrate was concentrated in vacuo and the resulting residue was dissolved in EtOAc and washed with NaHCO ₃ , H ₂ O and brine. The organic phase was dried (Na ₂ SO ₄ ) and concentrated in vacuo to give the title compound as a yellow gum (997 mg, 67%). LCMS (Method _A): R T 2.19 and 2.11 min ^{_{[M-C 5 H 9 O}} + H] + 407.3

ジオキサン（３０ｍＬ）中の４-{１-[２-クロロ-６-モルホリン-４-イル-９-(テトラヒドロピラン-２-イル)-９Ｈ-プリン-８-イルメチル]アゼチジン-３-イル}ピペラジン-２-オン（９９０ｍｇ、２．００ｍｍｏｌ）、２-エチルベンゾイミダゾール（３２２ｍｇ、２．２０ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（４６ｍｇ、０．０５ｍｍｏｌ）、ＸＰｈｏｓ（９５ｍｇ、０．２０ｍｍｏｌ）及びＣｓ_２ＣＯ_３（９８０ｍｇ、３．０１ｍｍｏｌ）の混合物にアルゴンをパージし、ついで１１５℃で６時間加熱した後、室温で１６時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ジオキサンで洗浄して、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物を得た（４７０ｍｇ、３９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．０１及び１．９２分［Ｍ＋Ｈ］^＋６０１．６ Example 76n 4- {1- [2- (2-ethylbenzimidazol-1-yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purin-8-ylmethyl] Azetidin-3-yl} piperazin-2-one

4- {1- [2-Chloro-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purin-8-ylmethyl] azetidin-3-yl} piperazine in dioxane (30 mL) -2-one (990 mg, 2.00 mmol), 2-ethylbenzimidazole (322 mg, 2.20 mmol), tris (dibenzylideneacetone) dipalladium (46 mg, 0.05 mmol), XPhos (95 mg, 0.20 mmol) and A mixture of Cs ₂ CO ₃ (980 mg, 3.01 mmol) was purged with argon, then heated at 115 ° C. for 6 hours and then stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite®, washed with dioxane and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound (470 mg, 39%). LCMS (Method A): R _T 2.01 and 1.92 min [M + H] ⁺ 601.6.

ＴＨＦ（３０ｍＬ）中の２-クロロ-６-モルホリン-４-イル-９-(テトラヒドロピラン-２-イル)-９Ｈ-プリン（１．５０ｇ、４．６３ｍｍｏｌ）及びＴＭＥＤＡ（１．７２ｍＬ、６．９４ｍｍｏｌ）の溶液を−７８℃に冷却した後、ｎ-ＢｕＬｉ（６．０８ｍＬ、９．７３ｍｍｏｌ、ヘキサン中１．６Ｍの溶液）を滴下して加えた。生じた混合物を−７８℃で４８５分間攪拌し、１-クロロ-２-ヨードエタン（９０２μＬ、１６．２２ｍｍｏｌ）を加えた。生じた混合物を２．５時間以上かけて０℃まで温めた後、Ｈ_２Ｏでクエンチして、ＤＣＭで抽出した。組み合わせた有機物をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。残留物を^ｉＰｒＯＡｃで倍散し、生じた固体を濾過により回収して、表題化合物を得た（１．８０ｇ、８７％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．９０分［Ｍ＋Ｈ］^＋４５０．３ Example 76 o 2-Chloro-8-iodo-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine

2-Chloro-6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine (1.50 g, 4.63 mmol) and TMEDA (1.72 mL, 6.3 mL) in THF (30 mL). 94 mmol) was cooled to −78 ° C. and then n-BuLi (6.08 mL, 9.73 mmol, 1.6 M solution in hexane) was added dropwise. The resulting mixture was stirred at −78 ° C. for 485 minutes and 1-chloro-2-iodoethane (902 μL, 16.22 mmol) was added. The resulting mixture was warmed to 0 ° C. over 2.5 h, then quenched with H ₂ O and extracted with DCM. The combined organics were washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The residue was triturated with ⁱ PrOAc and the resulting solid was collected by filtration to give the title compound (1.80 g, 87%). LCMS (Method A): R _T 3.90 min [M + H] ⁺ 450.3

トルエン（４ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．４８ｍｍｏｌ）、２-メチルベンゾイミダゾール（７６ｍｇ、０．５７ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（４４ｍｇ、０．０６ｍｍｏｌ）、ＸＰｈｏｓ（５８ｍｇ、０．１０ｍｍｏｌ）及びＣｓ_２ＣＯ_３（３２０ｍｇ、０．９５ｍｍｏｌ）の混合物にアルゴンをパージし、マイクロ波反応器で１４０℃で２時間加熱した。反応混合物をセライト（登録商標）で濾過し、ＭｅＯＨで洗浄し、濾液を真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−１００％）で精製し、表題化合物をオフホワイトの固形物として得た（１５６ｍｇ、６４％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．１１分［Ｍ＋Ｈ］^＋５１７．３ Example 76p 3- [2- (2- Methylbenzimidazol -1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine-1-carboxylic acid tert-butyl ester

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (200 mg, 0.48 mmol) in toluene (4 mL) 2-methylbenzimidazole (76 mg, 0.57 mmol), tris (dibenzylideneacetone) dipalladium (44 mg, 0.06 mmol), XPhos (58 mg, 0.10 mmol) and Cs ₂ CO ₃ (320 mg, 0.95 mmol) The mixture was purged with argon and heated in a microwave reactor at 140 ° C. for 2 hours. The reaction mixture was filtered through Celite®, washed with MeOH and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-100%) to give the title compound as an off-white solid (156 mg, 64%). LCMS (Method A): R _T 3.11 min [M + H] ⁺ 517.3

ＥｔＯＨ（１０ｍＬ）及びＡｃＯＨ（３ｍＬ）中の３-[２-(２-メチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２０５ｍｇ、０．４０ｍｍｏｌ）の溶液に１０％Ｐｄ／Ｃ（４０ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で６５時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＭｅＯＨで洗浄し、濾液を真空下で濃縮して、表題化合物を得た（２０７ｍｇ、定量的）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．９２分［Ｍ＋Ｈ］^＋５１９．４ Example 76q 3- [2- (2- Methylbenzimidazol -1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert-butyl ester

3- [2- (2- (2-Methylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine- in EtOH (10 mL) and AcOH (3 mL) To a solution of 1-carboxylic acid tert-butyl ester (205 mg, 0.40 mmol) was added 10% Pd / C (40 mg) and the resulting mixture was stirred for 65 h under H ₂ atmosphere. The reaction mixture was filtered through Celite®, washed with MeOH, and the filtrate was concentrated in vacuo to give the title compound (207 mg, quantitative). LCMS (Method H): R _T 2.92 min [M + H] ⁺ 519.4

ＤＣＭ（５ｍＬ）中の３-[２-(２-メチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２０７ｍｇ、０．４０ｍｍｏｌ）の溶液にＴＦＡ（５ｍＬ）を加え、生じた混合物を２時間室温で攪拌した。反応混合物をＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出した。表題化合物を白色の泡として得た（１３１ｍｇ、８０％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．８１分［Ｍ＋Ｈ］^＋４１９．４ Example 76r 8-azetidin-3-ylmethyl-2- (2-methylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine

3- [2- (2-Methylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert in DCM (5 mL) To a solution of -butyl ester (207 mg, 0.40 mmol) was added TFA (5 mL) and the resulting mixture was stirred for 2 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH. The title compound was obtained as a white foam (131 mg, 80%). LCMS (Method H): R _T 1.81 min [M + H] ⁺ 419.4

ＴＨＦ（３ｍＬ）中の８-アゼチジン-３-イルメチル-２-(２-メチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１３１ｍｇ、０．３１ｍｍｏｌ）、酢酸１-クロロカルボニル-１-メチルエチルエステル（４５μＬ、０．３１ｍｍｏｌ）及びＮＥｔ_３（４０μＬ、０．３１ｍｍｏｌ）の混合物を室温で１６時間攪拌し、ついで真空下で濃縮した。生じた残留物をＤＣＭ及びＨ_２Ｏの間で分配し、有機相を乾燥（Ｎａ_２ＳＯ_４）させ、真空下で濃縮した。残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して、表題化合物を白色固形物として得た（１２５ｍｇ、７３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．５０分［Ｍ＋Ｈ］^＋５４７．５ Example 76s 1,1-Dimethyl-2- {3- [9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purin-8-ylmethyl] acetic acid Azetidin-1-yl} -2-oxoethyl ester

8-azetidin-3-ylmethyl-2- (2-methylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (131 mg, 0.31 mmol) in THF (3 mL) , A mixture of acetic acid 1-chlorocarbonyl-1-methylethyl ester (45 μL, 0.31 mmol) and NEt ₃ (40 μL, 0.31 mmol) was stirred at room temperature for 16 hours and then concentrated in vacuo. The resulting residue was partitioned between DCM and H ₂ O and the organic phase was dried (Na ₂ SO ₄ ) and concentrated in vacuo. The residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a white solid (125 mg, 73%). LCMS (Method H): R _T 2.50 min [M + H] ⁺ 547.5

トルエン（４ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２００ｍｇ、０．４８ｍｍｏｌ）、２-イソプロピルベンゾイミダゾール（９２ｍｇ、０．５７ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（４４ｍｇ、０．０６ｍｍｏｌ）、ＸＰｈｏｓ（５８ｍｇ、０．１０ｍｍｏｌ）及びＣｓ_２ＣＯ_３（３１０ｍｇ、０．９５ｍｍｏｌ）の混合物にアルゴンをパージし、ついで１４０℃で４５分間マイクロ波反応器で加熱した。反応混合物をセライト（登録商標）で濾過し、ＭｅＯＨで洗浄して、濾液を真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−１００％）で精製して、表題化合物をオフホワイトの固形物として得た（２５５ｍｇ、９９％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．４０分［Ｍ＋Ｈ］^＋５４５．３ Example 76t 3- [2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine-1-carboxylic acid tert-butyl ester

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (200 mg, 0.48 mmol) in toluene (4 mL) 2-Isopropylbenzimidazole (92 mg, 0.57 mmol), tris (dibenzylideneacetone) dipalladium (44 mg, 0.06 mmol), XPhos (58 mg, 0.10 mmol) and Cs ₂ CO ₃ (310 mg, 0.95 mmol) The mixture was purged with argon and then heated in a microwave reactor at 140 ° C. for 45 minutes. The reaction mixture was filtered through Celite®, washed with MeOH and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-100%) to give the title compound as an off-white solid (255 mg, 99%). LCMS (Method A): R _T 3.40 min [M + H] ⁺ 545.3

ＥｔＯＨ（１５ｍＬ）及びＡｃＯＨ（５ｍＬ）中の３-[２-(２-イソプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２５５ｍｇ、０．４７ｍｍｏｌ）の溶液に１０％Ｐｄ／Ｃ（５５ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で６５時間攪拌した。反応混合物をセライト（登録商標）で濾過し、ＭｅＯＨで洗浄して、真空下で濾過濃縮し、表題化合物を得た（２５６ｍｇ、定量的）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．１６分［Ｍ＋Ｈ］^＋５４７．４ Example 76u 3- [2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert-butyl ester

3- [2- (2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene] azetidine- in EtOH (15 mL) and AcOH (5 mL) To a solution of 1-carboxylic acid tert-butyl ester (255 mg, 0.47 mmol) was added 10% Pd / C (55 mg) and the resulting mixture was stirred for 65 h under H ₂ atmosphere. The reaction mixture was filtered through Celite®, washed with MeOH, and concentrated by filtration under vacuum to give the title compound (256 mg, quantitative). LCMS (Method A): R _T 3.16 min [M + H] ⁺ 547.4.

ＤＣＭ（５ｍＬ）中の３-[２-(２-イソプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２５６ｍｇ、０．４７ｍｍｏｌ）の溶液にＴＦＡ（５ｍＬ）を加え、生じた混合物を２時間室温で攪拌した。反応混合物を、ＭｅＯＨ／ＤＣＭで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出させ、表題化合物をオレンジ色の泡として得た（２０５ｍｇ、９７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．９１分［Ｍ＋Ｈ］^＋４４７．４ Example 76v 8-azetidin-3-ylmethyl-2- (2-isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine

3- [2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] azetidine-1-carboxylic acid tert in DCM (5 mL) To a solution of -butyl ester (256 mg, 0.47 mmol) was added TFA (5 mL) and the resulting mixture was stirred for 2 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give the title compound as an orange foam (205 mg, 97 %). LCMS (Method H): R _T 1.91 min [M + H] ⁺ 447.4.

ＴＨＦ（３ｍＬ）中の８-アゼチジン-３-イルメチル-２-(２-イソプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１００ｍｇ、０．２２ｍｍｏｌ）、酢酸１-クロロカルボニル-１-メチルエチルエステル（３２μＬ、０．２２ｍｍｏｌ）及びＮＥｔ_３（２９μＬ、０．２２ｍｍｏｌ）の混合物を１６時間室温で攪拌し、ついで真空下で濃縮した。生じた残留物をＤＣＭ及びＨ_２Ｏの間で分配し、有機相を乾燥し（Ｎａ_２ＳＯ_４）、真空下で濃縮した。残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−７％）で精製して、表題化合物を白色の泡として得た（９７ｍｇ、７５％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．６５分［Ｍ＋Ｈ］^＋５７５．３ Example 76w 1,1-Dimethyl-2- {3- [9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purin-8-ylmethyl] acetic acid Azetidin-1-yl} -2-oxoethyl ester

8-azetidin-3-ylmethyl-2- (2-isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (100 mg, 0.22 mmol) in THF (3 mL) , A mixture of acetic acid 1-chlorocarbonyl-1-methylethyl ester (32 μL, 0.22 mmol) and NEt ₃ (29 μL, 0.22 mmol) was stirred for 16 hours at room temperature and then concentrated in vacuo. The resulting residue was partitioned between DCM and H ₂ O and the organic phase was dried (Na ₂ SO ₄ ) and concentrated in vacuo. The residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-7%) to give the title compound as a white foam (97 mg, 75%). LCMS (Method A): R _T 2.65 min [M + H] ⁺ 575.3.

ＴＨＦ（１０ｍＬ）中の２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（５００ｍｇ、１．３８ｍｍｏｌ）及びＴＭＥＤＡ（３１２μＬ、２．０７ｍｍｏｌ）の溶液に−７８℃でｎ-ＢｕＬｉ（６６０μＬ、１．６５ｍｍｏｌ、ヘキサン中２．５Ｍの溶液）を加え、生じた混合物を３０分間攪拌した後、ＴＨＦ（５ｍＬ）中の４-(メトキシメチルカルバモイル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５６４ｍｇ、２．０７ｍｍｏｌ）の溶液を加えた。生じた混合物を２時間攪拌した後、Ｈ_２Ｏをクエンチして、ＥｔＯＡｃで抽出した。組み合わせた有機相を乾燥させ（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をＥｔＯＡｃ：シクロヘキサンで倍散し、母液を真空下で濃縮して、表題化合物を油として得た（７６０ｍｇ、９６％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．６７分［Ｍ＋Ｈ］^＋５５７．３ Example 77a 4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl] piperidine-1-carboxylic acid tert-butyl ester

2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (500 mg, 1.38 mmol) and TMEDA (312 μL, 2.07 mmol) in THF (10 mL). N-BuLi (660 μL, 1.65 mmol, 2.5 M solution in hexane) at −78 ° C. and the resulting mixture was stirred for 30 minutes before 4- (methoxymethyl in THF (5 mL). A solution of carbamoyl) piperidine-1-carboxylic acid tert-butyl ester (564 mg, 2.07 mmol) was added. The resulting mixture was stirred for 2 hours before quenching H ₂ O and extracting with EtOAc. The combined organic phases were dried (MgSO ₄ ) and concentrated under vacuum. The resulting residue was triturated with EtOAc: cyclohexane and the mother liquor was concentrated in vacuo to give the title compound as an oil (760 mg, 96%). LCMS (Method A): R _T 3.67 min [M + H] ⁺ 557.3.

ＴＨＦ（３ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルボニル]ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１７７ｍｇ、０．３１ｍｍｏｌ）の溶液に０℃でメチル臭化マグネシウム（１３０μＬ、０．３７ｍｍｏｌ、Ｅｔ_２Ｏ中３Ｍの溶液）を加え、生じた混合物を１時間攪拌した後、更にメチル臭化マグネシウム（１３０μＬ、０．３７ｍｍｏｌ）を加えた。反応混合物を室温まで温め、１６時間攪拌した後、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製して表題化合物を透明の油として得た（１０４ｍｇ、５７％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．０９分［Ｍ＋Ｈ］^＋５９１．２ Example 77b 4- {1- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -1-hydroxyethyl} piperidine -1-carboxylic acid tert-butyl ester

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl] piperidine-1-carboxylic acid tert in THF (3 mL) -Methyl magnesium bromide (130 μL, 0.37 mmol, 3M solution in Et ₂ O) was added to a solution of butyl ester (177 mg, 0.31 mmol) at 0 ° C. and the resulting mixture was stirred for 1 hour before adding more methyl Magnesium bromide (130 μL, 0.37 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for 16 hours before being concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as a clear oil (104 mg, 57%). LCMS (Method A): R _T 3.09 min [M + H] ⁺ 591.2

トルエン（３ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１８０ｍｇ、０．４３ｍｍｏｌ）、(Ｒ)-１-(１Ｈ-ベンゾイミダゾール-２-イル)エタノール（８４ｍｇ、０．５２ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（４０ｍｇ、０．０４ｍｍｏｌ）、ＸＰｈｏｓ（８２ｍｇ、０．１７ｍｍｏｌ）及びＣｓ_２ＣＯ_３（２７９ｍｇ、０．８６ｍｍｏｌ）の混合物にアルゴンをパージし、ついでマイクロ波反応器で１４０℃で１時間加熱した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄し、真空下で濾液を濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１５％）で精製し、表題化合物を得た（１６７ｍｇ、７２％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．２４分［Ｍ＋Ｈ］^＋５４７．４ Example 77c 3- {2- [2-((R) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene} azetidine -1-carboxylic acid tert-butyl ester

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (180 mg, 0.43 mmol) in toluene (3 mL) , (R) -1- (1H-benzimidazol-2-yl) ethanol (84 mg, 0.52 mmol), tris (dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol), XPhos (82 mg, 0.17 mmol) And a mixture of Cs ₂ CO ₃ (279 mg, 0.86 mmol) was purged with argon and then heated in a microwave reactor at 140 ° C. for 1 hour. The reaction mixture was filtered through Celite®, washed with EtOAc, and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give the title compound (167 mg, 72%). LCMS (Method A): R _T 3.24 min [M + H] ⁺ 547.4.

ＥｔＯＡｃ（５ｍＬ）及びＥｔＯＨ（５ｍＬ）中の３-{２-[２-((Ｒ)-１-ヒドロキシエチル)ベンゾイミダゾール-１-イル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン}アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１６７ｍｇ、０．３１ｍｍｏｌ）の溶液に２０％のＰｄ（ＯＨ）_２／Ｃ（１６０ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で１６時間攪拌した。反応混合物をセライト（登録商標）で濾過し、濾液を真空下で濃縮して表題化合物を得た（１５６ｍｇ、９３％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．０７分［Ｍ＋Ｈ］^＋５４９．４ Example 77d 3- {2- [2-((R) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl} azetidine -1-carboxylic acid tert-butyl ester

3- {2- [2-((R) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H in EtOAc (5 mL) and EtOH (5 mL) 20% Pd (OH) ₂ / C (160 mg) was added to a solution of -purin-8-ylmethylene} azetidine-1-carboxylic acid tert-butyl ester (167 mg, 0.31 mmol) and the resulting mixture was H ₂ atmosphere Stirred under for 16 hours. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo to give the title compound (156 mg, 93%). LCMS (Method A): R _T 3.07 min [M + H] ⁺ 549.4

ＤＣＭ（５ｍＬ）中の３-{２-[２-((Ｒ)-１-ヒドロキシエチル)ベンゾイミダゾール-１-イル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル}アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１５６ｍｇ、０．２８ｍｍｏｌ）の溶液にＴＦＡ（２ｍＬ）を加え、生じた混合物を室温で４５分間攪拌した。反応混合物を真空下で濃縮させ、生じた残留物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、表題化合物を得た（１１４ｍｇ、９０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ１．８０分［Ｍ＋Ｈ］^＋４４９．４ Example 77e (R) -1- [1- (8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl) -1H-benzimidazol-2-yl ]ethanol

3- {2- [2-((R) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purine-8- in DCM (5 mL) To a solution of ilmethyl} azetidine-1-carboxylic acid tert-butyl ester (156 mg, 0.28 mmol) was added TFA (2 mL) and the resulting mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH to give the title compound. (114 mg, 90%). LCMS (Method A): R _T 1.80 min [M + H] ⁺ 449.4

トルエン（３ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１８０ｍｇ、０．４３ｍｍｏｌ）、(Ｓ)-１-(１Ｈ-ベンゾイミダゾール-２-イル)エタノール（８４ｍｇ、０．５２ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（４０ｍｇ、０．０４ｍｍｏｌ）、ＸＰｈｏｓ（８２ｍｇ、０．１７ｍｍｏｌ）及びＣｓ_２ＣＯ_３（２７９ｍｇ、０．８６ｍｍｏｌ）の混合物にアルゴンをパージし、ついでマイクロ波反応器で１４０℃で１時間加熱した。更に、トリス（ジベンジリデンアセトン）ジパラジウム（４０ｍｇ、０．０４ｍｍｏｌ）及びＸＰｈｏｓ（８２ｍｇ、０．１７ｍｍｏｌ）を加え、混合物を１４０℃で更に１時間加熱した。反応混合物をセライト（登録商標）で濾過し、ＥｔＯＡｃで洗浄して、濾液を真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１５％）で精製し、表題化合物を得た（１２７ｍｇ、５５％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．２７分［Ｍ＋Ｈ］^＋５４７．４ Example 77f 3- {2- [2-((S) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene} azetidine -1-carboxylic acid tert-butyl ester

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethylene) azetidine-1-carboxylic acid tert-butyl ester (180 mg, 0.43 mmol) in toluene (3 mL) , (S) -1- (1H-benzimidazol-2-yl) ethanol (84 mg, 0.52 mmol), tris (dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol), XPhos (82 mg, 0.17 mmol) And a mixture of Cs ₂ CO ₃ (279 mg, 0.86 mmol) was purged with argon and then heated in a microwave reactor at 140 ° C. for 1 hour. Further tris (dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol) and XPhos (82 mg, 0.17 mmol) were added and the mixture was heated at 140 ° C. for an additional hour. The reaction mixture was filtered through Celite®, washed with EtOAc, and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give the title compound (127 mg, 55%). LCMS (Method A): R _T 3.27 min [M + H] ⁺ 547.4.

ＥｔＯＡｃ（５ｍＬ）及びＥｔＯＨ（５ｍＬ）中の３-{２-[２-((Ｓ)-１-ヒドロキシエチル)ベンゾイミダゾール-１-イル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチレン}アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１２７ｍｇ、０．２３ｍｍｏｌ）の溶液に２０％のＰｄ（ＯＨ）_２／Ｃ（１３０ｍｇ）を加え、生じた混合物をＨ_２雰囲気下で１８時間攪拌した。反応混合物をセライト（登録商標）で濾過し、濾液を真空下で濃縮して表題化合物を得た（１０９ｍｇ、８６％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．０６分［Ｍ＋Ｈ］^＋５４９．４ Example 77g 3- {2- [2-((S) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl} azetidine -1-carboxylic acid tert-butyl ester

3- {2- [2-((S) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H in EtOAc (5 mL) and EtOH (5 mL) 20% Pd (OH) ₂ / C (130 mg) was added to a solution of -purin-8-ylmethylene} azetidine-1-carboxylic acid tert-butyl ester (127 mg, 0.23 mmol) and the resulting mixture was H ₂ atmosphere Stirring under for 18 hours. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo to give the title compound (109 mg, 86%). LCMS (Method A): R _T 3.06 min [M + H] ⁺ 549.4

ＤＣＭ（５ｍＬ）中の３-{２-[２-((Ｓ)-１-ヒドロキシエチル)ベンゾイミダゾール-１-イル]-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル}アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１０９ｍｇ、０．２０ｍｍｏｌ）の溶液にＴＦＡ（２ｍＬ）を加え、生じた混合物を室温で４５分間攪拌した。反応混合物を真空下で濃縮させ、生じた残留物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、表題化合物を得た（７０ｍｇ、８０％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ１．８７分［Ｍ＋Ｈ］^＋４４９．４ Example 77h (S) -1- [1- (8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl) -1H-benzimidazol-2-yl ]ethanol

3- {2- [2-((S) -1-hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purine-8- in DCM (5 mL) To a solution of ilmethyl} azetidine-1-carboxylic acid tert-butyl ester (109 mg, 0.20 mmol) was added TFA (2 mL) and the resulting mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH to give the title compound. (70 mg, 80%). LCMS (Method A): R _T 1.87 min [M + H] ⁺ 449.4

Formula I (iv) Furano Intermediate (where (iv) X ¹ is CR ⁷ and X ² is O)

ＤＣＥ（１２ｍＬ）中の２-クロロ-４-モルホリン-４-イル-フロ[３,２-ｄ]ピリミジン-６-カルバルデヒド（３００ｍｇ、１．１２ｍｍｏｌ）及び２-ピペラジン-１-イルイソブチルアミド二塩酸塩（３２７ｍｇ、１．３３ｍｍｏｌ）の溶液を雰囲気温度で１時間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（３５８ｍｇ、１．６９ｍｍｏｌ）を加え、混合物を６時間攪拌し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。ついで、カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出させた。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９０：１０の勾配）で精製して、表題化合物を黄褐色の固形物として得た（３９０ｍｇ、８２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３９分，Ｍ＋Ｈ^＋＝４２３ Example 80a 2- [4- (2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] -isobutyramide

2-Chloro-4-morpholin-4-yl-furo [3,2-d] pyrimidine-6-carbaldehyde (300 mg, 1.12 mmol) and 2-piperazin-1-ylisobutyramide in DCE (12 mL) A solution of hydrochloride (327 mg, 1.33 mmol) was stirred at ambient temperature for 1 hour. Sodium triacetoxyborohydride (358 mg, 1.69 mmol) was added and the mixture was stirred for 6 hours and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 90:10) to give the title compound as a tan solid (390 mg, 82%). LCMS (Method H): R _T = 2.39 min, M + H ⁺ = 423

ＤＣＥ（１２ｍＬ）中の２-クロロ-４-モルホリン-４-イルフロ[３,２-ｄ]ピリミジン-６-カルバルデヒド（３００ｍｇ、１．１２ｍｍｏｌ）及び４-アゼチジン-３-イル-モルホリン（１９１ｍｇ、１．３４ｍｍｏｌ）の溶液を１時間雰囲気温度で攪拌した。トリアセトキシ水素化ホウ素ナトリウム（３５８ｍｇ、１．６９ｍｍｏｌ）を加え、混合物を６時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９０：１０の勾配）で精製して、表題化合物を黄褐色の固形物として得た（３５７ｍｇ、８１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．２６分，Ｍ＋Ｈ^＋＝３９４ Example 80b 2-Chloro-4-morpholin-4-yl-6- (3-morpholin-4-ylazetidin-1-ylmethyl) furo [3,2-d] -pyrimidine

2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidine-6-carbaldehyde (300 mg, 1.12 mmol) and 4-azetidin-3-yl-morpholine (191 mg, DCE (12 mL)) 1.34 mmol) was stirred at ambient temperature for 1 hour. Sodium triacetoxyborohydride (358 mg, 1.69 mmol) was added and the mixture was stirred for 6 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 90:10) to give the title compound as a tan solid (357 mg, 81%). LCMS (Method H): R _T = 2.26 min, M + H ⁺ = 394

ＤＣＥ（３ｍＬ）中の２-クロロ-４-モルホリン-４-イルフロ[３,２-ｄ]ピリミジン-６-カルバルデヒド（７８ｍｇ、０．２９ｍｍｏｌ）及び２-ピペリジン-４-イルプロパン-２-オール（５０ｍｇ、０．３５ｍｍｏｌ）の溶液を雰囲気温度で４５分間攪拌した。トリアセトキシ水素化ホウ素ナトリウム（９３ｍｇ、０．４４ｍｍｏｌ）を加え、混合物を２時間攪拌し、ついでＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをメタノールで洗浄し、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９８：２から９５：５）で精製して、表題化合物を黄褐色の固形物として得た（１１０ｍｇ、９６％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝２．３３分，Ｍ＋Ｈ^＋＝３９５． Example 80c 2- [1- (2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] -propan-2-ol

2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidine-6-carbaldehyde (78 mg, 0.29 mmol) and 2-piperidin-4-ylpropan-2-ol in DCE (3 mL) A solution of (50 mg, 0.35 mmol) was stirred at ambient temperature for 45 minutes. Sodium triacetoxyborohydride (93 mg, 0.44 mmol) was added and the mixture was stirred for 2 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 98: 2 to 95: 5) to give the title compound as a tan solid (110 mg, 96% ). LCMS (Method H): R _T = 2.33 min, M + H ⁺ = 395.

１,４-ジオキサン(１.６ｍＬ)中の２-[１-(２-クロロ-４-モルホリン-４-イルフロ[３,２-ｄ]ピリミジン-６-イルメチル)ピペリジン-４-イル]プロパン-２-オール（１４０ｍｇ、０．３６ｍｍｏｌ）、ヘキサブチル二すず（２６６μＬ、０．５３ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（２５ｍｇ、０．０３４ｍｍｏｌ）の混合物にアルゴンをパージし、ついで１５０℃で３０分間マイクロ波照射を施した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出させた。生成物を収集し、真空下で濃縮して表題化合物を得、これを更に精製せずに用いた（１４７ｍｇ、５４％）。ＬＣＭＳ（方法Ｈ）Ｒ_Ｔ＝３．７２分；［Ｍ＋Ｈ］^＋６４９（^１１６Ｓｎ）６５１（^１１８Ｓｎ） Example 80d 2- [1- (4-morpholin-4-yl-2- (tributylstannanyl) furo [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -propane -2-all

2- [1- (2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] propane- in 1,4-dioxane (1.6 mL) To a mixture of 2-ol (140 mg, 0.36 mmol), hexabutyldistin (266 μL, 0.53 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (25 mg, 0.034 mmol) Argon was purged, followed by microwave irradiation at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum to give the title compound, which was used without further purification (147 mg, 54%). LCMS (Method H) R _T = 3.72 min; [M + H] ⁺ 649 ( ¹¹⁶ Sn) 651 ( ¹¹⁸ Sn)

１,４-ジオキサン（２．３ｍＬ）中の２-クロロ-４-モルホリン-４-イル-６-(３-モルホリン-４-イルアゼチジン-１-イルメチル)フロ[３,２-ｄ]ピリミジン（２００ｍｇ、０．５１ｍｍｏｌ）、ヘキサブチルジチン（３８０μＬ、０．７５ｍｍｏｌ）、及びＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（３６ｍｇ、０．０５１ｍｍｏｌ）の混合物にアルゴンガスをパージし、１５０℃で３０分間マイクロ波照射を施した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをついでＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ；１００：０から９８：２から９５：５）で精製して、表題化合物を黄色油として得た（２２７ｍｇ、６９％）。ＬＣＭＳ（方法Ｈ）Ｒ_Ｔ＝３．７２分；［Ｍ＋Ｈ］^＋６４８（^１１６Ｓｎ）６５０（^１１８Ｓｎ） Example 80e 4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) -2- (trinanstannyl) furo [3,2-d] pyrimidine

2-Chloro-4-morpholin-4-yl-6- (3-morpholin-4-ylazetidin-1-ylmethyl) furo [3,2-d] pyrimidine (200 mg) in 1,4-dioxane (2.3 mL) , 0.51 mmol), hexabutylditine (380 μL, 0.75 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (36 mg, 0.051 mmol) purged with argon gas Then, microwave irradiation was performed at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 98: 2 to 95: 5) to give the title compound as a yellow oil (227 mg, 69%). LCMS (Method H) R _T = 3.72 min; [M + H] ⁺ 648 ( ¹¹⁶ Sn) 650 ( ¹¹⁸ Sn)

ＩＭＳ（５０ｍＬ）中の２,６-ジクロロ-９Ｈ-プリン（２．１８ｇ、１１．５３ｍｍｏｌ）、(Ｒ)-３-メチルモルホリン（１．４０ｇ１３．８４ｍｍｏｌ）及びＤＩＰＥＡ（２．５７ｍＬ、１４．９９ｍｍｏｌ）の混合物を８０℃で８時間加熱した。反応混合物を真空下で濃縮させて体積を減少させ、残留物をＥｔＯＡｃ及びＨ_２Ｏの間で分配した。有機相を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１０％）で精製し、表題化合物をオフホワイトの固形物として得た（９１４ｍｇ、３１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．５３分［Ｍ＋Ｈ］^＋２５４．３ Example 81a 2-Chloro-6-((R) -3-methylmorpholin-4-yl) -9H-purine

2,6-Dichloro-9H-purine (2.18 g, 11.53 mmol), (R) -3-methylmorpholine (1.40 g 13.84 mmol) and DIPEA (2.57 mL, 14.99 mmol) in IMS (50 mL). ) Was heated at 80 ° C. for 8 hours. The reaction mixture was concentrated in vacuo to reduce the volume and the residue was partitioned between EtOAc and H ₂ O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give the title compound as an off-white solid (914 mg, 31%). LCMS (Method H): R _T 2.53 min [M + H] ⁺ 254.3

ＴＨＦ（１５ｍＬ）中の２-クロロ-６-((Ｒ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン（６３５ｍｇ、２．５０ｍｍｏｌ）、ヨウ化メチル（１８７μＬ、３．００ｍｍｏｌ）及びＫ_２ＣＯ_３（４８４ｍｇ、３．５０ｍｍｏｌ）の混合物を室温で１８時間攪拌した後、更なるヨウ化メチル（１８７μＬ、３．００ｍｍｏｌ）を加えた。生じた混合物を６５時間攪拌し、ついで真空下で濃縮した。生じた残留物をＥｔＯＡｃ及びＨ_２Ｏの間で分配し、有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮し、表題化合物をオフホワイトの固形物として得た（５５２ｍｇ、８３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．７６分［Ｍ＋Ｈ］^＋２６８．３ Example 81b 2-Chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purine

2-Chloro-6-((R) -3-methylmorpholin-4-yl) -9H-purine (635 mg, 2.50 mmol), methyl iodide (187 μL, 3.00 mmol) and K in THF (15 mL). A mixture of ₂ CO ₃ (484 mg, 3.50 mmol) was stirred at room temperature for 18 hours before additional methyl iodide (187 μL, 3.00 mmol) was added. The resulting mixture was stirred for 65 hours and then concentrated under vacuum. The resulting residue was partitioned between EtOAc and H ₂ O and the organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo to give the title compound as an off-white solid. (552 mg, 83%). LCMS (Method H): R _T 2.76 min [M + H] ⁺ 268.3

ＴＨＦ（２０ｍＬ）中の２-クロロ-９-メチル-６-((Ｒ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン（５５０ｍｇ、２．０５ｍｍｏｌ）の溶液に−７８℃でＬｉＨＭＤＳ（３．１ｍＬ、３．０８ｍｍｏｌ、ＴＨＦ中１Ｍの溶液）を加えた。生じた混合物を４５時間攪拌した後、ＤＭＦ（８００μＬ、１０．３３ｍｍｏｌ）を加えた。反応混合物を室温で１．５時間かけて温め、０．５ＭのＨＣｌに注いだ。生じた沈殿物を濾過により回収して、Ｈ_２ＯとついでＥｔ_２Ｏで洗浄し、表題化合物を黄色固形物として得た（４０６ｍｇ、６７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．３５分［Ｍ＋Ｈ］^＋２９６．３ Example 81c 2-chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purine-8-carbaldehyde

A solution of 2-chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purine (550 mg, 2.05 mmol) in THF (20 mL) at −78 ° C. at LiHMDS ( 3.1 mL, 3.08 mmol, 1 M solution in THF) was added. The resulting mixture was stirred for 45 hours before DMF (800 μL, 10.33 mmol) was added. The reaction mixture was warmed at room temperature over 1.5 hours and poured into 0.5 M HCl. The resulting precipitate was collected by filtration and washed with H ₂ O followed by Et ₂ O to give the title compound as a yellow solid (406 mg, 67%). LCMS (Method H): R _T 3.35 min [M + H] ⁺ 296.3

ＤＣＥ（１５ｍＬ）中の２-クロロ-９-メチル-６-((Ｒ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン-８-カルバルデヒド（２７９ｍｇ、０．９４ｍｍｏｌ）、２-ピペリジン-４-イルプロパン-２-オール（１４９ｍｇ、１．０４ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（７００ｍｇ）の混合物を５．５時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（４００ｍｇ、１．８９ｍｍｏｌ）を加えた。生じた混合物を１７時間攪拌した後、セライト（登録商標）で濾過し、ＭｅＯＨで洗浄した。生じた濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填して、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−１５％）で精製して、表題化合物を淡黄色固形物として得た（３６６ｍｇ、９２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．１１分［Ｍ＋Ｈ］^＋４２３．４ Example 81d 2- {1- [2-chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purin-8-ylmethyl] piperidin-4-yl} propane- 2-all

2-Chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purine-8-carbaldehyde (279 mg, 0.94 mmol), 2-piperidine in DCE (15 mL) After stirring a mixture of -4-ylpropan-2-ol (149 mg, 1.04 mmol) and 4Å powdered molecular sieve (700 mg) for 5.5 hours, sodium triacetoxyborohydride (400 mg, 1.89 mmol) was added. added. The resulting mixture was stirred for 17 hours, then filtered through Celite® and washed with MeOH. The resulting filtrate was loaded onto an Isolute® SCX-2 cartridge that was washed with MeOH and the product was eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give the title compound as a pale yellow solid (366 mg, 92%). LCMS (Method H): R _T 2.11 min [M + H] ⁺ 423.4.

ＩＭＳ（１５ｍＬ）中の２,６-ジクロロ-９Ｈ-プリン（５２７ｍｇ、２．７９ｍｍｏｌ）、３-オキサ-８-アザ-ビシクロ[３.２.１]オクタン塩酸塩（５００ｍｇ、３．３４ｍｍｏｌ）及びＤＩＰＥＡ（１．２ｍＬ、６．９８ｍｍｏｌ）の混合物を８０℃で３時間加熱し、ついで室温で１８時間攪拌した。生じた沈殿物を濾過により回収し、更にＩＭＳで洗浄した。生じた固形物を真空下で乾燥し、表題化合物を得た（６６３ｍｇ、９０％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ８．１４（１Ｈ，ｓ），５．６０（１Ｈ，ｂｒｄ ｓ），４．８０（１Ｈ，ｂｒｄ ｓ），３．６６（４Ｈ，ｂｒｄ ｓ），２．００（４Ｈ，ｓ） Example 82a 2-Chloro-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine

2,6-Dichloro-9H-purine (527 mg, 2.79 mmol), 3-oxa-8-aza-bicyclo [3.2.1] octane hydrochloride (500 mg, 3.34 mmol) in IMS (15 mL) and A mixture of DIPEA (1.2 mL, 6.98 mmol) was heated at 80 ° C. for 3 hours and then stirred at room temperature for 18 hours. The resulting precipitate was collected by filtration and further washed with IMS. The resulting solid was dried under vacuum to give the title compound (663 mg, 90%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.14 (1H, s), 5.60 (1H, brd s), 4.80 (1H, brd s), 3.66 (4H, brd s), 2 .00 (4H, s)

ＴＨＦ（１５ｍＬ）中の２-クロロ-６-(３-オキサ-８-アザビシクロ[３.２.１]オクタ-８-イル)-９Ｈ-プリン（６５０ｍｇ、２．４５ｍｍｏｌ）、ヨウ化メチル（１８３μＬ、２．９４ｍｍｏｌ）及びＫ_２ＣＯ_３（４７３ｍｇ、３．４３ｍｍｏｌ）の混合物を室温で１８時間攪拌した後、更なるヨウ化メチル（５０μＬ、０．８０ｍｍｏｌ）を加えた。生じた混合物を６５時間攪拌し、ついで真空下で濃縮した。生じた残留物をＥｔＯＡｃ及びＨ_２Ｏの間で分配し、有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮し、表題化合物をオフホワイトの固形物として得た（６７３ｍｇ、９８％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．６３分［Ｍ＋Ｈ］^＋２８０．３ Example 82b 2-Chloro-9-methyl-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine

2-Chloro-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine (650 mg, 2.45 mmol), methyl iodide (183 μL) in THF (15 mL) A mixture of 2.94 mmol) and K ₂ CO ₃ (473 mg, 3.43 mmol) was stirred at room temperature for 18 hours before additional methyl iodide (50 μL, 0.80 mmol) was added. The resulting mixture was stirred for 65 hours and then concentrated under vacuum. The resulting residue was partitioned between EtOAc and H ₂ O and the organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo to give the title compound as an off-white solid. (673 mg, 98%). LCMS (Method H): R _T 2.63 min [M + H] ⁺ 280.3

ＴＨＦ（１１ｍＬ）中の２-クロロ-９-メチル-６-(３-オキサ-８-アザビシクロ[３.２.１]オクタ-８-イル)-９Ｈ-プリン（６２０ｍｇ、２．２２ｍｍｏｌ）及びＴＭＥＤＡ（４９８μＬ、３．３３ｍｍｏｌ）の溶液に−７８℃でｎ-ＢｕＬｉ（１．３ｍＬ、３．３３ｍｍｏｌ、ヘキサン中２．５Ｍの溶液）を加えた。生じた混合物を−４０℃まで温め、３０分間攪拌した後、再び−７８℃に冷却した。ＤＭＦ（５１７μＬ、６．６５ｍｍｏｌ）を加え、生じた混合物を−７８℃で３０分間攪拌した後、１ＭのＨＣｌに注いだ。水性層をＥｔＯＡｃで抽出し、有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製し、表題化合物を淡黄色固形物として得た（５００ｍｇ、７３％）。^１Ｈ ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）：δ９．８８（１Ｈ，ｓ），５．７９（１Ｈ，ｄ，Ｊ＝６．１４Ｈｚ），５．０５（１Ｈ，ｄ，Ｊ＝６．８４Ｈｚ），４．０５（３Ｈ，ｓ），３．８０−３．７８（４Ｈ，ｍ），２．２９−２．０１（４Ｈ，ｍ） Example 82c 2-Chloro-9-methyl-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine-8-carbaldehyde

2-Chloro-9-methyl-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine (620 mg, 2.22 mmol) and TMEDA in THF (11 mL) To a solution (498 μL, 3.33 mmol) was added n-BuLi (1.3 mL, 3.33 mmol, 2.5 M solution in hexane) at −78 ° C. The resulting mixture was warmed to −40 ° C., stirred for 30 minutes, and then cooled back to −78 ° C. DMF (517 μL, 6.65 mmol) was added and the resulting mixture was stirred at −78 ° C. for 30 minutes before being poured into 1M HCl. The aqueous layer was extracted with EtOAc and the organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as a pale yellow solid (500 mg, 73%). ¹ H NMR (CDCl ₃ , 400 MHz): δ 9.88 (1H, s), 5.79 (1H, d, J = 6.14 Hz), 5.05 (1H, d, J = 6.84 Hz), 4 .05 (3H, s), 3.80-3.78 (4H, m), 2.29-2.01 (4H, m)

ＤＣＥ（１１ｍＬ）中の２-クロロ-９-メチル-６-(３-オキサ-８-アザビシクロ[３.２.１]オクタ-８-イル)-９Ｈ-プリン-８-カルバルデヒド（５００ｍｇ、１．６３ｍｍｏｌ）、２-ピペリジン-４-イルプロパン-２-オール（２５６ｍｇ、１．７９ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（５００ｍｇ）の混合物を４時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（６９０ｍｇ、３．２６ｍｍｏｌ）を加えた。生じた混合物を１７時間攪拌して、ついでセライト（登録商標）で濾過し、ＭｅＯＨで洗浄した。得られた濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−１０％）で精製して、表題化合物を淡黄色固形物として得た（５７７ｍｇ、８２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ０．３０及び２．００分［Ｍ＋Ｈ］^＋４３５．４ Example 82d 2- {1- [2-chloro-9-methyl-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purin-8-ylmethyl] piperidine -4-yl} propan-2-ol

2-Chloro-9-methyl-6- (3-oxa-8-azabicyclo [3.2.1] oct-8-yl) -9H-purine-8-carbaldehyde (500 mg, 1 mL) in DCE (11 mL). .63 mmol), a mixture of 2-piperidin-4-ylpropan-2-ol (256 mg, 1.79 mmol) and 4Å powdered molecular sieves (500 mg) was stirred for 4 hours before sodium triacetoxyborohydride (690 mg, 3.26 mmol) was added. The resulting mixture was stirred for 17 hours, then filtered through Celite® and washed with MeOH. The resulting filtrate was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH and the product was eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give the title compound as a pale yellow solid (577 mg, 82%). LCMS (Method H): R _T 0.30 and 2.00 min [M + H] ⁺ 435.4.

ＩＭＳ（１３０ｍＬ）中の２,６-ジクロロ-９Ｈ-プリン（５．２ｇ、２７．５１ｍｍｏｌ）、(Ｓ)-３-メチルモルホリン（３．３０ｇ、３２．６２ｍｍｏｌ）及びＤＩＰＥＡ（５．０ｍＬ、２８．７１ｍｍｏｌ）の混合物を８０℃で３時間加熱し、ついで室温で１７時間攪拌した。生じた白色沈殿物を濾過により回収して、濾液を真空下で濃縮して体積を減少させ、生じた沈殿物を濾過によりまた回収した。固形物の両バッチをＤＣＭに混合し、有機相をＨ_２Ｏ及びブラインで洗浄して、ついで乾燥させ（ＭｇＳＯ_４）、真空下で濃縮して、表題化合物を白色粉末として得た（５．３ｇ、７６％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．５４分［Ｍ＋Ｈ］^＋２５４．１ Example 83a 2-Chloro-6-((S) -3-methylmorpholin-4-yl) -9H-purine

2,6-Dichloro-9H-purine (5.2 g, 27.51 mmol), (S) -3-methylmorpholine (3.30 g, 32.62 mmol) and DIPEA (5.0 mL, 28 mL) in IMS (130 mL). .71 mmol) was heated at 80 ° C. for 3 hours and then stirred at room temperature for 17 hours. The resulting white precipitate was collected by filtration, the filtrate was concentrated under vacuum to reduce the volume, and the resulting precipitate was also collected by filtration. Both batches of solid were mixed in DCM and the organic phase was washed with H ₂ O and brine, then dried (MgSO ₄ ) and concentrated in vacuo to give the title compound as a white powder (5. 3g, 76%). LCMS (Method H): R _T 2.54 min [M + H] ⁺ 254.1

ＴＨＦ（１００ｍＬ）中の２-クロロ-６-((Ｓ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン（５．３ｇ、２０．８９ｍｍｏｌ）、ヨウ化メチル（１．６ｍＬ、２５．７０ｍｍｏｌ）及びＫ_２ＣＯ_３（４．０ｇ２８．９４ｍｍｏｌ）の混合物を室温で１８時間攪拌し、ついで真空下で濃縮した。生じた残留物をＥｔＯＡｃ及びＨ_２Ｏの間で分配し、有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮し表題化合物を得た（４．８４ｇ、８７％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．７４分［Ｍ＋Ｈ］^＋２６８．２ Example 83b 2-Chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purine

2-Chloro-6-((S) -3-methylmorpholin-4-yl) -9H-purine (5.3 g, 20.89 mmol), methyl iodide (1.6 mL, 25. 25 mL) in THF (100 mL). 70 mmol) and K ₂ CO ₃ (4.0 g 28.94 mmol) were stirred at room temperature for 18 hours and then concentrated in vacuo. The resulting residue was partitioned between EtOAc and H ₂ O and the organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo to give the title compound (4.84 g, 87 %). LCMS (Method H): R _T 2.74 min [M + H] ⁺ 268.2

ＴＨＦ（１０ｍＬ）中の２-クロロ-９-メチル-６-((Ｓ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン（５００ｍｇ、１．６７ｍｍｏｌ）及びＴＭＥＤＡ（４１９μＬ、２．８０ｍｍｏｌ）の溶液に−７８℃でｎ-ＢｕＬｉ（１．１２ｍＬ、２．８０ｍｍｏｌ、ヘキサン中２．５Ｍの溶液）を加えた。生じた混合物を−４０℃にまで温め、３０分間攪拌し、再び−７８℃に冷却した後、ＤＭＦ（４３５μＬ、５．６１ｍｍｏｌ）を加えた。反応混合物を−７８℃で３０分間攪拌し、１ＭのＨＣｌに注いだ。水性相をＥｔＯＡｃで抽出し、組み合わせた有機相をＨ_２Ｏ及びブラインで洗浄し、ついで乾燥させ、（ＭｇＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、０−５０％）で精製して、表題化合物を白色固形物として得た（４５０ｍｇ、８１％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．２８分［Ｍ＋Ｈ］^＋２９６．３ Example 83c 2-chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purine-8-carbaldehyde

2-Chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purine (500 mg, 1.67 mmol) and TMEDA (419 μL, 2.80 mmol) in THF (10 mL) N-BuLi (1.12 mL, 2.80 mmol, 2.5 M solution in hexane) was added to the solution at −78 ° C. The resulting mixture was warmed to −40 ° C., stirred for 30 minutes, cooled again to −78 ° C., and DMF (435 μL, 5.61 mmol) was added. The reaction mixture was stirred at −78 ° C. for 30 minutes and poured into 1M HCl. The aqueous phase was extracted with EtOAc and the combined organic phases were washed with H ₂ O and brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-50%) to give the title compound as a white solid (450 mg, 81%). LCMS (Method H): R _T 3.28 min [M + H] ⁺ 296.3

ＤＣＥ（１０ｍＬ）中の２-クロロ-９-メチル-６-((Ｓ)-３-メチルモルホリン-４-イル)-９Ｈ-プリン-８-カルバルデヒド（４５０ｍｇ、１．５２ｍｍｏｌ）、２-ピペリジン-４-イルプロパン-２-オール（２３９ｍｇ、１．６７ｍｍｏｌ）及び４Å粉末化モレキュラーシーブ（４５０ｍｇ）の混合物を６時間攪拌した後、トリアセトキシ水素化ホウ素ナトリウム（６４４ｍｇ、３．０４ｍｍｏｌ）を加えた。生じた混合物を１７時間攪拌し、ついでセライト（登録商標）で濾過し、ＭｅＯＨで洗浄した。生じた濾液を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨ／ＤＣＭで溶出させた。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＤＣＭ、０−４％）で精製して、表題化合物をクリーム状の固形物として得た（５３８ｍｇ、８４％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．０２分［Ｍ＋Ｈ］^＋４２３．３ Example 83d 2- {1- [2-chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purin-8-ylmethyl] piperidin-4-yl} propane- 2-all

2-Chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purine-8-carbaldehyde (450 mg, 1.52 mmol), 2-piperidine in DCE (10 mL) A mixture of -4-ylpropan-2-ol (239 mg, 1.67 mmol) and 4Å powdered molecular sieve (450 mg) was stirred for 6 hours before sodium triacetoxyborohydride (644 mg, 3.04 mmol) was added. . The resulting mixture was stirred for 17 hours, then filtered through Celite® and washed with MeOH. The resulting filtrate was loaded onto an Isolute® SCX-2 cartridge that was washed with MeOH and the product was eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-4%) to give the title compound as a creamy solid (538 mg, 84%). LCMS (Method H): R _T 2.02 min [M + H] ⁺ 423.3.

Example 101 4- (1-((2- (Isoquinolin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) morpholine 101
2-Chloro-4-morpholin-4-yl-6- (4-morpholin-4-yl-piperidin-1-ylmethyl) -thieno [3,2-d] pyrimidine (0.100 g, 0 .229 mmol), isoquinoline-5-boronic acid (0.048 g, 0.275 mmol), dichlorobis (triphenylphosphine) palladium (II) (0.008 g, 0.012 mmol), 1N aqueous sodium carbonate (1 mL) and acetonitrile (3 mL) was charged. The vessel was evacuated three times and refilled with argon, then sealed and heated at 130 ° C. for 90 minutes. The reaction mixture was cooled, concentrated, dissolved in ethyl acetate and filtered through celite. The filtrate was concentrated and purified by chromatography (silica, 10 to 20% methanol in dichloromethane) to give 101 (0.033 g, 27%) as a yellow solid. MS m / e 531 [M + H] ⁺ ; ¹ H NMR (300 MHz, CDCl ₃ ) δ ppm 1.54-1.71 (m, 2H) 1.87 (d, J = 11.3 Hz, 2H) 2.09-2.30 (M, 3H) 2.52-2.63 (m, 4H) 3.01-3.11 (m, 2H) 3.70-3.78 (m, 4H) 3.85 (s, 2H) 3 .87-3.94 (m, 4H) 4.03-4.12 (m, 4H) 7.35 (s, 1H) 7.67-7.75 (m, 1H) 8.06 (d, J = 8.3 Hz, 1H) 8.31-8.37 (m, 1H) 8.52-8.58 (m, 1H) 8.61-8.67 (m, 1H) 9.30 (s, 1H) )

Example 102 4- (6-((4- (cyclopropylmethyl) piperazin-1-yl) methyl) -2- (1H-pyrrolo [2,3-c] pyridin-4-yl) thieno [3,2 -d] pyrimidin-4-yl) morpholine 102

ＤＭＦ（３ｍＬ）中の２-クロロ-６-(４-(シクロプロピルメチル)ピペラジン-１-イルメチル)-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン（０．２ｇ、０．４９ｍｍｏｌ）をシールされたチューブ内でチオメトオキシドナトリウム（０．１２ｇ、１．７１ｍｍｏｌ）で処理し、反応混合物を攪拌しながら１００℃で加熱した。２時間後、チューブの内容物をＥｔＯＡｃで希釈した後、飽和ＮａＨＣＯ_３（×２）水溶液と続くブラインで洗浄し、有機相を単離し、乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮して、６-(４-(シクロプロピルメチル)ピペラジン-１-イルメチル)-２-メチルスルファニル-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジンを淡黄色の固形物として得た（０．２ｇ、９７％）。ＬＣＭＳ（方法Ｄ）：Ｒ_Ｔ＝２．０４分，［Ｍ＋Ｈ］^＋４１９ Step 1: 6- (4- (Cyclopropylmethyl) piperazin-1-ylmethyl) -2-methylsulfanyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidine

2-Chloro-6- (4- (cyclopropylmethyl) piperazin-1-ylmethyl) -4-morpholin-4-ylthieno [3,2-d] pyrimidine (0.2 g, 0.49 mmol) in DMF (3 mL) ) Was treated with sodium thiomethoxide (0.12 g, 1.71 mmol) in a sealed tube and the reaction mixture was heated at 100 ° C. with stirring. After 2 hours, the tube contents were diluted with EtOAc, then washed with saturated aqueous NaHCO ₃ (× 2) followed by brine, the organic phase was isolated, dried (Na ₂ SO ₄ ), filtered and concentrated. 6- (4- (cyclopropylmethyl) piperazin-1-ylmethyl) -2-methylsulfanyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidine was obtained as a pale yellow solid. (0.2 g, 97%). LCMS (Method D): R _T = 2.04 min, [M + H] ⁺ 419

Step 2: 6- (4-Cyclopropylmethylpiperazin-1-ylmethyl) -2-methylsulfanyl-4-morpholin-4-yl-thieno [3,2-d] pyrimidine (46 mg, 0) in DME (2 mL) .11 mmol) and 1-benzenesulfonyl-4-tributylstannanyl-1H-pyrrolo [2,3-c] pyridine (129 mg, 0.24 mmol) in a sealed tube with copper bromide (I ) After treatment with dimethyl sulfide complex (50 mg, 2.43 mmol), the solution was degassed with argon for 5 min. Pd (PPh ₃ ) ₄ (20 mg, 0.016 mmol) was added and the reaction mixture was heated at 100 ° C. for 3 hours. The mixture was filtered through Celite® washed with DME and the combined filtrates were evaporated to give a yellow gum. The gum was purified by flash chromatography on silica, extracted with EtOAc, and 2- (1-benzenesulfonyl-6- (4-cyclopropylmethylpiperazin-1-ylmethyl) -4-morpholin-4-yl-2 -(1H-pyrrolo [2,3-c] pyridin-4-yl) thieno [3,2-d] pyrimidine (34 mg, 54%) was obtained, and this intermediate was treated with IMS (1 mL) and 1,4- Dissolved in dioxane (1 mL) and treated the stirred solution with NaOH solution (2.5 g NaOH from 5 mL H ₂ O to 0.1 mL) After 10 min, the reaction mixture was adjusted to pH 7 with HCl (10 N). The reaction mixture was filtered to remove insoluble material, the solid was washed with 1,4-dioxane, the filtrate was evaporated, the resulting residue was taken up in DCM and washed with brine; The organic phase dried (MgSO ₄ Purification was carried out by flash chromatography eluting with 3-12% MeOH in DCM to give 102 (22 mg, 41%) ¹ H NMR (DMSO, 400 MHz) : Δ 11.76 (s, 1H); 9.13 (s, 1H); 8.81 (s, 1H); 7.71 (d, J = 2.71 Hz, 1H); 7.45 (s, 1H) ); 7.40-7.36 (m, 1H); 3.99 (t, J = 4.6 Hz, 4H); 3.87 (s, 2H); 3.83 (t, J = 4.65 Hz) , 4H); 3.30 (br s, 4H); 2.54 (br s, 4H); 2.24 (br s, 2H); 0.89-0.77 (m, 1H); 0.50 -0.41 (m, 2H); 0.12-0.04 (m, 2H) LCMS (Method F): _RT = 4.63 Min, [M + H] ⁺ 490.1

Example 103 4-((4-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl) methyl) morpholine 103

ＤＭＦ（３ｍＬ）中の２-クロロ-４-モルホリン-４-イル-６-モルホリン-４-イルメチル-チエノ[３,２-ｄ]ピリミジン（０．２ｇ、０．５６ｍｍｏｌ）をシールしたチューブ内でナトリウムチオメトキシド（０．１２ｇ、１．７１ｍｍｏｌ）と処理し、反応混合物を攪拌しながら１００℃で加熱した。２時間後、チューブの内容物をＥｔＯＡｃで希釈し、飽和ＮａＨＣＯ_３（×２）水溶液とついでブラインで洗浄し、有機相を分離し、乾燥させ（Ｎａ_２ＳＯ_４）、濾過し、濃縮して、表題化合物を淡褐色の固形物として得た（０．２０５ｇ、１００％）。ＬＣＭＳ（方法Ｄ）：Ｒ_Ｔ＝１．８０分，［Ｍ＋Ｈ］^＋３６６． Step 1: 2-Methylsulfanyl-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno [3,2-d] pyrimidine

In a tube sealed with 2-chloro-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno [3,2-d] pyrimidine (0.2 g, 0.56 mmol) in DMF (3 mL). Treatment with sodium thiomethoxide (0.12 g, 1.71 mmol) and the reaction mixture was heated at 100 ° C. with stirring. After 2 hours, the contents of the tube were diluted with EtOAc, washed with saturated aqueous NaHCO ₃ (× 2) followed by brine, the organic phase separated, dried (Na ₂ SO ₄ ), filtered and concentrated. The title compound was obtained as a light brown solid (0.205 g, 100%). LCMS (Method D): R _T = 1.80 min, [M + H] ⁺ 366.

Step 2: 2-Methylsulfanyl-4-morpholin-4-yl-6-morpholin-4-ylmethyl-thieno [3,2-d] pyrimidine (40 mg, 0.11 mmol) and 1-benzene in DME (2 mL) Copper (I) bromide dimethyl sulfide complex (50 mg) in a tube sealed with a solution of sulfonyl-4- (tributylstannanyl) -1H-pyrrolo [2,3-c] pyridine (129 mg, 0.24 mmol) 2.43 mmol) and the solution was degassed with argon for 5 min. Pd (PPh ₃ ) ₄ (19 mg, 0.016 mmol) was added and the reaction mixture was heated at 100 ° C. for 3 hours. The mixture was filtered through celite, washed with DME, and the combined filtrates were evaporated to give a yellow gum. The gum was purified by flash chromatography on silica, eluting with EtOAc to 2- (1-benzenesulfonyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholin-4-yl- 6-morpholin-4-ylmethyl-thieno [3,2-d] pyrimidine (34 mg, 54%) was obtained. The sulfone intermediate was dissolved in IMS (1 mL) and 1,4-dioxane (1 mL) and the stirred solution was treated with a NaOH solution (0.1 mL from 2.5 g NaOH in 5 mL H ₂ O). After 10 minutes, the reaction mixture was treated with HCl (10N) until pH7 was reached. The reaction mixture was filtered to remove insoluble material. The solid was washed with 1,4-dioxane and the filtrate was evaporated. The resulting residue was taken up in DCM and washed with brine; the separated organic phase was dried (MgSO ₄ ), filtered and evaporated. The resulting crude residue was purified by flash chromatography (Si-PPC) eluting with 2-8% MeOH in DCM to afford 103 as a white solid (14 mg, 29%). ¹ H NMR (MeOD, 400 MHz): δ 8.99 (s, 1 H); 8.75 (s, 1 H); 7.66 (d, J = 3.95 Hz, 1 H); 7.40-7.36 ( m, 2H); 4.14-4.05 (m, 4H); 3.94-3.85 (m, 6H); 3.73 (t, J = 4.6 Hz, 4H); 2.59 ( t, J = 4.35 Hz, 4H). LCMS (Method F): R _T = 4.59 min, [M + H] ⁺ 437.2.

Example 104 1-((2- (7-chloroquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidine-4- Amine 104
[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -dimethyl-amine (0.150 g) in a sealable tube , 0.380 mmol), 7-chloroquinoline-4-boronic acid pinacol ester (0.132 g, 0.456 mmol), dichlorobis (triphenylphosphine) palladium (II) (0.013 g, 0.02 mmol), 1N carbonic acid Aqueous sodium solution (1 mL) and acetonitrile (3 mL) were charged. The vessel was evacuated three times and refilled with argon, then sealed and heated at 130 ° C. for 90 minutes. The reaction mixture was cooled, concentrated, redissolved in ethyl acetate and filtered through celite. The filtrate was concentrated and then purified by chromatography (silica, 10 to 20% methanol in dichloromethane) to give 104 (0.085 g, 43%) as a yellow solid. MS m / e 531 [M + H] ⁺ ; ¹ H NMR (300 MHz, methanol-d ₄ ) δ ppm 1.48-1.67 (m, 2H) 1.82-1.96 (m, 2H) 2.07-2.26 (M, 3H) 2.30 (s, 6H) 3.07 (d, J = 11.7 Hz, 2H) 3.82-3.91 (m, 6H) 4.02-4.11 (m, 4H ) 7.36 (s, 1H) 7.60 (dd, J = 9.1, 2.3 Hz, 1H) 7.95 (d, J = 4.5 Hz, 1H) 8.10 (d, J = 2) .3 Hz, 1H) 8.67 (d, J = 9.4 Hz, 1H) 8.98 (d, J = 4.9 Hz, 1H)

Example 105 2-Methyl-2- (4-((4-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) propanamide 105
2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (20 mL) Isobutyramide (1.17 g, 1.69 mmol), 4-bromo-1H-pyrrolo [2,3-c] pyridine (432 mg, 2.19 mmol), tetrakis (triphenylphosphine) palladium (194 mg, 10 mol%) and CuI A mixture of (385 mg, 2.02 mmol) was purged with argon gas and then heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80). The resulting solid was dissolved in MeOH, loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then eluted with 2M NH ₃ in MeOH to give 105 as a pale yellow solid. (242 mg, 39%). LCMS (Method F): R _T 4.51 min, [M + H] ⁺ 521.2. ¹ H NMR (DMSO, 400 MHz): δ 11.75 (s, 1 H); 9.13 (s, 1 H); 8.81 (s, 1 H); 7.71 (t, J = 2.7 Hz, 1 H) 7.45 (s, 1 H); 7.40-7.37 (m, 1 H); 7.07 (d, J = 3.5 Hz, 1 H); 6.95 (d, J = 3.5 Hz, 1H); 4.01 (t, J = 4.6 Hz, 4H); 3.87 (s, 2H); 3.83 (t, J = 4.6 Hz, 4H); 2.58 (s, 4H) 2.49 (s, 4H); 1.10 (s, 6H)

Example 106 2-Methyl-2- (4-((4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) propanamide 106
2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine-1- in dioxane (2.5 mL) Yl] isobutyramide (150 mg, 0.22 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine (90 mg, 0.27 mmol), Pd (PPh ₃ ) ₄ (25 mg, 10 mol) %) And CuI (50 mg, 0.25 mmol) were purged with argon and then heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ in MeOH. The resulting residue was dissolved in IMS / dioxane (1: 1 mL) and 12.5 M aqueous NaOH (0.1 mL) was added. After stirring for 1 hour, the reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 05:95) to give 106 (28 mg, 24%) as a pale yellow solid. LCMS (Method F) R _T 4.86 min; [M + H] ⁺ 521.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 9.11 (s, 1H); 8.54 (d, J = 5.6 Hz, 1H); 7.45 (s, 1H); 7.41 (dd, J = 3.3, 0.9 Hz, 1 H); 7.38 (dd, J = 5.6, 0.95 Hz, 1 H); 7.36 (d, J = 3.3 Hz, 1 H); 7.10 ( d, J = 5.3 Hz, 1H); 5.25 (d, J = 5.2 Hz, 1H); 4.10 (t, J = 4.75 Hz, 4H); 3.91 (t, J = 4) .7 Hz, 4H); 3.85 (s, 2H); 2.60 (s, 8H); 1.24 (s, 6H)

Example 107 1-((2- (isoquinolin-8-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine 107
Dimethyl- [1- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidin-6-methyl) -piperidin-4-yl] -amine in a microwave container (0.106 g, 0.163 mmol), 8-bromoisoquinoline (0.041 g, 0.196 mmol), copper (I) iodide (0.037 g, 0.196 mmol), palladium tetrakis (triphenylphosphine) (0. 019 g, 0.016 mmol) and tetrahydrofuran (2 mL) were charged. The vessel was evacuated three times, refilled with argon, sealed, and heated at 140 ° C. for 20 minutes under microwave irradiation. The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated and then purified by chromatography (silica, 1 to 20% 49: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give a colorless residue. This residue was dissolved in dichloromethane (3 mL) and then 1N HCl in ether (0.2 mL) was added dropwise. The resulting precipitate was collected by filtration to give 107 (0.028 g, 29%) as a pale yellow powder and tetrahydrochloride salt. MS m / e 489 [M + H] ⁺ . ¹ H NMR (300 MHz, methanol-d ₄ ) δ ppm 2.45 (br.s., 4H) 2.94 (s, 6H) 3.47 (br.s., 2H) 3.64-4.09 (m 7H) 4.35 (br.s., 4H) 4.98 (br.s., 2H) 8.14 (br.s., 1H) 8.45 (br.s., 1H) 8.64 (D, J = 7.9 Hz, 1H) 8.70 (d, J = 6.0 Hz, 1H) 8.73-8.86 (m, 1H) 10.37 (br.s., 1H).

Example 108 2- (4-((2- (1-aminoisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl)- 2-Methylpropanamide 108

酢酸（２３ｍＬ）中の４-ブロモイソキノリン（１．１０２ｇ、７．６４４ｍｍｏｌ）、臭化カリウム（０．９３６９ｇ、７．８７３ｍｍｏｌ）、及びリンモリブデン酸（７０ｍｇ）の混合物に水（０．８８ｍＬ）中の３０％過酸化水素を５分にわたって加えた。混合物が懸濁液を形成し、室温で２時間攪拌した。水（５０ｍＬ）を加えた。懸濁液をＥｔＯＡｃ（２×１００ｍＬ）で抽出し、組み合わせたＥｔＯＡｃ抽出物を水（２×５０ｍＬ）、飽和ＮａＨＣＯ_３（２×５０ｍＬ）及びブライン（２０ｍＬ）で洗浄し、乾燥させた（Ｎａ_２ＳＯ_４）。粗物質（１．３２２ｇ）をフラッシュクロマトグラフィーで精製して、生成物をオフホワイトの粉末として得た（７１ｍｇ、６５％）。ＬＣＭＳ：Ｍ＋Ｈ^＋＝２２３。 Step 1: 4-Bromoisoquinoline-1-amine

A mixture of 4-bromoisoquinoline (1.102 g, 7.644 mmol), potassium bromide (0.9369 g, 7.873 mmol), and phosphomolybdic acid (70 mg) in acetic acid (23 mL) in water (0.88 mL). Of 30% hydrogen peroxide was added over 5 minutes. The mixture formed a suspension and was stirred at room temperature for 2 hours. Water (50 mL) was added. The suspension was extracted with EtOAc (2 × 100 mL) and the combined EtOAc extracts were washed with water (2 × 50 mL), saturated NaHCO ₃ (2 × 50 mL) and brine (20 mL) and dried (Na ₂ SO _4). The crude material (1.322 g) was purified by flash chromatography to give the product as an off-white powder (71 mg, 65%). LCMS: M + H ^< + ^> = 223.

Step 2: 4-Bromoisoquinolin-1-amine (126 mg, 0.565 mmol), Bispinacol ester boronic acid (358 mg, 1.41 mmol), and potassium acetate (333 mg, in 1,4-dioxane (4.6 mL) _3. N39 was diffused into the mixture of 3.39 mmol) for 10 minutes. A complex of [1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II) and dichloromethane (1: 1) (23.1 mg, 0.0282 mmol) was added. The mixture was sealed under N _{2 and} heated at 80 ° C. for 20 hours, diluted with DCM, the contents were filtered, washed with DCM and concentrated. The crude product was purified from 2- (4-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide (124 mg, 0 .282 mmol) mixed with 1 M sodium carbonate (0.85 mL) solution and 1,4-dioxane (3.4 mL, 44 mmol). The mixture was diffused with N ₂ for 10 minutes. A solution of palladium acetate (6.342 mg, 0.02825 mmol) and 1.0 M tri-tert-butylphosphine in toluene (0.0565 mL) was added. The mixture was sealed under N _{2 and} heated at 85 ° C. for 6 hours, diluted with DCM, the contents were filtered and concentrated. The residue was purified by flash chromatography. Fractions containing the desired product were collected, concentrated and purified by reverse phase HPLC to give 108 (25 mg, 16%). LCMS: M + H ^< + ^> = 467. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.91 (d, J = 8.6, 1H), 8.67 (s, 1H), 7.85 (d, J = 8.3, 1H), 7. 71-7.64 (m, 1H), 7.53 (t, J = 7.3, 1H), 7.34 (s, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.20 (s, 1H), 4.10-3.99 (m, 4H), 3.87 (dd, J = 9.1, 4.6, 6H), 2.61 (s, 8H), 1.24 (s, 6H)

Example 109 1-((2- (isoquinolin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine 109
[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -dimethyl-amine (0.630 g, 1.59 mmol), isoquinoline-5-boronic acid (0.331 g, 1.91 mmol), dichlorobis (triphenylphosphine) palladium (II) (0.056 g, 0.08 mmol), 1N aqueous sodium carbonate solution (2.5 mL) ) And acetonitrile (7.5 mL). The vessel was evacuated three times and filled with argon, then heated at 130 ° C. for 90 minutes. The reaction mixture was cooled, concentrated, redissolved in methanol and filtered through celite. The filtrate was concentrated and then purified by chromatography (C-18 reverse phase column, 5 to 95% in water with 0.1% TFA). Fractions containing the desired product were concentrated, then dissolved in MeOH / dichloromethane, basified with solid sodium carbonate, filtered and concentrated to give 109 as a white foam (0.386 g 50%). MS m / e 489 [M + H]; ¹ H NMR (300 MHz, MeOH-d ₄ ) δ ppm 1.61-1.91 (m, 2H) 1.99-2.15 (m, 2H) 2.17-2.36 ( m, 2H) 2.88 (s, 6H) 3.04-3.28 (m, 3H) 3.73-3.87 (m, 4H) 3.91 (s, 2H) 3.96-4. 07 (m, 4H) 7.33 (s, 1H) 7.69-7.83 (m, 1H) 8.18 (d, J = 8.3 Hz, 1H) 8.30 (d, J = 7. 2 Hz, 1H) 8.43 (d, J = 6.4 Hz, 1H) 8.57 (d, J = 6.0 Hz, 1H) 9.28 (s, 1H)

Example 110 1-((2- (1H-Benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidine- 4-Amine 110
[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] dimethylamine (1, mL) in 1,4-dioxane (1 mL) A mixture of 50 mg, 0.13 mmol), benzimidazole (32 mg, 0.27 mmol) and concentrated HCl (53 μL, 0.64 mmol) was subjected to microwave irradiation at 150 ° C. for 40 minutes. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (2 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The eluent was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: 2M NH _{3 in} MeOH 100: 0 to 98: 2 to 95: 5 to 90:10) to give 110 as a white solid. (38 mg, 63%). LCMS (Method F): R _T = 5.12 min, [M + H] ⁺ 478.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 9.04 (s, 1H); 8.61-8.57 (m, 1H); 7.86-7.82 (m, 1H); 7.43-7 .31 (m, 2H); 7.27 (s, 1H); 4.07 (t, J = 4.8 Hz, 4H); 3.92 (t, J = 4.8 Hz, 4H); 3.82 (S, 2H); 3.08-2.99 (m, 2H); 2.30 (s, 6H); 2.20-2.10 (m, 3H); 1.88-1.78 (m , 2H); 1.66-1.54 (m, 2H)

Example 112 2-methyl-2- (4-((7-methyl-4-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-4-yl) thieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 112
2- [4- (7-Methyl-4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine in toluene (2 mL) 1-yl] isobutyramide (109 mg, 0.15 mmol), 4-bromo-1H-pyrrolo [2,3-c] pyridine (39 mg, 0.20 mmol), tetrakis (triphenylphosphine) palladium (18 mg, 10 mol%) And a mixture of CuI (32 mg, 0.17 mmol) were purged with argon gas and heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was subjected to column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 05:95) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water, acetonitrile 80:20 to 2: 98) to give 112 as an off-white solid (17 mg, 21%). LCMS (Method F): R _T 4.93 min, [M + H] ⁺ 535.3. ¹ H NMR (MeOD plus CDCl ₃ , 400 MHz): δ 9.17 (s, 1H); 8.75 (s, 1H); 7.61 (d, J = 3.0 Hz, 1H); 7.56 (d , J = 3.0 Hz, 1H); 4.11 (t, J = 4.7 Hz, 4H); 3.94 (t, J = 4.7 Hz, 4H); 3.88 (s, 2H); 2 .74-2.56 (m, 8H); 2.53 (s, 3H); 1.24 (s, 6H)

４-ｔｅｒｔ-ブチルピペリジン（０．４５ｇ）を一般的手順Ｃを介して４-(８-(ブロモメチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（１．０ｇ）と反応させて４-(８-((４-ｔｅｒｔ-ブチルピペリジン-１-イル)メチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（０．８０ｇ）を白色固形物として得た。

４-(８-((４-ｔｅｒｔ-ブチルピペリジン-１-イル)メチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（６９７ｍｇ）、ビス-トリブチルすず（１．７１ｍＬ）及びＰｄＣｌ_２[ｔ-Ｂｕ_２Ｐ(Ｐｈ-ｐ-Ｎｍｅ_２)_２]（１９０ｍｇ、１,４-ジオキサン（８．５ｍＬ）中の混合物をＣＥＭマイクロ波で１４０℃で４０分間加熱した。反応混合物をついで濃縮し、粗生成物をついでフラッシュクロマトグラフィー（１５分にわたって０−３０％ヘキサン／酢酸エチル）で精製して、中間体４-(８-((４-ｔｅｒｔ-ブチルピペリジン-１-イル)メチル)-９-メチル-２-(トリブチルスタンニル)-９Ｈ-プリン-６-イル)モルホリン（６２７ｍｇ）を得た。

４-(８-((４-ｔｅｒｔ-ブチルピペリジン-１-イル)メチル)-９-メチル-２-(トリブチルスタンニル)-９Ｈ-プリン-６-イル)モルホリン（０．１ｇ）を一般的手順Ｄを介して４-ブロモイソキノリン-１-アミンと反応させ、逆相精製後に１１４（１０ｍｇ）を得た。ＭＳ（Ｑ１）５１５．３（Ｍ）＋。^１Ｈ ＮＭＲ（５００ＭＨｚ，ＣＤＣｌ_３）δ９．０２（ｄ，１Ｈ），７．９４−７．４５（ｍ，６Ｈ），４．３５（ｓ，４Ｈ），４．０２−３．６１（ｍ，９Ｈ），２．９７（ｓ，２Ｈ），２．１３（ｓ，２Ｈ），１．９２−１．５２（ｍ，５Ｈ），１．５２−０．６８（ｍ，２６Ｈ） Example 114 4- (8-((4-tert-butylpiperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) isoquinolin-1-amine 114

4-tert-Butylpiperidine (0.45 g) was added via general procedure C to 4- (8- (Bromomethyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (1.0 g) To give 4- (8-((4-tert-butylpiperidin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (0.80 g) as a white solid Obtained as a thing.

4- (8-((4-tert-Butylpiperidin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (697 mg), bis-tributyltin (1.71 mL) ) And PdCl ₂ [t-Bu ₂ P (Ph-p-Nme ₂ ) ₂ ] (190 mg, 1,4-dioxane (8.5 mL) was heated in a CEM microwave at 140 ° C. for 40 minutes. The mixture was then concentrated and the crude product was then purified by flash chromatography (0-30% hexane / ethyl acetate over 15 min) to give intermediate 4- (8-((4-tert-butylpiperidine-1- Yl) methyl) -9-methyl-2- (tributylstannyl) -9H-purin-6-yl) morpholine (627 mg) was obtained.

4- (8-((4-tert-Butylpiperidin-1-yl) methyl) -9-methyl-2- (tributylstannyl) -9H-purin-6-yl) morpholine (0.1 g) is commonly used. Reaction with 4-bromoisoquinolin-1-amine via Procedure D gave 114 (10 mg) after reverse phase purification. MS (Q1) 515.3 (M) +. ¹ H NMR (500 MHz, CDCl ₃ ) δ 9.02 (d, 1H), 7.94-7.45 (m, 6H), 4.35 (s, 4H), 4.02-3.61 (m, 9H), 2.97 (s, 2H), 2.13 (s, 2H), 1.92-1.52 (m, 5H), 1.52-0.68 (m, 26H)

Example 115 2- (1-((2- (1-Aminoisoquinolin-4-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -All 115
2- (1-((9-methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.1 g) Reaction with 4-bromoisoquinolin-1-amine via general procedure G gave 115 for reverse phase purification. MS (Q1) 517.3 (M) +. ¹ H NMR (400 MHz, DMSO) δ 9.01 (d, 1H), 8.56 (s, 1H), 8.25 (d, 1H), 7.67 (t, 1H), 7.49 (t, 1H), 7.07 (s, 2H), 4.23 (s, 4H), 4.02 (s, 1H), 3.87-3.66 (m, 10H), 2.89 (d, 3H) ), 1.99 (t, 2H), 1.66 (d, 2H), 1.35-1.10 (m, 3H), 1.02 (s, 6H).

Example 116 1-((2- (1H-indazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine 116
A solution of indazole (0.118 g) in DMF (8 mL) was cooled to 0 ° C. and then sodium hydride (0.06 g) was added. After 15 minutes, [1- (2-chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -dimethyl-amine (0.395 g) The reaction vessel was sealed and heated at 150 ° C. After 1 hour, the reaction mixture was cooled to room temperature and then diluted with water. The resulting precipitate was collected by filtration and then purified by chromatography (silica, 0-20% 49: 1 MeOH: NH ₄ OH mixture in dichloromethane) and triturated with ethyl acetate before 116 (0.233 g, 49%) as a white solid. MS m / e 478 [M + H] ⁺ ; ¹ H NMR (300 MHz, DMSO-d ₆ ) δ ppm 1.41 (dd, J = 11.68, 3.39 Hz, 2H) 1.73 (d, J = 10.93 Hz, 2H) ) 2.07 (t, J = 10.74 Hz, 3H) 2.17 (s, 6H) 2.94 (d, J = 11.68 Hz, 2H) 3.75-3.90 (m, 6H) 3 .93-4.13 (m, 4H) 7.31 (t, J = 7.54 Hz, 1H) 7.39 (s, 1H) 7.56 (dd, J = 7.91, 6.40 Hz, 1H) ) 7.88 (d, J = 7.91 Hz, 1H) 8.39 (s, 1H) 8.68 (d, J = 8.67 Hz, 1H).

Example 117 N, N-dimethyl-1-((2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) Methyl) piperidine-4-amine 117
N- [6- (4-Dimethylaminopiperidin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidin-2-yl] benzene-1,2 in DMF (1 mL) A mixture of diamine (80 mg, 0.17 mmol) and triethylorthoformate (1 mL, 6.0 mmol) was heated at 150 ° C. for 6 hours. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The eluent was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, 2M NH ₃ in DCM: MeOH 100: 0 to 98: 2 to 95: 5), then purified by reverse phase HPLC (Phenomenex Luna C18, acetonitrile 95: Gradient from 5 to 2:98 in 20 mM Et ₃ N in water) gave 117 as a white solid (20 mg, 24%). LCMS (Method F): R _T = 4.24 min, [M + H] ⁺ 492.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.09-8.04 (m, 1H); 7.74-7.68 (m, 1H); 7.29-7.24 (m, 3H); 4 .08-4.02 (m, 4H); 3.91-3.86 (m, 4H); 3.83 (s, 2H); 3.08-3.00 (m, 2H); 2.93 (S, 3H); 2.30 (s, 6H); 2.21-2.10 (m, 3H); 1.88-1.79 (m, 2H); 1.68-1.53 (m) , 2H)

Example 118 2- (1-((9-Methyl-6-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-4-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 118
2- (1-((9-methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (150 mg) is commonly used. Reaction with 4-bromo-6-azaindole via Procedure G gave 118 (31.8 mg) after reverse phase purification. MS (Q1) 491.2 (M) +. ¹ H NMR (400 MHz, DMSO) δ 11.70 (s, 1H), 9.14 (s, 1H), 8.79 (s, 1H), 7.70 (t, 1H), 7.43 (s, 1H), 4.30 (s, 4H), 4.02 (s, 1H), 3.89 (s, 3H), 3.83-3.76 (m, 4H), 3.73 (s, 2H) ), 2.92 (t, 2H), 1.97 (dd, 16.9, 2H), 1.69 (t, 2H), 1.40-1.09 (m, 3H), 1.02 ( s, 6H)

Example 119 2- (1-((9-Methyl-6-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 119
2- (1-((9-methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (150 mg) is commonly used. Reaction with 4-bromo-5-azaindole via Procedure G gave 119 (20 mg) after reverse phase purification. MS (Q1) 491.2 (M) +. ¹ H NMR (400 MHz, MeOD) δ 8.31 (d, 1H), 7.51 (d, 1H), 7.45 (d, 1H), 7.34 (d, 1H), 4.39 (s, 4H), 4.03-3.69 (m, 10H), 3.31 (d, 5H), 3.01 (d, 2H), 2.10 (t, 2H), 2.03 (s, 2H) ), 1.75 (d, 2H), 1.53-1.22 (m, 4H), 1.13 (s, 6H)

Example 120 4- (6-((4-Methylpiperazin-1-yl) methyl) -2- (quinolin-5-yl) thieno [3,2-d] pyrimidin-4-yl) morpholine 120
According to general procedure L for reductive amination, 4-morpholino-2- (quinolin-5-yl) thieno [3,2-d] pyrimidine-6-carbaldehyde and 1-methylpiperazine are reacted to give 120 It was. LCMS m / z: 461.6 (MH +)

Example 121 2- (4-((2- (7-Fluoro-1H-pyrrolo [3,2-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) -2-methylpropanamide 121
142 [2- (4- (4-morpholin-4-yl-2- (trinanstanyl)) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyl The amide was converted to 121. LCMS m / z: 539.2 (MH +)

Example 123 4-((4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl) methyl) morpholine 123
According to general procedure L for reductive amination, 4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) thieno [3,2-d] pyrimidine-6-carbaldehyde and morpholine To give 123. LCMS: M + H ⁺ = 437.5

１,４-ジオキサン（５ｍＬ）中の４-(１-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)モルホリン（５９３ｍｇ、１．３６ｍｍｏｌ）、ビス(トリブチルすず)（１．３６ｍＬ、２．７２ｍｍｏｌ）及びＰｄＣｌ_２[ｔ-Ｂｕ_２Ｐ(Ｐｈ-ｐ-Ｎｍｅ_２)_２]（１５０ｍｇ、０．２１ｍｍｏｌ）の混合物をマイクロ波反応器で１４０℃で４０分間加熱した。反応混合物をついで濃縮した。粗生成物をついでフラッシュクロマトグラフィー（ＤＣＭ中１０％ＭｅＯＨ）で精製して、表題化合物を得た（８５９ｍｇ、９１．４％）。ＬＣＭＳ：Ｍ＋Ｈ^＋＝６９１．４。 Example 124 4- (1-((9-methyl-6-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-4-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) morpholine 124
Step 1: 4- (1-((9-Methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) morpholine

4- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) morpholine (593 mg, 1 in 1,4-dioxane (5 mL) .36 mmol), bis (tributyltin) (1.36 mL, 2.72 mmol) and PdCl ₂ [t-Bu ₂ P (Ph-p-Nme ₂ ) ₂ ] (150 mg, 0.21 mmol) in a microwave reaction Heated at 140 ° C. for 40 minutes. The reaction mixture was then concentrated. The crude product was then purified by flash chromatography (10% MeOH in DCM) to give the title compound (859 mg, 91.4%). LCMS: M + H ^< + ^> = 691.4.

Step 2: 4- (1-((9-Methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidine-4- in 1,4-dioxane (10 mL) Yl) morpholine (859 mg, 1.24 mmol), 4-bromo-1- (phenylsulfonyl) -1H-pyrrolo [2,3-c] pyridine (385 mg, 1.14 mmol), copper (I) iodide (326 mg, 1.71 mmol) of degassed mixture was added Pd (PPh ₃ ) ₄ (100 mg, 0.09 mmol). The reaction mixture was stirred at 110 ° C. for 18 hours. The reaction mixture was concentrated then dissolved in DCM and filtered through a silica gel column (20% MeOH in DCM). The eluent was concentrated to give a yellow paste that was taken up in ethanol (2 mL) and 1,4-dioxane (3 mL). 12M aqueous NaOH (0.5 mL) was then added and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was then concentrated and the crude product was purified by flash chromatography on a Biotage KP-NH column (10% MeOH in DCM) followed by RP-HPLC to give 124. LCMS: M + H ^< + ^> = 518.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 11.70 (s, 1H), 9.14 (s, 1H), 8.79 (s, 1H), 7.70 (m, 1H), 7 .43 (m, 1H), 4.30 (s, br, 4H), 3.88 (s, 3H), 3.78 (m, 4H), 3.70 (s, 2H), 3.54 ( m, 4H), 2.86 (m, 2H), 2.43 (m, 4H), 2.09 (m, 2H), 1.75 (m, 2H), 1.36 (m, 3H).

Example 125 N, N-dimethyl-1-((4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-3-yl) thieno [3,2-d] pyrimidin-6-yl) Methyl) piperidine-4-amine 125
In a microwave vessel, dimethyl- [1- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidine-6-methyl) -piperidine in dioxane (8 mL) 4-yl] -amine (0.4 g) was charged. The vessel was evacuated and again filled with argon. To this mixture was added 3-iodo-pyrrolo [3,2-c] pyridine-1-carboxylic acid tert-butyl ester (0.254 g), copper iodide (0.14 g) and tetrakistriphenylphosphine palladium (0.08 g). Was added. The vessel was degassed and refilled with argon, then the mixture was irradiated in the microwave at 150 ° C. for 35 minutes. The reaction mixture was cooled to room temperature and then filtered through an HPLC filter. The filtrate was concentrated and the resulting residue was purified by chromatography (silica, 0 to 10% 49: 1 MeOH: NH ₄ OH mixture in dichloromethane). The resulting residue was dissolved in anhydrous methanol (2 mL) and 4.0 N HCl in dioxane (6 mL) was added. The mixture was stirred overnight at room temperature. The precipitated solid was collected by filtration and the resulting residue was dried under vacuum at 50 ° C. overnight to give 125 (0.086 g, 22%) as a white solid. MS m / e 478 [M + H] ⁺ . ¹ H NMR (300 MHz, DMSO-d ₆ ) δ ppm 2.19-2.34 (m, 4H) 2.71 (s, 6H) 3.06 (br.s., 2H) 3.43 (br.s. , 1H) 3.50-3.57 (m, 2H) 3.81-3.90 (m, 4H) 4.01-4.11 (m, 4H) 4.64 (s, 2H) 7.93 (S, 1H) 8.07 (d, J = 6.78 Hz, 1H) 8.50 (d, J = 6.78 Hz, 1H) 8.75 (s, 1H) 9.76 (s, 1H)

Example 126 2-Methyl-2- (4-((7-methyl-4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) thieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 126
2- [4- (7-Methyl-4-morpholin-4-yl-2- (stannanylyl) thieno [3,2-d] pyrimidine- in 1,4-dioxane (1.5 mL) 6-ylmethyl) piperazin-1-yl] isobutyramide (100 mg, 0.14 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine (60 mg, 0.18 mmol), Pd ( A degassed solution of PPh ₃ ) ₄ (16 mg, 0.014 mmol) and CuI (33 mg, 0.17 mmol) was subjected to microwave irradiation at 140 ° C. for 20 minutes. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The eluate was collected and concentrated to give 2- {4- [2- (1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -7-methyl-4-morpholine- 4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl] -piperazin-1-yl} -isobutyramide was obtained as a crude oil. Aqueous NaOH (12.5 M, 0.2 mL) was added to this intermediate in 1,4-dioxane (2 mL) and IMS (2 mL). The reaction mixture was stirred at ambient temperature for 1 hour and then concentrated under vacuum. The residue was dissolved in MeOH and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The eluent was collected and concentrated to give a crude solid. The solid was purified by flash chromatography (Si-PPC, DCM: 2M NH _{3 in} MeOH, 100: 0 to 99: 1 to 98: 2 to 95: 5 to 90: 0) to give 126 as creamy Obtained as a solid (36 mg, 48%). LCMS (Method F): R _T = 5.04 min, [M + H] ⁺ 535.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 9.76 (s, 1H); 8.46 (d, J = 5.6 Hz, 1H); 7.49 (dd, J = 3.2, 1.0 Hz, 7.34 (d, J = 3.25 Hz, 1H); 7.31 (dd, J = 5.6, 1.0 Hz, 1H); 7.12 (d, J = 5.3 Hz, 1H) 5.35 (d, J = 5.25 Hz, 1H); 4.08 (t, J = 4.7 Hz, 4H); 3.86 (t, J = 4.7 Hz, 4H); 3.82 (S, 2H); 2.60 (s, 8H); 2.58-2.45 (m, 3H); 1.33-1.17 (m, 6H)

Example 127 4- (6-((4- (1-Amino-2-methyl-1-oxopropan-2-yl) piperazin-1-yl) methyl) -4-morpholinothieno [3,2-d] Pyrimidin-2-yl) -1H-pyrrolo [2,3-c] pyridine 6-oxide 127
2- [4- (4-Morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine-1- in dioxane (2.5 mL) Yl] isobutyramide (170 mg, 0.25 mmol), 4-bromo-6-oxy-pyrrolo [2,3-c] pyridine-1-carboxylic acid tert-butyl ester (100 mg, 0.32 mmol), tetrakis (triphenyl) A mixture of phosphine) palladium (28 mg, 10 mol%) and CuI (55 mg, 0.28 mmol) was purged with argon and heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was dissolved in DCM (3 mL) and trifluoroacetic acid (0.4 mL) was added. After stirring for 3 hours, the reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 15:85) to give 127 (30 mg, 17%) as a pale yellow solid. LCMS (Method F): R _T 4.95 min, [M + H] ⁺ 537.9. ¹ H NMR (CDCl ₃ , 400 MHz): δ 12.52 (s, 1 H); 9.07 (s, 1 H); 8.79 (s, 1 H); 7.65 (d, J = 2.8 Hz, 1 H) 7.56 (d, J = 2.8 Hz, 1H); 7.34 (s, 1H); 7.09 (d, J = 5.3 Hz, 1H); 5.38 (d, J = 5) 4.05 (t, J = 4.6 Hz, 4H); 3.89 (t, J = 4.7 Hz, 4H); 3.84 (s, 2H); 2.60 (s) , 8H); 1.24 (m, 6H)

Example 128 2- (4-((2- (Benzofuran-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropane Amide 128
According to 140 procedures, 2- (benzofuran-3-yl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane was converted to 128. LCMS: M + H ^< + ^> = 521.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.73 (s, 1H), 8.52 (m, 1H), 7.66 (m, 1H), 7.39 (m, 3H), 7 .05 (s, 1H), 6.93 (s, 1H), 3.99 (m, 4H), 3.86 (s, 2H), 2.83 (m, 4H), 2.39-2. 61 (m, 8H), 1.08 (s, 6H)

Example 129 2- (1-((2- (3-Amino-1H-indazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) Propan-2-ol 129
Sodium hydride (1.5 eq) was added to 3-iodoindazole (0.5 g) in DMF (5 mL) and the reaction was stirred at 0 ° C. for 30 min. 2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was subsequently added to the reaction mixture and Biotage micro Heated at 180 ° C. for 10 minutes with waves. The reaction was purified by flash chromatography to give 2- (1-((2- (3-iodo-1H-indazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl). Methyl) piperidin-4-yl) propan-2-ol (0.4 g) was obtained as a brown solid.

  2- (1-((2- (3-Iodo-1H-indazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) in 1,4-dioxane (0.5 mL) ) Methyl) piperidin-4-yl) propan-2-ol (0.1 g), tris (dibenzylideneacetone) dipalladium (0) (3 mg), 4,5-bis (diphenylphosphino) -9,9- Benzophenone imine (40 μL) was added to a solution of dimethylxanthene (5.6 mg) and cesium carbonate (74 mg). The reaction was heated at 120 ° C. for about 90 minutes until the reaction was complete. The crude reaction mixture was loaded onto silica and purified by flash chromatography to give 2- (1-((2- (3- (diphenylmethyleneamino) -1H-indazol-1-yl) -9-methyl-6- Morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was obtained.

2- (1-((2- (3- (Diphenylmethyleneamino) -1H-indazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl in MeOH (2 mL) ) Piperidin-4-yl) propan-2-ol and hydroxylamine hydrochloride (12.4 mg) were stirred overnight at room temperature. The crude material was purified by reverse phase HPLC to give 129 as a white solid (32.6 mg). MS (Q1) 506.3 (M) +. ¹ H NMR (400 MHz, DMSO) δ 8.56 (d, 1H), 7.83 (d, 1H), 7.47 (t, 1H), 7.17 (t, 1H), 6.05 (s, 2H), 4.26 (s, 5H), 4.02 (s, 1H), 3.79 (s, 7H), 3.68 (s, 4H), 2.86 (t, 2H), 1. 97 (t, J = 2H), 1.66 (d, 2H), 1.33-1.11 (m, 4H), 1.02 (s, 6H).

Example 130 2- (1-((2- (1-aminoisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) propane- 2-all 130
According to the procedure of 108, 2- (1-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) propan-2-ol and 4-bromo Isoquinolin-1-amine was converted to 130. LCMS: M + H ^< + ^> = 519. ¹ H NMR (400 MHz, DMSO) δ 8.99 (d, J = 8.5, 1H), 8.58 (s, 1H), 8.26 (d, J = 8.5, 1H), 8.17 (S, 2H), 7.68 (t, J = 7.6, 1H), 7.50 (t, J = 7.5, 1H), 7.37 (s, 1H), 7.12 (s , 1H), 4.00-3.89 (m, 4H), 3.86-3.75 (m, 6H), 2.99 (d, J = 11.0, 2H), 1.97 (t , J = 11.2, 2H), 1.65 (t, J = 15.4, 2H), 1.37-1.11 (m, 3H), 1.04 (s, 6H)

Example 131 2-Methyl-2- (4-((7-morpholino-5- (1H-pyrrolo [2,3-c] pyridin-4-yl) thiazolo [5,4-d] pyrimidin-2-yl ) Methyl) piperazin-1-yl) propanamide 131
2- [4- (7-morpholin-4-yl-5- (trinanstannyl) thiazolo [5,4-d] pyrimidin-2-ylmethyl) piperazine-1- in dioxane (2.5 mL) Yl] isobutyramide (167 mg, 0.24 mmol), 4-bromo-1H-pyrrolo [2,3-c] pyridine (62 mg, 0.31 mmol), tetrakis (triphenylphosphine) palladium (28 mg, 10 mol%) and CuI A mixture of (55 mg, 0.28 mmol) was purged with argon gas and then heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 15:85) to give 131 as a pale yellow solid (12 mg, 10%). LCMS (Method F): R _T 4.70 min, [M + H] ⁺ 522.2. ¹ H NMR (DMSO, 400 MHz): δ 11.94 (s, 1 H); 9.10 (s, 1 H); 8.88 (s, 1 H); 7.82 (s, 1 H); 7.35 (s 7.15 (s, 1H); 7.04 (s, 1H); 4.37 (s, 4H); 3.95 (s, 2H); 3.82 (t, J = 4. 6 Hz, 4H); 2.68 (s, 4H); 2.56 (s, 4H); 1.13 (s, 6H)

Example 132 2-Methyl-2- (4-((2- (7-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 132
2- [4- (4-morpholin-4-yl-2- (tributylstannyl)) thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl in dioxane (3 mL) Isobutylamide (197 mg, 0.28 mmol), 4-bromo-7-methyl-1H-pyrrolo [2,3-c] pyridine (60 mg, 0.28 mmol), copper (I) 2-thiophenecarboxylate (11 mg, 0 0.056 mmol), and Pd (PPh ₃ ) ₄ (32 mg, 0.028 mmol) were placed in a microwave tube, which was sealed and degassed. The reaction vessel was degassed and purged with argon (x3). The reaction mixture was irradiated at 140 ° C. for 20 minutes. The chilled mixture was then poured onto an Isolute® SCX-II cartridge and the cartridge was washed with MeOH (100 mL). The product was eluted with 2M NH ₃ in MeOH. The pooled fractions were evaporated and the product was further purified by column chromatography on silica (Si-PPC) using DCM (0-10%) as eluent. Fractions containing the pooled product were evaporated and the product was crystallized from hot EtOAc to give 132 as a white crystalline solid (70 mg, 46%). LCMS: (Method F): R _T 5.02 min; [M + H] ⁺ 535.2. ¹ H NMR (DMSO, 400 MHz): δ 11.71 (s, 1 H); 9.02 (s, 1 H); 7.66 (t, J = 2.7 Hz, 1 H); 7.44 (s, 1 H) 7.38 (dd, J = 2.9, 1.9 Hz, 1H); 7.08 (d, J = 3.5 Hz, 1H); 6.95 (d, J = 3.5 Hz, 1H); 3.99 (t, J = 4.6 Hz, 4H); 3.86 (s, 2H); 3.85-3.80 (m, 4H); 2.73 (s, 3H); 2.62- 2.53 (m, 4H); 2.47 (s, 4H); 1.08 (s, 6H)

Example 133 4- (1-((9-methyl-6-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) morpholine 133
According to the procedure for preparing 124, 4- (1-((9-methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) morpholine and 4- Bromo-1H-pyrrolo [3,2-c] pyridine was reacted to give 133. LCMS: M + H ^< + ^> = 518.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 11.55 (s, 1H), 8.30 (d, 1H), 7.51 (d, 1H), 7.48 (d, 1H), 7 .20 (d, 1H), 4.30 (m, 4H), 3.80 (s, 3H), 3.78 (m, 6H), 3.55 (m, 4H), 2.88 (m, 2H), 2.44 (m, 4H), 2.09 (m, 2H), 1.77 (m, 2H), 1.40 (m, 3H)

Example 134 1-((2- (1H-indazol-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine 134
Dimethyl- [1- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidin-6-methyl) -piperidin-4-yl] -amine in a microwave container (0.400 g, 0.615 mmol), 1-boc-3-bromo-1H-indazole (0.219 g, 0.737 mmol), tetrakis (triphenylphosphine) palladium (0.071 g, 0.061 mmol), iodide Cuprous (0.140 g, 0.735 mmol) and THF (8 mL) were charged. The reaction vessel was sealed, evacuated and backfilled with argon. The mixture was then heated at 140 ° C. for 20 minutes under microwave irradiation. The reaction mixture was cooled to room temperature, ethyl acetate (30 mL) was added, and the mixture was filtered through celite. The filtrate was concentrated and then purified by chromatography (silica, 0 to 20% 9: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give a crude solid. This solid was dissolved in dichloromethane (10 mL) and methanol (0.5 mL). HCl (0.80 mL in ether, 1N) was then added dropwise. After stirring for 1 hour at room temperature, the mixture was concentrated and then purified by chromatography (C18, 0-90% 0.1% aqueous TFA mixture in methanol). Fractions containing the title compound were combined and volatile solvents were removed under reduced pressure. The remaining aqueous mixture was diluted with aqueous bicarbonate and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, collected by filtration and concentrated to give 134 (0.012 g, 9%) as a white solid. MS m / e 477 [M + H] ⁺ . ¹ H NMR (300 MHz, DMSO-d ₆ ) δ ppm 1.45 (dd, J = 12, 23 Hz, 2H), 1.77 (d, J = 12 Hz, 2H), 2.04-2.11 (m, 3H) ), 2.25 (s, 6H), 2.96 (d, J = 12 Hz, 2H), 3.81-3.85 (m, 6H), 3.99-4.02 (m, 4H), 7.24 (t, J = 9 Hz, 1H), 7.40 (t, J = 9 Hz, 1H), 7.42 (s, 1H), 7.62 (d, J = 9 Hz, 1H), 8. 54 (d, J = 9 Hz, 1H), 13.37 (s, 1H)

Example 135 2- (4-((2- (Isoquinolin-8-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropane Amide 135
2- [4- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl] -isobutyl in a microwave vessel Amide (0.200 g, 0.288 mmol), 5-bromoisoquinoline (0.072 g, 0.346 mmol), copper (I) iodide (0.066 g, 0.346 mmol), palladium tetrakis (triphenylphosphine) (0 0.033 g, 0.029 mmol) and dioxane (4 mL) were charged. The vessel was evacuated three times and again filled with argon, then sealed and heated at 140 ° C. for 20 minutes under microwave irradiation. The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated and then purified by chromatography (silica, 0 to 15% 9: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give a yellow residue. This residue was dissolved in dichloromethane and then 1N HCl in ether (0.2 mL) was added dropwise. The resulting precipitate was collected by filtration to give 135 (0.012 g, 6%) as a salt of tetrahydrochloride as a pale yellow powder. MS m / e 532 [M + H] ⁺ ; ¹ H NMR (300 MHz, 360 K, DMSO-d ₆ ) δ ppm 1.49 (s, 6H) 2.96-3.33 (m, 8H) 3.79-3.91 (m , 4H) 3.97-4.09 (m, 4H) 4.22 (br.s., 2H) 6.00 (br.s., 2H) 7.65 (s, 1H) 8.06-8 .18 (m, 1H) 8.23-8.35 (m, 2H) 8.54 (d, J = 7.5 Hz, 1H) 8.68 (br.s., 1H) 10.57 (br. s., 1H)

Example 136 N, N-dimethyl-1-((4-morpholino-2- (1H-pyrrolo [2,3-b] pyridin-3-yl) thieno [3,2-d] pyrimidin-6-yl) Methyl) piperidine-4-amine 136
In a microwave vessel, dimethyl- [1- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidine-6-methyl) -piperidine in dioxane (8 mL) 4-yl] -amine (0.2 g) was charged. The vessel was evacuated and refilled with argon. To this mixture was added 3-bromo-pyrrolo [2,3-b] pyridine-1-carboxylic acid tert-butyl ester (0.18 g), cuprous iodide (0.07 g) and tetrakistriphenylphosphine palladium (0. 04g) was added. The vessel was evacuated and backfilled with argon, then the mixture was irradiated with microwaves at 150 ° C. for 30 minutes. The reaction mixture was cooled to room temperature and then filtered through an HPLC filter. The filtrate was concentrated and the resulting residue was purified by chromatography (silica, 0 to 10% 49: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give 136 (0.026 g, 17%) as a light brown Obtained as a solid. MS m / e 478 [M + H] ⁺ . ¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 1.41 (d, J = 9.09 Hz, 2H) 1.74 (d, J = 11.12 Hz, 2H) 2.06 (t, J = 10. 61 Hz, 3H) 2.18 (s, 6H) 2.94 (d, J = 11.12 Hz, 2H) 3.75-3.88 (m, 6H) 3.91-4.05 (m, 4H) 7.21 (dd, J = 8.08, 4.55 Hz, 1H) 7.33 (s, 1H) 8.12-8.35 (m, 2H) 8.83 (dd, J = 7.83, 1.77 Hz, 1H) 12.09 (br.s., 1H)

Example 137 2- (1-((2- (1- (ethylamino) isoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl ) Propan-2-ol 137

ＭｅＯＨ（１０．３ｍＬ、２５４ｍｍｏｌ）中の４-ブロモ-１クロロイソキノリン（０．８３１ｇ、３．４３ｍｍｏｌ）の懸濁液にエチルアミン（水中７０％、１．１ｍＬ）を加えた。混合物を５０℃で１６時間加熱した。混合物を濃縮した。残留物を水（２０ｍＬ）及びＤＣＭ（２０ｍＬ）の間で分配した。ＤＣＭ層を分離した。水性層をＤＣＭで抽出した（１０ｍＬ）。混合したＤＣＭ溶液を乾燥させた（Ｎａ_２ＳＯ_４）。濾過し、濃縮して、４−ブロモ−Ｎ−エチルイソキノリン−１−アミン（０．７６１ｇ、８８％）を得た。ＬＣＭＳ：Ｍ＋Ｈ^＋＝２５１。 Step 1: 4-Bromo-N-ethylisoquinoline-1-amine

To a suspension of 4-bromo-1 chloroisoquinoline (0.831 g, 3.43 mmol) in MeOH (10.3 mL, 254 mmol) was added ethylamine (70% in water, 1.1 mL). The mixture was heated at 50 ° C. for 16 hours. The mixture was concentrated. The residue was partitioned between water (20 mL) and DCM (20 mL). The DCM layer was separated. The aqueous layer was extracted with DCM (10 mL). The combined DCM solution was dried (Na ₂ SO ₄ ). Filtration and concentration gave 4-bromo-N-ethylisoquinolin-1-amine (0.761 g, 88%). LCMS: M + H ^< + ^> = 251.

Step 2: Following the procedure for 108, 2- (1-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) propan-2-ol and 4-Bromo-N-ethylisoquinolin-1-amine was converted to 137. LCMS: M + H + = 547. ¹ H NMR (400 MHz, DMSO) δ 9.03 (d, J = 8.5, 1H), 8.67 (s, 1H), 8.28 (d, J = 8.3, 1H), 7.68 (Dd, J = 16.9, 6.5, 2H), 7.51 (t, J = 7.5, 1H), 7.37 (s, 1H), 4.04 (s, 1H), 3 .93 (d, J = 4.8, 4H), 3.80 (d, J = 6.3, 6H), 3.65-3.54 (m, 2H), 2.99 (d, J = 10.9, 2H), 2.07 (s, 1H), 1.97 (t, J = 11.5, 2H), 1.67 (d, J = 10.9, 2H), 1.36 1.12 (m, 6H), 1.04 (s, 6H)

Example 138 2- (1-((2- (Benzofuran-3-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 138
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol and 2- (benzofuran) -3-yl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane was converted to 138. LCMS: M + H ^< + ^> = 491.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.75 (s, 1H), 8.58 (m, 1H), 7.66 (m, 1H), 7.40 (m, 2H), 4 .66 (s, 2H), 4.31 (m, 4H), 3.90 (s, 3H), 3.80 (m, 4H), 3.68 (s, br, 1H), 3.12 ( m, 2H), 2.90 (m, 2H), 1.90 (m, 2H), 1.56 (m, 3H), 1.06 (s, 6H)

Example 139 4- (9-Methyl-6-morpholino-8-((4-morpholinopiperidin-1-yl) methyl) -9H-purin-2-yl) isoquinolin-1-amine 139
4- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) morpholine (84 mg, in toluene (3 mL) and ethanol (1 mL) 0.19 mmol), 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine (52 mg, 0.19 mmol), 2M Na ₂ CO ₃ To a degassed suspension of an aqueous solution (0.19 mL, 0.38 mmol) was added Pd (PPh ₃ ) ₄ (11 mg, 0.010 mmol). The suspension was then stirred at 100 ° C. for 18 hours under nitrogen. The reaction mixture was then diluted with EtOAc and water. The aqueous layer was extracted 3 times with EtOAc. The combined organic extracts were washed with water, dried over Na ₂ SO ₄ , filtered and concentrated. The crude product was purified by flash chromatography (25% MeOH in DCM) to give 139 as a white solid (14.3 mg, 14%). LCMS: M + H ^< + ^> = 544.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 9.01 (d, 1H), 8.25 (d, 1H), 8.16 (s, 1H), 7.67 (t, 1H), 7 .49 (t, 1H), 7.08 (s, 2H), 4.23 (s, br, 4H), 3.82 (s, 3H), 3.78 (m, 6H), 3.55 ( m, 4H), 2.88 (m, 2H), 2.43 (m, 4H), 2.07 (m, 3H), 1.75 (m, 2H), 1.38 (m, 2H)

Example 140 2-Methyl-2- (4-((2- (2-methylbenzofuran-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1- Yl) propanamide 140
2- (4-((2-Chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide (90 in acetonitrile (2 mL) Degassed suspension of 4,4,5,5-tetramethyl-2- (2-methylbenzofuran-3-yl) -1,3,2-dioxaborolane (120 mg, 0.46 mmol) 2M aqueous sodium carbonate (0.20 mL) and 1M aqueous potassium acetate (0.2 mL) were added. The mixture was then heated in the microwave at 140 ° C. for 30 minutes. The reaction mixture was diluted with water and EtOAc. The aqueous layer was extracted with EtOAc. The combined extracts were washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated. The crude product was purified by RP-HPLC to give 140 (33.6 mg, 30.6%). LCMS: M + H ^< + ^> = 535.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.45 (m, 1H), 7.55 (m, 1H), 7.42 (s, 1H), 7.31 (m, 2H), 7 .05 (s, 1H), 6.93 (s, 1H), 3.95 (m, 4H), 3.86 (s, 2H), 3.83 (m, 4H), 2.84 (s, 3H), 2.42-2.63 (m, 8H), 1.08 (s, 6H)

Example 141 2- (2- (1-Aminoisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) propan-2-ol 141
2- (2-Chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) propan-2-ol (63 mg, 0.20 mmol) in acetonitrile (3.6 mL) in a microwave reaction vessel 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine (110 mg, 0.40 mmol), bis (triphenylphosphine) palladium ( II) 1M sodium carbonate in chloride (7.02 mg, 0.010 mmol) and water (0.60 mL) was added. The reaction vessel was sealed and heated in a microwave at 140 ° C. for 20 minutes. LC-MS of the reaction mixture no longer showed starting material. The solvent was evaporated and the resulting oil was purified on silica gel (0-20% 2N NH _{3 in} MeOH / DCM). The resulting oil was further purified by reverse phase HPLC to give 141 as an off-white solid (4.7 mg, 6%) ¹ H NMR (DMSOd ₆ , 400 MHz) 9.02 (d, 1H, J = 8.4 Hz), 8.26 (s, 1 H), 8.26 (d, 1 H, J = 8.4 Hz), 7.67 (t, 1 H, J = 7.6 Hz), 7.50 (t, 1H, J = 7.6) m7.33 (s, 1H), 7.11 (s, 2H), 5.84 (s, 1H), 3.98-3.94 (m, 4H), 3. 81-3.78 (m, 4H), 1.61 (m, 6H). LCMS m / z: 422 (MH ^<+> )

５ｍＬのマイクロ波バイアルにジオキサン（３ｍＬ）中の２-[４-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミド（０．２２ｇ、０．３１ｍｍｏｌ）、１-ベンゼンスルホニル-４-ブロモ-２-メチル-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．１３ｇ、０．３７ｍｍｏｌ）、２-チオフェンカルボン酸銅(Ｉ)（０．０１２ｇ、０．０６２ｍｍｏｌ）及びＰｄ(ＰＰｈ_３)_４（０．０３６ｇ、０．０３１ｍｍｏｌ）の懸濁液を充填した。反応混合物をマイクロ波で１４０℃２０分間加熱した。粗反応混合物を、ＭｅＯＨで処理したＳＣＸ-２カートリッジ上に充填した。カートリッジをＭｅＯＨ（１００ｍＬ）で洗浄し、ついで生成物をＭｅＯＨ中の２Ｎのアンモニアで溶出した。溶離液を真空下で濃縮し、生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ中０％から１０％ＭｅＯＨ）で精製して白色の泡として得た（０．１７ｇ、８２％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝３．３６分，［Ｍ＋Ｈ］^＋６７５．１ Example 142 2-Methyl-2- (4-((2- (2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 142
Step 1: 2- {4- [2- (1-Benzenesulfonyl-2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholin-4-yl-thieno [3, 2-d] pyrimidin-6-ylmethyl] piperazin-1-yl} isobutyramide

2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) in dioxane (3 mL) in a 5 mL microwave vial Piperazin-1-yl] isobutyramide (0.22 g, 0.31 mmol), 1-benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [2,3-c] pyridine (0.13 g, 0.37 mmol) ) A suspension of copper (I) 2-thiophenecarboxylate (0.012 g, 0.062 mmol) and Pd (PPh ₃ ) ₄ (0.036 g, 0.031 mmol) was charged. The reaction mixture was heated in the microwave at 140 ° C. for 20 minutes. The crude reaction mixture was loaded onto a SCX-2 cartridge treated with MeOH. The cartridge was washed with MeOH (100 mL) and then the product was eluted with 2N ammonia in MeOH. The eluent was concentrated under vacuum and the resulting residue was purified by flash chromatography (Si-PPC, 0% to 10% MeOH in DCM) to give as a white foam (0.17 g, 82%). LCMS (Method C): R _T = 3.36 min, [M + H] ⁺ 675.1.

窒素下で、（Ｃｌａｉｓｅｎヘッドを介して）凝縮器／不活性ガスバブラーを備えた２５ｍＬの丸底フラスコに、ジオキサン（４ｍＬ）、ＩＭＳ（４ｍＬ）及びＮａＯＨ１２．５Ｍ（０．４ｍＬ）中の２-{４-[２-(１-ベンゼンスルホニル-２-メチル-１Ｈ-ピロロ[２,３-ｃ]ピリジン-４-イル)-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル]ピペラジン-１-イル}イソブチルアミド（０．１７ｇ、０．２５ｍｍｏｌ）の溶液を充填した。生じた混合物を室温で２．５時間攪拌した。溶液を真空下で濃縮し、残留物をＭｅＯＨで希釈し、ＭｅＯＨで処理したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填した。カートリッジをＭｅＯＨ（１００ｍＬ）で洗浄し、生成物をＭｅＯＨ中の２ＮのＮＨ_３で溶出して回収し、溶離液を濃縮し、ジオキサン／水中に懸濁させ、一晩凍結乾燥させた。生じた固体をＤＭＳＯに溶解させ、分取ＨＰＬＣ（Ｃ１８カラム）勾配：（水／２０ｍＭトリエチルアミン）中（アセトニトリル／２０ｍＭトリエチルアミン）１０％から９８％で２０分（流量１８ｍｌ／分）によって精製した。生成物を一晩凍結乾燥させ、１４２を白色粉末として得た（０．０４７ｇ、３５％）。ＬＣＭＳ（方法Ｅ）：Ｒ_Ｔ＝５．２７分，［Ｍ＋Ｈ］^＋５３５．２．^１Ｈ ＮＭＲ（ＤＭＳＯ，４００ＭＨｚ）：δ１１．４３（ｓ，１Ｈ）；８．２２（ｄ，Ｊ＝５．４Ｈｚ，１Ｈ）；７．４３（ｓ，１Ｈ）；７．３３（ｄｄ，Ｊ＝６．３，０．９Ｈｚ，１Ｈ）；７．０７（ｄ，Ｊ＝３．５Ｈｚ，１Ｈ）；６．９５（ｄ，Ｊ＝３．４５Ｈｚ，１Ｈ）；６．８７（ｓ，１Ｈ）；３．９８（ｔ，Ｊ＝４．６Ｈｚ，４Ｈ）；３．８７（ｓ，２Ｈ）；３．８１（ｔ，Ｊ＝４．６Ｈｚ，４Ｈ）；３．５７（ｓ，３Ｈ）；２．６１−２．５３（ｍ，２Ｈ）；２．４９−２．４５（ｍ，２Ｈ）；２．４４（ｓ，４Ｈ）；１．０８（ｓ，６Ｈ） Step 2: 2- {4- [2- (2-Methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine -6-ylmethyl] piperazin-1-yl} isobutyramide

Under nitrogen (through a Claisen head), a 25 mL round bottom flask equipped with a condenser / inert gas bubbler was charged with 2- {2 in dioxane (4 mL), IMS (4 mL) and NaOH 12.5 M (0.4 mL). 4- [2- (1-Benzenesulfonyl-2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine- A solution of 6-ylmethyl] piperazin-1-yl} isobutyramide (0.17 g, 0.25 mmol) was charged. The resulting mixture was stirred at room temperature for 2.5 hours. The solution was concentrated in vacuo and the residue was diluted with MeOH and loaded onto a MeOH-treated Isolute® SCX-2 cartridge. The cartridge was washed with MeOH (100 mL) and the product was collected by eluting with 2N NH ₃ in MeOH and the eluent was concentrated, suspended in dioxane / water and lyophilized overnight. The resulting solid was dissolved in DMSO and purified by preparative HPLC (C18 column) gradient: 10% to 98% in (water / 20 mM triethylamine) (acetonitrile / 20 mM triethylamine) for 20 minutes (flow rate 18 ml / min). The product was lyophilized overnight to give 142 as a white powder (0.047 g, 35%). LCMS (Method E): R _T = 5.27 min, [M + H] ⁺ 535.2. ¹ H NMR (DMSO, 400 MHz): δ 11.43 (s, 1H); 8.22 (d, J = 5.4 Hz, 1H); 7.43 (s, 1H); 7.33 (dd, J = 6.3, 0.9 Hz, 1H); 7.07 (d, J = 3.5 Hz, 1H); 6.95 (d, J = 3.45 Hz, 1H); 6.87 (s, 1H); 3.98 (t, J = 4.6 Hz, 4H); 3.87 (s, 2H); 3.81 (t, J = 4.6 Hz, 4H); 3.57 (s, 3H); 61-2.53 (m, 2H); 2.49-1.45 (m, 2H); 2.44 (s, 4H); 1.08 (s, 6H)

２０ｍＬのマイクロ波バイアルにジオキサン（８ｍＬ）及びＮＭＰ（２ｍＬ）中の２-[４-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミド（０．３８ｇ、０．５４ｍｍｏｌ）、１-ベンゼンスルホニル-４-ブロモ-２-メチル-１Ｈ-ピロロ[３,２-ｃ]ピリジン（０．２１ｇ、０．６０ｍｍｏｌ）、２-チオフェンカルボン酸銅(Ｉ)（０．０４２ｇ、０．２２ｍｍｏｌ）及びＰｄ(ＰＰｈ_３)_４（０．１２６ｇ、０．１０８ｍｍｏｌ）の懸濁液を充填した。反応混合物をマイクロ波で１４０℃で１００分間加熱した。粗反応混合物を、ＭｅＯＨで処理したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填した。カートリッジをＭｅＯＨ（１００ｍＬ）で洗浄し、ついで生成物をＭｅＯＨ中の２ＮのＮＨ_３で溶出して回収した。溶離液を真空下で濃縮し、生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ中０−１０％のＭｅＯＨ）で精製して黄色の泡として得た（０．２４ｇ、６５％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝３．５３分，［Ｍ＋Ｈ］^＋６７５．２ Example 143 2-Methyl-2- (4-((2- (2-methyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 143
Step 1: 2- {4- [2- (1-Benzenesulfonyl-2-methyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -4-morpholin-4-yl-thieno [3, 2-d] pyrimidin-6-ylmethyl] piperazin-1-yl} isobutyramide

2- [4- (4-morpholin-4-yl-2- (stannanyl)) thieno [3,2-d] pyrimidine in dioxane (8 mL) and NMP (2 mL) in a 20 mL microwave vial -6-ylmethyl) piperazin-1-yl] isobutyramide (0.38 g, 0.54 mmol), 1-benzenesulfonyl-4-bromo-2-methyl-1H-pyrrolo [3,2-c] pyridine (0. (21 g, 0.60 mmol) A suspension of copper (I) 2-thiophenecarboxylate (0.042 g, 0.22 mmol) and Pd (PPh ₃ ) ₄ (0.126 g, 0.108 mmol) was charged. The reaction mixture was heated in the microwave at 140 ° C. for 100 minutes. The crude reaction mixture was loaded onto an Isolute® SCX-2 cartridge treated with MeOH. The cartridge was washed with MeOH (100 mL) and then the product was collected by eluting with 2N NH ₃ in MeOH. The eluent was concentrated under vacuum and the resulting residue was purified by flash chromatography (Si-PPC, 0-10% MeOH in DCM) to give as a yellow foam (0.24 g, 65%). LCMS (Method A): R _T = 3.53 min, [M + H] ⁺ 675.2.

Step 2: Under nitrogen, in a 25 mL round bottom flask equipped with a condenser and inert gas bubbler (via Claisen head) in dioxane (5 mL), IMS (5 mL) and NaOH 12.5M (0.5 mL). 1-2- {4- [2- (1-Benzenesulfonyl-2-methyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -4-morpholin-4-yl-thieno [3,2 A solution of -d] pyrimidin-6-ylmethyl] piperazin-1-yl} isobutyramide (0.24 g, 0.35 mmol) was charged. The resulting mixture was stirred at room temperature for 2 hours and then concentrated under vacuum. The resulting residue was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge pretreated with MeOH. The cartridge was washed with MeOH (100 mL) and eluted with 2N ammonia in MeOH to collect the product and concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, 0 to 100% EtOAc in cyclohexane) to give a yellow powder. The solid was dissolved in DMSO and purified by preparative HPLC (C18 column, flow rate 18 mL / min) gradient: 25-98% in acetonitrile / 20 mM triethylamine / 20 mM triethylamine in water over 20 minutes. The product was lyophilized overnight to give 143 as a yellow powder (0.035 g, 21%). LCMS (Method E): R _T = 5.60 min, [M + H] ⁺ 535.2. ¹ H NMR (DMSO, 400 MHz): δ 11.43 (s, 1H); 8.22 (d, J = 5.4 Hz, 1H); 7.43 (s, 1H); 7.33 (dd, J = 6.3, 0.9 Hz, 1H); 7.07 (d, J = 3.5 Hz, 1H); 6.95 (d, J = 3.45 Hz, 1H); 6.87 (s, 1H); 3.98 (t, J = 4.6 Hz, 4H); 3.87 (s, 2H); 3.81 (t, J = 4.6 Hz, 4H); 3.57 (s, 3H); 61-2.53 (m, 2H); 2.49-1.45 (m, 2H); 2.44 (s, 4H); 1.08 (s, 6H)

Example 144 2- (4-((2- (1-acetamidoisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2 -Methylpropanamide 144

塩化メチレン（１１ｍＬ）中の４-ブロモイソキノリン-１-アミン（４０３ｍｇ、１．８１ｍｍｏｌ）の溶液に０℃でＮ,Ｎ-ジイソプロピルエチルアミン（１．５７ｍＬ、９．０３ｍｍｏｌ）と、ついでアセチルクロライド（０．３２１ｍＬ、４．５２ｍｍｏｌ）を滴下して加えた。混合物を０℃で１０分間攪拌し、ついで室温で２時間攪拌した。混合物をＤＣＭ（１０ｍＬ）で希釈した。水（２０ｍＬ）を加えた。有機層を分離した。水溶液をＤＣＭ（１０ｍＬ）で抽出した。混合したＤＣＭ溶液を乾燥させた（Ｎａ_２ＳＯ_４）。濾過及び濃縮後、粗物質をフラッシュクロマトグラフィーで精製して、所望の生成物を得た（４７０ｍｇ、８５％）。^１Ｈ ＮＭＲ（４００ＭＨｚ，ＤＭＳＯ）δ８．７９（ｓ，１Ｈ），８．２３（ｄ，Ｊ＝８．４，１Ｈ），８．１３（ｄ，Ｊ＝８．４，１Ｈ），８．０５（ｔ，Ｊ＝７．７，１Ｈ），７．８７（ｔ，Ｊ＝７．６，１Ｈ），２．２３（ｓ，６Ｈ）。 Step 1: N-acetyl-N- (4-bromoisoquinolin-1-yl) acetamide

A solution of 4-bromoisoquinolin-1-amine (403 mg, 1.81 mmol) in methylene chloride (11 mL) at 0 ° C. with N, N-diisopropylethylamine (1.57 mL, 9.03 mmol) followed by acetyl chloride (0 .321 mL, 4.52 mmol) was added dropwise. The mixture was stirred at 0 ° C. for 10 minutes and then at room temperature for 2 hours. The mixture was diluted with DCM (10 mL). Water (20 mL) was added. The organic layer was separated. The aqueous solution was extracted with DCM (10 mL). The combined DCM solution was dried (Na ₂ SO ₄ ). After filtration and concentration, the crude material was purified by flash chromatography to give the desired product (470 mg, 85%). ¹ H NMR (400 MHz, DMSO) δ 8.79 (s, 1H), 8.23 (d, J = 8.4, 1H), 8.13 (d, J = 8.4, 1H), 8.05 (T, J = 7.7, 1H), 7.87 (t, J = 7.6, 1H), 2.23 (s, 6H).

Step 2: According to General Procedure B for Suzuki coupling, N-acetyl-N- (4-bromoisoquinolin-1-yl) acetamide (57 mg) was treated with 2- (4-((2-chloro-4-morpholinothieno [ Reacted with 3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide (107 mg). After the reaction was complete, 1M Na ₂ CO ₃ (2 mL) and 1,4-dioxane (2 mL) were added to the mixture. The suspension was heated at 60 ° C. for 3 hours. The reaction mixture was concentrated. Water (5 mL) was added. The contents were extracted with DCM (2 × 10 mL). The combined DCM solution was dried (Na ₂ SO ₄ ). The crude material was purified by reverse phase HPLC to give 144 (20 mg, 22%). LCMS: M + H + = 589. ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.86 (2H), 8.07 (, s, br, 2H), 7.75 (t, J = 7.7, 1H), 7.64 (t, J = 7.6, 1H), 7.36 (s, 1H), 7.09 (s, 1H), 5.18 (s, 1H), 4.12-4.00 (m, 4H), 3. 94-3.81 (m, 6H), 2.62 (s, 8H), 2.44 (s, 3H), 1.25 (s, 6H)

Example 145 2- (1-((9-Methyl-2- (2-methylbenzofuran-3-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -All 145
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was converted to 145 according to the procedure for 140. . LCMS: M + H ⁺ = 505.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.49 (m, 1H), 7.54 (m, 1H), 7.31 (m, 2H), 4.26 (s, br, 4H) , 4.05 (s, 1H), 3.86 (s, 3H), 3.77 (m, 4H), 3.68 (s, 2H), 2.94 (s, 3H), 2.90 ( m, 2H), 2.01 (m, 2H), 1.66 (m, 2H), 1.21 (m, 3H), 0.94 (s, 6H).

Example 146 1-((2- (Benzo [b] thiophen-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidine-4- Amine 146
[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -dimethyl-amine (0.400 g 1. 01 mmol), benzo [b] thien-3-ylboronic acid (197 mg, 1.11 mmol), 1N sodium carbonate solution (2.5 mL), acetonitrile (7.5 mL) and Pd (dppf) Cl ₂ (82.4 mg, 0.100 mmol), then the mixture was degassed, sealed and heated at 140 ° C. for 20 minutes under microwave irradiation. After the reaction mixture was diluted with dichloromethane (100 mL) and 1N sodium carbonate solution (10 mL), the phases were separated. The organic phase was washed with saturated aqueous sodium bicarbonate solution (15 mL), then dried (MgSO ₄ ) and concentrated in vacuo. Purification by chromatography (silica, 0 to 15% 9.5: 0.5 MeOH: NH ₄ OH solution in dichloromethane) gave 146 (240 mg, 48.2%) as a light brown solid. MS m / e 494 [M + H] ⁺¹ H NMR (300 MHz, chloroform-d) δ ppm 1.47-1.68 (m, 2H) 1.81 (d, J = 12.43 Hz, 2H) 2.03-2.20 ( m, 3H) 2.28 (s, 6H) 3.02 (d, J = 12.06 Hz, 2H) 3.80 (s, 2H) 3.85-3.95 (m, 4H) 3.99- 4.10 (m, 4H) 7.32 (s, 1H) 7.34-7.42 (m, 1H) 7.43-7.53 (m, 1H) 7.89 (d, J = 7. 91 Hz, 1H) 8.44 (s, 1H) 9.00-9.15 (m, 1H).

Example 147 2- (1-((2- (1-aminoisoquinolin-5-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -All 147

１,４-ジオキサン（３ｍＬ）中の２-(１-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（２３５ｍｇ、０．５７５ｍｍｏｌ）、ビス(トリブチルすず)（０．５８ｍＬ、１．１５ｍｍｏｌ）及びＰｄＣｌ_２[ｔ-Ｂｕ_２Ｐ(Ｐｈ-ｐ-Ｎｍｅ_２)_２]（４１ｍｇ、０．０５７ｍｍｏｌ）の混合物を１４０℃で４０分間マイクロ波で加熱した。反応混合物をついで濃縮した。粗生成物をフラッシュクロマトグラフィー（０−１００％勾配ＥｔＯＡｃ−ヘプタン）で精製して、表題化合物を得た（２５６ｍｇ、６７．１％）。ＬＣＭＳ：Ｍ＋Ｈ^＋＝６６３．２ Step 1: 2- (1-((9-Methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol

2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol in 1,4-dioxane (3 mL) (235 mg, 0.575 mmol), a mixture of bis (tributyltin) (0.58 mL, 1.15 mmol) and PdCl ₂ [t-Bu ₂ P (Ph-p-Nme ₂ ) ₂ ] (41 mg, 0.057 mmol) Was heated in the microwave at 140 ° C. for 40 minutes. The reaction mixture was then concentrated. The crude product was purified by flash chromatography (0-100% gradient EtOAc-heptane) to give the title compound (256 mg, 67.1%). LCMS: M + H ^< + ^> = 663.2

Step 2: 2- (1-((9-Methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidine-4- in 1,4-dioxane (4 mL) Yl) propan-2-ol (256 mg, 0.386 mmol), 5-bromoisoquinolin-1-amine (86 mg, 0.386 mmol), thiophene-2-carboxylate (I) (74 mg, 0.386 mmol) To the gas mixture was added Pd (PPh ₃ ) ₄ (45 mg, 0.039 mmol). The reaction mixture was heated in the microwave at 140 ° C. for 35 minutes. The reaction mixture was loaded onto a Biotage Isolute SPE SCX-2 column. The column was first washed with MeOH. The product was eluted with 2M NH ₃ in MeOH and concentrated. The crude material was further purified by RP-HPLC to give 147 (36.3 mg, 18.2%). LCMS: M + H ^< + ^> = 517.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.28 (d, 1H), 8.11 (d, 1H), 7.79 (d, 1H), 7.70 (d, 1H), 7 .53 (t, 1H), 6.80 (s, 2H), 4.23 (s, br, 4H), 4.09 (s, 1H), 3.81 (s, 3H), 3.73 ( m, 6H), 2.90 (m, 2H), 2.02 (m, 2H), 1.66 (m, 2H), 1.19 (m, 3H), 1.02 (s, 6H)

Example 149 N, N-dimethyl-1-((4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-1-yl) thieno [3,2-d] pyrimidin-6-yl) Methyl) piperidine-4-amine 149
According to General Procedure I for Buchwald coupling, 1-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine and 1H -Pyrrolo [3,2-c] pyridine was reacted to give 149. MS m / e 478.6 [M + H] ⁺

Example 150 1-((2- (Isoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethylpiperidin-4-amine 150
2- [4- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl] -isobutyl in a microwave vessel Amide (0.226 g, 0.347 mmol), 4-bromoisoquinoline (0.086 g, 0.416 mmol), thiophene-2-carboxylic acid copper (I) (Cu (TC)) (0.066 g, 0.347 mmol) , Palladium tetrakis (triphenylphosphine) (0.040 g, 0.034 mmol) and dioxane (2 mL). The vessel was degassed, sealed, and heated at 140 ° C. for 20 minutes under microwave irradiation. The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated and then purified twice by chromatography (silica, 0-15% 9: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give 150 (0.026 g, 15.38%) as an off-white foam. Obtained. ¹ H NMR (400 MHz, CDCl ₃ -d) δ ppm 1.60 (qd, J = 12.04, 3.79 Hz, 2H) 1.83 (d, J = 12.63 Hz, 2H) 2.08-2.22 (M, 3H) 2.30 (s, 6H) 3.05 (d, J = 12.13 Hz, 2H) 3.84 (s, 2H) 3.86-3.92 (m, 4H) 4.03 -4.11 (m, 4H) 7.35 (s, 1H) 7.59-7.65 (m, 1H) 7.69-7.77 (m, 1H) 8.03 (d, J = 8 .59 Hz, 1H) 8.82 (d, J = 8.08 Hz, 1H) 9.11 (s, 1H) 9.30 (s, 1H). MS m / e 489 [M + H] ⁺

ジオキサン（３ｍＬ）中の２-[４-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペラジン-１-イル]イソブチルアミド（０．２４１ｇ、０．３５ｍｍｏｌ）、１-ベンゼンスルホニル-４-ブロモ-２-エチル-１Ｈ-ピロロ[２,３-ｃ]ピリジン（０．１４ｇ、０．３８ｍｍｏｌ）、２-チオフェンカルボン酸銅(Ｉ)（０．０１ｇ、０．０６９ｍｍｏｌ）及びＰｄ(ＰＰｈ_３)_４（０．０４０ｇ、０．０３５ｍｍｏｌ）の混合物に１５０℃で２０分間マイクロ波照射を施した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物を、２ＭのＮＨ_３を使用して溶出させた。溶離液を真空下で濃縮し、残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から２０：８０の勾配）で精製し、２-{４-[２-(１-ベンゼンスルホニル-２-エチル-１Ｈ-ピロロ[２,３-ｃ]ピリジン-４-イル)-４-モルホリン-４-イルチエノ[３,２-ｄ]ピリミジン-６-イルメチル]ピペラジン-１-イル}イソブチルアミドを黄色の泡として得た（０．１５ｇ、６４％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ＝３．５３分，［Ｍ＋Ｈ］^＋６８９．２ Example 151 2- (4-((2- (2-Ethyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) -2-methylpropanamide 151

2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (3 mL) Isobutylamide (0.241 g, 0.35 mmol), 1-benzenesulfonyl-4-bromo-2-ethyl-1H-pyrrolo [2,3-c] pyridine (0.14 g, 0.38 mmol), 2-thiophenecarboxylic A mixture of copper (I) acid (0.01 g, 0.069 mmol) and Pd (PPh ₃ ) ₄ (0.040 g, 0.035 mmol) was subjected to microwave irradiation at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted using 2M NH ₃ . The eluent is concentrated in vacuo and the residue is purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) and purified by 2- {4- [2- (1-benzene Sulfonyl-2-ethyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl] piperazin-1-yl} isobutyl The amide was obtained as a yellow foam (0.15 g, 64%). LCMS (Method A): R _T = 3.53 min, [M + H] ⁺ 689.2.

2- {4- [2- (1-benzenesulfonyl-2-ethyl-1H-pyrrolo [2,3-c] pyridine- in dioxane (3 mL), IMS (3 mL) and NaOH 12.5 M (0.34 mL) A mixture of 4-yl) -4-morpholin-4-ylthieno [3,2-d] pyrimidin-6-ylmethyl] piperazin-1-yl} isobutyramide (0.15 g, 0.22 mmol) was stirred at room temperature for 3 hours. And then concentrated under vacuum. The residue was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted using 2M NH ₃ . The residue was purified by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water with a gradient of acetonitrile 95: 5 to 2:98) to give 151 as a white powder (0.034 g, 29%). LCMS (Method E): R _T = 5.87 min, [M + H] ⁺ 549.2. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 11.56 (s, 1H); 9.09 (s, 1H); 8.65 (s, 1H); 7.45 (s, 1H); 14 (s, 1H); 7.07 (d, J = 3.5 Hz, 1H); 6.95 (d, J = 3.5 Hz, 1H); 3.99 (t, J = 4.6 Hz, 4H) 3.86 (s, 2H); 3.82 (t, J = 4.6 Hz, 4H); 2.86 (q, J = 7.6 Hz, 2H); 2.56-2.53 (m) , 4H); 2.51-2.45 (m, 4H); 1.34 (t, J = 7.6 Hz, 3H); 1.08 (s, 6H)

１,４-ジオキサン（１０ｍＬ）中の５-クロロ-７-モルホリン-４-イル-２-(３-モルホリン-４-イル-アゼチジン-１-イルメチル)チアゾロ[５,４-ｄ]ピリミジン（１．０ｇ、２．４３ｍｍｏｌ）、ＰｄＣｌ_２{Ｐ^ｔＢｕ_２(Ｐｈ-ｐ-Ｎｍｅ_２)}_２（１７０ｍｇ、０．２４ｍｍｏｌ）及びヘキサメチル二すず（１．８５ｍＬ、３．６６ｍｍｏｌ）の脱気溶液にマイクロ波照射を１５０℃で３０分間施した。反応混合物を雰囲気温度まで冷却し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３を使用して溶出した。生成物を収集し、濃縮して、黄色の油を得た。該油をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ，１００：０から９８：２から９５：５）で精製して、７-モルホリン-４-イル-２-(３-モルホリン-４-イル-アゼチジン-１-イルメチル)-５-(トリブチルスタンナニル(stannanyl))チアゾロ[５,４-ｄ]ピリミジンを淡黄色の油として得た（１．１８ｇ、７３％）。ＮＭＲ（ＣＤＣｌ_３，４００ＭＨｚ）δ４．３１（ｍ，４Ｈ），３．９７（ｓ，２Ｈ），３．８２（ｔ，Ｊ＝４．６Ｈｚ，４Ｈ），３．７２（ｍ，４Ｈ），３．６５−３．５９（ｍ，２Ｈ），３．１４−３．０５（ｍ，３Ｈ），２．３４（ｍ，４Ｈ），１．６５−１．５２（ｍ，６Ｈ），１．３９−１．２６（ｍ，６Ｈ），１．２３−１．０１（ｍ，６Ｈ），０．９３−０．８４（ｍ，９Ｈ）。 Example 152 4- (1-((7-morpholino-5- (1H-pyrrolo [3,2-c] pyridin-4-yl) thiazolo [5,4-d] pyrimidin-2-yl) methyl) azetidine -3-yl) morpholine 152

5-Chloro-7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) thiazolo [5,4-d] pyrimidine (1) in 1,4-dioxane (10 mL) 0.0g, 2.43 mmol), PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (170 mg, 0.24 mmol) and hexamethyltin tin (1.85 mL, 3.66 mmol) in a degassed solution Microwave irradiation was applied at 150 ° C. for 30 minutes. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated to give a yellow oil. The oil was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 95: 5) to give 7-morpholin-4-yl-2- (3-morpholin-4-yl -Azetidin-1-ylmethyl) -5- (stannanylyl) thiazolo [5,4-d] pyrimidine was obtained as a pale yellow oil (1.18 g, 73%). NMR (CDCl ₃ , 400 MHz) δ 4.31 (m, 4H), 3.97 (s, 2H), 3.82 (t, J = 4.6 Hz, 4H), 3.72 (m, 4H), 3 .65-3.59 (m, 2H), 3.14-3.05 (m, 3H), 2.34 (m, 4H), 1.65-1.52 (m, 6H), 1.39 -1.26 (m, 6H), 1.23-1.01 (m, 6H), 0.93-0.84 (m, 9H).

7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) -5- (tributylstannanyl) thiazolo [5,1,4-dioxane (4 mL) 4-d] pyrimidine (200 mg, 0.30 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine (132 mg, 0.39 mmol), PdCl ₂ {P ^t Bu ₂ (Ph -p-Nme _2)} subjected 2 (22mg, 0.03mmol) and thiophene-2-carboxylic acid copper (I) (12mg, 20 minutes at 140 ° C. the microwave irradiation to a degassed solution of 0.06 mmol). The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated to give 5- (1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -7-morpholin-4-yl-2- (3-morpholine- 4-yl-azetidin-1-ylmethyl) thiazolo [5,4-d] pyrimidine was obtained as a crude oil. Aqueous NaOH (12.5 M, 0.5 mL) was added 5- (1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridin-4-yl in 1,4-dioxane (4 mL) and IMS (4 mL). ) -7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) -thiazolo [5,4-d] pyrimidine. The reaction mixture was stirred to ambient temperature for 45 minutes and then concentrated under vacuum. The residue was dissolved in MeOH and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated to give a solid. The solid was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 96: 4) to give 152 as a yellow solid (56 mg, 38%). LCMS (Method E): R _T = 4.34 min, M + H ⁺ = 493.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.72 (bs, 1H), 8.56 (d, J = 5.7 Hz, 1H), 7.41 (m, 2H), 7.36 (d, J = 3.2 Hz, 1H), 4.49-4.44 (m, 4H), 4.02 (s, 2H), 3.90 (t, J = 4.7 Hz, 4H), 3.74-3. 65 (m, 6H), 3.16-3.07 (m, 3H), 2.35 (m, 4H)

Example 153 2-Methyl-2- (4-((2- (5-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 153
2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (1 mL) Isobutyramide (72 mg, 0.10 mmol), 4-bromo-5-methyl-1H-pyrrolo [2,3-c] pyridine (22 mg, 0.10 mmol), Pd (PPh ₃ ) ₄ (12 mg, 10 mol%) and A solution of copper (I) -thiophene-2-carboxylate (4 mg, 20 mol%) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, the cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-20% MeOH in DCM) to give 153 as a pale yellow solid (24 mg, 43%). LCMS (Method E): R _T = 4.19 min, [M + H] ⁺ 535.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.14 (s, 1H), 8.73 (s, 1H), 7.34-7.32 (m, 2H), 7.11 (d, J = 5.3 Hz, 1H), 6.67-6.65 (m, 1H), 5.30 (d, J = 4.7 Hz, 1H), 4.04 (t, J = 4.7 Hz, 4H) 3.87 (d, J = 4.7 Hz, 4H), 3.85 (s, 2H), 2.76 (s, 3H), 2.61 (m, 8H), 1.28-1.22. (M, 6H)

Example 154 4- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) morpholine 154
4- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) morpholine and acetic acid were converted to 154 according to the procedure for 178. LCMS: M + H ^< + ^> = 532.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): d8.09 (m, 1H), 7.60 (m, 1H), 7.25 (m, 2H), 4.26 (s, br, 4H) , 3.82 (s, 3H), 3.71 (m, 6H), 3.54 (m, 4H), 2.85 (m, 5), 2.43 (m, 4H), 2.08 ( m, 3H), 1.76 (m, 2H), 1.39 (m, 2H).

２-(ピペリジン-４-イル)プロパン-２-オール（１ｇ）を３０ｍＬのクロロホルム中の１．１当量のクロロギ酸ベンジル及び１．３当量のトリエチルアミンと反応させた。反応を室温で２日後に停止させ、ｉｓｃｏ（２０にわたって、０−６０％ヘキサン／酢酸エチル）で精製して、１．４９ｇの４-(２-ヒドロキシプロパン-２-イル)ピペリジン-１-カルボン酸ベンジルを得た。

Example 155 4- (8-((4- (2-methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) isoquinoline-1 -Amine 155

2- (Piperidin-4-yl) propan-2-ol (1 g) was reacted with 1.1 equivalents of benzyl chloroformate and 1.3 equivalents of triethylamine in 30 mL of chloroform. The reaction was stopped after 2 days at room temperature and purified on isco (0-60% hexane / ethyl acetate over 20) to give 1.49 g of 4- (2-hydroxypropan-2-yl) piperidine-1-carboxylic acid. Benzyl acid was obtained.

A suspension of sodium hydride in 10 mL THF, 60% dispersion in mineral oil (0.322 g) and methyl iodide (1.00 mL) at room temperature in 4-(-2-hydroxypropane in 15 mL THF. -2-yl) piperidine-1-carboxylate (1.49 g, 0.00537 mol) was carefully added dropwise. The reaction was heated at 50 ° C. for 18 hours, then cooled to 0 ° C., carefully quenched by the addition of saturated NH 4 Cl solution, and then extracted twice with EtOAc. The combined organics were washed with brine, dried over MgSO ₄ and concentrated in vacuo. The residue was purified by flash chromatography to give 1.2 g of benzyl 4- (2-methoxypropan-2-yl) piperidine-1-carboxylate as a colorless oil.

The cbz protecting group was hydrodesorbed using H-cube with palladium on charcoal. The product in a solution of methanol was then concentrated to give 0.44 g of 4- (2-methoxypropan-2-yl) piperidine as a colorless oil through an isolute scx-2 spe cartridge.

  4- (2-Methoxypropan-2-yl) piperidine (0.12 g) was prepared via general procedure E and 4- (8- (bromomethyl) -2-chloro-9-methyl-9H-purin-6-yl. ) Morpholine (0.25 g) and 300 mg of crude 4- (2-chloro-8-((4- (2-methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl- 9H-purin-6-yl) morpholine, of which 0.78 g is 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine Reaction via general procedure A gave 12 mg of 155 as a white solid after reverse phase purification. MS (Q1) 531.3 (M) +

Example 156 1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -1H- Benzo [d] imidazol-2 (3H) -one 156
2- (1-((2- (2-Aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 in acetonitrile (2 mL) A mixture of -ol (40 mg, 0.083 mmol) and N, N-carbonyldiimidazole (17 mg, 0.108 mmol) was stirred at reflux for 15 hours. The reaction mixture was filtered through paper and purified by RP-HPLC to give 156 (6.7 mg, 16%). LCMS: M + H ⁺ = 507.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 11.0 (s, 1H), 7.55 (d, 1H), 7.04 (m, 3H), 4.21 (s, br, 4H) , 4.02 (s, 1H), 3.78 (s, 3H), 3.74 (m, 6H), 2.88 (m, 2H), 2.00 (m, 2H), 1.66 ( m, 2H), 1.20 (m, 3H), 1.02 (s, 6H)

Example 157 2- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 157

Step 1: 2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol in toluene (30 mL) 1.21 g, 2.96 mmol), benzene-1,2-diamine (520 mg, 4.8 mmol), palladium acetate (66 mg, 0.29 mmol), bis (tri-t-butylphosphine) palladium (150 mg, 0.29 mmol). ) And sodium tert-butoxide (620 mg, 6.4 mmol) was stirred at 95 ° C. for 18 hours. The reaction mixture was filtered through paper and then concentrated. The crude product was then purified by flash chromatography using a Biotage KP-NH column (gradient MeOH in DCM with 0 to 10% gradient) and 2- (1-((2- (2-aminophenylamino) -9- Methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (1.2 g, 84%) was obtained. LCMS: M + H ^< + ^> = 481.2.

Step 2: 2- (1-((2- (2-Aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine-4- in acetic acid (1.5 mL) A mixture of yl) propan-2-ol (177 mg, 0.368 mmol) was stirred at reflux for 5 hours. The reaction mixture was concentrated then purified by flash chromatography (10% MeOH in DCM containing 1% 2M ammonia in MeOH) followed by RP-HPLC to give 157 (0.0373 g, 21.1% ). LCMS: M + H ⁺ = 505.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): d8.09 (m, 1H), 7.60 (m, 1H), 7.25 (m, 2H), 4.26 (s, br, 4H) , 4.02 (s, 1H), 3.83 (s, 3H), 3.78 (m, 4H), 3, 73 (s, 2H), 2.90 (m, 2H), 2.84 ( s, 3H), 1.99 (m, 2H), 1.66 (m, 2H), 1.21 (m, 3H), 1.02 (s, 6H).

Example 158 2- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 158
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All and propanoic acid were reacted to give 158. LCMS: M + H ^< + ^> = 519.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.02 (m, 1H), 7.63 (m, 1H), 7.26 (m, 2H), 4.24 (s, br, 4H) , 4.02 (s, 1H), 3.82 (s, 3H), 3.77 (m, 4H), 3.73 (s, 2H), 3.28 (q, 2H), 2.90 ( m, 2H), 2.00 (m, 2H), 1.66 (m, 2H), 1.34 (t, 3H), 1.22 (m, 3H), 1.02 (s, 6H)

Example 159 2- (1-((2- (2-Cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine -4-yl) propan-2-ol 159
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All and cyclopropanecarboxylic acid were reacted to give 159. LCMS: M + H ⁺ = 531.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 7.93 (m, 1H), 7.53 (m, 1H), 7.22 (m, 2H), 4.26 (s, br, 4H) , 4.08 (m, 2H), 4.03 (s, 1H), 3.82 (s, 3H), 3.77 (m, 4H), 3.74 (s, 2H), 3.17 ( d, 2H), 2.84-2.96 (m, 3H), 1.99 (m, 2H), 1.67 (m, 2H), 1.04-1.29 (m, 3H), 1 .02 (s, 6H)

Example 160 2- (4-((2- (isoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropane Amide 160
Following general procedure A for Suzuki coupling, 2- (4-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methyl Propanamide and 4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinoline were reacted to give 160. LCMS: M + H ⁺ = 532.2.

Example 161 2- (1-((2- (2- (methoxymethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) Piperidin-4-yl) propan-2-ol 161
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All and methoxyacetic acid were reacted to give 161. LCMS: M + H ^< + ^> = 535.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.13 (d, 1H), 7.71 (d, 1H), 7.32 (m, 2H), 5.08 (s, 2H), 4 .26 (s, br, 4H), 4.02 (s, 1H), 3.83 (s, 3H), 3.78 (m, 4H), 3.73 (s, 2H), 3.27 ( s, 3H), 2.90 (m, 2H), 2.00 (m, 2H), 1.65 (m, 2H), 1.22 (m, 3H), 1.02 (s, 6H)

Example 162 2- (1-((2- (1H-indazol-3-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All 162
2- (1-((9-methyl-6-morpholino-2- (tributylstannyl) -9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.5 g) Reaction with 3-iodo-1H-indazole via general procedure G gave 68.3 mg 162 as a white solid after reverse phase purification. MS (Q1) 491.2 (M) +

Example 163 2- (4-((2- (2-fluorobenzofuran-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2 -Methylpropanamide 163
2-Methyl-2- (4-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) in dioxane (2 mL) To a degassed mixture of propanamide (150 mg, 0.22 mmol), 3-bromo-2-fluorobenzofuran (0.22 mmol), copper (I) thiophene-2-carboxylate (41 mg, 0.22 mmol) was added Pd (PPh ₃ ) ₄ (12 mg, 0.011 mmol) was added. The reaction mixture was reacted in the microwave at 140 ° C. for 35 minutes. The reaction mixture was filtered through paper and concentrated. The crude product was purified by flash chromatography (20% MeOH in DCM) to give a yellow paste, which was dissolved in dioxane (5 mL) and ethanol (1 mL). An aqueous solution of 12M NaOH was then added. The resulting mixture was then stirred at 65 ° C. for 15 hours. The reaction mixture was loaded onto a Biotage Isolute SPE SCX-2 column. The column was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH and further purified by RP-HPLC to give 163. LCMS: M + H ^< + ^> = 539.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.46 (d, 1H), 7.63 (d, 1H), 7.41 (m, 3H), 7.05 (d, 1H), 6 .93 (d, 1H), 3.97 (m, 4H), 3.86 (s, 2H), 3.82 (m, 4H), 2.31-2.62 (m, 8H), 1. 08 (s, 6H)

Example 164 4- (6-((4- (dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) isoquinoline 2-oxide 164
2- [4- (4-morpholin-4-yl-2-tributylstannanyl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazin-1-yl] -isobutyl in a microwave vessel Amide (0.206 g, 0.316 mmol), 4-bromo-isoquinoline 2-oxide (0.085 g, 0.379 mmol), thiophene-2-carboxylate copper (I) (Cu (TC)) (0.060 g, 0.316 mmol), palladium tetrakis (triphenylphosphine) (0.036 g, 0.031 mmol) and dioxane (2 mL). The vessel was degassed, sealed and heated at 140 ° C. with a microwave irradiator for 20 minutes. The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated and then purified twice by chromatography (silica, 0-15% 9: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give 164 (0.017 g, 10.7%) as a pale yellow foam. Obtained. ¹ H NMR (400 MHz, CDCl ₃ -d) δ ppm 1.54-1.68 (m, 3H) 1.85 (d, J = 12.13 Hz, 2H) 1.97 (br.s., 2H) 10-2.23 (m, 3H) 2.31 (s, 6H) 3.04 (d, J = 11.62 Hz, 2H) 3.85 (s, 2H) 3.86-3.91 (m, 4H) 4.04-4.09 (m, 4H) 7.34 (s, 1H) 7.59-7.66 (m, 2H) 7.73-7.80 (m, 1H) 8.78- 8.82 (m, 2H) 8.86-8.93 (m, 1H). MS m / e 505 [M + H] ⁺

Example 165 2- (1-((9-Methyl-2- (2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-2-ol 165

Step 1: In a 20 mL microwave vial, add 2- [1- (9-methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purine-8 in dioxane (8 mL). -Ylmethyl) piperidin-4-yl] propan-2-ol (0.5 g, 0.75 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [2,3-c] pyridine (0.29 g, 0 .83 mmol), CuTC (0.029 g, 0.015 mmol) and Pd (PPh ₃ ) ₄ (0.087 g, 0.075 mmol) were charged. The reaction mixture was heated by microwave at 150 ° C. for 30 minutes. The cooled reaction mixture was loaded onto an SCX-2 cartridge. The cartridge was washed with 3 volumes of MeOH and then the product was collected by eluting with 2N ammonia in MeOH. The solution was concentrated, the residue was loaded onto a SiO ₂ column 40 g, flash chromatography; and purified by (Si-PCC 40gSiO ₂ column, 6% MeOH 0% in DCM), 2- {1- [2 -(1-Benzenesulfonyl-2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] piperidine- 4-yl} propan-2-ol was obtained as a white foam (0.414 g, 86%). LCMS (Method A): R _T = 3.24 min, [M + H] ⁺ 645.3.

Step 2: In a 50 mL round bottom flask equipped with a condenser / inert gas bubbler (via Claisen head), add 2- {1 in dioxane (8 mL), IMS (8 mL) and NaOH 12.5M (0.8 mL). -[2- (1-Benzenesulfonyl-2-methyl-1H-pyrrolo [2,3-c] pyridin-4-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl ] A solution of piperidin-4-yl} propan-2-ol (0.41 g, 0.64 mmol) was charged. The resulting mixture was stirred at room temperature for 2 hours. The solution was concentrated in vacuo, the residue was dissolved in DCM, and the fine solid was removed by filtration through a celite pad. The solution was purified by flash chromatography (Si-PCC; 25 g SiO ₂ column, 0% to 20% MeOH in DCM). The residue was then further purified by preparative HPLC [(C18 column) gradient: (acetonitrile / 20 mM triethylamine) 30% to 98% (flow 18 mL / min) in (water / 20 mM triethylamine) over 20 minutes]. The product was lyophilized overnight to give 165 as a white powder (0.136 g, 43%). LCMS (Method E): R _T = 4.89 min, [M + H] ⁺ 505.24. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.28 (s, 1H), 8.70 (s, 1H), 8.30 (s, 1H), 4.40 (m, 4H), 3.96 (s) , 3H), 3.89 (m, 4H), 3.74 (s, 2H), 2.96 (m, 2H), 2.58 (s, 3H), 2.10 (m, 2H), 1 .75 (m, 2H), 1.40-1.28 (m, 3H), 1.18 (s, 6H)

Example 166 2- (1-((2- (2-Methoxy-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 166
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All, tetramethyl orthocarboxylate and acetic acid were reacted to give 166. LCMS: M + H ⁺ = 521.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 7.83 (m, 1H), 7.48 (m, 1H), 7.18 (m, 2H), 4.23 (s, br, 4H) , 4.15 (s, 3H), 4.02 (s, 1H), 3.80 (s, 3H), 3.76 (m, 4H), 3.72 (s, 2H), 2.87 ( m, 2H), 1.99 (m, 2H), 1.65 (m, 2H), 1.20 (m, 3H), 1.02 (s, 6H)

Example 167 2- (1-((2- (2-amino-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 167
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 in ethanol (2 mL) A mixture of -ol (220 mg, 0.46 mmol) and cyanogen bromide (150 mg, 1.4 mmol) was stirred at 95 ° C. for 15 minutes. The reaction mixture was loaded onto a Biotage Isolute SPE SCX-2 column. The column was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH and further purified by RP-HPLC to give 167 (18.1 mg, 7.8%). LCMS: M + H ⁺ = 506.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.17 (d, 1H), 7.70 (s, br, 2H), 7.24 (d, 1H), 7.12 (t, 1H) , 7.03 (t, 1H), 4.26 (s, br, 4H), 4.10 (s, 1H), 3.84 (s, 3H), 3.80 (m, 4H), 1. 73 (m, 2H), 1.27 (m, 3H), 1.03 (s, 6H)

Example 168 4- (1-((7-morpholino-5- (1H-pyrrolo [2,3-c] pyridin-4-yl) thiazolo [5,4-d] pyrimidin-2-yl) methyl) azetidine -3-yl) morpholine 168
7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) -5- (tributylstannanyl) thiazolo [1,4-dioxane (2.5 mL)] 5,4-d] pyrimidine (120 mg, 0.18 mmol), 4-bromo-1H-pyrrolo [2,3-c] pyridine (46 mg, 0.23 mmol), PdCl ₂ {P ^t Bu ₂ (Ph-p- A degassed solution of Nme ₂ )} ₂ (13 mg, 0.018 mmol) and copper (I) thiophene-2-carboxylate (7 mg, 0.036 mmol) was subjected to microwave irradiation at 140 ° C. for 20 minutes. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated to give a yellow oil. The oil was purified by chromatography (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 95: 5) to give 168 as a yellow solid (12 mg, 14%). LCMS (Method E): R _T = 4.15 min, [M + H] ⁺ 493.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.28 (bs, 1H), 8.90 (s, 1H), 7.53 (m, 2H), 4.45 (m, 4H), 4.02 (s , 2H), 3.90 (t, J = 4.7 Hz, 4H), 3.76-3.65 (m, 6H), 3.19-3.09 (m, 3H), 2.36 (d , J = 4.76 Hz, 4H).

Example 169 2-Methyl-2- (4-((7-morpholino-5- (1H-pyrrolo [3,2-c] pyridin-4-yl) thiazolo [5,4-d] pyrimidin-2-yl ) Methyl) piperazin-1-yl) propanamide 169
2- [4- (7-morpholin-4-yl-5- (tributylstannanyl) thiazolo [5,4-d] pyrimidin-2-ylmethyl) piperazine- in 1,4-dioxane (4 mL) 1-yl] isobutyramide (250 mg, 0.36 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine (130 mg, 0.39 mmol), PdCl ₂ {P ^t Bu ₂ ( Ph-p-Nme ₂ )} ₂ (26 mg, 0.036 mmol) and copper (I) thiophene-2-carboxylate (14 mg, 0.07 mmol) degassed solution was subjected to microwave irradiation at 140 ° C. for 20 minutes . The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted in 2M NH ₃ in MeOH. The product was collected and concentrated to give 2- {4- [5- (1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -7-morpholin-4-ylthiazolo [5 , 4-d] pyrimidin-2-ylmethyl] piperazin-1-yl} isobutyramide was obtained as a crude oil. Aqueous NaOH (12.5 M, 0.4 mL) was added to 2- {4- [5- (1-benzenesulfonyl-1H-pyrrolo [3,2-c] pyridine-4- (4-mL) in 1,4-dioxane (4 mL). Yl) -7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-ylmethyl] -piperazin-1-yl} isobutyramide and IMS (4 mL). The reaction mixture was stirred to ambient temperature for 45 minutes and then concentrated under vacuum. The residue was dissolved in MeOH and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted in 2M NH ₃ in MeOH. The product was collected and concentrated to give a solid. The solid was flash chromatographed (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 96: 4) followed by reverse phase HPLC (Phenomenex Luna C-18, acetonitrile 95: 5 to 2:98). In water with a gradient of 20 mM Et ₃ N in to give 169 as a yellow solid (43 mg, 23%). LCMS (Method E): R _T = 5.03 min, [M + H] ⁺ = 522.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.55 (d, J = 5.6 Hz, 1H), 7.45-7.40 (m, 2H), 7.38 (d, J = 3.3 Hz, 1H) ), 7.11 (d, J = 5.3 Hz, 1H), 5.25 (d, J = 5.3 Hz, 1H), 4.53-4.42 (m, 4H), 3.90 (m) , 6H), 2.68 (m, 4H), 2.62 (m, 4H), 1.25 (s, 6H)

Example 170 2-methyl-2- (4-((2- (6-methyl-1H-pyrrolo [3,2-c] pyridin-4-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 170
2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) -piperazine-1 in dioxane (1.5 mL) -Yl] isobutyramide (100 mg, 0.14 mmol), 4-bromo-6-methyl-1H-pyrrolo [3,2-c] pyridine (20 mg, 0.09 mmol), tetrakis (triphenylphosphine) palladium (17 mg, 10 mol%) and copper (I) -thiophene-2-carboxylate (6 mg, 20 mol%) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 min. The cooled reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was subjected to column chromatography (Si-PPC, MeOH: 2M NH _{3 in} DCM, gradient 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 90:10 to 02). Purified with a gradient of 98: 20 mM triethylamine in water) to give 170 as an off-white solid (11 mg, 22%). LCMSR _T 5.14 min, [M + H] ⁺ 535. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.41 (s, 1H), 7.29-7.25 (m, 2H), 7.14 (s, 1H), 7.09 (d, J = 5. 3 Hz, 1H), 5.36 (d, J = 5.3 Hz, 1H), 4.07 (t, J = 4.6 Hz, 4H), 3.88 (t, J = 4.6 Hz, 4H), 3.83 (s, 2H), 2.70 (s, 3H), 2.58 (m, 8H), 1.23 (s, 6H)

Example 171 2-Methyl-2- (4-((4-morpholin-2- (quinolin-4-yl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) propane Amide 171
2-Methyl-2- (4-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) in dioxane (2 mL) Pd (PPh ₃ ) ₄ was added to a degassed mixture of propanamide (235 mg, 0.339 mmol), 4-bromoquinoline (60 mg, 0.288 mmol), thiophene-2-carboxylate copper (I) (55 mg, 0.228 mmol). (17 mg, 0.014 mmol) was added. The reaction mixture was reacted with CEM microwave at 140 ° C. for 30 minutes. The reaction mixture was loaded onto a Biotage Isolute SPE SCX-2 column. The column was washed with MeOH, eluted with 2M NH ₃ in MeOH and further purified by RP-HPLC to give 171 (44 mg, 29%). LCMS: M + H ⁺ = 532.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 9.39 (s, 1H), 9.04 (s, 1H), 8.86 (d, 1H), 8.22 (d, 1H), 7 .84 (t, 1H), 7.73 (t, 1H), 7.47 (s, 1H), 7.06 (s, 1H), 6.94 (s, 1H), 3.97 (m, 4H), 3.88 (s, 2H), 3.68 (m, 4H), 2.54-2.67 (m, 8H), 1.09 (s, 6H)

ＤＣＥ（５０ｍＬ）中の２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド（９５３ｍｇ、３．３６ｍｍｏｌ）の溶液に４-アゼチジン-３-イルモルホリン（５２５ｍｇ、３．６９ｍｍｏｌ）、トリメチルオルトギ酸エステル（３．６７ｍＬ、３３．５８ｍｍｏｌ）及び酢酸（０．１９ｍＬ、３．３６ｍｍｏｌ）を加えた。２時間室温で攪拌し、トリアセトキシ水素化ホウ素ナトリウム（１．１０ｇ、５．０３ｍｍｏｌ）を加え、生じた混合物を更に２時間攪拌した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、Ｈ_２Ｏ／ＭｅＯＨで洗浄し、ついでＭｅＯＨ／ＤＣＭ中の２ＭのＮＨ_３で溶出した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０：１００から２０：８０の勾配）で精製して、２-クロロ-４-モルホリン-４-イル-６-(３-モルホリン-４-イル-アゼチジン-１-イルメチル)チエノ[３,２-ｄ]ピリミジンを淡黄色の固形物として得た（８５６ｍｇ、６２％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．７７分，［Ｍ＋Ｈ］^＋４１０

Example 172 4- (1-((2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) azetidine -3-yl) morpholine 172

4-Azetidin-3-ylmorpholine in a solution of 2-chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidine-6-carbaldehyde (953 mg, 3.36 mmol) in DCE (50 mL). (525 mg, 3.69 mmol), trimethylorthoformate (3.67 mL, 33.58 mmol) and acetic acid (0.19 mL, 3.36 mmol) were added. Stir for 2 hours at room temperature, add sodium triacetoxyborohydride (1.10 g, 5.03 mmol) and stir the resulting mixture for an additional 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with H ₂ O / MeOH, then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, gradient 0: 100 to 20:80) to give 2-chloro-4-morpholin-4-yl-6- (3-morpholine. -4-yl-azetidin-1-ylmethyl) thieno [3,2-d] pyrimidine was obtained as a pale yellow solid (856 mg, 62%). LCMS (Method C): R _T = 2.77 min, [M + H] ⁺ 410

2-Chloro-4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) thieno [3,2-d] pyrimidine (401 mg, 0.98 mmol) in dioxane (4 mL) ), Hexabutyl distin (0.74 mL, 1.47 mmol), and PdCl ₂ {P ^t Bu ₂ (Ph-p-Nme ₂ )} ₂ (69 mg, 10 mol%) are purged with argon gas and microwave Heated in a reactor at 150 ° C. for 25 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, gradient 0: 100 to 20:80) and purified by 4-morpholin-4-yl-6- (3-morpholin-4-yl- Azetidin-1-ylmethyl) -2- (tributylstannanyl) thieno [3,2-d] pyrimidine was obtained as a colorless oil (405 mg, 62%). LCMS (Method C) R _T 3.87 min, [M + H] ⁺ 664 ( ¹¹⁶ Sn) 666 ( ¹¹⁸ Sn).

N- [4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) thieno [3,2-d] pyrimidin-2-yl] benzene-1,2-diamine ( A mixture of 100 mg, 0.21 mmol) and glacial acetic acid (0.5 mL) was heated at 120 ° C. for 3 hours. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: 2M NH _{3 in} MeOH 100: 0 to 98: 2 to 95: 5) followed by reverse phase HPLC (Phenomenex Luna C-18, acetonitrile 95: Purification with 20 mM Et ₃ N in water with a gradient of 5 to 2:98 afforded 172 as a white solid (45 mg, 43%). LCMS (Method A): R _T = 5.65 min, M + H ⁺ = 506.1. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.08-8.03 (m, 1H), 7.73-7.68 (m, 1H), 7.30-7.26 (m, 3H), 4. 05 (t, J = 4.8 Hz, 4H), 3.99 (s, 2H), 3.88 (t, J = 4.8 Hz, 4H), 3.73 (m, 4H), 3.65 ( s, 2H), 3.18-2.99 (m, 3H), 2.93 (s, 3H), 2.34 (m, 4H)

Alternatively, 2-chloro-4-morpholin-4-yl-6- (3-morpholin-4-ylazetidin-1-ylmethyl) thieno [3,2-d] pyrimidine (100 mg, 0.24 mmol) in DMF (2 mL) ), 2-methylbenzimidazole (32 mg, 0.24 mmol), tris (dibenzylideneacetone) dipalladium (11 mg, 0.01 mmol), Xphos (12 mg, 0.02 mmol) and Cs ₂ CO ₃ (158 mg, 0.48 mmol). ) Was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was dissolved in _EtOAc, washed with _H 2 O (× 6), followed by brine (× 2), then dried _(Na 2 _SO 4), and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%). The resulting oil was triturated with a mixture of Et ₂ O and pentane to give 172 as a pale yellow solid (33 mg, 27%).

１,４-ジオキサン（４ｍＬ））中の２-クロロ-４-モルホリン-４-イル-６-(３-モルホリン-４-イル-アゼチジン-１-イルメチル)チエノ[３,２-ｄ]ピリミジン（４００ｍｇ、０．９８ｍｍｏｌ）、１,２-ジアミノベンゼン（２４０ｍｇ、２．２２ｍｍｏｌ）、Ｐｄ(Ｏａｃ)_２（６４ｍｇ、０．２９ｍｍｏｌ）、ｒａｃ−ＢＩＮＡＰ（８８ｍｇ、０．１４ｍｍｏｌ）及びＣｓ_２ＣＯ_３（４８０ｍｇ、１．４７ｍｍｏｌ）の脱気混合物にマイクロ波照射を１５０℃で３０分間施した。反応混合物を雰囲気温度まで冷却し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（２５ｇ）に充填した。カートリッジをＭｅＯＨで洗浄して、所望の生成物を続けてＭｅＯＨ中の２ＭのＮＨ_３に溶出した。生成物を回収して、真空下で濃縮した。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＤＣＭ：ＭｅＯＨ中２ＭのＮＨ_３１００：０から９８：２から９６：４）で精製して、Ｎ-[４-モルホリン-４-イル-６-(３-モルホリン-４-イル-アゼチジン-１-イルメチル)チエノ[３,２-ｄ]ピリミジン-２-イル]ベンゼン-１,２-ジアミンを淡黄色の油として得た（３１０ｍｇ、６６％）。ＬＣＭＳ（方法Ｃ）：Ｒ_Ｔ＝２．０６分，［Ｍ＋Ｈ］^＋４８２．４ Example 173 1- (4-morpholino-6-((3-morpholinoazetidin-1-yl) methyl) thieno [3,2-d] pyrimidin-2-yl) -1H-benzo [d] imidazole-2 (3H) -On 173

2-chloro-4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) thieno [3,2-d] pyrimidine (1,4-dioxane (4 mL)) 400 mg, 0.98 mmol), 1,2-diaminobenzene (240 mg, 2.22 mmol), Pd (Oac) ₂ (64 mg, 0.29 mmol), rac-BINAP (88 mg, 0.14 mmol) and Cs ₂ CO ₃ ( (480 mg, 1.47 mmol) was subjected to microwave irradiation at 150 ° C. for 30 minutes. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with MeOH and the desired product was subsequently eluted in 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: 2M NH _{3 in} MeOH 100: 0 to 98: 2 to 96: 4) to give N- [4-morpholin-4-yl-6. -(3-morpholin-4-yl-azetidin-1-ylmethyl) thieno [3,2-d] pyrimidin-2-yl] benzene-1,2-diamine was obtained as a pale yellow oil (310 mg, 66% ). LCMS (Method C): R _T = 2.06 min, [M + H] ⁺ 482.4.

N- [4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) -thieno [3,2-d] pyrimidine in 1,4-dioxane (0.5 mL) A mixture of -2-yl] benzene-1,2-diamine (50 mg, 0.10 mmol) and N, N′-carbonyldiimidazole (50 mg, 0.31 mmol) was heated at 110 ° C. for 4 hours. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: 2M NH _{3 in} MeOH 100: 0 to 98: 2 to 96: 4) to give 173 as a tan solid (17 mg 32%). LCMS (Method E): R _T = 6.42 min, [M + H] ⁺ = 508.1. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.50 (bs, 1H), 7.76-7.72 (m, 1H), 7.32 (s, 1H), 7.13-7.04 (m, 3H), 4.05 (t, J = 4.7 Hz, 4H), 3.97 (s, 2H), 3.86 (t, J = 4.7 Hz, 4H), 3.73 (m, 4H) 3.62 (m, 2H), 3.06 (s, 3H), 2.33 (m, 4H)

Example 174 4- (1-((4-morpholino-2- (1H-pyrrolo [3,2-c] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl) methyl) azetidine -3-yl) morpholine 174
4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) -2- (tributylstannanyl) thieno [3,2-] in dioxane (2.0 mL) d] pyrimidine (192 mg, 0.29 mmol), 1-benzenesulfonyl-4-bromo-1H-pyrrolo [3,2-c] pyridine (117 mg, 0.35 mmol), tetrakis (triphenylphosphine) palladium (34 mg, 10 mol) %) And copper (I) -thiophene-2-carboxylate (11 mg, 20 mol%) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ in MeOH. The resulting residue was added to IMS / dioxane (1: 1 mL) and 12.5 M aqueous NaOH (0.1 mL). After stirring for 1 hour, the reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and then eluted with 2M NH ₃ in MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: 2M NH _{3 in} DCM, gradient 0: 100 to 10:90) and triturated from diethyl ether to 174 (38 mg, 27%) Was obtained as a pale yellow solid. LCMSR _T 4.52 min, [M + H] ⁺ 492. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.53 (m, 1H), 7.45-7.35 (m, 4H), 4.10 (t, J = 4.7 Hz, 4H), 3.97 ( s, 2H), 3.89 (t, J = 4.7 Hz, 4H), 3.72 (t, J = 4.5 Hz, 4H), 3.69-3.54 (m, 2H), 3. 08-3.01 (m, 3H), 2.33 (m, 4H).

Example 176 2-Methyl-2- (4-((2- (2-methyl-2H-indazol-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine -1-yl) propanamide 176
2-Methyl-2- (4-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1- in dioxane (2.3 mL) Yl) propanamide (270 mg, 0.389 mmol), 3-iodo-2-methyl-2H-indazole (95 mg, 0.368 mmol), thiophene-2-carboxylate (I) (70 mg, 0.368 mmol) To the gas mixture was added Pd (PPh ₃ ) ₄ (21 mg, 0.018 mmol). The reaction mixture was then reacted with CEM microwave at 140 ° C. for 30 minutes. The reaction mixture was loaded onto a Biotage Isolute SPE SCX-2 column. The column was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH and further purified by RP-HPLC to give 176 (44 mg, 29%). LCMS: M + H ^< + ^> = 535.2. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.40 (d, 1H), 7.67 (d, 1H), 7.47 (s, 1H), 7.31 (t, 1H), 7 .19 (t, 1H), 7.06 (s, 1H), 6.93 (s, 1H), 4.60 (s, 3H), 4.06 (m, 4H), 3.88 (s, 2H), 3.84 (m, 4H), 2.49-2.62 (m, 8H), 1.08 (s, 6H)

Example 177 1- (6-((4- (dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) indoline-2-one 177
[1- (2-Chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl) -piperidin-4-yl] -dimethyl- in dioxane (4 mL) in a microwave vessel Amine (0.2 g) was charged. The vessel was evacuated and refilled with argon. To this mixture was added 1,3-dihydro-indol-2-one (0.08 g), BINAP (0.015 g), cesium carbonate (0.2 g) and palladium acetate (0.009 g). The vessel was evacuated and backfilled with argon, and the mixture was irradiated with microwaves at 150 ° C. for 45 minutes. The reaction mixture was cooled to room temperature and then filtered through an HPLC filter. The filtrate was concentrated and the residue was purified by chromatography (silica, 0 to 10% 49: 1 MeOH: NH ₄ OH mixture in dichloromethane) to give 177 (0.022 g, 9%) as a light brown solid. Obtained. MS m / e 493 [M + H] ⁺ . ¹ H NMR (400 MHz, DMSO-d ₆ ) δ ppm 1.44 (br.s., 2H) 1.75 (d, J = 11.12 Hz, 2H) 2.03 to 2.13 (m, 3H) 20 (s, 6H) 2.95 (d, J = 11.62 Hz, 2H) 3.71-3.83 (m, 6H) 3.85 (s, 2H) 3.89-3.98 (m, 4H) 7.00-7.14 (m, 1H) 7.24 (d, J = 4.04 Hz, 2H) 7.29-7.39 (m, 2H)

Example 178 2- (1-((2- (2- (hydroxymethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) Piperidin-4-yl) propan-2-ol 178
According to the procedure for the synthesis of 157, 2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane- 2-ol and glycolic acid were reacted to give 178. LCMS: M + H ⁺ = 521.3. ¹ H-NMR (400 MHz, DMSO-d ₆ ): δ 8.17 (d, 1H), 7.68 (d, 1H), 7.31 (m, 2H), 5.28 (t, 1H), 5 .08 (d, 2H), 4.27 (s, br, 4H), 4.02 (s, 1H), 3.82 (s, 3H), 3.78 (m, 4H), 3.73 ( s, 2H), 2.90 (d, 2H), 2.01 (m, 2H), 1.66 (d, 2H), 1.21 (m, 3H), 1.02 (s, 6H).

トルエン（３０ｍＬ）中の４-(２-クロロ-８-((４-(２-メトキシプロパン-２-イル)ピペリジン-１-イル)メチル)-９-メチル-９Ｈ-プリン-６-イル)モルホリン（１．２１ｇ、２．９６ｍｍｏｌ）、ベンゼン-１,２-ジアミン（５２０ｍｇ、４．８ｍｍｏｌ）、酢酸パラジウム（６６ｍｇ、０．２９ｍｍｏｌ）、ビス(トリ-ｔ-ブチルホスフィン)パラジウム（１５０ｍｇ、０．２９ｍｍｏｌ）及びナトリウムｔ−ブトキシド（６２０ｍｇ、６．４ｍｍｏｌ）の混合物を９５℃で１８時間攪拌した。反応混合物を紙で濾過し、ついで濃縮した。粗生成物をついでＢｉｏｔａｇｅ ＫＰ-ＮＨカラム（ＤＣＭ中０から１０％の勾配のＭｅＯＨ）を用いるフラッシュクロマトグラフィーで精製して、Ｎ１-(８-((４-(２-メトキシプロパン-２-イル)ピペリジン-１-イル)メチル)-９-メチル-６-モルホリノ-９Ｈ-プリン-２-イル)ベンゼン-１,２-ジアミン（１．２ｇ、８４％）を得た。ＬＣＭＳ：Ｍ＋Ｈ^＋＝４８１．２。 Example 179 4- (8-((4- (2-methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazole- 1-yl) -9H-purin-6-yl) morpholine 179
Step 1: N1- (8-((4- (2-Methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) benzene-1 , 2-diamine

4- (2-Chloro-8-((4- (2-methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-9H-purin-6-yl) in toluene (30 mL) Morpholine (1.21 g, 2.96 mmol), benzene-1,2-diamine (520 mg, 4.8 mmol), palladium acetate (66 mg, 0.29 mmol), bis (tri-t-butylphosphine) palladium (150 mg, 0 .29 mmol) and sodium t-butoxide (620 mg, 6.4 mmol) were stirred at 95 ° C. for 18 hours. The reaction mixture was filtered through paper and then concentrated. The crude product was then purified by flash chromatography using a Biotage KP-NH column (0 to 10% gradient MeOH in DCM) to give N1- (8-((4- (2-methoxypropan-2-yl). ) Piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) benzene-1,2-diamine (1.2 g, 84%) was obtained. LCMS: M + H ^< + ^> = 481.2.

Step 2: N1- (8-((4- (2-Methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purine in acetic acid (1.5 mL) A mixture of -2-yl) benzene-1,2-diamine (177 mg, 0.368 mmol) was stirred at reflux for 5 hours. The reaction mixture was then concentrated and then purified by flash chromatography (10% MeOH in DCM containing 1% 2M ammonia in MeOH) followed by RP-HPLC to give 179 (0. 0373 g, 21.1%). LCMS: M + H ^< + ^> = 519.1.

  Alternatively, Xphos (0.1 eq), tris (dibenzylideneacetone) dipalladium (0) (0.05 eq), cesium carbonate (2 eq) in a microwave tube according to the general procedure I one-step Buchwald coupling 4- (2-Chloro-8-((4- (2-methoxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-9H-purin-6-yl) morpholine (80 mg, 1 Eq) and 2-methyl-1H-benzo [d] imidazole (1.2 eq). The vessel is evacuated and refilled with nitrogen before adding DMF or 1,4-dioxane. The mixture is heated to about 140 ° C. for about 25-35 minutes in a microwave apparatus such as Biotage. The reaction mixture is cooled to room temperature, filtered, concentrated and purified by RP-HPLC to give 17.1 mg of 179. MS (Q1) 519.1 (M) +.

Example 180 2- (4-((2- (1-Amino-6-fluoroisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1- Yl) -2-methylpropanamide 180
Following general procedure A for Suzuki coupling, 2- (4-((2-chloro-4-morpholinthieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropane The amide and 6-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine were reacted to give 180. LCMS: M + H ⁺ = 565.3

Example 181 (3S, 4R) -3-fluoro-N, N-dimethyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino -9H-purin-8-yl) methyl) piperidin-4-amine 181
According to General Procedure I for Buchwald coupling, (3S, 4R) -1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-fluoro-N, N -Dimethylpiperidine-4-amine and 2-methyl-1H-benzo [d] imidazole were reacted to give 181. LCMS m / z: 508.3 (MH +)

Example 182 4- (5- (1H-indazol-3-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine 182
7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) -5- (tributylstannanyl) thiazolo [5,4-d] pyrimidine (3 mL) in dioxane (3 mL) 0.25 g, 0.37 mmol), 3-iodo-1H-indazole (0.2 g, 0.82 mmol), copper (I) 2-thiophenecarboxylate (0.030 g, 0.150 mmol) and Pd (PPh ₃ ) ₄ (0.088 g, 0.075 mmol) was subjected to micro irradiation at 150 ° C. for 90 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The eluent was concentrated under vacuum and the residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5. To 20:98 trimethylamine with a gradient of 2:98) to give 182 as an off-white solid (0.036 g, 20%). LCMS (Method G): R _T = 7.40 min, [M + H] ⁺ 493.3. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.58 (d, J = 8.2 Hz, 1H); 7.55 (t, J = 8.2 Hz, 1H); 7.46-7.41 (m, 1H) ); 7.34-7.29 (m, 1H); 4.48-4.33 (m, 4H); 4.02 (s, 2H); 3.92 (t, J = 4.6 Hz, 4H) 3.73 (t, J = 4.6 Hz, 4H); 3.70-3.66 (m, 2H); 3.18-3.09 (m, 3H); 2.40-2.35 (M, 4H)

Example 183 1- (7-morpholino-2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-5-yl) -1H-benzo [d] imidazole-2 (3H) -On 183
N- [7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) thiazolo [5,4-d] pyrimidin-5-yl] in 1,4-dioxane (1 mL) A mixture of benzene-1,2-diamine (75 mg, 0.16 mmol) and 1,1′-carbonyldiimidazole (100 mg, 0.62 mmol) was heated at 110 ° C. for 3 hours. After cooling to ambient temperature, the mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, 2M NH ₃ in DCM: MeOH 100: 0 to 99: 1 to 98: 2) to give 183 as a creamy solid (45 mg 57%). LCMS (Method G): R _T = 6.72 min, M + H ⁺ = 509. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.71 (s, 1H); 7.77 (m, 1H); 7.15-7.05 (m, 3H); 4.42 (m, 4H); 4 .01 (s, 2H); 3.86 (m, 4H); 3.71 (m, 6H); 3.15 (s, 3H) and 2.36 (m, 4H)

Example 184 4- (5- (2- (difluoromethyl) -1H-benzo [d] imidazol-1-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5.4 -d] pyrimidin-7-yl) morpholine 184
N- [7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) thiazolo [5,4-d] pyrimidine-5- in 1,4-dioxane (0.5 mL) A mixture of [yl] benzene-1,2-diamine (65 mg, 0.14 mmol) and ethyl difluoroacetate (0.3 mL, 2.8 mmol) was heated at 100 ° C. for 3 days. The reaction mixture was cooled to ambient temperature and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was subsequently dissolved in 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by reversed-phase HPLC (Phenomenex Luna C-18, Et 3 in acetonitrile 20mM N30: 70 from a gradient of two ninety-eight water 20mM of _Et 3 N) to give the give the 184 as a white solid (26 mg, 35%). LCMS (Method G): R _T = 8.03 min, M + H ⁺ = 543. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.29 (d, J = 8.1 Hz, 1H); 7.91 (d, J = 7.8 Hz, 1H); 7.60 (t, J = 53.8 Hz) , 1H); 7.45-7.37 (m, 2H); 4.43 (m, 4H); 4.02 (s, 2H); 3.89 (t, J = 4.7 Hz, 4H); 3.74 (t, J = 4.5 Hz, 4H); 3.69 (t, J = 6.2 Hz, 2H); 3.21-3.07 (m, 3H) and 2.37 (m, 4H) )

Example 185 2- (4-((2- (1-Amino-7-fluoroisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1- Yl) -2-methylpropanamide 185
Following general procedure A for Suzuki coupling, 2- (4-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methyl Propanamide and 7-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine were reacted to give 185. LCMS: M + H ⁺ = 565.3

Example 186 2- (1-((9-Methyl-6-morpholino-2- (2- (trifluoromethyl) -1H-benzo [d] imidazol-1-yl) -9H-purin-8-yl) Methyl) piperidin-4-yl) propan-2-ol 186
2- (1-((2- (2-aminophenylamino) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2- All and trifluoroacetic acid were reacted to give 186. LCMS m / z: 559.3 (MH +)

Example 187 2-isobutyl-4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) morpholine 187
According to the procedure for 157, in step 1, 187 was prepared using 4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2-isobutylmorpholine. LCMS m / z: 505.3 (MH +)

Example 188 2- (1-((2- (2- (dimethylamino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) Piperidin-4-yl) propan-2-ol 188
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And N, N-dimethyl-1H-benzo [d] imidazol-2-amine was reacted to give 188. LCMS m / z: 534.3 (MH +)

Example 189 2- (1-((2- (2-Ethyl-2H-indazol-3-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) Propan-2-ol 189
2- [1- (9-Methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purin-8-ylmethyl) piperidin-4-yl] propane- 2-ol and 2-ethyl-3-iodo-2H-indazole were reacted to give 189. LCMS m / z: 519.3 (MH +)

Example 190 2- (4-((2- (2-Ethyl-2H-indazol-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl ) -2-Methylpropanamide 190
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyl according to the procedure for 143 Reaction of the amide and 2-ethyl-3-iodo-2H-indazole gave 190. LCMS m / z: 549.3 (MH +)

Example 191 2,2-diethyl-4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Morpholine 191
According to the procedure for 157 and general procedure J, 4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2,2-diethylmorpholine and benzene-1,2- The diamine was reacted and subsequently condensed with acetic acid to give 191. LCMS m / z: 505.3 (MH +)

Example 192 2-Methyl-2- (4-((2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) propanamide 192
2- (4-((2-Chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide (0.15 g) Reaction via methylbenzimidazole via general procedure I for Buchwald coupling gave 29.3 mg of 192 after reverse phase purification. MS (Q1) 535.2 (M) +.

Example 193 4- (5- (2-methyl-1H-benzo [d] imidazol-1-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] Pyrimidin-7-yl) morpholine 193
4- (5- (2-Methyl-1H-benzo [d] imidazol-1-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidine-7 -Yl) morpholine (75 mg) was reacted with 2-methylbenzimidazole via Buchwald coupling general procedure I to give 16.4 mg of 193 after reverse phase purification. MS (Q1) 507.2 (M) +

Example 194 2,6-Dimethyl-4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl Morpholine 194
In step 1, according to the procedure for 157 and general procedure J, 4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2,6-dimethylmorpholine and benzene- 1,2-diamine was reacted followed by condensation with acetic acid to give 194. LCMS m / z: 477.2 (MH +)

Example 195 2- (1-((2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 195
According to General Procedure I for Buchwald coupling, 2-isopropylbenzimidazole and 2- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Propan-2-ol was reacted to give 195. LCMS m / z: 533.3 (MH +). ¹ H-NMR (DMSO-d6): 7.89 (m, 1H), 7.64 (m, 1H), 7.24 (m, 2H), 4.25 (s, br, 4H), 4. 00 (s, 1H), 3.92 (m, 1H), 3.81 (s, 3H), 3.77 (t, 4H), 3.73 (s, 2H), 2.91 (d, 2H) ), 2.00 (t, 2H), 1.67 (t, 2H), 1.35 (d, 6H), 1.22 (m, 3H), 1.02 (s, 6H).

Example 196 2,2-Dimethyl-4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl Morpholine 196
4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2,2-dimethylmorpholine and benzene-1,2- The diamine was reacted and subsequently condensed with acetic acid to give 196. LCMS m / z: 477.2 (MH +)

Example 197 2- (1-((2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) piperidin-4-yl) propan-2-ol 197
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to the procedure for 157 and general procedure J (1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted, followed by condensation with 2,2-difluoropropionic acid to give 197. LCMS m / z: 555.3 (MH +)

Example 198 I-2- (1-((2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) piperidin-4-yl) propan-2-ol 198
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to the procedure for 157 and general procedure J (1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted and then condensed with lactic acid to obtain a racemic mixture. The enantiomers were separated by SFC to give 198. LCMS m / z: 535.3 (MH +)

Example 199 (S) -2- (1-((2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine -8-yl) methyl) piperidin-4-yl) propan-2-ol 199
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to the procedure for 157 and general procedure J (1.21 g, 2.96 mmol) and benzene-1,2-diamine were reacted and condensed with lactic acid to obtain a racemic mixture. The enantiomers were separated by SFC to give 199. LCMS m / z: 535.3 (MH +)

Example 201 2-Methyl-2- (4-((2- (8-methylimidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidine-6- Yl) methyl) piperazin-1-yl) propanamide 201
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) -thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl in dioxane (3 mL) ] Isobutyramide (205 mg, 0.30 mmol), 5-bromo-8-methylimidazo [1,2-a] pyridine (75 mg, 0.35 mmol), Pd (PPh ₃ ) ₄ (34 mg, 0.03 mmol) and thiophene A mixture of copper (I) -2-carboxylate (11 mg, 0.06 mmol) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was charged with an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give a solid that was triturated in MeOH, filtered and vacuumed And dried at 60 ° C. for 24 hours to give 201 as a white solid (97 mg, 62%). LCMS (Method G) R _T 5.11 min; [M + H] ⁺ 535. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.29 (s, 1H); 7.93 (d, J = 7.3 Hz, 1H); 7.75 (s, 1H); 7.37 (s 7.15 (d, J = 7.3 Hz, 1H); 7.13-6.96 (m, 1H); 5.21 (s, 1H); 4.06 (t, J = 4) 3.91 (t, J = 4.7 Hz, 4H); 3.86 (s, 2H); 2.73 (s, 3H); 2.62 (s, 8H); 25 (s, 6H)

Example 202 2- (4-((2- (imidazo [1,5-a] pyridin-8-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1 -Il) -2-Methylpropanamide 202
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (2 mL) Isobutyramide (132 mg, 0.19 mmol), 8-bromoimidazo [1,5-a] pyridine (45 mg, 0.23 mmol), Pd (PPh ₃ ) ₄ (22 mg, 0.02 mmol) and thiophene-2-carboxylic acid A mixture of copper (I) (7 mg, 0.04 mmol) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 202 as a yellow solid (72 mg, 73%). LCMS (Method G): R _T 5.12 min; [M + H] ⁺ 521. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.33 (s, 1H); 8.21 (s, 1H); 8.04 (d, J = 6.9 Hz, 1H); 7.93 (d , J = 6.9 Hz, 1H); 7.36 (s, 1H); 7.07 (m, 1H); 6.74-6.69 (m, 1H); 5.19 (s, 1H); 4.07 (t, J = 4.7 Hz, 4H); 3.96-3.86 (m, 4H); 3.88-3.83 (m, 2H); 2.61 (s, 8H); 1.25 (s, 6H)

１７２に対する手順に従って、２-クロロ-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-カルバルデヒド及び２-メチル-２-モルホリノプロパン-１-アミンを還元的アミノ化で反応させてＮ-((２-クロロ-４-モルホリノチエノ[３,２-ｄ]ピリミジン-６-イル)メチル)-２-メチル-２-モルホリノプロパン-１-アミンを得、これを２-トリブチルスタニル中間体に転換させ、２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾールと反応させて、２０３を得た。ＬＣＭＳｍ／ｚ：５２２．２（ＭＨ＋） Example 203 2-Methyl-N-((2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -2-morpholinopropane-1-amine 203

Reductive amination of 2-chloro-4-morpholin-4-yl-thieno [3,2-d] pyrimidine-6-carbaldehyde and 2-methyl-2-morpholinopropan-1-amine according to the procedure for 172 The reaction yields N-((2-chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -2-methyl-2-morpholinopropan-1-amine, which is converted into 2- Conversion to the tributylstannyl intermediate and reaction with 2-methyl-1H-benzo [d] imidazole gave 203. LCMS m / z: 522.2 (MH +)

ブッフバルトカップリングによる多工程ベンゾイミダゾール形成のための一般的手順Ｊに従って、４-(２-クロロ-６-((３,４-ジヒドロイソキノリン-２(１Ｈ)-イル)メチル)チエノ[３,２-ｄ]ピリミジン-４-イル)モルホリン及び１,２-ジアミノベンゼンを反応させてＮ１-(６-((３,４-ジヒドロイソキノリン-２(１Ｈ)-イル)メチル)-４-モルホリノチエノ[３,２-ｄ]ピリミジン-２-イル)ベンゼン-１,２-ジアミンを得、これを酢酸で環化させて２０４を得た。ＬＣＭＳｍ／ｚ：４９７．６（ＭＨ＋） Example 204 4- (6-((3,4-dihydroisoquinolin-2 (1H) -yl) methyl) -2- (2-methyl-1H-benzo [d] imidazol-1-yl) thieno [3, 2-d] pyrimidin-4-yl) morpholine 204

According to the general procedure J for multi-step benzimidazole formation by Buchwald couplings, 4- (2-chloro-6 - ((3,4-dihydro-isoquinoline -2 (IH) - yl) methyl) thieno [3,2 -d] pyrimidin-4-yl) morpholine and 1,2-diaminobenzene to react with N1- (6-((3,4-dihydroisoquinolin-2 (1H) -yl) methyl) -4-morpholinothieno [ 3,2-d] pyrimidin-2-yl) benzene-1,2-diamine was obtained, which was cyclized with acetic acid to give 204. LCMS m / z: 497.6 (MH +)

Example 205 2- (1-((2- (2- (benzyl (methyl) amino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 205
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (benzylmethylamino) benzimidazole to give 205. LCMS m / z: 610.4 (MH +)

Example 206 2- (1-((9-Methyl-2- (2- (methylamino) -1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Piperidin-4-yl) propan-2-ol 206
2- (1-((2- (2- (Benzyl (methyl) amino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine) in ethanol (10 mL) -8-yl) methyl) piperidin-4-yl) propan-2-ol 205 (0.2 g, 0.33 mmol) and a mixture of palladium carbon (10 wt%, 0.1 g) and acetic acid (0.1 mL). The mixture was stirred at 60 degrees for 18 hours in a hydrogen atmosphere. The reaction mixture was filtered through celite and concentrated. The crude product was purified by RP-HPLC to give 206 (28.5 mg, 17%). LCMS m / z: 520.3 (MH +)

Example 207 2- (1-((9-Methyl-6-morpholino-2- (2-phenyl-1H-benzo [d] imidazol-1-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol207
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-phenylbenzimidazole were reacted to give 207. LCMS m / z: 567.3 (MH +)

Example 208 1- (3- (6-((4- (Dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) benzo [b] thiophene -2-Ile) Ethanon 208
According to the general procedure G for Still coupling, N, N-dimethyl-1-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 Reaction of -amine and 1- (3-bromobenzo [b] thiophen-2-yl) ethanone gave 208. LCMS m / z: 536.7 (MH +)

Example 209 2- (1-((5- (1H-indazol-3-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) piperidin-4-yl) propane- 2-all 209
2- (1-((7-morpholino-5- (tributylstannyl) thiazolo [5,4-d] pyrimidin-2-yl) methyl) piperidin-4-yl) propane-2- in dioxane (3 mL) All (0.211 g, 0.32 mmol), 3-iodo-1H-indazole (0.116 g, 0.48 mmol), copper (I) 2-thiophenecarboxylate (0.012 g, 0.064 mmol) and Pd (PPh ₃ ) ₄ (0.037 g, 0.032 mmol) was subjected to microwave irradiation at 150 ° C. for 90 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted using 2M NH ₃ . The eluent was concentrated under vacuum and the resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 209 as a yellow solid ( 0.043 g, 28%). LCMS (Method G): R _T = 7.71 min, [M + H] ⁺ 494.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 13.45 (s, 1H); 8.48 (d, J = 8.3 Hz, 1H); 7.61 (d, J = 8.3 Hz, 1H) 7.41 (t, J = 7.6 Hz, 1H); 7.26 (t, J = 7.6 Hz, 1H); 4.37 (m, 4H); 3.88 (s, 2H); 3 .82 (t, J = 4.6 Hz, 4H); 3.02 (d, J = 11.0 Hz, 2H); 2.12 (t, J = 11.0 Hz, 2H); 1.74-1. 69 (m, 2H); 1.36-1.28 (m, 2H); 1.26-1.23 (m, 2H); 1.06 (s, 6H)

Example 210 2- (1-((5- (2-Methylbenzofuran-3-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) piperidin-4-yl) propane -2-All 210
2- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) -piperidine-4- in dioxane (3 mL) and H ₂ O (1.5 mL) Yl] propan-2-ol (50 mg, 0.12 mmol), 2-methyl-3- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) benzofuran (47 mg, 0.18 mmol), tetrakis (triphenylphosphine) palladium (14 mg, 0.01 mmol) and Cs ₂ CO ₃ (80 mg, 0.24 mmol) were purged with argon and then heated in a microreactor at 140 ° C. for 30 minutes. did. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM / MeOH and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 0-90%) to give 210 as a white solid (29 mg, 48%). LCMS (Method G): R _T 10.16 min, [M + H] ⁺ 508.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.40-8.37 (m, 1H); 7.45-7.40 (m, 1H); 7.32-7.24 (m, 2H); 4 .40 (m, 4H); 3.94-3.84 (m, 6H); 3.11 (m, 2H); 2.92 (s, 3H); 2.21 (m, 2H); 78 (m, 2H); 1.48 (m, 2H) and 1.21 (m, 7H)

Example 211 2-Methyl-2- (4-((5- (2-methylbenzofuran-3-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) piperazine-1 -Il) propanamide 211
1-amino-2- [4- (5-chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperazine-1 in dioxane (6 mL) and H ₂ O (3 mL) -Yl] -2-methylpropan-1-ol (100 mg, 0.23 mmol), 2-methyl-3- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl ) A mixture of benzofuran (88 mg, 0.34 mmol), tetrakis (triphenylphosphine) palladium (26 mg, 0.02 mmol) and Cs ₂ CO ₃ (148 mg, 0.45 mmol) was purged with argon, then at 140 ° C. for 30 minutes. Heated in a microreactor. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM / MeOH and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 50-100%) to give 211 as a creamy solid (75 mg, 61%). LCMS (Method G): R _T 10.35 min, [M + H] ⁺ 536.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.40-8.37 (m, 1H); 7.46-7.42 (m, 1H); 7.32-7.23 (m, 2H); 7 .10 (d, J = 5.3 Hz, 1H); 5.22 (d, J = 5.3 Hz, 1H); 4.40 (m, 4H); 3.93-3.87 (m, 6H) 2.92 (s, 3H); 2.69 (m, 4H); 2.62 (m, 4H) and 1.26 (s, 6H);

Example 212 4- (5- (2-Methylbenzofuran-3-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine 212
5-Chloro-7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) thiazolo [5,4-d] pyrimidine in dioxane (6 mL) and H ₂ O (3 mL) 100 mg, 0.24 mmol), 2-methyl-3- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) benzofuran (94 mg, 0.37 mmol), tetrakis (tri A mixture of phenylphosphine) palladium (28 mg, 0.02 mmol) and Cs ₂ CO ₃ (159 mg, 0.48 mmol) was purged with argon and then heated in a microreactor at 140 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM / MeOH and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-5%) to give 212 as a pale yellow solid (58 mg, 48%). LCMS (Method G): R _T 9.83 min, [M + H] ⁺ 507.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.39-8.36 (m, 1H); 7.45-7.42 (m, 1H); 7.32-7.24 (m, 2H); 4 .40 (m, 4H); 4.01 (s, 2H); 3.89 (m, 4H); 3.70 (m, 6H); 3.18-3.08 (m, 3H); 92 (s, 3H) and 2.36 (m, 4H)

Example 213 4- (1-((2- (2-Methylbenzofuran-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) azetidin-3-yl) morpholine 213
2-Chloro-4-morpholin-4-yl-6- (3-morpholin-4-ylazetidin-1-ylmethyl) thieno [3,2-d] pyrimidine in dioxane (6 mL) and H ₂ O (3 mL) 100 mg, 0.24 mmol), 2-methyl-3- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl) benzofuran (94 mg, 0.36 mmol), tetrakis (tri A mixture of phenylphosphine) palladium (28 mg, 0.02 mmol) and Cs ₂ CO ₃ (160 mg, 0.48 mmol) was purged with argon and then heated in a microreactor at 140 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with DCM / MeOH and then eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) to give 213 as a white foam (98 mg, 81%). LCMS (Method G): R _T 9.09 min, [M + H] ⁺ 506.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.42-8.39 (m, 1H); 7.46-7.42 (m, 1H); 7.32-7.24 (m, 3H); 4 .02 (t, J = 4.7 Hz, 4H); 3.97 (s, 2H); 3.89 (t, J = 4.7 Hz, 4H); 3.73 (m, 4H); 3.63 (S, 2H); 3.06 (m, 3H); 2.93 (s, 3H) and 2.33 (m, 4H)

Example 214 2- (4-((2- (6-Fluorimidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) Piperazin-1-yl) -2-methylpropanamide 214
2- [4- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (1 mL) Isobutyramide (69 mg, 0.10 mmol), 5-bromo-6-fluoro-imidazo [1,2-a] pyridine (25 mg, 0.12 mmol), Pd (PPh ₃ ) ₄ (12 mg, 0.01 mmol) and thiophene A mixture of copper (I) -2-carboxylate (4 mg, 0.02 mmol) was purged with argon gas and then heated at 150 ° C. for 20 minutes in a microwave reactor. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g), washed with MeOH and then eluted with 2M NH ₃ in MeOH. The resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient). Purified with 20 mM triethylamine in water) to give 214 as a white solid (20 mg, 37%). LCMS (Method G) R _T 4.52 min; [M + H] ⁺ 539. ¹ H NMR (400 MHz, CHCl ₃ -d): 8.20 (s, 1H); 7.71-7.62 (m, 2H); 7.35 (s, 1H); 7.25-7.16 (T, J = 9.5 Hz, 1H); 7.18-6.91 (m, 1H); 5.22 (s, 1H); 4.05 (t, J = 4.7 Hz, 4H); 3 .87 (t + m, J = 4.7 Hz, 6H); 2.62 (s, 8H); 1.25 (s, 6H)

Example 215 2- (4-((2- (1H-indazol-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2- Methylpropanamide 215
2-methyl-2- (4-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperazine- according to General Procedure G for Stille Coupling 1-yl) propanamide and 3-bromo-1H-indazole were reacted to give 215. LCMS m / z: 521.6 (MH +)

Example 216 N, N-dimethyl-1-((4-morpholino-2- (1H-pyrrolo [2,3-c] pyridin-3-yl) thieno [3,2-d] pyrimidin-6-yl) Methyl) piperidine-4-amine216
According to the general procedure G for Still coupling, N, N-dimethyl-1-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 Reaction of -amine and 3-bromo-1H-pyrrolo [2,3-c] pyridine gave 216. LCMS m / z: 478.6 (MH +)

Example 217 4- (6-((4- (dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) isoquinolin-1 (2H) -one 217
According to the general procedure G for Still coupling, N, N-dimethyl-1-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 -Amine and 4-bromoisoquinolin-1 (2H) -one were reacted to give 217. LCMS m / z: 505.7 (MH +)

Example 218 2- (1-((2- (2- (2-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl ) Methyl) piperidin-4-yl) propan-2-ol 218
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (1H-benzo [d] imidazol-2-yl) ethanol to give 218. LCMS m / z: 535.3 (MH +)

Example 219 2- (1-((9-Methyl-6-morpholino-2- (2- (pyridin-3-yl) -1H-benzo [d] imidazol-1-yl) -9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 219
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (pyridin-3-yl) -1H-benzo [d] imidazole to give 219. LCMS m / z: 568.3 (MH +)

Example 220 1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -2- Methyl-1H-indazol-3 (2H) -one 220
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-methyl-1,2-dihydroindazol-3-one to give 220. LCMS m / z: 521.3 (MH +)

Example 221 4- (6-((6-Fluoro-3,4-dihydroisoquinolin-2 (1H) -yl) methyl) -2- (2-methyl-1H-benzo [d] imidazol-1-yl) Thieno [3,2-d] pyrimidin-4-yl) morpholine 221
According to the general procedure L for reductive amination, 2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidine-6-carbaldehyde And 6-fluoro-1,2,3,4-tetrahydroisoquinoline to give 221. LCMS m / z: 515.6 (MH +)

Example 222 2- (1-((2- (imidazo [1,5-a] pyridin-8-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine-4- Il) Propan-2-ol 222
2- [1- (9-Methyl-6-morpholin-4-yl-2- (stannanylyl) -9H-purin-8-ylmethyl) piperidin-4-yl] propane in dioxane (2 mL) -2-ol (135 mg, 0.20 mmol), 8-bromoimidazo [1,5-a] pyridine (44 mg, 0.22 mmol), Pd (PPh ₃ ) ₄ (24 mg, 10 mol%) and copper (I) − A mixture of thiophene-2-carboxylate (8 mg, 20 mol%) was purged with argon and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give 222 as a yellow solid (58 mg, 58%). LCMS (Method G): R _T = 4.86 min, [M + H] ⁺ 491.4. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.42 (s, 1H), 8.19 (s, 1H), 8.02 (d, J = 6.9 Hz, 1H), 7.95 (dd , J = 6.9, 0.9 Hz, 1H), 6.74-6.67 (m, 1H), 4.38 (m, 4H), 3.96 (s, 3H), 3.91-3 .87 (m, 4H), 3.80-3.66 (m, 2H), 2.97 (d, J = 11.0 Hz, 2H), 2.22-1.99 (m, 2H), 1 .75 (d, J = 11.0 Hz, 2H), 1.4-1.26 (m, 4H), 1.20-1.17 (s, 6H)

Example 223 2- (1-((5- (2-Methyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Piperidin-4-yl) propan-2-ol 223
5-20 mL microwave vial with magnetic follower, Pd ₂ (dba) ₃ (28 mg, 0.03 mmol), Xphos (58 mg, 0.12 mmol), 2- [1- (5-chloro-7-morpholine- 4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propan-2-ol (500 mg, 1.21 mmol), 2-methyl-1H-benzimidazole (176 mg, 1.33 mmol) , Cesium carbonate (593 mg, 1.82 mmol) and dioxane (5 mL). The reaction mixture was degassed for 5 minutes and irradiated at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The solvent was removed and the residue was purified by flash chromatography (Si-PCC, _NH 3) of 0-10% (MeOH in 2M in EtOAc) was obtained as a red oil 223 was purified by (290mg, 47%). LCMS: (Method G): R _T 6.76 min; [M + H] ⁺ 508.4. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.10-8.05 (m, 1H); 7.73-7.69 (m, 1H); 7.32-7.26 (m, 2H) 4.42 (m, 4H); 3.88 (t, J = 4.6 Hz, 7H); 3.11 (d, J = 10.7 Hz, 2H); 2.95 (s, 3H); 2 .31-2.19 (m, 2H); 1.79 (d, J = 12.7 Hz, 2H); 1.50 (m, 2H); 1.34 (m, 1H); 1.22 (s) , 6H)

Example 224 2- (1-((9-methyl-6-morpholino-2- (2- (tetrahydrofuran-2-yl) -1H-benzo [d] imidazol-1-yl) -9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 224
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (tetrahydrofuran-2-yl) -1H-benzimidazole were reacted to give 224. LCMS m / z: 561.3 (MH +)

Example 225 2- (1-((2- (3-Fluoroquinolin-4-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -All 225
2- [1- (9-Methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purin-8-ylmethyl) piperidin-4-yl] propane- 2-ol and 3-fluoro-4-iodoquinoline were reacted to give 225. LCMS m / z: 520.2 (MH +)

Example 226 (3R, 4S) -1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) -3-Fluoro-N, N-dimethylpiperidin-4-amine 226
According to General Procedure I for Buchwald coupling, racemic 1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-fluoro-N, N-dimethylpiperidine- 4-Amine and 2-ethylbenzimidazole were reacted. The enantiomers were separated by SFC to give 226. LCMS m / z: 522.3 (MH +)

Example 227 (3S, 4R) -1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) -3-Fluoro-N, N-dimethylpiperidin-4-amine 227
According to General Procedure I for Buchwald coupling, racemic 1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-fluoro-N, N-dimethylpiperidine- 4-Amine and 2-ethylbenzimidazole were reacted. The enantiomers were separated by SFC to give 227. LCMS m / z: 522.3 (MH +)

Example 228 N, N-dimethyl-1-((2- (3-methylisoquinolin-4-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-amine 228
According to the general procedure G for Still coupling, N, N-dimethyl-1-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 Reaction of -amine and 4-bromo-3-methylisoquinoline gave 228. LCMS m / z: 503.7 (MH +)

Example 229 N, N-dimethyl-1-((2- (2-methylbenzo [b] thiophen-3-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidine- 4-Amine 229
According to the general procedure G for Still coupling, N, N-dimethyl-1-((4-morpholino-2- (tributylstannyl) thieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 -Amine and 3-bromo-2-methylbenzo [b] thiophene were reacted to give 229. LCMS m / z: 508.7 (MH +)

Example 230 2-methyl-2- (4-((7-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 230
2- (4-((2-chloro-7-methyl-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) according to general procedure I of Buchwald coupling Reaction of -2-methylpropanamide and 2-methyl-1H-benzo [d] imidazole gave 230. LCMS: M + H ⁺ = 549.3

Example 231 2- (1-((7-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl ) Methyl) piperidin-4-yl) propan-2-ol 231
Reduction of 2- (4-((2-chloro-7-methyl-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide 2- (1-((2-chloro-7-methyl-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) propan-2-ol was obtained and Reaction with 2-methyl-1H-benzo [d] imidazole according to general procedure I for Buchwald coupling gave 231. LCMS: M + H ⁺ = 521.3

Example 232 4- (1-((7-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl ) Methyl) piperidin-4-yl) morpholine 232
4- (1-((2-chloro-7-methyl-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidin-4-yl) according to general procedure I of Buchwald coupling Reaction of morpholine and 2-methyl-1H-benzo [d] imidazole gave 232. LCMS: M + H ⁺ = 548.3

Example 233 2- (1-((9-methyl-6-morpholino-2- (2-propyl-1H-benzo [d] imidazol-1-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol233
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-propylbenzimidazole was reacted to give 233. LCMS m / z: 533.3 (MH +)

Example 234 2- (4-((2- (3-Methoxy-1H-indazol-1-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl ) -2-Methylpropanamide 234
2- (4-((2-Chloro-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazin-1-yl) -2-methylpropanamide (0.1 g) Reaction with methoxy-1H-indazole via Buchwald coupling general procedure I gave 16.4 mg of 234 after reverse phase purification. MS (Q1) 507.2 (M) +

Example 235 2- (1-((2- (3-methoxy-1H-indazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) Propan-2-ol 235
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.2 g) was converted to 3-methoxy- Reaction with 1H-indazole via general procedure I of Buchwald coupling gave 119.5 mg of 235 after reverse phase purification. MS (Q1) 521.3 (M) +

ＭｅＯＨ（２００ｍＬ）中の２-クロロ-９-エチル-６-モルホリノ-９Ｈ-プリン-８-カルバルデヒド（２．４ｇ）の溶液を０℃で水素化ホウ素ナトリウム（０．８４ｇ）で少しずつ処理した。反応物を室温まで温め、１５分間攪拌した。反応混合物を飽和炭酸水素ナトリウム溶液でクエンチした。水性層を酢酸エチルで２回抽出した。組み合わせた有機層を硫酸マグネシウムで乾燥させ、真空下で濃縮して、粗(２-クロロ-９-エチル-６-モルホリノ-９Ｈ-プリン-８-イル)メタノール（２．３ｇ）を白色固形物として得た。

Example 236 2- (1-((9-Ethyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 236

A solution of 2-chloro-9-ethyl-6-morpholino-9H-purine-8-carbaldehyde (2.4 g) in MeOH (200 mL) was treated portionwise with sodium borohydride (0.84 g) at 0 ° C. did. The reaction was warmed to room temperature and stirred for 15 minutes. The reaction mixture was quenched with saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to give crude (2-chloro-9-ethyl-6-morpholino-9H-purin-8-yl) methanol (2.3 g) as a white solid. Got as.

(2-Chloro-9-ethyl-6-morpholino-9H-purin-8-yl) methanol (2.3 g) was reacted with 2-methylbenzimidazole via General Procedure I for Buchwald coupling. The crude product (9-ethyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methanol (3 g) was concentrated and the reaction mixture was concentrated. Obtained after adding water and filtering.

  (9-Ethyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methanol (3 g, 7) in tetrahydrofuran (150 mL, 1800 mmol) .65 mmol) was added dropwise phosphorus tribromide (1.44 mL, 15.3 mmol;). The mixture was stirred for 2 hours until the reaction was complete by LC / MS. The reaction was quenched with MeOH and extracted with ethyl acetate and water. The organic layer was collected, dried over magnesium sulfate, filtered and concentrated to give an orange crude oil. The oil was purified by flash chromatography and 2.6 g of 4- (8- (bromomethyl) -9-ethyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H- Purin-6-yl) morpholine is obtained as an orange solid, 50 mg of which is reacted with 2- (piperidin-4-yl) propan-2-ol via general procedure E to give 34 after reverse phase purification. .6 mg of 236 was obtained. MS (Q1) 519.3 (M) +

Example 237 2- (1-((2- (2-Cyclobutyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 237
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-cyclobutylbenzimidazole to give 237. LCMS m / z: 545.3 (MH +)

Example 238 2- (1-((9-methyl-6-morpholino-2- (2-morpholino-1H-benzo [d] imidazol-1-yl) -9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 238
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 4- (1H-benzo [d] imidazol-2-yl) morpholine was reacted to give 238. LCMS m / z: 576.4 (MH +)

Example 240 2-Methyl-2- (4-((2- (2-methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinofuro [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) propanamide 240
2- [4- (2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyramide (500 mg) in 1,4-dioxane (10 mL) 1.18 mmol) 2-methyl-1H-benzimidazole (180 mg, 1.36 mmol), Pd ₂ dba ₃ (27 mg, 0.029 mmol), Xphos (57 mg, 0.12 mmol) and cesium carbonate (580 mg, 1. 78 mmol) was heated at 110 ° C. for 18 hours. The reaction mixture is cooled to ambient temperature and then loaded onto an Isolute® SCX-2 cartridge, which is washed with MeOH / DCM before eluting the desired product with 2M NH ₃ in MeOH / DCM. It was. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) and then triturated with hot EtOAc to give 240 as a white solid (408 mg 67%). LCMS (Method G): R _T = 5.23 min, M + H ⁺ = 519. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.03-7.98 (m, 1H); 7.73-7.69 (m, 1H); 7.28-7.23 (m, 2H); 05 (bs, 1H); 6.76 (s, 1H); 5.27 (bs, 1H); 4.08 (t, J = 4.7 Hz, 4H); 3.89 (t, J = 4. 7 Hz, 4H); 3.76 (s, 2H); 2.90 (s, 3H); 2.62 (m, 8H) and 1.24 (s, 6H)

Example 241 2- (1-((2- (2-Methyl-1H-benzo [d] imidazol-1-yl) -4-morpholinofuro [3,2-d] pyrimidin-6-yl) methyl) piperidine -4-yl) propan-2-ol 241
2- [1- (2-Chloro-4-morpholin-4-ylfuro [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] propan-2-ol in DMF (2.5 mL) ( 110 mg, 0.28 mmol), 2-methyl-1H-benzimidazole (42 mg, 0.32 mmol), Pd ₂ dba ₃ (14 mg, 0.015 mmol), Xphos (15 mg, 0.031 mmol) and cesium carbonate (203 mg, 0 .62 mmol) was purged with argon, followed by microwave irradiation at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 97: 3 to 95: 5 to 90:10) to give 241 as a tan solid (55 mg, 40% ). LCMS (Method G): R _T = 5.19 min, M + H ⁺ = 491. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.9 (m, 1H); 7.71 (m, 1H); 7.25 (m, 2H); 6.77 (s, 1H); 4.09 (t , J = 4.7 Hz, 4H); 3.89 (t, J = 4.7 Hz, 4H); 3.77 (s, 2H); 3.11 (m, 2H); 2.90 (s, 3H) 2.16 (m, 2H); 1.80 (m, 2H); 1.49 (m, 2H); 1.33-1.22 (m, 2H) and 1.20 (s, 6H)

Example 242 2- (2-Methyl-1H-benzo [d] imidazol-1-yl) -4-morpholino-6-((3-morpholinoazetidin-1-yl) methyl) furo [3,2-d Pyrimidine 242
2-Chloro-4-morpholin-4-yl-6- (3-morpholin-4-ylazetidin-1-ylmethyl) furo [3,2-d] pyrimidine (100 mg, 0.25 mmol) in DMF (2.2 mL) ) A mixture of 2-methyl-1H-benzimidazole (38 mg, 0.29 mmol), Pd ₂ dba ₃ (12 mg, 0.013 mmol), Xphos (13 mg, 0.027 mmol) and cesium carbonate (184 mg, 0.56 mmol). After purging with argon gas, microwave irradiation was performed at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 97: 3 to 95: 5 to 90:10) to give 242 as a tan solid (37 mg, 30%). LCMS (Method G): R _T = 4.85 min, M + H ⁺ = 490. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.9 (m, 1H); 7.70 (m, 1H); 7.26 (m, 2H); 6.72 (s, 1H); 4.07 (t , J = 4.7 Hz, 4H); 3.90-3.79 (m, 6H); 3.75 (m, 4H); 3.64 (m, 2H); 3.17 (m, 1H); 3.11 (m, 1H); 2.89 (s, 3H) and 2.37 (m, 5H)

Example 244 2- (1-((5- (8-methylimidazo [1,2-a] pyridin-5-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl ) Piperidin-4-yl) propan-2-ol 244
2- [1- (7-morpholin-4-yl-5- (tributylstannanyl) thiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] in dioxane (2 mL) Propan-2-ol (118 mg, 0.18 mmol), 5-bromo-8-methylimidazo [1,2-a] pyridine (45 mg, 0.21 mmol), Pd (PPh ₃ ) ₄ (20 mg, 0.02 mmol) And a mixture of copper (I) thiophene-2-carboxylate (7 mg, 0.035 mmol) was purged with argon and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted in 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 244 as an off-white solid (80 mg, 89%). LCMS (Method G) R _T 5.09 min; [M + H] ⁺ 508. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.22 (s, 1H); 7.93 (d, J = 7.4 Hz, 1H); 7.75 (d, J = 1.3 Hz, 1H) 7.14 (d, J = 7.4 Hz, 1H); 4.43 (m, 4H); 3.90 (m, 4H); 3.87 (s, 2H); 3.10 (d, J = 11.5 Hz, 2H); 2.73 (s, 3H); 2.23 (t, J = 11.5 Hz, 2H); 1.78 (m, 2H); 1.55-1.41 (m) , 2H); 1.35 (m, 2H); 1.22 (s, 6H)

Example 246 2- (3- (6-((4- (Dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) benzo [b] thiophene -2-yl) propan-2-ol 246
1- (3- (6-((4- (Dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) benzoate in anhydrous THF (3 mL) To [b] thiophen-2-yl) ethanone 208 (64 mg, 0.119 mmol), 3M methyl magnesium bromide in ethyl ether (0.12 mL, 0.358 mmol) was added dropwise with stirring, and the mixture was added at room temperature. For 90 minutes. A saturated aqueous solution of NaHCO 3 (5 mL) was added and the product was extracted with CH 2 Cl 2 (3 × 15 mL). The combined organics were dried (MgSO4) and concentrated. Flash chromatography with CH2Cl2: methanol: ammonium hydroxide (100: 5: 0.5) gave 15 mg (21.4%) of 246. [M + H] ⁺ 552

Example 247 2- (1-((9-Isopropyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 247
2- (1-((2-Chloro-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.1 g) with isopropyl iodide and general procedure C To give 2- (1-((2-chloro-9-isopropyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol, Was then reacted with 2-methylbenzimidazole via Buchwald coupling general procedure I to give 43.3 g of 247 after reverse phase purification. MS (Q1) 533.3 (M) +

Example 249 2- (1-((2- (imidazo [1,2-a] pyridin-5-yl) -4-morpholinofuro [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 -Il) Propan-2-ol 249
2- [1- (4-Morpholin-4-yl-2-tributylstannanyl furo [3,2-d] pyrimidin-6-ylmethyl) piperidine- in 1,4-dioxane (2.5 mL) 4-yl] propan-2-ol (147 mg, 0.23 mmol), 5-bromoimidazo [1,2-a] pyridine (46 mg, 0.23 mmol), tetrakis (triphenylphosphine) palladium (22 mg, 8 mol%) And a mixture of CuTC (9 mg, 20 mol%) was purged with argon gas and then subjected to microwave irradiation at 140 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: NH ₃ / MeOH (2M); gradient from 100: 0 to 96: 4)) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5. To 249 as a white foam (46 mg, 42%). LCMS (Method G): R _T = 3.47 min, M + H ⁺ = 477. ¹ H NMR (CDCl ₃ , 400 MHz) 9.14 (s, 1H); δ 7.87 (dd, J = 8.5, 1.19 Hz, 2H); 7.76 (d, J = 8.9 Hz, 1H) ); 7.73 (d, J = 1.3 Hz, 1H); 7.30 (m, 1H); 6.79 (s, 1H); 4.11 (t, J = 4.7 Hz, 4H); 3.90 (t, J = 4.7 Hz, 4H); 3.75 (s, 2H); 3.08 (d, J = 11.0 Hz, 2H); 2.12 (t, J = 11.0 Hz) , 2H); 1.78 (m, 2H); 1.52-1.38 (m, 3H); 1.31 (m, 1H) and 1.19 (s, 6H)

Example 250 2- (Imidazo [1,2-a] pyridin-5-yl) -4-morpholino-6-((3-morpholinoazetidin-1-yl) methyl) furo [3,2-d] pyrimidine 250
4-morpholin-4-yl-6- (3-morpholin-4-yl-azetidin-1-ylmethyl) -2-tributylstannanyl furo [3,2-] in 1,4-dioxane (4 mL) d] pyrimidine (227 mg, 0.35 mmol), 5-bromoimidazo [1,2-a] pyridine (84 mg, 0.43 mmol), tetrakis (triphenylphosphine) palladium (40 mg, 10 mol%) and CuTC (16 mg, 24 mol) %) Was purged with argon gas, followed by microwave irradiation at 140 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g); the cartridge was washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: NH ₃ / MeOH (2M); gradient from 100: 0 to 96: 4)) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5. To 20:98 mM triethylamine with a gradient of 2:98 to give 250 as a creamy foam (79 mg, 47%). LCMS (Method G): R _T = 3.22 min, M + H ⁺ = 476. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.14 (s, 1H); 7.87 (dd, J = 7.2, 1.2 Hz, 1H); 7.77 (d, J = 8.9 Hz, 1H) ); 7.74 (d, J = 1.2 Hz, 1H); 7.31 (dd, J = 8.9, 7.2 Hz, 1H); 6.76 (s, 1H); 4.10 (t) , J = 4.7 Hz, 4H); 3.89 (t, J = 4.7 Hz, 4H); 3.84 (s, 2H); 3.74 (t, J = 4.5 Hz, 4H); 3 .62 (t, J = 6.2 Hz, 2H); 3.15-3.02 (m, 3H) and 2.35 (m, 4H)

Example 252 2-Ethyl-1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl ) -1H-indazole-3 (2H) -one 252
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-ethyl-1,2-dihydroindazol-3-one was reacted to give 252. LCMS m / z: 535.3 (MH +)

Example 253 (S) -2- (1-((9-methyl-6-morpholino-2- (2- (tetrahydrofuran-2-yl) -1H-benzo [d] imidazol-1-yl) -9H- Purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 253
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And racemic 2- (tetrahydrofuran-2-yl) -1H-benzimidazole were reacted to give a racemic mixture. The enantiomers were separated by SFC to give 253. LCMS m / z: 561.3 (MH +)

Example 254 I-2- (1-((9-methyl-6-morpholino-2- (2- (tetrahydrofuran-2-yl) -1H-benzo [d] imidazol-1-yl) -9H-purine- 8-yl) methyl) piperidin-4-yl) propan-2-ol 254
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And racemic 2- (tetrahydrofuran-2-yl) -1H-benzimidazole were reacted to give a racemic mixture. The enantiomers were separated by SFC to give 254. LCMS m / z: 561.3 (MH +)

エタノール（２０ｍＬ）中の２-(１-((２-(２-(ベンジル(エチル)アミノ)-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（０．６ｍｍｏｌ）及びパラジウムカーボン（１０重量％、０．３ｇ）及び酢酸（０．１ｍＬ）の混合物を水素雰囲気下、６５℃で１８時間攪拌した。反応混合物をセライトで濾過し、濃縮した粗生成物をＲＰ-ＨＰＬＣで精製して２５５（２８．５ｍｇ、１７％）を得た。ＬＣＭＳｍ／ｚ：５３４．３（ＭＨ＋） Example 255 2- (1-((2- (2- (ethylamino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) Piperidin-4-yl) propan-2-ol 255

2- (1-((2- (2- (Benzyl (ethyl) amino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine) in ethanol (20 mL) A mixture of -8-yl) methyl) piperidin-4-yl) propan-2-ol (0.6 mmol) and palladium carbon (10 wt%, 0.3 g) and acetic acid (0.1 mL) under a hydrogen atmosphere Stir at 18 ° C. for 18 hours. The reaction mixture was filtered through celite and the concentrated crude product was purified by RP-HPLC to give 255 (28.5 mg, 17%). LCMS m / z: 534.3 (MH +)

Example 256 4- (5- (2-Methyl-1H-benzo [d] imidazol-1-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [4,5-d] Pyrimidin-7-yl) morpholine 256
5-Chloro-7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) thiazolo [4,5-d] pyrimidine in 1,4-dioxane (1.5 mL) (50 mg, 0.12 mmol), 2-methyl-1H-benzimidazole (18 mg, 0.13 mmol), Pd ₂ (dba) ₃ (5.5 mg, 0.006 mmol), XPhos (5.7 mg, 0.02 mmol) And a mixture of cesium carbonate (78 mg, 0.24 mmol) was purged with argon gas for 15 minutes. The resulting reaction mixture was irradiated with microwaves at 145 ° C. for 30 minutes. The crude residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was extracted with a mixture of 2M NH ₃ in DCM and MeOH. The resulting residue was further purified by column chromatography (Si-PCC, gradient NH ₃ : DCM: 0: 100 to 4:96 in 2M MeOH). The solvent was reduced in vacuo to give 256 as a brown solid (43 mg, 70%). LCMS (Method G): R _T 5.52 min, [M + H] ⁺ 507. ¹ H NMR (400 MHz, CDCl ₃ ): δ 8.22-8.21 (1H, m), 7.71-7.70 (1H, m), 7.30-7.27 (2H, m), 4 .18 (2H, s), 4.03 (4H, t, J = 4.80 Hz), 3.89 (4H, t, J = 4.80 Hz), 3.76-3.72 (6H, m) , 3.27 (2H, m), 3.15 (1H, m), 3.00 (3H, s), 2.37 (4H, br s)

Example 257 3- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-Il) oxetane-3-ol 257
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 3- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Oxetane-3-ol was reacted to give 257. LCMS m / z: 519.3 (MH +)

Example 258 2,2-dimethyl-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Propan-1-amine 258
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and 2, 2-Dimethylpropan-1-amine was reacted to give 258. [M + H] ^< +> 449.6.

Example 259 1- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) -N-((3-methyl Oxetane-3-yl) methyl) methanamine 259
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and (3 -Methyloxetane-3-yl) methanamine was reacted to give 259. [M + H] ⁺ 463.6.

Example 260 1- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) cyclobutanol 260
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 1- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Cyclobutanol was reacted to give 260. LCMS m / z: 517.3 (MH +)

Example 261 2- (1-((9-Methyl-6-morpholino-2- (2- (pyrrolidin-1-yl) -1H-benzo [d] imidazol-1-yl) -9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 261
According to General Procedure I for Buchwald coupling, 2- (pyrrolidin-1-yl) -1H-benzo [d] imidazole and 2- (1-((2-chloro-9-methyl-6-morpholino-9H-purine) -8-yl) methyl) piperidin-4-yl) propan-2-ol was reacted to give 261. LCMS m / z: 560.3 (MH +)

Example 262 2- (1-((2- (2- (3-Fluoroxetane-3-yl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine -8-yl) methyl) piperidin-4-yl) propan-2-ol 262
According to the general procedure I of Buchwald coupling, 2- (3-fluorooxetane-3-yl) -1H-benzimidazole and 2- (1-((2-chloro-9-methyl-6-morpholino-9H-purine) -8-yl) methyl) piperidin-4-yl) propan-2-ol was reacted to give 262. LCMS m / z: 565.3 (MH +)

Example 263 3- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-Il) oxetane-3-ol 263
According to General Procedure I for Buchwald coupling, 2-ethylbenzimidazole and 3- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Oxetane-3-ol was reacted to give 263. LCMS m / z: 533.3 (MH +)

Example 264 2-Methyl-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperazin-1-yl) propan-1-ol 264
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropane according to general procedure I of Buchwald coupling Reaction of -1-ol and 2-methyl-1H-benzo [d] imidazole gave 264. LCMS m / z: 520.3 (MH +)

Example 265 2- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 3-yl) propan-2-ol 265
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and 2- (piperidin-3-yl) propan-2-ol were reacted to give 265. M + H ⁺ = 505.3

Example 266 2-Methyl-1- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-2-ol 266
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and 2-methyl-1- (piperidin-4-yl) propan-2-ol were reacted to give 266. LCMS: M + H ^< + ^> = 519.4

Example 267 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((4- (2,2,2-trifluoroethyl) piperazine-1 -Yl) methyl) -9H-purin-6-yl) morpholine 267
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and 1- (2,2,2-trifluoroethyl) piperazine were reacted to give 267. LCMS: M + H ⁺ = 530.2

Example 268 (4-methyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) Piperidin-4-yl) methanol 268
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and (4-methylpiperidin-4-yl) methanol were reacted to give 268. LCMS: M + H ⁺ = 491.3

ピペラジン-１-カルボン酸ｔｅｒｔ-ブチル（０．３６７ｇ）、Ｌ−（＋）−乳酸（０．２１３ｇ）及びＨＢＴＵ（０．８２２ｇ）の混合物を一晩室温で攪拌した。ＤＣＭで希釈して、混合物を水（２×）、ブライン、で洗浄し、乾燥させた（Ｎａ_２ＳＯ_４）。濾過と濃縮により、４-(２-ヒドロキシプロパノイル)ピペラジン-１-カルボン酸Ｉ-ｔｅｒｔ-ブチルを粘性のある油として得、これをジクロロメタン中のトリフルオロ酢酸で処理した。濃縮した後、残留物を４-(８-(ブロモメチル)-９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９Ｈ-プリン-６-イル)モルホリンと、ジイソプロピルエチルアミン（１０当量）の存在下で、アミンアルキル化の一般的手順Ｅに従って反応させて２６９を得た。ＬＣＭＳ：Ｍ＋Ｈ^＋＝５２０．３ Example 269 I-2-hydroxy-1- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) piperazin-1-yl) propan-1-one 269

A mixture of tert-butyl piperazine-1-carboxylate (0.367 g), L-(+)-lactic acid (0.213 g) and HBTU (0.822 g) was stirred overnight at room temperature. Diluted with DCM, the mixture was washed with water (2 ×), brine, and dried (Na ₂ SO ₄ ). Filtration and concentration gave I-tert-butyl 4- (2-hydroxypropanoyl) piperazine-1-carboxylate as a viscous oil, which was treated with trifluoroacetic acid in dichloromethane. After concentration, the residue is taken up with 4- (8- (bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine. In the presence of diisopropylethylamine (10 eq) according to general procedure E for amine alkylation to give 269. LCMS: M + H ⁺ = 520.3

(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メタノール(４.０ｇ)を２-メチルベンゾイミダゾール（１．９６ｇ）とブッフバルトカップリングの一般的手順Ｉを介して反応させた。固形物を反応混合物からまだ温かいうちに濾過した。水（ＤＭＦの体積の５倍）を濾過された反応混合物に加えて、生成物を反応混合物から沈殿させた。沈殿したオレンジ色の固形物を濾過し、真空下で乾燥させて、定量的な収率の(９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メタノールを得た。 Example 270 Adamantan-1-yl- [9-methyl-2- (2-methyl-benzimidazol-1-yl) -6-morpholin-4-yl-9H-purin-8-ylmethyl] -amine 270

(2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methanol (4.0 g) with 2-methylbenzimidazole (1.96 g) via general procedure I for Buchwald coupling I Reacted. The solid was filtered from the reaction mixture while still warm. Water (5 times the volume of DMF) was added to the filtered reaction mixture to precipitate the product from the reaction mixture. The precipitated orange solid was filtered and dried under vacuum to give a quantitative yield of (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6 -Morpholino-9H-purin-8-yl) methanol was obtained.

無水ＴＨＦ（４００ｍＬ）中の粗(９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メタノール（６ｇ）に三臭化リン（２．７ｍＬ）を加えた。反応を完了するまでＬＣ／ＭＳでモニターした。不均一な反応混合物をブフナー漏斗に通過させ、固形物を回収して、水で３回洗浄し、ＭｅＯＨで２回洗浄し、２ｇの粗４-(８-(ブロモメチル)-９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９Ｈ-プリン-６-イル)モルホリンを得、その５０ｍｇをビシクロ[２.２.２]オクタン-１-アミン(１-アダマンチルアミン)と一般的手順Ｅを介して反応させ、逆相精製後に５．７ｍｇの２７０を得た。ＭＳ（Ｑ１）５１３．３（Ｍ）＋

To crude (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methanol (6 g) in anhydrous THF (400 mL). Phosphorus tribromide (2.7 mL) was added. The reaction was monitored by LC / MS until complete. The heterogeneous reaction mixture was passed through a Buchner funnel and the solid was collected and washed three times with water, twice with MeOH and 2 g of crude 4- (8- (bromomethyl) -9-methyl-2. -(2-Methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine was obtained, 50 mg of which was added to bicyclo [2.2.2] octane-1-amine (1- Adamantylamine) via general procedure E to give 5.7 mg of 270 after reverse phase purification. MS (Q1) 513.3 (M) +

Example 271 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2,3- Dihydro-1H-indene-1-amine 271
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (25 mg) Reaction with dihydro-1H-indene-1-amine via general procedure E gave 10.6 mg of 271 after reverse phase purification. MS (Q1) 495.2 (M) +

Example 272 (4R) -N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) bicyclo [2.2.1] Heptane-2-amine 272
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to (1R, 4S Reaction with) -bicyclo [2.2.1] heptan-2-amine via general procedure E to give 16 mg of 272 after reverse phase purification. MS (Q1) 473.3 (M) +

Example 273 1-(((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) methyl) cyclo Hexanol 273
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 1- (amino Reaction with methyl) cyclohexanol via general procedure E gave 22 mg of 273 after reverse phase purification. MS (Q1) 491.3 (M) +

Example 274 (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) cyclopentyl) methanol 274
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to (1-amino Reaction with cyclopentyl) methanol via general procedure E gave 10.2 mg of 274 after reverse phase purification. MS (Q1) 477.2 (M) +

Example 275 N, 1-dimethyl-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Piperidine-4-amine 275
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to N, 1- Reaction with dimethylpiperidin-4-amine via general procedure E gave 5.2 mg of 275 after reverse phase purification. MS (Q1) 490.3 (M) +

Example 276 4- (8- (isoindoline-2-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 276
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) in general with isoindoline Reaction via general procedure E gave 10.7 mg of 276 after reverse phase purification. MS (Q1) 481.2 (M) +

Example 277 4- (8-((4- (cyclopropylmethyl) piperazin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl)- 9H-purin-6-yl) morpholine 277
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 1- (cyclo Reaction with (propylmethyl) piperazine via general procedure E gave 23.5 mg of 277 after reverse phase purification. MS (Q1) 502.3 (M) +

Example 278 4- (8-((4,4-difluoropiperidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H- Purin-6-yl) morpholine 278
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 4,4- Reaction with difluoropiperidine via general procedure E gave 19.3 mg of 278 after reverse phase purification. MS (Q1) 483.2 (M) +

Example 279 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -1-phenylethane Amine 279
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 1-phenylethane. Reaction with amine via general procedure E gave 10.8 mg of 279 after reverse phase purification. MS (Q1) 483.2 (M) +

Example 280 4- (8-((4- (methoxymethyl) piperidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H -Purin-6-yl) morpholine 280
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 4- (methoxy Reaction with methyl) piperidine via general procedure E gave 21.9 mg of 280 after reverse phase purification. MS (Q1) 491.3 (M) +

Example 281 4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) cyclohexanol 281
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 4-aminocyclo Reaction with hexanol via general procedure E yielded 11.1 mg of 281 after reverse phase purification. MS (Q1) 477.2 (M) +

Example 282 1- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) -N-((1-methyl Piperidin-2-yl) methyl) methanamine 282
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to (1-methyl Reaction with piperidin-2-yl) methanamine via general procedure E gave 4.1 mg of 282 after reverse phase purification. MS (Q1) 490.2 (M) +

Example 283 4- (8-((dihydro-1H-pyrido [1,2-a] pyrazin-2 (6H, 7H, 8H, 9H, 9aH) -yl) methyl) -9-methyl-2- (2 -Methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 283
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to octahydro-1H- Reaction with pyrido [1,2-a] pyrazine via general procedure E gave 24 mg of 284 after reverse phase purification. MS (Q1) 502.3 (M) +

Example 284 1-methyl-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine -4-amine 284
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 1-methylpiperidine. Reaction with -4-amine via general procedure E gave 4.6 mg of 284 after reverse phase purification. MS (Q1) 476.3 (M) +

Example 285 N, 2-dimethyl-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Propan-1-amine 285
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to N, 2- Reaction with dimethylpropan-1-amine via general procedure E gave 10.1 mg of 285 after reverse phase purification. MS (Q1) 449.2 (M) +

Example 286 1- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) piperidine -1-Ile) Ethanon 286
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) 1- (4 Reaction with -aminopiperidin-1-yl) ethanone via general procedure E gave 19.6 mg of 286 after reverse phase purification. MS (Q1) 504.3 (M) +

Example 287 4- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) pyrrolidine- 3-Il) morpholine 287
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 4- (pyrrolidine). Reaction with -3-yl) morpholine via general procedure E gave 26.9 mg of 287 after reverse phase purification. MS (Q1) 518.2 (M) +

Example 288 N-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) tetrahydro-2H-pyran -4-Amine 288
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to tetrahydro-2H- Reaction with pyran-4-amine via general procedure E gave 8.6 mg of 288 after reverse phase purification. MS (Q1) 463.2 (M) +

Example 289 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((3- (trifluoromethyl) pyrrolidin-1-yl) methyl)- 9H-purin-6-yl) morpholine 289
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to 3- (tri Reaction with fluoromethyl) pyrrolidine via general procedure E gave 19.9 mg of 289 after reverse phase purification. MS (Q1) 501.2 (M) +

Example 290 N-methyl-1- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) -N- ( (Tetrahydrofuran-2-yl) methyl) methanamine 290
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to N-methyl- Reaction with 1- (tetrahydrofuran-2-yl) methanamine via general procedure E gave 10.7 mg of 290 after reverse phase purification. MS (Q1) 477.2 (M) +

Example 291 1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine-4-carbo Nitrile 291
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to piperidine-4- Reaction with carbonitrile via general procedure E gave 21.9 mg of 291 after reverse phase purification. MS (Q1) 472.2 (M) +

Example 292 2-Methyl-1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) Propan-2-ol 292
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 1-amino- Reaction with 2-methylpropan-2-ol via general procedure E gave 8.1 mg of 292 after reverse phase purification. MS (Q1) 451.2 (M) +

Example 293 3,3,3-trifluoro-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) propan-1-amine 293
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) in 3,3 Reaction with 3-trifluoropropan-1-amine via general procedure E gave 8 mg of 293 after reverse phase purification. MS (Q1) 475.2 (M) +

Example 294 4,4-difluoro-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Cyclohexaneamine 294
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to 4,4- Reaction with difluorocyclohexaneamine via general procedure E gave 15.4 mg of 294 after reverse phase purification. MS (Q1) 497.2 (M) +

Example 295 1-isopropyl-N-methyl-N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl ) Methyl) piperidine-4-amine 295
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) in 1-isopropyl- Reaction with N-methylpiperidin-4-amine via general procedure E gave 22.1 mg of 295 after reverse phase purification. MS (Q1) 518.3 (M) +

Example 296 N, N-diethyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl Pyrrolidin-3-amine 296
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to N, N- Reaction with diethylpyrrolidin-3-amine via general procedure E gave 27.8 mg of 296 after reverse phase purification. MS (Q1) 504.3 (M) +

Example 297 1- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) -N-((tetrahydrofuran-3 -Yl) methyl) methanamine 297
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was added to (tetrahydrofuran-3 Reaction with -yl) methanamine via general procedure E gave 6.9 mg of 297 after reverse phase purification. MS (Q1) 463.2 (M) +

Example 298 N-methyl-N- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) pyrrolidin-3-yl) acetamide 298
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to N-methyl- Reaction with N- (pyrrolidin-3-yl) acetamide via general procedure E gave 25.5 mg of 298 after reverse phase purification. MS (Q1) 504.2 (M) +

Example 299 I- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) pyrrolidine- 3-yl) methanol 299
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to I-pyrrolidine- Reaction with 3-ylmethanol via general procedure E gave 19.1 mg of 299 after reverse phase purification. MS (Q1) 463.2 (M) +

Example 300 4- (8-((3,3-dimethylpyrrolidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H- Purin-6-yl) morpholine 300
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) Reaction with dimethylpyrrolidine via general procedure E gave 16.8 mg of 300 after reverse phase purification. MS (Q1) 461.2 (M) +

Example 301 4- (8-((3,3-diethylpyrrolidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H- Purin-6-yl) morpholine 301
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) Reaction with diethylpyrrolidine via general procedure E gave 26.5 mg 301 after reverse phase purification. MS (Q1) 4892 (M) +

Example 302 4- (8-((3-isobutylpyrrolidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purine- 6-yl) morpholine 302
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) with 3-isobutylpyrrolidine And via general procedure E to give 27 mg of 302 after reverse phase purification. MS (Q1) 489.2 (M) +

Example 303 N-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2-phenylpropane -2-Amine 303
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) in 2-phenylpropane Reaction with -2-amine via general procedure E gave 7.4 mg of 303 after reverse phase purification. MS (Q1) 497.2 (M) +

Example 304 4- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((1,1-dioxo-4- (tetrahydro-2H-thiopyran-4) -Yl) piperazin-1-yl) methyl) -9H-purin-6-yl) morpholine 304
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) is commonly used as an amine. Reaction via Procedure E gave 1 mg of 304 after reverse phase purification. MS (Q1) 580.3 (M) +

Example 305 (S)-(1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) Pyrrolidin-3-yl) methanol 305
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (50 mg) was converted to (S)- Reaction with pyrrolidin-3-ylmethanol via general procedure E gave 18.8 mg of 305 after reverse phase purification. MS (Q1) 463.2 (M) +

Example 306 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -N, N- Dimethylpiperidine-4-amine 306
1-((2-Chloro-9-methyl-6-morpholino-8,9-dihydro-7H-purin-8-yl) methyl) -N, N-dimethyl is added to the vial according to General Procedure I for Buchwald coupling. Piperidin-4-amine (0.044 g, 0.11 mmol), 2-ethyl-1H-benzo [d] imidazole (0.0171 g, 0.117 mmol), Xphos (0.00692 g, 0.0145 mmol), tris (di Benzylideneacetone) dipalladium (0) (0.00696 g, 7.60E-6 mol) and cesium carbonate (0.0728 g, 0.223 mmol) were added. The mixture was dissolved in N, N-dimethyl to form an amide (0.865 mL, 0.0112 mol). The reaction was pressurized and heated in a microreactor at 145 ° C. for 30 minutes. The reaction mixture was filtered and concentrated. The crude material was purified by reverse phase HPLC to give 306 (26.7 mg, 47%). [M + H] ⁺ = 536.3.

Example 307 2- (1-((2- (2- (1-fluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 307
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (1-fluorocyclopropyl) -1H-benzimidazole to give 307. LCMS m / z: 549.3 (MH +)

Example 308 2- (1-((2- (2- (cyclopropylmethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-2-ol 308
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2- (cyclopropylmethyl) -benzimidazole to give 308. LCMS m / z: 545.3 (MH +)

Example 309 4- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-Il) morpholine 309
8-Chloromethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (107 mg, 0.26 mmol) and 4-chloromethyl 2- (2-ethylbenzimidazol-1-yl) in DMF (3 mL) To a solution of azetidin-3-ylmorpholine (44 mg, 0.31 mmol) was added K ₂ CO ₃ (106 mg, 0.77 mmol). The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was dissolved in _EtOAc, washed with _H 2 O (× 4), then dried _(Na 2 _SO 4), and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%). The resulting residue was further purified on an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH followed by reverse phase HPLC (Phenomenex Luna C18, acetonitrile 95: A gradient of 20 mM Et ₃ N in 5 to 2:98 gave 20 309 Et ₃ N in water as a white solid (14 mg, 11%). LCMS (Method G): R _T 5.74 min, [M + H] ⁺ 518.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.98 (m, 1H); 7.77-7.73 (m, 1H); 7.27-7.23 (m, 2H); 4 3.35 (m, 4H); 3.89-3.82 (m, 6H); 3.83 (s, 3H); 3.72 (m, 4H); 3.56 (m, 2H); 34 (q, J = 7.5 Hz, 2H); 3.15-3.03 (m, 3H); 2.34 (m, 4H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 310 4- (8-((3,3-dimethyl-4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole) -1-yl) -9-methyl-9H-purin-6-yl) morpholine 310
8-chloromethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (107 mg, 0.26 mmol) and 1- in DMF (3 mL) To a solution of (2-methanesulfonylethyl) -2,2-dimethylpiperazine (68 mg, 0.31 mmol) was added K ₂ CO ₃ (106 mg, 0.77 mmol). The resulting mixture was stirred for 16 hours at room temperature. The reaction mixture was dissolved in EtOAc, washed with H ₂ O (x4), dried (Na ₂ SO ₄ ) and concentrated in vacuo. The residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) and (Si-PCC, MeOH: DCM 0-5%). The resulting residue was further purified by reverse phase HPLC (Phenomenex Luna C18, 20 mM Et ₃ N in water with a gradient of 20 mM Et ₃ N in acetonitrile 95: 5 to 5:95) to give a white solid (40 mg, 26%), 310 was obtained. LCMS (Method G): R _T 6.68 min, [M + H] ⁺ 596.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.04-7.99 (m, 1H); 7.77-7.72 (m, 1H); 7.28-7.23 (m, 2H); 4 .35 (m, 4H); 3.87 (m, 7H); 3.69 (s, 2H); 3.36 (q, J = 7.5 Hz, 2H); 3.11-3.03 (m , 5H); 2.92 (m, 2H); 2.62 (m2H); 2.51 (m, 2H); 2.37-2.22 (m, 2H); 1.45 (t, J = 7.5Hz, 3H) and 1.09 (s, 6H)

Example 311 2-((1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine -3-yl) (methyl) amino) -2-methylpropanamide 311
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.106 g, 0.27 mmol) in DCE (3 mL) 2- (azetidin-3-ylmethylamino) -2-methylpropionamide (0.055 g, 0.32 mmol), trimethoxymethane (0.314 mL, 2.9 mmol) and acetic acid (0.017 mL, 0.29 mmol) The mixture was stirred for 30 minutes at room temperature. Sodium triacetoxyborohydride (0.101 g, 0.48 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was partitioned between DCM and water and the organic layer was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM gradient 0: 100 to 7.5: 92.5) to give 311 as a white solid (0.096 g, 65%). LCMS (Method G): R _T = 5.87 min, [M + H] ⁺ 547.3. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02-7.98 (m, 1H); 7.79-7.75 (m, 1H);); 7.25-7.50 (m, 2H); 6.98 (s, 1H); 5.23 (s, 1H); 4.35 (m, 4H); 3.89-3.82 (m, 7H); 3.57-3.50 (m, 2H); 3.36 (q, J = 7.5 Hz, 2H); 3.28-3.23 (m, 1H); 2.27-2.22 (m, 2H); 1.70-1. 64 (m, 6H); 1.44 (t, J = 7.5 Hz, 2H); 1.20 (s, 6H)

Example 312 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) ) Methyl) -9H-purin-6-yl) morpholine 312
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (65 mg, 0.17 mmol) and 1-in DCE (4 mL) A mixture of (2-methanesulfonylethyl) piperazine (38 mg, 0.20 mmol) was stirred at room temperature for 1.5 hours and sodium triacetoxyborohydride (70 mg, 0.33 mmol) was added. The reaction mixture was stirred for 16 hours and then partitioned between brine and DCM. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 312 as a cream solid (29 mg, 30%). LCMS (Method G): R _T 5.97 min [M + H] ⁺ 568.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-7.99 (m, 1H); 7.78-7.73 (m, 1H); 7.30-7.24 (m, 2H); 4 .35 (m, 4H); 3.90-3.83 (m, 7H); 3.77 (s, 2H); 3.36 (q, J = 7.5 Hz, 2H); 3.22-3 .11 (m, 2H); 3.04 (s, 3H); 2.91 (t, J = 6.4 Hz, 2H); 2.59 (m, 8H) and 1.45 (t, J = 7) .5Hz, 3H)

Example 313 1- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) -2-methylpropan-1-ol 313
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (125 mg, 0.32 mmol) in 1,2-dichloroethane (5 mL) ) A mixture of 1-azetidin-3-yl-2-methylpropan-1-ol (50 mg, 0.38 mmol) and 4Å molecular sieves (1.0 g) was stirred at room temperature for 5 hours under a nitrogen atmosphere. Sodium triacetoxyborohydride (102 mg, 0.48 mmol) was added and the resulting reaction mixture was stirred at room temperature for 16 hours. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with DCM / MeOH and the desired product was then eluted with a mixture of 2M NH _{3 in} MeOH and DCM. The solvent was reduced under vacuum to give 313 as an off-white foam (60 mg, 37%). LCMS (Method G): R _T 6.95 min, [M + H] ⁺ 505. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.9-7.95 (1H, m), 7.72-7.71 (1H, m), 7.23 (2H, m), 4.32 (4H) , Brs), 3.85-3.78 (9H, m), 3.47-3.45 (3H, m), 3.32 (2H, q, J = 7.48 Hz), 3.25 (1H , T, J = 6.66 Hz), 3.13 (1H, t, J = 6.66 Hz), 2.66-2.65 (1H, m), 1.62-1.60 (2H, m) 1.41 (3H, t, J = 7.48 Hz), 0.87 (6H, dd, J = 11.85, 6.78 Hz)

Example 314 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (oxetane-3-yl) piperidin-1-yl) methyl ) -9H-purin-6-yl) morpholine 314
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.105 g, 0.27 mmol) in DCE (2 mL) A mixture of 4-oxetane-3-ylpiperidine (0.045 g, 0.32 mmol), trimethoxymethane (0.314 mL, 2.9 mmol) and acetic acid (0.017 mL, 0.29 mmol) was stirred at room temperature for 18 hours. . Sodium triacetoxyborohydride (0.101 g, 0.48 mmol) was added and the reaction mixture was stirred for 5 hours at room temperature. After adding sodium triacetoxyborohydride (0.101 g, 0.48 mmol), the reaction mixture was stirred for an additional 2 hours and the suspension was partitioned between DCM and water. The organic layer was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was flash chromatographed (Si-PPC, MeOH: DCM gradient 0: 100 to 5:95) followed by (Si-PPC, acetone: EtOAc, 0: 100 to 70:30), followed by reverse phase HPLC. Purification (Phenomenex Gemini 5u C18, 20 mM triethylamine in water with a gradient of acetonitrile 95: 5 to 2:98) gave 314 as an off-white solid (0.048 g, 35%). LCMS (Method G): R _T = 5.92 min, [M + H] ⁺ 517.3. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.03-7.99 (m, 1H); 7.78-7.74 (m, 1H); 7.29-7.25 (m, 2H); 76 (dd, J = 7.9, 6.2 Hz, 2H); 4.46 (t, J = 6.2 Hz, 2H); 4.44-4.35 (m, 4H); 3.90-3 .84 (m, 7H); 3.78-3.73 (m, 2H); 3.36 (q, J = 7.5 Hz, 2H); 2.95-2.91 (m, 2H); 2 79-2.71 (m, 1H); 2.21-2.17 (m, 2H); 1.81-1.50 (m, 4H); 1.49-1.41 (t, J = 7.5Hz, 3H); 1.21-1.15 (m, 1H)

Example 315 2- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) propan-2-ol 315
2- (2-Methylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.075 g, 0.20 mmol) in DCE (2 mL) A mixture of 2-azetidin-3-ylpropan-2-ol (0.023 g, 0.20 mmol), trimethoxymethane (0.215 mL, 2 mmol) and acetic acid (0.012 mL, 0.2 mmol) was stirred at room temperature for 1 hour. Stir. Sodium triacetoxyborohydride (0.042 g, 0.2 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was partitioned between DCM and water and the organic layer was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 315 as an off-white solid (0.020 g, 23%). LCMS (Method G): R _T = 5.61 min, [M + H] ⁺ 477.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.11-8.07 (m, 1H); 7.72-7.69 (m, 1H); 7.35-7.26 (m, 2H); 42-4.31 (m, 4H); 3.89-3.82 (m, 11H); 3.62-3.12 (m, 2H); 2.94 (s, 3H); 2.70- 2.55 (m, 1H); 1.18 (s, 6H)

Example 316 3- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-Il) pentane-3-ol 316
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 3- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Pentan-3-ol was reacted to give 316. LCMS m / z: 533.3 (MH +)

Example 317 4- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) tetrahydro-2H-pyran-4-ol 317
According to General Procedure I of Buchwald coupling, 2-methylbenzimidazole and 4- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) -Tetrahydro-2H-pyran-4-ol was reacted to give 317. LCMS m / z: 547.3 (MH +)

Example 318 (S) -4- (8-((3- (1,1-dioxo-isothiazolidin-2-yl) pyrrolidin-1-yl) methyl) -9-methyl-2- (2-methyl- 1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 318
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 4- (2-chloro-8-((3- (isodioxothiazolidin-2-yl) pyrrolidin-1-yl) methyl) -9- Methyl-9H-purin-6-yl) morpholine was reacted to give 318. LCMS m / z: 552.2 (MH +)

Example 319 2- (1-((9-methyl-2- (2- (1-methyl-1H-pyrazol-5-yl) -1H-benzo [d] imidazol-1-yl) -6-morpholino- 9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 319
According to general procedure I of Buchwald coupling, 2- (1-methyl-1H-pyrazol-5-yl) -1H-benzo [d] imidazole and 2- (1-((2-chloro-9-methyl-6 -Morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was reacted to give 319. LCMS m / z: 571.3 (MH +)

Example 320 I-4- (8-((3- (1,1-dioxo-isothiazolidin-2-yl) pyrrolidin-1-yl) methyl) -9-methyl-2- (2-methyl-1H- Benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 320
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 4- (2-chloro-8-((3- (isodioxothiazolidin-2-yl) pyrrolidin-1-yl) methyl) -9- Methyl-9H-purin-6-yl) morpholine was reacted to give 320. LCMS m / z: 552.2 (MH +)

Example 321 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2- (4 -Methylthiazol-2-yl) ethanamine 321
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and 2- Reaction of (4-methylthiazol-2-yl) ethanamine gave 321. [M + H] ^< +> 504.6.

Example 322 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2- (pyridine -2-yl) ethanamine 322
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and 2- (Pyridin-2-yl) ethanamine was reacted to give 322. [M + H] ^< +> 484.6.

Example 323 1- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) cyclopentanol 323
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 1- (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl ) Cyclopentanol was reacted to give 323. LCMS m / z: 531.3 (MH +)

Example 324 7-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2-oxa- 7-Azaspiro [3.5] Nonane 324
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6- in DCE (2 mL), trimethoxymethane (0.204 mL, 1.9 mmol) and acetic acid (0.011 mL, 0.2 mmol). Of morpholin-4-yl-9H-purine-8-carbaldehyde (0.075 g, 0.19 mmol), 2-oxa-7-azaspiro [3.5] nonanetrifluoroacetic acid (0.05 g, 0.20 mmol) The mixture was stirred for 2 hours at room temperature. Sodium triacetoxyborohydride (0.061 g, 0.29 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was partitioned between DCM and water and the organic layer was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM 0: 100 to 10:90 gradient) to give 324 as a white solid (0.066 g, 70%). LCMS (Method G): R _T = 5.88 min, [M + H] ⁺ 503.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.03-7.99 (m, 1H); 7.83-7.79 (m, 1H); 7.33-7.29 (m, 2H); 48-4.37 (m, 4H); 4.34-4.30 (m, 4H); 3.90-3.84 (m, 7H); 3.76-3.72 (m, 2H); 3.40 (d, J = 8.3 Hz, 2H); 2.49-2.44 (m, 4H); 1.95-1.91 (m, 4H); 1.48 (t, J = 7) .5Hz, 3H)

Example 325 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (tetrahydro-2H-pyran-4-yl) azetidine-1 -Yl) methyl) -9H-purin-6-yl) morpholine 325
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6- in DCE (2 mL), trimethoxymethane (0.277 mL, 2.6 mmol) and acetic acid (0.015 mL, 0.26 mmol). A mixture of morpholin-4-yl-9H-purine-8-carbaldehyde (0.10 g, 0.26 mmol), 3- (tetrahydropyran-4-yl) azetidine (0.050 g, 0.28 mmol) was stirred at room temperature for 2 hours. And stirred. Sodium triacetoxyborohydride (0.090 g, 0.43 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was partitioned between DCM and water and the organic phase was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc 0: 100 to 10:90 gradient) to give 325 as a yellow solid (0.072 g, 56%). LCMS (Method G): R _T = 6.14 min, [M + H] ⁺ 517.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02-7.98 (m, 1H); 7.78-7.73 (m, 1H); 7.35-7.25 (m, 2H); 40-4.32 (m, 4H); 3.98 (dd, J = 11.7, 4.3 Hz, 2H); 3.89-3.86 (m, 9H); 3.42-3.30 (M, 5H); 1.67-1.64 (m, 4H); 1.55 (d, J = 11.7 Hz, 2H); 1.48-1.39 (t, J = 7.5 Hz, 3H); 1.29-1.16 (m, 3H)

Example 326 N, N-dimethyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl Piperidine-4-carboxamide 326
9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and piperidine- in DCE (3 mL) A solution of 4-carboxylic acid dimethylamide (50 mg, 0.32 mmol) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0, 95: 5, 90:10, to 85:15) to give 326 as a white solid (69 mg, 51%). LCMS (Method G): R _T = 5.48 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.19 (m, 1H); 7.73-7.68 (m, 1H); 7.29-7.25 (m, 2H); 4.35 (m, 4H); 3.91-3.83 (m, 7H); 3.75 (s, 2H); 3.06 (s, 3H); 2.95 (s, 6H); 2.54 (m, 1H) 2.18 (m, 2H); 1.92-1.79 (m, 2H) and 1.71 (m, 4H)

Example 327 8-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -1-oxa- 3,8-Diazaspiro [4.5] decan-2-one 327
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and 1-in DCE (3 mL) A solution of oxa-3,8-diazaspiro [4.5] decan-2-one (50 mg, 0.32 mmol) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 95: 5 to 90:10 to 85:15) to give 327 as a white solid (77 mg, 56% ). LCMS (Method G): R _T = 5.35 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.9 (m, 1H); 7.72 (m, 1H); 7.29 (m, 2H); 4.99 (bs, 1H); 4.35 (m 3.90-3.83 (m, 7H); 3.80 (s, 2H); 3.36 (s, 2H); 2.95 (s, 3H); 65 (m, 4H); 2.03 (m, 2H) and 1.82 (m, 2H)

Example 328 4- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-Il) morpholine 328
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (80 mg, 0.21 mmol) in DCE (5 mL), 4- A mixture of azetidin-3-ylmorpholine (36 mg, 0.25 mmol) and 4Å powdered molecular sieve (100 mg) was stirred at room temperature for 4 hours, after which sodium triacetoxyborohydride (90 mg, 0.42 mmol) was added. The reaction mixture was stirred for 64 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 328 as a creamy solid (71 mg, 67 %). LCMS (Method G): R _T 5.18 min [M + H] ⁺ 504.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.69 (m, 1H); 7.28-7.23 (m, 2H); 4 .35 (m, 4H); 3.91-3.82 (m, 9H); 3.73 (m, 4H); 3.58 (m, 2H); 3.18-3.04 (m, 3H) ); 2.94 (s, 3H) and 2.35 (m, 4H)

Example 329 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) ) Methyl) -9H-purin-6-yl) morpholine 329
9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (60 mg, 0.16 mmol) in DCE (4 mL), 1- A mixture of (2-methanesulfonylethyl) piperazine (37 mg, 0.19 mmol) and 4Å powdered molecular sieve (100 mg) was stirred at room temperature for 4 hours and sodium triacetoxyborohydride (67 mg, 0.32 mmol) was added. . The reaction mixture was stirred for 64 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 329 as a creamy solid (55 mg, 62%). LCMS (Method G): R _T 5.54 min [M + H] ⁺ 554.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.11-8.06 (m, 1H); 7.74-7.70 (m, 1H); 7.30-7.25 (m, 2H); 4 .35 (m, 4H); 3.90-3.82 (m, 7H); 3.76 (s, 2H); 3.15 (t, J = 6.4 Hz, 2H); 3.04 (s , 3H); 2.95 (s, 3H); 2.90 (t, J = 6.4 Hz, 2H) and 2.57 (m, 8H)

Example 330 4- (8-((3,3-dimethyl-4- (2- (methylsulfonyl) ethyl) piperazin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 330
9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (80 mg, 0.21 mmol) in DCE (5 mL), 1- A mixture of (2-methanesulfonylethyl) -2,2-dimethylpiperazine (56 mg, 0.25 mmol) and 4Å powdered molecular sieve (100 mg) was stirred at room temperature for 4 hours and sodium triacetoxyborohydride (90 mg, 0 mg). .42 mmol) was added. The reaction mixture was stirred for 64 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 330 as a white solid (70 mg, 58 %). LCMS (Method G): R _T 6.62 min [M + H] ⁺ 582.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.12-8.07 (m, 1H); 7.74-7.70 (m, 1H); 7.29-7.25 (m, 2H); 4 .35 (m, 4H); 3.91-3.83 (m, 7H); 3.69 (s, 2H); 3.11 (m, 2H); 3.06 (s, 3H); 95 (s, 3H); 2.63 (m, 2H); 2.54 (m, 2H); 2.30 (s, 2H); 1.78 (m, 2H) and 1.10 (s, 6H) )

Example 331 4- (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) -2,2-dimethylmorpholine 331
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (112 mg, 0.29 mmol) in DCE (5 mL), 4- A mixture of azetidin-3-yl-2,2-dimethylmorpholine (58 mg, 0.34 mmol) and 4Å powdered molecular sieve (200 mg) was stirred at room temperature for 4 hours and sodium triacetoxyborohydride (121 mg, 0.57 mmol). ) Was added. The reaction mixture was stirred for 40 hours at room temperature, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 331 as a yellow solid (121 mg, 76 %). LCMS (Method G): R _T 6.85 min [M + H] ⁺ 546.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.77-7.73 (m, 1H); 7.29-7.22 (m, 2H); 4 .35 (m, 4H); 3.91-3.82 (m, 9H); 3.73 (m, 2H); 3.57 (t, J = 6.6 Hz, 2H); 3.35 (q , J = 7.5 Hz, 2H); 3.10 (t, J = 6.6 Hz, 2H); 2.98 (p, J = 6.6 Hz, 1H); 2.24 (m, 2H); 2 .04 (s, 2H); 1.44 (t, J = 7.5 Hz, 3H) and 1.25 (s, 6H)

Example 332 2- (1-((5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Piperidin-4-yl) propan-2-ol 332
2- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidin-4-yl] propan-2-ol in NMP (0.5 mL) 100 mg, 0.24 mmol) 2-ethyl-1H-benzimidazole (42 mg, 0.29 mmol), copper (I) thiophene-2-carboxylate (9 mg, 0.048 mmol) and cesium carbonate (119 mg, 0.36 mmol) Was stirred at 110 ° C. for 18 hours. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed and the residue was flash chromatographed (Si-PCC, 0-20% MeOH in EtOAc), followed by reverse phase HPLC (Phenomenex Gemini 5uC18, acetonitrile 95: 5 to 2:98 gradient in 20 mM triethylamine in water. ) To give 332 as a beige solid (45 mg, 36%). LCMS (Method G): R _T 7.37 min; [M + H] ⁺ 522. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.03-7.98 (m, 1H); 7.77-7.73 (m, 1H); 7.32-7.24 (m, 2H) 4.41 (m, 4H); 3.90-3.85 (m, 6H); 3.35 (q, J = 7.5 Hz, 2H); 3.11 (m, 2H); 2.33 -2.12 (m, 2H); 1.79 (m, 2H); 1.57 (m, 2H); 1.44 (t, J = 7.5Hz, 3H); 1.34 (m, 1H) 1.22 (s, 6H)

Example 337 2- (1-((2- (2-Ethoxy-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-ol 337
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-ethoxy-1H-benzo [d] imidazole to give 337. LCMS: M + H ^< + ^> = 535.3

Example 338 2- (1-((2- (2-Isopropoxy-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine -4-yl) propan-2-ol 338
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol according to general procedure I of Buchwald coupling And 2-isopropoxy-1H-benzo [d] imidazole to give 338. LCMS: M + H ⁺ = 549.3

Example 339 2-Methyl-2- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-1-ol 339
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and 2-methyl-2- (piperidin-4-yl) propan-1-ol were reacted to give 339. LCMS: M + H ^< + ^> = 519.3

Example 341 2- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) -2-methylpropan-1-ol 341
4- (8- (Bromomethyl) -9-methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Morpholine and 2-methyl-2- (piperidin-4-yl) propan-1-ol were reacted to give 341. LCMS: M + H ^< + ^> = 533.3

Example 342 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2- (pyrazine -2-yl) ethanamine 342
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and 2- (Pyrazin-2-yl) ethanamine was reacted to give 342. [M + H] ^< +> 485.6.

Example 343 7-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -7-azaspiro [ 3.5] Nonane-2-ol 343
To a solution of 9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (134 mg, 0.35 mmol) in DCE (5 mL) 7-azaspiro [3.5] nonan-2-ol (60 mg, 0.43 mmol), trimethylorthoformate ester (0.19 mL, 1.77 mmol) and acetic acid (0.02 mL, 0.35 mmol) were added. The reaction mixture was stirred for 3 hours at room temperature, sodium triacetoxyborohydride (113 mg, 0.53 mmol) was added and the resulting mixture was stirred for an additional 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-20% MeOH in EtOAc) to give 343 as a white solid (80 mg, 45%). LCMS (Method G): R _T = 5.23 min, [M + H] ⁺ 503.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.11-8.06 (m, 1H), 7.73-7.68 (m, 1H), 7.30-7.24 (m, 2H) 4.37-4.24 (m, 4H), 3.90-3.83 (m, 7H), 3.72 (s, 2H), 2.94 (s, 3H), 2.58-2. .31 (m, 4H), 2.30-2.23 (m, 2H), 1.75-1.55 (m, 8H)

Example 344 2- (1- (2- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) ethyl) Piperidin-4-yl) propan-2-ol 344
2- {1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -piperidin-4-yl} in dioxane (1.0 mL) Propan-2-ol (47 mg, 0.11 mmol), 2-methylbenzimidazole (16 mg, 0.12 mmol), Pd ₂ (dba) ₃ (2.5 mg, 2.5 mol%), Xphos (5.0 mg, 10 mol) %) And Cs ₂ CO ₃ (54 mg, 0.17 mmol) was purged with argon and then heated in a microreactor at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH, and then the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (RediSep amine cartridge, 0-5% MeOH in DCM) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of 30-50% acetonitrile). 344 (25 mg, 43%) was obtained as a white solid. LCMS: (Method G): R _T 5.64 min; [M + H] ⁺ 519.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.09-8.04 (m, 1H), 7.73-7.69 (m, 1H), 7.29-7.24 (m, 2H) 4.48-4.16 (m, 4H), 3.87 (t, J = 4.7 Hz, 4H), 3.79 (s, 3H), 3.23-1.05 (m, 4H) 2.93 (s, 3H), 2.93-2.75 (m, 2H), 2.11 (s, 3H), 1.90-1.75 (m, 2H), 1.55-1. .25 (m, 3H), 1.20 (s, 6H)

Example 345 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8-((3-fluoro-1,3′-biazetidin-1′-yl) methyl) -9 -Methyl-9H-purin-6-yl) morpholine 345
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholine in trimethoxymethane (0.22 mL, 2 mmol) and acetic acid (0.012 mL, 0.2 mmol) in DCE (3 mL) A mixture of -4-yl-9H-purine-8-carbaldehyde (0.079 g, 0.20 mmol), 3-fluoro- [1,3 ′] biazetidinyl (0.029 g, 0.22 mmol) was stirred at room temperature for 5 hours. Stir. Sodium triacetoxyborohydride (0.065 g, 0.30 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was partitioned between DCM and water. The organic layer was separated, washed with brine, dried over sodium sulfate and concentrated. The residue was flash chromatographed (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 16:84) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 5:95 gradient in 20 mM in water). To give 345 as an off-white solid (0.054 g, 53%). LCMS (Method G): R _T = 5.78 min, [M + H] ⁺ 506.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02-7.98 (m, 1H); 7.77-7.73 (m, 1H); 7.28-7.24 (m, 2H); 15 (dt, J = 57.3, 5.4 Hz, 1H); 4.38-4.33 (m, 4H); 3.90-3.85 (m, 6H); 3.83 (s, 2H) 3.72-3.62 (m, 3H); 3.48-3.39 (m, 3H); 3.35 (q, J = 7.5 Hz, 2H); 3.35-3.19 (M, 2H); 3.17-3.15 (m, 2H); 1.44 (t, J = 7.5 Hz, 3H)

Example 346 2-methyl-1- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-1-ol 346
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (200 mg, 0.53 mmol) in 1,2-dichloroethane (10 mL) ) A mixture of 2-methyl-1-piperidin-4-yl-propan-1-ol (125 mg, 0.79 mmol) and 4Å molecular sieve (1.0 g) was stirred at room temperature for 1.5 hours under a nitrogen atmosphere. . Sodium triacetoxyborohydride (167 mg, 0.79 mmol) was added and the resulting reaction mixture was stirred for 16 hours at room temperature. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with DCM / MeOH and the desired product was eluted with a mixture of DCM and 2M NH _{3 in} MeOH. The residue was purified by column chromatography (Si-PCC, MeOH: DCM: gradient 0: 100 to 5:95), then further purified (Si-PCC, acetone: cyclohexane: gradient 10:90 to 40:60). did. The solvent was reduced in vacuo to give 346 as a white solid (114 mg, 41%). LCMS (Method G): R _T 6.81 min, [M + H] ⁺ 519. ¹ H NMR (400 MHz, CH ₃ OH-d ₄ ): δ 8.06-8.05 (1H, m), 7.56-7.55 (1H, m), 7.25-7.24 (2H, m), 4.29 (4H, br s), 3.84 (3H, s), 3.81 (4H, t, J = 4.74 Hz), 3.74 (2H, s), 2.98- 2.95 (3H, m), 2.86 (3H, s), 2.11 (2H, m), 1.84 (1H, m), 1.72-1.71 (1H, m), 1 .57-1.20 (4H, m), 0.87 (6H, dd, J = 15.35, 6.73 Hz)

Example 347 Azetidin-1-yl (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl ) Azetidin-3-yl) methanone 347
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and azetidine- in DCE (3 mL) A solution of 3-ylazetidin-1-ylmethanone (45 mg, 0.31 mmol) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; 100: 0 to 90:10 to 85:15) to give 347 as a white solid (30 mg, 23%). LCMS (Method G): R _T = 5.33 min, M + H ⁺ = 502. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.07 (m, 1H); 7.69 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 4.13-4 .00 (m, 4H); 3.87 (m, 6H); 3.82 (s, 3H); 3.68-3.58 (m, 2H); 3.53-3.45 (m, 2H) 3.34-3.26 (m, 1H); 2.96 (s, 3H) and 2.33-2.23 (m, 2H)

Example 348 (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine-3- Yl) (pyrrolidin-1-yl) methanone 348
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and azetidine- in DCE (3 mL) A solution of 3-ylpyrrolidin-1-ylmethanone (50 mg, 0.32 mmol) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) to give 348 as a white foam (50 mg, 37%). LCMS (Method G): R _T = 5.81 min, M + H ⁺ = 516. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.08 (m, 1H); 7.71 (m, 1H); 7.26 (m, 2H); 4.35 (m, 4H); 3.89-3 .83 (m, 9H); 3.66 (m, 2H); 3.55-3.43 (m, 5H); 3.31 (m, 2H); 2.94 (s, 3H) and 1. 98-1.81 (m, 4H)

Example 349 I-azetidin-1-yl (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl ) Methyl) pyrrolidin-3-yl) methanone 349
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (141 mg, 0.37 mmol) and azetidine- in DCE (6 mL) A solution of 1-yl-I-pyrrolidin-3-ylmethanone (77 mg, 0.50 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (134 mg, 0.63 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 349 as a pale yellow solid (157 mg, 81%). LCMS (Method G): R _T = 5.52 min, M + H ⁺ = 516. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.09 (m, 1H); 7.70 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 4.18-4 .08 (m, 2H); 4.03 (m, 2H); 3.92 (s, 2H); 3.92-3.81 (m, 7H); 3.08-2.71 (m, 7H) 2.69 (m, 1H); 2.33-2.23 (m, 2H) and 2.10-2.03 (m, 2H)

Example 350 I- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) pyrrolidine- 3-yl) (pyrrolidin-1-yl) methanone 350
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (110 mg, 0.28 mmol) and pyrrolidine-in DCE (6 mL) A solution of 1-yl-I-pyrrolidin-3-ylmethanone (60 mg, 0.36 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, acetonitrile 80:20 to 2:98 gradient in water). Purification with 20 mM triethylamine) gave 350 as a white solid (61 mg, 37%). LCMS (Method G): R _T = 6.55 min, M + H ⁺ = 544. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.00 (m, 1H); 7.75 (m, 1H); 7.26 (m, 2H); 4.35 (m, 4H); 3.96 (s , 2H); 3.92-3.82 (m, 7H); 3.49-3.40 (m, 4H); 3.35 (q, J = 7.5 Hz, 2H); 3.25-2 .70 (m, 5H); 2.13 (m, 2H); 2.01-1.91 (m, 2H); 1.90-1.81 (m, 2H) and 1.47 (t, J = 7.5Hz, 3H)

Example 351 I-N, N-dimethyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl ) Methyl) pyrrolidine-3-carboxamide 351
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (135 mg, 0.36 mmol) and I − in DCE (6 mL) A solution of pyrrolidine-3-carboxylic acid dimethylamide (65 mg, 0.46 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 351 as a creamy solid (144 mg, 80%). LCMS (Method G): R _T = 5.48 min, M + H ⁺ = 504. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.09 (m, 1H); 7.70 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 3.93 (s) , 2H); 3.87 (m, 7H); 3.26 (m, 1H); 3.03 (s, 3H); 3.00-2.92 (m, 7H); 2.86 (m, 2H); 2.73-2.64 (m, 1H) and 2.15-2.06 (m, 2H)

Example 352 I-1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -N, N-dimethylpyrrolidine-3-carboxamide 352
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (140 mg, 0.36 mmol) and I − in DCE (6 mL) A solution of pyrrolidine-3-carboxylic acid dimethylamide (65 mg, 0.46 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 352 as a creamy solid (136 mg, 74%). LCMS (Method G): R _T = 5.90 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H); 7.80 (m, 1H); 7.28 (m, 2H); 4.34 (m, 4H); 3.93 (s , 2H); 3.90-3.84 (m, 7H); 3.35 (q, J = 7.5 Hz, 2H); 3.26 (m, 1H); 3.07-2.93 (m) , 7H); 2.87 (m, 2H); 2.70 (m, 1H); 2.16-2.06 (m, 2H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 353 2,2-dimethyl-4- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) azetidin-3-yl) morpholine 353
9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (5 mL), 4- A mixture of azetidin-3-yl-2,2-dimethylmorpholine (54 mg, 0.32 mmol) and 4Å powdered molecular sieve (200 mg) was stirred at room temperature for 4 hours and sodium triacetoxyborohydride (112 mg, 0.53 mmol). ) Was added. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 353 as a white solid (113 mg, 82 %). LCMS (Method G): R _T 6.47 min [M + H] ⁺ 532.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.69 (m, 1H); 7.29-7.24 (m, 2H); 4 .35 (m, 4H); 3.89-3.83 (m, 9H); 3.73 (m, 2H); 3.55 (t, J = 6.5 Hz, 2H); 3.08 (t , J = 6.8 Hz, 2H); 3.01-2.90 (m, 4H); 2.24 (m, 2H); 2.07 (s, 2H) and 1.25 (s, 6H)

Example 354 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (1,1-dioxo-thiomorpholino) azetidine-1- Yl) methyl) -9H-purin-6-yl) morpholine 354
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (1.2 g, 3.07 mmol) in DCE (65 mL), A mixture of 4-azetidin-3-ylthiomorpholine-1,1-dioxide (640 mg, 3.37 mmol) and 4Å powdered molecular sieve (2.5 g) was stirred at room temperature for 6.5 hours to give triacetoxyborohydride. Sodium (1.3 g, 6.13 mmol) was added. The reaction mixture was stirred for 18 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%). A mixture of the resulting yellow powder and 3-mercaptopropylethyl sulfide silica (250 mg) was stirred in a mixture of EtOH and DCM at 50 ° C. for 3 hours. The mixture was filtered and concentrated under vacuum. The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with EtOH and the product eluted with 2M NH ₃ / EtOH. The resulting oil was triturated with Et ₂ O and dried under vacuum at 60 ° C. to give 354 as a pale yellow solid (1.26 g, 73%). LCMS (Method I): R _T 2.43 min [M + H] ⁺ 566.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.77-7.73 (m, 1H); 7.29-7.22 (m, 2H); 4 .34 (m, 4H); 3.89-3.80 (m, 9H); 3.59 (m, 2H); 3.39-3.23 (m, 3H); 3.12-3.04 (M, 6H); 2.85 (m, 4H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 355 4- (2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (1,1-dioxo-thiomorpholino) azetidine-1- Yl) methyl) -9H-purin-6-yl) morpholine 355
2-Chloro-8- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -9-methyl-6-morpholin-4-yl- in dioxane (4 mL) 9H-purine (125 mg, 0.27 mmol), 2-methylbenzimidazole (402 mg, 0.30 mmol), tris (dibenzylideneacetone) dipalladium (13 mg, 0.01 mmol), Xphos (13 mg, 0.02 mmol) and Cs A mixture of ₂ CO ₃ (179 mg, 0.55 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH / DCM and eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) followed by an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was purified with 2M NH. Elution with ₃ / MeOH gave 355 as a creamy solid (125 mg, 84%). LCMS (Method G): R _T 4.73 min, [M + H] ⁺ 552.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.67 (m, 1H); 7.29-7.24 (m, 2H); 4 .35 (m, 4H); 3.90-3.82 (m, 9H); 3.59 (m, 2H); 3.28 (m, 1H); 3.11-3.04 (m, 6H) ); 2.94 (s, 3H) and 2.87-2.82 (m, 4H)

Example 356 2-Methyl-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperazin-1-yl) propane-1,3-diol 356
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl ) -2-Methylpropane-1,3-diol was reacted to give 356. LCMS m / z: 536.3 (MH +)

Example 357 I-3-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) piperazin-1-yl) butan-1-ol 357
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and racemic 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine-1 -Yl) -3-methylbutan-1-ol was reacted. The enantiomers were separated by SFC to give 357. LCMS m / z: 534.3 (MH +)

エタノール（１０ｍＬ）中の２-(１-((２-(２-(ベンジル(メトキシエチル)アミノ)-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（０．２２ｇ、０．３４ｍｍｏｌ）及びパラジウムカーボン（１０重量％、０．２ｇ）及び酢酸（０．１５ｍＬ）の混合物を水素雰囲気下７０℃で１８時間攪拌した。反応混合物をセライトで濾過し、濃縮した。粗生成物をＲＰ-ＨＰＬＣで精製して３５８を得た（５４ｍｇ、２８％）。ＬＣＭＳｍ／ｚ：５６４．４（ＭＨ＋） Example 358 2- (1-((2- (2- (2-methoxyethylamino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 358

2- (1-((2- (2- (Benzyl (methoxyethyl) amino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H- in ethanol (10 mL)) Purine-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.22 g, 0.34 mmol) and a mixture of palladium carbon (10 wt%, 0.2 g) and acetic acid (0.15 mL). The mixture was stirred at 70 ° C. for 18 hours under a hydrogen atmosphere. The reaction mixture was filtered through celite and concentrated. The crude product was purified by RP-HPLC to give 358 (54 mg, 28%). LCMS m / z: 564.4 (MH +)

Example 361 (S) -3-Methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine- 8-yl) methyl) piperazin-1-yl) butan-1-ol 361
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and racemic 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine-1 -Yl) -3-methylbutan-1-ol was reacted. The enantiomers were separated by SFC to give 361. LCMS m / z: 534.3 (MH +)

Example 362 2- (1-((5- (2-methyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Piperidin-3-yl) propan-2-ol 362
5- (2-Methylbenzimidazol-1-yl) -7-morpholin-4-yl-thiazolo [5,4-d] pyrimidine-2-carbaldehyde (78 mg, 0) in 1,2-dichloroethane (2 mL) .2 mmol) of 2-piperidin-3-yl-propan-2-ol (43 mg, 0.3 mmol) trimethylorthoformate ester (0.109 mL, 1.0 mmol) and glacial acetic acid (0.017 mL, 0.3 mmol). The mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. Sodium triacetoxyborohydride (85 mg, 0.4 mmol) was added and the resulting reaction mixture was stirred for 16 hours at room temperature. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with DCM / MeOH and the desired product was eluted using a mixture of DCM and 2M NH _{3 in} MeOH. The residue was purified by column chromatography (Si-PCC, acetone: cyclohexane: 10:90 to 35:65 (volume)). The solvent was reduced in vacuo to give the title compound as a white solid. The resulting solid was further purified by reverse phase HPLC (MeOH: H ₂ O + 0.1% HCCOH, gradient 10:90 to 90:10 over 25 minutes). The solvent was reduced in vacuo and the aqueous residue was lyophilized to give 362 as a white solid (23 mg, 23%). LCMS (Method G): R _T 6.73 min, [M + H] ⁺ 508. ¹ H NMR (400 MHz, CDCl ₃ ): δ 8.18 (1H, s), 8.04-8.03 (1H, m), 7.70-7.69 (1H, m), 7.27-7 .26 (2H, m), 4.38 (4H, br s), 3.90 (2H, s), 3.85 (4H, t, J = 4.74 Hz), 3.18 (2H, m) , 2.91 (5H, m), 2.28-2.15 (2H, m), 1.81 (2H, m), 1.75-1.60 (2H, m), 1.20 (3H) , S), 1.15 (3H, s)

Example 363 N, N-dimethyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl Azetidine-3-carboxamide 363
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and azetidine- in DCE (4 mL) A solution of 3-carboxylic acid dimethylamide hydrochloride (53 mg, 0.32 mmol) was stirred at ambient temperature for 1 hour. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) to give 363 as a white solid (83 mg, 64%). LCMS (Method G): R _T = 5.23 min, M + H ⁺ = 490. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.08 (m, 1H); 7.70 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 3.89-3 .82 (m, 9H); 3.69-3.62 (m, 2H); 3.57-3.46 (m, 3H); 2.96 (s, 3H); 2.93 (s, 3H) ) And 2.90 (s, 3H)

Example 364 I- (1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) pyrrolidine- 3-yl) (pyrrolidin-1-yl) methanone 364
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (105 mg, 0.28 mmol) and pyrrolidine-in DCE (6 mL) A solution of 1-yl-I-pyrrolidin-3-ylmethanone (60 mg, 0.36 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 364 as a white solid (110 mg, 74%). LCMS (Method G): R _T = 6.10 min, M + H ⁺ = 530. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.08 (m, 1H); 7.70 (m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 3.93 (s) , 2H); 3.92-3.81 (m, 7H); 3.50-3.38 (m, 4H); 3.19-3.08 (m, 1H); 2.99 (m, 1H) 2.94 (s, 3H); 2.86 (m, 2H); 2.70 (m, 1H); 2.12 (m, 2H); 2.02-1.90 (m, 2H) And 1.91-1.81 (m, 2H)

Example 365 (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine-3- Yl) (pyrrolidin-1-yl) methanone 365
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and azetidine- in DCE (3 mL) A solution of 3-ylpyrrolidin-1-ylmethanone (50 mg, 0.32 mmol) was stirred at ambient temperature for 90 minutes. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 80:20 to 2:98 gradient). To give 365 as a white solid (65 mg, 48%). LCMS (Method G): R _T = 6.26 min, M + H ⁺ = 530. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.73 (m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 3.86 (m , 6H); 3.83 (s, 3H); 3.69-3.63 (m, 2H); 3.55-3.42 (m, 5H); 3.39-3.27 (m, 4H) ); 1.98-1.82 (m, 4H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 366 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -N, N- Dimethylazetidine-3-carboxamide 366
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.27 mmol) and azetidine- in DCE (4 mL) A solution of 3-carboxylic acid dimethylamide hydrochloride (53 mg, 0.32 mmol) was stirred at ambient temperature for 1 hour. Sodium triacetoxyborohydride (86 mg, 0.41 mmol) was added and the mixture was stirred for 3 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) to give 366 as a pale yellow solid (107 mg, 83%). LCMS (Method G): R _T = 5.51 min, M + H ⁺ = 504. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.00 (m, 1H); 7.75 (m, 1H); 7.28 (m, 2H); 4.34 (m, 4H); 3.89-3 .83 (m, 6H); 3.83 (s, 3H); 3.70-3.62 (m, 2H); 3.57-3.46 (m, 3H); 3.34 (q, J = 7.5 Hz, 2H); 2.96 (s, 3H); 2.90 (s, 3H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 367 2- (1- (2- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) Piperidin-4-yl) propan-2-ol 367
2- {1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -piperidin-4-yl} in dioxane (1.0 mL) Propan-2-ol (71 mg, 0.17 mmol), 2-ethylbenzimidazole (27 mg, 0.19 mmol), Pd ₂ (dba) ₃ (3.8 mg, 2.5 mol%), Xphos (8.0 mg, 10 mol) %) And Cs ₂ CO ₃ (82 mg, 0.25 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 19 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-10% MeOH in DCM) to give 367 (45 mg, 50%) as a yellow solid. LCMS: (Method G): R _T 6.09 min; [M + H] ⁺ 533.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.97 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.23 (m, 2H) , 4.49-4.15 (m, 4H), 3.88-3.83 (m, 4H), 3.78 (s, 3H), 3.34 (q, J = 7.5, 2H) 3.14 (m, 4H), 2.93-2.75 (m, 2H), 2.20-2.08 (m, 2H), 1.85-1.78 (m, 2H), 1 .44 (t, J = 7.5 Hz, 3H), 1.40-1.21 (m, 3H), 1.24-1.18 (m, 6H)

Example 368 2-Methyl-2- (4- (2- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) ethyl) piperazin-1-yl) propanamide 368
2- {4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] piperazin-1-yl} isobutyl in dioxane (1.0 mL) Amide (80 mg, 0.18 mmol), 2-methylbenzimidazole (26 mg, 0.20 mmol), Pd ₂ (dba) ₃ (4 mg, 2.5 mol%), Xphos (8 mg, 10 mol%) and Cs ₂ CO ₃ ( 87 mg, 0.27 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 19 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-10% MeOH in DCM) to give 368 (63 mg, 65%) as a pale yellow solid. LCMS: (Method G): R _T 5.34 min; [M + H] ⁺ 547.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.09-8.05 (m, 1H), 7.73-7.69 (m, 1H), 7.29-7.24 (m, 1H) 7.06 (s, 1H), 5.23 (s, 1H), 4.47-4.14 (m, 4H), 3.87 (t, J = 4.7 Hz, 4H), 3.79. (S, 3H), 3.49 (s, 1H), 3.19-3.0 (m, 2H), 2.94 (s, 3H), 2.78-2.54 (m, 6H), 1.78-1.48 (m, 4H), 1.25 (s, 6H)

Example 369 8-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -1,4- Dioxa-8-azaspiro [4.5] decane 369
Following the general procedure I of Buchwald coupling, 8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1,4-dioxa-8-azaspiro [4.5 The reaction between decane and 2-methylbenzimidazole gave 369. LCMS m / z: 505.2 (MH +)

Example 370 8-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -1-oxa- 8-Azaspiro [4.5] Decane 370
According to General Procedure I for Buchwald coupling, 8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1-oxa-8-azaspiro [4.5] decane And 2-methylbenzimidazole to give 370. LCMS m / z: 503.2 (MH +)

  Alternatively, 4- (8- (bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) according to general procedure E for substitution of alkyl bromides with amines -9H-purin-6-yl) morpholine and 1-oxa-8-azaspiro [4.5] decane were reacted to give 370.

Example 379 8-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2,8- Diazaspiro [4.5] decan-1-one 379
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2,8-diazaspiro [4 .5] decan-1-one was reacted to give 379. LCMS m / z 258.6 (2M + H +)

Example 380 8-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -3-oxa- 8-azabicyclo [3.2.1] octane 380
According to the general procedure I for Buchwald coupling, 2-methylbenzimidazole and 8-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-oxa-8-aza -Bicyclo [3.2.1] octane was reacted to give 380. LCMS m / z: 475.2 (MH +)

Example 381 I-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) Piperazin-1-yl) butane-1-ol 381
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl ) Butan-1-ol was reacted. The enantiomers were separated by SFC to give 381. LCMS m / z: 520.3 (MH +)

Example 382 (S) -2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperazin-1-yl) butan-1-ol 382
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl ) Butan-1-ol was reacted. The enantiomers were separated by SFC to give 382. LCMS m / z: 520.3 (MH +)

Example 383 2- (1-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) propan-2-amine 383
[(9H-Fluoren-9-yl) methyl-2- (piperidin-4-yl) propane in THF (0.7 mL, 0.008 mol) and methanol (0.7 mL, 0.02 mol) according to general procedure E -2-ylcarbamate (0.0923 g, 0.253 mmol) and N, N-diisopropylethylamine (0.265 mL, 0.00152 mol) were mixed at room temperature to give 4- (8- (bromomethyl) -9-methyl-2. -(2-Methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine (0.112 g, 0.253 mmol) was added. The reaction was stirred overnight. The reaction mixture was concentrated to dryness. The crude residue was dissolved in N, N-dimethyl and amide (2.0 mL) and piperidine (0.200 mL) were added. The mixture was stirred overnight at room temperature. The reaction mixture was concentrated. The crude material was purified by reverse phase HPLC to give 383 (45.5 mg, 35.7%). [M + H] + = 504.3.

Example 384 5-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2-oxa- 5-azabicyclo [2.2.1] heptane 384
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 2-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -5-oxa-2-aza -Bicyclo [2.2.1] heptane was reacted to give 384. LCMS m / z: 461.2 (MH +)

Example 385 (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -4-methyl Piperidin-4-yl) methanol 385
According to General Procedure I for Buchwald coupling, (1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -4-methylpiperidin-4-yl) methanol and 2 -Ethyl-1H-benzo [d] imidazole was reacted to give 385. LCMS m / z: 505.3 (MH +)

Example 386 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((3- (piperidin-1-yl) azetidin-1-yl) methyl ) -9H-purin-6-yl) morpholine 386
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl according to general procedure E for amine alkylation ) Reaction of morpholine and 1- (azetidin-3-yl) piperidine gave 386. LCMS m / z: 502.3 (MH +)

Example 387 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H- Purin-6-yl) morpholine 387
According to General Procedure I for Buchwald coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 2 -Ethyl-1H-benzo [d] imidazole was reacted to give 387. LCMS m / z: 518.3 (MH +)

Example 389 N-methyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl)- N- (tetrahydrofuran-3-yl) piperidin-4-amine 389
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (72 mg, 0.19 mmol), methylpiperidine in DCE (5 mL) A mixture of -4-yl (tetrahydrofuran-3-yl) amine (42 mg, 0.23 mmol) and 4Å powdered molecular sieve (200 mg) was stirred at room temperature for 4 hours, then sodium triacetoxyborohydride (81 mg,. 38 mmol) was added. The reaction mixture was stirred for 16 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 389 as a white solid (55 mg, 53 %). LCMS (Method G): R _T 4.96 min [M + H] ⁺ 546.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.11-8.07 (m, 1H); 7.73-7.69 (m, 1H); 7.29-7.24 (m, 2H); 4 .35 (m, 4H); 3.96 (m, 1H); 3.92-3.80 (m, 8H); 3.83-3.71 (m, 4H); 3.43 (m, 1H) ); 3.02-2.90 (m, 4H); 2.52 (m, 1H); 2.26 (s, 3H); 2.16 (m, 2H); 2.03 (m, 1H) 1.90 (m, 1H); 1.77 (s, 3H) and 1.59 (m, 2H);

Example 390 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -N-methyl- N- (tetrahydrofuran-3-yl) piperidin-4-amine 390
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (72 g, 0.19 mmol), methylpiperidine in DCE (5 mL) A mixture of -4-yl (tetrahydrofuran-3-yl) amine (42 mg, 0.23 mmol) and 4Å powdered molecular sieve (200 mg) was stirred at room temperature for 6.5 hours, then sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 390 as a light yellow solid (55 mg, 53 %). LCMS (Method G): R _T 4.96 min [M + H] ⁺ 546.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-7.99 (m, 1H); 7.77-7.73 (m, 1H); 7.29-7.23 (m, 2H); 4 .34 (m, 4H); 3.96 (m, 1H); 3.91-3.69 (m, 12H); 3.45-3.26 (m, 3H); 2.97 (d, J = 11.3 Hz, 2H); 2.51 (m, 1H); 2.26 (s, 3H); 2.16 (t, J = 11.3 Hz, 2H); 2.03 (m, 1H); 1.89 (m, 2H); 1.76 (s, 2H); 1.66 (m, 1H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 391 7-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -2-methyl- 7-Azaspiro [3.5] nonane-2-ol 391
A solution of 2-hydroxy-2-methyl-7-azaspiro [3.5] nonane-7-carboxylic acid benzyl ester (96 mg, 0.33 mmol) in IMS (3 mL) was palladium (10 wt% on carbon, 10 mg). Added to. The vessel was evacuated and refilled with hydrogen and stirred at room temperature for 1 hour under hydrogen atmosphere. The reaction mixture was passed through a hydrophobic frit (PTFE) and the resulting filtrate was evaporated to give a residue (70 mg) that was taken up in DCE (5 mL). To this solution was added 2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (150 mg, 0.38 mmol), trimethylorthoformate ( 0.42 mL, 3.83 mmol) and acetic acid (0.02 mL, 0.38 mmol) were added. The reaction mixture was stirred for 6 hours at room temperature, sodium triacetoxyborohydride (122 mg, 0.57 mmol) was added and the resulting mixture was stirred for another 2 days. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 15-98%) to give 391 as a white solid (69 mg, 39% over 2 steps). LCMS (Method G): R _T = 6.29 min, [M + H] ⁺ 531.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.03-7.98 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.23 (m, 2H) 4.50-4.32 (m, 4H), 3.89-3.83 (m, 7H), 3.85-3.63 (m, 2H), 3.35 (q, J = 7. 5Hz, 2H), 2.57-2.23 (m, 4H), 2.00-1.85 (m, 4H), 1.65 (m, 5H), 1.45 (t, J = 7. 5Hz, 3H), 1.39 (s, 3H)

Example 392 4- (2- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -2, 2-Dimethylmorpholine 392
2-Chloro-8- [2- (2,2-dimethylmorpholin-4-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine (57 mg, in dioxane (1.0 mL) 0.14 mmol), 2-ethylbenzimidazole (23 mg, 0.16 mmol), Pd ₂ (dba) ₃ (3.3 mg, 2.5 mol%), Xphos (6.9 mg, 10 mol%) and Cs ₂ CO ₃ ( 71 mg, 0.27 mmol) was purged with argon and then heated at 120 ° C. for 16 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product into 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-5% MeOH in DCM) to give 392 (46 mg, 63%) as a pale yellow solid. LCMS: (Method G): R _T 6.31 min; [M + H] ⁺ 505.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.02-7.97 (m, 1H), 7.78-7.72 (m, 1H), 7.27-7.22 (m, 2H) 4.48-4.20 (m, 4H), 3.89-3.83 (m, 4H), 3.79 (s, 3H), 3.77-3.55 (m, 2H), 3 .35 (q, J = 7.5 Hz, 2H), 3.12-2.97 (m, 2H), 2.91-2.76 (m, 2H), 2.57-2.43 (m, 2H), 2.42-2.29 (m, 2H), 1.44 (t, J = 7.5 Hz, 3H), 1.26 (s, 6H)

Example 393 (S) -azetidin-1-yl (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) pyrrolidin-3-yl) methanone 393
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) and azetidine- in DCE (5 mL) A solution of 1-yl- (S) -pyrrolidin-3-ylmethanone (47 mg, 0.31 mmol) was stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, acetonitrile 80:20 to 2:98 gradient in water. Purification with 20 mM triethylamine) gave 393 as a white solid (62 mg, 46%). LCMS (Method G): R _T = 5.93 min, M + H ⁺ = 530. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H); 7.75 (m, 1H); 7.29-7.22 (m, 2H); 4.35 (m, 4H); 4 .22-4.08 (m, 2H); 4.02 (t, J = 7.9 Hz, 2H); 3.94 (s, 2H); 3.90-3.83 (m, 7H); 3 .35 (q, J = 7.5 Hz, 2H); 3.09-2.57 (m, 5H); 2.33-2.23 (m, 2H); 2.09 (m, 2H) and 1 .45 (t, J = 7.5Hz, 3H)

Example 394 9-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1-oxa- 4,9-Diazaspiro [5.5] undecan-3-one 394
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (5 mL), 1- A mixture of oxa-4,9-diazaspiro [5.5] undecan-3-one (61 mg, 0.36 mmol) and molecular sieves (4Å, powder, 255 mg) was stirred for 1 hour at ambient temperature. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the mixture was stirred for 17 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted into 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) to give 394 as a creamy solid (116 mg, 83%). LCMS (Method G): R _T = 5.76 min, M + H ⁺ = 546. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.77 (m, 1H); 7.32-7.24 (m, 2H); 5.93 (bs, 1H); 4 .35 (m, 4H); 4.18 (s, 2H); 3.90-3.84 (m, 7H); 3.82 (bs, 2H); 3.37 (q, J = 7.5 Hz) , 2H); 3.27 (m, 2H); 2.72 (m, 2H); 2.59 (m, 2H); 2.05-1.93 (m, 2H); 1.68 (m, 2H); 2H) and 1.46 (t, J = 7.5 Hz, 3H)

Example 395 4- (8-((1S, 4S) -2,5-diazabicyclo [2.2.1] heptan-2-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazole-1 -Yl) -9-methyl-9H-purin-6-yl) morpholine 395
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (200 mg, 0.51 mmol) in DCE (10 mL), (1S , 4S) -2,5-diazabicyclo [2.2.1] heptane-2-carboxylic acid tert-butyl ester (122 mg, 0.62 mmol) and molecular sieves (4 kg, powder, 520 mg) at ambient temperature 3 Stir for hours. Sodium triacetoxyborohydride (162 mg, 0.76 mmol) was added and the mixture was stirred for 17 hours before being loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with methanol and the desired product continued to elute 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 85:15) to give (1S, 4S) -5- [2- (2-ethylbenzimidazole- 1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -2,5-diazabicyclo [2.2.1] heptane-2-carboxylic acid tert-butyl ester white Obtained as a solid. TFA (3 mL) was added to (1S, 4S) -5- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine- in DCM (10 mL) 8-ylmethyl] -2,5-diazabicyclo [2.2.1] heptane-2-carboxylic acid tert-butyl ester was added to the solution and the mixture was stirred at ambient temperature for 30 minutes before isosolute® SCX— Two cartridges (25 g) were filled. The cartridge was then washed with methanol and the desired product continued to elute 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 85:15) to give 395 as a white solid (153 mg, 63%). LCMS (Method G): R _T = 5.78 min, M + H ⁺ = 474. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H); 7.26 (m, 2H); 4.34 (m, 4H); 4.00 (d , J = 13.6 Hz, 1H); 3.92-3.83 (m, 8H); 3.70 (s, 1H); 3.45 (s, 1H); 3.35 (q, J = 7) .5 Hz, 2H); 3.25 (d, J = 10.2 Hz, 1H); 2.97-2.91 (m, 2H); 2.70 (d, J = 10.2 Hz, 1H); 1 .85 (d, J = 10.1 Hz, 1H); 1.70 (d, J = 10.1 Hz, 1H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 396 (3-methyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) Pyrrolidin-3-yl) (pyrrolidin-1-yl) methanone 396
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (5 mL), (3 -Methylpyrrolidin-3-yl) pyrrolidin-1-ylmethanone (58 mg, 0.32 mmol), trimethoxyorthoformate (0.29 mL, 2.65 mmol) and acetic acid (15 μL, 0.26 mmol) After stirring for hours, sodium triacetoxyborohydride (90 mg, 0.42 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours, diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed and the residue was purified by flash chromatography (Si-PCC, 0-20% MeOH in EtOAc) to give 396 as a white solid (107 mg, 76%). LCMS (Method G): R _T 6.69 min; [M + H] ⁺ 544. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.12-8.07 (m, 1H); 7.74-7.70 (m, 1H); 7.30-7.26 (m, 2H) 4.35 (m, 4H); 3.90 (s, 3H); 3.87 (t, J = 4.75 Hz, 5H); 3.49 (m, 5H); 2.96 (s, 3H); 2.64 (s, 2H); 2.46-2.37 (m, 2H); 1.89 (m, 4H); 1.81 (m, 2H); 1.41 (s, 3H) .

Example 398 (S) -1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl)- N, N-dimethylpyrrolidine-3-carboxamide 398
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) and (S A solution of) -pyrrolidine-3-carboxylic acid dimethylamide (44 mg, 0.31 mmol) was stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 398 as a creamy solid (50 mg, 38%). LCMS (Method G): R _T = 5.90 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H); 7.28 (m, 2H); 4.35 (m, 4H); 3.98-3 .80 (m, 9H); 3.40-3.25 (m, 3H); 3.20-2.78 (m, 10H); 2.15-2.07 (m, 2H) and 1.50 -1.41 (m, 3H)

Example 399 (S)-(1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Pyrrolidin-3-yl) (pyrrolidin-1-yl) methanone 399
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) and pyrrolidine-in DCE (5 mL) A solution of 1-yl- (S) -pyrrolidin-3-ylmethanone (51 mg, 0.30 mmol) was stirred at ambient temperature for 2 hours. Sodium triacetoxyborohydride (96 mg, 0.45 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH and the product was collected and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 70:30) to give 399 as a white solid (132 mg, 86%). LCMS (Method G): R _T = 6.43 min, M + H ⁺ = 544. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.9 (m, 1H); 7.75 (m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 3.94 (s , 2H); 3.87 (m, 7H); 3.50-3.38 (m, 4H); 3.35 (q, J = 7.5 Hz, 2H); 3.20-3.10 (m) , 1H); 3.01 (m, 1H); 2.87 (m, 2H); 2.72 (m, 1H); 2.16-2.07 (m, 2H); 2.01-1. 90 (m, 2H); 1.91-1.81 (m, 2H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 400 9-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -1,5- Dioxa-9-azaspiro [5.5] undecane 400
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and 9-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1,5-dioxa-9 -Azaspiro [5.5] undecane was reacted to give 400. LCMS m / z: 519.2 (MH +)

ＴＨＦ（４００ｍＬ、５ｍｏｌ）中の４-(２-クロロ-９-(テトラヒドロ-２Ｈ-ピラン-２-イル)-９Ｈ-プリン-６-イル)モルホリン（１０．０ｇ、０．０３０９ｍｏｌ；）の攪拌溶液に−７８℃でヘキサン（１８ｍＬ）中２．５Ｍのｎ-ブチルリチウムを加えた。溶液を−７８℃で３０分間攪拌した。Ｎ,Ｎ-ジメチルホアルムアミド（５．３ｍＬ、０．０６８ｍｏｌ）を加え、−７８℃で１時間攪拌した。反応物を０．１ＮのＨＣｌの冷溶液を用いてゆっくりとクエンチした。生成物をＤＣＭで抽出した。有機抽出物を組み合わせ、ブラインで洗浄し、濾過し、濃縮乾固させ、２-クロロ-６-モルホリノ-９-(テトラヒドロ-２Ｈ-ピラン-２-イル)-９Ｈ-プリン-８-カルバルデヒド（１０．７６ｇ、９９％）を黄色固形物として得た。粗物質を更なる精製なしに用いた。

２-クロロ-６-モルホリノ-９-(テトラヒドロ-２Ｈ-ピラン-２-イル)-９Ｈ-プリン-８-カルバルデヒド（０．１４８ｇ、０．４２２ｍｍｏｌ）を１,２-ジクロロエタン（３．７ｍＬ、０．０４７ｍｏｌ）に溶解させた。１-ｔｅｒｔ-ブチルピペラジン（０．０６０ｇ、０．４２ｍｍｏｌ）と、続いて微粒子化した４Åモレキュラーシーブ（０．４５０ｇ）を加えた。２時間後にトリアセトキシ水素化ホウ素ナトリウム（０．１７９ｇ、０．８４４ｍｍｏｌ）を加え、反応を室温で一晩攪拌した。反応混合物を濾過した。濾過ケーキを更なるＤＣＭ及びＭｅＯＨで洗浄した。組み合わせた有機物を濃縮乾固させた。粗物質をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ；ＭｅＯＨ：ＤＣＭ０：１００から１０：９０の勾配）で精製して、４-(８-((４-ｔｅｒｔ-ブチルピペラジン-１-イル)メチル)-２-クロロ-９-(テトラヒドロ-２Ｈ-ピラン-２-イル)-９Ｈ-プリン-６-イル)モルホリン（１２６ｍｇ、６２％）を得た。［Ｍ＋Ｈ］^＋＝４７８．３ Example 401 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9H-purine-6- Il) Morpholine 401

Stirring of 4- (2-chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) morpholine (10.0 g, 0.0309 mol;) in THF (400 mL, 5 mol) To the solution was added 2.5 M n-butyllithium in hexane (18 mL) at −78 ° C. The solution was stirred at −78 ° C. for 30 minutes. N, N-dimethylformamide (5.3 mL, 0.068 mol) was added, and the mixture was stirred at −78 ° C. for 1 hour. The reaction was slowly quenched with a cold solution of 0.1N HCl. The product was extracted with DCM. The organic extracts were combined, washed with brine, filtered, concentrated to dryness, 2-chloro-6-morpholino-9- (tetrahydro-2H-pyran-2-yl) -9H-purine-8-carbaldehyde ( 10.76 g, 99%) was obtained as a yellow solid. The crude material was used without further purification.

2-Chloro-6-morpholino-9- (tetrahydro-2H-pyran-2-yl) -9H-purine-8-carbaldehyde (0.148 g, 0.422 mmol) was added to 1,2-dichloroethane (3.7 mL, 0.047 mol). 1-tert-Butyl piperazine (0.060 g, 0.42 mmol) was added followed by micronized 4Å molecular sieve (0.450 g). After 2 hours, sodium triacetoxyborohydride (0.179 g, 0.844 mmol) was added and the reaction was stirred at room temperature overnight. The reaction mixture was filtered. The filter cake was washed with additional DCM and MeOH. The combined organics were concentrated to dryness. The crude material was purified by flash chromatography (Si-PPC; MeOH: DCM 0: 100 to 10:90 gradient) to give 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2. -Chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) morpholine (126 mg, 62%) was obtained. [M + H] ⁺ = 478.3

4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) in a vial Morpholine (126 mg, 0.264 mmol), 2-ethyl-1H-benzo [d] imidazole (40.4 mg, 0.277 mmol), Xphos (16.3 mg, 0.0343 mmol), tris (dibenzylideneacetone) dipalladium ( 0) (16.4 mg, 0.0179 mmol) and cesium carbonate (172 mg, 0.527 mmol;) were added. The mixture was dissolved in N, N-dimethylformamide (2.02 mL, 0.0261 mol) and heated under pressure in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered and concentrated. The crude residue was dissolved in MeOH (5.0 mL) and para-toluenesulfonic acid (90.8 mg, 0.527 mmol) was added. The reaction was heated at 40 ° C. overnight. The reaction mixture was concentrated to dryness and purified by reverse phase HPLC to give 401 (50.9 mg, 38.3%). [M + H] ⁺ = 504.3

Example 404 2-((1R, 5S, 6r) -3-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine- 8-yl) methyl) -3-azabicyclo [3.1.0] hexane-6-yl) propan-2-ol 404
According to the general procedure I of Buchwald coupling, 2-methylbenzimidazole and 2-((1R, 5S, 6r) -3-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl 404) was obtained by reacting) methyl) -3-azabicyclo [3.1.0] hexane-6-yl) propan-2-ol. LCMS m / z: 503.3 (MH +)

Example 407 I-1- (1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purine-2- Yl) -1H-benzo [d] imidazol-2-yl) propan-2-ol 407
Following general procedure I for Buchwald coupling, 1- (1H-benzimidazol-2-yl) propan-2-ol and racemic 2- (1-((2-chloro-9-methyl-6-morpholino-9H -Purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was reacted. The enantiomers were separated by SFC to give 407. LCMS m / z: 549.3 (MH +)

Example 408 (S) -1- (1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purine- 2-yl) -1H-benzo [d] imidazol-2-yl) propan-2-ol 408
Following general procedure I for Buchwald coupling, 1- (1H-benzimidazol-2-yl) propan-2-ol and racemic 2- (1-((2-chloro-9-methyl-6-morpholino-9H -Purin-8-yl) methyl) piperidin-4-yl) propan-2-ol was reacted. The enantiomers were separated by SFC to give 408. LCMS m / z: 549.3 (MH +)

Example 409 I-8-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) octahydrode Pyrazine o [2,1-c] [1,4] oxazine 409
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (97 g, 0.25 mmol) in DCE (6 mL), (R ) -Octahydrodopyrazino [2,1-c] [1,4] oxazine (42 mg, 0.30 mmol) and 4Å powdered molecular sieve (200 mg) were stirred at room temperature for 5 hours, and then triacetoxyhydrogen Sodium borohydride (106 mg, 0.50 mmol) was added. The reaction mixture was stirred for 64 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-15%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH to give 409 as a cream solid (31 mg, 24%). LCMS (Method I): R _T 2.49 min [M + H] ⁺ 518.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-7.98 (m, 1H); 7.78-7.74 (m, 1H); 7.29-7.23 (m, 2H); 4 .34 (m, 4H); 3.89-3.82 (m, 7H); 3.84-3.70 (m, 2H); 3.70-3.63 (m, 1H); 3.42 −3.32 (m, 3H); 2.85 (d, J = 11.0 Hz, 2H); 2.74 (m, 1H); 2.63 (d, J = 11.4 Hz, 2H); 2 .56 (m, 1H); 2.43 (m, 3H); 2.08 (m, 1H) and 1.68 (s, 1H); 1.50-1.42 (m, 3H)

Example 410 4-Methyl-5-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylamino) Pentane-1,4-diol 410
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H according to general procedure E for substitution of alkyl bromides with amines 410 was obtained by reacting -purin-6-yl) morpholine and 5-amino-4-methylpentane-1,4-diol. [M + H] ⁺ 495.6

Example 413 2- (4-((2- (2-Cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine -1-yl) -2-methylpropane-1-ol 413
According to General Procedure I for Buchwald coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 2 -Cyclopropyl-1H-benzo [d] imidazole was reacted to give 413. LCMS: M + H ⁺ = 546.3

Example 415 (S) -4- (8-((Hexahydropyrrolo [1,2-a] pyrazin-2 (1H) -yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 415
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and racemic 4- (2-chloro-8-((hexahydropyrrolo [1,2-a] pyrazin-2 (1H) -yl) methyl) -9-methyl-9H-purin-6-yl) morpholine was reacted. The enantiomers were separated by SFC to give 415. LCMS m / z: 488.2 (MH +)

Example 416 I-4- (8-((Hexahydropyrrolo [1,2-a] pyrazin-2 (1H) -yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d ] Imidazole-1-yl) -9H-purin-6-yl) morpholine 416
According to General Procedure I for Buchwald coupling, 2-methylbenzimidazole and racemic 4- (2-chloro-8-((hexahydropyrrolo [1,2-a] pyrazin-2 (1H) -yl) methyl) -9-methyl-9H-purin-6-yl) morpholine was reacted. The enantiomers were separated by SFC to give 416. LCMS m / z: 488.2 (MH +)

Example 417 2-((1S, 4S) -5-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) -2,5-diazabicyclo [2.2.1] heptan-2-yl) ethyl 2-methylpropanoate 417
2-Bromo-2-methylpropionic acid ethyl ester (90 μL, 0.61 mmol) was added to potassium carbonate (84 mg, 0.61 mmol) and 8-[(1S, 4S) -1- (2,5-diazabicyclo) in anhydrous acetonitrile. [2.2.1] Hept-2-yl) methyl] -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (140 mg, .0. 30 mmol) solution. The resulting mixture was heated at 80 ° C. for 48 hours, then cooled to ambient temperature and partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; gradient from 100: 0 to 85:15) to give 417 as a creamy solid (100 mg, 58%). LCMS (Method I): R _T = 2.92 min, M + H ⁺ = 588. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H); 7.29-7.23 (m, 2H); 4.34 (m, 4H); 4 .15 (m, 2H); 3.93-3.82 (m, 9H); 3.64 (m, 1H); 3.35 (q, J = 7.5 Hz, 2H); 3.19 (m , 1H); 2.81-2.63 (m, 3H); 1.58 (m, 4H); 1.45 (t, J = 7.5 Hz, 3H); 1.36 (m, 2H) and 1.32-1.23 (m, 6H)

Example 418 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -N-methyl- N- (Oxetane-3-yl) piperidin-4-amine 418
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (179 mg, 0.46 mmol), methyl oxetane in DCE (10 mL) A mixture of -3-ylpiperidin-4-ylamine (94 mg, 0.55 mmol) and 4Å powdered molecular sieve (400 mg) was stirred at room temperature for 5 hours, and then sodium triacetoxyborohydride (233 mg, 0.92 mmol) was added. added. The reaction mixture was stirred for 16 hours, then filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-15%) to give 418 as a creamy solid (93 mg, 37%). LCMS (Method I): R _T 2.31 min [M + H] ⁺ 546.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-7.99 (m, 1H); 7.78-7.72 (m, 1H); 7.29-7.22 (m, 2H); 4 .67 (t, J = 6.5 Hz, 2H); 4.60 (t, J = 6.6 Hz, 2H); 4.34 (m, 4H); 3.98-3.88 (m, 1H) 3.89-3.82 (m, 7H); 3.72 (s, 2H); 3.35 (q, J = 7.5 Hz, 2H); 2.94 (d, J = 11.2 Hz, 2H); 2.35-2.24 (m, 1H); 2.21 (s, 3H); 2.13 (t, J = 11.2 Hz, 2H); 1.64 (d, J = 12. 2 Hz, 2H); 1.54 (m, 2H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 419 N-((1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine -3-yl) methyl) -N-methyltetrahydrofuran-3-amine 419
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (78 mg, 0.2 mmol) in 1,2-dichloroethane (2 mL) ), (Azetidin-3-ylmethyl) methyl (tetrahydrofuran-3-yl) amine (51 mg, 0.3 mmol) and 4Å molecular sieve (250 mg) were stirred at room temperature for 6 hours under a nitrogen atmosphere. Sodium triacetoxyborohydride (85 mg, 0.4 mmol) was added and the resulting reaction mixture was stirred for 36 hours at room temperature. The solvent was reduced under vacuum and the residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was eluted using a mixture of DCM and 2M NH _{3 in} MeOH. The residue was purified by column chromatography (Si-PCC, MeOH: DCM: 0: 100 to 10:90 gradient) to give 419 as a white foam (80 mg, 73%). LCMS (Method I): R _T 2.05 min, [M + H] ⁺ 546. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.9-7.95 (1H, m), 7.73-7.70 (1H, m), 7.23 (2H, m), 4.32 (4H) , S), 3.92 (1H, m), 3.82-3.80 (7H, m), 3.72 (1H, q, J = 8.06 Hz), 3.61 (1H, m), 3.51 (2H, t, J = 7.19 Hz), 3.31 (2H, q, J = 7.48 Hz), 3.08 (1H, m), 2.95 (2H, t, J = 6) .81 Hz), 2.76-2.44 (2H, m), 2.14 (3H, s), 2.03-1.93 (1H, m), 1.85-1.75 (1H, m) ), 1.63 (4H, br s), 1.41 (3H, t, J = 7.48 Hz)

Example 420 2- (1-((5- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [4,5-d] pyrimidin-2-yl) methyl) Piperidin-4-yl) propan-2-ol 420
2- [1- (5-Chloro-7-morpholin-4-yl-thiazolo [4,5-d] pyrimidin-2-ylmethyl) piperidin-4-yl] in 1,4-dioxane (1.5 mL) Propan-2-ol (100 mg, 0.243 mmol), 2-ethyl-1H-benzimidazole (39 mg, 0.267 mmol), Pd ₂ (dba) ₃ (11 mg, 0.0122 mmol), XPhos (23 mg, 0.049 mmol) ) And cesium carbonate (158 mg, 0.486 mmol) was purged with argon gas for 15 minutes. The resulting reaction mixture was irradiated with microwaves at 150 ° C. for 30 minutes. The crude residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was extracted with DCM and 2M NH ₃ in MeOH. The resulting residue was further purified by column chromatography (Si-PCC, 2M NH _{3 in} MeOH: DCM: gradient 0: 100 to 5:95) to give 420 as a brown solid (47 mg, 37% ) LCMS (Method I): R _T 2.53 min, [M + H] ⁺ 522. ¹ H NMR (400 MHz, CDCl ₃ ): δ 8.11 (1H, m), 7.77-7.70 (1H, m), 7.23 (2H, m), 4.01 to 3.99 (6H) , M), 3.87 (5H, m), 3.42-3.39 (2H, m), 3.10 (2H, m), 2.27 (2H, m), 1.79 (2H, m), 1.50 (2H, d, m), 1.46-1.40 (3H, m), 1.32 (1H, m), 1.20 (6H, s)

Example 421 N-((1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine -3-yl) methyl) -N-methyloxetane-3-amine 421
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (78 mg, 0.2 mmol) in 1,2-dichloroethane (2 mL) ), (Azetidin-3-ylmethyl) methyloxetane-3-yl-amine (47 mg, 0.3 mmol), and 4Å molecular sieve (250 mg) were stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (85 mg, 0.4 mmol) was added and the resulting reaction mixture was stirred at room temperature for 16 hours under a nitrogen atmosphere. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The crude residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was subsequently extracted with a mixture of DCM and 2M NH _{3 in} MeOH. The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 8:92) to give 421 as an off-white foam (63 mg, 59%). LCMS (Method I): R _T 2.11 min, [M + H] ⁺ 532. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.97-7.96 (1 H, m), 7.72-7.71 (1 H, m), 7.23 (2 H, t, J = 3.78 Hz) 4.61 (2H, t, J = 6.53 Hz), 4.53 (2H, t, J = 6.23 Hz), 4.32 (4H, s), 3.82-3.81 (9H, m), 3.51-3.50 (3H, m), 3.32 (2H, q, J = 7.48 Hz), 3.03-2.89 (2H, m), 2.68-2. 57 (1H, m), 2.40 (2H, d, J = 7.26 Hz), 2.04 (3H, s), 1.41 (3H, t, J = 7.47 Hz)

Example 422 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl ) -9H-purin-6-yl) morpholine 422
2- (2-Ethylbenzimidazol-1-yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -8- [3- (tetrahydro) in 1.25 M HCl (10 mL) A mixture of pyran-4-yl) azetidin-1-ylmethyl] -9H-purine (0.28 g, 0.48 mmol) was stirred at room temperature for 48 hours. The reaction mixture was concentrated under vacuum. The reaction mixture in MeOH was loaded onto an Isolute® SCX-2 cartridge. After washing the cartridge with MeOH, the desired product was eluted with DCM, 20-80% MeOH in DCM and 10-40% 2M NH ₃ in MeOH in DCM. The residue was purified by flash chromatography (Si-PPC, MeOH: 2M NH _{3 in} DCM, gradient 0: 100 to 4:96), (Si-PPC, 2M NH _{3 in} MeOH: EtOAc, 2. Purification with a gradient of 5: 97.5 to 10: 9 followed by 2M NH ₃ in MeOH: DCM, gradient 2:98 to 10:90) gave 422 as a white solid (0.14 g, 59 %). LCMS (Method I): R _T = 2.50 min, [M + H] ⁺ 503.4. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.96-7.92 (m, 1H); 7.64-7.60 (m, 1H); 7.25-7.20 (m, 2H) 4.28-4.19 (m, 4H); 3.83 (dd, J = 11.3, 4.3 Hz, 2H); 3.77 (t, J = 4.6 Hz, 2H); 72 (s, 2H); 3.43-3.38 (m, 7H); 3.27-3.19 (q, J = 7.4 Hz, 2H); 2.96 (t, J = 6.9 Hz) , 2H); 2.19-2.11 (m, 1H); 1.69-1.57 (m, 1H); 1.50 (d, J = 13.0 Hz, 2H); 1.31 (t , J = 7.4 Hz, 3H); 1.06 (td, J = 12.2, 4.3 Hz, 2H)

Example 427 2- (4-((2- (2- (2-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl ) Methyl) piperazin-1-yl) -2-methylpropan-1-ol 427
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropane according to general procedure I of Buchwald coupling Reaction of -1-ol and 2- (1H-benzo [d] imidazol-2-yl) ethanol gave 427. LCMS m / z: 550.3 (MH +)

Example 428 1- (8-((4-tert-butylpiperazin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -N-methyl-1H-benzo [d ] Imidazole-2-amine 428
According to General Procedure I for Buchwald coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and N -Methyl-1H-benzo [d] imidazol-2-amine was reacted to give 428. LCMS: M + H ^< + ^> = 519.3

Example 429 4-methyl-1-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azepane -4-all 429
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) according to general procedure E for substitution of alkyl bromides with amines -9H-purin-6-yl) morpholine and 4-methylazepan-4-ol were reacted to give 429. [M + H] ⁺ 491.6

Example 430 2- (1-((2- (2-Ethylbenzofuran-3-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propane-2 -All 430
According to the general procedure L for reductive amination, 2- (2-ethylbenzofuran-3-yl) -9-methyl-6-morpholino-9H-purine-8-carbaldehyde and 2- (piperidin-4-yl) Propan-2-ol was reacted to give 430. [M + H] ⁺ 519.6

Example 431 N-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) -2- (1H -Pyrazol-1-yl) ethanamine 431
According to the general procedure L for reductive amination, 9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8-carbaldehyde and 2- Reaction with (1H-pyrazol-1-yl) ethanamine gave 431. [M + H] ⁺ 473.3

Example 432 (1-aminocyclopropyl) (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl ) Methyl) piperazin-1-yl) methanone 432
(1- {4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] in DCM / TFA (5 mL / 5 mL) ] A mixture of piperazine-1-carbonyl} cyclopropyl) carbamic acid tert-butyl ester (0.123 g, 0.19 mmol) was stirred for 4 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The eluent is concentrated in vacuo, the eluent is concentrated in vacuo, and the residue is purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 432 Obtained as a white solid (0.066 g, 64%). LCMS (Method I): R _T = 2.47 min, [M + H] ⁺ 462.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-8.00 (m, 1H); 7.66-7.61 (m, 1H); 7.28-7.21 (m, 2H) 4.18-4.22 (m, 4H); 3.85 (s, 3H); 3.82 (s, 2H); 3.78 (t, J = 4.6 Hz, 4H); 3.58 −3.53 (m, 4H); 3.27 (q, J = 7.4 Hz, 2H); 2.55-2.45 (m, 4H); 1.34 (t, J = 7.4 Hz, 3H); 0.92-0.87 (m, 2H); 0.82-0.75 (m, 2H)

Example 433 2- (1- (2- (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) Ethyl) piperidin-4-yl) propan-2-ol 433
2- {1- [2- (5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-yl) ethyl] -piperidine-4- in dioxane (1.0 mL) IL} propan-2-ol (56 mg, 0.13 mmol), 2-ethylbenzimidazole (21 mg, 0.15 mmol), Pd ₂ (dba) ₃ (3.0 mg, 2.5 mol%), Xphos (6.3 mg 10 mol%) and Cs ₂ CO ₃ (64 mg, 0.20 mmol) were purged with argon gas and then heated at 120 ° C. for 18 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-10% MeOH in DCM) to give 433 (39 mg, 56%) as an orange solid. LCMS: (Method I): R _T 2.71 min; [M + H] ⁺ 536.4. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.97 (m, 1H), 7.76-7.71 (m, 1H), 7.29-7.24 (m, 2H) , 4.52-4.32 (m, 4H), 3.90-3.85 (m, 4H), 3.34 (q, 7.5 Hz, 2H), 3.35-3.23 (m, 2H), 3.21-3.10 (m, 2H), 2.87-2.83 (m, 2H), 2.17-2.05 (m, 2H), 1.86-1.75 ( m, 2H), 1.43 (t, J = 7.5 Hz, 3H), 1.38-1.23 (m, 3H), 1.22 (s, 6H)

Example 434 2- (1- (8-((4-tert-butylpiperazin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -1H-benzo [d] Imidazol-2-yl) ethanol 434
9-Methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (5 mL), (4 A mixture of -methylpiperidin-4-yl) pyrrolidin-1-ylmethanone (62 mg, 0.32 mmol), trimethyl orthoformate (0.29 mL, 2.65 mmol) and acetic acid (40 μL, 0.70 mmol) at room temperature for 1 hour After stirring, sodium triacetoxyborohydride (90 mg, 0.42 mmol) was added. The reaction mixture was stirred at room temperature for 18 hours, washed with MeOH and loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed and the residue was purified by flash chromatography (Si-PCC, 0-20% MeOH in EtOAc) to give 434 as a white solid (98 mg, 68%). LCMS (Method I): R _T 2.64 min; [M + H] ⁺ 558. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.11-8.07 (m, 1H); 7.73-7.68 (m, 1H); 7.31-7.26 (m, 2H) 4.34 (m, 4H); 3.90 (s, 3H); 3.90-3.79 (m, 5H); 3.76 (m, 2H); 3.58-3.50 (m) 2.95 (s, 3H); 2.66 (m, 2H); 2.49 (m, 2H); 2.28 (m, 4H); 1.87 (m, 2H); 1 .33 (s, 3H)

Example 435 N-methyl-1- (9-methyl-6-morpholino-8-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl) -9H-purine-2- Yl) -1H-benzo [d] imidazol-2-amine 435
2-Chloro-9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine (120 mg, DMF (2.5 mL) 0.29 mmol), (1H-benzimidazol-2-yl) methylamine (52 mg, 0.35 mmol), tris (dibenzylideneacetone) dipalladium (14 mg, 0.01 mmol), Xphos (28 mg, 0.06 mmol) and A mixture of Cs ₂ CO ₃ (192 mg, 0.59 mmol) was purged with argon and heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give 435 as a foam (104 mg, 69%). LCMS (Method I): R _T 2.45 min, [M + H] ⁺ 518.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.48 (d, J = 5.0 Hz, 1H); 8.28 (d, J = 8.0 Hz, 1H); 7.49 (d, J = 7. 7.19 (m, 1H); 7.10-7.04 (m, 1H); 4.34 (m, 4H); 3.97 (dd, J = 11.5,4. 8Hz, 1H); 3.90 (t, J = 4.7 Hz, 4H); 3.85 (s, 3H); 3.82 (s, 2H); 3.51 (t, J = 7.3 Hz, 1 Hz, 2H); 2H); 3.42-3.32 (m, 2H); 3.26 (d, J = 5.0 Hz, 3H); 3.03 (t, J = 7.0 Hz, 2H); 2.34- 2.25 (m, 1H); 1.74-1.62 (m, 1H); 1.54 (m, 2H) and 1.27-1.13 (m, 2H)

Example 436 4- (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -2-((3- (1,1-dioxo-thiomorpholino) azetidin-1-yl) methyl) Thiazolo [5,4-d] pyrimidin-7-yl) morpholine 436
5-Chloro-2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -7-morpholin-4-ylthiazolo [5,4-] in dioxane (3 mL) d] pyrimidine (150 mg, 0.33 mmol), 2-ethylbenzimidazole (58 mg, 0.39 mmol), tris (dibenzylideneacetone) dipalladium (15 mg, 0.02 mmol), Xphos (31 mg, 0.07 mmol) and Cs A mixture of ₂ CO ₃ (213 mg, 0.65 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 45 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give 436 as a foam (113 mg, 60%). LCMS (Method I): R _T 2.59 min, [M + H] ⁺ 569.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.79-7.75 (m, 1H); 7.33-7.27 (m, 2H); 4 .41 (m, 4H); 4.02 (s, 2H); 3.91-3.81 (m, 4H); 3.72 (m, 2H); 3.39-3.30 (m, 3H) 3.16 (m, 2H); 3.08 (m, 4H); 2.90-2.85 (m, 4H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 437 2- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine- 1-yl) -2-methylpropanamide 437
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropanamide (75 mg) was converted to 2-methylbenzimidazole. And Buchwald coupling via general procedure I to give 39.9 mg of 437 after reverse phase purification. MS (Q1) 547.1 (M) +

Example 438 2- (4-((2- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine -1-yl) -2-methylpropanamide 438
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropanamide (75 mg) was added to 2-cyclopropylbenzo Reaction via general procedure I of Buchwald coupling with imidazole gave 38.7 mg of 438 after reverse phase purification. MS (Q1) 559.1 (M) +

Example 439 2- (4-((2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine- 1-yl) -2-methylpropanamide 439
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropanamide (75 mg) and 2-isopropylbenzimidazole Was reacted via Buchwald coupling general procedure I to give 24.9 mg of 439 after reverse phase purification. MS (Q1) 561.7 (M) +

Example 440 2- (4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine- 1-yl) -2-methylpropane-1,3-diol 440
According to General Procedure I for Buchwald coupling, 2-ethylbenzimidazole and 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl ) -2-Methylpropane-1,3-diol was reacted to give 440. LCMS m / z: 550.3 (MH +)

Example 441 4- (8-((4-Isopropylpiperazin-1-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purine- 6-yl) morpholine 441
4- (8- (Bromomethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) according to general procedure E for substitution of alkyl bromides with amines -9H-purin-6-yl) morpholine and 1-isopropylpiperazine were reacted to give 441. LCMS m / z: 490.3 (MH +)

Example 443 1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -2- Isopropyl-1H-indazole-3 (2H) -one 443
According to the general procedure I of Buchwald coupling, 2-isopropyl-1,2-dihydroindazol-3-one and 2- (1-((2-chloro-9-methyl-6-morpholino-9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol was reacted to give 443. LCMS m / z: 549.3 (MH +)

Example 444 4- (8-((4-cyclobutylpiperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purine -6-yl) morpholine 444
According to General Procedure I for Buchwald coupling, 2-ethylbenzimidazole and 4- (2-chloro-8-((4-cyclobutylpiperazin-1-yl) methyl) -9-methyl-9H-purine-6- Yl) morpholine was reacted to give 444. LCMS m / z: 516.3 (MH +)

４-(８-((４-ｔｅｒｔ-ブチルピペラジン-１-イル)メチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリンをアミンＳＮ_２アルキル化の一般的手順Ｅに従って調製した。一般的手順Ａの鈴木カップリングに従って、４-(８-((４-ｔｅｒｔ-ブチルピペラジン-１-イル)メチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン及び４-(４,４,５,５-テトラメチル-１,３,２-ジオキサボロラン-２-イル)イソキノリンを反応させて４４５を得た。ＬＣＭＳ：Ｍ＋Ｈ^＋＝５０１.３ Example 445 4- (8-((4-tert-Butylpiperazin-1-yl) methyl) -2- (isoquinolin-4-yl) -9-methyl-9H-purin-6-yl) morpholine 445

4- (8-((4-tert-Butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine according to general procedure E for amine SN ₂ alkylation Prepared. Following the Suzuki coupling of general procedure A, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 4 Reaction of-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinoline gave 445. LCMS: M + H ⁺ = 501.3

Example 446 4- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((4- (oxetane-3-yl) piperidin-1-yl) methyl ) -9H-purin-6-yl) morpholine 446
2-Chloro-9-methyl-6-morpholin-4-yl-8- (4-oxetan-3-yl-piperidin-1-ylmethyl) -9H-purine (100 mg, 0.25 mmol) in DMF (2 mL) To a mixture of 2-methyl-1H-benzimidazole (38 mg, 0.29 mmol), Pd ₂ dba ₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesium carbonate (121 mg, 0.37 mmol) Argon gas was purged and microwave irradiation was applied at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 99: 1 to 98: 2) to give 446 as a white solid (29 mg, 23%). LCMS (Method I): R _T = 2.37 min, M + H ⁺ = 503. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.09 (m, 1H); 7.72 (m, 1H); 7.39 (m, 2H); 4.76 (dd, J = 7.9, 6. 4.46 (t, J = 6.0 Hz, 2H); 4.35 (m, 4H); 3.90-3.84 (m, 7H); 3.78 (s, 2H) 2.96 (m, 5H); 2.80-2.71 (m, 1H); 2.22 (m, 2H) and 1.69 (m, 5H)

Example 447 N-methyl-1- (9-methyl-6-morpholino-8-((4- (oxetane-3-yl) piperidin-1-yl) methyl) -9H-purin-2-yl) -1H -Benzo [d] imidazol-2-amine 447
2-Chloro-9-methyl-6-morpholin-4-yl-8- (4-oxetan-3-yl-piperidin-1-ylmethyl) -9H-purine (100 mg, 0.25 mmol) in DMF (2 mL) , (1H-benzimidazol-2-yl) methyl-amine (43 mg, 0.29 mmol), Pd ₂ dba ₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesium carbonate (121 mg, 0. 37 mmol) was purged with argon and then subjected to microwave irradiation at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 99: 1 to 98: 2) to give 447 as a creamy foam (58 mg, 45%). LCMS (Method I): R _T = 2.36 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.51 (bs, 1H); 8.29 (d, J = 7.9 Hz, 1H); 7.51 (d, J = 7.9 Hz, 1H); 19 (t, J = 7.8 Hz, 1H); 7.08 (t, J = 7.8 Hz, 1H); 4.75 (dd, J = 7.9, 6.1 Hz, 2H); 4.46 (T, J = 6.1 Hz, 2H); 4.33 (m, 4H); 3.92-3.85 (m, 7H); 3.73 (s, 2H); 3.26 (d, J = 4.9 Hz, 3H); 2.88 (m, 2H); 2.78-2.69 (m, 1H); 2.15 (m, 2H); 1.66 (m, 3H) and 1. 19-1.07 (m, 2H)

Example 448 4- (5- (2-Methyl-1H-benzo [d] imidazol-1-yl) -2-((3- (1,1-dioxo-thiomorpholino) azetidin-1-yl) methyl) Thiazolo [5,4-d] pyrimidin-7-yl) morpholine 448
5-Chloro-2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -7-morpholin-4-ylthiazolo [5,4-] in dioxane (3 mL) d] pyrimidine (150 mg, 0.33 mmol), 2-methylbenzimidazole (52 mg, 0.39 mmol), tris (dibenzylideneacetone) dipalladium (15 mg, 0.02 mmol), Xphos (31 mg, 0.07 mmol) and Cs A mixture of ₂ CO ₃ (213 mg, 0.65 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 45 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-5%) to give 448 as a foam (74 mg, 40%). LCMS (Method I): R _T 2.45 min, [M + H] ⁺ 555.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.09-8.04 (m, 1H); 7.74-7.69 (m, 1H); 7.34-7.26 (m, 2H); 4 .41 (m, 4H); 4.01 (s, 2H); 3.88 (m, 4H); 3.71 (t, J = 6.7 Hz, 2H); 3.37-3.30 (m , 1H); 3.15 (t, J = 6.7 Hz, 2H); 3.09 (m, 4H); 2.94 (s, 3H) and 2.88 (m, 4H)

Example 449 4- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (1,1-dioxo-thiomorpholino) azetidine-1- Yl) methyl) -9H-purin-6-yl) morpholine 449
2-Chloro-8- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-ylmethyl] -9-methyl-6-morpholin-4-yl- in dioxane (2 mL) 9H-purine (0.162 g, 0.36 mmol), 2-isopropyl-1H-benzimidazole (0.068 g, 0.43 mmol), Xphos (0.034 g, 0.071 mmol), Pd ₂ (dba) ₃ (0 .017 g, 0.018 mmol) and Cs ₂ CO ₃ (0.231 g, 0.71 mmol) were subjected to microwave irradiation at 145 ° C. for 45 minutes. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM 0: 100 to 7.5: 92.5 gradient) to give 449 as a yellow solid (0.1 g, 49%). LCMS (Method I): R _T = 2.56 min, [M + H] ⁺ 580.2. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.91-7.86 (m, 1H); 7.66-7.61 (m, 1H); 7.26-7.21 (m, 2H) 4.30-4.23 (m, 4H); 3.97-3.86 (m, 1H); 3.87 (s, 2H); 3.82-3.71 (m, 7H); 3 .46 (t, J = 6.6 Hz, 2H); 3.26-3.18 (m, 1H); 3.12-3.08 (m, 4H); 3.00 (t, J = 6. 8 Hz, 2H); 2.74 (m, 4H); 1.35 (d, J = 6.8 Hz, 6H)

Example 450 4- (2- (2-Cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (oxetane-3-yl) piperidin-1-yl) Methyl) -9H-purin-6-yl) morpholine 450
2-chloro-9-methyl-6-morpholin-4-yl-8- (4-oxetan-3-ylpiperidin-1-ylmethyl) -9H-purine (100 mg, 0.25 mmol) in DMF (2 mL), To a mixture of 2-cyclopropyl-1H-benzimidazole (47 mg, 0.30 mmol), Pd ₂ dba ₃ (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesium carbonate (121 mg, 0.37 mmol) Argon gas was purged and microwave irradiation was applied at 145 ° C. for 30 minutes. After loading the reaction mixture onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM, the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH 100: 0 to 99: 1 to 98: 2 to 95: 5) to give 450 as a pale purple foam (60 mg, 46% ). LCMS (Method I): R _T = 2.63 min, M + H ⁺ = 529. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.94 (dd, J = 7.1, 2.0 Hz, 1H); 7.68 (d, J = 7.4 Hz, 1H); 7.27-7.19 (M, 2H); 4.76 (dd, J = 7.8, 6.1 Hz, 2H); 4.46 (t, J = 6.1 Hz, 2H); 4.35 (m, 4H); 3 89-3.82 (m, 7H); 3.76 (s, 2H); 2.91-2.81 (m, 3H); 2.79-2.70 (m, 1H); 2.18 (M, 2H); 1.62 (m, 5H); 1.36 (m, 2H) and 1.08-1.01 (m, 2H)

Example 451 2- (1- (2- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) Azetidin-3-yl) propan-2-ol 451
2- {1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] azetidin-3-yl} propane in dioxane (1.5 mL) -2-ol (84 mg, 0.21 mmol), 2-ethylbenzimidazole (34 mg, 0.23 mmol), Pd ₂ (dba) ₃ (4.9 mg, 2.5 mol%), Xphos (10.1 mg, 10 mol%) ) And Cs ₂ CO ₃ (104 mg, 0.32 mmol) was purged with argon gas and then heated in a sealed tube at 120 ° C. for 23 hours. After the reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH, the desired product was purified with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-20% 2M NH ₃ / MeOH in DCM) to give 451 (38 mg, 35%) as a yellow solid. LCMS: (Method I): R _T 2.53 min; [M + H] ⁺ 505.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.77-7.73 (m, 1H), 7.27-7.22 (m, 2H) , 4.49-4.24 (m, 4H), 3.88-3.83 (m, 4H), 3.76 (s, 3H), 3.48-3.40 (m, 2H), 3 .38-3.27 (m, 4H), 3.15-2.95 (m, 2H), 2.95-2.90 (m, 2H), 2.55-2.47 (m, 1H) 1.43 (t, J = 7.48 Hz, 3H), 1.17 (s, 6H)

Example 452 1- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -4- Methylpiperidine-4-ol 452
1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -4-methylpiperidin-4-ol in dioxane (1.0 mL) ( 45 mg, 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.13 mmol), Pd ₂ (dba) ₃ (2.6 mg, 2.5 mol%), Xphos (5.4 mg, 10 mol%) and Cs ₂ CO A mixture of ₃ (56 mg, 0.17 mmol) was purged with argon gas and then heated at 120 ° C. for 17 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography _{(Si-PCC, NH 3 /} MeOH in 0-10% 2M in DCM) to afford 452 (46 mg, 80%) as a pale orange solid. LCMS: (Method I): R _T 2.46 min; [M + H] ⁺ 505.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.77-7.73 (m, 1H), 7.28-7.22 (m, 2H) 4.47-4.19 (m, 4H), 3.88-3.83 (m, 4H), 3.78 (s, 3H), 3.34 (q, J = 7.5 Hz, 2H) 3.15-3.05 (m, 2H), 2.98-2.80 (m, 2H), 2.78-2.73 (m, 2H), 2.65-2.57 (m, 2H), 1.69-1.65 (m, 4H), 1.44 (t, J = 7.5 Hz, 3H), 1.33-1.27 (s, 3H)

Example 453 2-methyl-2- (4-((9-methyl-2- (2- (methylamino) -1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8 -Yl) methyl) piperazin-1-yl) propan-1-ol 453
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropane according to general procedure I of Buchwald coupling Reaction of -1-ol and N-methyl-1H-benzo [d] imidazol-2-amine gave 453. LCMS m / z: 535.3 (MH +)

２-クロロ-１-((２-(トリメチルシリル)エトキシ)メチル)-１Ｈ-ベンゾ[ｄ]イミダゾール(０.５ｇ)を、１ｍＬのエタノール中のヒューニッヒ塩基（ｉＰｒ２Ｎｅｔ、１．５ｍＬ）、アゼチジン（０．４８ｍＬ）と共にフラスコに入れた。反応物を５０℃で一晩加熱し、濃縮乾固させて０．５５ｇの粗２-(アゼチジン-１-イル)-１-((２-(トリメチルシリル)エトキシ)メチル)-１Ｈ-ベンゾ[ｄ]イミダゾールを得た。

ＤＭＦ（１４ｍＬ）中の粗２-(アゼチジン-１-イル)-１-((２-(トリメチルシリル)エトキシ)メチル)-１Ｈベンゾ[ｄ]イミダゾール（０．５５ｇ）及びナトリウムエトキシド（１．２ｇ）をシールした容器に入れた。反応物を油浴中１５０℃で３０分間加熱した。反応混合物を水で希釈し、酢酸エチルで抽出した。有機層を硫酸マグネシウムで乾燥させ、濾過し、濃縮して、３１０ｍｇの２-(アゼチジン-１-イル)-１Ｈ-ベンゾ[ｄ]イミダゾールを黄色の固形物として得た。 Example 454 4- (2- (2- (azetidin-1-yl) -1H-benzo [d] imidazol-1-yl) -8-((4-tert-butylpiperazin-1-yl) methyl)- 9-methyl-9H-purin-6-yl) morpholine 454

2-Chloro-1-((2- (trimethylsilyl) ethoxy) methyl) -1H-benzo [d] imidazole (0.5 g) was added Hunig's base (iPr2Net, 1.5 mL), azetidine (0 mL) in 1 mL of ethanol. 48 mL) into a flask. The reaction was heated at 50 ° C. overnight and concentrated to dryness to give 0.55 g of crude 2- (azetidin-1-yl) -1-((2- (trimethylsilyl) ethoxy) methyl) -1H-benzo [d Imidazole was obtained.

Crude 2- (azetidin-1-yl) -1-((2- (trimethylsilyl) ethoxy) methyl) -1H benzo [d] imidazole (0.55 g) and sodium ethoxide (1.2 g) in DMF (14 mL) ) In a sealed container. The reaction was heated in an oil bath at 150 ° C. for 30 minutes. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated to give 310 mg of 2- (azetidin-1-yl) -1H-benzo [d] imidazole as a yellow solid.

  4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (75 mg) was converted to 2- (azetidin-1-yl). ) -1H-benzo [d] imidazole (33 mg) was reacted via Buchwald coupling general procedure f to give 36.1 mg of 454 after reverse phase purification. MS (Q1) 545.4 (M) +

Example 455 2- (1-((2- (2- (azetidin-1-yl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) piperidin-4-yl) propan-2-ol 455
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (75 mg) was converted to 2- (azetidine-1 -Il) -1H-benzo [d] imidazole (33 mg) was reacted via Buchwald coupling general procedure I to give 35.9 mg of 455 after reverse phase purification. MS (Q1) 546.3 (M) +

一般的手順Ｃに従って、４-(９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-８-(ピペリジン-４-イルメチル)-９Ｈ-プリン-６-イル)モルホリンを２-ブロモ-２-メチル-プロパン酸エチルエステルでアルキル化して４５６を得た。ＬＣＭＳｍ／ｚ：５６１．３（ＭＨ＋） Example 456 2-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) ethyl propanoate 456

According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl The morpholine was alkylated with 2-bromo-2-methyl-propanoic acid ethyl ester to give 456. LCMS m / z: 561.3 (MH +)

Example 457 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 457
N1- (8-((4-tert-butylpiperazin-1-yl) methyl) -6-morpholino-9- (tetrahydro-2H-pyran-2-yl) -9H-purin-2-yl) benzene-1 , 2-diamine (0.085 g, 0.15 mmol) and 2,2-difluoropropanoic acid (0.019 g, 0.17 mmol) were dissolved in N, N-dimethylformamide (2 mL, 0.02 mol). N, N-diisopropylethylamine (0.054 mL, 0.31 mmol) was added. The resulting solution was cooled at 0 ° C. for 20 minutes. N, N, N ′, N′-tetramethyl-O- (7-azabenzotriazol-1-yl) tetramethyluronium hexafluorophosphate (0.070 g, 0.00018 mol) was added and the reaction was allowed to stand overnight. Stir at room temperature. The reaction mixture was concentrated to dryness. Acetic acid (3.0 mL, 0.053 mol) was added to the crude residue and the reaction mixture was stirred at 90 ° C. for 18 hours. The reaction mixture was cooled, filtered and concentrated to dryness. The crude material was purified by reverse phase HPLC to give 457 (15.3 mg, 18%). [M + H] ⁺ = 540.3

Example 458 1- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -3- Methylazetidine-3-ol 458
1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -3-methylazetidin-3-ol in dioxane (2.0 mL) (80 mg, 0.22 mmol), 2-ethylbenzimidazole (35 mg, 0.24 mmol), Pd ₂ (dba) ₃ (5 mg, 2.5 mol%), Xphos (10.4 mg, 10 mol%) and Cs ₂ CO ₃ A mixture of (107 mg, 0.33 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 19 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM) to give 458 (77 mg, 74%) as a light beige solid. LCMS: (Method I): R _T 2.39 min; [M + H] ⁺ 477.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m, 1H), 7.26-7.22 (m, 2H) , 4.45-4.32 (m, 4H), 3.86 (t, J = 4.8 Hz, 4H), 3.77 (s, 3H), 3.40 (d, J = 7.3 Hz, 2H), 3.34 (q, J = 7.5 Hz, 2H), 3.14 (d, J = 7.3 Hz, 2H), 3.02 (t, J = 7.3 Hz, 3H), 2. 92 (t, J = 7.3 Hz, 2H), 1.53 (s, 3H), 1.44 (t, J = 7.5 Hz, 3H)

Example 459 4- (2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (oxetan-3-yl) Piperidin-1-yl) methyl) -9H-purin-6-yl) morpholine 459
N- [9-Methyl-6-morpholin-4-yl-8- (4-oxetan-3-ylpiperidin-1-ylmethyl) -9H-purin-2-yl] benzene-1, in DMF (7 mL), To a mixture of 2-diamine (0.115 g, 0.24 mmol) and 2,2-difluoropropionic acid (0.028 g, 0.25 mmol) and DIPEA (0.091 mL, 0.53 mL) was added HATU (0.11 g, 0. .29 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours and then at 90 ° C. for 24 hours. The reaction mixture was concentrated under vacuum and the residue in MeOH was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solution was concentrated in vacuo, the residue was diluted with acetic acid (15 mL) and the reaction mixture was stirred at 90 ° C. for 7 hours. The reaction mixture was concentrated in vacuo and the resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, acetonitrile 95: 5). Purification with 2: 98 gradient in 20 mM triethylamine in water) gave 459 as a white solid (0.032 g, 27%). LCMS (Method I): R _T = 3.30 min, [M + H] ⁺ 553.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.84-7.81 (m, 1H); 7.74-7.71 (m, 1H); 7.43-7.35 (m, 2H) 4.40-4.15 (m, 4H); 3.84 (s, 2H); 3.81 (d, J = 4.3 Hz, 2H); 3.78-3.71 (m, 7H) 3.37 (t, J = 6.9 Hz, 2H); 3.30-3.18 (m, 2H); 2.96 (t, J = 6.9 Hz, 2H); 2.34-2. 21 (t, J = 19.5 Hz, 3H); 2.20-2.08 (m, 1H); 1.64 (d, J = 12.1 Hz, 1H); 1.50 (d, J = 13) 1.0 Hz, 2H); 1.06 (td, J = 12.1, 4.3 Hz, 2H)

Example 460 (S)-(1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Azetidin-3-yl) (3-hydroxypyrrolidin-1-yl) methanone 460
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (75 mg, 0.19 mmol) in 1,2-dichloroethane (2 mL) ), Azetidin-3-yl-((S) -3-hydroxypyrrolidin-1-yl) methanone (65 mg, 0.38 mmol), and 4Å molecular sieves (250 mg) were stirred at room temperature for 4 hours. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the resulting reaction mixture was stirred at room temperature for 60 hours under a nitrogen atmosphere. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The crude residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was extracted with a mixture of 2M NH ₃ in DCM and MeOH. The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 460 as an off-white solid (32 mg, 30%). LCMS (Method I): R _T 2.33 min, [M + H] ⁺ 546. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.98-7.93 (1H, m), 7.71-7.70 (1H, m), 7.22 (2H, s), 4.49 (2H) , S), 4.31 (4H, s), 3.83-3.81 (8H, m), 3.52-3.50 (9H, m), 3.32-3.30 (2H, m) ), 2.04-1.88 (3H, m), 1.40 (3H, t, J = 7.47 Hz)

Example 461 (R)-(1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Azetidin-3-yl) (3-hydroxypyrrolidin-1-yl) methanone 461
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (75 mg, 0.19 mmol) in 1,2-dichloroethane (2 mL) ), Azetidin-3-yl-((R) -3-hydroxypyrrolidin-1-yl) methanone (65 mg, 0.38 mmol), and 4Å molecular sieves (250 mg) were stirred at room temperature for 4 hours. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the resulting reaction mixture was stirred at room temperature for 60 hours under a nitrogen atmosphere. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The crude residue was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with DCM / MeOH and the desired product was eluted with 2M NH ₃ in DCM and MeOH. The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 461 as a white solid (17 mg, 16%). LCMS (Method I): R _T 2.34 min, [M + H] ⁺ 546. ¹ H NMR (400 MHz, CDCl ₃ ): δ 7.96-7.95 (1H, m), 7.73-7.69 (1H, m), 7.22 (2H, s), 4.52-4 .48 (2H, m), 4.31 (4H, s), 3.82-3.82 (8H, m), 3.59-3.57 (9H, m), 3.32-3.30 (2H, m), 1.98-1.97 (2H, m), 1.40 (3H, t, J = 7.48 Hz)

Example 462 2- (1-((2- (2-tert-butyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Piperidin-4-yl) propan-2-ol 462
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.3 g) and tert-butylbenzo Imidazole was reacted via General Procedure I for Buchwald coupling to give 94.3 mg of 462 after reverse phase purification. MS (Q1) 547.3 (M) +

Example 463 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 463
4- (8-((4-tert-Butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl according to general procedure J for multistep benzimidazole formation ) Morpholine was converted to 463 using difluoroacetic acid. LCMS: M + H + = 554.3

Example 464 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -9-methyl-2- (2- (trifluoromethyl) -1H-benzo [d] imidazol-1-yl ) -9H-purin-6-yl) morpholine 464
4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) according to the general procedure for multi-step benzimidazole formation Morpholine was converted to 464 using trifluoroacetic acid. LCMS: M + H ^< + ^> = 558.3

Example 465 7- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -7- Azaspiro [3.5] nonane-2-ol 465
7- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -7-azaspiro [3.5] nonane in dioxane (2.0 mL) -2-ol (75 mg, 0.18 mmol), 2-ethylbenzimidazole (29 mg, 0.20 mmol), Pd ₂ (dba) ₃ (4.1 mg, 2.5 mol%), Xphos (8.5 mg, 10 mol%) ) And Cs ₂ CO ₃ (87 mg, 0.27 mmol) were purged with argon and then heated at 120 ° C. for 18 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography with (Si-PCC, 0-10% 2M NH 3 / MeOH in DCM in) and then reverse phase HPLC (Phenomenex Gemini 5μmC18, acetonitrile 20-98% gradient in water 20mM triethylamine ) To give 465 (42 mg, 44%) as a white solid. LCMS: (Method I): R _T 2.47 min; [M + H] ⁺ 531.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m, 1H), 7.28-7.22 (m, 2H) 4.37-4.27 (m, 5H), 3.86 (t, J = 4.7 Hz, 4H), 3.78 (s, 3H), 3.34 (q, J = 7.5 Hz, 2H), 3.17-3.02 (m, 2H), 2.99-2.81 (m, 2H), 2.71-2.39 (m, 4H), 2.31-2.24 ( m, 2H), 1.74-1.64 (m, 6H), 1.44 (t, J = 7.5 Hz, 3H)

Example 466 1- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -3- Isopropylazetidine-3-ol 466
1- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -3-isopropyl-azetidin-3-ol in dioxane (1.0 mL) (33 mg, 0.08 mmol), 2-ethylbenzimidazole (14 mg, 0.09 mmol), Pd ₂ (dba) ₃ (1.9 mg, 2.5 mol%), Xphos (4.0 mg, 10 mol%) and Cs ₂ A mixture of CO ₃ (41 mg, 0.13 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 18 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PCC, 0-10% 2M NH ₃ / MeOH in DCM), then reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 20-98% gradient in 20 mM in water). To give 466 (18 mg, 42%) as an off-white solid. LCMS: (Method I): R _T 2.62 min; [M + H] ⁺ 505.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.76-7.72 (m, 1H), 7.28-7.22 (m, 2H) , 4.45-4.33 (m, 4H), 3.86 (t, J = 4.7 Hz, 4H), 3.77 (s, 3H), 3.41 (d, J = 8.1 Hz, 2H), 3.34 (q, J = 7.5 Hz, 2H), 3.18 (d, J = 8.1 Hz, 2H), 3.04 (t, J = 7.2 Hz, 2H), 2. 93 (t, J = 7.2 Hz, 2H), 2.01-1.89 (m, 1H), 1.44 (t, J = 7.5 Hz, 3H), 0.94 (d, J = 6) .8Hz, 6H)

Example 467 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((3- (tetrahydro-2H-pyran-4-yl) azetidine-1 -Yl) methyl) -9H-purin-6-yl) morpholine 467
2-Chloro-9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purine (112 mg, 0. 1) in dioxane (3 mL). 28 mmol), 2-methylbenzimidazole (44 mg, 0.33 mmol), tris (dibenzylideneacetone) dipalladium (13 mg, 0.01 mmol), Xphos (26 mg, 0.06 mmol) and Cs ₂ CO ₃ (179 mg, .0. 55 mmol) was purged with argon and heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 467 creamy solid (105 mg, 75%). LCMS (Method I): R _T 2.46 min, [M + H] ⁺ 503.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.10-8.05 (m, 1H); 7.73-7.67 (m, 1H); 7.28-7.23 (m, 2H); 4 .35 (m, 4H); 3.97 (dd, J = 11.4, 4.1 Hz, 2H); 3.89-3.82 (m, 9H); 3.54 (m, 2H); 3 .37 (td, J = 11.4, 2.0 Hz, 2H); 3.06 (m, 2H); 2.94 (s, 3H); 2.38-2.27 (m, 1H); 1 .54 (m, 2H) and 1.32-1.14 (m, 3H)

Example 468 4- (2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (tetrahydro-2H-pyran- 4-yl) azetidin-1-yl) methyl) -9H-purin-6-yl) morpholine 468
N- {9-methyl-6-morpholin-4-yl-8- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] -9H-purin-2-yl} benzene-1,2-diamine (0.234 g, 0.49 mmol) and a mixture of DIPEA (0.185 mL, 1.08 mL) and 2,2-difluoropropionic acid (0.057 g, 0.51 mmol) and DMF (14 mL) in HATU (0. 223 g, 0.59 mmol) was added and the reaction mixture was stirred for 24 hours at room temperature. The reaction mixture was concentrated in vacuo and the residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 7.5: 92.5). The solution was concentrated in vacuo, the residue was diluted with acetic acid (30 mL), and the reaction mixture was stirred at 90 ° C. for 18 hours. The reaction mixture was concentrated in vacuo and the residue was flash chromatographed (Si-PPC, MeOH: DCM, 0: 100 to 7.5: 92.5) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile Purification with 20 mM triethylamine in water with a gradient of 95: 5 to 2:98) gave 468 as a white solid (0.063 g, 24%). LCMS (Method I): R _T = 3.34 min, [M + H] ⁺ 553.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.84-7.82 (m, 1H); 7.75-7.72 (m, 1H); 7.42-7.36 (m, 2H) 4.58 (dd, J = 7.85, 6.0 Hz, 2H); 4.40-4.00 (m, 4H); 4.32 (t, J = 6.0 Hz, 2H); 78 (s, 3H); 3.77 (s, 2H); 3.77-3.73 (m, 4H); 2.85 (d, J = 11.1 Hz, 2H); 2.68-2. 66 (m, 1H); 2.26 (t, J = 19.02 Hz, 3H); 2.09 (t, J = 11.1 Hz, 2H); 1.57 (d, J = 12.5 Hz, 3H) ); 1.03 (d, J = 12.5 Hz, 2H)

Example 469 4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1-isopropylpiperazine -2-On 469
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.15 g, DCE (5 mL) and MeOH (1 mL). 0.39 mmol), 1-isopropylpiperazin-2-one (0.082 g, 0.58 mmol) and 4Å molecular sieves (0.718 g) were stirred for 5 hours at room temperature. Sodium triacetoxyborohydride (0.163 g, 0.77 mmol) was added and the reaction mixture was stirred for 72 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was flash chromatographed (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 5:95) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient in 20 mM in water). Triethylamine) afforded 469 as an off-white solid (0.044 g, 22%). LCMS (Method I): R _T = 3.31 min, [M + H] ⁺ 518.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-8.00 (m, 1H); 7.65-7.61 (m, 1H); 7.28-7.21 (m, 2H) 4.64-4.58 (m, 1H); 4.28-4.25 (m, 4H); 3.86 (s, 2H); 3.81 (s, 3H); 3.80-3 .77 (m, 4H); 3.27 (q, 7.5 Hz, 2H); 3.17 (t, J = 5.3 Hz, 2H); 3.13 (s, 2H); 2.73 (t , J = 5.3 Hz, 2H); 1.34 (t, J = 7.5 Hz, 3H); 1.05 (d, J = 6.8 Hz, 6H)

Example 470 4- (5- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -2-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl ) Thiazolo [5,4-d] pyrimidin-7-yl) morpholine 470
5-Chloro-7-morpholin-4-yl-2- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] thiazolo [5,4-d] pyrimidine (0) in dioxane (1.5 mL) 0.1 g, 0.25 mmol), 2-isopropyl-1H-benzimidazole (0.078 g, 0.49 mmol), Xphos (0.024 g, 0.049 mmol), Pd ₂ (dba) ₃ (0.012 g, .0. 012 mmol) and Cs ₂ CO ₃ (0.159 g, 0.49 mmol) were subjected to microwave irradiation at 145 ° C. for 45 minutes. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) to give 470 as a yellow solid (0.044 g, 34%). LCMS (Method I): R _T = 2.88 min, [M + H] ⁺ 534.2. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.89-7.85 (m, 1H); 7.66-7.61 (m, 1H); 7.28-7.22 (m, 2H) 4.36-4.30 (m, 4H); 4.00 (s, 2H); 3.97-3.89 (m, 1H); 3.85 (dd, J = 11.2, 4.); 3.79 (t, J = 4.6 Hz, 4H); 3.49 (t, J = 7.3 Hz, 2H); 3.39-3.35 (m, 2H); 07 (t, J = 6.8 Hz, 2H); 2.27-2.21 (m, 1H); 1.73-1.64 (m, 1H); 1.52 (d, J = 13.1 Hz) , 2H); 1.33 (dd, J = 6.8, 4.0 Hz, 6H); 1.10 (td, J = 12.2, 4.6 Hz, 2H)

Example 471 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H- Purin-6-yl) morpholine 471
4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (80 mg) and 2-isopropylbenzimidazole in a Buchwald cup Reaction via General Procedure I of the ring gave 31.4 mg of 471 after reverse phase purification. MS (Q1) 532.4 (M) +

Example 472 1- (8-((4-tert-butylpiperazin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -2-ethyl-1H-indazole-3 (2H) -On 472
According to General Procedure I for Buchwald coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 2 -Ethyl-1H-indazol-3 (2H) -one was reacted to give 472. LCMS m / z: 534.3 (MH +)

Example 473 2- (4-((2- (2- (1,1-difluoroethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) piperazin-1-yl) -2-methylpropan-1-ol 473
2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2- Methylpropan-1-ol was converted to 473 using difluoroacetic acid. LCMS: M + H ⁺ = 570.3

Example 474 2-methyl-2- (4-((9-methyl-6-morpholino-2- (2- (trifluoromethyl) -1H-benzo [d] imidazol-1-yl) -9H-purine- 8-yl) methyl) piperazin-1-yl) propan-1-ol 474
2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2- Methylpropan-1-ol was converted to 474. LCMS: M + H ⁺ = 574.3

Example 475 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -9-methyl-2- (quinolin-4-yl) -9H-purin-6-yl) morpholine 475
According to the general procedure A for Suzuki coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 4 Reaction of-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) quinoline gave 475. LCMS: M + H ⁺ = 501.3

Example 476 2- (4-((2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine- 1-yl) -2-methylpropan-1-ol 476
2- (4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) -2-methylpropan-1-ol (70 mg) and 2- Isopropylbenzimidazole was reacted via General Procedure I for Buchwald coupling to give 28 mg of 476 after reverse phase purification. MS (Q1) 548.3 (M) +

Example 477 2- (1-((2- (2-((1R, 2S) -2-fluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino- 9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 477
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (75 mg) was converted to trans-2-fluorocyclo Reaction with propanecarboxylic acid via general procedure J for 2-step Buchwald coupling gave 16.3 mg of 477 after reverse phase purification followed by chiral separation from 479. MS (Q1) 549.3 (M) +

Example 478 I-2- (1-((2- (2- (2,2-difluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H- Purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 478
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.1 g) was added to 2,2- 8.8 mg of 478 [MS (Q1) 567 after reaction with difluorocyclopropanecarboxylic acid via general procedure J for two step Buchwald coupling followed by reverse phase purification followed by chiral separation from 8.8 mg of enantiomer 481 .3 (M) +]. MS (Q1) 567.3 (M) +].

Example 479 2- (1-((2- (2-((1S, 2R) -2-fluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino- 9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 479
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (75 mg) was converted to trans-2-fluorocyclo Reaction with propanecarboxylic acid via general procedure J for 2-step Buchwald coupling gave 16.1 mg of 479 after reverse phase purification followed by chiral separation from 477. MS (Q1) 549.3 (M) +

Example 480 2- (1-((2- (2-((1R, 2R) -2-fluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino- 9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 480
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (75 mg) and cis-2-fluorocyclo Reaction via general procedure J of two-step Buchwald coupling with propanecarboxylic acid followed by reverse phase purification followed by 2- (1-((2- (2-((1S, 2S) -2 -Fluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (MS After chiral separation from (Q1) 549.3 (M) +), 13 mg of 480 [MS (Q1) 549.3 (M) +] was obtained.

Example 481 (S) -2- (1-((2- (2- (2,2-difluorocyclopropyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino- 9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol 481
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.1 g) was added to 2,2- Reaction with difluorocyclopropane carboxylic acid in general procedure J for two step Buchwald coupling gave 8.8 mg 481 after reverse phase purification and subsequent chiral separation from 8.8 mg enantiomer 478 [MS ( Q1) 567.3 (M) +].

Example 482 4- (5- (2-methyl-1H-benzo [d] imidazol-1-yl) -2-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl ) Thiazolo [5,4-d] pyrimidin-7-yl) morpholine 482
5-Chloro-7-morpholin-4-yl-2- (3-morpholin-4-yl-azetidin-1-ylmethyl) -thiazolo [5,4-d] pyrimidine (100 mg, 0.2 mg) in DMF (2 mL). 24 mmol), 2-methylbenzimidazole (32 mg, 0.24 mmol), tris (dibenzylideneacetone) dipalladium (11 mg, 0.01 mmol), Xphos (12 mg, 0.02 mmol) and Cs ₂ CO ₃ (159 mg, .0. 48 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was dissolved in _EtOAc, washed with _H 2 O (× 6), then dried _(Na 2 _SO 4), and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) to give 482 as an orange solid (47 mg, 39%). LCMS (Method I): R _T 2.59 min, [M + H] ⁺ 507.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.09-8.04 (m, 1H); 7.73-7.68 (m, 1H); 7.29-7.24 (m, 2H); 4 4.01 (m, 4H); 4.02 (s, 2H); 3.88 (t, J = 4.7 Hz, 4H); 3.71 (m, 6H); 3.17 (m, 3H); 2.92 (s, 3H) and 2.37 (m, 4H)

Example 483 4- (5- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -2-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl ) Thiazolo [5,4-d] pyrimidin-7-yl) morpholine 483
5-Chloro-7-morpholin-4-yl-2- [3- (tetrahydro-pyran-4-yl) azetidin-1-ylmethyl] thiazolo [5,4-d] pyrimidine in dioxane (2.5 mL) 90 mg, 0.22 mmol), 2-ethylbenzimidazole (38 mg, 0.26 mmol), tris (dibenzylideneacetone) dipalladium (10 mg, 0.01 mmol), Xphos (21 mg, 0.04 mmol) and Cs ₂ CO ₃ ( 143 mg, 0.44 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-7%). The resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 483 as an orange solid ( 82 mg, 72%). LCMS (Method I): R _T 2.70 min, [M + H] ⁺ 520.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.30-7.24 (m, 2H); 4 .41 (m, 4H); 4.04-3.94 (m, 4H); 3.91-3.82 (m, 4H); 3.61 (m, 2H); 3.44-3.30 (M, 4H); 3.10 (m, 2H); 2.40-2.30 (m, 1H); 1.70 (m, 1H); 1.55 (m, 2H); 1.43 ( t, J = 7.5 Hz, 3H) and 1.32-1.18 (m, 2H)

Example 484 4- (5- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -2-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) Methyl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine 484
5-Chloro-7-morpholin-4-yl-2- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] thiazolo [5,4-d] pyrimidine (90 mg) in dioxane (2.5 mL) 0.22 mmol), 2-cyclopropylbenzimidazole (42 mg, 0.26 mmol), tris (dibenzylideneacetone) dipalladium (10 mg, 0.01 mmol), Xphos (21 mg, 0.04 mmol) and Cs ₂ CO ₃ ( 143 mg, 0.44 mmol) was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-7%). The resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 484 as an orange solid (83 mg 71%). LCMS (Method I): R _T 2.89 min, [M + H] ⁺ 532.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.94-7.89 (m, 1H); 7.69-7.65 (m, 1H); 7.26-7.20 (m, 2H); 4 .43 (m, 4H); 3.99 (m, 4H); 3.87 (m, 4H); 3.61 (m, 2H); 3.38 (m, 2H); 3.10 (m, 2H); 2.89-2.82 (m, 1H); 2.36 (m, 1H); 1.71 (m, 1H); 1.56 (m, 2H); 1.37-1.31 (M, 2H); 1.30-1.18 (m, 2H) and 1.10-1.04 (m, 2H)

磁気フォロアーを備えたマイクロ波容器に、Ｐｄ_２(ｄｂａ)_３（５．７ｍｇ、０．００６ｍｍｏｌ）、Ｘｐｈｏｓ（１１．９ｍｇ、０．０２５ｍｍｏｌ）、２-[１-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル)-ピペリジン-４-イル]-プロパン-２-オール（１０２ｍｇ、０．２５ｍｍｏｌ）、３-フルオロ-２-ニトロ-フェニルアミン（４７ｍｇ、０．３０ｍｍｏｌ）、炭酸セシウム（１１４ｍｇ、０．３５ｍｍｏｌ）及びＤＭＦ（１ｍＬ）を充填した。容器に蓋をし、反応混合物を５分間脱気して、１５０℃で３０分間照射した。反応混合物をＭｅＯＨで希釈し、Ｉｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）に充填した。カートリッジをＭｅＯＨで洗浄し、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。溶媒を除去し、残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ中の０−５％ＭｅＯＨ）で精製して、２-{１-[２-(３-フルオロ-２-ニトロフェニルアミノ)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]ピペリジン-４-イル}プロパン-２-オールを赤色油として得た（９７ｍｇ、７３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ０．２７分及び３．１８分；［Ｍ＋Ｈ］^＋５２９

ＩＭＳ（５ｍＬ）中の２-{１-[２-(３-フルオロ-２-ニトロフェニルアミノ)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]ピペリジン-４-イル}プロパン-２-オール（９５ｍｇ、０．１８ｍｍｏｌ）の混合物にアルゴン雰囲気下、１０％Ｐｄ炭（２０ｍｇ）を加えた。この容器を排気し、水素を再び満たした（この工程を３回繰り返した）。反応混合物を室温で１８時間攪拌し、ついでセライトで濾過した。濾過物を真空下で濃縮し、残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＣＣ、０−ＥｔＯＡｃ中１０％のＭｅＯＨ）で精製して、２-{１-[２-(２-アミノ-３-フルオロ-フェニルアミノ)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イルメチル]ピペリジン-４-イル}プロパン-２-オールを赤色油として得た（６５ｍｇ、７２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ＝０．２８分及び２．８２分，［Ｍ＋Ｈ］^＋４９９ Example 485 2- (1-((2- (2-Ethyl-4-fluoro-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) piperidin-4-yl) propan-2-ol 485

To a microwave vessel equipped with a magnetic follower, Pd ₂ (dba) ₃ (5.7 mg, 0.006 mmol), Xphos (11.9 mg, 0.025 mmol), 2- [1- (2-chloro-9-methyl) -6-morpholin-4-yl-9H-purin-8-ylmethyl) -piperidin-4-yl] -propan-2-ol (102 mg, 0.25 mmol), 3-fluoro-2-nitro-phenylamine (47 mg , 0.30 mmol), cesium carbonate (114 mg, 0.35 mmol) and DMF (1 mL). The vessel was capped and the reaction mixture was degassed for 5 minutes and irradiated at 150 ° C. for 30 minutes. The reaction mixture was diluted with MeOH and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed and the residue was purified by flash chromatography (Si-PCC, 0-5% MeOH in EtOAc) to give 2- {1- [2- (3-fluoro-2-nitrophenylamino)- 9-Methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] piperidin-4-yl} propan-2-ol was obtained as a red oil (97 mg, 73%). LCMS (Method H): R _T 0.27 min and 3.18 min; [M + H] ⁺ 529

2- {1- [2- (3-Fluoro-2-nitrophenylamino) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] piperidine-4- in IMS (5 mL) Ir} propan-2-ol (95 mg, 0.18 mmol) was added to 10% Pd charcoal (20 mg) under an argon atmosphere. The vessel was evacuated and refilled with hydrogen (this process was repeated 3 times). The reaction mixture was stirred at room temperature for 18 hours and then filtered through celite. The filtrate was concentrated under vacuum and the residue was purified by flash chromatography (Si-PCC, 10% MeOH in 0-EtOAc) to give 2- {1- [2- (2-amino-3-fluoro -Phenylamino) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] piperidin-4-yl} propan-2-ol was obtained as a red oil (65 mg, 72%). LCMS (Method H): R _T = 0.28 min and 2.82 min, [M + H] ⁺ 499.

2- {1- [2- (2-Amino-3-fluorophenylamino) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] piperidine-4- in DMF (3 mL) HATU (59 mg, 0.16 mmol) was added to a solution of yl} propan-2-ol (65 mg, 0.13 mmol), propionic acid (78 uL, 0.14 mmol) and DIPEA (49 uL, 0.29 mmol). The reaction mixture was stirred at room temperature for 18 hours. Propionic acid (78 uL, 0.14 mmol), DIPEA (49 uL, 0.29 mmol) and HATU (59 mg, 0.16 mmol) were added and the reaction mixture was stirred for 2 days at room temperature, diluted with water and extracted with EtOAc. The organic layer was separated, washed with water, saturated aqueous sodium bicarbonate solution and brine, dried over Na ₂ SO ₄ , filtered and concentrated to give a red oil that was dissolved in acetic acid (2 mL). The mixture was stirred at 90 ° C. for 18 hours and then concentrated under vacuum. The residue was azeotroped with toluene and then taken up in MeOH. The resulting solution was loaded onto an Isolute® SCX-2 cartridge (5 g). The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The solvent was removed and the residue was purified by flash chromatography (Si-PCC, 0-20% MeOH in EtOAc) to give 485 (36 mg, 52%). LCMS (Method I): R _T 3.18 min; [M + H] ⁺ 537. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 7.78-7.75 (m, 1H); 7.21-7.12 (m, 1H); 6.97 (dd, J = 10.3, 8.0 Hz, 1H); 4.34 (m, 4H); 3.90-3.84 (m, 7H); 3.73 (s, 2H); 3.35 (q, 7.5 Hz, 2H) 2.97 (d, J = 11.4 Hz, 2H); 2.12 (m, 2H); 1.77 (m, 2H); 1.44 (t, J = 7.5 Hz, 3H); 1 .44-1.28 (m, 4H); 1.24-1.15 (m, 6H)

Example 486 1- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) piperidin-4-ol 486
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.167 g, 0.43 mmol) in DCE (8 mL), A mixture of 1-azetidin-3-ylpiperidin-4-ol (0.1 g, 0.64 mmol) and 4Å molecular sieve (0.8 g) was stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (0.272 g, 1.28 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) to give 486 as a yellow solid (0.123 g, 55%). LCMS (Method I): R _T = 2.31 min, [M + H] ⁺ 532.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H); 7.65-7.61 (m, 1H); 7.27-7.20 (m, 2H) 4.54 (d, J = 4.0 Hz, 1H); 4.29-4.22 (m, 4H); 3.86 (s, 2H); 3.82-3.73 (m, 7H); 3.42 (t, J = 6.5 Hz, 2H); 3.30-3.27 (m, 3H); 3.27 (q, J = 7.4 Hz, 2H); 2.96 (t, J = 6.5 Hz, 2H); 2.89-2.86 (m, 1H); 1.88-1.85 (m, 2H); 1.71-1.68 (m, 2H); 39-1.35 (m, 2H); 1.33 (t, J = 7.4 Hz, 3H)

Example 491 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8-((3- (4-fluoropiperidin-1-yl) azetidin-1-yl) methyl) -9-methyl-9H-purin-6-yl) morpholine 491
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.165 g, 0.42 mmol) in DCE (8 mL), A mixture of 1-azetidin-3-yl-4-fluoropiperidine (0.1 g, 0.63 mmol) and 4Å molecular sieve (0.8 g) was stirred for 18 hours at room temperature. Sodium triacetoxyborohydride (0.179 g, 0.84 mmol) was added and the reaction mixture was stirred at room temperature for 6 hours. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 491 as a yellow solid (0.1 g, 45%). LCMS (Method I): R _T = 2.52 min, [M + H] ⁺ 534.2. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H); 7.64-7.61 (m, 1H); 7.26-7.21 (m, 2H) 4.81-4.52 (m, 1H); 4.51-3.96 (m, 4H); 3.86 (s, 2H); 3.79-3.76 (m, 7H); 3 .43 (t, J = 6.3 Hz, 2H); 3.26 (q, J = 7.4 Hz, 2H); 2.97 (t, J = 6.3 Hz, 2H); 2.95-2. 91 (m, 1H); 2.37-2.33 (m, 2H); 2.18-2.13 (m, 2H); 1.90-1.75 (m, 2H); 1.76- 1.64 (m, 2H); 1.33 (t, J = 7.4 Hz, 3H)

Example 492 4- (8-((3- (4,4-difluoropiperidin-1-yl) azetidin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole-1- Yl) -9-methyl-9H-purin-6-yl) morpholine 492
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.1 g, 0.26 mmol) in DCE (6 mL), A mixture of 1-azetidin-3-yl-4,4-difluoropiperidine (0.087 g, 0.38 mmol) and 4Å molecular sieve (0.6 g) was stirred for 18 hours at room temperature. Sodium triacetoxyborohydride (0.109 g, 0.51 mmol) was added and the reaction mixture was stirred for 5 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 3:97) to give 492 as a yellow solid (0.097 g, 69%). LCMS (Method I): R _T = 2.82 min, [M + H] ⁺ 552.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H); 7.65-7.61 (m, 1H); 7.28-7.21 (m, 2H) 4.30-4.23 (m, 4H); 3.87 (s, 2H); 3.80-3.75 (m, 7H); 3.46-3.43 (m, 2H); 3 .25 (q, J = 7.4 Hz, 2H); 3.01-2.98 (m, 3H); 2.37-2.33 (m, 4H); 2.00-1.87 (m, 4H); 1.33 (t, J = 7.4 Hz, 3H)

Example 493 4- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -1- Isopropylpiperazine-2-one 493
4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -1-isopropylpiperazin-2-one in dioxane (1.5 mL) ( 51 mg, 0.12 mmol), 2-ethylbenzimidazole (20 mg, 0.13 mmol), Pd ₂ (dba) ₃ (2.8 mg, 2.5 mol%), Xphos (5.8 mg, 10 mol%) and Cs ₂ CO A mixture of ₃ (59 mg, 0.18 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 19 hours. After the reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH, the desired product was purified with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography with (Si-PCC, 0-10% 2M NH 3 / MeOH in DCM in) and then reverse phase HPLC (Phenomenex Gemini 5μmC18, acetonitrile 20-98% gradient in water 20mM triethylamine ) To give 493 (28 mg, 44%) as an off-white solid. LCMS: (Method I): R _T 2.75 min; [M + H] ⁺ 532.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.80-7.76 (m, 1H), 7.28 (m, 2H), 4.91 -4.82 (m, 1H), 4.5-4.21 (m, 4H), 3.87 (t, J = 4.7 Hz, 4H), 3.77 (s, 3H), 3.37 (Q, J = 7.5 Hz, 2H), 3.29 (s, 2H), 3.26 (t, J = 5.4 Hz, 2H), 3.08-3.01 (m, 2H), 3 .00-2.93 (m, 2H), 2.81 (t, J = 5.4 Hz, 2H), 1.45 (t, J = 7.5 Hz, 3H), 1.14 (d, J = 6.9Hz, 6H)

Example 494 1 '-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -1,3 '-Biazetidine-3-ol 494
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.15 g, 0.38 mmol) in DCE (8 mL), A mixture of [1,3 ′] biazetidinyl-3-ol (0.098 g, 0.77 mmol) and 4Å molecular sieve (0.8 g) was stirred for 4 hours at room temperature. Sodium triacetoxyborohydride (0.162 g, 0.77 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) to give 494 as an off-white solid (0.101 g, 53%). LCMS (Method I): R _T = 2.31 min, [M + H] ⁺ 504.2. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.98 (m, 1H); 7.65-7.60 (m, 1H); 7.28-7.22 (m, 2H) 5.26 (d, J = 6.8 Hz, 1H); 4.28-4.21 (m, 4H); 4.19-4.15 (m, 3H); 3.83 (s, 2H); 3.79-3.75 (m, 7H); 3.47-3.35 (m, 2H); 3.20 (q, J = 7.4 Hz, 2H); 3.02 (t, J = 6.8 Hz, 2H); 2.82 (t, J = 6.8 Hz, 3H); 1.36-1.29 (q, J = 7.4 Hz, 3H)

Example 495 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (tetrahydro-2H-pyran-4-yl) piperazine-1 -Yl) methyl) -9H-purin-6-yl) morpholine 495
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (360 mg, 0.92 mmol) in DCE (10 mL), 1- A solution of (tetrahydropyran-4-yl) piperazine (250 mg, 1.47 mmol) and molecular sieves (4 kg, powder, 1.5 g) was stirred at ambient temperature for 6 hours. Sodium triacetoxyborohydride (530 mg, 2.50 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently washed using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, EtOAc: MeOH; gradient from 100: 0 to 70:30) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 80:20 to 2:98 gradient). Purification by 20 mM triethylamine in water) gave 495 as a cream foam (439 mg, 87%). LCMS (Method I): R _T = 2.50 min, M + H ⁺ = 546. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.76 (m, 1H); 7.27 (m, 2H); 4.35 (m, 4H); 4.03 (d , J = 11.3 Hz, 2H); 3.87 (m, 7H); 3.78 (s, 2H); 3.42-3.29 (m, 4H); 2.64 (m, 8H); 1.79 (m, 3H); 1.62 (m, 2H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 496 4- (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -2-((4- (oxetan-3-yl) piperidin-1-yl) methyl) thiazole [5 , 4-d] pyrimidin-7-yl) morpholine 496
5-Chloro-7-morpholin-4-yl-2- (4-oxetane-3-ylpiperidin-1-ylmethyl) thiazole [5,4-d] pyrimidine (200 mg, 1,4-dioxane (3 mL) 0.49 mmol), 2-ethyl-1H-benzimidazole (79 mg, 0.54 mmol), Pd ₂ dba ₃ (12 mg, 0.013 mmol), Xphos (24 mg, 0.050 mmol) and cesium carbonate (240 mg, 0.74 mmol) ) Was purged with argon and subjected to microwave irradiation at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 99: 1 to 98: 2) to give 496 as a white solid (121 mg, 48%). LCMS (Method I): R _T = 2.65 min, M + H ⁺ = 520. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H); 7.77 (m, 1H); 7.30 (m, 2H); 4.78 (dd, J = 7.8, 6. 4.47 (t, J = 6.1 Hz, 2H); 4.41 (m, 4H); 3.88 (m, 6H); 3.36 (q, J = 7.5 Hz, 1 Hz, 2H); 2H); 3.05 (m, 2H); 2.84-2.76 (m, 1H); 2.30 (m, 2H); 1.80-1.61 (m, 4H); 1.44 (T, J = 7.5 Hz, 3H) and 1.28 (m, 1H)

Example 497 4- (5- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -2-((4- (oxetan-3-yl) piperidin-1-yl) methyl) thiazole [ 5,4-d] pyrimidin-7-yl) morpholine 497
5-Chloro-7-morpholin-4-yl-2- (4-oxetane-3-ylpiperidin-1-ylmethyl) thiazole [5,4-d] pyrimidine (200 mg, 1,4-dioxane (3 mL) 0.49 mmol), 2-cyclopropyl-1H-benzimidazole (93 mg, 0.59 mmol), Pd ₂ dba ₃ (12 mg, 0.013 mmol), Xphos (24 mg, 0.050 mmol) and cesium carbonate (240 mg, 0. 74 mmol) was purged with argon and subjected to microwave irradiation at 145 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) and washed with MeOH / DCM before eluting the desired product with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 99: 1) to give 497 as a salmon solid (118 mg, 45%). LCMS (Method I): R _T = 2.83 min, M + H ⁺ = 532. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.92 (m, 1H); 7.68 (m, 1H); 7.27 (m, 2H); 4.78 (dd, J = 7.9, 6. 4.52-4.39 (m, 6H); 3.87 (m, 6H); 3.04 (m, 2H); 2.92-2.76 (m, 2H); 2 .29 (m, 2H); 1.79-1.61 (m, 4H); 1.43-1.18 (m, 3H) and 1.11-1.05 (m, 2H)

Example 498 N-methyl-1- (7-morpholino-2-((3- (tetrahydro-2H-pyran-4-yl) azetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidine-5 -Yl) -1H-benzo [d] imidazol-2-amine 498
5-Chloro-7-morpholin-4-yl-2- [3- (tetrahydropyran-4-yl) azetidin-1-ylmethyl] thiazole [5,4-d] pyrimidine (90 mg) in dioxane (2.5 mL) , 0.22 mmol), (1H-benzimidazol-2-yl) methylamine (39 mg, 0.26 mmol), tris (dibenzylideneacetone) dipalladium (10 mg, 0.01 mmol), Xphos (21 mg, 0.04 mmol) And a mixture of Cs ₂ CO ₃ (143 mg, 0.44 mmol) were purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated under vacuum and purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%). The resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH. 498 was obtained as an orange solid (60 mg, 52%). LCMS (Method I): R _T 2.43 min, [M + H] ⁺ 521.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.37 (d, J = 5.0 Hz, 1H); 8.19 (d, J = 8.0 Hz, 1H); 7.48 (d, J = 7. 7.19 (t, J = 7.8 Hz, 1H); 7.06 (t, J = 8.0 Hz, 1H); 4.41 (m, 4H); 4.02-3. 88 (m, 8H); 3.58 (m, 2H); 3.38 (m, 2H); 3.25 (d, J = 5.0 Hz, 3H); 3.09 (m, 2H); 2 .40-2.29 (m, 1H); 1.71 (m, 1H); 1.56 (m, 2H) and 1.30-1.17 (m, 2H)

Example 499 4- (2- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((3- (tetrahydro-2H-pyran-4-yl) azetidine- 1-yl) methyl) -9H-purin-6-yl) morpholine 499
2- (2-Cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.25 mmol) in DCE (5 mL), 3 A mixture of-(tetrahydropyran-4-yl) azetidine (37 mg, 0.26 mmol) and 4Å powdered molecular sieve (250 mg) was stirred at room temperature for 5 hours, and sodium triacetoxyborohydride (233 mg, 0.92 mmol) was added. added. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%). The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH to give 499 as an orange solid (76 mg 57%). LCMS (Method I): R _T 2.72 min [M + H] ⁺ 529.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.93 (d, J = 7.6 Hz, 1H); 7.67 (d, J = 7.4 Hz, 1H); 7.27-7.18 (m, 2H); 4.36 (m, 4H); 4.00-3.93 (m, 2H); 3.88-3.83 (m, 9H); 3.55 (m, 2H); 3.37 (M, 2H); 3.06 (m, 2H); 2.89-2.81 (m, 1H); 2.34 (m, 1H); 1.71 (m, 1H); 1.54 ( m, 2H); 1.38-1.32 (m, 2H); 1.22 (m, 2H) and 1.06 (m, 2H)

Example 500 2- (4-((2- (2-Cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine -1-yl) -2-methylpropanoic acid ethyl ester 500
According to General Procedure I for Buchwald coupling, 2-cyclopropylbenzimidazole and 2- (4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine-1- Yl) -2-methylpropanoic acid ethyl was reacted to give 500. LCMS m / z: 588.4 (MH +)

Example 501 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((1- (tetrahydro-2H- (1,1-dioxo) -thiopyran) -4-yl) azetidin-3-yl) methyl) -9H-purin-6-yl) morpholine 501
According to general procedure L, 1,1-dioxo-tetrahydrothiopyran-4-one was converted to 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazole-1- Yl) -9-methyl-9H-purin-6-yl) morpholine reductive amination gave 501. LCMS m / z: 565.3 (MH +)

Example 502 2-Methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperazin-1-yl) ethyl propanoate 502
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperazin-1-ylmethyl) -9H-purin-6-yl ) Alkylation of morpholine with ethyl 2-bromo-2-methyl-propionate gave 502. LCMS m / z: 281.7 (2M + H +)

Example 503 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((1- (tetrahydro-2H-pyran-4-yl) azetidine-3 -Yl) methyl) -9H-purin-6-yl) morpholine 503
According to general procedure L, 2H-pyran-4 (3H) -one was converted to 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl)- Reductive amination with 9-methyl-9H-purin-6-yl) morpholine gave 503. 517.3 (MH +)

Example 505 4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine-1-carvone 505 was prepared according to the procedure for tert-butyl acid 520. LCMS m / z: 547.3 (MH +)

Example 506 2-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperazin-1-yl) propanoic acid 506
2-Methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl)-in 2M LiOH (5.0 mL) and THF (8 mL) A mixture of 6-morpholino-9H-purin-8-yl) methyl) piperazin-1-yl) ethyl propanoate 507 (0.14 g, 0.25 mmol) was stirred at reflux for 18 hours. The reaction was then cooled to room temperature and concentrated to 1/3 of the original volume. The residue was loaded onto an SCX-2 column. The column was first washed with MeOH. The product was then eluted with 2M NH ₃ in MeOH and then concentrated. The residue was purified by RP-HPLC to give 506. LCMS m / z: 534.3 (MH +)

Example 507 2-Methyl-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) methyl propanoate 507
According to general procedure C, 2-bromo-2-methyl-propionic acid methyl ester and 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidine) -4-ylmethyl) -9H-purin-6-yl) morpholine was reacted to give 507. LCMS m / z: 274.2 (2M + H)

Example 508 2-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) propanamide 508
According to general procedure C, 2-bromo-2-methyl-propionamide and 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidine-4) -Illmethyl) -9H-purin-6-yl) morpholine was reacted to give 508. LCMS m / z: 532.2 (MH +)

Example 509 2-Methyl-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) propan-1-ol 509
Methyl 2-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine- in THF (10 mL) A solution of 8-yl) methyl) piperidin-1-yl) methyl propanoate 507 (0.10 g, 0.183 mmol) was charged with 1.0 M lithium aluminum hydride in THF (0.18 mL, 0.18 mmol). Added at ° C. The reaction was stirred at 0 ° C. for 1 hour. The reaction was quenched by adding 2 mL of saturated NH ₄ Cl solution. The cloudy mixture was loaded onto an Isolute® SCX-2 column. The column was first washed with MeOH and 2M NH ₃ in MeOH was added to elute the product. The crude product was then concentrated and purified by RP-HPLC to give 509. LCMS m / z: 519.3 (MH +)

Example 510 4- (8-((4-tert-Butylpiperazin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) isoquinolin-1-amine 510
According to the general procedure A for Suzuki coupling, 4- (8-((4-tert-butylpiperazin-1-yl) methyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine and 4 -(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoquinolin-1-amine was reacted to give 510. LCMS: M + H ^< + ^> = 519.3

Example 511 8- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -3- Oxa-8-azabicyclo [3.2.1] octane 511
2-Chloro-9-methyl-6-morpholin-4-yl-8- [2- (3-oxa-8-aza-bicyclo [3.2.1] octa-8- in dioxane (2.0 mL) Yl) ethyl] -9H-purine (75 mg, 0.19 mmol), 2-ethylbenzimidazole (31 mg, 0.21 mmol), Pd ₂ (dba) ₃ (4.4 mg, 2.5 mol%), Xphos (9. A mixture of 1 mg, 10 mol%) and Cs ₂ CO ₃ (93 mg, 0.29 mmol) was purged with argon and heated at 120 ° C. for 18 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH, then the desired product was purified with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of 30 to 90% acetonitrile) to give 511 (50 mg, 52%) as an off-white solid. LCMS: (Method I): R _T 2.49 min; [M + H] ⁺ 503.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.02-7.97 (m, 1H), 7.77-7.73 (m, 1H), 7.29-7.22 (m, 2H) 4.52-4.20 (m, 4H), 3.86 (t, J = 4.7 Hz, 4H), 3.82 (s, 3H), 3.79-3.65 (m, 2H) 3.58-3.50 (m, 2H), 3.35 (q, J = 7.5 Hz, 2H), 3.18-3.09 (m, 2H), 3.09-2.99 ( m, 2H), 2.90-2.76 (m, 2H), 2.07-1.88 (m, 4H), 1.44 (t, J = 7.5 Hz, 3H)

Example 512 2- (1- (9-Methyl-6-morpholino-8-((4- (oxetane-3-yl) piperidin-1-yl) methyl) -9H-purin-2-yl) -1H- Benzo [d] imidazol-2-yl) ethanol 512
2- [2- (2-Hydroxyethyl) benzimidazol-1-yl] -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (200 mg, 0.2 mg) in DCE (5 mL). 49 mmol), a solution of 4-oxetane-3-ylpiperidine (83 mg, 0.59 mmol) and molecular sieves (4 kg, powder, 1 g) was stirred at ambient temperature for 5 hours. Sodium triacetoxyborohydride (156 mg, 0.74 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 99: 1 to 98: 2 to 97: 3 to 95: 5) to give 512 as a white solid. (51 mg, 20%). LCMS (Method I): R _T = 2.39 min, M + H ⁺ = 533. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.04 (m, 1H); 7.75 (m, 1H); 7.33 (m, 2H); 4.76 (dd, J = 7.8, 6. 4.45 (t, J = 6.0 Hz, 2H); 4.35 (m, 4H); 4.19 (t, J = 5.5 Hz, 2H); 3.94-3. 80 (m, 9H); 3.54 (t, J = 5.5 Hz, 2H); 3.02 (m, 2H); 2.81-2.72 (m, 1H); 2.29 (m, 2H); 1.71 (m, 5H) and 1.28 (m, 1H)

Example 513 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (oxetane-3-yl) piperazin-1-yl) methyl ) -9H-purin-6-yl) morpholine 513
TFA (2 mL) is added to a solution of 4-oxetane-3-ylpiperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.62 mmol) in DCM (10 mL) and the mixture is stirred at ambient temperature; Then, it was filled into an Isolute (registered trademark) SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated in vacuo to give 1-oxetane-3-ylpiperazine as a colorless oil. 2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (200 mg, 0.51 mmol) in DCE (10 mL), 1- A solution of oxetane-3-ylpiperazine (88 mg, 0.62 mmol) and molecular sieves (4 kg, powder, 1 g) was stirred at ambient temperature for 5 hours. Sodium triacetoxyborohydride (162 mg, 0.76 mmol) was added and the mixture was stirred for 18 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH; 100: 0 to 99: 1 to 98: 2 to 95: 5) to give 513 as a white solid (98 mg, 37 %). LCMS (Method I): R _T = 2.43 min, M + H ⁺ = 518. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (dd, J = 6.9, 2.4 Hz, 1H); 7.78 (m, 1H); 7.33-7.23 (m, 2H); 4.70-4.60 (m, 4H); 4.35 (m, 4H); 3.97-3.75 (m, 7H); 3.79 (s, 2H); 3.57-3. 49 (m, 1H); 3.37 (q, J = 7.5 Hz, 2H); 2.66 (m, 4H); 2.42 (m, 4H); 1.46 (t, J = 7. 5Hz, 3H)

Example 514 4- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) piperazin-2-one 514
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.2 mL) in MeOH (2 mL) and DCE (5 mL). 26 mmol) 4-azetidin-3-ylpiperazin-2-one (44 mg, 0.28 mmol) and 4Å powdered molecular sieves (250 mg) were stirred at room temperature for 2 hours, and sodium triacetoxyborohydride (108 mg, 0.51 mmol) was added. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-7%) and the resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM. The product was eluted with 2M NH ₃ / MeOH to give 514 as a yellow foam (42 mg, 31%). LCMS (Method I): R _T 2.28 min [M + H] ⁺ 531.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.79-7.74 (m, 1H); 7.31-7.24 (m, 2H); 5 3.93 (bs, 1H); 4.35 (m, 4H); 3.94 (s, 2H); 3.94-3.80 (m, 7H); 3.66 (bs, 2H); 43-3.33 (m, 4H); 3.21 (s, 3H); 3.06 (s, 2H); 2.58 (t, J = 5.37 Hz, 2H) and 1.45 (t, J = 7.5Hz, 3H)

テトラヒドロフラン（８０ｍＬ）中の４-(２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（５．０ｇ）及びＮ,Ｎ,Ｎ’,Ｎ’-テトラメチルエチレンジアミン（４．４６ｍＬ）の攪拌溶液に−７８℃で２．５ＭのＴＨＦ（１７ｍＬ）中のｎ-ブチルリチウムを加えた。溶液を−７８℃で１５分間攪拌し、ついで−４０℃まで温度を上昇させ、溶液が透明な暗赤色になるまで行った（完全にリチオ化したことを指し示す）。溶液を再び−７８℃まで冷却し、１０ｍＬのＴＨＦ中の３-オキソピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（８．６４ｇ）を５分かけてゆっくり加え、１．５時間攪拌し、ついで水でクエンチした。反応混合物を酢酸エチルで希釈し、飽和塩化アンモニウム溶液で抽出した。有機層を乾燥させ、濾過し、濃縮した。残存する出発物質を熱エーテルで倍散して、粗生成物３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルをオレンジ色の油として定量的収率で得た。

３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（８０ｍｇ）をエタノール中の１．２５Ｍの塩化水素中に取り上げ、反応が完了するまで５０℃で数時間加熱した。反応混合物を濃縮乾固して、７０ｍｇの３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)ピペリジン-３-オールのＨＣｌ塩を得た。

３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)ピペリジン-３-オール（７０ｍｇ）のＨＣｌ塩をＤＭＦ（１ｍＬ）中のヨウ化イソプロピル（１．５当量）、炭酸セシウム（２当量）及びＤＩＰＥＡ（３当量）と反応させた。反応物を反応が完了するまで５０℃で数時間加熱した。反応混合物を酢酸エチルで希釈し、飽和塩化アンモニウム溶液で抽出した。有機層を乾燥させ、濾過し、濃縮して、７０ｍｇの粗３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)-１-イソプロピルピペリジン-３-オールを得、これを２-エチルベンゾイミダゾールとブッフバルトカップリングの一般的手順Ｉを介して反応させ、逆相精製と続くキラル分離後に５１５［７．６ｍｇ；ＭＳ（Ｑ１）５０５．３（Ｍ）＋］及び５１８［７．７ｍｇ；ＭＳ（Ｑ１）５０５．２（Ｍ）＋］を得た。 Example 515 (S) -3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1-isopropyl Piperidine-3-ol 515

4- (2-Chloro-9-methyl-9H-purin-6-yl) morpholine (5.0 g) and N, N, N ′, N′-tetramethylethylenediamine (4.46 mL) in tetrahydrofuran (80 mL) To a stirred solution of was added n-butyllithium in 2.5 M THF (17 mL) at −78 ° C. The solution was stirred at −78 ° C. for 15 minutes, then the temperature was raised to −40 ° C. until the solution became a clear dark red color (indicating complete lithiation). The solution was again cooled to −78 ° C. and tert-butyl 3-oxopiperidine-1-carboxylate (8.64 g) in 10 mL of THF was added slowly over 5 minutes, stirred for 1.5 hours, then with water Quenched. The reaction mixture was diluted with ethyl acetate and extracted with saturated ammonium chloride solution. The organic layer was dried, filtered and concentrated. The remaining starting material is triturated with hot ether to give the crude product 3- (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylic acid tert -Butyl was obtained in quantitative yield as an orange oil.

Tert-butyl 3- (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylate (80 mg) in 1.25 M hydrogen chloride in ethanol And heated at 50 ° C. for several hours until the reaction was complete. The reaction mixture was concentrated to dryness to give 70 mg of the HCl salt of 3- (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) piperidin-3-ol.

HCl salt of 3- (2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) piperidin-3-ol (70 mg) in isopropyl iodide (1.5 eq) in DMF (1 mL) , Reacted with cesium carbonate (2 eq) and DIPEA (3 eq). The reaction was heated at 50 ° C. for several hours until the reaction was complete. The reaction mixture was diluted with ethyl acetate and extracted with saturated ammonium chloride solution. The organic layer was dried, filtered and concentrated to give 70 mg of crude 3- (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) -1-isopropylpiperidin-3-ol. This was reacted with 2-ethylbenzimidazole via general procedure I of Buchwald coupling and after reverse phase purification followed by chiral separation 515 [7.6 mg; MS (Q1) 505.3 (M) +] and 518 [7.7 mg; MS (Q1) 505.2 (M) +] was obtained.

２-(１-クロロエチル)-１Ｈ-ベンゾ[ｄ]イミダゾール（０．３９ｇ）及び１０ｍＬのメタノール中ののナトリウムメトキシド（０．９６ｍＬ）の２５重量％溶液をマイクロ波合成機で１５０℃で２０分間加熱した。反応混合物をＥｔＯＡｃ及び飽和塩化ＮＨ_４で抽出した。有機層を乾燥させ、濾過し、濃縮して、粗２-(１-メトキシエチル)-１Ｈ-ベンゾ[ｄ]イミダゾールを定量的収率で得た。
２-(１-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（０．１５ｇ）を２-(１-メトキシエチル)-１Ｈ-ベンゾ[ｄ]イミダゾール（９７ｍｇ）とブッフバルトカップリングの一般的手順Ｉを介して反応させ、逆相精製と続くキラル分離後に３２．１ｍｇの５１６［ＭＳ（Ｑ１）５４９．４（Ｍ）＋］及び３２．４ｍｇの５１９［ＭＳ（Ｑ１）５４９．３（Ｍ）＋］を得た。 Example 516 (S) -2- (1-((2- (2- (1-methoxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine -8-yl) methyl) piperidin-4-yl) propan-2-ol 516

A 25 wt% solution of 2- (1-chloroethyl) -1H-benzo [d] imidazole (0.39 g) and sodium methoxide (0.96 mL) in 10 mL of methanol was heated at 150 ° C. at 150 ° C. Heated for minutes. The reaction mixture was extracted with EtOAc and saturated chloride NH _4. The organic layer was dried, filtered and concentrated to give crude 2- (1-methoxyethyl) -1H-benzo [d] imidazole in quantitative yield.
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.15 g) was treated with 2- (1 -Methoxyethyl) -1H-benzo [d] imidazole (97 mg) was reacted via general procedure I of Buchwald coupling and after reverse phase purification followed by chiral separation 32.1 mg 516 [MS (Q1) 549. 4 (M) +] and 32.4 mg of 519 [MS (Q1) 549.3 (M) +].

２-クロロ-１Ｈ-ベンゾ[ｄ]イミダゾール（１ｇ）をジベンジルアミン（７ｍＬ）のニート溶液に加え、Ｂｉｏｔａｇｅマイクロ波合成機で１．５時間１７０℃で加熱した。反応混合物を濃縮乾固させ、フラッシュカラムクロマトグラフィーを介して精製して０．６ｇのＮ,Ｎ-ジベンジル-１Ｈ-ベンゾ[ｄ]イミダゾール-２-アミンを得た。

２-(１-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（０．３５ｇ）をＮ,Ｎ-ジベンジル-１Ｈ-ベンゾ[ｄ]イミダゾール-２-アミンとブッフバルトカップリングの一般的手順Ｊを介して反応させ、フラッシュクロマトグラフィー後に２５５ｍｇの２-(１-((２-(２-(ジベンジルアミノ)-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オールを得た。

エタノール（５．４ｍＬ）中の２-(１-((２-(２-(ジベンジルアミノ)-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オール（１２５ｍｇ）のフラスコに１０％パラジウムカーボン（０．２ｇ）及び酢酸（８３ｕＬ）を加えた。フラスコに窒素バルーンをパージし、ついで水素バルーン下に配した。反応物を７０℃で４８時間加熱した。反応物をセライトで濾過し、セライトケーキをメタノール中の１％酢酸の混合物で数回洗浄した。溶媒を濃縮乾固させ、７０ｍｇの粗２-(１-((２-(２-アミノ-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-４-イル)プロパン-２-オールを得、その７０ｍｇをＤＭＦ（０．８ｍＬ）中のＨＡＴＵ（１０５ｍｇ）、ＤＩＰＥＡ（０．１２ｍＬ）及び酢酸（２４ｕＬ）に加えた。完了時に、反応を酢酸エチルで希釈し、水で抽出した。有機層を乾燥させ、濾過し、濃縮して粗生成物を得た。粗物質を逆相ＨＰＬＣで精製して１１．５ｍｇの５１７を白色固形物として得た。ＭＳ（Ｑ１）５４８．３（Ｍ）＋ Example 517 N- (1- (8-((4- (2-hydroxypropan-2-yl) piperidin-1-yl) methyl) -9-methyl-6-morpholino-9H-purin-2-yl) -1H-benzo [d] imidazol-2-yl) acetamide 517

2-Chloro-1H-benzo [d] imidazole (1 g) was added to a neat solution of dibenzylamine (7 mL) and heated on a Biotage microwave synthesizer for 1.5 hours at 170 ° C. The reaction mixture was concentrated to dryness and purified via flash column chromatography to give 0.6 g of N, N-dibenzyl-1H-benzo [d] imidazol-2-amine.

2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.35 g) was replaced by N, N- Reaction with dibenzyl-1H-benzo [d] imidazol-2-amine via general procedure J of Buchwald coupling and, after flash chromatography, 255 mg of 2- (1-((2- (2- (dibenzylamino ) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol.

2- (1-((2- (2- (Dibenzylamino) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine) in ethanol (5.4 mL) To a flask of -8-yl) methyl) piperidin-4-yl) propan-2-ol (125 mg) was added 10% palladium on carbon (0.2 g) and acetic acid (83 uL). The flask was purged with a nitrogen balloon and then placed under a hydrogen balloon. The reaction was heated at 70 ° C. for 48 hours. The reaction was filtered through celite and the celite cake was washed several times with a mixture of 1% acetic acid in methanol. The solvent was concentrated to dryness and 70 mg of crude 2- (1-((2- (2-amino-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) piperidin-4-yl) propan-2-ol was obtained, 70 mg of which was added to HATU (105 mg), DIPEA (0.12 mL) and acetic acid (24 uL) in DMF (0.8 mL). Upon completion, the reaction was diluted with ethyl acetate and extracted with water. The organic layer was dried, filtered and concentrated to give the crude product. The crude material was purified by reverse phase HPLC to give 11.5 mg of 517 as a white solid. MS (Q1) 548.3 (M) +

Example 518 I-3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1-isopropylpiperidine- 3-all 518
HCl salt of 3- (2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) piperidin-3-ol (70 mg) in isopropyl iodide (1.5 eq) in DMF (1 mL) , Reacted with cesium carbonate (2 eq) and DIPEA (3 eq). The reaction was heated at 50 ° C. for several hours until the reaction was complete. The reaction mixture was diluted with ethyl acetate and extracted with saturated ammonium chloride solution. The organic layer was dried, filtered and concentrated to give 70 mg of crude 3- (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) -1-isopropylpiperidin-3-ol. This was reacted with 2-ethylbenzimidazole via general procedure I of Buchwald coupling to yield 515 [7.6 mg; MS (Q1) 505.3 (M) +] after reverse phase purification and subsequent chiral separation. And 518 [7.7 mg; MS (Q1) 505.2 (M) +].

Example 519 I-2- (1-((2- (2- (1-methoxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8 -Yl) methyl) piperidin-4-yl) propan-2-ol 519
2- (1-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidin-4-yl) propan-2-ol (0.15 g) was treated with 2- (1 -Methoxyethyl) -1H-benzo [d] imidazole (97 mg) was reacted via general procedure I of Buchwald coupling and after reverse phase purification followed by chiral separation 32.1 mg 516 [MS (Q1) 549. 4 (M) +] and 32.4 mg of 519 [MS (Q1) 549.3 (M) +].

４-(８-(ブロモメチル)-２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（０．２５ｇ、０．７２ｍｍｏｌ）及びトリメチル亜リン酸エステル（４．０ｍＬ、３４ｍｍｏｌ）の混合物を１２０度で１．２５時間攪拌した。生じた懸濁液を水とジクロロメタンの間で分配させた。水性層を中和させ、ジクロロメタンで再び抽出した。有機抽出物を水で洗浄し、ＭｇＳＯ_４で乾燥させ、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−５％のメタノール）で精製し、表題化合物を得た（２０７ｍｇ、７６％）。 Example 520 4- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl) morpholine 520
Step 1: Dimethyl (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylphosphonate

Mixture of 4- (8- (bromomethyl) -2-chloro-9-methyl-9H-purin-6-yl) morpholine (0.25 g, 0.72 mmol) and trimethyl phosphite (4.0 mL, 34 mmol) Was stirred at 120 degrees for 1.25 hours. The resulting suspension was partitioned between water and dichloromethane. The aqueous layer was neutralized and extracted again with dichloromethane. The organic extract was washed with water, dried over MgSO ₄ , filtered and concentrated. The crude product was purified by flash chromatography (0-5% methanol in DCM) to give the title compound (207 mg, 76%).

ＴＨＦ（８．０ｍＬ）中のジメチル(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチルホスホネート（０．３５ｇ、０．９３ｍｍｏｌ）の冷（−７８℃）懸濁液にＴＨＦ（０．４９ｍＬ）中の２．０ＭのＬＤＡ溶液を加えた。生じた溶液を室温まで温め、ＴＨＦ（３ｍＬ）中の１-Ｂｏｃ-４-ピペリドン（０．１９ｇ、０．９５ｍｍｏｌ）の溶液を加えた。反応混合物を室温で２時間攪拌し、ブラインとＤＣＭの間で分配した。有機層を分離し、ブラインで洗浄し、ＭｇＳＯ_４で乾燥させ、濃縮した粗残留物をフラッシュクロマトグラフィー（ヘプタン中の０−７５％ＥｔＯＡｃ）で精製して、表題化合物を得た（０．３８ｇ、９１％）。ＬＣＭＳｍ／ｚ：４４９．２（ＭＨ＋）。 Step 2: 4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylene) piperidine-1-carboxylate tert-butyl

Cold (−78 ° C.) suspension of dimethyl (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylphosphonate (0.35 g, 0.93 mmol) in THF (8.0 mL) To the solution was added a 2.0 M LDA solution in THF (0.49 mL). The resulting solution was warmed to room temperature and a solution of 1-Boc-4-piperidone (0.19 g, 0.95 mmol) in THF (3 mL) was added. The reaction mixture was stirred at room temperature for 2 hours and partitioned between brine and DCM. The organic layer was separated, washed with brine, dried over MgSO ₄ and the concentrated crude residue was purified by flash chromatography (0-75% EtOAc in heptane) to give the title compound (0.38 g). 91%). LCMS m / z: 449.2 (MH +).

ＤＭＦ（３．５ｍＬ）中の４-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチレン)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（０．３７５ｇ、０．８３５ｍｍｏｌ）、２-メチルベンゾイミダゾール（０．１３２ｇ、１．０ｍｍｏｌ）、Ｘｐｈｏｓ（０．０４０ｇ、０．０８４ｍｍｏｌ）、Ｐｄ_２（ｄｂａ）_３（０．０４０ｇ、０．０４２ｍｍｏｌ）及び炭酸セシウム（０．５４ｇ、１．６７ｍｍｏｌ）をＢｉｏｔａｇｅマイクロ波で１４０℃で３０分間加熱した。反応混合物を紙で濾過し、ブラインとＥｔＯＡｃの間で分配した。混合抽出物をブラインで洗浄し、Ｎａ２ＳＯ４上で乾燥させ、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を得た（０．３９ｇ、８７％）。ＬＣＭＳｍ／ｚ：５４５．３（ＭＨ＋）。 Step 3: 4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylene) piperidine-1-carvone Tert-butyl acid

Tert-Butyl 4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylene) piperidine-1-carboxylate (0.375 g, 0.3 mL) in DMF (3.5 mL). 835 mmol), 2-methylbenzimidazole (0.132 g, 1.0 mmol), Xphos (0.040 g, 0.084 mmol), Pd ₂ (dba) ₃ (0.040 g, 0.042 mmol) and cesium carbonate (0. 54 g, 1.67 mmol) was heated in a Biotage microwave at 140 ° C. for 30 minutes. The reaction mixture was filtered through paper and partitioned between brine and EtOAc. The combined extract was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography (0-10% MeOH in DCM) to give the title compound (0.39 g, 87%). LCMS m / z: 545.3 (MH +).

エタノール（１５ｍＬ）中の４-((９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチレン)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（０．３９ｇ、０．７２９ｍｍｏｌ）及びＰｄ／Ｃ（１０重量％、０．１ｇ）の懸濁液を室温で１９時間水素雰囲気下（バルーン）で攪拌した。反応混合物をついでセライトで濾過し、濃縮した粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中の０−５％ＭｅＯＨ）で精製して、表題化合物を得た（０．３６ｇ、９０％）。ＬＣＭＳｍ／ｚ：５４７．２（ＭＨ＋） Step 4: 4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine-1-carvone Tert-butyl acid

4-(((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylene) piperidine- in ethanol (15 mL) A suspension of tert-butyl 1-carboxylate (0.39 g, 0.729 mmol) and Pd / C (10 wt%, 0.1 g) was stirred at room temperature for 19 hours under a hydrogen atmosphere (balloon). The reaction mixture was then filtered through celite and the concentrated crude product was purified by flash chromatography (0-5% MeOH in DCM) to give the title compound (0.36 g, 90%). LCMS m / z: 547.2 (MH +)

Step 5: 4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8 in 1,4-dioxane (10 mL) To a solution of -yl) methyl) piperidine-1-carboxylate (0.36 g, 0.66 mmol) was added a 4M solution of hydrogen chloride in 1,4-dioxane. The reaction mixture was then stirred at room temperature for 1 hour. The resulting suspension was then filtered. The collected solid was washed with 1,4-dioxane and dried under vacuum to give 520 (hydrochloride) as an off-white solid (0.34 g, quantitative). LCMS m / z: 484.2 (MH +)

Example 521 2-((1S, 4S) -5-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) -2,5-diazabicyclo [2.2.1] heptan-2-yl) -2-methylpropan-1-ol 521
2-[(1S, 4S) -5- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -2,5-diazabicyclo [2 in DMF (1 mL) 2.2.1] Hept-2-yl] -2-methylpropan-1-ol (50 mg, 0.12 mmol), 2-ethyl-1H-benzimidazole (20 mg, 0.14 mmol), Pd ₂ dba ₃ (3 mg , 0.003 mmol), Xphos (6 mg, 0.012 mmol) and cesium carbonate (56 mg, 0.17 mmol) were purged with argon and subjected to microwave irradiation at 150 ° C. for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM and the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 95: 5 to 90:10 to 80:20) to give 521 as a tan solid (27 mg, 44 %). LCMS (Method I): R _T = 2.50 min, M + H ⁺ = 546. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.75 (m, 1H); 7.28 (m, 2H); 4.34 (m, 4H); 4.02 (m , 2H); 3.93-3.79 (m, 7H); 3.49 (m, 2H); 3.45-3.27 (m, 3H); 2.89 (m, 2H); 85 (s, 2H); 1.64 (m, 3H); 1.48-1.42 (m, 3H) and 1.33-1.08 (m, 6H)

Example 522 4- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -6- Isopropylpiperazine-2-one 522
4- [2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] -6-isopropylpiperazin-2-one in dioxane (2.0 mL) ( 90 mg, 0.21 mmol), 2-ethylbenzimidazole (35 mg, 0.24 mmol), Pd ₂ (dba) ₃ (4.9 mg, 2.5 mol%), Xphos (10.2 mg, 10 mol%) and Cs ₂ CO ₃ (104 mg, 0.32 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 19 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a 20-90% gradient of acetonitrile) to give 522 (50 mg, 44%) as a light beige solid. LCMS: (Method I): R _T 2.90 min; [M + H] ⁺ 532.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.84-7.78 (m, 1H), 7.32-7.28 (m, 2H) , 5.82 (s, 1H), 4.62-4.07 (m, 4H), 3.86 (t, J = 4.7 Hz, 4H), 3.78 (s, 3H), 3.47. -3.23 (m, 4H), 3.08-2.99 (m, 4H), 3.01-2.93 (m, 2H), 2.40 (dd, J = 11.7, 8.. 9 Hz, 1H), 1.79-1.67 (m, 1H), 1.47 (t, J = 7.5 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0. 95 (d, J = 6.88 Hz, 3H)

Example 524 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidin-3-ol 524
Reaction of 2-ethylbenzimidazole and 1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidin-3-ol according to general procedure I of Buchwald coupling 524 was obtained. LCMS m / z: 449.2 (MH +)

Example 525 2-methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) propanoic acid 525
2-Methyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) piperidin-1-yl) methyl ester of methyl propanoate 507 was hydrolyzed with lithium hydroxide to give 525. LCMS m / z: 267.2 (2M + H +)

テトラヒドロフラン（３８ｍＬ、４６０ｍｍｏｌ）中の４-(２-クロロ-９-メチル-９Ｈ-プリン-６-イル)モルホリン（７５０ｍｇ、３．０ｍｍｏｌ）及びＮ,Ｎ,Ｎ’,Ｎ’-テトラメチルエチレンジアミン（０．９８１６ｍＬ、６．５０４ｍｍｏｌ）の溶液にヘキサン（４．０６５ｍＬ）中の１．６Ｍのｎ-ブチルリチウムを−７８℃で加えた。生じたオレンジ色の濁った混合物を−７８℃で４５分間攪拌し、−４０℃で５分間攪拌した。２ｍＬのＴＨＦ中の４-ホルミルピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（１．２６１ｇ、５．９１３ｍｍｏｌ）をついで加えた。生じた黄色の混合物を−７８℃で１時間攪拌した。反応物をついで室温で２０分間攪拌した。反応物をついで飽和ＮＨ_４Ｃｌに注ぎ込んだ。生成物をＥｔＯＡｃで抽出した。組み合わせた抽出物をブラインで洗浄し、Ｎａ２ＳＯ４で乾燥させ、濾過し、濃縮した。粗生成物をＦＣＣ（ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を白色の泡として得た。ＬＣＭＳｍ／ｚ４６７．３（ＭＨ＋）。 Example 526 2- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl ) Piperidin-1-yl) -2-methylpropanoic acid I-methyl 526
Step 1: 4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl) piperidine-1-carboxylate tert-butyl

4- (2-Chloro-9-methyl-9H-purin-6-yl) morpholine (750 mg, 3.0 mmol) and N, N, N ′, N′-tetramethylethylenediamine in tetrahydrofuran (38 mL, 460 mmol) ( To a solution of 0.9816 mL, 6.504 mmol) was added 1.6 M n-butyllithium in hexane (4.065 mL) at −78 ° C. The resulting orange cloudy mixture was stirred at -78 ° C for 45 minutes and then at -40 ° C for 5 minutes. Tert-Butyl 4-formylpiperidine-1-carboxylate (1.261 g, 5.913 mmol) in 2 mL of THF was then added. The resulting yellow mixture was stirred at −78 ° C. for 1 hour. The reaction was then stirred at room temperature for 20 minutes. The reaction was then poured into saturated NH ₄ Cl. The product was extracted with EtOAc. The combined extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by FCC (0-10% MeOH in DCM) to give the title compound as a white foam. LCMS m / z 467.3 (MH +).

ＤＭＦ（４．０ｍＬ）中の４-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)(ヒドロキシ)メチル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（０．３７５ｇ、０．８０３ｍｍｏｌ）、２-エチルベンゾイミダゾール(０.１８２ｇ、１.２３ｍｍｏｌ)、Ｘｐｈｏｓ(０.０４０ｇ、０.０８４ｍｍｏｌ)、Ｐｄ_２(ｄｂａ)_３（０．０４０ｇ、０．０４２ｍｍｏｌ）及び炭酸セシウム（０．５２ｇ、１．６７ｍｍｏｌ）の混合物をＢｉｏｔａｇｅマイクロ波で１４０℃で３０分間加熱した。反応混合物を紙で濾過し、ついでブラインとＥｔＯＡｃの間で分配した。混合抽出物をブラインで洗浄し、Ｎａ２ＳＯ４で乾燥させ、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−５％のＭｅＯＨ）で精製して、表題化合物を得た（０．３２ｇ、６９％）。ＬＣＭＳｍ／ｚ：５７７．２（ＭＨ＋）。 Step 2: 4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl) piperidine- Tert-Butyl 1-carboxylate

Tert-Butyl 4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl) piperidine-1-carboxylate (0.375 g) in DMF (4.0 mL) 0.803 mmol), 2-ethylbenzimidazole (0.182 g, 1.23 mmol), Xphos (0.040 g, 0.084 mmol), Pd ₂ (dba) ₃ (0.040 g, 0.042 mmol) and cesium carbonate. A mixture of (0.52 g, 1.67 mmol) was heated in a Biotage microwave at 140 ° C. for 30 minutes. The reaction mixture was filtered through paper and then partitioned between brine and EtOAc. The combined extract was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography (0-5% MeOH in DCM) to give the title compound (0.32 g, 69%). LCMS m / z: 577.2 (MH +).

塩化メチレン（１０ｍＬ、２００ｍｍｏｌ；）中の４-((２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)(ヒドロキシ)メチル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（０．３２０ｇ、０．５５５ｍｍｏｌ）の溶液にトリフルオロ酢酸（０．５０ｍＬ、６．５ｍｍｏｌ；）を加えた。反応物を室温で１時間攪拌し、反応混合物を蒸発乾固させた。残留物をＭｅＯＨ中の２ＭのＮＨ_３に加えて残存する酸を中和させた。混合物をついで蒸発乾固させた。粗物質をフラッシュクロマトグラフィー（ＤＣＭ中０−１５％のＭｅＯＨ）で精製して、所望の生成物をピンクがかったペーストとして得た（０．２４ｇ、９１％）。ＬＣＭＳｍ／ｚ４７７．４（ＭＨ＋）。 Step 3: (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (piperidin-4-yl) methanol

4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) in methylene chloride (10 mL, 200 mmol;) To a solution of tert-butyl (hydroxy) methyl) piperidine-1-carboxylate (0.320 g, 0.555 mmol) was added trifluoroacetic acid (0.50 mL, 6.5 mmol;). The reaction was stirred at room temperature for 1 hour and the reaction mixture was evaporated to dryness. The residue was added to 2M NH ₃ in MeOH to neutralize the remaining acid. The mixture was then evaporated to dryness. The crude material was purified by flash chromatography (0-15% MeOH in DCM) to give the desired product as a pinkish paste (0.24 g, 91%). LCMS m / z 477.4 (MH +).

Step 4: 2- (4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl ) Piperidin-1-yl) -2-methylpropanoic acid I-methyl According to general procedure C, (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino -9H-purin-8-yl) (piperidin-4-yl) methanol was alkylated with 2-bromo-2-methylpropionic acid methyl ester to give the desired racemic product (0.22 g, 83% ). The enantiomers were separated by SFC to give 526. LCMS m / z: 289.2 (2M + H +)

Example 527 2- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl ) Piperidin-1-yl) -2-methylpropanoic acid (S) -methyl 527
(S) Enantiomer 527 was obtained after separation by SFC by the procedure of preparing (R) enantiomer 526. LCMS m / z: 289.2 (2M + H +)

塩化メチレン（５．０ｍＬ、７８ｍｍｏｌ）中の５２６及び５２７に対する手順からのラセミの２-(４-((２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)(ヒドロキシ)メチル)ピペリジン-１-イル)-２-メチルプロパン酸メチル（０．１１５ｇ、０．１９９ｍｍｏｌ）の溶液にデス−マーチンペルヨージナン（０．０９３０ｇ、０．２１９ｍｍｏｌ）を加えた。生じた混合物を室温で１時間攪拌した。反応混合物を紙で濾過し、全ての固形沈殿物を除去し、ついで濃縮した。残留物をＲＰ-ＨＰＬＣで精製して５２８を得た（５２ｍｇ、６４％）。ＬＣＭＳｍ／ｚ：２８８．３（２Ｍ＋Ｈ＋） Example 528 2- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-carbonyl) piperidin-1-yl ) Methyl-2-methylpropanoate 528

Racemic 2- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl from the procedure for 526 and 527 in methylene chloride (5.0 mL, 78 mmol) To a solution of methyl-6-morpholino-9H-purin-8-yl) (hydroxy) methyl) piperidin-1-yl) -2-methylpropanoate (0.115 g, 0.199 mmol) 0.0930 g, 0.219 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered through paper to remove any solid precipitate and then concentrated. The residue was purified by RP-HPLC to give 528 (52 mg, 64%). LCMS m / z: 288.3 (2M + H +)

還元的アミノ化の一般的手順Ｌに従って、４-(８-(アゼチジン-３-イルメチル)-２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-９Ｈ-プリン-６-イル)モルホリン５３０及び３-オキセタノンを反応させて５２９を得た。ＬＣＭＳｍ／ｚ：４８９．２（ＭＨ＋） Example 529 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((1- (oxetane-3-yl) azetidin-3-yl) methyl ) -9H-purin-6-yl) morpholine 529

According to the general procedure L for reductive amination, 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H- Purine-6-yl) morpholine 530 and 3-oxetanone were reacted to give 529. LCMS m / z: 489.2 (MH +)

Example 530 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 530

ＴＨＦ（２６ｍＬ）中のジメチル(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチルホスホネート（１．１ｇ、２．９ｍｍｏｌ）の冷（−７８℃）懸濁液にＴＨＦ（１．６ｍＬ）中の２．０ＭのＬＤＡ溶液を加えた。生じた溶液を室温まで温めた後、ＴＨＦ（１２ｍＬ）中の１-Ｂｏｃ-３-アゼチジノン（０．５８ｇ、３．４ｍｍｏｌ）の溶液を加えた。反応混合物を室温で２時間攪拌し、ブラインとＤＣＭの間で分配した。有機層を分離し、ブラインで洗浄し、ＭｇＳＯ_４で乾燥させ、濃縮した。粗残留物をフラッシュクロマトグラフィー（ヘプタン中０−１００％ＥｔＯＡｃ）で精製して、表題化合物を得た（１．１５ｇ、９３％）。ＬＣＭＳｍ／ｚ：４２１．３（ＭＨ＋）。 Step 1: 3-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylene) azetidine-1-carboxylate tert-butyl

To a cold (−78 ° C.) suspension of dimethyl (2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylphosphonate (1.1 g, 2.9 mmol) in THF (26 mL). A 2.0 M LDA solution in THF (1.6 mL) was added. After the resulting solution was warmed to room temperature, a solution of 1-Boc-3-azetidinone (0.58 g, 3.4 mmol) in THF (12 mL) was added. The reaction mixture was stirred at room temperature for 2 hours and partitioned between brine and DCM. The organic layer was separated, washed with brine, dried over MgSO ₄ and concentrated. The crude residue was purified by flash chromatography (0-100% EtOAc in heptane) to give the title compound (1.15 g, 93%). LCMS m / z: 421.3 (MH +).

ＤＭＦ（４．０ｍＬ）中の３-((２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)メチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチル（０．８８ｇ、２．９ｍｍｏｌ）、２-エチルベンゾイミダゾール（０．４０ｇ、２．７４ｍｍｏｌ）、Ｘｐｈｏｓ（０．１０ｇ、０．２１ｍｍｏｌ）、Ｐｄ_２（ｄｂａ）_３（０．１０ｇ、０．１１ｍｍｏｌ）及び炭酸セシウム（１．４ｇ、４．２ｍｍｏｌ）の混合物をＢｉｏｔａｇｅマイクロ波で１４０℃で３０分間加熱した。反応混合物を紙で濾過し、ブライン及びＥｔＯＡｃで分配した。混合抽出物をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−１０％のＭｅＯＨ）で精製して、表題化合物を得た（１．２ｇ、定量的）。ＬＣＭＳｍ／ｚ：５３１．２（ＭＨ＋）。 Step 2: 3-((9-Methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylene) azetidine-1-carvone Tert-butyl acid

Tert-butyl 3-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl) methylene) azetidine-1-carboxylate (0.88 g, 2. mL) in DMF (4.0 mL). 9 mmol), 2-ethylbenzimidazole (0.40 g, 2.74 mmol), Xphos (0.10 g, 0.21 mmol), Pd ₂ (dba) ₃ (0.10 g, 0.11 mmol) and cesium carbonate (1. 4 g, 4.2 mmol) was heated in a Biotage microwave at 140 ° C. for 30 minutes. The reaction mixture was filtered through paper and partitioned between brine and EtOAc. The combined extract was washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated. The crude product was purified by flash chromatography (0-10% MeOH in DCM) to give the title compound (1.2 g, quantitative). LCMS m / z: 531.2 (MH +).

エタノール（２５ｍＬ）中の３-((９-メチル-２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチレン)アゼチジン-１-カルボン酸ｔｅｒｔ-ブチル（１．１ｇ、２．１ｍｍｏｌ）及びＰｄ／Ｃ（１０重量％、０．４ｇ）の懸濁液を攪拌して、水素雰囲気下（バルーン）、室温で２４時間攪拌した。反応混合物をセライトで濾過し、濃縮した粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−５％のＭｅＯＨ）で精製して、表題化合物を得た（０．６４ｇ、５８％）。ＬＣＭＳｍ／ｚ：５４７．２（ＭＨ＋） Step 3: 3-((9-Methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine-1-carvone Tert-butyl acid

3-((9-Methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methylene) azetidine- in ethanol (25 mL) Stir a suspension of tert-butyl 1-carboxylate (1.1 g, 2.1 mmol) and Pd / C (10 wt%, 0.4 g) under hydrogen atmosphere (balloon) at room temperature for 24 hours. did. The reaction mixture was filtered through celite and the concentrated crude product was purified by flash chromatography (0-5% MeOH in DCM) to give the title compound (0.64 g, 58%). LCMS m / z: 547.2 (MH +)

Step 4: 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl) morpholine 530
3-((9-Methyl-2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine- in DCM (10 mL) To a solution of tert-butyl 1-carboxylate (0.64 g, 1.2 mmol) was added trifluoroacetic acid (1.0 mL, 13 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then evaporated to dryness. The residue was then redissolved in MeOH and neutralized by the addition of 2M NH3 in MeOH. The solution was concentrated and purified by flash chromatography using a KP-NH ₂ column (0-10% MeOH in DCM) to give 530. LCMS m / z: 433.2 (MH +)

Example 531 2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-methylpropanamide 531
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Morpholine 530 was alkylated with 2-bromo-2-methyl-propionamide to give 531. LCMS m / z: 259.7 (2M + H +)

Example 532 2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-methylpropanoic acid methyl 532
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Morpholine 530 was alkylated with 2-bromo-2-methyl-propionic acid methyl ester to give 532. LCMS m / z: 267.2 (2M + H +)

Example 533 2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-methylpropan-1-ol 533
According to the procedure of 509, methyl 2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl ) Azetidin-1-yl) -2-methylpropanoate was reacted with lithium aluminum hydride to give 533. LCMS m / z: 253.2 (2M + H +)

Example 534 1- (3-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-methylpropan-2-ol 534
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Morpholine and isobutylene oxide were reacted at room temperature to give 534. LCMS m / z: 253.2 (2M + H +)

Example 535 4- (2- (2- (2-ethyl-1-H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -3, 3-Dimethylmorpholine 535
2-Chloro-8- [2- (3,3-dimethylmorpholin-4-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine (44 mg, in dioxane (1.5 mL) 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.12 mmol), Pd ₂ (dba) ₃ (5.2 mg, 5 mol%), Xphos (5.3 mg, 10 mol%) and Cs ₂ CO ₃ (54 mg, 0.17 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 24 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 30-90%) to give 535 (33 mg, 59%) as a pale beige solid. LCMS: (Method I): R _T 2.52 min; [M + H] ⁺ 505.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.02-7.97 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.22 (m, 2H) 4.52-4.14 (m, 4H), 3.86 (t, J = 4.8 Hz, 4H), 3.80 (s, 3H), 3.79-3.67 (m, 2H) 3.35 (q, J = 7.5 Hz, 2H), 3.34-3.23 (m, 2H), 3.05-2.92 (m, 2H), 2.92-2.80 ( m, 2H), 2.77-2.54 (m, 2H), 1.44 (t, J = 7.5 Hz, 3H), 0.99 (s, 6H)

Example 536 (S) -1- (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) azetidin-3-yl) pyrrolidin-3-ol 536
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (6 mL), (S ) -1-azetidin-3-ylpyrrolidin-3-ol (41 mg, 0.28 mmol) and 4Å powdered molecular sieves (200 mg) were stirred at room temperature for 2 hours, and sodium triacetoxyborohydride (108 mg, 0 mg) was stirred. .51 mmol) was added. The reaction mixture was stirred for 65 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-15%) to give 536 as a yellow foam (71 mg, 53%). LCMS (Method I): R _T 2.31 min [M + H] ⁺ 518.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.29-7.22 (m, 2H); 4 .53 (bs, 1H); 4.35 (m, 4H); 3.96 (s, 2H); 3.90-3.82 (m, 7H); 3.67 (bs, 2H); 55 (m, 3H); 3.34 (q, J = 7.5 Hz, 2H); 3.17 (m, 1H); 2.99 (m, 1H); 2.30 (m, 2H); 2 .02 (m, 2H) and 1.44 (t, J = 7.5 Hz, 3H)

Example 537 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8- (2- (3- (1,1-dioxo-thiomorpholino) azetidine- 1-yl) ethyl) -9H-purin-6-yl) morpholine 537
2-Chloro-8- {2- [3- (1,1-dioxo-1-thiomorpholin-4-yl) azetidin-1-yl] -ethyl} -9-methyl- in dioxane (2.0 mL) 6-morpholin-4-yl-9H-purine (93 mg, 0.20 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol), Pd ₂ (dba) ₃ (4.5 mg, 2.5 mol%), Xphos A mixture of (9.4 mg, 10 mol%) and Cs ₂ CO ₃ (97 mg, 0.30 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 20 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 20-90%) to give 537 (79 mg, 69%) as a beige solid. LCMS: (Method I): R _T 2.42 min; [M + H] ⁺ 580.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.22 (m, 2H) 4.57-4.09 (m, 4H), 3.86 (t, J = 4.8 Hz, 4H), 3.77 (s, 3H), 3.71-3.57 (m, 2H) 3.34 (q, J = 7.5 Hz, 2H), 3.33-3.22 (m, 1H), 3.07 (m, 8H), 3.00-2.89 (m, 2H) 2.85 (t, J = 4.8 Hz, 4H), 1.44 (t, J = 7.5 Hz, 3H)

Example 538 I-1- (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Azetidin-3-yl) pyrrolidin-3-ol 538
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (6 mL), (R ) -1-azetidin-3-ylpyrrolidin-3-ol (41 mg, 0.28 mmol) and 4Å powdered molecular sieves (200 mg) were stirred at room temperature for 2 hours, and sodium triacetoxyborohydride (108 mg, 0 mg) was stirred. .51 mmol) was added. The reaction mixture was stirred for 65 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-15%) to give 538 as a yellow foam (49 mg, 36%). LCMS (Method I): R _T 2.31 min [M + H] ⁺ 518.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.76-7.71 (m, 1H); 7.30-7.23 (m, 2H); 4 .60 (bs, 1H); 4.35 (m, 4H); 4.00 (s, 2H); 3.89-3.81 (m, 7H); 3.72 (m, 4H); 34 (m, 3H); 3.17 (m, 3H); 2.39-2.29 (m, 2H); 2.16-2.07 (m, 2H) and 1.44 (t, J = 7.5Hz, 3H)

Example 539 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8- (2- (1,1-dioxo-thiomorpholino) ethyl) -9H- Purin-6-yl) morpholine 539
To a solution of (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) acetaldehyde (120 mg, 0.24 mmol) in DCE (15 mL) is thiomorpholine, 1-1-dioxide. (100 mg, 0.74 mmol), powdered 4Å molecular sieves and sodium triacetoxyborohydride (314 mg, 1.48 mmol) were added. The reaction mixture was stirred for 6 hours at room temperature and the reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was triturated with EtOAc, filtered and the mother liquor was evaporated to give a yellow oil (97 mg). This crude material in dioxane (2 mL), 2-ethylbenzimidazole (38 mg, 0.26 mmol), Pd ₂ (dba) ₃ (5.4 mg), Xphos (11.1 mg) and Cs ₂ CO ₃ (114 mg, 0 .35 mmol) was purged with argon gas and then heated at 120 ° C. for 20 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 30-90%) to give 539 (11 mg, 5% over 2 steps) as a pale orange solid. It was. LCMS: (Method I): R _T 2.94 min; [M + H] ⁺ 525.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.02-7.97 (m, 1H), 7.79 (d, J = 7.17 Hz, 1H), 7.32-7.26 (m, 2H), 4.47-4.19 (m, 4H), 3.89-3.83 (m, 4H), 3.78 (s, 3H), 3.38 (q, J = 7.5 Hz, 2H), 3.18-3.12 (m, 5H), 3.12-3.01 (m, 7H), 1.46 (t, J = 7.5 Hz, 3H)

Example 540 4- (8- (2- (4,4-difluoropiperidin-1-yl) ethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl- 9H-purin-6-yl) morpholine 540
2-Chloro-8- [2- (4,4-difluoropiperidin-1-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H-purine (30 mg, in dioxane (1.0 mL) 0.08 mmol), 2-ethylbenzimidazole (12 mg, 0.08 mmol), Pd ₂ (dba) ₃ (1.7 mg, 2.5 mol%), Xphos (3.6 mg, 10 mol%) and Cs ₂ CO ₃ ( 37 mg, 0.11 mmol) was purged with argon and heated in a sealed tube at 120 ° C. for 20 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 30-90%) to give 540 (25 mg, 64%) as a beige solid. LCMS: (Method I): R _T 2.61 min; [M + H] ⁺ 511.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.96 (m, 1H), 7.78-7.74 (m, 1H), 7.29-7.23 (m, 2H) 4.68-4.02 (m, 4H), 3.86 (t, J = 4.8 Hz, 4H), 3.78 (s, 3H), 3.35 (q, J = 7.5 Hz, 2H), 3.12-2.99 (m, 4H), 2.81-2.65 (m, 4H), 2.15-1.99 (m, 4H), 1.44 (t, J = 7.5Hz, 3H)

Example 541 2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) acetamide 541
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Morpholine and 2-bromoacetamide were reacted at room temperature to give 541. LCMS m / z: 490.3 (MH +)

Example 542 2-Methyl-1- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) propan-2-ol 542
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Reaction of morpholine and isobutylene oxide gave 542. LCMS m / z: 519.3 (MH +)

Example 543 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((1- (2- (methylsulfonyl) ethyl) azetidin-3-yl) ) Methyl) -9H-purin-6-yl) morpholine 543
According to general procedure C, 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl ) Reaction of morpholine and methyl vinyl sulfone gave 543. LCMS m / z: 525.3 (MH +)

Example 544 4- (9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((1- (2- (methylsulfonyl) ethyl) piperidin-4-yl) ) Methyl) -9H-purin-6-yl) morpholine 544
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Reaction of morpholine and methyl vinyl sulfone 544. LCMS m / z: 553.3 (MH +)

Example 545 I-2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) Azetidin-1-yl) propanamide 545
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Reacting morpholine and 2-bromopropionamide gave a racemic mixture. The enantiomers were separated by SFC to give 545. LCMS m / z: 252.7 (2M + H +)

Example 546 (S) -2- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) propanamide 546
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl ) Reacting morpholine and 2-bromopropionamide gave a racemic mixture. The enantiomers were separated by SFC to give 546. LCMS m / z: 252.7 (2M + H +)

Example 547 4- (1-((2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) morpholine 547
2-Chloro-9-methyl-6-morpholin-4-yl-8- (3-morpholin-4-yl-azetidin-1-ylmethyl) -9H-purine (83 mg, 0.20 mmol) in dioxane (2 mL) 2-Isopropylbenzimidazole (39 mg, 0.24 mmol), tris (dibenzylideneacetone) dipalladium (9 mg, 0.01 mmol), Xphos (19 mg, 0.04 mmol) and Cs ₂ CO ₃ (133 mg, 0.41 mmol) The mixture was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (Si-PCC, MeOH: DCM, 0-15%) to give 547 as a beige foam (72 mg, 68%). LCMS (Method I): R _T 2.50 min, [M + H] ⁺ 532.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.89-7.84 (m, 1H); 7.80-7.75 (m, 1H); 7.29-7.21 (m, 2H); 4 .34 (m, 4H); 4.00-3.92 (m, 3H); 3.88-3.81 (m, 7H); 3.76 (m, 4H); 3.64 (m, 2H) 3.24 (m, 2H); 3.13 (m, 1H); 2.40 (m, 4H); 1.47 (s, 3H) and 1.46 (s, 3H)

Example 548 4- (1-((2- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine -3-yl) morpholine 548
2-Chloro-9-methyl-6-morpholin-4-yl-8- (3-morpholin-4-yl-azetidin-1-ylmethyl) -9H-purine (83 mg, 0.20 mmol) in dioxane (2 mL) 2-cyclopropylbenzimidazole (39 mg, 0.24 mmol), tris (dibenzylideneacetone) dipalladium (9 mg, 0.01 mmol), Xphos (19 mg, 0.04 mmol) and Cs ₂ CO ₃ (133 mg, 0.41 mmol) ) Was purged with argon and then heated in a microwave reactor at 145 ° C. for 30 minutes. The reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated under vacuum and purified by column chromatography (Si-PCC, MeOH: DCM, 0-20%) to give 548 as a beige foam (92 mg, 87%). LCMS (Method I): R _T 2.52 min, [M + H] ⁺ 530.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.95-7.91 (m, 1H); 7.69-7.65 (m, 1H); 7.27-7.18 (m, 2H); 4 3.36 (m, 4H); 3.93 (s, 2H); 3.89-3.83 (m, 7H); 3.75 (m, 4H); 3.65 (m, 2H); 24 (m, 2H); 3.13 (m, 1H); 2.89-2.81 (m, 1H); 2.39 (m, 4H); 1.37-1.32 (m, 2H) And 1.08-1.02 (m, 2H)

Example 549 2- (5- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) -1- (4- (2-Hydroxypropan-2-yl) piperidin-1-yl) ethanone 549
2- (5-Chloro-7-morpholin-4-yl-thiazolo [5,4-d] pyrimidin-2-yl) -1- [4- (1-hydroxy-1-] in dioxane (1.5 mL) (Methylethyl) piperidin-1-yl] ethanone (40 mg, 0.09 mmol), 2-ethylbenzimidazole (15 mg, 0.10 mmol), Pd ₂ (dba) ₃ (2.1 mg, 2.5 mol%), Xphos ( A mixture of 4.3 mg, 10 mol%) and Cs ₂ CO ₃ (44 mg, 0.14 mmol) was purged with argon and heated at 120 ° C. for 20 hours in a sealed tube. The reaction mixture was diluted with EtOAc, filtered through Celite® and evaporated. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in EtOAc) to give 549 as a light beige solid (19 mg, 38%). LCMS (Method I): R _T = 3.47 min, [M + H] ⁺ 550.2. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.02-7.98 (m, 1H), 7.81-7.76 (m, 1H), 7.33-7.29 (m, 2H) 4.81-4.75 (m, 1H), 4.52-4.29 (m, 4H), 4.19 (s, 2H), 4.07 (m, 1H), 3.89-3 .84 (m, 4H), 3.38 (q, J = 7.5 Hz, 2H), 3.15-3.06 (m, 1H), 2.63-2.54 (m, 1H), 1 .90-1.92 (m, 2H), 1.92-1.80 (m, 2H), 1.61-1.50 (m, 1H), 1.44 (t, J = 7.5 Hz, 3H), 1.36-1.23 (m, 1H), 1.20 (d, J = 11.0 Hz, 6H)

Example 550 1- (1-((2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) piperidin-4-ol 550
2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.150 g, 0.37 mmol) in DCE (3 mL), A mixture of 1-azetidin-3-ylpiperidin-4-ol (0.069 g, 0.44 mmol) and 4Å molecular sieve (0.37 g) was stirred for 2 hours at room temperature. Sodium triacetoxyborohydride (0.157 g, 0.74 mmol) was added and the reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) to give 550 as a white solid (0.137 g, 68%). LCMS (Method I): R _T = 2.41 min, [M + H] ⁺ 546.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.90-7.85 (m, 1H); 7.66-7.61 (m, 1H); 7.25-7.21 (m, 2H) 4.53 (d, J = 4.1 Hz, 1H); 4.28-4.23 (m, 4H); 3.96-3.86 (m, 1H); 3.86 (s, 2H); 3.85-3.68 (m, 7H); 3.48-3.43 (m, 1H); 3.42 (t, J = 6.5 Hz, 2H); 2.95 (t, J = 6.5 Hz, 2H); 2.90-2.82 (m, 1H); 2.45-2.55 (m, 2H); 1.85 (t, J = 10.6 Hz, 2H); 71-1.68 (m, 2H); 1.40-1.34 (m, 2H); 1.35 (d, J = 6.80 Hz, 6H)

Example 551 1- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) -4-methylpiperidin-4-ol 551
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.207 g, 0.53 mmol) in DCE (5 mL), A mixture of 1-azetidin-3-yl-4-methylpiperidin-4-ol (0.108 g, 0.63 mmol) and 4Å molecular sieve (0.5 g) was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.224 g, 1.06 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 30:70) to give 551 as a white solid (0.247 g, 86%). LCMS (Method I): R _T = 2.35 min, [M + H] ⁺ 546.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-7.98 (m, 1H); 7.65-7.60 (m, 1H); 7.27-7.20 (m, 2H) 4.34-3.83 (m, 4H); 3.85 (s, 2H); 3.79-3.75 (m, 7H); 3.43 (t, J = 7.4 Hz, 2H); 3.31-3.20 (q, J = 7.4 Hz, 2H); 2.96-2.93 (m, 2H); 2.92-2.83 (m, 1H); 2.27- 2.23 (m, 2H); 2.18-2.14 (m, 2H); 1.48-1.36 (m, 4H); 1.33 (t, J = 7.4 Hz, 3H); 1.12-1.06 (s, 3H)

Example 552 4- (8-((3,3-dimethylpiperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H- Purin-6-yl) morpholine 552
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (530 mg, 1.35 mmol) in DCE (30 mL), 2, A mixture of 2-dimethylpiperazine-1-carboxylic acid tert-butyl ester (350 mg, 1.63 mmol) and molecular sieves (4 kg, powder, 2.5 g) was stirred at ambient temperature for 5 hours. Sodium triacetoxyborohydride (427 mg, 2.02 mmol) was added and the mixture was stirred for 17 hours and loaded onto an Isolute® SCX-2 cartridge (25 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH; 100: 0 to 95: 5 to 90:10) to give 4- [2- (2-ethylbenzimidazol-1-yl) -9-Methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -2,2-dimethylpiperazine-1-carboxylic acid tert-butyl ester was obtained. TFA (3 mL) was added to 4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -2 in DCM (10 mL) , 2-dimethylpiperazine-1-carboxylic acid tert-butyl ester was added to the solution and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH 100: 0 to 98: 2 to 95: 5 to 90:10 to 80:20) to give 552 as a creamy solid. (144 mg, 22%). LCMS (Method I): R _T = 2.56 min, M + H ⁺ = 490. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H); 7.75 (m, 1H); 7.29 (m, 2H); 4.35 (m, 4H); 3.92-3 .83 (m, 7H); 3.70 (s, 2H); 3.36 (q, J = 7.5 Hz, 2H); 2.97 (m, 2H); 2.47 (m, 2H); 2.28 (s, 2H); 1.49-1.42 (m, 3H) and 1.19 (s, 6H)

Example 553 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-(((1S, 4S) -5- (methylsulfonyl) -2,5 -Diazabicyclo [2.2.1] heptan-2-yl) methyl) -9H-purin-6-yl) morpholine 553
2-Chloro-8-((1S, 4S) -5-methanesulfonyl-2,5-diazabicyclo [2.2.1] hept-2-ylmethyl) -9-methyl in 1,4-dioxane (3 mL) -6-morpholin-4-yl-9H-purine (150 mg, 0.34 mmol), 2-ethyl-1H-benzimidazole (59 mg, 0.40 mmol), Pd ₂ dba ₃ (9 mg, 0.009 mmol), Xphos ( A mixture of 18 mg, 0.036 mmol) and cesium carbonate (165 mg, 0.51 mmol) was purged with argon and subjected to microwave irradiation at 150 ° C. for 30 minutes. After loading the reaction mixture onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM, the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, EtOAc: MeOH 100: 0 to 99: 1 to 98: 2) to give 553 as a white solid (153 mg, 82%). LCMS (Method I): R _T = 2.53 min, M + H ⁺ = 552. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H); 7.77 (m, 1H); 7.28 (m, 2H); 4.35 (m, 5H); 4.06 (d , J = 13.6 Hz, 1H); 3.96 (d, J = 13.6 Hz, 1H); 3.87 (m, 7H); 3.65 (d, J = 9.5 Hz, 1H); 3 .61 (bs, 1H); 3.37 (q, J = 7.5 Hz, 2H); 3.27 (dd, J = 9.5, 2.3 Hz, 1H); 3.02-2.93 ( m, 2H); 2.91 (s, 3H); 1.99 (d, J = 10.2 Hz, 1H); 1.79 (d, J = 10.2 Hz, 1H) and 1.45 (t, J = 7.5Hz, 3H)

Example 554 1- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 4-yl) azetidine-3-ol 554
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.157 g, 0.40 mmol) in DCE (5 mL), A mixture of 1-piperidin-4-ylazetidin-3-ol (0.075 g, 0.48 mmol) and 4Å molecular sieve (0.4 g) was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.17 g, 0.80 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 20:80) to give 554 as a white solid (0.145 g, 68%). LCMS (Method I): R _T = 2.20 min, [M + H] ⁺ 532.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-7.98 (m, 1H); 7.65-7.60 (m, 1H); 7.27-7.20 (m, 2H) 4.27-4.19 (m, 4H); 3.80 (s, 3H); 3.77 (t, J = 4.7 Hz, 4H); 3.74 (s, 2H); 3.44 (T, J = 7.1 Hz, 2H); 3.26 (q, J = 7.4 Hz, 3H); 2.78-2.70 (m, 2H); 2.62 (t, J = 7. 2.12 (t, J = 11.0 Hz, 2H); 1.99-1.90 (m, 1H); 1.60 (d, J = 11.0 Hz, 2H); 33 (t, J = 7.4 Hz, 3H); 1.21-1.10 (m, 2H)

Example 555 1-isopropyl-4-((2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperazine -2-on 555
2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.15 g, 0.37 mmol) in DCE (3 mL), A mixture of 1-isopropylpiperazin-2-one (0.078 g, 0.44 mmol) and 4Å molecular sieves (0.372 g) was stirred for 3 hours at room temperature. Sodium triacetoxyborohydride (0.157 g, 0.74 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 10:90) to give 555 as an off-white solid (0.168 g, 84%). LCMS (Method I): R _T = 3.43 min, [M + H] ⁺ 532.3. ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 7.93-7.89 (m, 1H); 7.68-7.63 (m, 1H); 7.28-7.23 (m, 2H) 4.64-4.58 (m, 1H); 4.29-4.21 (m, 4H); 3.97-3.90 (m, 1H); 3.90 (d, J = 4. 3.80 (s, 3H); 3.78 (t, J = 4.6 Hz, 4H); 3.21-3.15 (m, 4H); 2.78-2.75 ( m, 2H); 1.36 (d, J = 6.8 Hz, 6H); 1.05 (d, J = 6.8 Hz, 6H)

Example 556 4- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) -1-methylpiperazin-2-one 556
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (162 mg, 0.41 mmol) in DCE (10 mL), 4- A mixture of azetidin-3-yl-1-methylpiperazin-2-one (77 mg, 0.46 mmol) and 4Å powdered molecular sieve (250 mg) was stirred at room temperature for 2 hours, and sodium triacetoxyborohydride (175 mg, 0 .83 mmol) was added. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine (x1) and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-30%) to give 556 as a yellow foam. (182 mg, 82%). LCMS (Method I): R _T 2.34 min [M + H] ⁺ 545.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.97 (m, 1H); 7.77-7.72 (m, 1H); 7.29-7.22 (m, 2H); 4 .35 (m, 4H); 3.89-3.84 (m, 6H); 3.83 (s, 3H); 3.59 (t, J = 5.3 Hz, 2H); 3.39-3 .31 (m, 4H); 3.18-3.10 (m, 3H); 3.05 (m, 2H); 2.96 (s, 3H); 2.59 (t, J = 5.3 Hz) , 2H) and 1.43 (t, J = 7.5 Hz, 3H)

Example 557 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8- (2- (4- (tetrahydro-2H-pyran-4-yl) piperazine) -1-yl) ethyl) -9H-purin-6-yl) morpholine 557
2-Chloro-9-methyl-6-morpholin-4-yl-8- {2- [4- (tetrahydropyran-4-yl) piperazin-1-yl] ethyl} -9H in dioxane (1.5 mL) - purine (37mg, 0.08mmol), 2- ethyl-benzimidazole _{(13mg, 0.09mmol), Pd 2} (dba) 3 (1.9mg, 2.5mol%), Xphos (3.9mg, 10mol%) and A mixture of Cs ₂ CO ₃ (37 mg, 0.11 mmol) was purged with argon gas and then heated in a sealed tube at 120 ° C. for 19 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of 30-90% acetonitrile) to give 557 (32 mg, 70%) as a light beige solid. LCMS: (Method I): R _T 2.42 min; [M + H] ⁺ 560.3. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.01-7.97 (m, 1H), 7.77-7.72 (m, 1H), 7.29-7.22 (m, 2H) , 4.56-4.21 (m, 4H), 4.04 (dd, J = 11.4, 4.2 Hz, 2H), 3.86 (t, J = 4.7 Hz, 4H), 3. 77 (s, 3H), 3.38-3.34 (m, 2H), 3.34 (q, J = 7.5 Hz, 2H), 3.13-3.00 (m, 2H), 3. 00-2.87 (m, 2H), 2.82-2.58 (m, 6H), 2.57-2.42 (m, 1H), 1.88-1.75 (m, 2H), 1.71-1.55 (m, 4H), 1.44 (t, J = 7.5 Hz, 3H)

Example 558 2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 1-yl) acetamide 558
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Reaction of morpholine and 2-bromoacetamide gave 558. LCMS m / z: 252.7 (2M + H +)

Example 559 I-2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) Piperidin-1-yl) propanamide 559
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Reacting morpholine and 2-bromopropionamide gave a racemic mixture. The enantiomers were separated by SFC to give 559. LCMS m / z: 259.7 (2M + H +)

Example 560 (S) -2- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) propanamide 560
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Reacting morpholine and 2-bromopropionamide gave a racemic mixture. The enantiomers were separated by SFC to give 560. LCMS m / z: 259.7 (2M + H +)

Example 561 I-4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8-((4- (3-fluoropyrrolidin-1-yl) piperidin-1-yl) Methyl) -9-methyl-9H-purin-6-yl) morpholine 561
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.15 g, 0.383 mmol) in DCE (5 mL), A mixture of 4- (I-3-fluoropyrrolidin-1-yl) piperidine (0.080 g, 0.46 mmol) and 4Å molecular sieve (0.4 g) was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.163 g, 0.77 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 40:60) to give 561 as a white solid (0.14 g, 67%). LCMS (Method I): R _T = 2.26 min, [M + H] ⁺ 548.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-7.98 (m, 1H), 7.65- 7.60 (m, 1H), 7.26-7.21 (m, 2H), 5.16 (dt, J = 55.97, 5.52 Hz, 1H), 4.50-3.65 (m , 4H), 3.82 (s, 3H), 3.80-3.74 (m, 4H), 3.75 (s, 2H), 3.27 (q, J = 7.4 Hz, 2H), 2.89-2.74 (m, 4H), 2.68-2.53 (m, 1H), 2.37-2.28 (m, 1H), 2.15-1.97 (m, 4H) ), 1.94-1.76 (m, 3H), 1.45-1.34 (m, 2H), 1.34 (t, J = 7.4 Hz, 3H)

Example 562 4- (8-((3,3-difluoro-1,3′-biazetidin-1′-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 562
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.0725 g, 0.18 mmol) in DCE (5 mL), A mixture of 3,3-difluoro- [1,3 ′] biazetidinyl (0.033 g, 0.22 mmol) and 4Å molecular sieve (0.2 g). The reaction mixture was stirred for 7 hours at room temperature. Sodium triacetoxyborohydride (0.079 g, 0.37 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 40:60) to give 562 as a yellow solid (0.075 g, 78%). LCMS (Method I): R _T = 2.66 min, [M + H] ⁺ 524.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.98 (m, 1H), 7.65- 7.60 (m, 1H), 7.27-7.20 (m, 2H), 4.50-3.96 (m, 4H), 3.88 (s, 2H), 3.86-3. 67 (m, 7H), 3.71-3.55 (m, 4H), 3.48-3.39 (m, 1H), 3.37-3.35 (m, 2H), 3.26 ( q, J = 7.5 Hz, 2H), 3.06 (dd, J = 7.5, 5.3 Hz, 2H), 1.33 (t, J = 7.5 Hz, 3H)

Example 564 4- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((4- (tetrahydro-2H-pyran-4-yl) piperazine-1 -Yl) methyl) -9H-purin-6-yl) morpholine 564
2-Chloro-9-methyl-6-morpholin-4-yl-8- [4- (tetrahydropyran-4-yl) piperazin-1-ylmethyl] -9H-purine (180 mg, 0. 1) in DMF (4 mL). 41 mmol), 2-isopropyl-1H-benzimidazole (80 mg, 0.50 mmol), Pd ₂ dba ₃ (11 mg, 0.012 mmol), Xphos (22 mg, 0.046 mmol) and cesium carbonate (201 mg, 0.62 mmol). The mixture was purged with argon gas and subjected to microwave irradiation at 145 ° C. for 30 minutes. After loading the reaction mixture onto an Isolute® SCX-2 cartridge (10 g) washed with MeOH / DCM, the desired product was eluted with 2M NH ₃ in MeOH / DCM. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: MeOH 100: 0 to 95: 5) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 60:40 to 10:90 gradient of 20 mM triethylamine in water). ) To give 564 as a white solid (85 mg, 37%). LCMS (Method I): R _T = 2.61 min, M + H ⁺ = 560. ¹ H NMR (CDCl ₃ , 400 MHz) δ 7.89 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 7.26 (m, 2H), 4. 34 (m, 4H), 4.03 (d, J = 10.1 Hz, 2H), 3.95 (m, 1H), 3.86 (m, 7H), 3.77 (s, 2H), 3 .38 (t, J = 11.7 Hz, 2H), 2.63 (m, 9H), 1.79 (m, 2H), 1.60 (m, 2H), 1.48 (s, 3H) and 1.46 (s, 3H)

Example 565 (S) -4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8-((4- (3-fluoropyrrolidin-1-yl) piperidine-1- Yl) methyl) -9-methyl-9H-purin-6-yl) morpholine 565
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.1 g, 0.255 mmol) in DCE (4 mL), A mixture of 4-((S) -3-fluoropyrrolidin-1-yl) piperidine (0.053 g, 0.307 mmol) and 4Å molecular sieve (0.25 g) was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.109 g, 0.51 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 40:60) to give 565 as a white solid (0.121 g, 87%). LCMS (Method I): R _T = 2.26 min, [M + H] ⁺ 548.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.04-8.00 (m, 1H), 7.65- 7.61 (m, 1H), 7.26-7.21 (m, 2H), 5.16 (dt, J = 56.0, 5.5 Hz, 1H), 4.50-3.96 (m , 4H), 3.82 (s, 3H), 3.79-3.74 (m, 4H), 3.75 (s, 2H), 3.32-3.19 (q, J = 7.4 Hz). , 2H), 2.89-2.74 (m, 4H), 2.69-2.55 (m, 1H), 2.37-2.28 (m, 1H), 2.15-1.97. (M, 4H), 1.90-1.74 (m, 3H), 1.45-1.34 (m, 2H), 1.34 (t, J = 7.4Hz, 3H)

エタノール中の２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-カルバルデヒド（１５ｇ、３８ｍｍｏｌ）の懸濁液に硝酸銀（８．１ｇ、４８ｍｍｏｌ）及び１．５ＭのＮａＯＨ溶液（１５０ｍＬ）を加えた。生じた混合物を室温で３０分間攪拌し、セライトで濾過した。溶液をついで濃縮した。残留する固形物に水を加え、１ＭのＮａＯＨ（濁った混合物）を加えて塩基性にした。混合物をついでＤＣＭで洗浄した。水性層を、ついで濃ＨＣｌを添加することによって酸性（ｐＨ２）とした。酸性の混合物をついで真空下で濃縮した。沈殿物が濃縮している間にゆっくりと生じた。体積を１／３に減じた後、懸濁液を氷浴に１５分間入れて冷やした後、濾過して固形物を回収した。固形物をついで真空下で乾燥させて、２-(２-エチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-カルボン酸をベージュの粉末として得た（１５．２ｇ、９７％）。ＬＣＭＳｍ／ｚ：４０８．３（ＭＨ＋） Example 566 2- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carbonyl) piperazin-1-yl ) -2-Methylpropanamide 566

Silver nitrate in a suspension of 2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carbaldehyde (15 g, 38 mmol) in ethanol (8.1 g, 48 mmol) and 1.5 M NaOH solution (150 mL) were added. The resulting mixture was stirred at room temperature for 30 minutes and filtered through celite. The solution was then concentrated. Water was added to the remaining solid and made basic with 1M NaOH (turbid mixture). The mixture was then washed with DCM. The aqueous layer was then made acidic (pH 2) by adding concentrated HCl. The acidic mixture was then concentrated under vacuum. Slowly formed while the precipitate was concentrated. After reducing the volume to 1/3, the suspension was placed in an ice bath for 15 minutes to cool and then filtered to recover the solid. The solid was then dried under vacuum to give 2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carboxylic acid in beige Obtained as a powder (15.2 g, 97%). LCMS m / z: 408.3 (MH +)

  2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carboxylic acid was converted to 2-methyl-2- (piperazin-1-yl) Coupling with propanamide dihydrochloride according to general procedure K to give 566. LCMS m / z: 281.3 (2M + H +)

Example 567 (4-tert-butylpiperazin-1-yl) (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Il) Methanone 567
According to General Procedure K 2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carboxylic acid was prepared according to General Procedure K Coupling with tert-butyl piperazine gave 567. LCMS m / z: 266.7 (2M + H +)

Example 568 3- (4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine- 1-yl) propanenitrile 568
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Morpholine and acrylonitrile were reacted to give 568. LCMS m / z: 250.7 (2M + H +)

Example 569 (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (4- (2-hydroxypropane-2 -Yl) piperidin-1-yl) methanone 569
According to general procedure K, 2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carboxylic acid was converted to 2- (piperidine-4- Yl) Coupling with propan-2-ol to give 569. LCMS m / z: 533.3 (M + H +)

Example 570 4- (8-((1- (isoxazol-5-ylmethyl) piperidin-4-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl ) -9H-purin-6-yl) morpholine 570
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Morpholine and 5- (bromomethyl) isoxazole were reacted to give 570. LCMS m / z: 264.7 (2M + H +)

Example 571 4- (8-((1- (isoxazol-5-ylmethyl) azetidin-3-yl) methyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl ) -9H-purin-6-yl) morpholine 571
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl ) Morpholine and 5- (bromomethyl) isoxazole were reacted to give 571. LCMS m / z: 250.7 (2M + H +)

Example 572 (S) -4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((1- (tetrahydrofuran-3-yl) azetidine-3 -Yl) methyl) -9H-purin-6-yl) morpholine 572
According to general procedure L 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl ) Morpholine and dihydrofuran-3 (2H) -one were reacted to give a racemic mixture. The enantiomers were separated by SFC to give 572. LCMS m / z: 245.2 (2M + H +)

Example 573 (R) -4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8-((1- (tetrahydrofuran-3-yl) azetidine-3 -Yl) methyl) -9H-purin-6-yl) morpholine 573
According to general procedure L 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl ) Morpholine and dihydrofuran-3 (2H) -one were reacted to give a racemic mixture. The enantiomers were separated by SFC to give 573. LCMS m / z: 245.2 (2M + H +)

Example 575 4- (8- (2- (3,3-dimethyl-4- (methylsulfonyl) piperazin-1-yl) ethyl) -2- (2-ethyl-1H-benzo [d] imidazole-1- Yl) -9-methyl-9H-purin-6-yl) morpholine 575
2-Chloro-8- [2- (4-methanesulfonyl-3,3-dimethylpiperazin-1-yl) ethyl] -9-methyl-6-morpholin-4-yl-9H in dioxane (1.5 mL) - purine (35mg, 0.07mmol), 2- ethyl-benzimidazole _{(12mg, 0.08mmol), Pd 2} (dba) 3 (1.7mg, 2.5mol%), Xphos (3.5mg, 10mol%) and A mixture of Cs ₂ CO ₃ (36 mg, 0.11 mmol) was purged with argon and heated at 120 ° C. for 24 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 30-90%) to give 575 (20 mg, 46%) as a light beige solid. LCMS: (Method I): R _T 2.74 min, [M + H] ⁺ 582.2 ¹ H NMR (400 MHz, CDCl ₃ d): δ 8.01-7.96 (m, 1H), 7.79-7. .75 (m, 1H), 7.28-7.25 (m, 2H), 4.50-3.96 (m, 4H), 3.86 (t, J = 4.7 Hz, 4H), 3 .78 (s, 3H), 3.50-3.44 (m, 2H), 3.36 (q, J = 7.4 Hz, 2H), 3.04 (t, J = 7.4 Hz, 2H) 2.94 (s, 3H), 2.87 (t, J = 7.4 Hz, 2H), 2.64-2.58 (m, 2H), 2.38 (s, 2H), 1.50. (S, 6H), 1.45 (t, J = 7.4 Hz, 3H)

Example 576 4- (8-((4- (3,3-difluoroazetidin-1-yl) piperidin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole-1 -Yl) -9-methyl-9H-purin-6-yl) morpholine 576
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.139 g, 0.36 mmol) in DCE (5 mL), A mixture of 4- (3,3-difluoroazetidin-1-yl) piperidine (0.075 g, 0.43 mmol) and 4 mol molecular sieves (0.4 g). The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.15 g, 0.71 mmol) was added and the reaction mixture was stirred for 72 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 12:88) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient). Purified with 20 mM triethylamine in water) to give 576 as an off-white solid (0.104 g, 53%). LCMS (Method I): R _T = 2.61 min, [M + H] ⁺ 552.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H), 7.65- 7.61 (m, 1H), 7.27-7.20 (m, 2H), 4.60-3.95 (s, 4H), 3.81 (s, 3H), 3.80-3. 74 (m, 6H), 3.52 (t, J = 12.3 Hz, 4H), 3.27 (q, J = 7.4 Hz, 2H), 2.79-2.70 (m, 2H), 2.20-2.10 (m, 3H), 1.68-1.59 (m, 2H), 1.34 (t, J = 7.4 Hz, 3H), 1.30-1.17 (m , 2H)

Example 577 1-tert-butyl-4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl Piperazine-2-one 577
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.15 g, 0.39 mmol) in DCE (5 mL), A mixture of 1-tert-butylpiperazin-2-one (0.072 g, 0.46 mmol) and 4Å molecular sieve (0.4 g) was stirred for 4 hours at room temperature. Sodium triacetoxyborohydride (0.163 g, 0.77 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) to give 777 as a white solid (0.178 g, 87%). LCMS (Method I): R _T = 3.59 min, [M + H] ⁺ 532.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.98 (m, 1H), 7.65- 7.60 (m, 1H), 7.26-7.21 (m, 2H), 4.50-3.95 (m, 5H), 3.83-3.79 (m, 6H), 3. 78 (m, 4H), 3.27 (q, J = 7.4 Hz, 2H), 3.08 (s, 2H), 2.69-2.64 (m, 2H), 1.36 (s, 9H), 1.34 (t, J = 7.4 Hz, 3H)

Ｎ,Ｎ-ジメチルホルムアミド（５．０ｍＬ、０．０６４ｍｏｌ）中のＮ-(ｔｅｒｔ-ブトキシカルボニル)-Ｌ-アラニン（８０．０ｍｇ、０．４２３ｍｍｏｌ）の溶液にＨＡＴＵ（０．１５４ｇ、０．４０４ｍｍｏｌ）、１-ヒドロキシベンゾトリアゾール（ＨＯＢｔ、０．００８３９ｇ、０．０６２１ｍｍｏｌ）及びトリエチルアミン（０．１０ｍＬ、０．７２ｍｍｏｌ）を加えた。生じた黄色溶液を室温で５分間攪拌し、４-(９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-８-(ピペリジン-４-イルメチル)-９Ｈ-プリン-６-イル)モルホリン５２０（０．１５０ｇ、０．３１０ｍｍｏｌ；）を加えた。反応物を室温で２時間攪拌した。反応混合物をブラインとＥｔＯＡｃの間で分配した。有機抽出物をブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー（ＤＣＭ中０−５％のＭｅＯＨ）で精製して、４-((９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルを得た（０．１５ｇ、７８％）。ＬＣＭＳｍ／ｚ：６１８．３（ＭＨ＋）。 Example 578 (S) -2-amino-1- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine- 8-yl) methyl) piperidin-1-yl) propan-1-one 578

To a solution of N- (tert-butoxycarbonyl) -L-alanine (80.0 mg, 0.423 mmol) in N, N-dimethylformamide (5.0 mL, 0.064 mol) was added HATU (0.154 g, 0.404 mmol). ) 1-hydroxybenzotriazole (HOBt, 0.00839 g, 0.0621 mmol) and triethylamine (0.10 mL, 0.72 mmol) were added. The resulting yellow solution was stirred at room temperature for 5 minutes and 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H -Purin-6-yl) morpholine 520 (0.150 g, 0.310 mmol;) was added. The reaction was stirred at room temperature for 2 hours. The reaction mixture was partitioned between brine and EtOAc. The organic extract was washed with brine, dried over Na ₂ SO ₄ , filtered and concentrated. The crude product was purified by flash chromatography (0-5% MeOH in DCM) to give 4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl)- 6-morpholino-9H-purin-8-yl) methyl) piperidine-1-carboxylate tert-butyl was obtained (0.15 g, 78%). LCMS m / z: 618.3 (MH +).

  4-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine-in dioxane (5 mL) To a solution of tert-butyl 1-carboxylate (0.18 g, 0.29 mmol) was added 2M HCl solution in ether (1 mL). The reaction was stirred for 1 hour at room temperature and concentrated. The crude material was purified by RP-HPLC to give 578 (75 mg, 50%). LCMS m / z: 259.7 (2M + H +)

Example 579 3-methyl-2- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) butanamide 579

３-メチル-２-(３-((９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)アゼチジン-１-イル)ブタン酸エチルを一般的手順Ｃに従って２-ブロモ-３-メチルブタン酸エチルを求電子試薬として用いて合成した。 Step 1: 3-Methyl-2- (3-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) ethyl butanoate

3-Methyl-2- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidine Ethyl-1-yl) butanoate was synthesized following general procedure C using ethyl 2-bromo-3-methylbutanoate as the electrophile.

エタノール中の（１．０ｍＬ、１７ｍｍｏｌ）中の３-メチル-２-(３-((９-メチル-２-(２-メチル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-６-モルホリノ-９Ｈ-プリン-８-イル)メチル)アゼチジン-１-イル)ブタン酸エチル（０．１８０ｇ、０．３２９ｍｍｏｌ）溶液に水（２．０ｍＬ）中の１．０Ｍの水酸化リチウムを加えた。生じた混合物を２時間室温で攪拌した。反応混合物を１ＭのＨＣｌで中和し、濃縮した。残留物を再びＭｅＯＨに溶解させ、ＳＣＸ-２カラムに充填した。カラムを最初にＭｅＯＨで洗浄した。生成物をＭｅＯＨ中の２ＭのＮＨ_３に溶出し、濃縮した。ＬＣＭＳｍ／ｚ：５１９．３（ＭＨ＋） Step 2: 3-Methyl-2- (3-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) butanoic acid

3-Methyl-2- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino in (1.0 mL, 17 mmol) in ethanol To a solution of -9H-purin-8-yl) methyl) azetidin-1-yl) butanoate (0.180 g, 0.329 mmol) was added 1.0 M lithium hydroxide in water (2.0 mL). The resulting mixture was stirred for 2 hours at room temperature. The reaction mixture was neutralized with 1M HCl and concentrated. The residue was redissolved in MeOH and loaded onto an SCX-2 column. The column was first washed with MeOH. The product was eluted with 2M NH ₃ in MeOH and concentrated. LCMS m / z: 519.3 (MH +)

Step 3: 3-Methyl-2- (3-((9-Methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) butanamide 579
According to general procedure K, 3-methyl-2- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8 -Yl) methyl) azetidin-1-yl) butanoic acid and ammonium hydroxide were coupled to give 579. LCMS m / z: 259.7 (2M + H +)

Example 580 N, 2-dimethyl-2- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) azetidin-1-yl) propanamide 580
According to general procedure C 4- (8- (azetidin-3-ylmethyl) -9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -9H-purin-6-yl ) The reaction of morpholine and 2-bromo-N, 2-dimethylpropanamide gave 580. LCMS m / z: 259.7 (2M + H +)

３-(２-クロロ-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチル（１ｇ）を２-イソプロピルベンゾイミダゾールとブッフバルトカップリングの一般的手順Ｉを介して反応させて、フラッシュクロマトグラフィー後に０．６５ｇの３-ヒドロキシ-３-(２-(２-イソプロピル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルを得た。 Example 581 (S) -3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1-methyl Piperidine-3-ol 581

3- (2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylate tert-butyl (1 g) was coupled to Buchwald coupling with 2-isopropylbenzimidazole. Reaction via general procedure I, 0.65 g 3-hydroxy-3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl- after flash chromatography 6-morpholino-9H-purin-8-yl) piperidine-1-carboxylate tert-butyl was obtained.

ＤＣＭ（７ｍＬ）中の３-ヒドロキシ-３-(２-(２-イソプロピル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルの溶液に雰囲気温度で１,４-ジオキサン（２．８ｍＬ）中の４Ｍの塩酸を加えた。完了したところで、反応混合物を濃縮乾固して、３-(２-(２-イソプロピル-１Ｈ-ベンゾ[ｄ]イミダゾール-１-イル)-９-メチル-６-モルホリノ-９Ｈ-プリン-８-イル)ピペリジン-３-オールの粗ＨＣｌ塩を得た。

3-Hydroxy-3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidine in DCM (7 mL) To a solution of tert-butyl-1-carboxylate was added 4M hydrochloric acid in 1,4-dioxane (2.8 mL) at ambient temperature. When complete, the reaction mixture was concentrated to dryness and 3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Il) Crude HCl salt of piperidin-3-ol was obtained.

  HCl salt of 3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidin-3-ol (80 mg) Was reacted with isopropyl iodide (1.5 eq) and potassium carbonate (5 eq) in a 1: 1 mixture of DMF and acetonitrile (2 mL). The reaction was heated at 75 ° C. for 18 hours until the reaction was complete. The reaction mixture was diluted with ethyl acetate and extracted with saturated ammonium chloride solution. The organic layer was dried, filtered, concentrated, and after reverse phase purification followed by chiral separation, 581 [4.6 mg; MS (Q1) 491.3 (M) +] and 582 [4.7 mg; MS (Q1 ) 491.3 (M) +].

Example 582 I-3- (2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1-methylpiperidine- 3-all 582
HCl salt of 3- (2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidin-3-ol (80 mg) Was reacted with isopropyl iodide (1.5 eq) and potassium carbonate (5 eq) in a 1: 1 mixture of DMF and acetonitrile (2 mL). The reaction was heated at 75 ° C. for 18 hours until the reaction was complete. The reaction mixture was diluted with ethyl acetate and extracted with saturated ammonium chloride solution. The organic layer was dried, filtered, concentrated, and after reverse phase purification followed by chiral separation, 581 [4.6 mg; MS (Q1) 491.3 (M) +] and 582 [4.7 mg; MS (Q1 ) 491.3 (M) +].

Example 585 N, 2-dimethyl-2- (4-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine-8- Yl) methyl) piperidin-1-yl) propanamide 585
According to general procedure C 4- (9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -8- (piperidin-4-ylmethyl) -9H-purin-6-yl ) Morpholine and 2-bromo-N, 2-dimethylpropanamide were reacted to give 585. LCMS m / z: 273.8 (2M + H +)

Example 586 (S) -4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8-((3- (3-fluoropyrrolidin-1-yl) azetidine-1- Yl) methyl) -9-methyl-9H-purin-6-yl) morpholine 586
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.245 g, 0.627 mmol) in DCE (5 mL), A mixture of (S) -1-azetidin-3-yl-3-fluoropyrrolidine (0.109 g, 0.752 mmol) and 4Å molecular sieve (0.5 g). The reaction mixture was stirred for 90 minutes at room temperature. Sodium triacetoxyborohydride (0.266 g, 1.254 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient in 20 mM in water). Triethylamine) gave 586 as an off-white solid (0.204 g, 63%). LCMS (Method I): R _T = 2.46 min, [M + H] ⁺ 520.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H), 7.65- 7.61 (m, 1H), 7.27-7.21 (m, 2H), 5.19 (dt, J = 55.8, 5.4 Hz, 1H), 4.50-3.95 (m , 4H), 3.87 (s, 2H), 3.81-3.72 (m, 7H), 3.40 (dd, J = 7.1, 6.1 Hz, 2H), 3.26 (q , J = 7.4 Hz, 2H), 3.21-3.12 (m, 1H), 3.12-3.03 (m, 2H), 2.79-2.65 (m, 2H), 2 .64-2.51 (m, 1H), 2.34-2.25 (m, 1H), 2.15-2.03 (m, 1H), 1.76-1.95 (m, 1H) , 1.33 (t J = 7.4Hz, 3H)

Example 587 1 '-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-methyl -1,3'-Biazetidine-3-ol 587
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.092 g, 0.234 mmol) in DCE (3 mL), A mixture of 3-methyl- [1,3 ′] biazetidinyl-3-ol (0.040 g, 0.28 mmol) and 4Å molecular sieves (0.25 g). The reaction mixture was stirred for 90 minutes at room temperature. Sodium triacetoxyborohydride (0.099 g, 0.47 mmol) was added and the reaction mixture was stirred for 18 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 587 as a white solid (0.107 g, 89%). LCMS (Method I): R _T = 2.33 min, [M + H] ⁺ 518.2 ¹ H NMR (300 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H), 7.65- 7.61 (m, 1H), 7.27-7.22 (m, 2H), 4.49-3.95 (m, 4H), 3.84 (s, 2H), 3.80-3. 74 (m, 4H), 3.36-3.31 (s, 3H), 3.31-3.20 (m, 6H), 3.11-3.01 (m, 4H), 2.98- 2.93 (m, 2H), 1.34 (m, 5H)

Example 588 1- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 3-yl) pyrrolidin-2-one 588
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (165 mg, 0.42 mmol) in DCE (4 mL), 1- A mixture of azetidin-3-ylpyrrolidin-2-one (65 mg, 0.46 mmol) and 4Å powdered molecular sieve was stirred at room temperature for 2 hours and sodium triacetoxyborohydride (180 mg, 0.84 mmol) was added. The reaction mixture was stirred for 65 hours, filtered through celite and washed with DCM. The organic phase was washed with brine and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-15%) to give 588 as an orange foam (138 mg, 64%). LCMS (Method I): R _T 2.42 min [M + H] ⁺ 516.2 ¹ H NMR (CDCl ₃ , 300 MHz): δ 8.00 (m, 1H), 7.76 (m, 1H), 7.27 (M, 2H), 4.83 (t, J = 6.9 Hz, 1H), 4.35 (m, 4H), 3.89-3.82 (m, 9H), 3.67-3.54 (M, 4H), 3.36 (m, 4H), 2.42 (t, J = 8.1 Hz, 2H), 2.07 (m, 2H) and 1.45 (t, J = 7.5 Hz) , 3H)

Example 589 4- (8-((3- (3,3-difluoropyrrolidin-1-yl) azetidin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole-1- Yl) -9-methyl-9H-purin-6-yl) morpholine 589
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (100 mg, 0.26 mmol) in DCE (6 mL), 1- A mixture of azetidin-3-yl-3,3-difluoropyrrolidine (46 mg, 0.28 mmol) and 4Å powdered molecular sieve was stirred at room temperature for 2 hours and sodium triacetoxyborohydride (108 mg, 0.52 mmol) was added. It was. The reaction mixture was stirred for 16 hours, filtered through celite and washed with DCM. The organic phase was washed with brine and concentrated under vacuum. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) to give 589 as an orange foam (97 mg, 69%). LCMS (Method I): R _T 2.74 min [M + H] ⁺ 538.2 ¹ H NMR (CDCl ₃ , 300 MHz): δ 8.00 (m, 1H), 7.75 (m, 1H), 7.27 (M, 2H), 4.42-4.27 (m, 4H), 3.87-3.84 (m, 9H), 3.54 (t, J = 6.5 Hz, 2H), 3.32. -3.30 (m, 3H), 3.19 (t, J = 6.5 Hz, 2H), 2.89 (t, J = 13.1 Hz, 2H), 2.70 (t, J = 6. 9Hz, 2H), 2.29-2.28 (m, 2H) and 1.44 (t, J = 7.5Hz, 3H)

Example 590 I-4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8-((3- (3-fluoropyrrolidin-1-yl) azetidin-1-yl) Methyl) -9-methyl-9H-purin-6-yl) morpholine 590
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.188 g, 0.479 mmol) in DCE (4 mL), Mixture of I-1-azetidin-3-yl-3-fluoropyrrolidine (0.083 g, 0.575 mmol) and 4 mol molecular sieves (0.4 g). The reaction mixture was stirred at room temperature for 3 hours. Sodium triacetoxyborohydride (0.203 g, 0.959 mmol) was added and the reaction mixture was stirred for 72 hours at room temperature. The suspension was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: EtOAc, gradient 0: 100 to 40:60) to give 590 as a yellow solid (0.2 g, 81%). LCMS (Method I): R _T = 2.46 min, [M + H] ⁺ 520.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.99 (m, 1H), 7.65- 7.61 (m, 1H), 7.27-7.21 (m, 2H), 5.19 (dt, J = 55.8, 5.4 Hz, 1H), 4.50-3.95 (m , 4H), 3.87 (s, 2H), 3.82-3.72 (m, 7H), 3.40 (dd, J = 7.1, 6.1 Hz, 2H), 3.26 (q , J = 7.4 Hz, 2H), 3.22-3.12 (m, 1H), 3.10-2.95 (m, 2H), 2.79-2.64 (m, 2H), 2 .64-2.50 (m, 1H), 2.34-2.25 (m, 1H), 2.18-2.02 (m, 1H), 1.94-1.78 (m, 1H) , 1.33 (t J = 7.4Hz, 3H)

Example 595 N- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) tetrahydro (1 , 1-Dioxo) thiophene-3-amine 595
[2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -ethyl]-(1,1-dioxo-tetrahydro-1 in dioxane (1.5 mL) -Thiophen-3-yl) amine (45 mg, 0.11 mmol), 2-ethylbenzimidazole (18 mg, 0.12 mmol), Pd ₂ (dba) ₃ (2.5 mg, 2.5 mol%), Xphos (5. A mixture of 2 mg, 10 mol%) and Cs ₂ CO ₃ (53 mg, 0.16 mmol) was purged with argon gas and heated at 120 ° C. for 4 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and the desired product was eluted with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give 595 (35 mg, 62%) as a pale yellow solid. LCMS: (Method I): R _T 2.43 min, [M + H] ⁺ 525.2 ¹ H NMR (300 MHz, CDCl ₃ d): δ 8.02-7.98 (m, 1H), 7.78-7. .74 (m, 1H), 7.31-7.23 (m, 2H), 4.50-4.95 (m, 4H), 3.87 (t, J = 4.7 Hz, 4H), 3 .76 (s, 3H), 3.73-3.67 (m, 1H), 3.40-3.24 (m, 4H), 3.23-3.14 (m, 2H), 3.14 −3.00 (m, 4H), 2.94 (dd, J = 13.2, 6.0 Hz, 1H), 2.49-2.45 (m, 1H), 2.15 to 2.05 ( m, 1H), 1.44 (t, J = 7.5 Hz, 3H)

Example 596 4- (8-((2,2-dimethyl-4- (methylsulfonyl) piperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 596
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (167 mg, 0.43 mmol) in DCE (10 mL), 1- A solution of methanesulfonyl-3,3-dimethylpiperazine (100 mg, 0.52 mmol) and molecular sieves (4 kg, powder, 830 mg) was stirred at ambient temperature for 5 hours. Sodium triacetoxyborohydride (136 mg, 0.64 mmol) was added and the mixture was stirred for 17 hours and loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted using 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was flash chromatographed (Si-PPC, DCM: MeOH, 100: 0 to 99: 1 to 98: 2 to 95: 5) followed by reverse phase HPLC (Phenomenex Gemini 5uC18, acetonitrile 51:49 to 49. Purified with a gradient of 51: 20 mM triethylamine in water) to give 596 as a cream foam (31 mg, 13%). LCMS (Method I): R _T = 3.42 min, M + H ⁺ = 568. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.01 (m, 1H), 7.77 (m, 1H), 7.26 (m, 2H), 4.34 (m, 4H), 3.87 (m , 9H), 3.36 (q, J = 7.5 Hz, 2H), 3.16 (m, 2H), 3.02 (s, 2H), 2.77 (s, 3H), 2.64 ( m, 2H), 1.46 (t, J = 7.5 Hz, 3H) and 1.29 (s, 6H)

Example 597 2-((1S, 4S) -5-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8- Yl) methyl) -2,5-diazabicyclo [2.2.1] heptan-2-yl) acetamide 597
Triethylamine (85 μL, 0.61 mmol) was added 8-[(1S, 4S) -1- (2,5-diazabicyclo [2.2.1] hept-2-yl) methyl] -2- in DCM (10 mL). To a solution of (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (250 mg, 0.53 mmol) and 2-chloroacetamide (60 mg, 0.64 mmol) It was. The mixture was stirred for 24 hours at ambient temperature and then loaded onto an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 99: 1 to 98: 2) to give 597 as a creamy solid (175 mg, 62%). . LCMS (Method I): R _T = 2.35 min, M + H ⁺ = 531. ¹ H NMR (CDCl ₃ , 400 MHz) δ 12.12 (bs, 1H), 8.01 (m, 1H), 7.77 (m, 1H), 7.26 (m, 2H), 5.62 (bs) , 1H), 4.34 (m, 4H), 3.92-3.83 (m, 9H), 3.54 (m, 2H), 3.37 (q, J = 7.4 Hz, 2H), 3.09 (m, 4H), 2.93 (m, 2H), 2.00 (m, 2H) and 1.42 (t, J = 7.4 Hz, 3H)

Example 598 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-(((1S, 4S) -5- (oxetane-3-yl)- 2,5-Diazabicyclo [2.2.1] heptan-2-yl) methyl) -9H-purin-6-yl) morpholine 598
8-[(1S, 4S) -1- (2,5-diazabicyclo [2.2.1] hept-2-yl) methyl] -2- (2-ethyl-benzimidazole-1) in DCE (7 mL) -Yl) -9-methyl-6-morpholin-4-yl-9H-purine (250 mg, 0.53 mmol), oxetan-3-one (40 mg, 0.31 mmol) and molecular sieves (4 kg, powder, 200 mg) The solution was stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (148 mg, 0.70 mmol) was added and the mixture was stirred for 16 hours. It was then loaded into an Isolute® SCX-2 cartridge (10 g). The cartridge was then washed with methanol and the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH, gradient from 100: 0 to 90: 0) to give 598 as a white solid (125 mg, 45%). LCMS (Method I): R _T = 2.39 min, M + H ⁺ = 530. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H), 7.76 (m, 1H), 7.26 (m, 2H), 4.72-4.65 (m, 4H), 4 .34 (m, 4H), 4.01-3.86 (m, 10H), 3.35 (m, 4H), 2.99 (m, 1H), 2.82 (m, 1H), 2. 76 (m, 2H), 1.79 (m, 2H) and 1.45 (t, J = 7.5 Hz, 3H)

Example 607 N- (2- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -N- Methyl-1,1-dioxo-tetrahydrothiophene-3-amine 607
(1,1-Dioxo-tetrahydro-1-thiophen-3-yl)-{2- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholine- in DCE (5 mL) To a solution of 4-yl-9H-purin-8-yl] ethyl} amine (31 mg, 0.06 mmol) was added formaldehyde (37 wt% in water, 50 μL, 0.67 mmol). The reaction mixture was stirred for 5 hours at room temperature, sodium triacetoxyborohydride (25 mg, 0.12 mmol) was added and the resulting mixture was further stirred for 16 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge, washed with MeOH and the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by column chromatography (Si-PCC, 0-10% MeOH in DCM) to give 607 as an off-white solid (21 mg, 66%). LCMS (Method I): R _T = 2.55 min, [M + H] ⁺ 539.14 ¹ H NMR (400 MHz, CDCl ₃ d): δ 8.02-7.97 (m, 1H), 7.80-7 .75 (m, 1H), 7.34-7.24 (m, 2H), 4.49-3.5 (m4H), 3.87 (t, J = 4.7 Hz, 4H), 3.77 (S, 3H), 3.59-3.49 (m, 1H), 3.37 (q, J = 7.5 Hz, 2H), 3.25 (dd, J = 13.27.7 Hz, 2H) 3.10-2.98 (m, 6H), 2.42 (s, 3H), 2.40-2.32 (m, 1H), 2.21-2.11 (m, 1H), 1 .45 (t, J = 7.5Hz, 3H)

Example 608 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8-((4- (3-fluoroazetidin-1-yl) piperidin-1-yl) methyl ) -9-Methyl-9H-purin-6-yl) morpholine 608
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (0.155 g, 0.395 mmol) in DCE (6 mL), A mixture of 4- (3-fluoroazetidin-1-yl) piperidine (0.075 g, 0.474 mmol) and 4Å molecular sieve (0.5 g) was stirred for 3 hours at room temperature. Sodium triacetoxyborohydride (0.168 g, 0.79 mmol) was added and the reaction mixture was stirred for 72 hours at room temperature. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 15:85) to give 608 as a white solid (0.177 g, 84%). LCMS (Method I): R _T = 2.25 min, [M + H] ⁺ 534.2 ¹ H NMR (400 MHz, DMSO-d ₆ ): δ 8.03-7.98 (m, 1H), 7.65- 7.60 (m, 1H), 7.27-7.21 (m, 2H), 5.20-5.00 (m, 1H), 4.50-3.96 (m, 4H), 3. 80 (s, 3H), 3.80-3.74 (m, 4H), 3.75 (s, 2H), 3.56-3.45 (m, 2H), 3.26 (q, J = 7.4 Hz, 2H), 3.06-2.94 (m, 2H), 2.78-2.68 (m, 2H), 2.19-2.09 (m, 2H), 2.07 ( s, 1H), 1.66 to 1.57 (m, 2H), 1.33 (t, J = 7.4 Hz, 3H), 1.25 to 1.12 (m, 2H)

Example 646 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) pyrrolidine-1-carboxylic acid tert- Butyl 646
3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -pyrrolidine-1-carboxylic acid tert-butyl ester (44 mg, 0) in dioxane (1.5 mL) .10 mmol), 2-ethylbenzimidazole (17 mg, 0.11 mmol), Pd ₂ (dba) ₃ (2.4 mg, 2.5 mol%), Xphos (5.0 mg, 10 mol%) and Cs ₂ CO ₃ (51 mg) , 0.16 mmol) was purged with argon gas and heated in a sealed tube at 120 ° C. for 20 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 0-100% EtOAc in cyclohexane) to give 646 (37 mg, 67%) as a yellow solid. LCMS: (Method I): R _T 4.34 min, [M + H] ⁺ 533.2 ¹ H NMR (400 MHz, CDCl ₃ d): δ 8.01-7.97 (m, 1H), 7.78-7. .73 (m, 1H), 7.29-7.22 (m, 2H), 4.55-4.10 (m, 4H), 3.86 (t, J = 4.67 Hz, 4H), 3 .80 (s, 3H), 3.80-3.44 (m, 4H), 3.35 (q, J = 7.48 Hz, 2H), 2.36 (s, 3H), 1.49 (s , 9H), 1.44 (t, J = 7.48 Hz, 3H)

無水ＤＭＡ（３ｍＬ）中の亜鉛粉末（３２０ｍｇ、４．９２ｍｍｏｌ）及びＣｅｌｐｕｒｅ（登録商標）Ｐ６５の懸濁液にＴＭＳ-Ｃｌ：１,２-ジブロモエタン（６５μＬ）の７：５（ｖ：ｖ）の混合物を滴下して加えた。反応混合物を１５分間室温で攪拌した。無水ＤＭＡ（２ｍＬ）中の４-ヨードピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．２２ｇ、３．９５ｍｍｏｌ）を上述した混合物に滴下して加え、反応混合物を３０分間室温で攪拌した。亜鉛酸塩混合物をで素早く濾過し、２-クロロ-８-ヨード-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１．０ｇ、２．６３ｍｍｏｌ）、Ｐｄ(ｄｐｐｆ)Ｃｌ_２.ＤＣＭ（１０７ｍｇ、０．１３ｍｍｏｌ）及びＣｕＩ（５０ｍｇ、０．２６ｍｍｏｌ）の混合物に加えた。ついで容器を排気し、窒素を再び充填した。生じた混合物を８５℃で１８時間攪拌し、３時間後にＰｄ（ｄｐｐｆ）Ｃｌ_２．ＤＣＭ及びＣｕＩを加えた。混合物を室温まで冷却し、ＥｔＯＡｃ及び塩化アンモニウム塩の水溶液の間で分配した。有機層を水ブラインで洗浄し、Ｎａ_２ＳＯ_４で乾燥させ、濾過し、真空下で濃縮した。残留物をカラムクロマトグラフィー（シクロヘキサン：ＥｔＯＡｃ、２０−７０％）で精製して、４-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを固形物として得た（３７５ｍｇ、３３％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ４．５７分，［Ｍ＋Ｈ］^＋４３７．４６^１Ｈ ＮＭＲ（４００ＭＨｚ，ＣＤＣｌ_３）：δ４．４０−４．１５（ｍ，６Ｈ）；３．８１（ｔ，Ｊ＝１２．１Ｈｚ，４Ｈ）；３．７１（ｓ，３）；２．９９−２．８７（ｍ，３Ｈ）；１．９４−１．８５（ｍ，４Ｈ）；１．７１−１．５９（ｍ，１Ｈ）；１．４８（ｓ，９Ｈ）。 Example 647 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidine-1-carboxylic acid tert- Butyl 647

7: 5 (v: v) of TMS-Cl: 1,2-dibromoethane (65 μL) in a suspension of zinc powder (320 mg, 4.92 mmol) and Celpure® P65 in anhydrous DMA (3 mL) Was added dropwise. The reaction mixture was stirred for 15 minutes at room temperature. 4-Iodopiperidine-1-carboxylic acid tert-butyl ester (1.22 g, 3.95 mmol) in anhydrous DMA (2 mL) was added dropwise to the above mixture and the reaction mixture was stirred for 30 minutes at room temperature. The zincate mixture was quickly filtered with 2-chloro-8-iodo-9-methyl-6-morpholin-4-yl-9H-purine (1.0 g, 2.63 mmol), Pd (dppf) Cl ₂ . To a mixture of DCM (107 mg, 0.13 mmol) and CuI (50 mg, 0.26 mmol). The vessel was then evacuated and refilled with nitrogen. The resulting mixture was stirred at 85 ° C. for 18 hours and after 3 hours Pd (dppf) Cl ₂ . DCM and CuI were added. The mixture was cooled to room temperature and partitioned between EtOAc and an aqueous solution of ammonium chloride. The organic layer was washed with water brine, dried over Na ₂ SO ₄ , filtered and concentrated under vacuum. The residue was purified by column chromatography (cyclohexane: EtOAc, 20-70%) to give 4- (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -piperidine. -1-Carboxylic acid tert-butyl ester was obtained as a solid (375 mg, 33%). LCMS (Method H): R _T 4.57 min, [M + H] ⁺ 437.46 ¹ H NMR (400 MHz, CDCl ₃ ): δ 4.40-4.15 (m, 6H); 3.81 (t, J = 12.1 Hz, 4H); 3.71 (s, 3); 2.99-2.87 (m, 3H); 1.94-1.85 (m, 4H); 1.71-1.59 (M, 1H); 1.48 (s, 9H).

4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) piperidine-1-carboxylic acid tert-butyl ester (375 mg, 0.858 mmol) in dioxane (5 mL) A mixture of 2-ethylbenzimidazole (151 mg, 1.03 mmol), Xphos (43 mg, 0.09 mmol) and Cs ₂ CO ₃ (421 mg, 1.29 mmol) was degassed with nitrogen bubbling for 15 minutes. Tris (dibenzylideneacetone) dipalladium (20 mg, 0.022 mmol) was added and the mixture was heated at 120 ° C. for 20 hours. The reaction mixture was diluted with EtOAc, filtered, concentrated in vacuo and purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 40-90%) to give 647 (390 mg, 83%). LCMS: R _T 4.54 min, [M + H] ⁺ 547.24 ¹ H NMR (400 MHz, DMSO): δ 8.00-7.99 (m; 1H); 7.68-7.60 (m; 1H) 7.25-7.24 (m; 2H); 4.45-4.12 (m; 4H); 4.12-4.01 (d; J = 13.26 Hz, 2H); 3.85- 3.70 (m; 6H); 3.25-3.10 (m, 4H); 3.04-2.82 (m, 2H); 2.00-1.90 (d; J = 13.26 Hz) , 2H); 1.76-1.59 (m, 2H); 1.43 (s; 9H); 1.35 (t, J = 7.44 Hz, 3H).

Example 648 4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-isopropylpiperazine -2-On 648
4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl) -3-isopropylpiperazin-2-one (198 mg, 0.49 mmol) in dioxane (4 mL), 2-Ethylbenzimidazole (78 mg, 0.53 mmol), Pd ₂ (dba) ₃ (11.1 mg, 2.5 mol%), Xphos (23.1 mg, 10 mol%) and Cs ₂ CO ₃ (237 mg, 0.16 mmol) ) Was purged with argon gas and heated in a sealed tube at 110 ° C. for 17 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge and washed with MeOH before eluting the desired product with 2M NH ₃ / MeOH in DCM. The resulting residue was purified by column chromatography (Si-PCC, 10% MeOH in 0-EtOAc) to give 648 (196 mg, 78%) as a white solid. LCMS: (Method I): R _T 3.37 min, [M + H] ⁺ 518.2 ¹ H NMR (400 MHz, CDCl ₃ d): δ 8.05-8.00 (m, 1H), 7.79-7. .75 (m, 1H), 7.30-7.23 (m, 2H), 6.02 (s, 1H), 4.50-3.96 (m, 4H), 4.09 (d, J = 13.6 Hz, 1H), 3.94 (d, J = 13.6 Hz, 1H), 3.89 (s, 3H), 3.87 (t, J = 4.80 Hz, 4H), 3.63 -3.54 (m, 1H), 3.37 (q, J = 7.5 Hz, 2H), 3.34-3.28 (m, 1H), 3.13-3.04 (m, 1H) , 3.03 (d, J = 5.5 Hz, 1H), 2.74-2.66 (m, 1H), 2.25-2.14 (m, 1H), 1.46 (t, J = 7.5Hz 3H), 1.11 (d, J = 6.8Hz, 3H), 1.03 (d, J = 6.8Hz, 3H)

Example 649 4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3,3- Dimethylpiperazin-2-one 649
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (250 mg, 0.64 mmol) in DCE (15 mL), 3, A solution of 3-dimethylpiperazin-2-one (100 mg, 0.78 mmol) and molecular sieves (4 kg, powder, 1 g) was stirred at ambient temperature for 4 hours. Sodium triacetoxyborohydride (204 mg, 0.96 mmol) was added and the mixture was stirred for 16 hours and then loaded onto an Isolute® SCX-2 cartridge (10 g). After the cartridge was then washed with methanol, the desired product was subsequently eluted with 2M NH ₃ in MeOH. The product was collected and concentrated under vacuum. The resulting residue was purified by flash chromatography (Si-PPC, DCM: MeOH, 100: 0 to 98: 2 to 95: 5) to give 649 as a yellow solid (34 mg, 11%). LCMS (Method I): R _T = 3.12 min, M + H ⁺ = 504. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.02 (m, 1H), 7.79 (m, 1H), 7.30 (m, 2H), 5.75 (bs, 1H), 4.34 (m , 4H), 3.94 (s, 2H), 3.92 (s, 3H), 3.87 (m, 4H), 3.38 (q, J = 7.4 Hz, 2H), 3.23 ( m, 2H), 2.80 (m, 2H), 1.54 (s, 6H), and 1.47 (t, J = 7.4 Hz, 3H)

ＤＣＭ（２０ｍＬ）及びＭｅＯＨ（５ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（３９０ｍｇ、０．７１ｍｍｏｌ）の溶液にジオキサン（２０ｍＬ）中の４ＭのＨＣｌを加えた。生じた混合物を４時間室温で攪拌し、Ｅｔ_２Ｏ（８０ｍＬ）を加えた。生じた沈殿物を濾過により回収して、Ｅｔ_２Ｏで洗浄して、真空下で乾燥して２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-８-ピペリジン-４-イル-９Ｈ-プリン塩酸塩（３２２ｍｇ、９３％）を得た。ＬＣＭＳ（方法Ｉ）：Ｒ_Ｔ２．４３分［Ｍ＋Ｈ］^＋４４７．２ Example 677 2- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidin-1-yl Acetamide 677

4- [2- (2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidine- in DCM (20 mL) and MeOH (5 mL) To a solution of 1-carboxylic acid tert-butyl ester (390 mg, 0.71 mmol) was added 4M HCl in dioxane (20 mL). The resulting mixture was stirred for 4 hours at room temperature and Et ₂ O (80 mL) was added. The resulting precipitate was collected by filtration, washed with Et ₂ O, dried under vacuum and 2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl -8-piperidin-4-yl-9H-purine hydrochloride (322 mg, 93%) was obtained. LCMS (Method I): R _T 2.43 min [M + H] ⁺ 447.2.

2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-8-piperidin-4-yl-9H-purine hydrochloride (150 mg, 0. 1) in MeCN (3 mL). 31 mmol), a mixture of 2-bromoacetamide (45 mg, 0.33 mmol), sodium iodide (5 mg, 0.03 mmol) and K ₂ CO ₃ (90 mg, 0.65 mmol) at 50 ° C. in a sealed tube. Heated for hours. The reaction mixture was diluted with EtOAc, filtered and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-30%) to give 677 (119 mg, 76%). LCMS (Method I): R _T 2.40 min, [M + H] ⁺ 504.2. ¹ H NMR (DMSO, 400 MHz): δ 8.02-7.98 (1H, m), 7.64-7.63 (1H, m), 7.25-7.24 (4H, m), 4. 27 (4H, brds), 3.82-3.72 (7H, m), 3.35-3.30 (2H, m), 3.26 (2H, q, J = 7.45 Hz), 3 .11-2.90 (4H, m), 2.38-2.31 (1H, m), 1.97 (4H, s), 1.33 (3H, t, J = 7.44 Hz)

Example 678 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) azetidine-1-carboxylic acid tert- Butyl 678
A suspension of zinc powder (190 mg, 2.91 mmol) and Celpure® P65 (60 mg) in DMA (2 mL) in TMSCl: 1,2-dibromoethane (38 μL) 7: 5 (v: v) The mixture was added dropwise. The reaction mixture was stirred for 15 minutes at room temperature. A solution of 3-iodoazetidine-1-carboxylic acid tert-butyl ester obtained from Example 1 (651 mg, 2.30 mmol) in DMA (2 mL) was added dropwise to the above mixture. The resulting mixture was stirred for 1 hour at room temperature.

2- (2-Ethylbenzimidazol-1-yl) -8-iodo-9-methyl-6-morpholin-4-yl-9H-purine (750 mg, 1.53 mmol) from Example 75 mm in DMA (9 mL). ), Pd (dppf) ₂ Cl _2. A mixture of DCM (125 mg, 0.15 mmol) and CuI (38 mg, 0.20 mmol) was purged with argon. The zincate mixture was added to the reaction mixture through a PTFE filter and the resulting mixture was stirred at 85 ° C. for 24 hours. The reaction mixture was partitioned between EtOAc and _{H 2} O. The organic phase was washed with H ₂ O (× 3) and brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10% and MeOH: EtOAc, 0-5%) to give 678 as a solid (350 mg, 44%). LCMS (Method I): R _T 4.16 min, [M + H] ⁺ 519.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00 (1H, d, J = 7.15 Hz), 7.76 (1H, d, J = 7.06 Hz), 7.32-7.23 (2H, m), 4.57-4.24 (8H, m), 4.00-3.99 (1H, m), 3.88 (4H, t, J = 4.68 Hz), 3.69 (3H, s), 3.35 (2H, q, J = 7.47 Hz), 1.48 (12H, s).

Example 679 (R) -1- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) -2-hydroxypropan-1-one 679
8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (2 mL) and DMF (1.5 mL) HATU (60 mg, 0.16 mmol) was added to a mixture of (57 mg, 0.13 mmol), D-lactic acid (14 mg, 0.16 mmol) and DIPEA (27 μL, 0.16 mmol). The resulting yellow mixture was stirred for 2 hours at room temperature and partitioned between DCM and H ₂ O. The combined organic phases were dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) and loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was loaded with 2M Elution with NH ₃ / MeOH gave 679 as a creamy foam (23 mg, 35%). LCMS: R _T 2.92 min, [M + H] ⁺ 505.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00-7.98 (1H, m), 7.81-7.70 (1H, m), 7.26 (2H, s), 4.49-4 .20 (7H, m), 3.91 (1H, dd, J = 10.38, 5.67 Hz), 3.86 (5H, t, J = 4.71 Hz), 3.76-3.75 ( 3H, m), 3.36-3.35 (4H, m), 3.18-3.15 (2H, m), 1.44 (3H, t, J = 7.46 Hz), 1.34 ( 3H, dd, J = 6.68, 4.79 Hz)

Example 680 4- (8- (azetidin-3-yl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 680
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] azetidine-1-carboxylic acid tert in DCM (4 mL) -To a solution of butyl ester 678 (325 mg, 0.63 mmol) was added TFA (2 mL). The resulting mixture was stirred for 2.5 hours at room temperature, loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-20%) to give 680 as a creamy foam (224 mg, 85%). LCMS (Method I): R _T 2.30 min, [M + H] ⁺ 419.1. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00-8.00 (1H, m), 7.75-7.74 (1H, m), 7.26 (2H, s), 4.34-4 .32 (7H, m), 3.89-3.88 (6H, m), 3.71-3.69 (3H, m), 3.35-3.34 (2H, m), 1.44 -1.43 (3H, m)

Example 681 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3-isopropylpiperazine -2-on 681
4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -2-isopropyl-3- in DCM (3 mL) To a solution of oxopiperazine-1-carboxylic acid tert-butyl ester (104 mg, 0.17 mmol) was added TFA (1 mL) and the resulting mixture was stirred for 2 h. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 681 as an off-white solid (55 mg, 67%). LCMS (Method I): R _T 2.54 min, [M + H] ⁺ 518.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00-8.00 (1H, m), 7.76-7.76 (1H, m), 7.32-7.22 (2H, m), 4 .95-4.79 (1H, m), 4.35 (4H, brds), 3.90-3.82 (7H, m), 3.47-3.45 (3H, m), 3. 35 (2H, q, J = 7.48 Hz), 3.23-3.22 (1H, m), 3.02 (1H, ddd, J = 12.50, 11.03, 3.93 Hz), 2 .57-2.56 (1H, m), 1.44 (3H, t, J = 7.48 Hz), 1.21 (1H, t, J = 7.02 Hz), 1.04 (3H, d, J = 7.12 Hz), 0.93 (3H, d, J = 6.80 Hz)

Example 687 4- (1-((2- (imidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperidine-4 -Il) Morpholine 687
4-morpholin-4-yl-6- (4-morpholin-4-ylpiperidin-1-ylmethyl) -2- (trinanstannyl) thieno [3,2-d] pyrimidine in THF (1 mL) (69 mg, 0.10 mmol), 5-bromoimidazo [1,2-a] pyridine (24 mg, 0.12 mmol), Pd (PPh ₃ ) ₄ (11 mg, 0.01 mmol) and copper (I) iodide (23 mg , 0.12 mmol) was purged with argon gas and then heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g) and the cartridge was washed with MeOH before eluting the product with 2M NH ₃ in MeOH. Appropriate fractions were evaporated and the resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 3:97) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 70: Purification with 20 mM triethylamine in water with a gradient of 30 to 2:98 gave 687 as a white solid (22 mg, 42%). LCMS (Method F): R _T 3.90 min; [M + H] ⁺ 520. ¹ H NMR (400 MHz, CHCl ₃ -d): δ9.23 (s, 1H); 7.95 (dd, J = 7.2, 1.2 Hz, 1H); 7.77 (d, J = 8. 9.75 (d, J = 1.2 Hz, 1H); 7.35 (s, 1H); 7.31 (dd, J = 8.9, 7.2 Hz, 1H); 07 (t, J = 4.7 Hz, 4H); 3.91 (t, J = 4.7 Hz, 4H); 3.84 (s, 2H); 3.74 (t, J = 4.4 Hz, 4H) 3.05 (d, J = 11.4 Hz, 2H); 2.57 (t, J = 4.4 Hz, 4H); 2.29-2.19 (m, 1H); 2.15 (t) , J = 11.4 Hz, 2H); 1.87 (d, J = 12.5 Hz, 2H); 1.65-1.59 (m, 2H)

Example 688 1-((2- (imidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) -N, N-dimethyl Piperidine-4-amine 688
Dimethyl- [1- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperidine-4- in THF (2.5 mL) Yl] amine (156 mg, 0.24 mmol), 5-bromoimidazo [1,2-a] pyridine (56 mg, 0.29 mmol), Pd (PPh ₃ ) ₄ (28 mg, 0.02 mmol) and copper iodide (I ) (55 mg, 0.29 mmol) was purged with argon gas and then heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (5 g), washed with MeOH and then eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) to give 688 as a white solid (72 mg, 63%). LCMS (Method F): R _T 3.89 min; [M + H] ⁺ 478. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.23 (s, 1H); 7.95 (dd, J = 8.6, 1.3 Hz, 1H); 7.77 (d, J = 8. 6.75 (d, J = 1.3 Hz, 1H); 7.35 (s, 1H); 7.32-7.29 (m, 1H); 4.07 (t, J = 4.8 Hz, 4H); 3.91 (t, J = 4.8 Hz, 4H); 3.84 (s, 2H); 3.04 (d, J = 11.25 Hz, 2H); 2.33- 2.25 (m, 6H); 2.21-2.10 (m, 3H); 1.84 (d, J = 12.5 Hz, 2H); 1.61 (m, 2H)

ジオキサン（３ｍＬ）中のジメチル-[１-(４-モルホリン-４-イル-２-(トリブチルスタンナニル(stannanyl))チエノ[３,２-ｄ]ピリミジン-６-イルメチル)ピペリジン-４-イル]アミン（２３０ｍｇ、０．３５ｍｍｏｌ）、８-ベンジルオキシ-５-ブロモイミダゾ[１,２-ａ]ピリジン（１２７ｍｇ、０．４２ｍｍｏｌ）、Ｐｄ(ＰＰｈ_３)_４（４０ｍｇ、０．０３５ｍｍｏｌ）及びヨウ化銅(Ｉ)（６６ｍｇ、０．３５ｍｍｏｌ）の混合物にアルゴンガスをパージし、マイクロ波反応器で１４０℃で２０分間加熱した。反応混合物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（１０ｇ）で充填した。カートリッジをＭｅＯＨで洗浄した後、所望の生成物をＭｅＯＨ中の２ＭのＮＨ_３で溶出した。適当な画分を混合して、蒸発させた。生じた残留物をフラッシュクロマトグラフィー（Ｓｉ-ＰＰＣ、ＭｅＯＨ：ＤＣＭ、０：１００から２０：８０の勾配）で精製して{１-[２-(８-ベンジルオキシイミダゾ[１,２-ａ]ピリジン-５-イル)-４-モルホリン-４-イル-チエノ[３,２-ｄ]ピリミジン-６-イルメチル]ピペリジン-４-イル}ジメチルアミンを白色固形物として得た（１８９ｍｇ、９２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．０７分；［Ｍ＋Ｈ］^＋５８４ Example 689 5- (6-((4- (dimethylamino) piperidin-1-yl) methyl) -4-morpholinothieno [3,2-d] pyrimidin-2-yl) imidazo [1,2-a] Pyridine-8-ol 689

Dimethyl- [1- (4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperidin-4-yl] in dioxane (3 mL) Amine (230 mg, 0.35 mmol), 8-benzyloxy-5-bromoimidazo [1,2-a] pyridine (127 mg, 0.42 mmol), Pd (PPh ₃ ) ₄ (40 mg, 0.035 mmol) and iodide A mixture of copper (I) (66 mg, 0.35 mmol) was purged with argon gas and heated in a microwave reactor at 140 ° C. for 20 minutes. The reaction mixture was charged with an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. Appropriate fractions were combined and evaporated. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 20:80) {1- [2- (8-benzyloxyimidazo [1,2-a] Pyridin-5-yl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl] piperidin-4-yl} dimethylamine was obtained as a white solid (189 mg, 92%) . LCMS (Method H): R _T 3.07 min; [M + H] ⁺ 584

{1- [2- (8-Benzyloxyimidazo [1,2-a] pyridin-5-yl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidin-6-ylmethyl in TFA A mixture of piperidin-4-yl} dimethylamine (381 mg, 0.65 mmol) was heated in a microwave reactor at 140 ° C. for 10 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. Appropriate fractions were combined and evaporated. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water with a gradient of acetonitrile 95: 5 to 2:98) to give 689 as a yellow solid (32 mg, 10%). LCMS (Method F) R _T 3.98 min; [M + H] ⁺ 494. ¹ H NMR (400 MHz, CH ₃ OH-d ₆ ): δ 9.43 (d, J = 1.6 Hz, 1H); 8.04 (d, J = 8.2 Hz, 1H); 7.65 (d, J = 1.6 Hz, 1H); 7.34 (s, 1H); 6.71 (d, J = 8.2 Hz, 1H); 4.03 (t, J = 4.7 Hz, 4H); 87 (m, 7H); 3.07 (d, J = 11.5 Hz, 2H); 2.37 (s, 6H); 2.34 (m, 1H); 2.16 (t, J = 1.11. 5 Hz, 2H); 1.91 (d, J = 12.3 Hz, 2H); 1.66 to 1.54 (m, 2H)

Example 690 2- (4-((2-([1,2,4] triazolo [4,3-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidine-6- Yl) methyl) piperazin-1-yl) -2-methylpropanamide 690
2- [4- (4-Morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine-1- in dioxane (2.5 mL) Yl] isobutyramide (150 mg, 0.22 mmol), 5-bromo- [1,2,4] triazolo [4,3-a] pyridine (51 mg, 0.26 mmol), bis [di-tert-butyl (4- A mixture of (dimethylaminophenyl) phosphine] dichloropalladium (II) (15 mg, 0.02 mmol) and copper (I) iodide (41 mg, 0.22 mmol) was purged with argon gas and then at 150 ° C. in a microwave reactor. Heated for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. Appropriate fractions were combined and evaporated. The resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient). Purification with 20 mM triethylamine in water) gave 690 as a white solid (14 mg, 12%). LCMS (Method F) R _T 5.50 min; [M + H] ⁺ 522. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 10.53 (d, J = 0.9 Hz, 1H); 8.08 (dd, J = 7.0, 0.9 Hz, 1H); 7.93 ( d, J = 9.1 Hz, 1H); 7.41 (dd, J = 9.1, 7.0 Hz, 1H); 7.38 (s, 1H); 7.08 (d, J = 5.3 Hz) , 1H); 5.20 (d, J = 5.3 Hz, 1H); 4.07 (t, J = 4.8 Hz, 4H); 3.92 (t, J = 4.8 Hz, 4H); 3 .88 (s, 2H); 2.62 (m, 8H); 1.25 (s, 6H)

Example 691 2- (4-((2- (imidazo [1,2-a] pyridin-5-yl) -7-methyl-4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl ) Piperazin-1-yl) -2-methylpropanamide 691
2- [4- (7-Methyl-4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine-in dioxane (2 mL) 1-yl] isobutyramide (150 mg, 0.21 mmol), 5-bromoimidazo [1,2-a] pyridine (50 mg, 0.25 mmol), Pd (PPh ₃ ) ₄ (24 mg, 0.02 mmol) and thiophene- A mixture of copper (I) 2-carboxylate (8 mg, 0.04 mmol) was purged with argon gas and heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g), washed with MeOH and then eluted with 2M NH ₃ in MeOH. The resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 100: 0) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient in water. Purification with 20 mM triethylamine) gave 691 as a white solid (30 mg, 26%). LCMS (Method E) R _T 5.27 min; [M + H] ⁺ 535. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.45 (s, 1H); 8.09-8.05 (m, 1H); 7.80-7.76 (m, 2H); 7.32 (Dd, J = 8.9, 7.19 Hz, 1H); 7.10 (d, J = 5.3 Hz, 1H); 5.20 (d, J = 5.3 Hz, 1H); 4.07 ( t, J = 4.7 Hz, 4H); 3.91 (t, J = 4.7 Hz, 4H); 3.84 (s, 2H); 2.61 (m, 8H); 2.51 (s, 3H); 1.25 (s, 6H)

Example 692 2- (1-((9-Methyl-2- (2-methylimidazo [1,2-a] pyridin-5-yl) -6-morpholino-9H-purin-8-yl) methyl) piperidine -4-yl) propan-2-ol 692
2- [1- (9-Methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purin-8-ylmethyl) -piperidin-4-yl] in dioxane (2 mL) Propan-2-ol (127 mg, 0.19 mmol), 5-bromo-2-methyl-imidazo [1,2-a] pyridine (48 mg, 0.23 mmol), Pd (PPh ₃ ) ₄ (22 mg, 0.02 mmol) ) And copper (I) thiophene-2-carboxylate (7 mg, 0.04 mmol) were purged with argon gas and then heated at 150 ° C. for 20 minutes in a microwave reactor. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 100: 0) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient). Purification with 20 mM triethylamine in water) gave 692 as a pale yellow solid (30 mg, 31%). LCMS (Method E) R _T 4.77 min; [M + H] ⁺ 505. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.98 (s, 1H); 7.91 (dd, J = 7.2, 1.2 Hz, 1H); 7.66 (d, J = 8. 7.30-7.25 (m, 1H); 4.38 (s, 4H); 3.96 (s, 3H); 3.89 (t, J = 4.7 Hz, 4H) 3.75 (s, 2H); 2.96 (d, J = 11.0 Hz, 2H); 2.54 (s, 3H); 2.12 (t, J = 11.0 Hz, 2H); 1 81-1.71 (m, 1H); 1.45-1.23 (m, 4H); 1.19 (s, 6H)

Example 693 2-methyl-2- (4-((2- (2-methylimidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidine-6- Yl) methyl) piperazin-1-yl) propanamide 693
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (2 mL) Isobutyramide (150 mg, 0.21 mmol), 5-bromo-2-methyl-imidazo [1,2-a] pyridine (55 mg, 0.26 mmol), Pd (PPh ₃ ) ₄ (24 mg, 0.02 mmol) and thiophene A mixture of copper (I) -2-carboxylate (8 mg, 0.04 mmol) was purged with argon gas and then heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98 gradient). Purification with 20 mM triethylamine in water) gave 693 as a white solid (55 mg, 47%). LCMS (Method E): R _T 4.99 min; [M + H] ⁺ 535. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 8.98 (s, 1H); 7.92-7.89 (m, 1H); 7.68 (d, J = 8.8 Hz, 1H); 7 .39 (s, 1H); 7.27-7.23 (m, 1H); 7.09 (d, J = 5.3 Hz, 1H); 5.22 (d, J = 5.3 Hz, 1H) 4.09-4.04 (m, 4H); 3.94-3.87 (m, 4H); 3.87 (s, 2H); 2.62 (m, 8H); 2.54 (s); , 3H); 1.29-1.23 (m, 6H)

Example 694 2-methyl-2- (4-((2- (7-methylimidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidine-6- Yl) methyl) piperazin-1-yl) propanamide 694
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (2 mL) Isobutyramide (150 mg, 0.22 mmol), 5-bromo-7-methyl-imidazo [1,2-a] pyridine (55 mg, 0.26 mmol), Pd (PPh ₃ ) ₄ (25 mg, 0.02 mmol) and thiophene A mixture of copper (I) -2-carboxylate (8 mg, 0.04 mmol) was purged with argon gas and then heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g). After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ in MeOH. The resulting residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2:98). In a gradient of 20 mM triethylamine in water) to give 694 as a white solid (38 mg, 32%). LCMS (Method E): R _T 5.09 min; [M + H] ⁺ 535. ¹ H NMR (400 MHz, CHCl ₃ -d): δ 9.05 (s, 1H); 7.76 (d, J = 1.5 Hz, 1H); 7.66 (d, J = 1.5 Hz, 1H) 7.55 (s, 1H); 7.37 (s, 1H); 7.09 (d, J = 5.3 Hz, 1H); 5.22 (d, J = 5.3 Hz, 1H); 4 .10-4.04 (m, 4H); 3.93-3.88 (m, 4H); 3.87 (s, 2H); 2.61 (m, 8H); 2.50 (s, 3H) ); 1.25 (s, 6H)

Example 695 2-methyl-2- (4-((4-morpholino-2- (1H-pyrrolo [2,3-b] pyridin-4-yl) thieno [3,2-d] pyrimidin-6-yl ) Methyl) piperazin-1-yl) propanamide 695
2- [4- (4-Morpholin-4-yl-2- (tributlystannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] isobutyl in toluene (8 mL) Amide (0.331 g, 0.48 mmol), 4-bromopyrrolo [2,3-b] pyridine-1-carboxylic acid tert-butyl ester (0.170 g, 0.573 mmol), Pd (Ph ₃ ) ₄ (55. A mixture of 1 mg, 0.048 mmol) and CuI (109 mg, 0.573 mmol) was purged with argon and exposed to microwave irradiation at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The residue was dissolved in DCM / TFA (8 mL / 8 mL) and the resulting solution was stirred for 2 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 5:95) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 70:30 to 40:60 gradient in water 20 mM). Of triethylamine) to give 695 as a white powder (0.049 g, 20%). LCMS (Method F): R _T 5.07 min, [M + H] ⁺ 521.3. ¹ H NMR (CDCl ₃ , 400 MHz) δ 8.93 (s, 1H); 8.43 (d, J = 5.2 Hz, 1H); 8.08 (d, J = 5.2 Hz, 1H); 43 (d, J = 2.2 Hz, 2H); 7.38 (s, 1H); 7.09 (d, J = 5.2 Hz, 1H); 5.24 (d, J = 5.2 Hz, 1H) ); 4.10 (t, J = 4.7 Hz, 4H); 3.92 (t, J = 4.7 Hz, 4H); 3.86 (s, 2H); 2.65-2.58 (m) , 4H); 1.60-1.55 (m, 4H); 1.24 (s, 6H)

Example 696 2-methyl-2- (4-((7-methyl-4-morpholino-2- (1H-pyrrolo [2,3-b] pyridin-4-yl) thieno [3,2-d] pyrimidine -6-yl) methyl) piperazin-1-yl) propanamide 696
2- [4- (7-methyl-4-morpholin-4-yl-2- (tributylstannanyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazine in toluene (5 mL) 1-yl] isobutyramide (200 mg, 0.28 mmol), 4-bromo-pyrrolo [2,3-b] pyridine-1-carboxylic acid tert-butyl ester (100 mg, 0.34 mmol), Pd (Ph ₃ ) ₄ A mixture of (33 mg, 0.028 mmol) and CuI (65 mg, 0.34 mmol) was purged with argon gas and then exposed to microwave irradiation at 140 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ . The residue was dissolved in DCM / TFA (8 mL / 8 mL) and stirred for 2 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted using 2M NH ₃ . The residue was purified by column chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 05:95) to give 696 as a white powder (0.036 g, 24%). LCMS (Method F): R _T 5.68 min, [M + H] ⁺ 535.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.42-8.74 (m, 1H); 8.59-7.95 (m, 1H); 7.92-7.49 (m, 1H); 46-7.35 (m, 2H); 7.14-7.06 (m, 1H); 5.27 (s, 1H); 4.09 (t, J = 4.2 Hz, 4H); 92 (t, J = 4.2 Hz, 4H); 3.85 (s, 2H); 2.66-2.61 (m, 4H); 2.53 (s, 3H); 1.63-1. 58 (m, 4H); 1.26 (s, 6H)

Example 697 2- (4-((2- (imidazo [1,2-a] pyridin-5-yl) -4-morpholinothieno [3,2-d] pyrimidin-6-yl) methyl) piperazine-1 -Il) -2-Methylpropanamide 697
2- [4- (4-morpholin-4-yl-2- (trinanstannyl) thieno [3,2-d] pyrimidin-6-ylmethyl) piperazin-1-yl] in dioxane (5 mL) Isobutyramide (0.35 g, 0.51 mmol), 5-bromoimidazo [1,2-a] pyridine (0.11 g, 0.56 mmol), copper (I) 2-thiophenecarboxylate (0.019 g, .0. 1 mmol) and Pd (PPh ₃ ) ₄ (0.059 g, 0.05 mmol) were subjected to microwave irradiation at 140 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. After washing the cartridge with MeOH, the desired product was eluted with 2M NH ₃ . The eluent was concentrated under vacuum and the residue was purified by flash chromatography (Si-PPC, MeOH: DCM, gradient 0: 100 to 10:90). The residue was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted using 2M NH ₃ in MeOH. The solution was concentrated in vacuo and the residue was purified by reverse phase HPLC (Phenomenex Gemini 5u C18, 20 mM triethylamine in water with a gradient of acetonitrile 75:25 to 2:98) to give 697 as a white powder (0 117 g, 45%). LCMS: R _T = 4.35 min, [M + H] ⁺ 521.2. ¹ H NMR (400 MHz, DMSO-d6): δ 9.33 (d, J = 1.1 Hz, 1H); 8.04 (dd, J = 7.5, 1.2 Hz, 1H); 7.78 (dd , J = 8.9, 1.1 Hz, 1H); 7.74 (d, J = 1.2 Hz, 1H); 7.54 (s, 1H); 7.41 (dd, J = 8.9, 7.07 (d, J = 3.5 Hz, 1H); 6.95 (d, J = 3.5 Hz, 1H); 4.00 (t, J = 4.7 Hz, 4H) 3.89 (s, 2H); 3.82 (t, J = 4.7 Hz, 4H); 2.56-2.54 (m, 4H); 2.49-2.44 (m, 4H) ); 1.08 (s, 6H)

Example 698 2- (1-((2- (imidazo [1,2-a] pyridin-5-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine-4- Il) Propan-2-ol 698
2- [1- (9-Methyl-6-morpholin-4-yl-2- (tributylstannanyl) -9H-purin-8-ylmethyl) piperidin-4-yl] propane in dioxane (5 mL) -2-ol (0.2 g, 0.30 mmol), 5-bromoimidazo [1,2-a] pyridine (0.066 g, 0.33 mmol), copper (I) 2-thiophenecarboxylate (0.018 g, 0.09 mmol) and Pd (PPh ₃ ) ₄ (0.052 g, 0.045 mmol) were subjected to microwave irradiation at 150 ° C. for 60 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The eluent was concentrated under vacuum and the resulting residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 94: 6) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95). Purification of 20 mM triethylamine in water with a gradient of 5 to 2:98) gave 698 as a yellow powder (0.085 g, 58%). LCMS: R _T = 4.17 min, [M + H] ⁺ 491.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.26 (d, J = 1.2 Hz, 1H); 7.96 (dd, J = 8.2, 1.2 Hz, 1H); 7.76-7.73 (M, 2H); 7.31 (dd, J = 8.2, 5.2 Hz, 1H); 4.38 (t, J = 4.6 Hz, 4H); 3.96 (s, 3H); 3 .89 (t, J = 4.6 Hz, 4H); 3.75 (s, 2H); 2.96 (d, J = 11.0 Hz, 2H); 2.11 (t, J = 11.0 Hz, 2H); 1.76 (d, J = 11.0 Hz, 2H); 1.44-1.29 (m, 3H); 1.18 (s, 6H)

Example 699 2- (1-((5- (imidazo [1,2-a] pyridin-5-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) piperidine- 4-yl) propan-2-ol 699
2- [1- (5-Imidazo [1,2-a] pyridin-5-yl-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) piperidine-in dioxane (3 mL) 4-yl] propan-2-ol (0.25 g, 0.37 mmol), 5-bromoimidazo [1,2-a] pyridine (0.082 g, 0.41 mmol), copper (I) 2-thiophenecarboxylate A mixture of (0.015 g, 0.075 mmol) and Pd (PPh ₃ ) ₄ (0.044 g, 0.037 mmol) was subjected to microwave irradiation at 150 ° C. for 60 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The eluent was concentrated under vacuum and the residue was flash chromatographed (Si-PPC, MeOH: DCM, gradient 0: 100 to 90:10) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5. To 699 as a yellow powder (0.052 g, 28%). LCMS (Method E): R _T = 4.38 min, [M + H] ⁺ 494.2. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.19 (s, 1H); 7.99 (dd, J = 7.2, 1.3 Hz, 1H); 7.81 (d, J = 8.9 Hz, 1H) ); 7.76 (d, J = 1.3 Hz, 1H); 7.33 (dd, J = 8.9, 7.2 Hz, 1H); 4.48-4.35 (m, 4H); 3 .92-3.85 (m, 7H); 3.10 (d, J = 11.2 Hz, 2H); 2.23 (t, J = 11.2 Hz, 2H); 1.83-1.77 ( m, 2H); 1.54-1.41 (m, 2H); 1.38-1.29 (m, 1H); 1.22 (s, 6H)

Example 700 4- (5- (imidazo [1,2-a] pyridin-5-yl) -2-((3-morpholinoazetidin-1-yl) methyl) thiazolo [5,4-d] pyrimidine- 7-yl) morpholine 700
7-morpholin-4-yl-2- (3-morpholin-4-ylazetidin-1-ylmethyl) -5- (tributylstannanyl) thiazolo [5,4-d] pyrimidine (3 mL) in dioxane (3 mL) 0.25 g, 0.37 mmol), 5-bromoimidazo [1,2-a] pyridine (0.082 g, 0.41 mmol), copper (I) 2-thiophenecarboxylate (0.015 g, 0.075 mmol) and A mixture of Pd (PPh ₃ ) ₄ (0.044 g, 0.037 mmol) was subjected to microwave irradiation at 150 ° C. for 60 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the desired product was eluted with 2M NH ₃ . The eluent was concentrated under vacuum and the residue was flash chromatographed (Si-PPC, MeOH: DCM, 0: 100 to 10:90) followed by reverse phase HPLC (Phenomenex Gemini 5u C18, acetonitrile 95: 5 to 2 Purified with a gradient of 98 mM 20 mM triethylamine in water) to give 700 as a yellow solid (0.101 g, 55%). LCMS (Method E): R _T = 3.98 min, [M + H] ⁺ 493.15. ¹ H NMR (CDCl ₃ , 400 MHz) δ 9.16 (s, 1H); 7.98 (dd, J = 7.2, 1.2 Hz, 1H); 7.81 (d, J = 8.9 Hz, 1H) ); 7.76 (d, J = 1.2 Hz, 1H); 7.33 (dd, J = 8.9, 7.2 Hz, 1H); 4.47-4.32 (m, 4H); 4 .04 (s, 2H); 3.89 (t, J = 4.6 Hz, 4H); 3.74 (t, J = 4.6 Hz, 4H); 3.69 (t, J = 6.4 Hz, 2H); 3.23-3.15 (m, 2H); 3.14 (t, J = 6.4 Hz, 1H); 2.40-2.36 (m, 4H)

ＴＨＦ（３ｍＬ）及びＨ_２Ｏ（４ｍＬ）中の２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-８-ピペリジン-４-イル-９Ｈ-プリン塩酸塩（３９６ｍｇ、０．８９ｍｍｏｌ）の溶液に１ＭのＨＣｌを加えてｐＨ４とし、続いてＮａＣＮ（２６１ｍｇ、５．３２ｍｍｏｌ）及びプロパン-２-オン（５９０μＬ、７．９８ｍｍｏｌ）を加えた。生じた混合物を室温で１６時間攪拌し、Ｈ_２Ｏ及びＤＣＭの間で分配した。有機相を乾燥させ（相分離器）、真空下で濃縮した。生じた残留物をＥｔ_２Ｏで倍散し、濾過により固形物を回収し、真空下で乾燥して、２-{４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]ピペリジン-１-イル}-２-メチルプロピオニトリル（３１６ｍｇ、６９％）を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．６４分，［Ｍ＋Ｈ］^＋５１４．４ Example 703 2- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) piperidin-1-yl ) -2-Methylpropanamide 703

2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-8-piperidin-4-yl-9H-purine in THF (3 mL) and H ₂ O (4 mL) To a solution of hydrochloride (396 mg, 0.89 mmol) was added 1 M HCl to pH 4 followed by NaCN (261 mg, 5.32 mmol) and propan-2-one (590 μL, 7.98 mmol). The resulting mixture was stirred at room temperature for 16 hours and partitioned between H ₂ O and DCM. The organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was triturated with Et ₂ O and the solid was collected by filtration and dried under vacuum to give 2- {4- [2- (2-ethylbenzimidazol-1-yl) -9- Methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-1-yl} -2-methylpropionitrile (316 mg, 69%) was obtained. LCMS (Method H): R _T 2.64 min, [M + H] ⁺ 514.4.

2- {4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-1-yl} -2-methyl Propionitrile (300 mg, 0.58 mmol) was slowly added to concentrated H ₂ SO ₄ (3.5 mL). The resulting mixture was stirred at room temperature for 3 hours, poured onto ice and basified with K ₂ CO ₃ . The resulting mixture was extracted with DCM and the combined organic phases were dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) and loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product was 2M Eluting with NH ₃ / MeOH gave 703 (177 mg, 57%). LCMS (Method I): R _T 2.45 min, [M + H] ⁺ 532.3. ¹ H NMR (DMSO, 400 MHz): δ 8.01-7.97 (1H, m), 7.63-7.62 (1H, m), 7.23-7.22 (3H, m), 6. 93 (1H, d, J = 3.36 Hz), 4.26 (4H, brds), 3.79-3.74 (7H, m), 3.26 (2H, q, J = 7.42 Hz) 3.07-2.97 (1H, m), 2.88 (2H, d, J = 10.76 Hz), 2.32-2.21 (2H, m), 1.93-1.91 ( 4H, m), 1.33 (3H, t, J = 7.44 Hz), 1.12 (6H, s)

Example 711 1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -4-isopropylpiperazine -2-on 711
To a solution of 4-isopropylpiperazin-2-one (56 mg, 0.35 mmol) in DMF (3 mL) was added sodium hydride (18 mg, 0.45 mmol, 60% dispersion in mineral oil) at 0 ° C. resulting The mixture was stirred for 30 minutes and 8-bromomethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (200 mg, 0) in DMF (2 mL). .44 mmol) solution was added. The resulting mixture was stirred for 72 hours at room temperature and partitioned between DCM and H ₂ O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of 30-70% acetonitrile). 711 was obtained as a white solid (22 mg, 15%). LCMS: R _T 2.43 min, [M + H] ⁺ 518.2. ¹ H NMR (DMSO, 400 MHz): δ 8.01-8.01 (1H, m), 7.63-7.62 (1H, m), 7.25-7.24 (2H, m), 4. 83 (2H, s), 4.26 (4H, brd s), 3.77 (4H, t, J = 4.61 Hz), 3.74 (3H, s), 3.31 (2H, m), 3.26 (2H, q, J = 7.45 Hz), 3.15 (2H, s), 2.69-2.68 (3H, m), 1.33 (3H, t, J = 7.44 Hz) ), 0.98 (6H, d, J = 6.50 Hz)

Example 712 2- (5- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) -1- (4- (1-Hydroxy-2-methylpropan-2-yl) piperazin-1-yl) ethanone 712
2- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl) -1- [4- (2-hydroxy-1,1-dimethylethyl) in dioxane (2 mL) ) Piperazin-1-yl] ethanone (65 mg, 0.14 mmol), 2-ethylbenzimidazole (23 mg, 0.16 mmol), tris (dibenzylideneacetone) dipalladium (4 mg, 2.5 mol%), Xphos (7 mg, 10 mol%) and Cs ₂ CO ₃ (70 mg, 0.21 mmol) were purged with argon and then heated at 110 ° C. for 24 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product was eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 10-95% gradient in 20 nM NEt ₃ in water). To give 712 as a yellow solid (14 mg, 17%). LCMS (Method I): R _T 2.58 min, [M + H] ⁺ 565.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-7.98 (1H, m), 7.76-7.75 (1H, m), 7.29-7.29 (2H, m), 4 .41 (4H, s), 4.18 (2H, s), 3.93-3.75 (9H, m), 3.56 (2H, brds), 3.34 (2H, q, J = 7) .47 Hz), 2.90-2.70 (4H, brd m), 1.43 (3H, t, J = 7.47 Hz), 1.23-1.21 (6H, m)

ＴＨＦ（１００ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（３．５ｇ、１３．８ｍｍｏｌ）及びＴＭＥＤＡ（３．１ｍＬ、２０．７ｍｍｏｌ）の混合物に−７８℃でｎ-ＢｕＬｉ（８．３ｍＬ、ヘキサン中２．５Ｍ、２０．７ｍｍｏｌ）を加えた。生じた混合物を−３０℃まで４５分かけて温め、ついで−７８℃に再び冷却し、ＴＨＦ（１０ｍＬ）中の３-オキソ-ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（４．１ｇ、２０．７ｍｍｏｌ）を加えた。反応混合物を室温まで温め、２時間攪拌し、Ｈ_２Ｏでクエンチして、ＥｔＯＡｃで抽出した。組み合わせた有機相をブラインで洗浄し、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をＥｔ_２Ｏで倍散して、未反応の出発物質を濾過により除去した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、３０−８０％）で精製し、ついでシクロヘキサンで倍散し、３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５．０ｇ、８１％）を得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．５０分［Ｍ＋Ｈ］^＋４５３．３ Example 713 4- (2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -8- (3-methoxy-1- (2- (methylsulfonyl) ethyl) piperidin-3-yl) -9-methyl-9H-purin-6-yl) morpholine 713

-78 to a mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (3.5 g, 13.8 mmol) and TMEDA (3.1 mL, 20.7 mmol) in THF (100 mL). N-BuLi (8.3 mL, 2.5 M in hexane, 20.7 mmol) was added at ° C. The resulting mixture was warmed to −30 ° C. over 45 min, then re-cooled to −78 ° C. and 3-oxo-piperidine-1-carboxylic acid tert-butyl ester (4.1 g, 20 .20) in THF (10 mL). 7 mmol) was added. The reaction mixture was warmed to room temperature, stirred for 2 h, quenched with H ₂ O and extracted with EtOAc. The combined organic phases were washed with brine, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was triturated with Et ₂ O and unreacted starting material was removed by filtration. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 30-80%), then triturated with cyclohexane and 3- (2-chloro-9-methyl-6-morpholine-4- Ile-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (5.0 g, 81%) was obtained. LCMS (Method A): R _T 3.50 min [M + H] ⁺ 453.3.

ＴＨＦ（１００ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（４．５４ｇ、１０．０２ｍｍｏｌ）の溶液にＮａＨ（４８１ｍｇ、１２．０２ｍｍｏｌ、鉱油中６０％の分散液）を加え、混合物を５分間攪拌し、ヨードメタン（７５０μＬ、１２．０２ｍｍｏｌ）及び１５−クラウン−５（１０滴）を加えた。生じた混合物を２．５時間攪拌した。ついで真空下で濃縮した。生じた残留物をＥｔＯＡｃ及びＨ_２Ｏの間で分配し、水性層を更に２-メチルＴＨＦで抽出した。組み合わせた有機相を乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮して３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-３-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（４．３０ｇ、９２％）を得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ４．０５分，［Ｍ＋Ｈ］^＋４６７．２

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylic acid tert-butyl ester in THF (100 mL) (4. 54 g, 10.02 mmol) NaH (481 mg, 12.02 mmol, 60% dispersion in mineral oil) was added and the mixture was stirred for 5 minutes before iodomethane (750 μL, 12.02 mmol) and 15-crown-5 ( 10 drops) was added. The resulting mixture was stirred for 2.5 hours. It was then concentrated under vacuum. The resulting residue was partitioned between EtOAc and H ₂ O and the aqueous layer was further extracted with 2-methyl THF. The combined organic phases were dried (Na ₂ SO ₄ ) and concentrated in vacuo to give 3- (2-chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -3- Methoxypiperidine-1-carboxylic acid tert-butyl ester (4.30 g, 92%) was obtained. LCMS (Method A): R _T 4.05 min, [M + H] ⁺ 467.2.

ジオキサン（５０ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-３-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（３．０ｇ、６．４２ｍｍｏｌ）、２-イソプロピルベンゾイミダゾール（１．２４ｇ、７．７１ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（１５０ｍｇ、０．１６ｍｍｏｌ）、ＸＰｈｏｓ（３０６ｍｇ、０．６４ｍｍｏｌ）及びＣｓ_２ＣＯ_３（３．１４ｇ、９．６４ｍｍｏｌ）の混合物にアルゴンをパージし、ついで１１０℃で１６時間加熱した。反応混合物をＥｔＯＡｃ及びＨ_２Ｏの間で分配し、有機相をブラインで洗浄し、ついで乾燥させた（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、３０−７０％）で精製して、３-[２-(２-イソプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２．４７ｇ、６５％）を得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ３．５２分，［Ｍ＋Ｈ］^＋５９１．５

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -3-methoxypiperidine-1-carboxylic acid tert-butyl ester in dioxane (50 mL) (3. 0 g, 6.42 mmol), 2-isopropylbenzimidazole (1.24 g, 7.71 mmol), tris (dibenzylideneacetone) dipalladium (150 mg, 0.16 mmol), XPhos (306 mg, 0.64 mmol) and Cs ₂ CO A mixture of ₃ (3.14 g, 9.64 mmol) was purged with argon and then heated at 110 ° C. for 16 hours. The reaction mixture was partitioned between EtOAc and H ₂ O and the organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 30-70%) to give 3- [2- (2-isopropylbenzimidazol-1-yl) -9-methyl-6- Morpholin-4-yl-9H-purin-8-yl] -3-methoxypiperidine-1-carboxylic acid tert-butyl ester (2.47 g, 65%) was obtained. LCMS (Method A): R _T 3.52 min, [M + H] ⁺ 591.5.

ＤＣＭ（１００ｍＬ）中の３-[２-(２-イソプロピルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２．４７ｇ、４．１８ｍｍｏｌ）の溶液にジオキサン（１０ｍＬ）中の４ＭのＨＣｌを加えた。生じた混合物を室温で２時間攪拌し、更にＭｅＯＨ（２０ｍＬ）中の１．２５ＭのＨＣｌを加えた。生じた混合物を１．５時間攪拌し、ついで真空下で濃縮した。生じた残留物をＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジ（ＭｅＯＨで洗浄した）に充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出して、２-(２-イソプロピルベンゾイミダゾール-１-イル)-８-(３-メトキシピペリジン-３-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（１．８３ｇ、８９％）を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．１２分［Ｍ＋Ｈ］^＋４９１．４

3- [2- (2-Isopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-methoxypiperidine-1 in DCM (100 mL) To a solution of carboxylic acid tert-butyl ester (2.47 g, 4.18 mmol) was added 4M HCl in dioxane (10 mL). The resulting mixture was stirred at room temperature for 2 hours, and more 1.25 M HCl in MeOH (20 mL) was added. The resulting mixture was stirred for 1.5 hours and then concentrated under vacuum. The resulting residue was loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product eluted with 2M NH ₃ / MeOH to give 2- (2-isopropylbenzimidazol-1-yl. ) -8- (3-Methoxypiperidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (1.83 g, 89%) was obtained. LCMS (Method H): R _T 2.12 min [M + H] ⁺ 491.4.

2- (2-Isopropylbenzimidazol-1-yl) -8- (3-methoxypiperidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (150 mg in IMS (5 mL) , 0.31 mmol) and methanesulfonylethene (32 μL, 0.37 mmol) were stirred for 4 hours at room temperature, and then the reaction mixture was poured into H ₂ O. The resulting precipitate was collected by filtration and dried under vacuum to give 713 (141 mg, 77%). LCMS (Method I): R _T 2.82 min, [M + H] ⁺ 597.2. ¹ H NMR (DMSO, 400 MHz): δ 7.92-7.91 (1H, m), 7.65-7.64 (1H, m), 7.24-7.23 (2H, m), 4. 25 (4H, brd s), 4.00-3.85 (4H, m), 3.8-3.75 (4H, m), 3.40-3.20 (2H, m), 3.15 -3.00 (4H, m), 2.95 (3H, s), 2.81-2.76 (4H, m), 2.30-2.20 (1H, m), 2.10-2 .95 (2H, m), 1.84 to 1.74 (2H, m), 1.36 (6H, dd, J = 6.77, 2.96 Hz)

Example 714 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxyazetidine-1 Tert-Butyl carboxylic acid 714
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-hydroxyazetidine- in THF (3 mL) To a solution of 1-carboxylic acid tert-butyl ester (208 mg, 0.39 mmol) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil) and stirred for 5 hours, the mixture was stirred for 5 hours and iodomethane. (29 μL, 66 mg, 0.47 mmol) was added. The resulting mixture was stirred for 3.5 hours and more iodomethane (29 μL, 66 mg, 0.47 mmol) was added. The mixture was stirred for 16 hours and then concentrated under vacuum. The resulting residue was partitioned between EtOAc and _{H 2} O. The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 40-80%) to give 714 as an oil (123 mg, 57%). LCMS (Method I): R _T 4.49 min, [M + H] ⁺ 549.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.90 (1H, m), 7.74-7.64 (1H, m), 7.25-7.16 (2H, m), 4 .60-4.40 (4H, brd m), 4.18 (2H, d, J = 9.17 Hz), 3.82-3.81 (6H, m), 3.71 (3H, s), 3.29 (2H, t, J = 7.54 Hz), 3.07 (3H, s), 1.42-1.33 (12H, m).

Example 715 (2,2-dimethyl-4- (methylsulfonyl) piperazin-1-yl) (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino -9H-purin-8-yl) methanone 715
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylic acid (117 mg, 0.26 mmol) in DMF (1 mL), 1- NEt ₃ (720 μL, 5.18 mmol) was added to a mixture of methanesulfonyl-3,3-dimethylpiperazine (51 mg, 0.26 mmol) and HATU (100 mg, 0.26 mmol). The resulting mixture was stirred at room temperature for 16 hours and partitioned between EtOAc and H ₂ O. The organic phase was dried (MgSO _4), concentrated under vacuum and the resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc , 0-5%) was purified by. The resulting solid was recrystallized from EtOAc and Et ₂ O to give 715 (50 mg, 33%). LCMS (Method I): R _T 3.68 min, [M + H] ⁺ 582.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-8.03 (1H, m), 7.76-7.75 (1H, m), 7.31-7.27 (2H, m), 4 .35 (4H, brd s), 4.03 (2H, t, J = 5.39 Hz), 3.95 (3H, s), 3.87 (4H, t, J = 4.70 Hz), 3. 50 (2H, t, J = 5.40 Hz), 3.37 (2H, q, J = 7.47 Hz), 3.31 (2H, s), 2.90 (3H, s), 1.68 ( 6H, s), 1.45 (3H, t, J = 7.47 Hz)

Example 716 2- (3- (2- (2- (Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxypiperidine -1-yl) acetamide 716
2- (2-Isopropylbenzimidazol-1-yl) -8- (3-methoxypiperidin-3-yl) -9-methyl-6-morpholin-4-yl- from Example 713 in MeCN (20 mL) A mixture of 9H-purine (1.0 g, 2.10 mmol), 2-bromoacetamide (290 mg, 2.10 mmol), sodium iodide (32 mg, 0.21 mmol) and K ₂ CO ₃ (610 mg, 4.41 mmol). Stir at room temperature for 66 hours. The reaction mixture was diluted with EtOAc, filtered and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) and triturated with Et ₂ O to give 716 (675 mg, 59%). LCMS (Method I): R _T 2.66 min, [M + H] ⁺ 548.2. ¹ H NMR (DMSO, 400 MHz): δ 7.93-7.92 (1H, m), 7.66-7.62 (1 H, m), 7.26-7.22 (2H, m), 7. 14 (1H, s), 7.07 (1H, s), 4.26 (4H, brds), 3.98-3.88 (4H, m), 3.80-3.75 (4H, m ), 3.10-3.00 (4H, m), 3.00-2.90 (3H, m), 2.70-2.60 (1H, m), 2.45-2.35 (1H) M), 2.15-1.95 (2H, m), 1.95-1.77 (1H, m), 1.78-1.68 (1H, m), 1.37-1.37. (6H, m)

Example 717 2- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3 , 3-Dimethylpiperazin-1-yl) acetamide 717
8- (2,2-Dimethylpiperazin-1-ylmethyl) -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (5 mL) (120 mg, 0.25 mmol) A mixture of 2-chloroacetamide (50 mg, 0.54 mmol) and NEt ₃ (50 μL, 0.36 mmol) was stirred at room temperature for 5 hours, and further 2-chloroacetamide (100 mg, 1.07 mmol). ) And NEt ₃ (100 μL, 0.72 mmol). The resulting mixture was stirred for 84 hours, loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product eluted with 2M NH ₃ / MeOH. The resulting residue was charged with column chromatography (Si-PCC, MeOH: EtOAc, 0-5%) to give 717 (65 mg, 49%). LCMS (Method I): R _T 2.54 min, [M + H] ⁺ 547.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.99 (1H, m), 7.77-7.74 (1H, m), 7.32-7.22 (2H, m), 6 .95 (1H, brd s), 5.43 (1H, brd s), 4.34 (4H, brd s), 3.90 (3H, s), 3.86 (6H, t, J = 4. 76 Hz), 3.35 (2H, q, J = 7.48 Hz), 2.96 (2H, s), 2.62-2.45 (4H, m), 2.38 (2H, s), 1 .45 (3H, t, J = 7.48 Hz), 1.25 (6H, s)

Example 718 (S) -1- (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) -2-hydroxypropan-1-one 718
8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (100 mg, 0.23 mmol) in DCM (2 mL) , HATU (96 mg, 0.25 mmol) was added to a mixture of L-lactic acid (23 mg, 0.25 mmol) and DIPEA (45 μL, 0.25 mmol). The resulting yellow mixture was stirred for 2.5 hours at room temperature and then partitioned between DCM and H ₂ O. The combined organic phases were dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting oil was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was subjected to column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 20-35% gradient in 0.1% HCO ₂ H in water. ) To give 718 as a white solid (19 mg, 16%). LCMS (Method I): R _T 2.92 min, [M + H] ⁺ 505.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.98-7.97 (1H, m), 7.90-7.80 (1H, m), 7.40-7.30 (2H, m), 4 .33-4.32 (7H, m), 4.01-4.00 (1H, m), 3.86-3.85 (5H, m), 3.77 (3H, d, J = 1. 96 Hz), 3.50-3.35 (4H, m), 3.19-3.17 (2H, m), 1.48 (3H, t, J = 7.42 Hz), 1.34 (3H, dd, J = 6.69, 4.73 Hz)

Example 720 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1- (tetrahydro-2H- Pyran-4-yl) azetidine-3-ol 720
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -azetidin-3-ol (15 mL) in DCE (15 mL) 490 mg, 1.13 mmol), tetrahydropyran-4-one (158 mg, 1.58 mmol), AcOH (130 μL, 2.25 mmol) and 4Å powdered molecular sieves (640 mg) are stirred for 5 minutes and triacetoxy hydrogenated Sodium boron (478 mg, 2.25 mmol) was added in portions over 5 minutes. The resulting mixture was stirred for 4 hours at room temperature and more tetrahydropyran-4-one (158 mg, 1.58 mmol) and sodium triacetoxyborohydride (478 mg, 2.25 mmol) were added. The mixture was stirred for 2 hours, diluted with DCM and washed with 1M NaOH. The organic phase was dried (phase separator) and concentrated under vacuum. The resulting oil was purified by column chromatography (Si-PCC, 2M in _{NH 3 / MeOH: DCM, 0-15} %) and then _{(C18, MeOH: H 2 O} , 7.5-25%) was purified by. The resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with DCM and MeOH and the product was eluted with 2M NH ₃ / MeOH to give 720 as a white foam (309 mg, 53%). LCMS (Method I): R _T 2.40 min, [M + H] ⁺ 519.3. ¹ H NMR (MeOD, 400 MHz): δ 8.01-8.00 (1H, m), 7.66-7.61 (1H, m), 7.28-7.27 (2H, m), 4. 38 (4H, s), 4.24 (2H, d, J = 8.76 Hz), 3.97-3.94 (2H, m), 3.85 (7H, s), 3.56 (2H, d, J = 8.75 Hz), 3.31-3.31 (5H, m), 2.54-2.52 (1H, m), 1.83-1.73 (2H, m), 1. 38 (5H, t, J = 7.49Hz)

Example 721 1- (3-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-hydroxy-2-methylpropan-1-one 721
8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (60 mg, 0.14 mmol) in DCM (1 mL) HATU (63 mg, 0.17 mmol) was added to a mixture of 2-hydroxyisobutyric acid (17 mg, 0.17 mmol) and DIPEA (29 μL, 0.17 mmol). The resulting yellow mixture was stirred for 1.5 hours at room temperature, then the reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM and MeOH and the product eluted with 2M NH ₃ / MeOH. I let you. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-6%) to give 721 as a foam (41 mg, 56%). LCMS (Method I): R _T 3.00 min, [M + H] ⁺ 519.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00-7.97 (1H, m), 7.75-7.74 (1H, m), 7.27-7.25 (2H, m), 4 .62 (1H, s), 4.33 (5H, s), 4.20 (1H, s), 3.93 (1H, s), 3.86 (4H, t, J = 4.72 Hz), 3.76 (3H, s), 3.64 (1H, s), 3.34 (3H, q, J = 7.44 Hz), 3.15-3.14 (2H, m), 1.43- 1.42 (9H, m)

Example 722 (R) -1- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) -3,3-dimethylpiperazin-1-yl) -2-hydroxypropan-1-one 722
8- (2,2-Dimethylpiperazin-1-ylmethyl) -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (2 mL) A mixture of (100 mg, 0.20 mmol), D-lactic acid (20 mg, 0.22 mmol), HATU (85 mg, 0.22 mmol) and DIPEA (40 μL, 0.23 mmol) was stirred at room temperature for 16 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 2%) to give 722 as a white solid (37 mg, 33%). LCMS (Method I): R _T 2.90 min, [M + H] ⁺ 562.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.04-7.99 (1H, m), 7.77-7.76 (1H, m), 7.35-7.25 (2H, m), 4 .47-4.45 (1H, m), 4.34 (4H, brd s), 4.02-3.98 (1H, m), 3.91 (3H, s), 3.86 (4H, t, J = 4.67 Hz), 3.82-3.68 (2H, m), 3.50-3.49 (1H, m), 3.40-3.31 (3H, m), 3. 27-3.16 (1H, m), 2.57-2.55 (2H, m), 1.45 (3H, t, J = 7.47 Hz), 1.39-1.28 (4H, m ), 1.27-1.15 (5H, m)

Example 723 (S) -1- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) -3,3-dimethylpiperazin-1-yl) -2-hydroxypropan-1-one 723
8- (2,2-Dimethylpiperazin-1-ylmethyl) -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (2 mL) A mixture of (100 mg, 0.20 mmol), L-lactic acid (17 μL, 0.22 mmol), HATU (85 mg, 0.22 mmol) and DIPEA (40 μL, 0.23 mmol) was stirred at room temperature for 16 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 2%) to give 723 as a white solid (27 mg, 29%). LCMS (Method I): R _T 2.90 min, [M + H] ⁺ 562.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-8.00 (1H, m), 7.78-7.74 (1H, m), 7.35-7.25 (2H, s), 4 .46-4.43 (1H, m), 4.34 (4H, brd s), 4.06-3.94 (1H, m), 3.91 (3H, s), 3.86 (4H, t, J = 4.68 Hz), 3.76-3.75 (2H, m), 3.50-3.48 (1H, m), 3.37-3.35 (3H, m), 3. 24-3.22 (1H, m), 2.59-2.53 (2H, m), 1.45 (3H, t, J = 7.48 Hz), 1.34-1.30 (4H, m ), 1.26-1.15 (5H, m)

Example 737 4- (8-(((2R, 6S) -2,6-dimethyl-4- (methylsulfonyl) piperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] Imidazol-1-yl) -9-methyl-9H-purin-6-yl) morpholine 737
8-Bromomethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine hydrobromic acid (200 mg, 0.37 mmol) in DMF (1 mL) , (3S, 5R) -1-methanesulfonyl-3,5-dimethylpiperazine (88 mg, 0.46 mmol) and K ₂ CO ₃ (150 mg, 1.09 mmol) were stirred at room temperature for 24 hours. The reaction mixture was partitioned between EtOAc and H ₂ O and the organic phase was dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%) and then recrystallized from EtOAc to give 737 (57 mg, 28%). LCMS (Method I): R _T 3.05 min, [M + H] ⁺ 568.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-7.98 (1H, m), 7.76-7.75 (1H, m), 7.26-7.25 (2H, m), 4 .34 (4H, s), 4.18 (2H, s), 3.87 (4H, t, J = 4.70 Hz), 3.84 (3H, s), 3.54-3.51 (2H M), 3.35 (2H, q, J = 7.48 Hz), 3.29-3.23 (2H, m), 2.80 (3H, s), 2.68-2.66 (2H M), 1.45 (3H, dd, J = 7.69, 7.26 Hz), 1.17 (6H, d, J = 6.36 Hz)

ＴＨＦ（４０ｍＬ）中の２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（２．５ｇ、６．８８ｍｍｏｌ）及びＴＭＥＤＡ（１．６ｍＬ、１０．３３ｍｍｏｌ）の混合物に−７８℃でｎ-ＢｕＬｉ（４．１ｍＬ、ヘキサン中２．５Ｍ，１０．３３ｍｍｏｌ）を加えた。生じた混合物を−４０℃まで３０分かけて温め、ついで再び−７８℃に冷却し、ＴＨＦ（１０ｍＬ）中の３-オキソアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．８ｇ、１０．３３ｍｍｏｌ）の溶液を加えた。反応混合物を−１０℃まで２時間以上温め、ついで飽和水性ＮＨ_４Ｃｌでクエンチし、ＥｔＯＡｃで抽出した。組み合わせた有機相をブラインで洗浄し、乾燥（Ｎａ_２ＳＯ_４）させ、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＭｅＯＨ：ＥｔＯＡｃ、０−５％）で精製して、^ｉＰｒＯＡｃ及びペンタンから再結晶化させて、３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-ヒドロキシ-アゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステルをクリーム状固形物として得た（２．４ｇ、６４％）。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．８３分［Ｍ＋Ｈ］^＋５３５．４

Example 738 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1-isopropylazetidine-3 -All 738

2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (2.5 g, 6.88 mmol) and TMEDA (1.6 mL) in THF (40 mL). N-BuLi (4.1 mL, 2.5 M in hexane, 10.33 mmol) was added to the mixture at −78 ° C. The resulting mixture was warmed to −40 ° C. over 30 minutes, then cooled again to −78 ° C. and 3-oxoazetidine-1-carboxylic acid tert-butyl ester (1.8 g, 10.33 mmol) in THF (10 mL). A solution of was added. The reaction mixture was warmed to −10 ° C. over 2 h, then quenched with saturated aqueous NH ₄ Cl and extracted with EtOAc. The combined organic phases were washed with brine, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-5%) and recrystallized from ⁱ PrOAc and pentane to give 3- [2- (2-ethylbenzimidazole- 1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester was obtained as a cream solid (2 .4g, 64%). LCMS (Method A): R _T 2.83 min [M + H] ⁺ 535.4.

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-hydroxyazetidine- in DCM (5 mL) To a solution of 1-carboxylic acid tert-butyl ester (620 mg, 1.16 mmol) was added TFA (2 mL) and the resulting mixture was stirred at room temperature for 1.5 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM and MeOH and the product eluted with 2M NH ₃ / MeOH to give 3- [2- (2-ethylbenzimidazole- 1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] azetidin-3-ol was obtained as a yellow oil (450 mg, 89%). LCMS: (Method A): R _T 1.84 min [M + H] ⁺ 435.2.

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -azetidin-3-ol (3 mL) in DCE (3 mL) 100 mg, 0.23 mmol), propan-2-one (34 μL, 27 mg, 0.46 mmol) and 4Å powdered molecular sieve (150 mg) were stirred for 3 hours and sodium triacetoxyborohydride (96 mg, 0.46 mmol). ) Was added. The resulting mixture was stirred for 16 hours at room temperature, then filtered through Celite® and washed with DCM. The filtrate was washed with brine, dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of 50-70% acetonitrile). , 738 was obtained as a white solid (15 mg, 13%). LCMS (Method I): R _T 2.43 min, [M + H] ⁺ 477.2. ¹ H NMR (MeOD, 400 MHz): δ 8.01-8.01 (1H, m), 7.64-7.61 (1H, m), 7.29-7.28 (2H, m), 4. 39 (5H, s), 4.19-4.17 (2H, m), 3.85 (4H, s), 3.46 (2H, d, J = 8.87 Hz), 3.31-3. 30 (5H, m), 2.56-2.54 (1H, m), 1.39 (3H, t, J = 7.50 Hz), 1.01 (6H, d, J = 6.25 Hz)

ＤＣＭ（２ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-メトキシアゼチジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１０９ｍｇ、０．２０ｍｍｏｌ）の溶液にＴＦＡ（１ｍＬ）を加え、生じた混合物を１．５時間室温で攪拌した。反応混合物を、ＤＣＭ及びＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出して、２-(２-エチルベンゾイミダゾール-１-イル)-８-(３-メトキシアゼチジン-３-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンを油として得た（７２ｍｇ、８０％）。ＬＣＭＳ：（方法Ａ）：Ｒ_Ｔ１．８６分［Ｍ＋Ｈ］^＋４４９．２ Example 739 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8- (1-isopropyl-3-methoxyazetidin-3-yl) -9-methyl-9H- Purin-6-yl) morpholine 739

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-methoxyazetidine- in DCM (2 mL) To a solution of 1-carboxylic acid tert-butyl ester (109 mg, 0.20 mmol) was added TFA (1 mL) and the resulting mixture was stirred for 1.5 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with DCM and MeOH and the product was eluted with 2M NH ₃ / MeOH to give 2- (2-ethylbenzimidazol-1-yl). -8- (3-Methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine was obtained as an oil (72 mg, 80%). LCMS: (Method A): R _T 1.86 min [M + H] ⁺ 449.2.

2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (20 mL) in MeOH (20 mL) 553 mg, 1.23 mmol) and propan-2-one (1.0 mL) as a slurry of 10% Pd / C (30 mg) in MeOH (0.5 mL) and the resulting mixture under H ₂ atmosphere Stir at room temperature for 1.5 hours. The reaction mixture was filtered through Celite®, washed with MeOH, and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, _NH of 2M 3 / MeOH: EtOAc, 0-12 %) and then _{(C18, MeOH: H 2 O} , 5-25%) was purified by. The resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with DCM and MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting colorless foam was recrystallized from ⁱ PrOAc and pentane to give 739 as colorless crystals (166 mg, 28%). LCMS (Method I): R _T 2.48 min, [M + H] ⁺ 491.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-8.02 (1H, m), 7.64-7.63 (1H, m), 7.29-7.28 (2H, m), 4 .40 (4H, s), 4.05 (2H, d, J = 8.89 Hz), 3.86 (4H, s), 3.81 (3H, s), 3.57-3.55 (2H , M), 3.31-3.30 (2H, m), 3.10 (3H, s), 2.54-2.53 (1H, m), 1.40 (3H, t, J = 7 .50 Hz), 1.02 (6H, d, J = 6.24 Hz)

Example 740 4- (8-((2,2-dimethyl-4- (oxetane-3-yl) piperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole-1 -Yl) -9-methyl-9H-purin-6-yl) morpholine 740
2-Chloro-8- (2,2-dimethyl-4-oxetane-3-ylpiperazin-1-ylmethyl) -9-methyl-6-morpholin-4-yl-9H-purine (90 mg) in dioxane (1 mL) 0.21 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol), tris (dibenzylideneacetone) dipalladium (5 mg, 2.5 mol%), Xphos (9 mg, 10 mol%) and Cs ₂ CO ₃ (95 mg). , 0.29 mmol) was purged with argon and then heated in a microwave reactor at 150 ° C. for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 1-3%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 5-98%). 740 was obtained (54 mg, 48%). LCMS (Method I): R _T 2.62 min [M + H] ⁺ 546.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-8.01 (1H, m), 7.75-7.74 (1H, m), 7.31-7.22 (2H, m), 4 .64 (2H, t, J = 6.47 Hz), 4.57 (2H, t, J = 6.07 Hz), 4.34 (4H, brd s), 3.90 (3H, s), 3. 86 (6H, t, J = 4.78 Hz), 3.36-3.35 (3H, m), 2.52 (2H, s), 2.24 (2H, s), 2.11 (2H, s), 1.45 (3H, t, J = 7.48 Hz), 1.24 (6H, s)

Example 741 1- (4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) -3 , 3-Dimethylpiperazin-1-yl) -2-hydroxy-2-methylpropan-1-one 741
8- (2,2-Dimethylpiperazin-1-ylmethyl) -2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine in DCM (2 mL) (100 mg, 0.20 mmol) A mixture of 2-hydroxyisobutyric acid (24 mg, 0.23 mmol), HATU (85 mg, 0.22 mmol) and DIPEA (40 μL, 0.23 mmol) was stirred at room temperature for 17 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-3%) to give 741 as a white solid (55 mg, 46%). LCMS (Method I): R _T 2.89 min, [M + H] ⁺ 576.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-8.02 (1H, m), 7.76-7.75 (1H, m), 7.33-7.22 (2H, m), 4 .40-4.20 (5H, m), 3.92 (3H, s), 3.88-3.83 (5H, m), 3.63 (2H, s), 3.53 (2H, s ), 3.36 (2H, q, J = 7.48 Hz), 2.59-2.53 (2H, m), 1.50 (6H, s), 1.45 (3H, t, J = 7) .48Hz), 1.23 (6H, s)

Example 744 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8-((7- (oxetane-3-yl) -4,7-diazaspiro [ 2.5] Octane-4-yl) methyl) -9H-purin-6-yl) morpholine 744
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbaldehyde (183 mg, 0.47 mmol) in DCE (10 mL), 7- A mixture of oxetane-3-yl-4,7-diazaspiro [2.5] octane (90 mg, 0.54 mmol) and 4Å powdered molecular sieve (1.0 g) was stirred at room temperature for 6 hours to obtain triacetoxyborohydride. Sodium (144 mg, 0.68 mmol) was added. The reaction mixture was stirred for 16 hours, loaded with an Isolute® SCX-2 cartridge washed with MeOH and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 5%, then MeOH: DCM, 1-5%) and then recrystallized with Et ₂ O to give 744 (156 mg, 61 %). LCMS (Method I): R _T 2.53 min [M + H] ⁺ 544.2. ¹ H NMR (DMSO, 400 MHz): δ 8.00-7.99 (1H, m), 7.65-7.61 (1H, m), 7.24-7.23 (2H, m), 4. 53 (2H, t, J = 6.46 Hz), 4.42 (2H, t, J = 6.05 Hz), 4.24 (4H, brd s), 4.07 (2H, s), 3.77. (4H, t, J = 4.61 Hz), 3.73 (3H, s), 3.50-3.42 (1H, m), 3.26 (2H, q, J = 7.44 Hz), 2 .85-2.75 (2H, m), 2.32 (2H, t, J = 4.72 Hz), 2.17 (2H, brds), 1.33 (3H, t, J = 7.44 Hz) ), 0.72-0.65 (2H, m), 0.52-0.51 (2H, m)

ジオキサン（８０ｍＬ）中の３-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（３．０ｇ６．６２ｍｍｏｌ）、２-エチルベンゾイミダゾール（１．１６ｇ、７．９４ｍｍｏｌ）、トリス(ジベンジリデンアセトン)ジパラジウム（１５２ｍｇ、０．１７ｍｍｏｌ）、ＸＰｈｏｓ（３１６ｍｇ、０．６６ｍｍｏｌ）及びＫ_３ＰＯ_４（２．８１ｇ、１３．２４ｍｍｏｌ）の混合物にＮ_２をパージした後、９０℃で２２時間加熱し、更にトリス（ジベンジリデンアセトン）ジパラジウム（１５２ｍｇ、０．１７ｍｍｏｌ）及びＸＰｈｏｓ（３１６ｍｇ、０．６６ｍｍｏｌ）を加えた。生じた混合物を１００℃で６５時間加熱して、２-メチルＴＨＦで希釈し、シリカプラグで濾過した。濾過物をＨ_２Ｏ及びブラインで洗浄した。ついで乾燥させた（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、２０−８５％）で精製し、３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを得た（３．１５ｇ、８５％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ２．８７分，［Ｍ＋Ｈ］^＋５６３．５ Example 746 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1- (2-hydroxy- 2-Methylpropyl) piperidin-3-ol 746

3- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -3-hydroxypiperidine-1-carboxylic acid tert-butyl ester in dioxane (80 mL) (3. 0 g 6.62 mmol), 2-ethylbenzimidazole (1.16 g, 7.94 mmol), tris (dibenzylideneacetone) dipalladium (152 mg, 0.17 mmol), XPhos (316 mg, 0.66 mmol) and K ₃ PO ₄ ( A mixture of 2.81 g, 13.24 mmol) was purged with N ₂ and then heated at 90 ° C. for 22 hours, and further tris (dibenzylideneacetone) dipalladium (152 mg, 0.17 mmol) and XPhos (316 mg, 0.66 mmol). ) Was added. The resulting mixture was heated at 100 ° C. for 65 hours, diluted with 2-methyl THF and filtered through a silica plug. The filtrate was washed with H ₂ O and brine. It was then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 20-85%) and 3- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholine. -4-yl-9H-purin-8-yl] -3-hydroxypiperidine-1-carboxylic acid tert-butyl ester was obtained (3.15 g, 85%). LCMS (Method H): R _T 2.87 min, [M + H] ⁺ 563.5.

ＤＣＭ（５ｍＬ）及びＭｅＯＨ（１ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．０ｇ１．７８ｍｍｏｌ）の溶液にジオキサン（５ｍＬ）中の４ＭのＨＣｌを加えた。生じた混合物を２時間室温で攪拌し、Ｅｔ_２Ｏを加えた。生じた沈殿物を濾過により回収して、Ｅｔ_２Ｏで洗浄し、真空下で乾燥して３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]ピペリジン-３-オール二塩酸塩を得た（８７０ｍｇ、９２％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．８４分［Ｍ＋Ｈ］^＋４６３．３

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3 in DCM (5 mL) and MeOH (1 mL) To a solution of -hydroxypiperidine-1-carboxylic acid tert-butyl ester (1.0 g 1.78 mmol) was added 4M HCl in dioxane (5 mL). The resulting mixture was stirred for 2 hours at room temperature and Et ₂ O was added. The resulting precipitate was collected by filtration, washed with Et ₂ O, dried under vacuum and 3- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholine-4 -Ile-9H-purin-8-yl] piperidin-3-ol dihydrochloride was obtained (870 mg, 92%). LCMS (Method H): R _T 1.84 min [M + H] ⁺ 463.3.

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-3-ol dihydrochloride in MeCN (4 mL) A mixture of salt (150 mg, 0.28 mmol), 2,2-dimethyloxirane (100 μL, 1.12 mmol) and DIPEA (192 μL, 1.12 mmol) was stirred at room temperature for 20 hours and heated at 70 ° C. for 24 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18 acetonitrile 5% 30% gradient 0.1% HCO ₂ H in water) to give 746 (35 mg, 23%). LCMS (Method I): R _T 2.57 min, [M + H] ⁺ 535.2. ¹ H NMR (DMSO, 400 MHz): δ 8.03-7.98 (1 H, m), 7.65-7.61 (1 H, m), 7.28-7.21 (2 H, m), 5. 46 (1H, s), 4.45-4.05 (5H, m), 3.96 (3H, s), 3.77-3.76 (4H, m), 3.30-3.22 ( 2H, m), 3.07-2.99 (1H, m), 2.91-2.83 (1H, m), 2.70-2.60 (1H, m), 2.45-2. 35 (1H, m), 2.26 (2H, s), 2.15-2.00 (1H, m), 1.96-1.69 (3H, m), 1.32 (3H, t, J = 7.43 Hz), 1.01 (6H, d, J = 15.78 Hz)

Example 747 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-8- (1- (tetrahydro-2H-pyran-4-yl) azetidine-3- Yl) -9H-purin-6-yl) morpholine 747
4- (8- (azetidin-3-yl) -2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-9H-purin-6-yl in DCE (3 mL) ) After stirring a mixture of morpholine 680 (100 mg, 0.24 mmol), tetrahydropyran-4-one (34 mg, 0.33 mmol) and 4 化 powdered molecular sieves (130 mg) for 5.5 hours, sodium triacetoxyborohydride Was added (101 mg, 0.48 mmol). The resulting mixture was stirred for 16 hours at room temperature, then filtered through Celite® and washed with DCM. The filtrate was washed with brine, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-30%), then washed with MeOH / DCM, loaded onto an Isolute® SCX-2 cartridge, and the product Was eluted with 2M NH ₃ / MeOH. The resulting solid was triturated with EtOAc to give 747 as a white powder (37 mg, 31%). LCMS (Method I): R _T 2.46 min, [M + H] ⁺ 503.1. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-7.97 (1H, m), 7.75-7.74 (1H, m), 7.26 (2H, s), 4.37 (4H) , S), 4.02-3.80 (9H, m), 3.70 (3H, s), 3.51-3.37 (4H, m), 3.34 (2H, q, J = 7) .48 Hz), 2.41-2.33 (1 H, m), 1.77-1.66 (3 H, m), 1.43 (4 H, t, J = 7.47 Hz)

Example 748 N- (2- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ethyl) -N, 3-Dimethyl-1,1-dioxotetrahydrothiophene-3-amine 748
[2- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) ethyl] methyl- (3-methyl-1,1-dioxotetrahydro in dioxane (2 mL) Thiophen-3-yl) amine (87 mg, 0.20 mmol), 2-ethylbenzimidazole (32 mg, 0.22 mmol), tris (dibenzylideneacetone) dipalladium (5 mg, 2.5 mol%), Xphos (9 mg, 10 mol) %) And Cs ₂ CO ₃ (96 mg, 0.30 mmol) were purged with argon and then heated in a sealed tube at 110 ° C. for 20 hours. The reaction mixture was loaded with an Isolute® SCX-2 cartridge (washed with MeOH) and the product eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) to give 748 as an off-white solid (60 mg, 55%). LCMS (Method I): R _T 2.63 min, [M + H] ⁺ 553.1. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-7.98 (1H, m), 7.75-7.74 (1H, m), 7.30-7.23 (2H, m), 4 .34 (4H, brd s), 3.87 (4H, t, J = 4.78 Hz), 3.78 (3H, s), 3.37-3.30 (3H, m), 3.01- 3.00 (7H, m), 2.40-2.30 (4H, m), 2.08-2.08 (1H, m), 1.44 (3H, t, J = 7.48 Hz), 1.29 (3H, s)

Example 765 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1- (methylsulfonyl) piperidine -3-All 765
3- [2- (2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidine-3 of Example 746 in THF (3 mL) A mixture of all dihydrochloride (150 mg, 0.28 mmol) and DIPEA (192 μL, 1.12 mmol) was stirred for 5 minutes and methanesulfonyl chloride was added (22 μL, 0.28 mmol). The resulting mixture was stirred at room temperature for 4 hours and partitioned between H ₂ O and DCM. The organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 765 (67 mg, 44%). LCMS (Method I): R _T 3.30 min, [M + H] ⁺ 541.2. ¹ H NMR (DMSO, 400 MHz): δ 8.02-8.01 (1H, m), 7.64-7.64 (1H, m), 7.25-7.24 (2H, m), 6. 05 (1H, s), 4.26 (4H, brds), 3.96 (3H, s), 3.78 (4H, t, J = 4.60 Hz), 3.61 (2H, s), 3 .44-3.41 (1H, m), 3.28-3.26 (2H, m), 3.06-3.03 (1H, m), 2.95 (3H, s), 2.17 -2.14 (1H, m), 2.09-1.92 (2H, m), 1.80-1.70 (1H, m), 1.33 (3H, t, J = 7.43 Hz)

ＴＨＦ（２０ｍＬ）中の３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．０ｇ、１．７８ｍｍｏｌ）の溶液にＮａＨ（８６ｍｇ、２．１４ｍｍｏｌ、鉱油中６０％の分散液）を加え、生じた混合物を５分間攪拌し、ヨードメタン（１３５μＬ、２．１４ｍｍｏｌ）、１５-クラウン-５（４滴）を加えた。生じた混合物を３時間攪拌し、更にＮａＨ（８６ｍｇ、２．１４ｍｍｏｌ）及びヨードメタン（１３５μＬ、２．１４ｍｍｏｌ）を加えた。生じた混合物を８日間攪拌し、２-メチルＴＨＦ及びＨ_２Ｏの間で分配した。有機相を飽和水性ＮａＨＣＯ_３及びブラインで洗浄し、ついで乾燥させた（Ｎａ_２ＳＯ_４）、真空下で濃縮して３-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-３-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．２８分［Ｍ＋Ｈ］^＋５７７．５

Example 766 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8- (3-methoxy-1- (methylsulfonyl) piperidin-3-yl) -9-methyl- 9H-purin-6-yl) morpholine 766

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-hydroxypiperidine-1 in THF (20 mL) -NaH (86 mg, 2.14 mmol, 60% dispersion in mineral oil) was added to a solution of carboxylic acid tert-butyl ester (1.0 g, 1.78 mmol) and the resulting mixture was stirred for 5 minutes before iodomethane (135 μL 2.14 mmol), 15-crown-5 (4 drops) was added. The resulting mixture was stirred for 3 hours and more NaH (86 mg, 2.14 mmol) and iodomethane (135 μL, 2.14 mmol) were added. The resulting mixture was stirred for 8 days and partitioned between ₂ -methyl THF and H ₂ O. The organic phase was washed with saturated aqueous NaHCO ₃ and brine, then dried (Na ₂ SO ₄ ), concentrated in vacuo to 3- [2- (2-ethylbenzimidazol-1-yl) -9-methyl. -6-morpholin-4-yl-9H-purin-8-yl] -3-methoxypiperidine-1-carboxylic acid tert-butyl ester was obtained. LCMS (Method H): R _T 3.28 min [M + H] ⁺ 577.5

3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-methoxypiperidine-1 in DCM (10 mL) To a solution of carboxylic acid tert-butyl ester i and MeOH (10 mL) was added 4M HCl in dioxane (10 mL). The resulting mixture was stirred at room temperature for 16 hours. It was then concentrated under vacuum. The resulting residue was triturated with Et ₂ O and the solid was collected by filtration and dried under vacuum to give 2- (2-ethylbenzimidazol-1-yl) -8- (3-methoxypiperidine-3 -Iyl) -9-methyl-6-morpholin-4-yl-9H-purine dihydrochloride was obtained (1.0 g, quantitative). LCMS (Method H): R _T 2.05 min [M + H] ⁺ 477.2.

2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxypiperidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine dihydrochloride in THF (3 mL) A mixture of salt (150 mg, 0.27 mmol) and DIPEA (190 μL, 1.09 mmol) was stirred for 5 minutes and methanesulfonyl chloride (21 μL, 0.27 mmol) was added. The resulting mixture was stirred at room temperature for 4 hours and partitioned with H ₂ O and DCM. The organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: TBME, 0-100%) to give 766 (39 mg, 26%). LCMS (Method I): R _T 3.74 min, [M + H] ⁺ 555.2. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.64-7.63 (1H, m), 7.28-7.24 (2H, m), 4. 27 (4H, brd s), 3.97 (1H, d, J = 13.24 Hz), 3.92 (3H, s), 3.79 (4H, t, J = 4.61 Hz), 3.50 -3.47 (2H, m), 3.28-3.26 (2H, m), 3.08 (3H, s), 3.05-2.95 (4H, m), 2.35-2 .25 (1H, m), 1.98-1.95 (2H, m), 1.76-1.72 (1H, m), 1.35 (3H, t, J = 7.43 Hz)

Example 771 (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) (4- (2-hydroxypropane) -2-yl) piperidin-1-yl) methanone 771
(5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-[4- (1-hydroxy-1-methylethyl) piperidin-1-yl in DMF (6 mL) ] Methanone (250 mg, 0.59 mmol), 2-ethylbenzimidazole (90 mg, 0.62 mmol), tris (dibenzylideneacetone) dipalladium (15 mg, 2.5 mol%), Xphos (25 mg, 10 mol%) and Cs ₂ A mixture of CO ₃ (270 mg, 0.83 mmol) was purged with argon and heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was purified by column chromatography (Si-PCC, MeOH: DCM, 1-5%) and recrystallized from Et ₂ O and EtOAc to give 771 (109 mg, 35%). LCMS (Method I): R _T 3.96 min [M + H] ⁺ 536.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.06-8.05 (1H, m), 7.76-7.75 (1H, m), 7.32-7.28 (2H, m), 5 .22 (1H, d, J = 13.34 Hz), 4.84 (1H, d, J = 13.16 Hz), 4.41 (4H, brds), 3.89 (4H, t, J = 4) .74 Hz), 3.37 (2H, q, J = 7.46 Hz), 3.17-3.15 (1H, m), 2.84-2.82 (1H, m), 1.94 (2H , T, J = 13.72 Hz), 1.72-1.62 (1H, m), 1.49-1.40 (5H, m), 1.23 (6H, d, J = 7.01 Hz)

Example 772 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1- (tetrahydro-2H- Pyran-4-yl) piperidin-3-ol 772
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidine- from Example 746 in DCE (3 mL) Two mixtures of 3-ol dihydrochloride (150 mg, 0.28 mmol), tetrahydropyran-2-one (39 μL, 0.42 mmol), NEt ₃ (78 μL, 0.56 mmol) and 4Å powdered molecular sieve (300 mg) Stir for hours and add sodium triacetoxyborohydride (119 mg, 0.56 mmol). The resulting mixture was stirred for 20 hours at room temperature, diluted with DCM and filtered. The filtrate was concentrated in vacuo and the residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%). The resulting residue was dissolved in DCM and treated with 4M HCl in dioxane. The resulting solid was triturated with Et ₂ O and dried under vacuum to give 772 (124 mg, 72%). LCMS (Method I): R _T 2.52 min, [M + H] ⁺ 547.2. ¹ H NMR (DMSO, 400 MHz): δ 9.36 (1H, s), 8.18-8.14 (1H, m), 7.80-7.79 (1H, m), 7.50-7. 48 (2H, m), 4.28 (4H, brds), 4.10-3.90 (6H, m), 3.78-3.77 (5H, m), 3.43-3.39 (7H, m), 3.25-3.10 (1H, m), 2.30-1.65 (7H, m), 1.44-1.38 (3H, m)

Example 775 (S) -2- (1-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6- (3-methylmorpholino) -9H-purine -8-yl) methyl) piperidin-4-yl) propan-2-ol 775
2- {1- [2-Chloro-9-methyl-6-((S) -3-methylmorpholin-4-yl) -9H-purin-8-ylmethyl] piperidin-4-yl in DMF (6 mL) } Propan-2-ol (200 mg, 0.47 mmol), 2-ethylbenzimidazole (73 mg, 0.50 mmol), tris (dibenzylideneacetone) dipalladium (12 mg, 2.5 mol%), Xphos (20 mg, 10 mol%) ) And Cs ₂ CO ₃ (218 mg, 0.67 mmol) were purged with argon and then heated in a microwave reactor at 150 ° C. for 1 hour. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) followed by (Si-PCC, MeOH: DCM, 0-3%) to give 775 (95 mg 38%). LCMS (Method I): R _T 2.65 min, [M + H] ⁺ 533.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-8.02 (1H, m), 7.75-7.74 (1H, m), 7.27-7.24 (2H, m), 5 .40 (2H, brd s), 4.09-4.03 (1H, m), 3.88 (3H, s), 3.83 (2H, s), 3.75-3.55 (4H, m), 3.36 (2H, q, J = 7.48 Hz), 2.98-2.95 (2H, m), 2.11 (2H, t, J = 10.92 Hz), 1.81- 1.71 (2H, m), 1.45-1.44 (6H, m), 1.34-1.31 (4H, m), 1.19 (6H, s)

Example 780 (1-aminocyclopropyl) (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl ) Methyl) -3,3-dimethylpiperazin-1-yl) methanone 780
(1- {4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-ylmethyl] -3, in DCM (3 mL), To a solution of 3-dimethylpiperazine-1-carbonyl} cyclopropyl) carbamic acid tert-butyl ester was added TFA (2 mL), and the resulting mixture was stirred at room temperature for 30 min and washed with MeOH. Two cartridges were filled. The product was eluted with 2M NH ₃ / MeOH. The resulting residue was charged with column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 780 as a white foam (99 mg, 60%). LCMS (Method I): R _T 2.67 min, [M + H] ⁺ 573.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.02-8.01 (1H, m), 7.76-7.75 (1H, m), 7.32-7.22 (2H, m), 4 .34 (4H, s), 3.93 (3H, s), 3.88-3.86 (6H, m), 3.65 (2H, s), 3.48 (2H, s), 3. 36 (2H, q, J = 7.48 Hz), 2.57 (2H, t, J = 5.16 Hz), 1.85-1.75 (2H, brds), 1.45 (3H, t, J = 7.46 Hz), 1.23 (6H, s), 1.05-0.99 (2H, m), 0.81-0.80 (2H, m)

Example 781 (R) -2- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6- (3-methylmorpholino) -9H-purine -8-yl) methyl) piperidin-4-yl) propan-2-ol 781
2- {1- [2-Chloro-9-methyl-6-((R) -3-methylmorpholin-4-yl) -9H-purin-8-ylmethyl] piperidin-4-yl in dioxane (3 mL) } Propan-2-ol (120 mg, 0.28 mmol), 2-ethylbenzimidazole (46 mg, 0.31 mmol), tris (dibenzylideneacetone) dipalladium (7 mg, 2.5 mol%), Xphos (14 mg, 10 mol%) ) And Cs ₂ CO ₃ (139 mg, 0.43 mmol) was purged with argon and then heated at 110 ° C. for 4 hours in a sealed tube. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH. The product was eluted with 2M NH ₃ / MeOH / DCM. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) followed by (Si-PCC, MeOH: DCM, 0-10%) to give 781 as a white solid. Obtained (65 mg, 43%). LCMS (Method I): R _T 2.64 min, [M + H] ⁺ 533.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-8.02 (1H, m), 7.76-7.75 (1H, m), 7.30-7.25 (2H, m), 4 .06-4.05 (1H, m), 3.88 (3H, s), 3.83 (2H, s), 3.73 (2H, s), 3.70-3.55 (2H, m ), 3.36 (2H, q, J = 7.48 Hz), 2.99-2.96 (2H, m), 2.16-2.06 (2H, m), 1.81-1.71. (2H, m), 1.58 (2H, brd s), 1.48-1.42 (6H, m), 1.43-1.27 (3H, m), 1.19 (6H, s)

ＴＨＦ（８０ｍＬ）中の２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン（２．５ｇ、９．８６ｍｍｏｌ）及びＴＭＥＤＡ（２．１ｍＬ、１４．８ｍｍｏｌ）の混合物に−７８℃でｎ-ＢｕＬｉ（６ｍＬ、ヘキサン中２．５Ｍ、１４．８ｍｍｏｌ）を加えた。生じた混合物を−３０℃で３０分間温め、再び−７８℃に冷却し、ＴＨＦ（２０ｍＬ）中の４-オキソ-ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（２．９ｇ、１４．８ｍｍｏｌ）の溶液を加えた。反応混合物をゆっくりと室温まで温め、Ｈ_２Ｏで１６時間クエンチし、ＥｔＯＡｃで抽出した。組み合わせた有機相をブラインで洗浄し、乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、１０−７５％）で精製して、４-(２-クロロ-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル)-４-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（３．２ｇ、７１％）を得た。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．５２分［Ｍ＋Ｈ］^＋４５３．３

Example 790 1- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -4-hydroxypiperidine -1-yl) -2-hydroxy-2-methylpropan-1-one 790

-78 to a mixture of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.5 g, 9.86 mmol) and TMEDA (2.1 mL, 14.8 mmol) in THF (80 mL). N-BuLi (6 mL, 2.5 M in hexane, 14.8 mmol) was added at ° C. The resulting mixture was warmed at −30 ° C. for 30 minutes, cooled again to −78 ° C., and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (2.9 g, 14.8 mmol) in THF (20 mL). The solution was added. The reaction mixture was slowly warmed to room temperature, quenched with H ₂ O for 16 hours and extracted with EtOAc. The combined organic phases were washed with brine, dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 10-75%) to give 4- (2-chloro-9-methyl-6-morpholin-4-yl-9H-purine- 8-yl) -4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (3.2 g, 71%) was obtained. LCMS (Method H): R _T 3.52 min [M + H] ⁺ 453.3

4- (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl) -4-hydroxypiperidine-1-carboxylic acid tert-butyl ester in dioxane (50 mL) (2. 5 g, 5.52 mmol), 2-ethylbenzimidazole (968 mg, 6.62 mmol), tris (dibenzylideneacetone) dipalladium (126 mg, 0.14 mmol), XPhos (263 mg, 0.55 mmol) and K ₃ PO ₄ ( 2.34 g, 11.04 mmol) was purged with N ₂ and heated at 100 ° C. for 6 hours, then tris (dibenzylideneacetone) dipalladium (126 mg, 0.14 mmol) and XPhos (263 mg, 0.55 mmol) Was added. The resulting mixture was heated at 100 ° C. for 18 hours, diluted with 2-methyl THF and filtered through Celite®. The filtrate was filtered with H ₂ O and brine, then dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 40-100%) to give 4- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6- Morpholin-4-yl-9H-purin-8-yl] -4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (2.6 g, 84%) was obtained. LCMS (Method H): R _T 2.99 min, [M + H] ⁺ 563.4.

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -4-hydroxypiperidine-1 in DCM (10 mL) -To a solution of carboxylic acid tert-butyl ester (1.3 g, 2.31 mmol) was added TFA (2 mL) and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH to give 4- [2 -(2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-4-ol (1.1 g, quantitative) was obtained. LCMS (Method H): R _T 1.79 min, [M + H] ⁺ 463.3.

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-4-ol (150 mg) in DCM (2 mL) HATU (149 mg, 0.39 mmol) was added to a mixture of 2-hydroxyisobutyric acid (41 mg, 0.39 mmol) and DIPEA (68 μL, 0.39 mmol). The resulting mixture was stirred at room temperature for 18 hours, diluted with DCM and washed with saturated aqueous NaHCO ₃ . The organic phase was dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 790 (60 mg, 34%). LCMS (Method I): R _T 3.09 min, [M + H] ⁺ 549.3. ¹ H NMR (DMSO, 400 MHz): δ 8.02-8.01 (1H, m), 7.64-7.63 (1H, m), 7.27-7.23 (2H, m), 5. 84 (1H, s), 5.42 (1H, s), 4.25 (6H, brd s), 3.98 (3H, s), 3.77 (4H, t, J = 4.55 Hz), 3.60 (1H, brd s), 3.2-3.24 (3H, m), 2.11-2.10 (2H, m), 2.06-1.94 (2H, m), 1 .38-1.30 (9H, m)

Example 791 1- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxypiperidine -1-yl) -2-methylpropane-2-ol 791
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxypiperidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine dihydrochloride in MeCN (3 mL) A mixture of salt (150 mg, 0.27 mmol), 2,2-dimethyloxirane (242 μL, 2.73 mmol) and DIPEA (187 μL, 1.09 mmol) was stirred at 70 ° C. for 3 hours at room temperature. (242 μL, 2.73 mmol) was added and the mixture was heated at 90 ° C. for 6 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%) to give 791 (51 mg, 34%). LCMS (Method I): R _T 2.72 min, [M + H] ⁺ 549.3. ¹ H NMR (DMSO, 400 MHz): δ 8.03-8.02 (1H, m), 7.64-7.63 (1H, m), 7.25-7.24 (2H, m), 4. 26 (4H, brd s), 4.08 (1H, s), 3.91 (3H, s), 3.79 (4H, t, J = 4.72 Hz), 3.27-3.26 (2H M), 3.20-3.15 (1H, m), 3.06 (3H, s), 3.01-2.97 (1H, m), 2.69-2.61 (1H, m ), 2.46-2.38 (1H, m), 2.25 (2H, s), 2.17-2.14 (1H, m), 1.92-1.75 (3H, m), 1.33 (3H, t, J = 7.43 Hz), 1.03 (3H, s), 0.94 (3H, s)

Example 792 4- (6-((2,2-dimethyl-4- (oxetane-3-yl) piperazin-1-yl) methyl) -2- (2-ethyl-1H-benzo [d] imidazole-1 -Yl) thieno [3,2-d] pyrimidin-4-yl) morpholine 792
2-Chloro-6- (2,2-dimethyl-4-oxetane-3-ylpiperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine in DMF (4 mL) (136 mg, 0.31 mmol), 2-ethyl-benzimidazole (48 mg, 0.33 mmol), tris (dibenzylideneacetone) dipalladium (8mg, 3mol%), Xphos (14mg, 9mol%) and _Cs 2 _CO 3 (143 mg , 0.44 mmol) was purged with argon and then heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) followed by (Si-PCC, 2M NH ₃ / MeOH: DCM, 0-2%) to give 792 Was obtained as a creamy solid (45 mg, 26%). LCMS (Method I): R _T 2.78 min [M + H] ⁺ 548.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.97-7.96 (1H, m), 7.75-7.74 (1H, m), 7.32-7.22 (3H, m), 4 .66 (2H, t, J = 6.47 Hz), 4.59 (2H, t, J = 6.08 Hz), 4.04 (4H, t, J = 4.72 Hz), 3.91-3. 86 (6H, m), 3.46-3.45 (1H, m), 3.33 (2H, q, J = 7.48 Hz), 2.64 (2H, t, J = 4.98 Hz), 2.33 (2H, s), 2.14 (2H, s), 1.42 (3H, t, J = 7.47 Hz), 1.20 (6H, s)

Example 793 (2,2-dimethyl-4- (oxetane-3-yl) piperazin-1-yl) (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothia Zolo [5,4-d] pyrimidin-2-yl) methanone 793
(5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-(2,2-dimethyl-4-oxetane-3-ylpiperazine-1-- in DMF (4 mL) Yl) methanone (137 mg, 0.30 mmol), 2-ethylbenzimidazole (47 mg, 0.32 mmol), tris (dibenzylideneacetone) dipalladium (8 mg, 2.5 mol%), Xphos (13 mg, 10 mol%) and Cs A mixture of ₂ CO ₃ (140 mg, 0.43 mmol) was purged with argon and then heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 1-2%) and triturated with EtOAc to give 793 (22 mg, 13%). LCMS (Method I): R _T 3.79 min [M + H] ⁺ 563.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.07-8.03 (1H, m), 7.76-7.75 (1H, m), 7.30-7.29 (2H, m), 4 .72 (2H, t, J = 6.51 Hz), 4.62 (2H, t, J = 6.07 Hz), 4.40 (4H, brds), 4.07-4.06 (2H, m ), 3.89 (4H, t, J = 4.72 Hz), 3.53-3.52 (1H, m), 3.36 (2H, q, J = 7.46 Hz), 2.47 (2H , T, J = 5.08 Hz), 2.25 (2H, s), 1.56 (6H, s), 1.44 (3H, t, J = 7.45 Hz)

Example 796 4- (1-((5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Azetidin-3-yl) piperazin-2-one 796
4- [1- (5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl) azetidin-3-yl] piperazin-2-one (315 mg, in dioxane (10 mL) 0.74 mmol), 2-ethylbenzimidazole (120 mg, 0.82 mmol), tris (dibenzylideneacetone) dipalladium (17 mg, 0.02 mmol), XPhos (35 mg, 0.07 mmol) and Cs ₂ CO ₃ (365 mg, 1.12 mmol) was purged with argon, then heated at 115 ° C. for 4 hours and then stirred at room temperature for 16 hours. The reaction mixture was filtered through Celite®, washed with dioxane and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 1-10%) to give 796 (146 mg, 37%). LCMS (Method G): R _T 4.90 min, [M + H] ⁺ 534.3. ¹ H NMR (DMSO, 400 MHz): δ 7.9-7.9 (1H, m), 7.75 (1H, s), 7.64-7.63 (1H, m), 7.26-7. 25 (2H, m), 4.32 (4H, brds), 4.04 (2H, s), 3.79 (4H, t, J = 4.61 Hz), 3.57-3.52 (2H M), 3.31 (2H, s), 3.25 (2H, q, J = 7.43 Hz), 3.18-3.14 (5H, m), 2.87 (2H, s), 1.32 (3H, t, J = 7.42 Hz)

Example 797 (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (3- (4-hydroxypiperidine-1 -Il) azetidine-1-yl) methanone 797
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylic acid (215 mg, 0.53 mmol) in DMF (2 mL), 2- A mixture of chloro-1-methylpyridinium iodide (324 mg, 1.27 mmol) and DIPEA (460 μL, 2.64 mmol) was stirred for 5 minutes and 1-azetidin-3-ylpiperidin-4-ol in DMF (2 mL). (140 mg, 0.90 mmol) was added. The resulting mixture was stirred for 2 hours, then loaded onto an Isolute® SCX-2 cartridge (washed with MeOH) and the product taken up in 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 797 as a pale yellow solid (76 mg, 26%). LCMS (Method G): R _T 5.26 min, [M + H] ⁺ 546.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.06-8.06 (1H, m), 7.76-7.75 (1H, m), 7.31-7.24 (2H, m), 4 .72-4.71 (1H, m), 4.50 (1H, dd, J = 10.65, 5.40 Hz), 4.30-4.20 (1H, m), 4.14 (3H, s), 4.14-4.07 (1H, m), 3.88 (4H, t, J = 4.71 Hz), 3.81 (1H, s), 3.37 (2H, q, J = 7.47 Hz), 3.28-3.27 (1 H, m), 2.72 (2 H, d, J = 27.26 Hz), 2.25-2.10 (2 H, m), 2.01- 1.91 (2H, m), 1.68-1.60 (5H, m), 1.46-1.43 (4H, m)

Example 798 (2- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (4- (2-hydroxypropane- 2-yl) piperidin-1-yl) methanone 798
2- (2-Cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylic acid (200 mg, 0.48 mmol) in DCM (5 mL), 2 A mixture of -piperidin-4-ylpropan-2-ol (78 mg, 0.55 mmol), HATU (205 mg, 0.54 mmol) and DIPEA (96 μL, 0.55 mmol) was stirred for 19 hours at room temperature. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-3%) and (Si-PCC, MeOH: EtOAc, 0-5%) to give 798 as a white solid. (138 mg, 53%). LCMS (Method G): R _T 7.50 min, [M + H] ⁺ 545.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.97-7.96 (1H, m), 7.68-7.67 (1H, m), 7.28-7.20 (2H, s), 4 91-4.82 (1H, m), 4.68-4.65 (1H, m), 4.40 (4H, brds), 3.97 (3H, s), 3.86 (4H, t, J = 4.70 Hz), 3.18-3.10 (1H, m), 2.84-2.83 (2H, m), 1.94-1.92 (2H, m), 1. 64-1.62 (1H, m), 1.44-1.43 (2H, m), 1.35-1.34 (2H, m), 1.24-1.22 (7H, m), 1.06-1.05 (2H, m)

Example 799 (2- (2-cyclopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (3-morpholinoazetidine-1- Il) Methanone 799
2- (2-Cyclopropylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carboxylic acid (500 mg, 1.19 mmol) in DMF (10 mL), 2 4-Azetidin-3-ylmorpholine (288 mg, 2.0 mmol) was added to a mixture of 2-chloro-1-methylpyridinium iodide (729 mg, 2.86 mmol) and DIPEA (500 μL, 2.87 mmol) and the resulting mixture was Stir at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the resulting residue was dissolved in EtOAc, washed with H ₂ O and brine, then dried (MgSO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-5%) to give 799 creamy solid (290 mg, 45%). LCMS (Method G): R _T 5.90 min, [M + H] ⁺ 544.5. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.99 (1H, m), 7.67-7.67 (1H, m), 7.28-7.20 (2H, m), 4 73-4.72 (1H, m), 4.70-4.00 (4H, brds), 4.53-4.51 (1H, m), 4.29-4.21 (1H, m ), 4.18-4.08 (4H, m), 3.87 (4H, t, J = 4.67 Hz), 3.78 (4H, t, J = 4.60 Hz), 3.30-3 .30 (1H, m), 2.88-2.88 (1H, m), 2.47-2.45 (4H, m), 1.35-1.34 (2H, m), 1.06 -1.05 (2H, m)

ＴＨＦ（５０ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-４-ヒドロキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１．３ｇ、２．３１ｍｍｏｌ）の溶液にＮａＨ（１１２ｍｇ、２．８０ｍｍｏｌ、鉱油中６０％の分散液）を加え、生じた混合物を５分間攪拌し、ヨードメタン（１７５μＬ、２．８０ｍｍｏｌ）、及び１５-クラウン-５（５滴）を加えた。生じた混合物を２０時間攪拌し、Ｈ_２Ｏでクエンチして、２-メチルＴＨＦで抽出した。有機相をブラインで洗浄し、ついで乾燥させ（Ｎａ_２ＳＯ_４）、真空下で濃縮した。生じた残留物をカラムクロマトグラフィー（Ｓｉ-ＰＣＣ、ＥｔＯＡｃ：シクロヘキサン、４０−８０％）で精製して、４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-４-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステルを得た（９１５ｍｇ、６９％）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ３．４０分［Ｍ＋Ｈ］^＋５７７．５ Example 800 1- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -4-methoxypiperidine -1-yl) -2-hydroxy-2-methylpropan-1-one 800

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -4-hydroxypiperidine-1 in THF (50 mL) -NaH (112 mg, 2.80 mmol, 60% dispersion in mineral oil) was added to a solution of carboxylic acid tert-butyl ester (1.3 g, 2.31 mmol) and the resulting mixture was stirred for 5 minutes before iodomethane (175 μL 2.80 mmol), and 15-crown-5 (5 drops). The resulting mixture was stirred for 20 hours, quenched with H ₂ O and extracted with 2-methyl THF. The organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 40-80%) to give 4- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6- Morpholin-4-yl-9H-purin-8-yl] -4-methoxypiperidine-1-carboxylic acid tert-butyl ester was obtained (915 mg, 69%). LCMS (Method H): R _T 3.40 min [M + H] ⁺ 577.5

ＤＣＭ（１５ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-４-メトキシピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（９１５ｍｇ、１．５９ｍｍｏｌ）の溶液にＴＦＡ（３ｍＬ）を加え、生じた混合物を室温で２時間攪拌した。反応混合物を真空下で濃縮させ、生じた残留物を、ＭｅＯＨで洗浄したＩｓｏｌｕｔｅ（登録商標）ＳＣＸ-２カートリッジに充填し、生成物を２ＭのＮＨ_３／ＭｅＯＨで溶出し、２-(２-エチルベンゾイミダゾール-１-イル)-８-(４-メトキシピペリジン-４-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリンを得た（７７５ｍｇ、定量的）。ＬＣＭＳ（方法Ｈ）：Ｒ_Ｔ１．９５分，［Ｍ＋Ｈ］^＋４７７．３

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -4-methoxypiperidine-1 in DCM (15 mL) -To a solution of carboxylic acid tert-butyl ester (915 mg, 1.59 mmol) was added TFA (3 mL) and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH to give 2- (2- Ethylbenzimidazol-1-yl) -8- (4-methoxypiperidin-4-yl) -9-methyl-6-morpholin-4-yl-9H-purine was obtained (775 mg, quantitative). LCMS (Method H): R _T 1.95 min, [M + H] ⁺ 477.3.

To a solution of 2-hydroxyisobutyric acid (49 mg, 0.47 mmol) in THF (3 mL) was added 2- (2-ethylbenzimidazol-1-yl) -8- (4-methoxypiperidin-4-yl) -9- Methyl-6-morpholin-4-yl-9H-purine (150 mg, 0.32 mmol), HOBt (47 mg, 0.35 mmol), NMM (77 μL, 0.69 mmol) and EDCI (91 mg, 0.47 mmol) were added. . The resulting mixture was stirred at room temperature for 4 hours, quenched with saturated aqueous NH ₄ Cl and extracted with DCM. The organic phase was washed with brine, then dried (Na ₂ SO ₄ ) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc , 0-20%) to afford was triturated with MeOH / _{H 2} O. The resulting solid was collected by filtration and dried under vacuum to give 800 (111 mg, 63%). LCMS (Method G): R _T 7.36 min, [M + H] ⁺ 563.4. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.66-7.62 (1H, m), 7.25-7.24 (2H, m), 5. 44 (1H, s), 4.26 (6H, brds), 3.92 (3H, s), 3.78 (4H, t, J = 4.52 Hz), 3.30-3.23 (4H , M), 3.09 (3H, s), 2.6-2.16 (2H, m), 2.19-2.02 (2H, m), 1.35-1.33 (9H, m )

Example 811 1- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxyazeti Gin-1-yl) -2-hydroxy-2-methylpropan-1-one 811
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (3 mL) in THF (3 mL) 150 mg, 0.33 mmol), 2-hydroxy-2-methylpropionic acid (52 mg, 0.50 mmol), HOBt (50 mg, 0.37 mmol), NMM (81 μL, 0.74 mmol) and EDCI (96 mg, 0.50 mmol) The mixture was stirred at room temperature for 4 hours. The resulting mixture was diluted with DCM, washed with saturated aqueous NaHCO ₃ , dried (phase separator) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, THF: EtOAc , 0-50%) to afford was triturated with _Et 2 O / cyclohexane. The resulting solid was collected by filtration and dried under vacuum to give 811 (108 mg, 60%). LCMS (Method I): R _T 3.21 min, [M + H] ⁺ 535.3. ¹ H NMR (DMSO, 400 MHz): δ 8.06-8.05 (1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 5. 23 (1 H, s), 5.05 (1 H, d, J = 10.74 Hz), 4.67 (1 H, d, J = 10.76 Hz), 4.55 (1 H, d, J = 10.69 Hz) ), 4.29 (4H, brd s), 4.16 (1H, d, J = 10.75 Hz), 3.79 (4H, t, J = 4.62 Hz), 3.73 (3H, s) 3.29-3.27 (2H, m), 3.09 (3H, s), 1.35 (3H, t, J = 7.43 Hz), 1.30 (3H, s), 1.25 (3H, s)

Example 812 4- (1-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) methyl) azetidin-3-yl) Piperazine-2-one 812
4- {1- [2- (2-Ethylbenzimidazol-1-yl) -6-morpholin-4-yl-9- (tetrahydropyran-2-yl) -9H-purine-8 in dioxane (20 mL) To a solution of -ylmethyl] azetidin-3-yl} piperazin-2-one (470 mg, 0.78 mmol) was added 4M HCl in dioxane (1 mL). The resulting suspension was stirred at room temperature for 24 hours, then the precipitate was collected by filtration and washed with dioxane. The resulting solid was partitioned between EtOAc and H ₂ O and the aqueous phase was basified to pH 11 with NH ₄ OH. The aqueous phase was neutralized with HCl to pH 7 and loaded onto an Isolute® SCX-2 cartridge washed with H ₂ O and MeOH. The product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (C18, MeOH: H ₂ O, 30-95%) and loaded onto an Isolute® SCX-2 cartridge washed with H ₂ O and MeOH. The product was eluted with 2M NH ₃ / MeOH to give 812 (69 mg, 17%). LCMS (Method I): R _T 2.16 min, [M + H] ⁺ 517.3. ¹ H NMR (DMSO, 400 MHz): δ 7.95-7.94 (1H, m), 7.73 (1H, s), 7.63-7.62 (1H, m), 7.25-7. 22 (2H, m), 4.24 (4H, brd s), 3.79-3.74 (6H, m), 3.46 (2H, s), 3.23 (3H, q, J = 7) .46 Hz), 3.16-3.04 (5H, m), 2.84 (2H, s), 2.45-2.44 (2H, m), 1.31 (3H, t, J = 7) .45Hz)

Example 813 4- (2-((2,2-dimethyl-4- (oxetane-3-yl) piperazin-1-yl) methyl) -5- (2-ethyl-1H-benzo [d] imidazole-1 -Yl) thiazolo [5,4-d] pyrimidin-7-yl) morpholine 813
5- (2-Ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine-2-carbaldehyde (200 mg, 0.51 mmol) in DCE (10 mL), 3, A mixture of 3-dimethyl-1-oxetane-3-ylpiperazine (100 mg, 0.65 mmol) and 4Å powdered molecular sieve (200 mg) was stirred at room temperature for 1 hour and sodium triacetoxyborohydride (150 mg, 0.71 mmol). ) Was added. The resulting mixture was stirred for 5 hours and loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH. The product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-1%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 5-98%). To give 813 (111 mg, 40%). LCMS (Method G): R _T 6.17 min [M + H] ⁺ 549.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-8.00 (1H, m), 7.75-7.74 (1H, m), 7.32-7.22 (2H, m), 4 .67 (2H, t, J = 6.47 Hz), 4.59 (2H, t, J = 6.08 Hz), 4.40 (4H, brds), 3.87 (6H, t, J = 4) 72 Hz), 3.47-3.46 (1 H, m), 3.34 (2 H, q, J = 7.47 Hz), 2.75 (2 H, t, J = 4.94 Hz), 2.37. (2H, brd s), 2.15 (2H, brd s), 1.43 (3H, t, J = 7.47 Hz), 1.20 (6H, s)

Example 814 1- (3-((5- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Azetidin-1-yl) -2-hydroxy-2-methylpropan-1-one 814
2-Azetidin-3-ylmethyl-5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine (209 mg, 0.48 mmol) in DCM (5 mL) A mixture of 2-hydroxyisobutyric acid (56 mg, 0.54 mmol), HATU (200 mg, 0.53 mmol) and DIPEA (94 μL, 0.54 mmol) was stirred at room temperature for 2 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that had been washed with MeOH. The product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-2%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 20 mM triethylamine in water with a gradient of acetonitrile 5-98%). 814 was obtained as a white solid (89 mg, 35%). LCMS (Method I): R _T 3.39 min, [M + H] ⁺ 522.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.00-7.99 (1H, m), 7.75-7.74 (1H, m), 7.28-7.28 (2H, m), 4 .62-4.12 (7H, m), 4.05-3.92 (1H, m), 3.88 (4H, t, J = 4.76 Hz), 3.45 (1H, s), 3 .43-3.38 (2H, m), 3.33 (2H, q, J = 7.47 Hz), 3.27-3.21 (1H, m), 1.43-1.42 (9H, m)

Example 823 1- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -4-methoxypiperidine -1-yl) -2-hydroxyethanone 823
2- (2-Ethylbenzimidazol-1-yl) -8- (4-methoxypiperidin-4-yl) -9-methyl-6-morpholin-4-yl-9H-purine (150 mg in THF (3 mL) , 0.32 mmol), hydroxyacetic acid (36 mg, 0.47 mmol), HOBt (47 mg, 0.35 mmol), NMM (77 μL, 0.69 mmol) and EDCI (91 mg, 0.47 mmol) were stirred at room temperature for 4 hours. did. The resulting mixture was diluted with DCM, washed with saturated aqueous NaHCO ₃ , dried (phase separator) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, THF: EtOAc, 0-50%), then loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was loaded with 2M NH. Elution with ₃ / MeOH gave 823 (88 mg, 52%). LCMS (Method I): R _T 3.25 min, [M + H] ⁺ 535.3. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4. 54 (1H, t, J = 5.40 Hz), 4.17-4.06 (6H, m), 3.92 (3H, s), 3.78 (4H, t, J = 4.51 Hz), 3.65-3.55 (1H, m), 3.40-3.25 (3H, m), 3.18 (1H, m), 3.09 (3H, s), 2.17-2. 14 (4H, m), 1.35 (3H, t, J = 7.43 Hz)

Example 824 1- (3-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) -2-methylpropan-1-one 824
8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (121 mg, 0.28 mmol) in DCM (1 mL) , A mixture of isobutyryl chloride (30 mg, 0.29 mmol) and NEt ₃ (50 μL, 0.36 mmol) was stirred at room temperature for 2 hours. It was then concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-6%) and triturated with Et ₂ O to give 824 as a white solid (86 mg, 61%). LCMS (Method I): R _T 3.42 min, [M + H] ⁺ 503.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.9 (1H, m), 7.75-7.74 (1H, m), 7.30-7.22 (2H, m), 4 .50-4.20 (4H, brds), 4.41 (1H, t, J = 8.45 Hz), 4.32-4.21 (1H, m), 3.98 (1H, dd, J = 8.63, 5.41 Hz), 3.90-3.80 (5H, m), 3.76 (3H, s), 3.34 (2H, q, J = 7.49 Hz), 3.28. -3.25 (1H, m), 3.16-3.11 (2H, m), 2.47-2.46 (1H, m), 1.44 (3H, t, J = 7.48Hz) 1.12 (6H, dd, J = 6.82, 2.82 Hz)

Example 825 Cyclopropyl (3-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) azetidine- 1-yl) methanone 825
8-azetidin-3-ylmethyl-2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine (108 mg, 0.25 mmol) in DCM (1 mL) , Cyclopropanecarbonyl chloride (27 mg, 0.25 mmol) and NEt ₃ (50 μL, 0.36 mmol) were stirred at room temperature for 2 hours. It was then concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) and triturated with Et ₂ O to give 825 as a white solid (107 mg, 85%). LCMS (Method I): R _T 3.33 min, [M + H] ⁺ 501.2. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.9-7.98 (1H, m), 7.76-7.73 (1H, m), 7.32-7.22 (2H, m), 4 .53 (1H, t, J = 8.31 Hz), 4.45-4.20 (4H, brds), 4.28 (1H, t, J = 9.30 Hz), 4.09 (1H, dd) , J = 8.45, 5.41 Hz), 3.86 (5H, t, J = 4.77 Hz), 3.77 (3H, s), 3.34-3.33 (3H, m), 3 .18-3.15 (2H, m), 1.45-1.43 (4H, m), 0.99-0.98 (2H, m), 0.77-0.76 (2H, m)

Example 826 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8- (3-methoxy-1- (2- (methylsulfonyl) ethyl) azetidin-3-yl) -9-methyl-9H-purin-6-yl) morpholine 826
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine in IMS (2 mL) ( Methanesulfonylethane (21 μL, 0.25 mmol) was added to a solution of 100 mg, 0.22 mmol) and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%). The resulting residue was triturated with EtOAc and cyclohexane and the resulting solid was dried under vacuum to give 826 (83 mg, 67%). LCMS (Method I): R _T 2.65 min, [M + H] ⁺ 555.3. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.05 (1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4. 27 (4H, brd s), 4.02 (2H, d, J = 7.94 Hz), 3.79 (4H, t, J = 4.57 Hz), 3.72 (3H, s), 3.42 (2H, d, J = 7.9 Hz), 3.28-3.25 (2H, m), 3.17 (2H, t, J = 6.52 Hz), 3.05 (3H, s), 2 .89 (2H, t, J = 6.53 Hz), 1.40 (3H, s), 1.35 (3H, t, J = 7.43 Hz)

Example 827 4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -8- (3-methoxy-1- (tetrahydro-2H-pyran-4-yl) azetidine-3- Yl) -9-methyl-9H-purin-6-yl) morpholine 827
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (2 mL) in DCE (2 mL) 100 mg, 0.22 mmol), a mixture of tetrahydropyran-4-one (27 mg, 0.27 mmol) and AcOH (50 μL) at room temperature for 20 minutes and added sodium triacetoxyborohydride (104 mg, 0.49 mmol) It was. The resulting mixture was stirred for 18 hours and triturated between DCM and H ₂ O. The organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%), partitioned between MeCN and H ₂ O, and the resulting solid was dried in vacuo to 827. (92 mg, 82%) was obtained. LCMS (Method I): R _T 2.65 min, [M + H] ⁺ 555.3. ¹ H NMR (DMSO, 400 MHz): δ 8.04-8.04 (1H, m), 7.65-7.62 (1H, m), 7.25-7.24 (2H, m), 4. 40-4.10 (4H, brd s), 3.91 (2H, d, J = 8.05 Hz), 3.80-3.79 (6H, m), 3.71 (3H, s), 3 .41 (2H, d, J = 8.07 Hz), 3.28-3.26 (4H, m), 3.02 (3H, s), 2.37-2.28 (1 H, m), 1 .67-1.63 (2H, m), 1.34 (3H, t, J = 7.43 Hz), 1.23-1.10 (2H, m)

Example 828 3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-fluoroazetidine-1 Tert-Butyl carboxylate 828
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-hydroxy-azetidine- in THF (2 mL) A solution of 1-carboxylic acid tert-butyl ester (300 mg, 0.56 mmol) in bis (2-methoxyethyl) aminosulfur trifluoride (275 μL, 0.62 mmol, 50% in THF) in THF (3 mL) at 5 ° C. Solution) was added. The resulting mixture was stirred at 5 ° C. for 15 minutes, then allowed to warm to room temperature and then stirred for an additional 15 minutes. The reaction mixture was partitioned with saturated aqueous NaHCO ₃ and DCM and the organic phase was dried (phase separator) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, EtOAc: cyclohexane, 35-85%) to give 828 as a pale yellow solid (238 mg, 79%). LCMS (Method I): R _T 4.65 min, [M + H] ⁺ 537.4. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.64-7.64 (1H, m), 7.26-7.25 (2H, m), 4. 77 (2H, dd, J = 20.08, 10.62 Hz), 4.60-4.10 (4H, brds), 4.48 (2H, dd, J = 21.54, 10.50 Hz), 3.79 (4H, t, J = 0.55Hz), 3.76 (3H, d, J = 1.32Hz), 3.28-3.27 (2H, m), 1.42 (9H, s ), 1.34 (3H, t, J = 7.46 Hz)

Example 829 (S) -1- (4-((5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidine-2- Yl) methyl) -3,3-dimethylpiperazin-1-yl) -2-hydroxypropan-1-one 829
2- (2,2-Dimethylpiperazin-1-ylmethyl) -5- (2-ethylbenzimidazol-1-yl) -7-morpholin-4-ylthiazolo [5,4-d] pyrimidine in DCM (4 mL) A mixture of (200 mg, 0.41 mmol), L-lactic acid (34 μL, 85% solution in water), HATU (170 mg, 0.45 mmol) and DIPEA (80 μL, 0.46 mmol) was stirred at room temperature for 3 hours. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge that was washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc , 0-2%) and, was purified by _{(C18, MeOH H 2 O,} 10-20%). The resulting residue was purified on an Isolute® SCX-2 cartridge washed with MeOH and the product eluted with 2M NH ₃ / MeOH to give 829 (41 mg, 18%). LCMS (Method I): R _T 3.79 min, [M + H] ⁺ 565.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.03-7.98 (1H, m), 7.76-7.75 (1H, m), 7.32-7.22 (2H, m), 4 41-4.38 (5H, m), 4.08-4.01 (1H, m), 3.89-3.88 (5H, m), 3.79-3.77 (1H, m) 3.59-3.44 (2H, m), 3.34 (2H, q, J = 7.47 Hz), 3.27-3.25 (1 H, m), 2.75 (2H, s) , 1.44 (3H, t, J = 7.47 Hz), 1.37-1.35 (3H, m), 1.27-1.11 (6H, m)

Example 833 1- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxyazeti Gin-1-yl) -2-methylpropan-2-ol 833
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (2 mL) in MeCN (2 mL) 2,2-dimethyloxirane (198 μL, 2.23 mmol) was added to a solution of 100 mg, 0.22 mmol) and the resulting mixture was stirred at 80 ° C. for 3 hours, followed by 2,2-dimethyloxirane (1.0 mL, 11 .15 mmol) was added. The resulting mixture was stirred at 80 ° C. for an additional 20 hours. It was then concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-20%), triturated with Et ₂ O, and the resulting solid was dried in vacuo to give 833. (31 mg, 27%). LCMS (Method I): R _T 2.59 min, [M + H] ⁺ 521.3. ¹ H NMR (DMSO, 400 MHz): δ 8.04-8.04 (1H, m), 7.66-7.62 (1H, m), 7.25-7.24 (2H, m), 4. 29 (4H, brd s), 4.07 (1H, s), 3.99 (2H, d, J = 8.32 Hz), 3.80 (4H, t, J = 4.57 Hz), 3.70 (3H, s), 3.52 (2H, d, J = 8.34 Hz), 3.34-3.19 (2H, m), 3.02 (3H, s), 2.43 (2H, s ), 1.34 (3H, t, J = 7.43 Hz), 1.05 (6H, s)

Example 834 4- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -8- (3-fluoroazetidin-3-yl) -9-methyl-9H-purine-6- Il) Morpholine 834
3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-fluoroazetidine- in DCM (10 mL) To a solution of 1-carboxylic acid tert-butyl ester (235 mg, 0.44 mmol) was added TFA (2 mL) and the resulting mixture was stirred for 3.5 hours at room temperature. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto an Isolute® SCX-2 cartridge washed with MeOH / DCM and the product eluted with 2M NH ₃ / MeOH. The resulting residue was triturated with Et ₂ O and the resulting solid was dried under vacuum to give 834 (185 mg, 97%). LCMS (Method I): R _T 2.50 min, [M + H] ⁺ 437.3. ¹ H NMR (DMSO, 400 MHz): δ 8.06-8.05 (1H, m), 7.64-7.63 (1H, m), 7.28-7.24 (2H, m), 4. 60-4.10 (4H, brds), 4.26 (2H, dd, J = 19.18, 10.17 Hz), 4.01 (2H, dd, J = 22.47, 10.23 Hz), 3.80 (4H, t, J = 4.63 Hz), 3.74-3.73 (3H, m), 3.28-3.27 (2H, m), 1.34 (3H, t, J = 7.43Hz)

Example 839 1- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-fluoroazeti Gin-1-yl) -2-methylpropan-2-ol 839
2- (2-Ethylbenzimidazol-1-yl) -8- (3-fluoroazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (2 mL) in IMS (2 mL) A mixture of 90 mg, 0.21 mmol) and 2,2-dimethyloxirane (1 mL) was heated at 80 ° C. for 24 hours. It was then concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc , 0-5%) was triturated with Et ₂ O to and purified by. The resulting residue was further purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 5-95% gradient in 0.1% HCO ₂ H in water) to give 839 (22 mg, 21%). LCMS (Method I): R _T 2.63 min, [M + H] ⁺ 509.3. ¹ H NMR (DMSO, 400 MHz): δ 8.04-8.03 (1H, m), 7.65-7.62 (1H, m), 7.26-7.25 (2H, m), 4. 28 (4H, brd s), 4.14 (2H, dd, J = 18.78, 9.71 Hz), 3.82-3.74 (9H, m), 3.31-3.29 (4H, m), 1.34 (3H, t, J = 7.43 Hz), 1.07 (6H, s)

Example 840 (S) -1- (3- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl)- 3-methoxyazetidin-1-yl) -2-hydroxypropan-1-one 840
2- (2-Ethylbenzimidazol-1-yl) -8- (3-methoxyazetidin-3-yl) -9-methyl-6-morpholin-4-yl-9H-purine (2 mL) in DCM (2 mL) HOBt (33 mg, 0.25 mmol) and EDCI (64 mg, 0.34 mmol) were added to a mixture of 100 mg, 0.22 mmol) and L-sodium lactate (38 mg, 0.34 mmol). The resulting mixture was stirred at room temperature for 18 hours and partitioned between DCM and saturated aqueous NH ₄ Cl. The organic phase was dried (phase separator), concentrated under vacuum and the resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-25%). The resulting residue was triturated with Et ₂ O and further purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, MeOH 45-60% gradient in 0.1% HCO ₂ H in water) to give 840 ( 29 mg, 23%). LCMS (Method I): R _T 3.10 min, [M + H] ⁺ 521.3. ¹ H NMR (DMSO, 400 MHz): δ 8.44 (1H, brds), 8.07-8.03 (1H, m), 7.64-7.63 (1H, m), 7.25-7 .24 (2H, m), 5.24 (1H, brd s), 4.94 (1H, dd, J = 21.10, 10.14 Hz), 4.59-4.58 (2H, m), 4.46-4.12 (4H, brd s), 4.18-4.17 (2H, m), 3.79 (4H, t, J = 4.51 Hz), 3.72 (3H, s) 3.34-3.32 (2H, m), 3.09 (3H, s), 1.34 (3H, t, J = 7.43 Hz), 1.20 (3H, d, J = 6. 71Hz)

Example 846 (5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) (3-morpholinoazetidine-1 -Il) Methanone 846
(5-Chloro-7-morpholin-4-ylthiazolo [5,4-d] pyrimidin-2-yl)-(3-morpholin-4-ylazetidin-1-yl) methanone (98 mg, 0) in DMF (3 mL) .23 mmol), 2-ethylbenzimidazole (36 mg, 0.25 mmol), tris (dibenzylideneacetone) dipalladium (6 mg, 2.5 mol%), Xphos (10 mg, 9 mol%) and Cs ₂ CO ₃ (107 mg, 0 .33 mmol) was purged with argon and then heated in a microwave reactor at 150 ° C. for 30 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-4%) and then triturated with EtOAc to give 846 as a white solid (61 mg, 50%). LCMS (Method I): R _T 2.96 min, [M + H] ⁺ 535.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.09-8.05 (1H, m), 7.80-7.75 (1H, m), 7.31-7.30 (2H, m), 4 68-4.67 (1H, m), 4.60-4.20 (4H, brds), 4.52 (1H, dd, J = 10.01, 5.05 Hz), 4.33-4 .27 (1H, m), 4.17 (1H, dd, J = 10.73, 5.02 Hz), 3.89 (4H, t, J = 4.65 Hz), 3.78 (4H, t, J = 4.57 Hz), 3.42-3.33 (3H, m), 2.52-2.35 (4H, m), 1.46 (3H, t, J = 7.44 Hz)

Example 849 2- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-methoxyazeti Gin-1-yl) ethanol 849
1- {3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-methoxy in THF (2 mL) To a solution of azetidin-1-yl} -2-hydroxyethanone (88 mg, 0.17 mmol) was added BH ₃ at 0 ° C. The THF complex (350 μL, 0.35 mmol, 1M solution) and the resulting mixture was stirred for 1 hour. Furthermore, BH ₃ . THF complex (800 μL, 0.80 mmol) was added and the mixture was stirred at room temperature for 17 hours. The reaction mixture was quenched with H ₂ O, acidified with 2M HCl, then loaded onto an Isolute® SCX-2 cartridge washed with MeOH, and the product eluted with 2M NH ₃ / MeOH. The resulting residue was dissolved in a mixture of MeCN and H ₂ O and lyophilized to give 849 as a white solid (74 mg, 86%). LCMS (Method I): R _T 2.48 min, [M + H] ⁺ 493.4. ¹ H NMR (DMSO, 400 MHz): δ 8.04-8.04 (1H, m), 7.64-7.63 (1H, m), 7.27-7.23 (2H, m), 4. 50-4.42 (1H, m), 4.39-4.14 (4H, brd m), 4.05-3.98 (2H, m), 3.80 (4H, t, J = 4. 56 Hz), 3.70 (3H, s), 3.52-3.45 (2H, m), 3.40 (2H, q, J = 5.63 Hz), 3.34-3.24 (2H, m), 3.01 (3H, s), 2.65-2.57 (2H, m), 1.34 (3H, t, J = 7.43 Hz)

Example 850 2- (3- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -3-fluoroazeti Gin-1-yl) -2-methylpropan-1-ol 850
2- {3- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -3-fluoro in IMS (4 mL) NaBH ₄ (28 mg, 0.73 mmol) was added to a solution of azetidin-1-yl} -2-methylpropionic acid ethyl ester (40 mg, 0.07 mmol) and the resulting mixture was stirred at room temperature for 3 hours. More NaBH ₄ (28 mg, 0.73 mmol) was added and the mixture was stirred for an additional 18 hours. The reaction mixture was quenched with H ₂ O and extracted with EtOAc, the organic phase was dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%), dissolved in a mixture of MeCN and H ₂ O and lyophilized to give 850 as a white solid ( 20 mg, 54%). LCMS (Method I): R _T 2.64 min, [M + H] ⁺ 509.4. ¹ H NMR (DMSO, 400 MHz): δ 8.05-8.04 (1H, m), 7.64-7.63 (1H, m), 7.26-7.25 (2H, m), 4. 58-4.49 (1H, m), 4.44-4.14 (4H, brd m), 4.08 (2H, dd, J = 18.70, 9.19 Hz), 3.81-3. 74 (9H, m), 3.28-3.26 (2H, m), 3.19 (2H, d, J = 5.40 Hz), 1.34 (3H, t, J = 7.43 Hz), 0.91 (6H, s)

Example 851 1- (4-((2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 1-yl) -2-methylpropan-1-one 851
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purine (230 mg, 0.50 mmol) in DCM (10 mL) , A mixture of isobutyryl chloride (59 mg, 0.55 mmol) and NEt ₃ (140 μL, 1.00 mmol) was stirred at room temperature for 5 hours and then concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) and further by reverse-phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 40-98% gradient in 20 mM triethylamine in water). Purification gave 851 as a white solid (57 mg, 21%). LCMS (Method I): R _T 3.69 min, [M + H] ⁺ 531.4. ¹ H NMR (DMSO, 400 MHz): δ 8.01-8.00 (1H, m), 7.63-7.62 (1H, m), 7.27-7.23 (2H, m), 4. 40 (1 H, d, J = 13.34 Hz), 4.25 (4 H, brds), 3.94 (1 H, d, J = 13.78 Hz), 3.77-3.74 (7 H, m) 3.26 (2H, q, J = 7.45 Hz), 3.01 (1H, t, J = 13.02 Hz), 2.87-2.85 (3H, m), 2.50-2. 50 (1H, m), 2.12-2.08 (1H, m), 1.77-1.73 (2H, m), 1.33 (3H, t, J = 7.44 Hz), 1. 29-1.07 (2H, m), 1.00-0.98 (6H, m)

Example 852 Cyclopropyl (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) methyl) piperidine- 1-yl) methanone 852
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purine (230 mg, 0.50 mmol) in DCM (10 mL) , A mixture of cyclopropylcarbonyl chloride (50 μL, 0.55 mmol) and NEt ₃ (140 μL, 1.00 mmol) was stirred at room temperature for 5 hours and then concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) and further purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 40-98% gradient in 20 mM triethylamine in water). To give 852 as a white solid (46 mg, 17%). LCMS (Method I): R _T 3.59 min, [M + H] ⁺ 529.4. ¹ H NMR (DMSO, 400 MHz): δ 8.03-7.99 (1H, m), 7.64-7.63 (1H, m), 7.25-7.24 (2H, m), 4. 45-4.10 (6H, m), 3.77-3.75 (6H, m), 3.27-3.24 (3H, m), 3.16-3.00 (1H, m), 2.86 (2H, d, J = 7.07 Hz), 2.64-2.47 (1H, m), 2.20-2.08 (1H, m), 2.01-1.93 (1H , M), 1.79-1.71 (2H, m), 1.33 (3H, t, J = 7.43 Hz), 1.30-1.07 (2H, m), 0.74-0 .66 (4H, m)

Example 854 2-hydroxy-1- (3-((2- (2-isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) azetidin-1-yl) -2-methylpropan-1-one 854
1,1-Dimethyl-2- {3- [9-methyl-2- (2-isopropylbenzimidazol-1-yl) -6-morpholin-4-yl-acetic acid in THF (3 mL) and MeOH (1 mL) A mixture of 9H-purin-8-ylmethyl] azetidin-1-yl} -2-oxoethyl ester (56 mg, 0.17 mmol) and LiOH (84 μL, 0.33 mmol, 4M solution) was stirred at room temperature for 18 hours. Further LiOH (495 μL, 1.98 mmol, 4M solution) and the mixture were stirred at 50 ° C. for 5 days. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-5%), partitioned with DCM and H ₂ O, the organic phase was dried (Na ₂ SO ₄ ) and under vacuum. Concentrated. The resulting residue was dissolved in MeCN and H ₂ O and lyophilized to give 854 as a white solid (62 mg, 70%). LCMS (Method I): R _T 3.15 min, [M + H] ⁺ 533.4. ¹ H NMR (DMSO, 400 MHz): δ 7.87-7.86 (1H, m), 7.65-7.64 (1 H, m), 7.25-7.24 (2H, m), 5. 02 (1H, brd s), 4.57 (1 H, t, J = 8.92 Hz), 4.25 (4 H, brd s), 4.18 (1 H, dd, J = 10.40, 5.66 Hz) ), 4.03 (1H, t, J = 9.00 Hz), 3.91-3.90 (1H, m), 3.76 (4H, t, J = 4.59 Hz), 3.72 (3H , S), 3.68 (1H, dd, J = 9.99, 5.41 Hz), 3.22-3.21 (3H, m), 1.36 (3H, s), 1.34 (3H , S), 1.25 (6H, d, J = 2.06 Hz)

Example 855 2-hydroxy-2-methyl-1- (3-((9-methyl-2- (2-methyl-1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purine- 8-yl) methyl) azetidin-1-yl) propan-1-one 855
1,1-Dimethyl-2- {3- [9-methyl-2- (2-methylbenzimidazol-1-yl) -6-morpholin-4-yl-acetic acid in THF (3 mL) and MeOH (1 mL) A mixture of 9H-purin-8-ylmethyl] azetidin-1-yl} -2-oxoethyl ester (125 mg, 0.23 mmol) and LiOH (114 μL, 0.46 mmol, 4 M solution) was stirred at room temperature for 18 hours. Further LiOH (343 μL, 1.37 mmol, 4M solution) and the mixture were stirred at 50 ° C. for 5 days. The reaction mixture was concentrated in vacuo and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-10%), dissolved in a mixture of MeCN and H ₂ O and lyophilized to give 855 as a white solid ( 88 mg, 77%). LCMS (Method I): R _T 2.88 min, [M + H] ⁺ 505.3. ¹ H NMR (DMSO, 400 MHz): δ 8.09-8.08 (1H, m), 7.64-7.61 (1H, m), 7.28-7.27 (2H, m), 5. 02 (1H, brd s), 4.57 (1 H, t, J = 8.94 Hz), 4.26 (4 H, brd s), 4.17 (1 H, dd, J = 10.24, 5.60 Hz) ), 4.03 (1H, t, J = 8.97 Hz), 3.77 (4H, t, J = 4.64 Hz), 3.74 (3H, s), 3.67 (1H, dd, J = 9.96, 5.41 Hz), 3.21-3.20 (3H, m), 2.85 (3H, s), 1.28-1.21 (6H, m)

Example 859 (S) -1- (3-((2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine -8-yl) methyl) azetidin-1-yl) -2-methylpropan-1-one 859
(S) -1- [1- (8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl) -1H-benzimidazole- in THF (2 mL) To a solution of 2-yl] ethanol (70 mg, 0.16 mmol) was added DIPEA (30 μL, 0.17 mmol) and isobutyryl chloride (17 μL, 0.16 mmol) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was partitioned between DCM and saturated aqueous NaHCO ₃ and the organic phase was dried (phase separator) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, MeOH: EtOAc, 0-30%), (Si-PCC, MeOH: DCM, 0-8%) to give 859 (22 mg, 27% ). LCMS (Method I): R _T 3.46 min, [M + H] ⁺ 519.3. ¹ H NMR (DMSO, 400 MHz): δ 7.95-7.95 (1H, m), 7.70-7.69 (1H, m), 7.30-7.26 (2H, m), 5. 59-5.57 (1H, m), 5.39 (1H, d, J = 6.33 Hz), 4.39-4.10 (4H, brds), 4.34 (1H, t, J = 8.25 Hz), 4.02 (1H, t, J = 8.79 Hz), 3.95 (1H, dd, J = 8.47, 5.27 Hz), 3.80-3.75 (4H, m ), 3.72 (3H, s), 3.67-3.65 (1H, m), 3.27-3.21 (3H, m), 2.48-2.39 (1H, m), 1.60 (3H, d, J = 6.48 Hz), 0.98 (3 H, d, J = 1.76 Hz), 0.96 (3 H, d, J = 1.78 Hz)

Example 860 (R) -1- (3-((2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine -8-yl) methyl) azetidin-1-yl) -2-methylpropan-1-one 860
(R) -1- [1- (8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl) -1H-benzimidazole- in DCM (2 mL) To a solution of 2-yl] ethanol (57 mg, 0.13 mmol) was added DIPEA (24 μL, 0.14 mmol) and isobutyryl chloride (14 μL, 0.13 mmol) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was partitioned between DCM and H ₂ O and the organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-8%) to give 860 (16 mg, 24%). LCMS (Method I): R _T 3.46 min, [M + H] ⁺ 519.3. ¹ H NMR (DMSO, 400 MHz): δ 7.96-7.95 (1H, m), 7.70-7.69 (1H, m), 7.30-7.25 (2H, m), 5. 58-5.57 (1H, m), 5.39 (1H, d, J = 6.34 Hz), 4.36-4.09 (4H, brd s), 4.35 (1H, t, J = 8.22 Hz), 4.02 (1H, t, J = 8.79 Hz), 3.95-3.94 (1H, m), 3.80-3.75 (4H, m), 3.72 ( 3H, s), 3.67 (1H, dd, J = 9.77, 5.28 Hz), 3.24-3.23 (3H, m), 2.45-2.44 (1H, m), 1.60 (3H, d, J = 6.49 Hz), 0.98 (3H, d, J = 1.77 Hz), 0.97 (3H, d, J = 1.79 Hz)

Example 861 (R) -2-hydroxy-1- (3-((2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino -9H-purin-8-yl) methyl) azetidin-1-yl) -2-methylpropan-1-one 861
(R) -1- [1- (8-Azetidin-3-ylmethyl-9-methyl-6-morpholin-4-yl-9H-purin-2-yl) -1H-benzimidazole- in DCM (2 mL) 2-Hydroxy-2-methyl-propionic acid (15 mg, 0.14 mmol), HOBt (19 mg, 0.14 mmol), NMM (31 μL, 0.28 mmol) in a solution of 2-yl] ethanol (57 mg, 0.13 mmol) And EDCI (27 mg, 0.14 mmol) were added and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was partitioned between DCM and H ₂ O and the organic phase was dried (phase separator) and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 861 (14 mg, 21%). LCMS (Method I): R _T 3.05 min, [M + H] ⁺ 535.3. ¹ H NMR (DMSO, 400 MHz): δ 7.97-7.94 (1H, m), 7.71-7.68 (1H, m), 7.30-7.26 (2H, m), 5. 58-5.57 (1H, m), 5.39 (1H, d, J = 6.33 Hz), 5.02 (1H, s), 4.57-4.56 (1H, m), 4. 39-4.14 (4H, brds), 4.18 (1H, dd, J = 10.39, 5.70 Hz), 4.04-4.02 (1H, m), 3.80-3. 75 (4H, m), 3.72 (3H, s), 3.68 (1H, dd, J = 9.67, 5.21 Hz), 3.23-3.20 (2H, m), 1. 60 (3H, d, J = 6.48 Hz), 1.25 (6H, s)

Example 862 (S) -1- (4-((2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) Methyl) piperidin-1-yl) -2-hydroxypropan-1-one 862
2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-8-piperidin-4-ylmethyl-9H-purine hydrochloride (13 mg, 0. 1) in THF (1 mL). NMM (5 μL, 0.05 mmol) and EDCI (8 mg, 0.04 mmol) were added to a mixture of 02 mmol), L-sodium lactate (5 mg, 0.04 mmol) and HOBt (4 mg, 0.03 mmol) and the resulting reaction mixture Was stirred for 1 hour at room temperature. The reaction mixture was partitioned between EtOAc and H ₂ O and the organic phase was washed with brine, dried (Na ₂ SO ₄ ) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si-PCC, _NH of 2M 3 / MeOH: DCM, 0-10 %) to give the 862 was purified by (12mg, 92%). LCMS (Method I): R _T 3.18 min, [M + H] ⁺ 533.3. ¹ H NMR (MeOD, 400 MHz): δ 8.00-7.96 (1H, m), 7.65-7.61 (1H, m), 7.28-7.27 (2H, m), 4. 56-4.54 (2H, m), 4.33 (4H, brds), 4.04-4.04 (1H, m), 3.84 (4H, t, J = 4.75 Hz), 3 .79 (3H, s), 3.17-3.04 (2H, m), 2.92-2.86 (2H, m), 2.76-2.64 (1H, m), 2.28 -2.25 (1H, m), 1.92-1.82 (2H, m), 1.38 (3H, t, J = 7.51 Hz), 1.36-1.26 (6H, m)

ＤＣＭ（１ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルボニル]ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル(５８ｍｇ、０.１０ｍｍｏｌ)の溶液にＴＦＡ（１ｍＬ）を加え、生じた混合物を室温で１時間攪拌した。反応混合物を真空下で濃縮させ、ＤＣＭと共に共沸させて[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]ピペリジン-４-イルメタノンを得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．０３分，［Ｍ＋Ｈ］＋４７５．３ Example 863 1- (4- (2- (2-Ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine-8-carbonyl) piperidin-1-yl ) -2-Methylpropan-1-one 863

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl] piperidine-1-carboxylic acid tert in DCM (1 mL) To a solution of -butyl ester (58 mg, 0.10 mmol) was added TFA (1 mL) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under vacuum and azeotroped with DCM [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] Piperidin-4-ylmethanone was obtained. LCMS (Method A): R _T 2.03 min, [M + H] +475.3.

[2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-4-ylmethanone and NEt ₃ (5 mL) in DCM (5 mL). To a solution of 27 μL, 0.20 mmol) was added isobutyryl chloride (10 μL, 0.12 mmol) and the resulting reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with H ₂ O and extracted with DCM. The combined organic phases were dried (MgSO ₄ ), concentrated in vacuo, and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product was loaded with 2M NH ₃ / MeOH. And eluted. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH ₄ OH with a gradient of acetonitrile 40-70%) to give 863 (7 mg, 13%). LCMS (Method I): R _T 4.19 min, [M + H] ⁺ 545.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.06-8.05 (1H, m), 7.88-7.81 (1H, m), 7.39-7.31 (2H, m), 4 .75-4.63 (2H, m), 4.14-4.02 (5H, m), 3.93-3.91 (5H, m), 3.51-3.40 (2H, m) 3.31-3.40 (1H, m), 2.84-2.82 (2H, m), 2.08-1.96 (2H, m), 1.89-1.62 (4H, m), 1.49 (3H, t, J = 7.43 Hz), 1.20-1.12 (6H, m)

ＤＣＭ（１ｍＬ）中の４-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-カルボニル]ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（５８ｍｇ、０．１０ｍｍｏｌ）の溶液をＴＦＡ（１ｍＬ）に加え、生じた混合物を室温で１時間攪拌した。反応混合物を真空下で濃縮させ、ＤＣＭと共沸させて、[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]ピペリジン-４-イルメタノンを得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ２．０３分，［Ｍ＋Ｈ］^＋４７５．３ Example 864 (1- (cyclopropanecarbonyl) piperidin-4-yl) (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purine- 8-yl) methanone 864

4- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purine-8-carbonyl] piperidine-1-carboxylic acid tert in DCM (1 mL) A solution of -butyl ester (58 mg, 0.10 mmol) was added to TFA (1 mL) and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo and azeotroped with DCM to give [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl. ] Piperidin-4-ylmethanone was obtained. LCMS (Method A): R _T 2.03 min, [M + H] ⁺ 475.3.

[2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] piperidin-4-ylmethanone (47 mg, 0) in DCM (5 mL) .10 mmol) and NEt ₃ (27 μL, 0.20 mmol) was added to cyclopropanecarbonyl chloride (10 μL, 0.12 mmol) and the resulting reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with H ₂ O and extracted with DCM. The combined organic phases were dried (MgSO ₄ ), concentrated in vacuo, and the resulting residue was loaded onto a MeOH washed Isolute® SCX-2 cartridge and the product was loaded with 2M NH ₃ / MeOH. Eluted with. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, gradient acetonitrile 30-70% gradient 0.1% NH ₄ OH in water) to give 864 (13 mg, 25%). LCMS (Method I): R _T 4.06 min, [M + H] ⁺ 543.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.07-8.06 (1H, m), 7.89-7.82 (1H, m), 7.40-7.30 (2H, m), 4 .70-4.56 (3H, m), 4.39-4.28 (1H, m), 4.13 (3H, s), 3.93-3.90 (6H, m), 3.52 -3.27 (3H, m), 2.94-2.80 (1H, m), 2.08-1.97 (2H, m), 1.97-1.57 (4H, m), 1 .50 (3H, t, J = 7.40 Hz), 1.04-0.98 (2H, m), 0.79-0.78 (2H, m)

ＤＣＭ（１ｍＬ）中の４-｛１-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-１-ヒドロキシエチル｝ピペリジン-１-カルボン酸ｔｅｒｔ-ブチルエステル（１０４ｍｇ、０．１８ｍｍｏｌ）の溶液にＴＦＡ（１ｍＬ）を加え、生じた混合物を１時間攪拌した。反応混合物を真空下で濃縮し、ＤＣＭと共沸させ１-[２-(２-エチルベンゾイミダゾール-１-イル)-９-メチル-６-モルホリン-４-イル-９Ｈ-プリン-８-イル]-１-ピペリジン-４-イルエタノールを得た。ＬＣＭＳ（方法Ａ）：Ｒ_Ｔ１．８８分，［Ｍ＋Ｈ］^＋４９１．２ Example 865 cyclopropyl (4- (1- (2- (2-ethyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) -1 -Hydroxyethyl) piperidin-1-yl) methanone 865

4- {1- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -1-hydroxy in DCM (1 mL) To a solution of ethyl} piperidine-1-carboxylic acid tert-butyl ester (104 mg, 0.18 mmol) was added TFA (1 mL) and the resulting mixture was stirred for 1 hour. The reaction mixture is concentrated in vacuo, azeotroped with DCM and 1- [2- (2-ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl ] -1-Piperidin-4-ylethanol was obtained. LCMS (Method A): R _T 1.88 min, [M + H] ⁺ 491.2.

1- [2- (2-Ethylbenzimidazol-1-yl) -9-methyl-6-morpholin-4-yl-9H-purin-8-yl] -1-piperidin-4-ylethanol and DCM (5 mL A solution of NEt ₃ (74 μL, 0.53 mmol) in) was cooled to −78 ° C. and cyclopropanecarbonyl chloride (18 μL, 0.20 mmol) was added. The resulting mixture was stirred for 15 minutes, then quenched with H ₂ O and extracted with DCM. The combined organic phases were dried (phase separator) and concentrated under vacuum. The resulting residue was purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH ₄ OH in water with a gradient of 10-70% acetonitrile) to give 865 as a white solid (44 mg, 44%). LCMS (Method I): R _T 3.51 min, [M + H] ⁺ 559.4. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.01-8.00 (1H, m), 7.80 (1H, d, J = 7.13 Hz), 7.33-7.28 (2H, m) 4.71 (1H, brd s), 4.32 (4H, brd s), 3.98 (3H, s), 3.87 (4H, t, J = 4.69 Hz), 3.40 (2H) , Q, J = 7.47 Hz), 3.14-2.98 (1H, m), 2.60-2.43 (1H, m), 2.20-2.09 (1H, m), 1 .86-1.65 (6H, m), 1.62-1.36 (3H, m), 1.47 (3H, t, J = 7.47 Hz), 1.00-0.93 (2H, m), 0.75-0.74 (2H, m)

Example 866 (9-methyl-2- (2- (methylamino) -1H-benzo [d] imidazol-1-yl) -6-morpholino-9H-purin-8-yl) (3-morpholinoazetidine- 1-yl) methanone 866
(2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl) methanone (211 mg, 0) in dioxane (10 mL) .50 mmol), (1H-benzimidazol-2-yl) methylamine (81 mg, 0.55 mmol), tris (dibenzylideneacetone) dipalladium (12 mg, 0.01 mmol), XPhos (24 mg, 0.05 mmol) and Cs A mixture of ₂ CO ₃ (245 mg, 0.75 mmol) was purged with argon and then heated at 105 ° C. for 65 hours. The reaction mixture was filtered through Celite®, washed with dioxane and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%), then reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 10-90% gradient 0.1% NH in water. 866 was purified by ₄ OH) was obtained as a white solid (54mg, 20%). LCMS (Method I): R _T 2.57 min, [M + H] ⁺ 533.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.48 (1H, brds), 8.27 (1H, d, J = 8.02 Hz), 7.51 (1H, d, J = 7.84 Hz), 7 20-7.19 (1H, m), 7.09-7.07 (1H, m), 4.73-4.66 (1H, m), 4.68-4.16 (4H, brd s ), 4.50 (1H, dd, J = 10.48, 5.14 Hz), 4.24-4.23 (1H, m), 4.16-4.08 (4H, m), 3.90. (4H, t, J = 4.66 Hz), 3.77 (4H, t, J = 4.58 Hz), 3.30-3.26 (4H, m), 2.45-2.42 (4H, m)

Example 867 (R)-(2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ( 3-Morpholinoazetidin-1-yl) methanone (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholine-4--) in toluene (4 mL) Irazetidin-1-yl) methanone (164 mg, 0.39 mmol), (R) -1- (1H-benzimidazol-2-yl) ethanol (70 mg, 0.43 mmol), tris (dibenzylideneacetone) dipalladium (36 mg , 0.04 mmol), XPhos (75 mg, 0.16 mmol) and Cs ₂ CO ₃ (255 mg, 0.78 mmol) were purged with argon and then heated in a microwave reactor at 140 ° C. for 1 h. The reaction mixture was filtered through Celite®, washed with toluene, and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 867 (40 mg, 18%). LCMS (Method I): R _T 2.73 min, [M + H] ⁺ 548.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.13-8.12 (1H, m), 7.85-7.81 (1H, m), 7.35-7.34 (2H, m), 5 .64 (1H, s), 5.41-5.40 (1H, m), 4.78-4.20 (4H, brd s), 4.76-4.68 (1H, m), 4. 60-4.50 (1H, m), 4.26-4.25 (1H, m), 4.20-4.10 (4H, m), 3.89 (4H, t, J = 4.72 Hz) ), 3.85-3.75 (4H, m), 3.37-3.29 (1H, m), 2.58-2.41 (4H, m), 1.80 (3H, d, J) = 6.53 Hz)

Example 868 (S)-(2- (2- (1-hydroxyethyl) -1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) ( 3-Morpholinoazetidin-1-yl) methanone (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholine-4--) in toluene (4 mL) Irazetidin-1-yl) methanone (164 mg, 0.39 mmol), (S) -1- (1H-benzimidazol-2-yl) ethanol (70 mg, 0.43 mmol), tris (dibenzylideneacetone) dipalladium (36 mg) , 0.04 mmol), XPhos (75 mg, 0.16 mmol) and Cs ₂ CO ₃ (255 mg, 0.78 mmol) were purged with argon and then heated in a microwave reactor at 140 ° C. for 1 h. The reaction mixture was filtered through Celite®, washed with toluene and DCM, and the filtrate was concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) to give 868 (121 mg, 55%). LCMS (Method I): R _T 2.74 min, [M + H] ⁺ 548.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 8.14-8.09 (1H, m), 7.83-7.82 (1H, m), 7.37-7.33 (2H, m), 5 .64 (1H, s), 5.42-5.40 (1H, m), 4.76-4.20 (4H, brd s), 4.73-4.71 (1H, m), 4. 59-4.51 (1H, m), 4.26-4.25 (1H, m), 4.20-4.12 (4H, m), 3.88 (4H, t, J = 4.71 Hz) ), 3.83-3.76 (4H, m), 3.37-3.29 (1H, m), 2.58-2.42 (4H, m), 1.80 (3H, d, J) = 6.54 Hz)

Example 869 (2- (2-Isopropyl-1H-benzo [d] imidazol-1-yl) -9-methyl-6-morpholino-9H-purin-8-yl) (3-morpholinoazetidin-1-yl) ) Methanone (2-Chloro-9-methyl-6-morpholin-4-yl-9H-purin-8-yl)-(3-morpholin-4-ylazetidin-1-yl) methanone (211 mg) in dioxane (10 mL) , 0.50 mmol), 2-iso-propylbenzimidazole (88 mg, 0.55 mmol), tris (dibenzylideneacetone) dipalladium (12 mg, 0.01 mmol), XPhos (24 mg, 0.05 mmol) and Cs ₂ CO ₃ A mixture of (245 mg, 0.75 mmol) was purged with argon and then heated at 105 ° C. for 22 hours. The mixture was filtered through Celite®, washed with dioxane and concentrated under vacuum. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-10%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, acetonitrile 10-90% gradient in 0.1% in water). Purification with NH ₄ OH) gave 869 as a white solid (167 mg, 61%). LCMS (Method I): R _T 2.86 min, [M + H] ⁺ 546.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 7.93-7.92 (1H, m), 7.81 (1H, d, J = 7.28 Hz), 7.33-7.23 (2H, m) , 4.77-4.36 (4H, brds), 4.73 (1H, dd, J = 10.47, 7.11 Hz), 4.52 (1H, dd, J = 10.63,5. 21Hz), 4.27-4.24 (1H, m), 4.17-4.08 (5H, m), 4.02-3.99 (1H, m), 3.87 (4H, t, J = 4.64 Hz), 3.78 (4H, t, J = 4.60 Hz), 3.34-3.28 (1H, m), 2.50-2.43 (3H, m), 1. 49 (6H, d, J = 6.83Hz)

Example 875 (4- (2-hydroxypropan-2-yl) piperidin-1-yl) (2- (imidazo [1,2-a] pyridin-5-yl) -9-methyl-6-morpholino-9H -Purin-8-yl) methanone [4- (1-hydroxy-1-methylethyl) piperidin-1-yl]-(9-methyl-6-morpholin-4-yl-2 in dioxane (1.5 mL) -Stannyl-9H-purin-8-yl) methanone (101 mg, 0.15 mmol), 5-bromoimidazo [1,2-a] pyridine (32 mg, 0.16 mmol), Pd (PPh ₃ ) A mixture of ₄ (17 mg, 10 mol%) and Cu (TC) (6 mg, 20 mol%) was purged with argon and then heated in a microwave reactor at 150 ° C. for 20 minutes. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge washed with MeOH and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was further purified by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% NH ₄ OH in water with a gradient of acetonitrile 10-90%) to give 975 as a white solid (22 mg, 29%). . LCMS (Method I): R _T 2.84 min, [M + H] ⁺ 505.3. ¹ H NMR (CDCl ₃ , 400 MHz): δ 9.30 (1H, s), 8.07-8.05 (1H, m), 7.87 (1H, d, J = 8.89 Hz), 7.78 (1H, d, J = 1.39 Hz), 7.38 (1H, dd, J = 8.90, 7.23 Hz), 4.89-4.86 (1H, m), 4.64-4. 61 (1H, m), 4.39 (4H, brd s), 4.03 (3H, s), 3.89 (4H, t, J = 4.76 Hz), 3.22-3.05 (1H M), 2.81 (1H, td, J = 12.92, 2.90 Hz), 1.98-1.95 (1H, m), 1.90-1.87 (1H, m), 1 .66-1.59 (1H, m), 1.44 (2H, qd, J = 12.58, 4.23 Hz), 1.24 (6H, d, J = 5.99 Hz)

Example 876 1- (4-((5- (2-ethyl-1H-benzo [d] imidazol-1-yl) -7-morpholinothiazolo [5,4-d] pyrimidin-2-yl) methyl) Piperidin-1-yl) -2-hydroxy-2-methylpropan-1-one Acetic acid 2- {4- [5- (2-ethylbenzimidazol-1-yl) -7-morpholine- in THF (3 mL) 4-ylthiazolo [5,4-d] pyrimidin-2-ylmethyl] piperidin-1-yl} -1,1-dimethyl-2-oxoethyl ester (122 mg, 0.21 mmol) and LiOH (500 μL, 1.96 mmol, 4M solution) and MeOH (3 mL) were stirred at room temperature for 2 h. The reaction mixture was loaded onto a MeOH washed Isolute RSCX-2 cartridge and the product was eluted with 2M NH ₃ / MeOH. The resulting residue was purified by column chromatography (Si-PCC, MeOH: DCM, 0-5%) followed by reverse phase HPLC (Phenomenex Gemini 5 μm C18, 0.1% in water with a gradient of 40-80% acetonitrile). Of NH ₄ OH) to give 876 as a white solid (45 mg, 39%). LCMS (method I): R _T 3.94 min, [M + H] +550.4. ¹ H NMR (DMSO, 400 MHz): δ 8.00-7.99 (1H, m), 7.84-7.80 (1 H, m), 7.35-7.30 (2H, m), 4. 43 (4H, brds), 3.89 (4H, t, J = 4.72 Hz), 3.39 (2H, q, J = 7.46 Hz), 3.05 (2H, d, J = 7. 14 Hz), 2.91 (2H, brds), 2.17-2.15 (1 H, m), 1.90 (3 H, d, J = 13.40 Hz), 1.50 (6 H, s), 1 .46 (3Ht, J = 7.49 Hz), 1.39-1.28 (3H, m)

Example 901 PI3K Isoform Inhibition Assay (p110 alpha, beta, gamma, delta: α, β, γ, δ)
PI3K enzymatic activity is determined by measuring the amount of product phosphatidylinositol 3,4,5-phosphate (PIP3) formed from the substrate 4,5 phosphatidylinositol 4,5-phosphate (PIP2) using a fluorescence polarization displacement assay. Assayed by measuring. The decrease in fluorescence polarization of the fluorescent PIP ₃ probe is measured as it is displaced from the PIP ₃ binding protein GRP-1 detector by the PI3K catalyst product. The assay consists of 10 mM Tris (pH 7.5), 50 mM NaCl, 4 mM MgCl ₂ , 5% glycerol, 25 μM ATP, 10 μM PIP ₂ (Echelon Biosciences), 0.05% 3-[(3- Choleamidopropyl) dimethylammonio] -1-propanesulfonate, 1 mM dithiothreitol, and 2% DMSO were performed in 384 well black proxy plates. Kinase reactions were performed at 40 ng / mL p110α / p85α, 300 ng / mL p110β / p85α, 40 ng / mL p110γ, or 40 ng / mL p110δ / p85α (Upstate Group, Millipore; Dundee, UK), and 10 μM PIP ₂ (Echelon Biosciences) was started by adding to the wells. The reaction was performed in fluorescence polarization consistent with initial rate conditions by adding 12.5 mM EDTA, 100 nM GRP-1 detector, and 5 nM tetramethylrhodamine labeled PIP ₃ (TAMRA-PIP ₃ ; Echelon Biosciences). It was stopped when a fixed change occurred (typically 30 minutes). After incubation for 60 minutes at room temperature to allow equilibration of labeled and unlabeled PIP3 binding, the parallel and vertical components of fluorescence emission from each sample were converted to an Envision fluorescence plate reader (PerkinElmer Life and Analytical Sciences; equipped with a rhodamine filter; Using a wellsley, MA) with an excitation wavelength of 530 nm and an emission wavelength of 590 nm. The assay can detect PIP ₃ product 0.1-2.0MyuM. IC ₅₀ values were obtained by fitting dose-dependent inhibition data to a four parameter equation using assay explorer software (MDL, San Ramon, CA.).

Alternatively, PI3K inhibition was quantified in a radiometric assay using ATP and purified recombinant enzyme at a concentration of 1 uM. Formula I compounds were diluted serially with 100% DMSO. The kinase reaction was incubated for 1 hour at room temperature and PBS was added to terminate the reaction. IC ₅₀ values were subsequently determined using sigmoidal dose response curve fitting (variable slope).

The same protocol can be used to verify IC ₅₀ values for p110α (alpha) PI3K binding.
Recombinant PI3Kp110 isoforms α, β and δ were prepared according to U.S. Patent Application Publication No. 2008/0275067 according to BAC-TO-BAC. RTM. Prepared and purified from a recombinant PI3K heterodimer complex consisting of a p85 regulatory subunit and a p110 catalytic subunit overexpressed using the HT baculovirus expression system (GIBCO / BRL), followed by a biochemical assay Can be purified for use in. Four class I PI3 kinases are cloned into baculovirus vectors as follows:

  p110δ: A FLAG ™ labeled form of human p110δ (Eastman Kodak Co., US Pat. No. 4,703,004; US Pat. No. 4,782,137; US Pat. No. 4,851,341) (Chantry et al., J. Biol. Chem. (1997) 272 : 19236-41) using standard DNA technology in the BamH1-Xba1 site of the insect cell culture expression vector pFastbac HTb (Life Technologies, Gaithersburg, Md.) So that the clone is in frame with the His tag of the vector. Use for subcloning.

  p110α: Similar to the method used for p110δ described above, the FLAG ™ -labeled form of p110α (Volinia et al. (1994) Genomics, 24 (3): 427-77) and the clone with the His tag of the vector It was subcloned into the BamHI-HindIII site of pFastbac HTb (Life Technologies) so as to be in-frame.

  p110β: p110β (see Hu et al. (1993) Mol. Cell. Biol., 13: 7677-88) clones were isolated from human MARATHON ™ Ready spleen cDNA live according to the manufacturer's protocol using the identified primers. Amplified from rally (Clontech, Palo Alto Calif.).

The p110δ binding IC50 values and δ / α selectivity of compounds selected from Tables 1 and 2 include:

Example 902 Collagen-Induced Arthritis Efficacy Test The efficacy of PI3Kδ Formula I compound inhibitors that inhibit the induction and / or progression of collagen-induced arthritis was tested in mice. DBA1 / J male mice (Jackson Labs; 5-6 weeks old) were acclimated for 1 week, then 0.1 ml of bovine type II collagen (100 mg) emulsion and an equal volume of complete Freund's adjuvant (200 mg of Mycobacterium Tuberculus) is injected intradermally at the base of the tail. Three weeks later, mice are injected intradermally with 0.1 ml of bovine type II collagen (100 mg) emulsion and an equal volume of incomplete Freund's adjuvant at the base of the tail for booster immunization. In general, dosing begins as soon as the animal shows signs of joint inflammation or a clinical score of 1-2.

  All mice are evaluated for arthritis 2-3 times a week using a macroscopic scoring system for each paw. At the end of the experiment, a clinical score is obtained to assess the intensity of the four paw edema. Assign a score of 0 to 4 to each foot. Animals have signs of inflammation (swelling) in either small joints (intraphalangeal, metacarpophalangeal joints, metatarsal joints) or large joints (wrist / carpal bones, ankle / tarsal bones). And redness) is not observed, the score is 0. Animals score 1 if very little or slight inflammation (swelling and / or redness of the foot or one finger) is observed, moderate edema (swelling in two or more joints) is observed Score 2 if severe edema (overall swelling of the foot with more than 2 joints involved) is observed, and if there is very severe edema (severe foot and finger severity) A score of 4). The arthritic index of each mouse is assessed by adding 4 scores for each individual paw, giving a maximum score of 16. Plasma and serum samples were collected 1 hour after administration (orbital blood collection) and 24 hours after administration (cardiac puncture). Samples are stored at −20 ° C. until analysis. Finally, the hind leg is cut at the distal tibia immediately adjacent to the tarsal joint. The left and right hind legs are individually placed in a histology cassette and fixed with 10% formalin. These legs are sent to the histology department for further processing.

Materials: Bovine type II collagen from Chondrex, LLC, Seattle, WA, immunograde, 2 mg / ml (5 mL / vial) in 0.05 M acetic acid (solution), stored at −20 ° C. Complete adjuvant H37Ra, 6 × 10 mL / box contains 1 mg / ml Mycobacterium tuberculosis. Store at + 4 ° C. from Difco Laboratories, Detroit, Michigan 48232-7058 USA for use in animal immunological experiments. Incomplete adjuvant H37Ra, 6 × 10 mL / box: Store at + 4 ° C. from Difco Laboratories for laboratory use for use in animal immunological experiments.

Example 903 CD69 Whole Blood Assay Human blood is obtained from a healthy person who meets the following conditions: one week off, non-smoker. Blood (approximately 20 mL to test 8 compounds) is collected by venipuncture into a vacutainer tube containing sodium heparin.
Cynomolgus monkey blood is obtained in favor of the LAT group from monkeys that have not been administered in the past or after a drug withdrawal period. Additional cynomolgus monkey blood aspirates may be collected during the course of pharmacokinetic or toxicity experiments. Blood (25-30 ml for naive monkeys or 3-4 ml for monkeys in studies that require repeated collections) is collected by venipuncture into a vacutainer tube containing sodium heparin.

Solutions of 1000 or 2000 μM compound of Formula I in PBS (20 ×) are diluted by 3-fold serial dilution with 10% DMSO in PBS for a 9 point dose response curve. 5.5 μl aliquots of each compound are added in duplicate to a 2 mL 96 well plate; 5.5 μl of 10% DMSO in PBS is added to control and unstimulated wells. Human whole blood-HWB (100 μl) is added to each well. After mixing, the plate is incubated for 30 minutes at 37 ° C., 5% CO ₂ , 100% humidity. Goat F (ab ′) 2 anti-human IgM (10 μL of a 500 μg / ml solution, final 50 μg / ml) is added to each well with mixing (excluding unstimulated wells) and the plate is incubated for an additional 20 hours. At the end of the 20 hour incubation, the sample is incubated with fluorescently labeled antibody for 30 minutes at 37 ° C., 5% CO ₂ , 100% humidity. Include control induced, unstained and single stained for compensation adjustment and initial voltage setting. Samples are then dissolved in Pharmingen Lyse according to manufacturer's instructions. The sample is then transferred to a 96-well plate suitable for running on an AMS 96-well system on a BD Calibur FACs instrument. Acquired data and average fluorescence intensity values were obtained using Cell Quest software. The results are first analyzed by FACS analysis software (Flow Jo). The IC50 of a test compound is defined as the concentration that reduces 50% of CD69 positive cells that are also CD20 positive stimulated by anti-IgM (average of 8 control wells after subtracting the 8 well average against unstimulated background). . The IC50 value is calculated by ActivityBase using Xlfit version 3, equation 201.

IC50 values for compounds selected from Tables 1 and 2 in the CD69 whole blood assay include:

  The foregoing description is considered as illustrative only of the principles of the invention. Further, since numerous modifications and changes will be readily apparent to those skilled in the art, it is not desired to limit the invention to the precise construction and methods illustrated above. Accordingly, all suitable modifications and equivalents may be considered as falling within the scope of the invention as defined by the following claims.

  As used in this specification and the following claims, “comprise”, “comprising”, “include”, “including”, and “including” The term “includes” is intended to identify the presence of the stated feature, integer, component, or step, but the presence of one or more other features, integers, components, steps, or groups thereof. Or do not exclude additions.

  Reference is made to US Provisional Application No. 61 / 181,452 filed May 27, 2009 and 61 / 287,607 filed December 17, 2009, which are incorporated by reference in their entirety for all purposes.

Claims (30)

Formulas Ia and Ib:

And a stereoisomer, tautomer or pharmaceutically acceptable salt thereof selected from
Where (i) X ¹ is N and X ² is S; (ii) X ¹ is CR ⁷ and X ² is S; (iii) X ¹ is N and X ² is NR ² or (iv) X ¹ is CR ⁷ and X ² is O;
R ¹ is
C ₁ -C ₁₂ alkyl,
C ₂ -C ₈ alkenyl,
C ₂ -C ₈ alkynyl,
C ₆ -C ₂₀ aryl,
C ₂ -C ₂₀ heterocyclyl,
C ₃ -C ₁₂ carbocyclyl,
C ₁ -C ₂₀ heteroaryl,
-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 6} -C ₂₀ aryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) -NHR ² ',
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 3}} -C 12 carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 2}} -C 20 heterocyclyl),
-(C ₁ -C ₁₂ alkylene) -NR ² '-(C ₁ -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 6}} -C 20 aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heterocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 6} -C ₂₀ aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) -NHC (= O) - ( C 1 -C 20 heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 2} -C ₁₂ alkenylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 3} -C ₁₂ carbocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl),
_{-C (= O) - (C} 1 -C 20 heteroaryl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 1} -C ₂₀ heteroaryl),
_{-C (= O) - (C} 1 -C 12 alkyl),
^{-C (= O) -NR 2 '} - (C 1 -C 12 alkyl), and
-CR ⁴ = CR ⁵ R ⁶ selected, wherein R ⁴ is selected from H, F, Cl, Br, I and C ₁ -C ₁₂ alkyl, R ⁵ and R ⁶ are C ₂ -C ₂₀ heterocyclyl, Forming a C ₁ -C ₂₀ heteroaryl, or C ₃ -C ₁₂ carbocyclyl;
Here, alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH (CH ₃ ) ₂ , _{-CH 2 NH 2, -CH 2 N} (CH 3) 2, -CH 2 CH 2 NH 2, -CH 2 CH 2 N (CH 3) 2, -CH 2 OH, -CH 2 OH, -CH 2 OCH ₃ , —CH ₂ CH ₂ OH, —C (CH ₃ ) ₂ OH, —CH ₂ C (CH ₃ ) ₂ OH, —CH (OH) CH (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CH ₂ OH, —CH ₂ CH ₂ SO ₂ CH ₃ , —CN, —CF ₃ , —CO ₂ H, —CHO, —COCH ₃ , —CO ₂ CH ₃ , —CO ₂ C (CH ₃ ) ₃ , —COCH ₂ OH, -COC (OH) (CH 3) 2, -COCH (OH) CH 3, -CONH 2 _{-CONHCH 3, -CON (CH 3)} 2, -CH 2 CONH 2, -CH 2 CON (CH 3) 2, -C (CH 3) 2 CONH 2, -NO 2, -NH 2, -NHCH 3, _{-N (CH 3) 2, -NHCOCH} 3, -N (CH 3) COCH 3, -NHS (O) 2 CH 3, -N (CH 3) C (CH 3) 2 CONH 2, -N (CH 3 ) CH ₂ CH ₂ S (O) ₂ CH ₃ , = O, —OH, —OCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , —S (O ) May be substituted with one or more groups independently selected from ₂ CH ₃ , —C (O) -cyclopropyl, cyclopropyl, cyclobutyl, oxetanyl, and morpholino;
R ² and R ² ′ are H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl), -(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene) -C (═O)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene)-(C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene , Carbocyclyl, heterocyclyl, aryl, and heteroaryl are F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —COC (CH ₃ ) ₃ , —COCF ₃ , —CO ₂ CH ₃ , —CONH ₂ , —C ONHCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —NHCOCH ₃ , —NHS (O) ₂ CH ₃ , —OH, —OCH ₃ , —S (O) ₂ N Optionally substituted with one or more groups independently selected from (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , and —S (O) ₂ CH ₃ ;
R ³ is

C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl, C ₃ -C ₁₂ carbocyclyl, C ₂ -C ₂₀ heterocyclyl, C ₆ -C ₂₀ aryl, C ₁ -C ₂₀ heteroaryl,-(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), -NH- (C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), -N (C _1- C ₁₂ alkyl)-(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), —NH— (C ₂ -C ₂₀ heterocyclyl), —O— (C ₂ -C ₂₀ heterocyclyl), —NH— (C ₃ -C ₁₂ carbocyclyl), —O— (C ₃ -C ₁₂ carbocyclyl), F, Cl, Br, I, —CN, —CO ₂ H, —CONH ₂ , —CONH (C ₁ -C ₁₂ alkyl ), -CON (C ₁ -C ₁₂ alkyl) ₂ , -CO (C ₁ -C ₁₂ alkyl) ), -NO ₂ , -NH ₂ , -NH (C ₁ -C ₁₂ alkyl), -N (C ₁ -C ₁₂ alkyl) ₂ , -NHCO (C ₁ -C ₁₂ alkyl), -NHS (O) ₂ (C ₁ -C ₁₂ alkyl), —N (C ₁ -C ₁₂ alkyl) S (O) ₂ (C ₁ -C ₁₂ alkyl), —OH, —O (C ₁ -C ₁₂ alkyl), —NHC (═O) NH (C ₁ -C ₁₂ alkyl), —SH, —S (C ₁ -C ₁₂ alkyl), —S (O) (C ₁ -C ₁₂ alkyl), —S (O) ₂ (C _1- C ₁₂ alkyl), —S (O) ₂ NH ₂ , —S (O) ₂ NH (C ₁ -C ₁₂ alkyl), and —S (O) ₂ N (C ₁ -C ₁₂ alkyl) ₂ A bicyclic heteroaryl group optionally substituted with one or more independently selected groups, wherein alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and Heteroaryl is F, Cl, Br, I, -CN, -CF 3, -CO 2 H, -COCH 3, -CO 2 CH 3, -CONH 2, -CONHCH 3, -CON (CH 3) 2, -NO _{2, -NH 2, -NHCH 3,} -NHCOCH 3, -NHS (O) 2 CH 3, = O, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SH, - Optionally substituted with one or more groups independently selected from SCH ₃ , —CH ₂ OCH ₃ , and —S (O) ₂ CH ₃ ;
R ⁷ is H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),-(C _1- C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl), - _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl), - _{(C 1} -C ₁₂ alkylene) - ( C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and hetero aryl F, Cl, Br, I, -CH 3, -CH 2 CH 3, -CH 2 OH, -CN, -CF 3, -CO 2 H, -COCH 3, -CO 2 CH 3, -CONH 2 , -CONHCH ₃ , -CON (CH ₃ ) ₂ , -NO _{2, -NH 2, -NHCH 3,} -NHCOCH 3, -NHS (O) 2 CH 3, = O, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, Optionally substituted with one or more groups independently selected from —CH ₂ OCH ₃ and —S (O) ₂ CH ₃ ;
mor is a morpholine group or

A bicyclic structure selected from F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH _{3) 3, -CH 2 OCH 3} , -CHF 2, -CN, -CF 3, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -CH 2 C (CH 3) 2 OH, _{-CH (CH 3) OH, -CH} (CH 2 CH 3) OH, -CH 2 CH (OH) CH 3, -C (CH 3) 2 OH, -C (CH 3) 2 OCH 3, -CH ( CH ₃ ) F, —C (CH ₃ ) F ₂ , —CH (CH ₂ CH ₃ ) F, —C (CH ₂ CH ₃ ) ₂ F, —CO ₂ H, —CONH ₂ , —CON (CH ₂ CH _{3) 2, -COCH 3, -CON} (CH 3) 2, -NO 2, -NH 2, -NHCH 3, -N (CH 3) 2, -NHCH 2 CH 3, -NHCH (CH 3) 2, -NHC H ₂ CH ₂ OH, —NHCH ₂ CH ₂ OCH ₃ , —NHCOCH ₃ , —NHCOCH ₂ CH ₃ , —NHCOCH ₂ OH, —NHS (O) ₂ CH ₃ , —N (CH ₃ ) S (O) ₂ CH ₃ , ═O, —OH, —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O) NHCH ₂ CH ₃ , — S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH ₃ , —S (O) ₂ Optionally substituted with one or more groups selected from N (CH ₃ ) ₂ , —CH ₂ S (O) ₂ CH ₃ ;
And where the IC50 binding activity to p110δ is 10 times or more lower than the binding activity to p110α;
Wherein (ii) X ¹ is CR ⁷ , X ² is S, R ¹ is — (C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), and R ³ is A compound of formula Ib which is optionally substituted benzo [d] imidazol-1-yl and R ⁷ is H is a C ₂ -C _{20 of} R ¹ substituted with —S (O) ₂ CH _3. A compound that excludes heterocyclyl. Construction:

The compound of claim 1 selected from. Construction:

The compound of claim 1 selected from. Construction:

The compound of claim 1 selected from. Construction:

The compound of claim 1 selected from. R ¹ is the structure

The compound of claim 1, wherein the wavy line indicates a binding site. R ² is F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —CONH ₃ , —CO ₂ CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —NHCOCH ₃ , —NHS (O) ₂ CH ₃ , —OH, —OCH ₃ , —S (O) ₂ N (CH ₃ ) C ₁ -C ₁₂ alkyl optionally substituted with one or more groups independently selected from ₂ , SCH ₃ , -CH ₂ OCH ₃ , and -S (O) ₂ CH ₃ The compound of claim 1. The compound according to claim 7, wherein R ² is CH ₃ . R ³ bicyclic heteroaryl is F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) _{3 , -CH 2 OCH 3, -CHF 2} , -CH 2 CN, -CN, -CF 3, -CH 2 OH, -CH 2 OCH 3, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, _{-CH 2 C (CH 3) 2} OH, -CH (CH 3) OH, -CH (CH 2 CH 3) OH, -CH 2 CH (OH) CH 3, -CH 2 CH (OCH 3) CH 3, _{-C (CH 3) 2 OH,} -CH (CH 3) OCH 3, -C (CH 3) 2 OCH 3, -CH (CH 3) F, -C (CH 3) F 2, -CH (CH 2 _{CH 3) F, -C (CH} 2 CH 3) 2 F, -C (CH 2 CH 3) F 2, -CO 2 H, -CONH 2, -CON (CH 2 CH 3) 2, -COCH 3, - CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , —NHCH ₂ CH ₃ , —NHCH (CH ₃ ) ₂ , —NHCH ₂ CH ₂ OH, —NHCH ₂ CH ₂ OCH ₃ , —NHCOCH ₃ , —NHCOCH ₂ CH ₃ , —NHCOCH ₂ OH, —NHS (O) ₂ CH ₃ , —N (CH ₃ ) S (O) ₂ CH ₃ , ═O, —OH, —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O) NHCH ₂ CH ₃ , —S (O) CH ₃ , — _{S (O) CH 2 CH 3} , -S (O) 2 CH 3, -S (O) 2 NH 2, -S (O) 2 NHCH 3, -S (O) 2 N (CH 3) 2, - _{CH 2 S (O) 2 CH} 3 and,

The compound according to claim 1, which is substituted with one or more groups independently selected from a group selected from: R ³ is

[Wherein R ⁸ is H, F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) ₃ , —CH ₂ OCH ₃ , —CHF ₂ , —CH ₂ CN, —CN, —CF ₃ , —CH ₂ OH, —CH ₂ OCH ₃ , —CH ₂ CH ₂ OH, —CH ₂ C (CH ₃ ) _{2 OH, -CH (CH 3)} OH, -CH (CH 2 CH 3) OH, -CH 2 CH (OH) CH 3, -CH 2 CH (OCH 3) CH 3, -C (CH 3) 2 OH _{, -C (CH 3) 2 OCH} 3, -CH (CH 3) F, -C (CH 3) F 2, -CH (CH 2 CH 3) F, -C (CH 2 CH 3) 2 F, - CO ₂ H, —CONH ₂ , —CON (CH ₂ CH _{3) 2} , —COCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , -NHCH ₂ CH _{, -NHCH (CH 3) 2,} -NHCH 2 CH 2 OH, -NHCH 2 CH 2 OCH 3, -NHCOCH 3, -NHCOCH 2 CH 3, -NHCOCH 2 OH, -NHS (O) 2 CH 3, -N (CH ₃ ) S (O) ₂ CH ₃ , —OH, —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O ) NHCH ₂ CH ₃ , —S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH _{3 , -S (O) 2 N (} CH 3) 2, -CH 2 S (O) 2 CH 3 and,

Selected from the group selected from:
R ⁹ is independently F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , —CH ₂ OH, —CH ₂ CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —CO ₂ CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , _{-NO 2, -NH 2, -NHCH 3} , -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, - Selected from CH ₂ OCH ₃ and —S (O) ₂ CH ₃ ; and n is 0, 1, 2, 3, or 4]
The compound according to claim 1, wherein Construction:

11. A compound according to claim 10 having The compound according to claim 1, wherein R ⁷ is H. R ⁷ is F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —CONH ₃ , —CO ₂ CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —NHCOCH ₃ , —NHS (O) ₂ CH ₃ , —OH, —OCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , and —S (O) ₂ CH _3, which is C ₁ -C ₁₂ alkyl optionally substituted with one or more groups selected from Item 1. The compound according to Item 1. 13. A compound according R ⁷ is is CH _3. Construction:

[Wherein R ¹ is — (C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl), wherein C ₂ -C ₂₀ heterocyclyl is F, Cl, Br, I, —CH _{3 , -CH 2 CH 3, -CH 2} CH (CH 3) 2, -CH 2 OH, -CH 2 CH 2 OH, -C (CH 3) 2 OH, -CH (OH) CH (CH 3) 2, _{-C (CH 3) 2 CH 2} OH, -CH 2 CH 2 SO 2 CH 3, -CN, -CF 3, -CO 2 H, -COCH 3, -CO 2 CH 3, -CO 2 C (CH 3 ) ₃ , —COCH (OH) CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CONH ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , — _{N (CH 3) 2, -NHCOCH} 3, -N (CH 3) COCH 3, -NHS (O) 2 CH 3, -N (CH 3) C (CH 3) 2 CO _{H 2, -N (CH 3)} CH 2 CH 2 S (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, -CH 2 OCH 3 , Cyclopropyl, oxetanyl, and morpholino may be substituted with one or more groups independently selected; and R ⁷ is H or —CH ₃ ]
12. The compound of claim 11 having: Construction:

And a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof,
here,
C ₁ -C ₁₂ alkyl,
C ₂ -C ₈ alkenyl,
C ₂ -C ₈ alkynyl,
C ₆ -C ₂₀ aryl,
C ₂ -C ₂₀ heterocyclyl,
C ₃ -C ₁₂ carbocyclyl,
C ₁ -C ₂₀ heteroaryl,
-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 6} -C ₂₀ aryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 1} -C ₂₀ heteroaryl) - _{(C 1} -C ₁₂ alkyl),
- _{(C 1} -C ₁₂ alkylene) -C (= O) - ( C 2 -C 20 heterocyclyl),
- _{(C 1} -C ₁₂ alkylene) -NHR ² ',
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 3}} -C 12 carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 2}} -C 20 heterocyclyl),
-(C ₁ -C ₁₂ alkylene) -NR ² '-(C ₁ -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 6}} -C 20 aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 3} -C ₁₂ carbocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heteroaryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 1} -C ₂₀ heterocyclyl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) - _{(C 6} -C ₂₀ aryl),
- _{(C 1} -C _{12 ^{alkylene) -NR 2 '- (C 1}} -C 12 alkylene) -NHC (= O) - ( C 1 -C 20 heteroaryl),
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 1} -C ₁₂ alkylene) - _{(C 2} -C ₂₀ heterocyclyl) - _{(C 1} -C ₁₂ alkyl) -N _{(C 1} -C ₁₂ alkyl) ^{R 2} ',
- _{(C 2} -C ₁₂ alkenylene) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 2} -C ₂₀ heterocyclyl),
- _{(C 1} -C ₂₀ heteroaryl) - _{(C 3} -C ₁₂ carbocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl),
_{-C (= O) - (C} 1 -C 20 heteroaryl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 2} -C ₂₀ heterocyclyl),
_{-C (= O) - (C} 2 -C 20 heterocyclyl) - _{(C 1} -C ₂₀ heteroaryl),
_{-C (= O) - (C} 1 -C 12 alkyl),
^{-C (= O) -NR 2 '} - (C 1 -C 12 alkyl), and
-CR ⁴ = CR ⁵ R ⁶ , wherein R ⁴ is selected from H, F, Cl, Br, I and C ₁ -C ₁₂ alkyl, R ⁵ and R ⁶ are C ₂ -C ₂₀ heterocyclyl, Forming a C ₁ -C ₂₀ heteroaryl, or C ₃ -C ₁₂ carbocyclyl;
Here, alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH (CH ₃ ) ₂ , _{-CH 2 NH 2, -CH 2 N} (CH 3) 2, -CH 2 CH 2 NH 2, -CH 2 CH 2 N (CH 3) 2, -CH 2 OH, -CH 2 OH, -CH 2 OCH ₃ , —CH ₂ CH ₂ OH, —C (CH ₃ ) ₂ OH, —CH ₂ C (CH ₃ ) ₂ OH, —CH (OH) CH (CH ₃ ) ₂ , —C (CH ₃ ) ₂ CH ₂ OH, —CH ₂ CH ₂ SO ₂ CH ₃ , —CN, —CF ₃ , —CO ₂ H, —CHO, —COCH ₃ , —CO ₂ CH ₃ , —CO ₂ C (CH ₃ ) ₃ , —COCH ₂ OH, -COC (OH) (CH 3) 2, -COCH (OH) CH 3, -CONH 2 _{-CONHCH 3, -CON (CH 3)} 2, -CH 2 CONH 2, -CH 2 CON (CH 3) 2, -C (CH 3) 2 CONH 2, -NO 2, -NH 2, -NHCH 3, _{-N (CH 3) 2, -NHCOCH} 3, -N (CH 3) COCH 3, -NHS (O) 2 CH 3, -N (CH 3) C (CH 3) 2 CONH 2, -N (CH 3 ) CH ₂ CH ₂ S (O) ₂ CH ₃ , = O, —OH, —OCH ₃ , —S (O) ₂ N (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , —S (O ) May be substituted with one or more groups independently selected from ₂ CH ₃ , —C (O) -cyclopropyl, cyclopropyl, cyclobutyl, oxetanyl, and morpholino;
R ² and R ² ′ are H, C ₁ -C ₁₂ alkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ alkynyl,-(C ₁ -C ₁₂ alkylene)-(C ₃ -C ₁₂ carbocyclyl), -(C ₁ -C ₁₂ alkylene)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene) -C (═O)-(C ₂ -C ₂₀ heterocyclyl),-(C ₁ -C ₁₂ alkylene)-(C ₆ -C ₂₀ aryl), and — (C ₁ -C ₁₂ alkylene)-(C ₁ -C ₂₀ heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, Carbocyclyl, heterocyclyl, aryl, and heteroaryl are F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —COCH ₃ , —COC (CH ₃ ) ₃ , -COCF ₃ , -CO ₂ CH ₃ , -CONH ₂ , -CON HCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —NHCOCH ₃ , —NHS (O) ₂ CH ₃ , —OH, —OCH ₃ , —S (O) ₂ N Optionally substituted with one or more groups independently selected from (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , and —S (O) ₂ CH ₃ ;
R ⁸ is H, F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —C (CH ₃ ) ₃ , —CH ₂ OCH ₃ , —CHF ₂ , —CN, —CF ₃ , —CH ₂ OH, —CH ₂ OCH ₃ , —CH ₂ CH ₂ OH, —CH ₂ C (CH ₃ ) ₂ OH, —CH (CH ₃ ) OH, —CH (CH ₂ CH ₃ ) OH, —CH ₂ CH (OH) CH ₃ , —CH ₂ CH (OCH ₃ ) CH ₃ , —C (CH ₃ ) ₂ OH, —C (CH ₃ ) ₂ OCH ₃ , —CH (CH ₃ ) F, —C (CH ₃ ) F ₂ , —CH (CH ₂ CH ₃ ) F, —C (CH ₂ CH ₃ ) ₂ F, —CO ₂ H, —CONH ₂ , — CON (CH ₂ CH ₃ ) ₂ , —COCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —N (CH ₃ ) ₂ , —NHCH ₂ CH ₃ , —NHCH ( CH ₃ ) ₂ , -NHCH ₂ CH ₂ OH, -NHCH ₂ CH ₂ OCH ₃ , -NHCOCH ₃ , -NHCOCH ₂ CH ₃ , -NHCOCH ₂ OH, -NHS (O) ₂ CH ₃ , -N (CH ₃ ) S (O ) ₂ CH ₃ , ═O, —OH, —OCH ₃ , —OCH ₂ CH ₃ , —OCH (CH ₃ ) ₂ , —SH, —NHC (═O) NHCH ₃ , —NHC (═O) NHCH ₂ CH ₃ , —S (O) CH ₃ , —S (O) CH ₂ CH ₃ , —S (O) ₂ CH ₃ , —S (O) ₂ NH ₂ , —S (O) ₂ NHCH ₃ , —S ( O) ₂ N (CH ₃ ) ₂ , —CH ₂ S (O) ₂ CH ₃ , and

Selected from the group selected from:
R ⁹ is F, Cl, Br, I, —CH ₃ , —CH ₂ CH ₃ , —CH ₂ CH ₂ CH ₃ , —CH (CH ₃ ) ₂ , —CH ₂ CH (CH ₃ ) ₂ , —CH _{2 OH, -CH 2 CH 2 OH} , -CN, -CF 3, -CO 2 H, -COCH 3, -CO 2 CH 3, -CONH 2, -CONHCH 3, -CON (CH 3) 2, -NO _{2, -NH 2, -NHCH 3,} -NHCOCH 3, -NHS (O) 2 CH 3, -OH, -OCH 3, -S (O) 2 N (CH 3) 2, -SCH 3, -CH 2 A compound wherein N is independently selected from OCH ₃ and —S (O) ₂ CH ₃ ; and n is 0, 1, 2, 3, or 4. R ¹ is the structure

The compound of claim 1, wherein the wavy line indicates a binding site. R ² is F, Cl, Br, I, —CH ₃ , —CH ₂ OH, —CN, —CF ₃ , —CO ₂ H, —CONH ₃ , —CO ₂ CH ₃ , —CONH ₂ , —CONHCH ₃ , —CON (CH ₃ ) ₂ , —NO ₂ , —NH ₂ , —NHCH ₃ , —NHCOCH ₃ , —NHS (O) ₂ CH ₃ , ═O, —OH, —OCH ₃ , —S (O) ₂ C ₁ -C ₁₂ optionally substituted with one or more groups independently selected from N (CH ₃ ) ₂ , —SCH ₃ , —CH ₂ OCH ₃ , and —S (O) ₂ CH _3. 17. A compound according to claim 16 which is alkyl. 18. A compound according R ² is CH _3.   The compound of claim 1 selected from Table 1.   The compound of claim 1 selected from Table 2.   The compound of claim 1 selected from Table 3.   23. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 and a pharmaceutically acceptable carrier, glidant, diluent or excipient.   24. The pharmaceutical composition according to claim 23, further comprising a second therapeutic agent.   23. A process for producing a pharmaceutical composition comprising combining a compound according to any one of claims 1 to 22 with a pharmaceutically acceptable carrier, glidant, diluent or excipient.   Claims in the manufacture of a medicament for treating a disease or disorder selected from cancer, immune disease, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction and neuropathy and mediated by isoform p110δ of PI3 kinase Item 23. Use of the compound according to any one of Items 1 to 22.   23. A patient having a disease or disorder selected from cancer, immune disease, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction and neuropathy mediated by PI3 kinase isoform p110δ. A method for treating a disease or disorder, comprising administering a compound according to any one of the above.   Selected from chemotherapeutic agents, anti-inflammatory agents, immunomodulators, neurotrophic factors, cardiovascular disease treatment agents, liver disease treatment agents, antiviral agents, blood disease treatment agents, diabetes treatment agents, and immunodeficiency disorder treatment agents 28. The method of claim 27, further comprising administering an additional therapeutic agent. A kit for treating a condition mediated by the p110δ isoform of PI3 kinase comprising:
A kit comprising: a) a first pharmaceutical composition comprising a compound according to any one of claims 1 to 22; and b) instructions for use.   Selected from cancer, immune disease, cardiovascular disease, viral infection, inflammation, metabolic / endocrine dysfunction and neuropathy and used in the treatment of a disease or disorder mediated by the p110δ isoform of PI3 kinase 23. A compound according to any one of claims 1 to 22 for use in a method of treatment of the body.